TTD - Therapeutic Targets Database Full Data Download File Title - TTD targets information in raw format Version 10.1.01 (2024.01.10) Provided by IDRB Lab of Innovative Drug Reasearch and Bioinformatics College of Pharmaceutical Sciences Zhejiang University https://idrblab.org/ Provided by BIDD BioInformatic and Drug Design Group Department of Pharmacy National Unviersity of Singapore https://bidd.group/ Any question about data provided here, please contact with: Dr. Zhou (zhou_ying@zju.edu.cn) and Dr. Zhang (zhangyintao@zju.edu.cn) -------------------------------------------------------------------------------------------------------- Abbreviations: TARGETID TTD Target ID TARGNAME Target Name INDICATI Clinical Status Disease Entry [ICD-11] -------------------------------------------------------------------------------------------------------- T00033 TARGETID T00033 T00033 TARGNAME Transforming growth factor alpha (TGFA) T00033 INDICATI Phase 1/2 Chronic kidney disease [ICD-11: GB61] T00039 TARGETID T00039 T00039 TARGNAME CTGF messenger RNA (CTGF mRNA) T00039 INDICATI Phase 2 Fibrosis [ICD-11: GA14-GC01] T00043 TARGETID T00043 T00043 TARGNAME HUMAN cyclin G-associated kinase (GAK) T00043 INDICATI Phase 3 COVID-19 [ICD-11: 1D6Y] T00043 INDICATI Approved Rheumatoid arthritis [ICD-11: FA20] T00099 TARGETID T00099 T00099 TARGNAME HUMAN calpain-1/calpain small subunit 1 heterodimer (CAPN1/CAPNS1) T00099 INDICATI Phase 2 COVID-19 [ICD-11: 1D6Y] T00100 TARGETID T00100 T00100 TARGNAME Ubiquitin-activating enzyme (UBA) T00100 INDICATI Phase 1 Solid tumour/cancer [ICD-11: 2A00-2F9Z] T00140 TARGETID T00140 T00140 TARGNAME Arachidonate 5-lipoxygenase (5-LOX) T00140 INDICATI Terminated Allergic/hypersensitivity disorder [ICD-11: 4A80-4A8Z] T00140 INDICATI Terminated Arterial occlusive disease [ICD-11: BD40] T00140 INDICATI Approved Asthma [ICD-11: CA23] T00140 INDICATI Phase 2 Atopic eczema [ICD-11: EA80] T00140 INDICATI Phase 2 Carcinoid syndrome [ICD-11: 5B10] T00140 INDICATI Discontinued in Phase 2 Cardiovascular disease [ICD-11: BA00-BE2Z] T00140 INDICATI Discontinued in Phase 2 Chronic obstructive pulmonary disease [ICD-11: CA22] T00140 INDICATI Discontinued in Phase 2 Eczema [ICD-11: EA80-EA89] T00140 INDICATI Approved Filariasis [ICD-11: 1F66] T00140 INDICATI Phase 2 Fungal infection [ICD-11: 1F29-1F2F] T00140 INDICATI Phase 2 Idiopathic interstitial pneumonitis [ICD-11: CB03] T00140 INDICATI Phase 2 Influenza [ICD-11: 1E30-1E32] T00140 INDICATI Phase 3 Lung cancer [ICD-11: 2C25] T00140 INDICATI Investigative Malaria [ICD-11: 1F40-1F45] T00140 INDICATI Investigative Nasopharyngeal cancer [ICD-11: 2B6B] T00140 INDICATI Discontinued in Phase 1 Osteoarthritis [ICD-11: FA00-FA05] T00140 INDICATI Phase 1 Pain [ICD-11: MG30-MG3Z] T00140 INDICATI Phase 2 Pituitary gland disorder [ICD-11: 5A60-5A61] T00140 INDICATI Phase 3 Postoperative inflammation [ICD-11: 1A00-CA43] T00140 INDICATI Discontinued in Phase 2 Pruritus [ICD-11: EC90] T00140 INDICATI Phase 2 Psoriasis [ICD-11: EA90] T00140 INDICATI Withdrawn from market Respiratory system disease [ICD-11: CB40-CB7Z] T00140 INDICATI Phase 3 Rheumatoid arthritis [ICD-11: FA20] T00140 INDICATI Phase 2 Solid tumour/cancer [ICD-11: 2A00-2F9Z] T00140 INDICATI Phase 4 Thrombocytopenia [ICD-11: 3B64] T00140 INDICATI Discontinued in Phase 2 Thrombosis [ICD-11: DB61-GB90] T00145 TARGETID T00145 T00145 TARGNAME HUMAN pH-dependent viral fusion/replication (pH-DVF/R) T00145 INDICATI Phase 3 COVID-19 [ICD-11: 1D6Y] T00145 INDICATI Approved Malaria [ICD-11: 1F40-1F45] T00145 INDICATI Investigative Middle East Respiratory Syndrome [ICD-11: 1D64] T00145 INDICATI Investigative Severe acute respiratory syndrome [ICD-11: 1D65] T00156 TARGETID T00156 T00156 TARGNAME Short transient receptor potential channel 5 (TRPC5) T00156 INDICATI Phase 2 Chronic kidney disease [ICD-11: GB61] T00156 INDICATI Phase 2 Depression [ICD-11: 6A70-6A7Z] T00158 TARGETID T00158 T00158 TARGNAME HUMAN glycosylation of host receptor (GHR) T00158 INDICATI Phase 3 COVID-19 [ICD-11: 1D6Y] T00158 INDICATI Approved Malaria [ICD-11: 1F40-1F45] T00158 INDICATI Investigative Middle East Respiratory Syndrome [ICD-11: 1D64] T00158 INDICATI Investigative Severe acute respiratory syndrome [ICD-11: 1D65] T00176 TARGETID T00176 T00176 TARGNAME Ubiquitin-protein ligase E3 Mdm2 (MDM2) T00176 INDICATI Phase 3 Acute myeloid leukaemia [ICD-11: 2A60] T00176 INDICATI Investigative Breast cancer [ICD-11: 2C60-2C6Y] T00176 INDICATI Phase 1 Liposarcoma [ICD-11: 2B59] T00176 INDICATI Phase 1 Lung cancer [ICD-11: 2C25] T00176 INDICATI Phase 2 Malignant haematopoietic neoplasm [ICD-11: 2B33] T00176 INDICATI Phase 2 Mature B-cell leukaemia [ICD-11: 2A82] T00176 INDICATI Phase 1 Myelodysplastic syndrome [ICD-11: 2A37] T00176 INDICATI Phase 2 Myeloproliferative neoplasm [ICD-11: 2A20] T00176 INDICATI Phase 2 Neuroendocrine carcinoma [ICD-11: 2C34] T00176 INDICATI Phase 1 Prostate cancer [ICD-11: 2C82] T00176 INDICATI Phase 3 Solid tumour/cancer [ICD-11: 2A00-2F9Z] T00216 TARGETID T00216 T00216 TARGNAME HUAMN alpha-1 adrenergic receptor (ADRA1) T00216 INDICATI Investigative COVID-19 [ICD-11: 1D6Y] T00216 INDICATI Approved Heart failure [ICD-11: BD10-BD1Z] T00238 TARGETID T00238 T00238 TARGNAME NFKB messenger RNA (NFKB mRNA) T00238 INDICATI Phase 3 Ulcerative colitis [ICD-11: DD71] T00239 TARGETID T00239 T00239 TARGNAME Interleukin-4 (IL4) T00239 INDICATI Investigative Allergic/hypersensitivity disorder [ICD-11: 4A80-4A8Z] T00239 INDICATI Phase 2 Asthma [ICD-11: CA23] T00239 INDICATI Phase 1 Atopic eczema [ICD-11: EA80] T00239 INDICATI Phase 2 Idiopathic interstitial pneumonitis [ICD-11: CB03] T00239 INDICATI Phase 2 Myeloproliferative neoplasm [ICD-11: 2A20] T00239 INDICATI Phase 3 Pulmonary eosinophilia [ICD-11: CB02] T00239 INDICATI Phase 2 Systemic sclerosis [ICD-11: 4A42] T00254 TARGETID T00254 T00254 TARGNAME V-erbA-related protein 1 (NR1D1) T00254 INDICATI Preclinical Cardiomyopathy [ICD-11: BC43] T00254 INDICATI Preclinical Postoperative inflammation [ICD-11: 1A00-CA43] T00254 INDICATI Preclinical Solid tumour/cancer [ICD-11: 2A00-2F9Z] T00259 TARGETID T00259 T00259 TARGNAME HUAMN eIF4E-eIF4G interaction (eIF4E-eIF4G) T00259 INDICATI Investigative COVID-19 [ICD-11: 1D6Y] T00259 INDICATI Investigative Severe acute respiratory syndrome [ICD-11: 1D65] T00419 TARGETID T00419 T00419 TARGNAME Fast skeletal muscle troponin complex (TNNC2) T00419 INDICATI Phase 3 Motor neuron disease [ICD-11: 8B60] T00419 INDICATI Phase 2 Muscle disorder [ICD-11: FB32-FB3Z] T00419 INDICATI Phase 2 Muscular atrophy [ICD-11: 8B61] T00420 TARGETID T00420 T00420 TARGNAME Human immunodeficiency virus Rev protein (HIV rev) T00420 INDICATI Phase 1 Human immunodeficiency virus disease [ICD-11: 1C60-1C62] T00477 TARGETID T00477 T00477 TARGNAME Serine Racemase (SRR) T00477 INDICATI Investigative Neurodegenerative disorder [ICD-11: 8A20-8A23] T00484 TARGETID T00484 T00484 TARGNAME Interleukin 23 receptor (IL23R) T00484 INDICATI Investigative Diabetes mellitus [ICD-11: 5A10] T00484 INDICATI Investigative Indeterminate colitis [ICD-11: DD72] T00484 INDICATI Phase 3 Postoperative inflammation [ICD-11: 1A00-CA43] T00484 INDICATI Investigative Solid tumour/cancer [ICD-11: 2A00-2F9Z] T00494 TARGETID T00494 T00494 TARGNAME ATP-binding cassette transporter A1 (ABCA1) T00494 INDICATI Approved Coronary atherosclerosis [ICD-11: BA80] T00494 INDICATI Investigative Dyslipidemia [ICD-11: 5C80-5C81] T00494 INDICATI Discontinued in Phase 1 Inborn lipid metabolism error [ICD-11: 5C52] T00496 TARGETID T00496 T00496 TARGNAME Prostate apoptosis response-4 (PAWR) T00496 INDICATI Phase 2 Thrombosis [ICD-11: DB61-GB90] T00523 TARGETID T00523 T00523 TARGNAME Glucose transporter type 9 (GLUT9) T00523 INDICATI Phase 2 Gout [ICD-11: FA25] T00523 INDICATI Discontinued in Phase 2 Inborn purine/pyrimidine/nucleotide metabolism error [ICD-11: 5C55] T00663 TARGETID T00663 T00663 TARGNAME Stress-activated protein kinase JNK3 (JNK3) T00663 INDICATI Investigative CNS birth injury [ICD-11: KA40] T00749 TARGETID T00749 T00749 TARGNAME MEK kinase kinase 1 (MAP4K1) T00749 INDICATI Phase 1/2 Solid tumour/cancer [ICD-11: 2A00-2F9Z] T00750 TARGETID T00750 T00750 TARGNAME Galactoside 3(4)-L-fucosyltransferase (FUT3) T00750 INDICATI Phase 2 Fallopian tube cancer [ICD-11: 2C74] T00852 TARGETID T00852 T00852 TARGNAME Serine/threonine-protein kinase cot (COT) T00852 INDICATI Phase 1 Indeterminate colitis [ICD-11: DD72] T00884 TARGETID T00884 T00884 TARGNAME C-X-C chemokine receptor type 1 (CXCR1) T00884 INDICATI Phase 2 Chronic obstructive pulmonary disease [ICD-11: CA22] T00884 INDICATI Withdrawn from market Gout [ICD-11: FA25] T00884 INDICATI Phase 2 Indeterminate colitis [ICD-11: DD72] T00884 INDICATI Phase 2 Liver vascular disorder [ICD-11: DB98] T00884 INDICATI Phase 2 Medical/surgical procedure injury [ICD-11: PK80-PK81] T00884 INDICATI Phase 1 Melanoma [ICD-11: 2C30] T00884 INDICATI Phase 1 Myelodysplastic syndrome [ICD-11: 2A37] T00884 INDICATI Approved Pain [ICD-11: MG30-MG3Z] T00884 INDICATI Phase 1 Solid tumour/cancer [ICD-11: 2A00-2F9Z] T00884 INDICATI Phase 3 Transplant rejection [ICD-11: NE84] T00884 INDICATI Phase 2 Ulcerative colitis [ICD-11: DD71] T00890 TARGETID T00890 T00890 TARGNAME Hydroxycarboxylic acid receptor 3 (HCAR3) T00890 INDICATI Phase 2 Cardiovascular disease [ICD-11: BA00-BE2Z] T00890 INDICATI Phase 2 Dyslipidemia [ICD-11: 5C80-5C81] T00890 INDICATI Phase 2 Hyper-lipoproteinaemia [ICD-11: 5C80] T00890 INDICATI Clinical trial Psoriasis [ICD-11: EA90] T00895 TARGETID T00895 T00895 TARGNAME Protein kinase C epsilon (PRKCE) T00895 INDICATI Phase 2 Alzheimer disease [ICD-11: 8A20] T00895 INDICATI Approved Anxiety disorder [ICD-11: 6B00-6B0Z] T00895 INDICATI Discontinued in Phase 1 Liver vascular disorder [ICD-11: DB98] T00895 INDICATI Approved Malaria [ICD-11: 1F40-1F45] T00895 INDICATI Terminated Postoperative inflammation [ICD-11: 1A00-CA43] T00902 TARGETID T00902 T00902 TARGNAME Neurotrophin-4 (NTF4) T00902 INDICATI Terminated Central nervous system disease [ICD-11: 8A04-8D87] T00938 TARGETID T00938 T00938 TARGNAME Melanoma antigen gp75 (TYRP1) T00938 INDICATI Phase 1 Melanoma [ICD-11: 2C30] T00938 INDICATI Phase 2 Motor neuron disease [ICD-11: 8B60] T00938 INDICATI Phase 2 Multiple sclerosis [ICD-11: 8A40] T00938 INDICATI Phase 2 Tonus and reflex abnormality [ICD-11: MB47] T00972 TARGETID T00972 T00972 TARGNAME Human immunodeficiency virus Envelope glycoprotein gp120 (HIV gp120) T00972 INDICATI Approved Human immunodeficiency virus disease [ICD-11: 1C60-1C62] T01003 TARGETID T01003 T01003 TARGNAME Endoplasmic reticulum to nucleus signaling 1 (ERN1) T01003 INDICATI Phase 1/2 Breast cancer [ICD-11: 2C60-2C6Y] T01003 INDICATI Investigative Solid tumour/cancer [ICD-11: 2A00-2F9Z] T01011 TARGETID T01011 T01011 TARGNAME Aurora kinase (AURK) T01011 INDICATI Phase 2 Lung cancer [ICD-11: 2C25] T01110 TARGETID T01110 T01110 TARGNAME Colony stimulating factor-1 receptor (CSF-1R) T01110 INDICATI Phase 2 Bone/articular cartilage neoplasm [ICD-11: 2F7B] T01110 INDICATI Phase 2 Breast cancer [ICD-11: 2C60-2C6Y] T01110 INDICATI Phase 1/2 Diabetes mellitus [ICD-11: 5A10] T01110 INDICATI Phase 2 Hodgkin lymphoma [ICD-11: 2B30] T01110 INDICATI Phase 1 Inflammatory arthropathy [ICD-11: FA2Z] T01110 INDICATI Phase 2 Metastatic tumour [ICD-11: 2D50-2E2Z] T01110 INDICATI Phase 2 Rheumatoid arthritis [ICD-11: FA20] T01110 INDICATI Phase 2 Solid tumour/cancer [ICD-11: 2A00-2F9Z] T01141 TARGETID T01141 T01141 TARGNAME microRNA hsa-miR-191 (MIR191) T01141 INDICATI Investigative Liver cancer [ICD-11: 2C12] T01232 TARGETID T01232 T01232 TARGNAME T-cells (T-cells) T01232 INDICATI Phase 1/2 Acute myeloid leukaemia [ICD-11: 2A60] T01232 INDICATI Phase 2 Diabetes mellitus [ICD-11: 5A10] T01232 INDICATI Phase 2 Diffuse large B-cell lymphoma [ICD-11: 2A81] T01232 INDICATI Phase 2 Heart failure [ICD-11: BD10-BD1Z] T01232 INDICATI Phase 2 Hodgkin lymphoma [ICD-11: 2B30] T01232 INDICATI Phase 1/2 Immunodeficiency [ICD-11: 4A00-4A85] T01232 INDICATI Phase 2 Immunoproliferative disorder [ICD-11: 2B32] T01232 INDICATI Phase 1/2 Low bone mass disorder [ICD-11: FB83] T01232 INDICATI Phase 2 Lymphoma [ICD-11: 2A80-2A86] T01232 INDICATI Phase 1/2 Mature B-cell lymphoma [ICD-11: 2A85] T01232 INDICATI Phase 1 Multiple sclerosis [ICD-11: 8A40] T01232 INDICATI Phase 2 Renal cell carcinoma [ICD-11: 2C90] T01232 INDICATI Phase 1/2 Solid tumour/cancer [ICD-11: 2A00-2F9Z] T01232 INDICATI Phase 3 Transplant rejection [ICD-11: NE84] T01232 INDICATI Phase 1/2 Transplanted organ/tissue [ICD-11: QB63] T01271 TARGETID T01271 T01271 TARGNAME Fusion protein Bcr-Abl T315I mutant (Bcr-Abl T315I) T01271 INDICATI Investigative Solid tumour/cancer [ICD-11: 2A00-2F9Z] T01280 TARGETID T01280 T01280 TARGNAME Beta-site APP-cleaving enzyme 2 (BACE2) T01280 INDICATI Clinical trial Urinary system clinical sympton [ICD-11: MF8Y] T01283 TARGETID T01283 T01283 TARGNAME Tumor susceptibility gene protein 101 (TSG101) T01283 INDICATI Phase 1 Influenza [ICD-11: 1E30-1E32] T01318 TARGETID T01318 T01318 TARGNAME Plasmodium Dihydroorotate dehydrogenase (Malaria DHOdehase) T01318 INDICATI Approved Fungal infection [ICD-11: 1F29-1F2F] T01318 INDICATI Phase 1 Hepatitis virus infection [ICD-11: 1E50-1E51] T01318 INDICATI Approved Hyper-lipoproteinaemia [ICD-11: 5C80] T01318 INDICATI Phase 3 Lung cancer [ICD-11: 2C25] T01318 INDICATI Approved Malaria [ICD-11: 1F40-1F45] T01318 INDICATI Approved Multiple sclerosis [ICD-11: 8A40] T01318 INDICATI Investigative Nasopharyngeal cancer [ICD-11: 2B6B] T01318 INDICATI Approved Rheumatoid arthritis [ICD-11: FA20] T01358 TARGETID T01358 T01358 TARGNAME Cell cycle (CC) T01358 INDICATI Phase 2 Breast cancer [ICD-11: 2C60-2C6Y] T01385 TARGETID T01385 T01385 TARGNAME HUMAN valosin-containing protein p97 (VCP) T01385 INDICATI Investigative COVID-19 [ICD-11: 1D6Y] T01447 TARGETID T01447 T01447 TARGNAME NEDD8-activating enzyme (NAE) T01447 INDICATI Phase 2 BCR-ABL1-negative chronic myeloid leukaemia [ICD-11: 2A41] T01447 INDICATI Phase 3 Myelodysplastic syndrome [ICD-11: 2A37] T01447 INDICATI Investigative Nasopharyngeal cancer [ICD-11: 2B6B] T01447 INDICATI Phase 1 Solid tumour/cancer [ICD-11: 2A00-2F9Z] T01521 TARGETID T01521 T01521 TARGNAME Glutathione S-transferase omega-1 (GSTO-1) T01521 INDICATI Preclinical Solid tumour/cancer [ICD-11: 2A00-2F9Z] T01575 TARGETID T01575 T01575 TARGNAME Sphingosine-1-phosphate lyase 1 (SGPL1) T01575 INDICATI Phase 2 Congenital ichthyosis [ICD-11: EC20] T01575 INDICATI Terminated Diabetes mellitus [ICD-11: 5A10] T01575 INDICATI Phase 2 Rheumatoid arthritis [ICD-11: FA20] T01597 TARGETID T01597 T01597 TARGNAME Catalase (CAT) T01597 INDICATI Phase 1 Skin sensation disturbance [ICD-11: ME65] T01674 TARGETID T01674 T01674 TARGNAME CEP290 messenger RNA (CEP290 mRNA) T01674 INDICATI Phase 2/3 Inherited retinal dystrophy [ICD-11: 9B70] T01777 TARGETID T01777 T01777 TARGNAME Adrenergic receptor alpha-2C (ADRA2C) T01777 INDICATI Discontinued in Phase 2 Acute diabete complication [ICD-11: 5A2Y] T01777 INDICATI Phase 2 Alzheimer disease [ICD-11: 8A20] T01777 INDICATI Terminated Asthma [ICD-11: CA23] T01777 INDICATI Phase 2 Chronic arterial occlusive disease [ICD-11: BD4Z] T01777 INDICATI Phase 2 Chronic kidney disease [ICD-11: GB61] T01777 INDICATI Phase 3 Chronic pain [ICD-11: MG30] T01777 INDICATI Preclinical Coronavirus infection [ICD-11: 1D92] T01777 INDICATI Investigative Dementia [ICD-11: 6D80-6D8Z] T01777 INDICATI Discontinued in Phase 3 Depression [ICD-11: 6A70-6A7Z] T01777 INDICATI Phase 3 Dissociative neurological symptom disorder [ICD-11: 6B60] T01777 INDICATI Phase 2 General pain disorder [ICD-11: 8E43] T01777 INDICATI Terminated Genetic cardiac arrhythmia [ICD-11: BC65] T01777 INDICATI Approved Glaucoma [ICD-11: 9C61] T01777 INDICATI Discontinued in Phase 3 Heart failure [ICD-11: BD10-BD1Z] T01777 INDICATI Approved Herpes simplex infection [ICD-11: 1F00] T01777 INDICATI Approved Hypertension [ICD-11: BA00-BA04] T01777 INDICATI Approved Hypotension [ICD-11: BA20-BA21] T01777 INDICATI Phase 2 Non-specific cutaneous vascular sympton [ICD-11: ME64] T01777 INDICATI Approved Obesity [ICD-11: 5B80-5B81] T01777 INDICATI Discontinued in Phase 3 Orgasmic dysfunction [ICD-11: HA02] T01777 INDICATI Phase 2 Pain [ICD-11: MG30-MG3Z] T01777 INDICATI Discontinued in Preregistration Peptic ulcer [ICD-11: DA61] T01777 INDICATI Phase 3 Post-traumatic stress disorder [ICD-11: 6B40] T01777 INDICATI Discontinued in Phase 2 Prostate disease [ICD-11: GA91] T01777 INDICATI Discontinued in Phase 2 Sexual dysfunction [ICD-11: HA00-HA01] T01777 INDICATI Approved Substance abuse [ICD-11: 6C40] T01777 INDICATI Investigative Unspecific body region injury [ICD-11: ND56] T01777 INDICATI Investigative Unspecific substance harmful effect [ICD-11: NE6Z] T01777 INDICATI Phase 4 Vasomotor/allergic rhinitis [ICD-11: CA08] T01788 TARGETID T01788 T01788 TARGNAME COVID-19 non-structural protein 14 (nsp14) T01788 INDICATI Investigative COVID-19 [ICD-11: 1D6Y] T01822 TARGETID T01822 T01822 TARGNAME Haematin (HA) T01822 INDICATI Phase 2 Malaria [ICD-11: 1F40-1F45] T01840 TARGETID T01840 T01840 TARGNAME Protease unspecific (PRO) T01840 INDICATI Approved Alpha-1-antitrypsin deficiency [ICD-11: 5C5A] T01840 INDICATI Terminated Alzheimer disease [ICD-11: 8A20] T01840 INDICATI Phase 2 Atopic eczema [ICD-11: EA80] T01840 INDICATI Phase 1 Chronic obstructive pulmonary disease [ICD-11: CA22] T01840 INDICATI Phase 2 Coagulation defect [ICD-11: 3B10] T01840 INDICATI Terminated Cystic fibrosis [ICD-11: CA25] T01840 INDICATI Terminated Rheumatoid arthritis [ICD-11: FA20] T01840 INDICATI Terminated Solid tumour/cancer [ICD-11: 2A00-2F9Z] T01851 TARGETID T01851 T01851 TARGNAME Integrin beta-1 (ITGB1) T01851 INDICATI Phase 1 Brain cancer [ICD-11: 2A00] T01851 INDICATI Phase 1/2 Lung cancer [ICD-11: 2C25] T01851 INDICATI Phase 1 Retinopathy [ICD-11: 9B71] T01865 TARGETID T01865 T01865 TARGNAME Plasmodium Hexose transporter 1 (Malaria ht1) T01865 INDICATI Investigative Malaria [ICD-11: 1F40-1F45] T01908 TARGETID T01908 T01908 TARGNAME Tissue kallikrein (KLK2) T01908 INDICATI Discontinued in Phase 2 Atopic eczema [ICD-11: EA80] T01908 INDICATI Phase 2 Epidermal dysplasias [ICD-11: EK90] T01908 INDICATI Phase 2/3 Innate/adaptive immunodeficiency [ICD-11: 4A00] T01908 INDICATI Phase 1 Prostate cancer [ICD-11: 2C82] T01943 TARGETID T01943 T01943 TARGNAME Plasmodium Beta-hydroxyacyl-ACP dehydratase (Malaria FabZ) T01943 INDICATI Phase 3 Hepatic fibrosis/cirrhosis [ICD-11: DB93] T01973 TARGETID T01973 T01973 TARGNAME Macrophage-stimulating protein receptor (RON) T01973 INDICATI Phase 1/2 Alzheimer disease [ICD-11: 8A20] T01973 INDICATI Investigative Solid tumour/cancer [ICD-11: 2A00-2F9Z] T02001 TARGETID T02001 T02001 TARGNAME Phosphodiesterase 4D (PDE4D) T02001 INDICATI Investigative Acute upper respiratory infection [ICD-11: CA07] T02001 INDICATI Terminated Allergic/hypersensitivity disorder [ICD-11: 4A80-4A8Z] T02001 INDICATI Phase 2 Alzheimer disease [ICD-11: 8A20] T02001 INDICATI Terminated Amyloidosis [ICD-11: 5D00] T02001 INDICATI Phase 3 Asthma [ICD-11: CA23] T02001 INDICATI Phase 2 Atopic eczema [ICD-11: EA80] T02001 INDICATI Phase 1 Choreiform disorder [ICD-11: 8A01] T02001 INDICATI Terminated Chronic arterial occlusive disease [ICD-11: BD4Z] T02001 INDICATI Phase 2 Chronic obstructive pulmonary disease [ICD-11: CA22] T02001 INDICATI Phase 2 Crohn disease [ICD-11: DD70] T02001 INDICATI Investigative Mature B-cell leukaemia [ICD-11: 2A82] T02001 INDICATI Phase 3 Mild neurocognitive disorder [ICD-11: 6D71] T02001 INDICATI Phase 1 Mood disorder [ICD-11: 6A60-6E23] T02001 INDICATI Discontinued in Phase 2 Multiple sclerosis [ICD-11: 8A40] T02001 INDICATI Discontinued in Phase 1 Mycosis fungoides [ICD-11: 2B01] T02001 INDICATI Phase 1 Parkinsonism [ICD-11: 8A00] T02001 INDICATI Investigative Pneumonia [ICD-11: CA40] T02001 INDICATI Investigative Postoperative inflammation [ICD-11: 1A00-CA43] T02001 INDICATI Phase 2 Psoriasis [ICD-11: EA90] T02001 INDICATI Phase 2 Rheumatoid arthritis [ICD-11: FA20] T02001 INDICATI Approved Tonus and reflex abnormality [ICD-11: MB47] T02001 INDICATI Investigative Vitamin deficiency [ICD-11: 5B55-5B5F] T02024 TARGETID T02024 T02024 TARGNAME HUMAN inosine-5'-monophosphate dehydrogenase 1 (IMPDH1) T02024 INDICATI Investigative COVID-19 [ICD-11: 1D6Y] T02024 INDICATI Approved Hepatitis virus infection [ICD-11: 1E50-1E51] T02024 INDICATI Investigative Middle East Respiratory Syndrome [ICD-11: 1D64] T02024 INDICATI Investigative Severe acute respiratory syndrome [ICD-11: 1D65] T02107 TARGETID T02107 T02107 TARGNAME COVID-19 replicase polyprotein 1ab (pp1ab) T02107 INDICATI Investigative COVID-19 [ICD-11: 1D6Y] T02119 TARGETID T02119 T02119 TARGNAME N-acetylgalactosamine-4-sulfatase (G4S) T02119 INDICATI Approved Lysosomal disease [ICD-11: 5C56] T02122 TARGETID T02122 T02122 TARGNAME HUAMN monocyte differentiation antigen CD14 (CD14) T02122 INDICATI Phase 2 COVID-19 [ICD-11: 1D6Y] T02134 TARGETID T02134 T02134 TARGNAME Glutamate--cysteine ligase modifier (GCLM) T02134 INDICATI Investigative Malaria [ICD-11: 1F40-1F45] T02134 INDICATI Investigative Solid tumour/cancer [ICD-11: 2A00-2F9Z] T02203 TARGETID T02203 T02203 TARGNAME HUAMN serine protease factor Xa (SERPINA5) T02203 INDICATI Preclinical COVID-19 [ICD-11: 1D6Y] T02228 TARGETID T02228 T02228 TARGNAME Streptococcus Topoisomerase IV A (Stre-coc parC) T02228 INDICATI Investigative Bacterial infection [ICD-11: 1A00-1C4Z] T02228 INDICATI Phase 3 Otitis externa [ICD-11: AA00-AA13] T02246 TARGETID T02246 T02246 TARGNAME Iron (Fe) T02246 INDICATI Phase 2 Anemia [ICD-11: 3A00-3A9Z] T02246 INDICATI Phase 1 Cardiovascular disease [ICD-11: BA00-BE2Z] T02246 INDICATI Phase 3 Iron deficiency anaemia [ICD-11: 3A00] T02246 INDICATI Approved Low bone mass disorder [ICD-11: FB83] T02246 INDICATI Approved Mineral absorption/transport disorder [ICD-11: 5C64] T02246 INDICATI Phase 1 Solid tumour/cancer [ICD-11: 2A00-2F9Z] T02246 INDICATI Approved Thalassaemia [ICD-11: 3A50] T02258 TARGETID T02258 T02258 TARGNAME DNA-dependent DNA polymerase (DPOL) T02258 INDICATI Phase 3 Solid tumour/cancer [ICD-11: 2A00-2F9Z] T02262 TARGETID T02262 T02262 TARGNAME Calcium-activated potassium channel KCa4.1 (KCNT1) T02262 INDICATI Phase 2 Acute myeloid leukaemia [ICD-11: 2A60] T02262 INDICATI Phase 2 Hodgkin lymphoma [ICD-11: 2B30] T02318 TARGETID T02318 T02318 TARGNAME B-cell-activating factor (TNFSF13B) T02318 INDICATI Approved Lupus erythematosus [ICD-11: 4A40] T02318 INDICATI Discontinued in Phase 1 Lymphoma [ICD-11: 2A80-2A86] T02318 INDICATI Phase 3 Multiple myeloma [ICD-11: 2A83] T02318 INDICATI Discontinued in Phase 2 Rheumatoid arthritis [ICD-11: FA20] T02318 INDICATI Discontinued in Phase 2 Thrombocytopenia [ICD-11: 3B64] T02333 TARGETID T02333 T02333 TARGNAME Growth hormone receptor (GHR) T02333 INDICATI Phase 1 Binge eating disorder [ICD-11: 6B82] T02333 INDICATI Discontinued in Phase 2 Obesity [ICD-11: 5B80-5B81] T02333 INDICATI Approved Pituitary gland disorder [ICD-11: 5A60-5A61] T02333 INDICATI Phase 1 Short stature [ICD-11: 5B11] T02389 TARGETID T02389 T02389 TARGNAME HUMAN cysteinyl leukotriene receptor (CysLTR) T02389 INDICATI Phase 2/3 COVID-19 [ICD-11: 1D6Y] T02392 TARGETID T02392 T02392 TARGNAME HUMAN dipeptidyl peptidase 1 (CTSC) T02392 INDICATI Preclinical COVID-19 [ICD-11: 1D6Y] T02469 TARGETID T02469 T02469 TARGNAME Phosphatidylinositol-3-phosphate 5-kinase (PIP5K3) T02469 INDICATI Phase 2 Malignant haematopoietic neoplasm [ICD-11: 2B33] T02469 INDICATI Phase 2 Mature B-cell leukaemia [ICD-11: 2A82] T02506 TARGETID T02506 T02506 TARGNAME HUMAN estrogen receptor (ESR1) T02506 INDICATI Investigative COVID-19 [ICD-11: 1D6Y] T02532 TARGETID T02532 T02532 TARGNAME T-cell surface antigen CD2 (CD2) T02532 INDICATI Phase 2 Lymphoma [ICD-11: 2A80-2A86] T02532 INDICATI Discontinued in Phase 2 Psoriasis [ICD-11: EA90] T02546 TARGETID T02546 T02546 TARGNAME Voltage-gated sodium channel alpha Nav1.4 (SCN4A) T02546 INDICATI Discontinued in Phase 2 Dissociative neurological symptom disorder [ICD-11: 6B60] T02546 INDICATI Phase 3 Musculoskeletal disorder [ICD-11: FA00-FC0Z] T02546 INDICATI Investigative Pain [ICD-11: MG30-MG3Z] T02551 TARGETID T02551 T02551 TARGNAME Dopamine D3 receptor (D3R) T02551 INDICATI Phase 1 Alzheimer disease [ICD-11: 8A20] T02551 INDICATI Phase 1 Attention deficit hyperactivity disorder [ICD-11: 6A05] T02551 INDICATI Approved Bipolar disorder [ICD-11: 6A60] T02551 INDICATI Phase 2 Brain cancer [ICD-11: 2A00] T02551 INDICATI Discontinued in Phase 2 Cocaine use disorder [ICD-11: 6C45] T02551 INDICATI Phase 1 Depression [ICD-11: 6A70-6A7Z] T02551 INDICATI Phase 2 Endometrial cancer [ICD-11: 2C76] T02551 INDICATI Phase 2 Gastroduodenal motor/secretory disorder [ICD-11: DA41] T02551 INDICATI Phase 1/2 Leukaemia [ICD-11: 2A60-2B33] T02551 INDICATI Phase 1/2 Lymphoma [ICD-11: 2A80-2A86] T02551 INDICATI Phase 2 Multiple myeloma [ICD-11: 2A83] T02551 INDICATI Investigative Nasopharyngeal cancer [ICD-11: 2B6B] T02551 INDICATI Terminated Nausea/vomiting [ICD-11: MD90] T02551 INDICATI Terminated Nicotine use disorder [ICD-11: 6C4A] T02551 INDICATI Investigative Oesophagus motility disorder [ICD-11: DA21] T02551 INDICATI Discontinued in Phase 3 Orgasmic dysfunction [ICD-11: HA02] T02551 INDICATI Approved Parkinsonism [ICD-11: 8A00] T02551 INDICATI Phase 2 Psychoactive substances use disorder [ICD-11: 6C4G] T02551 INDICATI Discontinued in Phase 2 Psychotic disorder [ICD-11: 6A20-6A25] T02551 INDICATI Phase 2 Respiratory infection [ICD-11: CA07-CA4Z] T02551 INDICATI Phase 3 Schizophrenia [ICD-11: 6A20] T02551 INDICATI Phase 1 Sexual dysfunction [ICD-11: HA00-HA01] T02551 INDICATI Phase 1 Solid tumour/cancer [ICD-11: 2A00-2F9Z] T02551 INDICATI Phase 2 Stomach cancer [ICD-11: 2B72] T02551 INDICATI Terminated Unspecific substance use disorder [ICD-11: 6C4Z] T02562 TARGETID T02562 T02562 TARGNAME Prostaglandin E synthase (PTGES) T02562 INDICATI Phase 1 Alzheimer disease [ICD-11: 8A20] T02562 INDICATI Patented Circulatory system disease [ICD-11: BE2Z] T02562 INDICATI Patented Joint pain [ICD-11: ME82] T02562 INDICATI Patented Solid tumour/cancer [ICD-11: 2A00-2F9Z] T02584 TARGETID T02584 T02584 TARGNAME Mycobacterium Leucine-tRNA ligase (MycB leuS) T02584 INDICATI Phase 2 HIV-infected patients with tuberculosis [ICD-11: 1B10-1B14] T02591 TARGETID T02591 T02591 TARGNAME Human immunodeficiency virus Envelope glycoprotein gp160 (HIV env) T02591 INDICATI Phase 1 Human immunodeficiency virus disease [ICD-11: 1C60-1C62] T02598 TARGETID T02598 T02598 TARGNAME Leukocyte (WBC) T02598 INDICATI Phase 1 Postoperative inflammation [ICD-11: 1A00-CA43] T02617 TARGETID T02617 T02617 TARGNAME Transferrin (TF) T02617 INDICATI Phase 1 Solid tumour/cancer [ICD-11: 2A00-2F9Z] T02653 TARGETID T02653 T02653 TARGNAME HUMAN mineralocorticoid receptor (MR) T02653 INDICATI Investigative COVID-19 [ICD-11: 1D6Y] T02677 TARGETID T02677 T02677 TARGNAME Apoptosis inhibitor survivin (BIRC5) T02677 INDICATI Phase 2 Brain cancer [ICD-11: 2A00] T02677 INDICATI Phase 1/2 Lung cancer [ICD-11: 2C25] T02677 INDICATI Phase 1 Multiple myeloma [ICD-11: 2A83] T02677 INDICATI Phase 3 Solid tumour/cancer [ICD-11: 2A00-2F9Z] T02702 TARGETID T02702 T02702 TARGNAME Bacterial Dihydrofolate reductase (Bact DHFR) T02702 INDICATI Phase 3 Bacterial infection [ICD-11: 1A00-1C4Z] T02702 INDICATI Phase 2 Pneumonia [ICD-11: CA40] T02703 TARGETID T02703 T02703 TARGNAME Nitric-oxide synthase inducible (NOS2) T02703 INDICATI Discontinued in Phase 1 Arteries/arterioles disorder [ICD-11: BD52] T02703 INDICATI Phase 2 Asthma [ICD-11: CA23] T02703 INDICATI Phase 2 Bowel habit change [ICD-11: ME05] T02703 INDICATI Phase 2 Cardiovascular disease [ICD-11: BA00-BE2Z] T02703 INDICATI Phase 2/3 Chronic kidney disease [ICD-11: GB61] T02703 INDICATI Phase 1/2 Coronary atherosclerosis [ICD-11: BA80] T02703 INDICATI Discontinued in Phase 2 Insulin-resistance syndrome [ICD-11: 5A44] T02703 INDICATI Phase 3 Osteoarthritis [ICD-11: FA00-FA05] T02703 INDICATI Phase 2 Pain [ICD-11: MG30-MG3Z] T02703 INDICATI Investigative Postoperative inflammation [ICD-11: 1A00-CA43] T02703 INDICATI Phase 1 Retinopathy [ICD-11: 9B71] T02703 INDICATI Discontinued in Phase 2 Rheumatoid arthritis [ICD-11: FA20] T02703 INDICATI Phase 3 Sepsis [ICD-11: 1G40-1G41] T02703 INDICATI Phase 3 Solid tumour/cancer [ICD-11: 2A00-2F9Z] T02719 TARGETID T02719 T02719 TARGNAME Metabotropic glutamate receptor 3 (mGluR3) T02719 INDICATI Phase 2 Alzheimer disease [ICD-11: 8A20] T02719 INDICATI Discontinued in Phase 3 Anxiety disorder [ICD-11: 6B00-6B0Z] T02719 INDICATI Phase 2 Depression [ICD-11: 6A70-6A7Z] T02719 INDICATI Discontinued in Phase 2 Mood disorder [ICD-11: 6A60-6E23] T02719 INDICATI Phase 2 Obesity [ICD-11: 5B80-5B81] T02719 INDICATI Phase 2 Psychotic disorder [ICD-11: 6A20-6A25] T02719 INDICATI Phase 3 Schizophrenia [ICD-11: 6A20] T02728 TARGETID T02728 T02728 TARGNAME Neurotensin receptor type 1 (NTSR1) T02728 INDICATI Terminated Acute/chronic pain [ICD-11: MG30-MG31] T02728 INDICATI Investigative Dissociative neurological symptom disorder [ICD-11: 6B60] T02728 INDICATI Phase 2/3 Indeterminate colitis [ICD-11: DD72] T02728 INDICATI Terminated Pain [ICD-11: MG30-MG3Z] T02728 INDICATI Investigative Substance abuse [ICD-11: 6C40] T02752 TARGETID T02752 T02752 TARGNAME C-C chemokine receptor type 3 (CCR3) T02752 INDICATI Discontinued in Phase 1 Asthma [ICD-11: CA23] T02752 INDICATI Phase 2 Parkinsonism [ICD-11: 8A00] T02752 INDICATI Discontinued in Phase 1 Vasomotor/allergic rhinitis [ICD-11: CA08] T02777 TARGETID T02777 T02777 TARGNAME ATP-binding cassette transporter C9 (ABCC9) T02777 INDICATI Approved Acute diabete complication [ICD-11: 5A2Y] T02777 INDICATI Approved Angina pectoris [ICD-11: BA40] T02777 INDICATI Discontinued in Phase 1 Multiple sclerosis [ICD-11: 8A40] T02777 INDICATI Approved Type 2 diabetes mellitus [ICD-11: 5A11] T02779 TARGETID T02779 T02779 TARGNAME Dystrophin nonsense mutant (DMD) T02779 INDICATI Phase 3 Cystic fibrosis [ICD-11: CA25] T02779 INDICATI Phase 2 Epilepsy/seizure [ICD-11: 8A61-8A6Z] T02779 INDICATI Phase 1 Eye anterior segment structural developmental anomaly [ICD-11: LA11] T02779 INDICATI Phase 1 Lysosomal disease [ICD-11: 5C56] T02779 INDICATI Phase 2 Muscular dystrophy [ICD-11: 8C70] T02808 TARGETID T02808 T02808 TARGNAME Interferon-beta (IFNB1) T02808 INDICATI Phase 1 Brain cancer [ICD-11: 2A00] T02808 INDICATI Terminated Diabetes mellitus [ICD-11: 5A10] T02808 INDICATI Phase 3 Intrathoracic organs injury [ICD-11: NB32] T02808 INDICATI Phase 1 Lupus erythematosus [ICD-11: 4A40] T02808 INDICATI Approved Multiple sclerosis [ICD-11: 8A40] T02808 INDICATI Phase 2 Rheumatoid arthritis [ICD-11: FA20] T02808 INDICATI Phase 2 Skin fungal infection disorder [ICD-11: EA60] T02808 INDICATI Approved Type 2 diabetes mellitus [ICD-11: 5A11] T02918 TARGETID T02918 T02918 TARGNAME HUMAN phosphatidylinositol 3-phosphate 5-kinase (PIKfyve) T02918 INDICATI Preclinical COVID-19 [ICD-11: 1D6Y] T02957 TARGETID T02957 T02957 TARGNAME HUMAN programmed cell death protein 1 (PD-1) T02957 INDICATI Investigative COVID-19 [ICD-11: 1D6Y] T02974 TARGETID T02974 T02974 TARGNAME Interleukin 1 receptor accessory protein (IL1RAP) T02974 INDICATI Phase 1 Lung cancer [ICD-11: 2C25] T03006 TARGETID T03006 T03006 TARGNAME Acetylcholine release (Ach rele) T03006 INDICATI Approved Cervical cancer [ICD-11: 2C77] T03006 INDICATI Discontinued in Phase 1 Mild neurocognitive disorder [ICD-11: 6D71] T03006 INDICATI Discontinued in Phase 1 Postoperative inflammation [ICD-11: 1A00-CA43] T03046 TARGETID T03046 T03046 TARGNAME Mutated KRAS (mKRAS) T03046 INDICATI Phase 2 Pancreatic cancer [ICD-11: 2C10] T03189 TARGETID T03189 T03189 TARGNAME Tumor expressed melanoma antigen (PRAME) T03189 INDICATI Phase 1 Malignant haematopoietic neoplasm [ICD-11: 2B33] T03189 INDICATI Phase 1/2 Solid tumour/cancer [ICD-11: 2A00-2F9Z] T03279 TARGETID T03279 T03279 TARGNAME Ribosomal protein S6 kinase alpha-3 (RSK3) T03279 INDICATI Preclinical Mature B-cell leukaemia [ICD-11: 2A82] T03313 TARGETID T03313 T03313 TARGNAME Interleukin 2 receptor alpha (IL2RA) T03313 INDICATI Terminated Diabetes mellitus [ICD-11: 5A10] T03313 INDICATI Phase 1 Hodgkin lymphoma [ICD-11: 2B30] T03313 INDICATI Phase 2 Human immunodeficiency virus disease [ICD-11: 1C60-1C62] T03313 INDICATI Phase 2 Mature B-cell leukaemia [ICD-11: 2A82] T03313 INDICATI Phase 1 Solid tumour/cancer [ICD-11: 2A00-2F9Z] T03313 INDICATI Approved Transplant rejection [ICD-11: NE84] T03346 TARGETID T03346 T03346 TARGNAME Interleukin 4 receptor alpha (IL4R) T03346 INDICATI Phase 3 Asthma [ICD-11: CA23] T03346 INDICATI Approved Atopic eczema [ICD-11: EA80] T03346 INDICATI Phase 2 Idiopathic interstitial pneumonitis [ICD-11: CB03] T03346 INDICATI Phase 2 Solid tumour/cancer [ICD-11: 2A00-2F9Z] T03346 INDICATI Phase 2 Systemic sclerosis [ICD-11: 4A42] T03403 TARGETID T03403 T03403 TARGNAME Prostaglandin G/H synthase (COX) T03403 INDICATI Discontinued in Phase 1 Asthma [ICD-11: CA23] T03403 INDICATI Phase 2 Atopic eczema [ICD-11: EA80] T03403 INDICATI Phase 3 Cardiovascular disease [ICD-11: BA00-BE2Z] T03403 INDICATI Approved Cerebral ischaemia [ICD-11: 8B1Z] T03403 INDICATI Discontinued in Phase 2 Chemotherapy/radiotherapy-induced mucositis [ICD-11: DA42-DA60] T03403 INDICATI Discontinued in Phase 2 Female pelvic pain [ICD-11: GA34] T03403 INDICATI Approved Hyper-lipoproteinaemia [ICD-11: 5C80] T03403 INDICATI Discontinued in Phase 2 Immune system disease [ICD-11: 4A01-4B41] T03403 INDICATI Phase 1 Indeterminate colitis [ICD-11: DD72] T03403 INDICATI Approved Inflammatory spondyloarthritis [ICD-11: FA92] T03403 INDICATI Approved Inherited coagulation factor deficiency [ICD-11: 3B14] T03403 INDICATI Approved Joint pain [ICD-11: ME82] T03403 INDICATI Approved Migraine [ICD-11: 8A80] T03403 INDICATI Approved Myocardial infarction [ICD-11: BA41-BA43] T03403 INDICATI Approved Osteoarthritis [ICD-11: FA00-FA05] T03403 INDICATI Approved Otitis media [ICD-11: AA80-AB0Z] T03403 INDICATI Approved Pain [ICD-11: MG30-MG3Z] T03403 INDICATI Phase 2 Parkinsonism [ICD-11: 8A00] T03403 INDICATI Approved Postoperative inflammation [ICD-11: 1A00-CA43] T03403 INDICATI Discontinued in Phase 3 Qualitative platelet defect [ICD-11: 3B62] T03403 INDICATI Discontinued in Phase 2 Reactive arthropathy [ICD-11: FA11] T03403 INDICATI Approved Rheumatoid arthritis [ICD-11: FA20] T03403 INDICATI Approved Spinal pain [ICD-11: ME84] T03403 INDICATI Discontinued in Phase 2 Type 2 diabetes mellitus [ICD-11: 5A11] T03403 INDICATI Discontinued in Phase 2 Urinary system disease [ICD-11: GC2Z] T03410 TARGETID T03410 T03410 TARGNAME Mycobacterium Membrane protein mmpL3 (MycB mmpL3) T03410 INDICATI Phase 1 Asthma [ICD-11: CA23] T03410 INDICATI Phase 2 Bacterial infection [ICD-11: 1A00-1C4Z] T03410 INDICATI Phase 2 HIV-infected patients with tuberculosis [ICD-11: 1B10-1B14] T03485 TARGETID T03485 T03485 TARGNAME CFB messenger RNA (CFB mRNA) T03485 INDICATI Phase 2 Urinary system clinical sympton [ICD-11: MF8Y] T03500 TARGETID T03500 T03500 TARGNAME Matrix metalloproteinase-12 (MMP-12) T03500 INDICATI Investigative Aneurysm/dissection [ICD-11: BD50] T03500 INDICATI Investigative Arterial occlusive disease [ICD-11: BD40] T03500 INDICATI Phase 1 Asthma [ICD-11: CA23] T03500 INDICATI Discontinued in Phase 2 Chronic obstructive pulmonary disease [ICD-11: CA22] T03500 INDICATI Discontinued in Phase 2 Corneal disease [ICD-11: 9A76-9A78] T03500 INDICATI Phase 1 Lung cancer [ICD-11: 2C25] T03500 INDICATI Discontinued in Phase 1 Postoperative inflammation [ICD-11: 1A00-CA43] T03500 INDICATI Phase 1 Renal cell carcinoma [ICD-11: 2C90] T03513 TARGETID T03513 T03513 TARGNAME Dopamine receptor (DR) T03513 INDICATI Phase 2 Brain cancer [ICD-11: 2A00] T03513 INDICATI Phase 2 Endometrial cancer [ICD-11: 2C76] T03513 INDICATI Phase 3 Gastroduodenal motor/secretory disorder [ICD-11: DA41] T03513 INDICATI Phase 1/2 Leukaemia [ICD-11: 2A60-2B33] T03513 INDICATI Phase 1/2 Lymphoma [ICD-11: 2A80-2A86] T03513 INDICATI Phase 2 Multiple myeloma [ICD-11: 2A83] T03513 INDICATI Phase 3 Parkinsonism [ICD-11: 8A00] T03513 INDICATI Phase 2 Respiratory infection [ICD-11: CA07-CA4Z] T03513 INDICATI Phase 4 Restless legs syndrome [ICD-11: 7A80] T03513 INDICATI Phase 1 Solid tumour/cancer [ICD-11: 2A00-2F9Z] T03513 INDICATI Phase 2 Stomach cancer [ICD-11: 2B72] T03573 TARGETID T03573 T03573 TARGNAME Immunoglobulin gamma Fc receptor IIB (FCGR2B) T03573 INDICATI Phase 1 Autoimmune disease [ICD-11: 4A40-4A45] T03573 INDICATI Phase 1/2 B-cell lymphoma [ICD-11: 2A86] T03573 INDICATI Phase 2 Diabetes mellitus [ICD-11: 5A10] T03573 INDICATI Phase 1/2 Leukaemia [ICD-11: 2A60-2B33] T03573 INDICATI Phase 2 Lupus erythematosus [ICD-11: 4A40] T03573 INDICATI Phase 1/2 Mature B-cell leukaemia [ICD-11: 2A82] T03573 INDICATI Phase 1/2 Rheumatoid arthritis [ICD-11: FA20] T03573 INDICATI Phase 2 Sjogren syndrome [ICD-11: 4A43] T03634 TARGETID T03634 T03634 TARGNAME CREB-binding protein (CREBBP) T03634 INDICATI Phase 1/2 Acute myeloid leukaemia [ICD-11: 2A60] T03634 INDICATI Phase 1 Prostate cancer [ICD-11: 2C82] T03634 INDICATI Phase 1/2 Solid tumour/cancer [ICD-11: 2A00-2F9Z] T03634 INDICATI Phase 1/2 Systemic sclerosis [ICD-11: 4A42] T03644 TARGETID T03644 T03644 TARGNAME Synuclein alpha (SNCA) T03644 INDICATI Phase 1 Alzheimer disease [ICD-11: 8A20] T03644 INDICATI Phase 2 Autonomic nervous system disorder [ICD-11: 8D87] T03644 INDICATI Phase 2 Parkinsonism [ICD-11: 8A00] T03661 TARGETID T03661 T03661 TARGNAME Adenosine deaminase (ADA) T03661 INDICATI Approved Adaptive immunity immunodeficiency [ICD-11: 4A01] T03661 INDICATI Preregistration Chronic pain [ICD-11: MG30] T03661 INDICATI Phase 3 Immunodeficiency [ICD-11: 4A00-4A85] T03661 INDICATI Approved Malignant haematopoietic neoplasm [ICD-11: 2B33] T03661 INDICATI Approved Mature B-cell leukaemia [ICD-11: 2A82] T03661 INDICATI Phase 3 Multiple sclerosis [ICD-11: 8A40] T03672 TARGETID T03672 T03672 TARGNAME Cellular disintegrin-related protein (ADAM9) T03672 INDICATI Phase 1 Solid tumour/cancer [ICD-11: 2A00-2F9Z] T03691 TARGETID T03691 T03691 TARGNAME Leukotriene A-4 hydrolase (LTA4H) T03691 INDICATI Approved Acute myeloid leukaemia [ICD-11: 2A60] T03691 INDICATI Phase 1 Chronic skin disorder [ICD-11: ME63] T03691 INDICATI Discontinued in Phase 2 Myocardial infarction [ICD-11: BA41-BA43] T03691 INDICATI Investigative Postoperative inflammation [ICD-11: 1A00-CA43] T03691 INDICATI Phase 2 Ulcerative colitis [ICD-11: DD71] T03755 TARGETID T03755 T03755 TARGNAME Apoptosis regulator Bcl-W (BCL-W) T03755 INDICATI Phase 2 Mature B-cell leukaemia [ICD-11: 2A82] T03755 INDICATI Phase 3 Myeloproliferative neoplasm [ICD-11: 2A20] T03755 INDICATI Discontinued in Phase 2 Solid tumour/cancer [ICD-11: 2A00-2F9Z] T03818 TARGETID T03818 T03818 TARGNAME PPAR-gamma messenger RNA (PPARG mRNA) T03818 INDICATI Phase 2 Pulmonary hypertension [ICD-11: BB01] T03818 INDICATI Phase 3 Sjogren syndrome [ICD-11: 4A43] T03818 INDICATI Terminated Type 2 diabetes mellitus [ICD-11: 5A11] T03871 TARGETID T03871 T03871 TARGNAME H-ras messenger RNA (HRAS mRNA) T03871 INDICATI Investigative Solid tumour/cancer [ICD-11: 2A00-2F9Z] T03896 TARGETID T03896 T03896 TARGNAME Hepatitis C virus Serine protease NS3/4A (HCV NS3/4A) T03896 INDICATI Approved Hepatitis virus infection [ICD-11: 1E50-1E51] T03917 TARGETID T03917 T03917 TARGNAME Sodium/potassium-transporting ATPase (SPT ATPase) T03917 INDICATI Approved Cardiac arrhythmia [ICD-11: BC9Z] T03917 INDICATI Discontinued in Phase 2 Cardiovascular disease [ICD-11: BA00-BE2Z] T03917 INDICATI Approved Dental disease [ICD-11: DA08] T03917 INDICATI Terminated Genetic cardiac arrhythmia [ICD-11: BC65] T03917 INDICATI Approved Heart failure [ICD-11: BD10-BD1Z] T03917 INDICATI Phase 2 Hypertension [ICD-11: BA00-BA04] T03917 INDICATI Phase 2 Pancreatic cancer [ICD-11: 2C10] T03917 INDICATI Phase 2 Solid tumour/cancer [ICD-11: 2A00-2F9Z] T03963 TARGETID T03963 T03963 TARGNAME Heat shock protein 90 (HSP90) T03963 INDICATI Phase 1 Acute myeloid leukaemia [ICD-11: 2A60] T03963 INDICATI Phase 2 Asthma [ICD-11: CA23] T03963 INDICATI Phase 1 COVID-19 [ICD-11: 1D6Y] T03963 INDICATI Phase 1 Malignant haematopoietic neoplasm [ICD-11: 2B33] T03963 INDICATI Phase 1 Motor neuron disease [ICD-11: 8B60] T03963 INDICATI Phase 2 Multiple sclerosis [ICD-11: 8A40] T03963 INDICATI Phase 1 Neuropathy [ICD-11: 8C0Z] T03985 TARGETID T03985 T03985 TARGNAME Pneumocystis jirovecii DNA topoisomerase 2 (PJ top2) T03985 INDICATI Discontinued in Phase 1 Human immunodeficiency virus disease [ICD-11: 1C60-1C62] T04079 TARGETID T04079 T04079 TARGNAME Plasmodial phospholipid metabolism (PPP metab) T04079 INDICATI Phase 2 Malaria [ICD-11: 1F40-1F45] T04084 TARGETID T04084 T04084 TARGNAME ERBB3 messenger RNA (ERBB3 mRNA) T04084 INDICATI Investigative Solid tumour/cancer [ICD-11: 2A00-2F9Z] T04321 TARGETID T04321 T04321 TARGNAME Staphylococcus Alpha-hemolysin (Stap-coc hly) T04321 INDICATI Phase 3 Medical/surgical procedure injury [ICD-11: PK80-PK81] T04321 INDICATI Phase 3 Phlegmy cough [ICD-11: SA80-SA8Z] T04321 INDICATI Phase 2 Pneumonia [ICD-11: CA40] T04361 TARGETID T04361 T04361 TARGNAME TGF-beta-activated kinase 1 (MAP3K7) T04361 INDICATI Investigative Mature B-cell lymphoma [ICD-11: 2A85] T04388 TARGETID T04388 T04388 TARGNAME Calcium-activated potassium channel KCa2.3 (KCNN3) T04388 INDICATI Clinical trial Myelopathy [ICD-11: 8B42] T04389 TARGETID T04389 T04389 TARGNAME ATP phosphatase (ATPase) T04389 INDICATI Terminated Angina pectoris [ICD-11: BA40] T04389 INDICATI Discontinued in Phase 2 Mild neurocognitive disorder [ICD-11: 6D71] T04389 INDICATI Phase 2 Psoriasis [ICD-11: EA90] T04389 INDICATI Phase 2 Ulcerative colitis [ICD-11: DD71] T04394 TARGETID T04394 T04394 TARGNAME Vasopressin receptor (VR) T04394 INDICATI Terminated Abnormal micturition [ICD-11: MF50] T04394 INDICATI Approved Acute diabete complication [ICD-11: 5A2Y] T04394 INDICATI Phase 1 Essential hypertension [ICD-11: BA00] T04394 INDICATI Phase 1 Heart failure [ICD-11: BD10-BD1Z] T04507 TARGETID T04507 T04507 TARGNAME Presynaptic density protein 95 (DLG4) T04507 INDICATI Phase 3 Cerebral ischaemia [ICD-11: 8B1Z] T04507 INDICATI Phase 3 Ischaemic/haemorrhagic stroke [ICD-11: 8B20] T04689 TARGETID T04689 T04689 TARGNAME Neuronal acetylcholine receptor alpha-1 (CHRNA1) T04689 INDICATI Approved Tonus and reflex abnormality [ICD-11: MB47] T04741 TARGETID T04741 T04741 TARGNAME Phosphoribosylaminoimidazolecarboxamide formyltransferase (ATIC) T04741 INDICATI Investigative Solid tumour/cancer [ICD-11: 2A00-2F9Z] T04773 TARGETID T04773 T04773 TARGNAME Stromal cell-derived factor 1 (CXCL12) T04773 INDICATI Phase 3 Acute myeloid leukaemia [ICD-11: 2A60] T04773 INDICATI Phase 2 Chronic arterial occlusive disease [ICD-11: BD4Z] T04773 INDICATI Phase 3 Heart failure [ICD-11: BD10-BD1Z] T04773 INDICATI Phase 1 Retinopathy [ICD-11: 9B71] T04820 TARGETID T04820 T04820 TARGNAME Plasmodium CDK Pfmrk (Malaria Pfmrk) T04820 INDICATI Investigative Malaria [ICD-11: 1F40-1F45] T04894 TARGETID T04894 T04894 TARGNAME Liver and activation-regulated chemokine (CCL20) T04894 INDICATI Phase 1 Psoriatic arthritis [ICD-11: FA21] T04902 TARGETID T04902 T04902 TARGNAME Calpain-2 (CAPN2) T04902 INDICATI Phase 1 Alzheimer disease [ICD-11: 8A20] T04902 INDICATI Terminated Cerebral ischaemic stroke [ICD-11: 8B11] T04902 INDICATI Preclinical Coronavirus infection [ICD-11: 1D92] T04902 INDICATI Discontinued in Phase 3 Dissociative neurological symptom disorder [ICD-11: 6B60] T04902 INDICATI Withdrawn from market Trematode disease [ICD-11: 1F8Y] T04911 TARGETID T04911 T04911 TARGNAME Hepatitis C virus Non-structural 4B (HCV NS4B) T04911 INDICATI Phase 1 Hepatitis virus infection [ICD-11: 1E50-1E51] T04977 TARGETID T04977 T04977 TARGNAME Oxalate absorption (Oxalate absor) T04977 INDICATI Phase 3 Inborn carbohydrate metabolism error [ICD-11: 5C51] T05031 TARGETID T05031 T05031 TARGNAME PI3-kinase beta (PIK3CB) T05031 INDICATI Phase 3 Breast cancer [ICD-11: 2C60-2C6Y] T05031 INDICATI Phase 1/2 Colorectal cancer [ICD-11: 2B91] T05031 INDICATI Phase 2 Metastatic lymph node neoplasm [ICD-11: 2D60] T05031 INDICATI Phase 1 Pain [ICD-11: MG30-MG3Z] T05031 INDICATI Phase 1 Prostate cancer [ICD-11: 2C82] T05031 INDICATI Phase 1 Solid tumour/cancer [ICD-11: 2A00-2F9Z] T05031 INDICATI Terminated Thrombosis [ICD-11: DB61-GB90] T05034 TARGETID T05034 T05034 TARGNAME Fatty acid-binding protein (FABP) T05034 INDICATI Terminated Obesity [ICD-11: 5B80-5B81] T05089 TARGETID T05089 T05089 TARGNAME Calcium-dependent chloride channel anoctamin (ANO) T05089 INDICATI Approved Gout [ICD-11: FA25] T05089 INDICATI Approved Viral intestinal infection [ICD-11: 1A2Z] T05090 TARGETID T05090 T05090 TARGNAME Histone deacetylase 3 (HDAC3) T05090 INDICATI Phase 1/2 Lymphoma [ICD-11: 2A80-2A86] T05090 INDICATI Phase 1 Solid tumour/cancer [ICD-11: 2A00-2F9Z] T05114 TARGETID T05114 T05114 TARGNAME Chymase (CYM) T05114 INDICATI Phase 2 Atopic eczema [ICD-11: EA80] T05114 INDICATI Investigative Cardiovascular disease [ICD-11: BA00-BE2Z] T05114 INDICATI Phase 2 Chronic obstructive pulmonary disease [ICD-11: CA22] T05114 INDICATI Phase 2 Gram-positive bacterial infection [ICD-11: 1B74-1F40] T05114 INDICATI Phase 1 Heart failure [ICD-11: BD10-BD1Z] T05114 INDICATI Phase 2 Left ventricular failure [ICD-11: BD11] T05114 INDICATI Phase 2 Myocardial infarction [ICD-11: BA41-BA43] T05152 TARGETID T05152 T05152 TARGNAME Hepatitis C virus RNA-directed RNA polymerase (HCV NS5B) T05152 INDICATI Approved Hepatitis virus infection [ICD-11: 1E50-1E51] T05152 INDICATI Phase 2 Virus infection [ICD-11: 1A24-1D9Z] T05196 TARGETID T05196 T05196 TARGNAME Uric acid (URA) T05196 INDICATI Approved Gout [ICD-11: FA25] T05351 TARGETID T05351 T05351 TARGNAME Myristoylated alanine-rich C-kinase substrate (MARCKS) T05351 INDICATI Phase 2 Chronic obstructive pulmonary disease [ICD-11: CA22] T05351 INDICATI Phase 2 Lung cancer [ICD-11: 2C25] T05387 TARGETID T05387 T05387 TARGNAME Tissue transglutaminase (TG2) T05387 INDICATI Phase 2 Coeliac disease [ICD-11: DA95] T05387 INDICATI Preclinical Kidney fibrosis [ICD-11: GC01] T05387 INDICATI Phase 2 Non-alcoholic fatty liver disease [ICD-11: DB92] T05409 TARGETID T05409 T05409 TARGNAME Neutral endopeptidase (MME) T05409 INDICATI Phase 2 Asthma [ICD-11: CA23] T05409 INDICATI Phase 1 Cardiovascular disease [ICD-11: BA00-BE2Z] T05409 INDICATI Phase 2 Choreiform disorder [ICD-11: 8A01] T05409 INDICATI Discontinued in Phase 2/3 Chronic kidney disease [ICD-11: GB61] T05409 INDICATI Phase 1 Chronic pain [ICD-11: MG30] T05409 INDICATI Terminated Heart disease [ICD-11: BA41-BA42] T05409 INDICATI Approved Heart failure [ICD-11: BD10-BD1Z] T05409 INDICATI Phase 3 Hypertension [ICD-11: BA00-BA04] T05409 INDICATI Phase 2 Hypotension [ICD-11: BA20-BA21] T05409 INDICATI Phase 2 Intracranial injury [ICD-11: NA07] T05409 INDICATI Discontinued in Phase 2/3 Kidney failure [ICD-11: GB60-GB6Z] T05409 INDICATI Phase 1 Leukaemia [ICD-11: 2A60-2B33] T05409 INDICATI Phase 1 Lung cancer [ICD-11: 2C25] T05409 INDICATI Phase 1 Mature B-cell lymphoma [ICD-11: 2A85] T05409 INDICATI Phase 1 Multiple sclerosis [ICD-11: 8A40] T05409 INDICATI Discontinued in Phase 2 Pain [ICD-11: MG30-MG3Z] T05409 INDICATI Phase 1 Sexual dysfunction [ICD-11: HA00-HA01] T05643 TARGETID T05643 T05643 TARGNAME Leucine-rich repeat neuronal protein 1 (LINGO1) T05643 INDICATI Phase 2 Multiple sclerosis [ICD-11: 8A40] T05661 TARGETID T05661 T05661 TARGNAME Lecithin-cholesterol acyltransferase (LCAT) T05661 INDICATI Phase 2 Coronary atherosclerosis [ICD-11: BA80] T05661 INDICATI Phase 1 Myocardial infarction [ICD-11: BA41-BA43] T05849 TARGETID T05849 T05849 TARGNAME Gastrin/cholecystokinin type B receptor (CCKBR) T05849 INDICATI Phase 2 Anxiety disorder [ICD-11: 6B00-6B0Z] T05849 INDICATI Phase 2 Diabetes mellitus [ICD-11: 5A10] T05849 INDICATI Approved Diagnostic imaging [ICD-11: N.A.] T05849 INDICATI Terminated Digestive system disease [ICD-11: DE2Z] T05849 INDICATI Phase 3 Duodenal ulcer [ICD-11: DA63] T05849 INDICATI Terminated Dyspepsia [ICD-11: MD92] T05849 INDICATI Phase 2 Gastric ulcer [ICD-11: DA60] T05849 INDICATI Preclinical Gastro-oesophageal reflux disease [ICD-11: DA22] T05849 INDICATI Discontinued in Phase 1 General pain disorder [ICD-11: 8E43] T05849 INDICATI Discontinued in Phase 1 Malignant intestine neoplasm [ICD-11: 2C0Z] T05849 INDICATI Preclinical Obesity [ICD-11: 5B80-5B81] T05849 INDICATI Approved Pancreatic internal secretion disorder [ICD-11: 5A4Y] T05849 INDICATI Phase 2 Pancreatic malfunction [ICD-11: DC30-DC3Z] T05849 INDICATI Phase 3 Solid tumour/cancer [ICD-11: 2A00-2F9Z] T05849 INDICATI Phase 2 Stomach disease [ICD-11: DA43-DA4Y] T05849 INDICATI Phase 1 Thyroid cancer [ICD-11: 2D10] T05849 INDICATI Phase 2 Ulcerative colitis [ICD-11: DD71] T05876 TARGETID T05876 T05876 TARGNAME Ebola virus Envelope glycoprotein (EV GP) T05876 INDICATI Approved Filovirus disease [ICD-11: 1D60] T05880 TARGETID T05880 T05880 TARGNAME Gamma-secretase subunit APH-1A/1B (APH-1) T05880 INDICATI Patented Alzheimer disease [ICD-11: 8A20] T05880 INDICATI Patented Herpes simplex infection [ICD-11: 1F00] T05904 TARGETID T05904 T05904 TARGNAME Phosphodiesterase 8 (PDE8) T05904 INDICATI Investigative Itching [ICD-11: 1F28-1G07] T05904 INDICATI Investigative Postoperative inflammation [ICD-11: 1A00-CA43] T05938 TARGETID T05938 T05938 TARGNAME Ovarian carcinoma antigen CA125 (MUC16) T05938 INDICATI Phase 1 Fallopian tube cancer [ICD-11: 2C74] T05938 INDICATI Phase 2 Malignant mesenchymal neoplasm [ICD-11: 2B5D-2B5Y] T05938 INDICATI Phase 1 Mature B-cell lymphoma [ICD-11: 2A85] T05938 INDICATI Phase 3 Ovarian cancer [ICD-11: 2C73] T05938 INDICATI Phase 1 Peritoneal cancer [ICD-11: 2C51] T06011 TARGETID T06011 T06011 TARGNAME Transforming growth factor beta (TGFB) T06011 INDICATI Phase 1 Anemia [ICD-11: 3A00-3A9Z] T06011 INDICATI Phase 2 Brain cancer [ICD-11: 2A00] T06011 INDICATI Preclinical Cardiac arrest [ICD-11: MC82] T06011 INDICATI Phase 2 Chronic kidney disease [ICD-11: GB61] T06011 INDICATI Phase 1/2 Myelodysplastic syndrome [ICD-11: 2A37] T06011 INDICATI Phase 2 Myeloproliferative neoplasm [ICD-11: 2A20] T06011 INDICATI Phase 2 Non-small-cell lung cancer [ICD-11: 2C25] T06011 INDICATI Phase 2 Pancreatic cancer [ICD-11: 2C10] T06011 INDICATI Phase 2 Solid tumour/cancer [ICD-11: 2A00-2F9Z] T06011 INDICATI Phase 2 Ureteral cancer [ICD-11: 2C92] T06020 TARGETID T06020 T06020 TARGNAME Neonatal Fc receptor (FCGRT) T06020 INDICATI Phase 3 Acquired haemolytic anaemia ICD-11: 3A20 T06020 INDICATI Phase 2 Idiopathic inflammatory myopathy ICD-11: 4A41 T06020 INDICATI Phase 3 Inflammatory polyneuropathy [ICD-11: 8C01] T06020 INDICATI Phase 2 Lupus erythematosus [ICD-11: 4A40] T06020 INDICATI Approved Myasthenia gravis [ICD-11: 8C6Y] T06020 INDICATI Phase 3 Myasthenia gravis ICD-11: 8C60 T06020 INDICATI Phase 2 Rheumatoid arthritis [ICD-11: FA20] T06020 INDICATI Phase 2 Sjogren syndrome [ICD-11: 4A43] T06037 TARGETID T06037 T06037 TARGNAME JNK2 messenger RNA (JNK2 mRNA) T06037 INDICATI Investigative Solid tumour/cancer [ICD-11: 2A00-2F9Z] T06042 TARGETID T06042 T06042 TARGNAME Sinus node I(f) channel (SA node IfC) T06042 INDICATI Approved Angina pectoris [ICD-11: BA40] T06046 TARGETID T06046 T06046 TARGNAME Nitric-oxide synthase endothelial (NOS3) T06046 INDICATI Phase 2 Angina pectoris [ICD-11: BA40] T06046 INDICATI Phase 2 Coronary atherosclerosis [ICD-11: BA80] T06046 INDICATI Phase 2 Hypertension [ICD-11: BA00-BA04] T06046 INDICATI Phase 2 Hypotension [ICD-11: BA20-BA21] T06046 INDICATI Phase 2 Intracranial injury [ICD-11: NA07] T06046 INDICATI Phase 3 Myocardial infarction [ICD-11: BA41-BA43] T06046 INDICATI Phase 1 Pulmonary hypertension [ICD-11: BB01] T06093 TARGETID T06093 T06093 TARGNAME Rho-associated protein kinase 2 (ROCK2) T06093 INDICATI Investigative Chronic obstructive pulmonary disease [ICD-11: CA22] T06093 INDICATI Phase 1 Glaucoma [ICD-11: 9C61] T06093 INDICATI Approved Graft-versus-host disease [ICD-11: 4B24] T06093 INDICATI Phase 1 Lupus erythematosus [ICD-11: 4A40] T06093 INDICATI Clinical trial Postoperative inflammation [ICD-11: 1A00-CA43] T06093 INDICATI Phase 2 Psoriasis [ICD-11: EA90] T06093 INDICATI Phase 1 Psoriatic arthritis [ICD-11: FA21] T06093 INDICATI Phase 2 Rheumatoid arthritis [ICD-11: FA20] T06093 INDICATI Investigative Solid tumour/cancer [ICD-11: 2A00-2F9Z] T06093 INDICATI Phase 1 Systemic sclerosis [ICD-11: 4A42] T06128 TARGETID T06128 T06128 TARGNAME Insulin receptor substrate 2 (IRS2) T06128 INDICATI Phase 1/2 Solid tumour/cancer [ICD-11: 2A00-2F9Z] T06182 TARGETID T06182 T06182 TARGNAME Helodermin-preferring VIP receptor (VIPR2) T06182 INDICATI Phase 1 Cardiomyopathy [ICD-11: BC43] T06182 INDICATI Phase 1 Chronic obstructive pulmonary disease [ICD-11: CA22] T06182 INDICATI Phase 2 Heart failure [ICD-11: BD10-BD1Z] T06182 INDICATI Phase 1 Hypertension [ICD-11: BA00-BA04] T06182 INDICATI Phase 1 Muscular dystrophy [ICD-11: 8C70] T06182 INDICATI Phase 2 Pulmonary hypertension [ICD-11: BB01] T06273 TARGETID T06273 T06273 TARGNAME Poly [ADP-ribose] polymerase 1 (PARP1) T06273 INDICATI Approved Acquired cutaneous blood vessel malformation [ICD-11: EF20] T06273 INDICATI Phase 3 Acute myeloid leukaemia [ICD-11: 2A60] T06273 INDICATI Investigative Adaptive immunity immunodeficiency [ICD-11: 4A01] T06273 INDICATI Investigative Cerebral ischaemia [ICD-11: 8B1Z] T06273 INDICATI Phase 3 Cerebrovascular disease [ICD-11: 8B22-8B2Z] T06273 INDICATI Preclinical Coronavirus infection [ICD-11: 1D92] T06273 INDICATI Phase 1 Diffuse large B-cell lymphoma [ICD-11: 2A81] T06273 INDICATI Approved Fallopian tube cancer [ICD-11: 2C74] T06273 INDICATI Investigative Ischaemic/haemorrhagic stroke [ICD-11: 8B20] T06273 INDICATI Phase 2 Melanoma [ICD-11: 2C30] T06273 INDICATI Phase 3 Myelodysplastic syndrome [ICD-11: 2A37] T06273 INDICATI Investigative Myocardial infarction [ICD-11: BA41-BA43] T06273 INDICATI Approved Ovarian cancer [ICD-11: 2C73] T06273 INDICATI Approved Peritoneal cancer [ICD-11: 2C51] T06273 INDICATI Phase 2 Prostate cancer [ICD-11: 2C82] T06273 INDICATI Phase 1/2 Solid tumour/cancer [ICD-11: 2A00-2F9Z] T06281 TARGETID T06281 T06281 TARGNAME Klebsiella Fimbrial subunit type 3 (Klebsiella mrkA) T06281 INDICATI Preclinical Pneumonia [ICD-11: CA40] T06320 TARGETID T06320 T06320 TARGNAME Galectin (LGALS) T06320 INDICATI Phase 2 Chronic kidney disease [ICD-11: GB61] T06365 TARGETID T06365 T06365 TARGNAME Alanine glyoxylate aminotransferase (AGXT) T06365 INDICATI Terminated Inborn carbohydrate metabolism error [ICD-11: 5C51] T06413 TARGETID T06413 T06413 TARGNAME PKC-alpha messenger RNA (PRKCA mRNA) T06413 INDICATI Investigative Lung cancer [ICD-11: 2C25] T06421 TARGETID T06421 T06421 TARGNAME Interferon alpha/beta receptor 2 (IFNAR2) T06421 INDICATI Phase 1 Endometriosis [ICD-11: GA10] T06421 INDICATI Approved Hepatitis virus infection [ICD-11: 1E50-1E51] T06421 INDICATI Approved Lupus erythematosus [ICD-11: 4A40] T06421 INDICATI Approved Mature B-cell leukaemia [ICD-11: 2A82] T06421 INDICATI Approved Multiple sclerosis [ICD-11: 8A40] T06421 INDICATI Approved Myeloproliferative neoplasm [ICD-11: 2A20] T06421 INDICATI Approved Renal cell carcinoma [ICD-11: 2C90] T06438 TARGETID T06438 T06438 TARGNAME Oxidoreductase unspecific (OR) T06438 INDICATI Phase 1/2 Ataxic disorder [ICD-11: 8A03] T06438 INDICATI Phase 1/2 Muscular dystrophy [ICD-11: 8C70] T06438 INDICATI Approved Ulcerative colitis [ICD-11: DD71] T06446 TARGETID T06446 T06446 TARGNAME Leukotriene biosynthesis (LT synth) T06446 INDICATI Investigative Asthma [ICD-11: CA23] T06455 TARGETID T06455 T06455 TARGNAME Cytochrome P450 2A6 (CYP2A6) T06455 INDICATI Approved Mycosis fungoides [ICD-11: 2B01] T06455 INDICATI Approved Psoriasis [ICD-11: EA90] T06475 TARGETID T06475 T06475 TARGNAME Nucleolin (NCL) T06475 INDICATI Phase 2 Leukaemia [ICD-11: 2A60-2B33] T06475 INDICATI Phase 2 Solid tumour/cancer [ICD-11: 2A00-2F9Z] T06542 TARGETID T06542 T06542 TARGNAME Cytokine ML-1 (IL17F) T06542 INDICATI Approved Psoriasis [ICD-11: EA90] T06542 INDICATI Phase 2 Psoriatic arthritis [ICD-11: FA21] T06569 TARGETID T06569 T06569 TARGNAME Carbonic anhydrase VI (CA-VI) T06569 INDICATI Approved Bacterial infection [ICD-11: 1A00-1C4Z] T06569 INDICATI Phase 2 Breast cancer [ICD-11: 2C60-2C6Y] T06569 INDICATI Approved Seborrhoeic dermatitis [ICD-11: EA81] T06569 INDICATI Phase 3 Solid tumour/cancer [ICD-11: 2A00-2F9Z] T06575 TARGETID T06575 T06575 TARGNAME Choriogonadotropin beta (CG-beta) T06575 INDICATI Phase 2 Bladder cancer [ICD-11: 2C94] T06671 TARGETID T06671 T06671 TARGNAME Interleukin-18 (IL18) T06671 INDICATI Phase 3 Adaptive immunity immunodeficiency [ICD-11: 4A01] T06671 INDICATI Phase 1 Chronic obstructive pulmonary disease [ICD-11: CA22] T06671 INDICATI Phase 1 Follicular lymphoma [ICD-11: 2A80] T06671 INDICATI Phase 1 Malignant haematopoietic neoplasm [ICD-11: 2B33] T06671 INDICATI Phase 1 Ovarian cancer [ICD-11: 2C73] T06671 INDICATI Discontinued in Phase 1 Rheumatoid arthritis [ICD-11: FA20] T06671 INDICATI Investigative Supraventricular tachyarrhythmia [ICD-11: BC81] T06671 INDICATI Phase 2 Type 2 diabetes mellitus [ICD-11: 5A11] T06770 TARGETID T06770 T06770 TARGNAME Human immunodeficiency virus Glycoprotein 41 (HIV gp41) T06770 INDICATI Approved Human immunodeficiency virus disease [ICD-11: 1C60-1C62] T06841 TARGETID T06841 T06841 TARGNAME Interleukin-23 (IL23) T06841 INDICATI Phase 3 Asthma [ICD-11: CA23] T06841 INDICATI Phase 3 Crohn disease [ICD-11: DD70] T06841 INDICATI Phase 2/3 Indeterminate colitis [ICD-11: DD72] T06841 INDICATI Phase 2 Inflammatory spondyloarthritis [ICD-11: FA92] T06841 INDICATI Investigative Malaria [ICD-11: 1F40-1F45] T06841 INDICATI Phase 3 Mature B-cell leukaemia [ICD-11: 2A82] T06841 INDICATI Approved Psoriasis [ICD-11: EA90] T06841 INDICATI Phase 3 Psoriatic arthritis [ICD-11: FA21] T06841 INDICATI Phase 2 Rheumatoid arthritis [ICD-11: FA20] T06841 INDICATI Phase 1 Solid tumour/cancer [ICD-11: 2A00-2F9Z] T06841 INDICATI Phase 2 Ulcerative colitis [ICD-11: DD71] T06850 TARGETID T06850 T06850 TARGNAME Ghrelin (GHRL) T06850 INDICATI Phase 1 Diabetes mellitus [ICD-11: 5A10] T06869 TARGETID T06869 T06869 TARGNAME Platelet-derived growth factor A (PDGFA) T06869 INDICATI Phase 2 Retinopathy [ICD-11: 9B71] T06869 INDICATI Phase 3 Solid tumour/cancer [ICD-11: 2A00-2F9Z] T06955 TARGETID T06955 T06955 TARGNAME C-C chemokine receptor type 4 (CCR4) T06955 INDICATI Phase 2 Asthma [ICD-11: CA23] T06955 INDICATI Investigative Diabetes mellitus [ICD-11: 5A10] T06955 INDICATI Phase 1 Immune system disease [ICD-11: 4A01-4B41] T06955 INDICATI Phase 1 Immunoproliferative disorder [ICD-11: 2B32] T06955 INDICATI Phase 1 Lymphatic vessel/lymph nodes disorder [ICD-11: BD9Z] T06955 INDICATI Phase 1 Lymphoma [ICD-11: 2A80-2A86] T06955 INDICATI Phase 2 Mature T-cell lymphoma [ICD-11: 2A90] T06955 INDICATI Approved Mycosis fungoides [ICD-11: 2B01] T06955 INDICATI Approved Sezary syndrome [ICD-11: 2B02] T06955 INDICATI Phase 1/2 Solid tumour/cancer [ICD-11: 2A00-2F9Z] T06958 TARGETID T06958 T06958 TARGNAME DNA polymerase beta (POLB) T06958 INDICATI Phase 1/2 Solid tumour/cancer [ICD-11: 2A00-2F9Z] T07035 TARGETID T07035 T07035 TARGNAME Cytomegalovirus IE2 region messenger RNA (CMV IE2 mRNA) T07035 INDICATI Approved Retinal inflammation [ICD-11: 9B72] T07035 INDICATI Investigative Virus infection [ICD-11: 1A24-1D9Z] T07045 TARGETID T07045 T07045 TARGNAME Pituitary adenylate cyclase-activating 38 (PACAP-38) T07045 INDICATI Phase 1 Unspecific body region injury [ICD-11: ND56] T07063 TARGETID T07063 T07063 TARGNAME Sodium/iodide cotransporter (SLC5A5) T07063 INDICATI Phase 1 Prostate cancer [ICD-11: 2C82] T07137 TARGETID T07137 T07137 TARGNAME Hydroxyphenylpyruvate dioxygenase (HPD) T07137 INDICATI Approved Metabolism inborn error [ICD-11: 5C50] T07137 INDICATI Terminated Viral encephalitis [ICD-11: 1C80] T07173 TARGETID T07173 T07173 TARGNAME Tropomyosin-related kinase A (TrkA) T07173 INDICATI Phase 1 Adrenal cancer [ICD-11: 2D11] T07173 INDICATI Phase 3 Alzheimer disease [ICD-11: 8A20] T07173 INDICATI Phase 1 Breast cancer [ICD-11: 2C60-2C6Y] T07173 INDICATI Patented Chronic pain [ICD-11: MG30] T07173 INDICATI Phase 2 Colorectal cancer [ICD-11: 2B91] T07173 INDICATI Patented General pain disorder [ICD-11: 8E43] T07173 INDICATI Phase 1 Lymphoma [ICD-11: 2A80-2A86] T07173 INDICATI Approved Non-small-cell lung cancer [ICD-11: 2C25] T07173 INDICATI Preclinical Pain [ICD-11: MG30-MG3Z] T07173 INDICATI Phase 1 Pancreatic cancer [ICD-11: 2C10] T07173 INDICATI Phase 2 Pruritus [ICD-11: EC90] T07173 INDICATI Phase 2 Psoriasis [ICD-11: EA90] T07173 INDICATI Approved Solid tumour/cancer [ICD-11: 2A00-2F9Z] T07173 INDICATI Patented Thymoma [ICD-11: 2C27] T07191 TARGETID T07191 T07191 TARGNAME MEK kinase kinase 2 (MAP4K2) T07191 INDICATI Phase 1 Breast cancer [ICD-11: 2C60-2C6Y] T07279 TARGETID T07279 T07279 TARGNAME Serine/threonine-protein kinase pim-2 (PIM2) T07279 INDICATI Phase 1/2 Multiple myeloma [ICD-11: 2A83] T07279 INDICATI Investigative Postoperative inflammation [ICD-11: 1A00-CA43] T07279 INDICATI Phase 1 Solid tumour/cancer [ICD-11: 2A00-2F9Z] T07289 TARGETID T07289 T07289 TARGNAME Duffy antigen chemokine receptor (ACKR1) T07289 INDICATI Approved Malaria [ICD-11: 1F40-1F45] T07303 TARGETID T07303 T07303 TARGNAME Vascular endothelial growth factor receptor 3 (FLT-4) T07303 INDICATI Phase 1/2 Alzheimer disease [ICD-11: 8A20] T07303 INDICATI Phase 2 Breast cancer [ICD-11: 2C60-2C6Y] T07303 INDICATI Phase 3 Circulatory system disease [ICD-11: BE2Z] T07303 INDICATI Phase 3 Liver cancer [ICD-11: 2C12] T07303 INDICATI Phase 1/2 Lung cancer [ICD-11: 2C25] T07303 INDICATI Phase 2 Prostate cancer [ICD-11: 2C82] T07303 INDICATI Approved Renal cell carcinoma [ICD-11: 2C90] T07303 INDICATI Phase 3 Solid tumour/cancer [ICD-11: 2A00-2F9Z] T07303 INDICATI Phase 3 Stomach cancer [ICD-11: 2B72] T07341 TARGETID T07341 T07341 TARGNAME Dabigatran (Dabi) T07341 INDICATI Approved Reversal of the anticoagulant effects of dabigatran [ICD-11:N.A.] T07374 TARGETID T07374 T07374 TARGNAME Beta-microseminoprotein (MSMB) T07374 INDICATI Phase 1 Prostate cancer [ICD-11: 2C82] T07394 TARGETID T07394 T07394 TARGNAME Notch-1 receptor (NOTCH1) T07394 INDICATI Phase 1 Lymphoma [ICD-11: 2A80-2A86] T07394 INDICATI Phase 1/2 Mature T-cell lymphoma [ICD-11: 2A90] T07394 INDICATI Phase 1/2 Solid tumour/cancer [ICD-11: 2A00-2F9Z] T07400 TARGETID T07400 T07400 TARGNAME Advanced glycosylation end product receptor (AGER) T07400 INDICATI Phase 3 Alzheimer disease [ICD-11: 8A20] T07400 INDICATI Phase 3 Chronic kidney disease [ICD-11: GB61] T07400 INDICATI Phase 3 Dementia [ICD-11: 6D80-6D8Z] T07400 INDICATI Phase 2/3 Hypotension [ICD-11: BA20-BA21] T07403 TARGETID T07403 T07403 TARGNAME Integrin alpha-4/beta-7 (ITGA4/B7) T07403 INDICATI Approved Crohn disease [ICD-11: DD70] T07403 INDICATI Phase 2 Indeterminate colitis [ICD-11: DD72] T07403 INDICATI Discontinued in Phase 1 Multiple sclerosis [ICD-11: 8A40] T07403 INDICATI Phase 1 Postoperative inflammation [ICD-11: 1A00-CA43] T07403 INDICATI Discontinued in Phase 1 Rheumatoid arthritis [ICD-11: FA20] T07403 INDICATI Phase 2 Ulcerative colitis [ICD-11: DD71] T07448 TARGETID T07448 T07448 TARGNAME Mannan-binding lectin serine protease-2 (MASP2) T07448 INDICATI Phase 2 Amyloidosis [ICD-11: 5D00] T07448 INDICATI Phase 3 Hereditary haemolytic anaemia [ICD-11: 3A10] T07448 INDICATI Phase 2 Lupus erythematosus [ICD-11: 4A40] T07448 INDICATI Phase 2 Thrombotic microangiopathy [ICD-11: 3B65] T07448 INDICATI Phase 3 Urinary system clinical sympton [ICD-11: MF8Y] T07485 TARGETID T07485 T07485 TARGNAME Respiratory syncytial virus protein F (RSV F) T07485 INDICATI Approved Low bone mass disorder [ICD-11: FB83] T07485 INDICATI Approved Viral encephalitis [ICD-11: 1C80] T07485 INDICATI Discontinued in Phase 1 Virus infection [ICD-11: 1A24-1D9Z] T07507 TARGETID T07507 T07507 TARGNAME Myosin-7 (MYH7) T07507 INDICATI Phase 1/2 Deafness [ICD-11: AB52] T07507 INDICATI Phase 1 Inherited retinal dystrophy [ICD-11: 9B70] T07533 TARGETID T07533 T07533 TARGNAME Apolipoprotein B-100 (APOB) T07533 INDICATI Phase 1 Hyper-lipoproteinaemia [ICD-11: 5C80] T07569 TARGETID T07569 T07569 TARGNAME Electron transport complex III (Complex III) T07569 INDICATI Approved Malaria [ICD-11: 1F40-1F45] T07584 TARGETID T07584 T07584 TARGNAME Ubiquitin carboxyl-terminal hydrolase 13 (USP13) T07584 INDICATI Preclinical Postoperative inflammation [ICD-11: 1A00-CA43] T07601 TARGETID T07601 T07601 TARGNAME Calcium signal-modulating cyclophilin ligand (CAML) T07601 INDICATI Terminated Allergic/hypersensitivity disorder [ICD-11: 4A80-4A8Z] T07601 INDICATI Preclinical Glaucoma [ICD-11: 9C61] T07601 INDICATI Phase 2 Hepatitis virus infection [ICD-11: 1E50-1E51] T07601 INDICATI Phase 3 Muscular dystrophy [ICD-11: 8C70] T07663 TARGETID T07663 T07663 TARGNAME Phosphodiesterase 5A (PDE5A) T07663 INDICATI Discontinued in Phase 2 Allergic/hypersensitivity disorder [ICD-11: 4A80-4A8Z] T07663 INDICATI Discontinued in Phase 2 Angina pectoris [ICD-11: BA40] T07663 INDICATI Terminated Asthma [ICD-11: CA23] T07663 INDICATI Discontinued in Phase 2 Cardiovascular disease [ICD-11: BA00-BE2Z] T07663 INDICATI Phase 2 Chronic obstructive pulmonary disease [ICD-11: CA22] T07663 INDICATI Phase 3 Colorectal cancer [ICD-11: 2B91] T07663 INDICATI Approved Hypertension [ICD-11: BA00-BA04] T07663 INDICATI Approved Innate/adaptive immunodeficiency [ICD-11: 4A00] T07663 INDICATI Phase 2 Raynaud phenomenon [ICD-11: BD42] T07663 INDICATI Approved Sexual dysfunction [ICD-11: HA00-HA01] T07663 INDICATI Approved Tonus and reflex abnormality [ICD-11: MB47] T07806 TARGETID T07806 T07806 TARGNAME 5-HT 1B receptor (HTR1B) T07806 INDICATI Phase 2 Alzheimer disease [ICD-11: 8A20] T07806 INDICATI Terminated Anxiety disorder [ICD-11: 6B00-6B0Z] T07806 INDICATI Phase 3 Attention deficit hyperactivity disorder [ICD-11: 6A05] T07806 INDICATI Terminated Depression [ICD-11: 6A70-6A7Z] T07806 INDICATI Phase 2 Malignant haematopoietic neoplasm [ICD-11: 2B33] T07806 INDICATI Approved Migraine [ICD-11: 8A80] T07806 INDICATI Phase 1 Mood disorder [ICD-11: 6A60-6E23] T07806 INDICATI Terminated Pain [ICD-11: MG30-MG3Z] T07806 INDICATI Phase 2 Parkinsonism [ICD-11: 8A00] T07806 INDICATI Approved Pituitary gland disorder [ICD-11: 5A60-5A61] T07806 INDICATI Approved Psychotic disorder [ICD-11: 6A20-6A25] T07806 INDICATI Approved Schizophrenia [ICD-11: 6A20] T07806 INDICATI Phase 2 Tonus and reflex abnormality [ICD-11: MB47] T07816 TARGETID T07816 T07816 TARGNAME Leishmania major Proteasome (Leishm Proteasome) T07816 INDICATI Phase 2 Leishmaniasis [ICD-11: 1F54] T07861 TARGETID T07861 T07861 TARGNAME IL-1 synthesis/release (IL-1 synth/rele) T07861 INDICATI Phase 2 Asthma [ICD-11: CA23] T07893 TARGETID T07893 T07893 TARGNAME Polyamine transport (Poly trans) T07893 INDICATI Phase 1 Solid tumour/cancer [ICD-11: 2A00-2F9Z] T07931 TARGETID T07931 T07931 TARGNAME Leukocyte immunoglobulin-like receptor B2 (LILRB2) T07931 INDICATI Phase 2 Solid tumour/cancer [ICD-11: 2A00-2F9Z] T07958 TARGETID T07958 T07958 TARGNAME Erythropoietin (EPO) T07958 INDICATI Phase 2 Anemia [ICD-11: 3A00-3A9Z] T07958 INDICATI Terminated Cerebral ischaemia [ICD-11: 8B1Z] T07958 INDICATI Phase 2 Retinopathy [ICD-11: 9B71] T08014 TARGETID T08014 T08014 TARGNAME TAR DNA binding protein 43 (TARDBP) T08014 INDICATI Phase 3 Acute myeloid leukaemia [ICD-11: 2A60] T08014 INDICATI Phase 3 Alzheimer disease [ICD-11: 8A20] T08014 INDICATI Phase 1 Cerebral ischaemic stroke [ICD-11: 8B11] T08029 TARGETID T08029 T08029 TARGNAME Complement factor P (CFP) T08029 INDICATI Phase 2 Retinopathy [ICD-11: 9B71] T08029 INDICATI Phase 2 Sickle-cell disorder [ICD-11: 3A51] T08123 TARGETID T08123 T08123 TARGNAME Leucine-rich repeat kinase 2 (LRRK2) T08123 INDICATI Phase 1 Parkinsonism [ICD-11: 8A00] T08133 TARGETID T08133 T08133 TARGNAME Transient receptor potential cation channel V6 (TRPV6) T08133 INDICATI Phase 1 Alzheimer disease [ICD-11: 8A20] T08133 INDICATI Phase 1 Ovarian cancer [ICD-11: 2C73] T08133 INDICATI Phase 1 Solid tumour/cancer [ICD-11: 2A00-2F9Z] T08139 TARGETID T08139 T08139 TARGNAME Fanconi anemia group A protein (FANCA) T08139 INDICATI Phase 2 Aplastic anaemia [ICD-11: 3A70] T08156 TARGETID T08156 T08156 TARGNAME Interferon-alpha 5 (IFNA5) T08156 INDICATI Phase 1/2 Hepatitis virus infection [ICD-11: 1E50-1E51] T08156 INDICATI Phase 1/2 Postoperative inflammation [ICD-11: 1A00-CA43] T08231 TARGETID T08231 T08231 TARGNAME HLA-DR antigens-associated invariant (CD74) T08231 INDICATI Phase 1 Lupus erythematosus [ICD-11: 4A40] T08231 INDICATI Phase 1/2 Mature B-cell leukaemia [ICD-11: 2A82] T08298 TARGETID T08298 T08298 TARGNAME Granzyme B (GZMB) T08298 INDICATI Investigative Aneurysm/dissection [ICD-11: BD50] T08306 TARGETID T08306 T08306 TARGNAME B-cell-specific glycoprotein B29 (CD79B) T08306 INDICATI Phase 1 Autoimmune disease [ICD-11: 4A40-4A45] T08306 INDICATI Approved Diffuse large B-cell lymphoma [ICD-11: 2A81] T08306 INDICATI Phase 2 Follicular lymphoma [ICD-11: 2A80] T08306 INDICATI Phase 2 Malignant haematopoietic neoplasm [ICD-11: 2B33] T08306 INDICATI Phase 2 Mature B-cell lymphoma [ICD-11: 2A85] T08326 TARGETID T08326 T08326 TARGNAME Cyclin-dependent kinase 12 (CDK12) T08326 INDICATI Phase 1 Leishmaniasis [ICD-11: 1F54] T08326 INDICATI Investigative Solid tumour/cancer [ICD-11: 2A00-2F9Z] T08378 TARGETID T08378 T08378 TARGNAME Solute carrier family 23 member 2 (SLC23A2) T08378 INDICATI Approved Autoimmune liver disease [ICD-11: DB96] T08378 INDICATI Phase 2 Urinary tract infection [ICD-11: GC08] T08378 INDICATI Approved Vitamin deficiency [ICD-11: 5B55-5B5F] T08383 TARGETID T08383 T08383 TARGNAME Ketogenesis (KG) T08383 INDICATI Phase 2 Cognition symptoms/signs/clinical sympton [ICD-11: MB21] T08391 TARGETID T08391 T08391 TARGNAME Janus kinase 2 (JAK-2) T08391 INDICATI Phase 1/2 Acquired hypomelanotic disorder [ICD-11: ED63] T08391 INDICATI Phase 2 Alopecia [ICD-11: ED70] T08391 INDICATI Phase 2 Asthma [ICD-11: CA23] T08391 INDICATI Approved Atopic eczema [ICD-11: EA80] T08391 INDICATI Phase 2 B-cell lymphoma [ICD-11: 2A86] T08391 INDICATI Phase 2 Breast cancer [ICD-11: 2C60-2C6Y] T08391 INDICATI Investigative Diffuse large B-cell lymphoma [ICD-11: 2A81] T08391 INDICATI Phase 1 Leukaemia [ICD-11: 2A60-2B33] T08391 INDICATI Investigative Liver cancer [ICD-11: 2C12] T08391 INDICATI Phase 2 Lung cancer [ICD-11: 2C25] T08391 INDICATI Phase 2 Lupus erythematosus [ICD-11: 4A40] T08391 INDICATI Phase 1/2 Malignant haematopoietic neoplasm [ICD-11: 2B33] T08391 INDICATI Terminated Multiple myeloma [ICD-11: 2A83] T08391 INDICATI Phase 1 Multiple sclerosis [ICD-11: 8A40] T08391 INDICATI Phase 3 Muscular dystrophy [ICD-11: 8C70] T08391 INDICATI Approved Myeloproliferative neoplasm [ICD-11: 2A20] T08391 INDICATI Phase 3 Pancreatic cancer [ICD-11: 2C10] T08391 INDICATI Approved Rheumatoid arthritis [ICD-11: FA20] T08391 INDICATI Phase 3 Solid tumour/cancer [ICD-11: 2A00-2F9Z] T08391 INDICATI Approved Thrombocytosis [ICD-11: 3B63] T08391 INDICATI Terminated Transplant rejection [ICD-11: NE84] T08441 TARGETID T08441 T08441 TARGNAME Viral Maturation (VM) T08441 INDICATI Phase 1 Human immunodeficiency virus disease [ICD-11: 1C60-1C62] T08499 TARGETID T08499 T08499 TARGNAME Caterpiller protein 1.1 (NLRP3) T08499 INDICATI Phase 2 Chronic pain [ICD-11: MG30] T08499 INDICATI Phase 2 Gout [ICD-11: FA25] T08499 INDICATI Phase 1 Postoperative inflammation [ICD-11: 1A00-CA43] T08499 INDICATI Phase 1 Solid tumour/cancer [ICD-11: 2A00-2F9Z] T08583 TARGETID T08583 T08583 TARGNAME Thrombomodulin (THBD) T08583 INDICATI Discontinued in Phase 3 Disseminated intravascular coagulation [ICD-11: 3B20] T08735 TARGETID T08735 T08735 TARGNAME Aspergillus Mannitol 2-dehydrogenase (Asperg M2DH) T08735 INDICATI Approved Bronchiectasis [ICD-11: CA24] T08735 INDICATI Approved Kidney failure [ICD-11: GB60-GB6Z] T08743 TARGETID T08743 T08743 TARGNAME Aminopeptidase (AMP) T08743 INDICATI Phase 2 Acute myeloid leukaemia [ICD-11: 2A60] T08743 INDICATI Phase 2 Myelodysplastic syndrome [ICD-11: 2A37] T08743 INDICATI Terminated Postoperative inflammation [ICD-11: 1A00-CA43] T08856 TARGETID T08856 T08856 TARGNAME Matrix metalloproteinase-8 (MMP-8) T08856 INDICATI Discontinued in Phase 2 Corneal disease [ICD-11: 9A76-9A78] T08856 INDICATI Terminated Multiple sclerosis [ICD-11: 8A40] T08856 INDICATI Phase 3 Rheumatoid arthritis [ICD-11: FA20] T08884 TARGETID T08884 T08884 TARGNAME Plasmodium Thrombospondin relate anonymous protein (Plasm TRAP) T08884 INDICATI Phase 2 Malaria [ICD-11: 1F40-1F45] T08898 TARGETID T08898 T08898 TARGNAME Melanocortin receptor 2 (MC2R) T08898 INDICATI Approved Adrenocortical insufficiency [ICD-11: 5A74] T08910 TARGETID T08910 T08910 TARGNAME GABA(A) receptor gamma-2 (GABRG2) T08910 INDICATI Discontinued in Phase 1 Anxiety disorder [ICD-11: 6B00-6B0Z] T08910 INDICATI Approved Depression [ICD-11: 6A70-6A7Z] T08910 INDICATI Phase 3 Epilepsy/seizure [ICD-11: 8A61-8A6Z] T08910 INDICATI Discontinued in Phase 3 Female pelvic pain [ICD-11: GA34] T08910 INDICATI Phase 2 Indeterminate colitis [ICD-11: DD72] T08910 INDICATI Approved Mental/behavioural/neurodevelopmental disorder [ICD-11: 6E20-6E8Z] T08910 INDICATI Investigative Postoperative inflammation [ICD-11: 1A00-CA43] T08910 INDICATI Phase 3 Status epilepticus [ICD-11: 8A66] T08910 INDICATI Terminated Substance abuse [ICD-11: 6C40] T08910 INDICATI Approved Tonus and reflex abnormality [ICD-11: MB47] T08910 INDICATI Phase 2 Tremor-related disorder [ICD-11: 8A04] T08922 TARGETID T08922 T08922 TARGNAME Acetyl-CoA carboxylase 2 (ACACB) T08922 INDICATI Discontinued in Phase 3 Obesity [ICD-11: 5B80-5B81] T08922 INDICATI Investigative Parkinsonism [ICD-11: 8A00] T08922 INDICATI Investigative Skin disease [ICD-11: EA00-EM0Z] T08922 INDICATI Approved Type 2 diabetes mellitus [ICD-11: 5A11] T09005 TARGETID T09005 T09005 TARGNAME Corynebacterium Mutated CRM197 (Cory mTOX) T09005 INDICATI Approved Infectious meningitis [ICD-11: 1D01] T09005 INDICATI Approved Meningococcal disease [ICD-11: 1C1C] T09037 TARGETID T09037 T09037 TARGNAME Ebola virus VP35 messenger RNA (EV VP35 mRNA) T09037 INDICATI Phase 1 Filovirus disease [ICD-11: 1D60] T09058 TARGETID T09058 T09058 TARGNAME Oncotrophoblast glycoprotein 5T4 (TPBG) T09058 INDICATI Terminated Breast cancer [ICD-11: 2C60-2C6Y] T09058 INDICATI Phase 1/2 Lung cancer [ICD-11: 2C25] T09058 INDICATI Phase 3 Prostate cancer [ICD-11: 2C82] T09058 INDICATI Phase 2/3 Solid tumour/cancer [ICD-11: 2A00-2F9Z] T09092 TARGETID T09092 T09092 TARGNAME Interleukin-10 (IL10) T09092 INDICATI Phase 1/2 Diabetes mellitus [ICD-11: 5A10] T09092 INDICATI Phase 2 Endometriosis [ICD-11: GA10] T09092 INDICATI Phase 1 Indeterminate colitis [ICD-11: DD72] T09092 INDICATI Phase 2 Knee osteoarthritis [ICD-11: FA01] T09092 INDICATI Phase 1 Lung cancer [ICD-11: 2C25] T09092 INDICATI Phase 3 Pancreatic cancer [ICD-11: 2C10] T09092 INDICATI Investigative Psoriasis [ICD-11: EA90] T09092 INDICATI Phase 1 Renal cell carcinoma [ICD-11: 2C90] T09092 INDICATI Phase 2 Rheumatoid arthritis [ICD-11: FA20] T09092 INDICATI Phase 2 Sarcoidosis [ICD-11: 4B20] T09092 INDICATI Phase 1 Solid tumour/cancer [ICD-11: 2A00-2F9Z] T09130 TARGETID T09130 T09130 TARGNAME Muscarinic acetylcholine receptor (CHRM) T09130 INDICATI Approved Abnormal micturition [ICD-11: MF50] T09130 INDICATI Approved Addictive disorder [ICD-11: 6C50-6C5Z] T09130 INDICATI Terminated Alzheimer disease [ICD-11: 8A20] T09130 INDICATI Investigative Asthma [ICD-11: CA23] T09130 INDICATI Phase 1 Breast cancer [ICD-11: 2C60-2C6Y] T09130 INDICATI Approved Cataract [ICD-11: 9B10] T09130 INDICATI Approved Chronic obstructive pulmonary disease [ICD-11: CA22] T09130 INDICATI Terminated Cognition symptoms/signs/clinical sympton [ICD-11: MB21] T09130 INDICATI Approved Functional bladder disorder [ICD-11: GC50] T09130 INDICATI Approved Irritable bowel syndrome [ICD-11: DD91] T09130 INDICATI Phase 2 Lips/oral mucosa miscellaneous disorder [ICD-11: DA02] T09130 INDICATI Discontinued in Phase 3 Mild neurocognitive disorder [ICD-11: 6D71] T09130 INDICATI Approved Nausea/vomiting [ICD-11: MD90] T09130 INDICATI Approved Peptic ulcer [ICD-11: DA61] T09130 INDICATI Approved Vasomotor/allergic rhinitis [ICD-11: CA08] T09227 TARGETID T09227 T09227 TARGNAME Protein tyrosine phosphatase (PTP) T09227 INDICATI Phase 2 Acute diabete complication [ICD-11: 5A2Y] T09227 INDICATI Phase 1/2 Diabetes mellitus [ICD-11: 5A10] T09227 INDICATI Phase 2a Type 2 diabetes mellitus [ICD-11: 5A11] T09347 TARGETID T09347 T09347 TARGNAME Neurotransmitter release (NT rele) T09347 INDICATI Phase 2 Mild neurocognitive disorder [ICD-11: 6D71] T09423 TARGETID T09423 T09423 TARGNAME Inward rectifier potassium channel Kir1.2 (KCNJ10) T09423 INDICATI Approved Acute diabete complication [ICD-11: 5A2Y] T09423 INDICATI Approved Type 2 diabetes mellitus [ICD-11: 5A11] T09483 TARGETID T09483 T09483 TARGNAME EGR1 messenger RNA (EGR1 mRNA) T09483 INDICATI Phase 2 Pain [ICD-11: MG30-MG3Z] T09507 TARGETID T09507 T09507 TARGNAME APOB messenger RNA (APOB mRNA) T09507 INDICATI Approved Hyper-lipoproteinaemia [ICD-11: 5C80] T09528 TARGETID T09528 T09528 TARGNAME C-X-C chemokine receptor type 5 (CXCR5) T09528 INDICATI Phase 1 Lupus erythematosus [ICD-11: 4A40] T09528 INDICATI Preclinical Solid tumour/cancer [ICD-11: 2A00-2F9Z] T09528 INDICATI Phase 2 Thrombocytopenia [ICD-11: 3B64] T09538 TARGETID T09538 T09538 TARGNAME Alkaline phosphatase tissue-nonspecific (ALPL) T09538 INDICATI Withdrawn from market Colon cancer [ICD-11: 2B90] T09538 INDICATI Approved Genetic prion disease [ICD-11: 8E02] T09538 INDICATI Phase 1 Mineral absorption/transport disorder [ICD-11: 5C64] T09538 INDICATI Approved Parasitic infection [ICD-11: 1D0Y-1G2Z] T09538 INDICATI Phase 2 Pseudoxanthoma elasticum ICD-11: EC40 T09572 TARGETID T09572 T09572 TARGNAME Melanin-concentrating hormone receptor 1 (MCHR1) T09572 INDICATI Preclinical Anxiety disorder [ICD-11: 6B00-6B0Z] T09572 INDICATI Preclinical Depression [ICD-11: 6A70-6A7Z] T09572 INDICATI Phase 1 Obesity [ICD-11: 5B80-5B81] T09572 INDICATI Investigative Supraventricular tachyarrhythmia [ICD-11: BC81] T09756 TARGETID T09756 T09756 TARGNAME Polyamine unspecific (PLA) T09756 INDICATI Discontinued in Phase 1 Solid tumour/cancer [ICD-11: 2A00-2F9Z] T09826 TARGETID T09826 T09826 TARGNAME DNA topoisomerase I (TOP1) T09826 INDICATI Approved Bacterial infection [ICD-11: 1A00-1C4Z] T09826 INDICATI Clinical trial Bladder cancer [ICD-11: 2C94] T09826 INDICATI Phase 2 Brain cancer [ICD-11: 2A00] T09826 INDICATI Phase 3 Breast cancer [ICD-11: 2C60-2C6Y] T09826 INDICATI Approved Colorectal cancer [ICD-11: 2B91] T09826 INDICATI Phase 2 Esophageal cancer [ICD-11: 2B70] T09826 INDICATI Phase 1 Gastrointestinal stromal tumour [ICD-11: 2B5B] T09826 INDICATI Phase 3 Human immunodeficiency virus disease [ICD-11: 1C60-1C62] T09826 INDICATI Approved Lung cancer [ICD-11: 2C25] T09826 INDICATI Phase 1 Lymphoma [ICD-11: 2A80-2A86] T09826 INDICATI Phase 1 Mature B-cell lymphoma [ICD-11: 2A85] T09826 INDICATI Phase 2 Myelodysplastic syndrome [ICD-11: 2A37] T09826 INDICATI Phase 3 Non-small-cell lung cancer [ICD-11: 2C25] T09826 INDICATI Approved Ovarian cancer [ICD-11: 2C73] T09826 INDICATI Phase 2 Renal cell carcinoma [ICD-11: 2C90] T09826 INDICATI Approved Solid tumour/cancer [ICD-11: 2A00-2F9Z] T09826 INDICATI Phase 3 Stomach cancer [ICD-11: 2B72] T09909 TARGETID T09909 T09909 TARGNAME Angiotensin II receptor type-2 (AGTR2) T09909 INDICATI Approved Hypertension [ICD-11: BA00-BA04] T09909 INDICATI Phase 2 Neuropathy [ICD-11: 8C0Z] T09909 INDICATI Approved Secondary hypertension [ICD-11: BA04] T09909 INDICATI Phase 2 Zoster [ICD-11: 1E91] T09937 TARGETID T09937 T09937 TARGNAME Receptor unspecific (Rec) T09937 INDICATI Phase 1 Diabetes mellitus [ICD-11: 5A10] T09937 INDICATI Phase 2 General pain disorder [ICD-11: 8E43] T09937 INDICATI Phase 1 Oral mucositis [ICD-11: DA01] T09937 INDICATI Discontinued in Phase 2 Skin sensation disturbance [ICD-11: ME65] T09937 INDICATI Phase 2 Solid tumour/cancer [ICD-11: 2A00-2F9Z] T09960 TARGETID T09960 T09960 TARGNAME C-C chemokine receptor type 5 (CCR5) T09960 INDICATI Phase 2 Chronic kidney disease [ICD-11: GB61] T09960 INDICATI Phase 3 Chronic obstructive pulmonary disease [ICD-11: CA22] T09960 INDICATI Investigative Diabetes mellitus [ICD-11: 5A10] T09960 INDICATI Approved Human immunodeficiency virus disease [ICD-11: 1C60-1C62] T09960 INDICATI Phase 2a Postoperative inflammation [ICD-11: 1A00-CA43] T09960 INDICATI Discontinued in Phase 1 Rheumatoid arthritis [ICD-11: FA20] T09960 INDICATI Phase 1 Solid tumour/cancer [ICD-11: 2A00-2F9Z] T09960 INDICATI Terminated Transplant rejection [ICD-11: NE84] T10052 TARGETID T10052 T10052 TARGNAME G1/S-specific cyclin-E1 (CCNE1) T10052 INDICATI Terminated Retina cancer [ICD-11: 2D02] T10091 TARGETID T10091 T10091 TARGNAME Rhodopsin (RHO) T10091 INDICATI Investigative Solid tumour/cancer [ICD-11: 2A00-2F9Z] T10092 TARGETID T10092 T10092 TARGNAME Follicle stimulating hormone (FSHB) T10092 INDICATI Phase 1 Female infertility [ICD-11: GA31] T10092 INDICATI Phase 2 Male infertility [ICD-11: GB04] T10147 TARGETID T10147 T10147 TARGNAME Protein-tyrosine phosphatase sigma (R-PTP-sigma) T10147 INDICATI Approved Bone paget disease [ICD-11: FB85] T10191 TARGETID T10191 T10191 TARGNAME T-cell surface glycoprotein CD4 (CD4) T10191 INDICATI Phase 3 Acute myeloid leukaemia [ICD-11: 2A60] T10191 INDICATI Phase 2 Asthma [ICD-11: CA23] T10191 INDICATI Approved Human immunodeficiency virus disease [ICD-11: 1C60-1C62] T10191 INDICATI Phase 2 Influenza [ICD-11: 1E30-1E32] T10191 INDICATI Phase 3 Lymphoma [ICD-11: 2A80-2A86] T10191 INDICATI Phase 1 Mature T-cell lymphoma [ICD-11: 2A90] T10191 INDICATI Phase 3 Myelodysplastic syndrome [ICD-11: 2A37] T10191 INDICATI Phase 2 Psoriasis [ICD-11: EA90] T10191 INDICATI Discontinued in Phase 2 Rheumatoid arthritis [ICD-11: FA20] T10191 INDICATI Investigative Solid tumour/cancer [ICD-11: 2A00-2F9Z] T10249 TARGETID T10249 T10249 TARGNAME Histamine/peptide leukotriene release (His/p-LT rele) T10249 INDICATI Phase 3 Asthma [ICD-11: CA23] T10265 TARGETID T10265 T10265 TARGNAME Phosphodiesterase 4B (PDE4B) T10265 INDICATI Investigative Acute upper respiratory infection [ICD-11: CA07] T10265 INDICATI Terminated Allergic/hypersensitivity disorder [ICD-11: 4A80-4A8Z] T10265 INDICATI Terminated Amyloidosis [ICD-11: 5D00] T10265 INDICATI Phase 3 Asthma [ICD-11: CA23] T10265 INDICATI Phase 2 Atopic eczema [ICD-11: EA80] T10265 INDICATI Phase 1 Choreiform disorder [ICD-11: 8A01] T10265 INDICATI Terminated Chronic arterial occlusive disease [ICD-11: BD4Z] T10265 INDICATI Phase 2 Chronic obstructive pulmonary disease [ICD-11: CA22] T10265 INDICATI Phase 2 Crohn disease [ICD-11: DD70] T10265 INDICATI Phase 3 Idiopathic interstitial pneumonitis [ICD-11: CB03] T10265 INDICATI Investigative Mature B-cell leukaemia [ICD-11: 2A82] T10265 INDICATI Phase 3 Mild neurocognitive disorder [ICD-11: 6D71] T10265 INDICATI Phase 1 Mood disorder [ICD-11: 6A60-6E23] T10265 INDICATI Discontinued in Phase 2 Multiple sclerosis [ICD-11: 8A40] T10265 INDICATI Discontinued in Phase 1 Mycosis fungoides [ICD-11: 2B01] T10265 INDICATI Phase 1 Parkinsonism [ICD-11: 8A00] T10265 INDICATI Investigative Pneumonia [ICD-11: CA40] T10265 INDICATI Investigative Postoperative inflammation [ICD-11: 1A00-CA43] T10265 INDICATI Phase 2 Psoriasis [ICD-11: EA90] T10265 INDICATI Phase 2 Rheumatoid arthritis [ICD-11: FA20] T10265 INDICATI Investigative Vitamin deficiency [ICD-11: 5B55-5B5F] T10339 TARGETID T10339 T10339 TARGNAME Lipoxygenase (ALOX) T10339 INDICATI Discontinued in Phase 1 Postoperative inflammation [ICD-11: 1A00-CA43] T10339 INDICATI Phase 2 Rheumatoid arthritis [ICD-11: FA20] T10362 TARGETID T10362 T10362 TARGNAME Enzyme unspecific (Enz) T10362 INDICATI Terminated Acute diabete complication [ICD-11: 5A2Y] T10362 INDICATI Terminated Bacterial infection [ICD-11: 1A00-1C4Z] T10362 INDICATI Terminated Colorectal cancer [ICD-11: 2B91] T10362 INDICATI Approved Female genital tract inflammatory disorder [ICD-11: GA0Z] T10362 INDICATI Terminated Hepatitis virus infection [ICD-11: 1E50-1E51] T10362 INDICATI Approved Human immunodeficiency virus disease [ICD-11: 1C60-1C62] T10362 INDICATI Phase 1 Infectious meningitis [ICD-11: 1D01] T10362 INDICATI Terminated Lysosomal disease [ICD-11: 5C56] T10362 INDICATI Phase 1/2 Malignant haematopoietic neoplasm [ICD-11: 2B33] T10362 INDICATI Terminated Mycobacterium infection [ICD-11: 1B10-1B21] T10362 INDICATI Phase 2 Nail/perionychium infection [ICD-11: EE12] T10362 INDICATI Phase 2 Obesity [ICD-11: 5B80-5B81] T10362 INDICATI Phase 2 Onchocerciasis [ICD-11: 1F6A] T10383 TARGETID T10383 T10383 TARGNAME Phospholipase D2 (PLD2) T10383 INDICATI Clinical trial Coagulation defect [ICD-11: 3B10] T10445 TARGETID T10445 T10445 TARGNAME Lipase unspecific (LIP) T10445 INDICATI Discontinued in Phase 2 Obesity [ICD-11: 5B80-5B81] T10482 TARGETID T10482 T10482 TARGNAME Factor XII messenger RNA (FA12 mRNA) T10482 INDICATI Clinical trial Alzheimer disease [ICD-11: 8A20] T10491 TARGETID T10491 T10491 TARGNAME C-X-C chemokine receptor type 7 (ACKR3) T10491 INDICATI Discontinued in Phase 2 Asthma [ICD-11: CA23] T10491 INDICATI Preclinical Solid tumour/cancer [ICD-11: 2A00-2F9Z] T10513 TARGETID T10513 T10513 TARGNAME Integrin beta-2 (ITGB2) T10513 INDICATI Discontinued in Phase 1 Cerebral ischaemia [ICD-11: 8B1Z] T10513 INDICATI Phase 1/2 Innate/adaptive immunodeficiency [ICD-11: 4A00] T10513 INDICATI Discontinued in Phase 2 Ischaemic/haemorrhagic stroke [ICD-11: 8B20] T10513 INDICATI Discontinued in Phase 2 Psoriasis [ICD-11: EA90] T10592 TARGETID T10592 T10592 TARGNAME DNM2 messenger RNA (DNM2 mRNA) T10592 INDICATI Phase 2 Congenital myopathy [ICD-11: 8C72] T10592 INDICATI Phase 1/2 Congenital myopathy ICD-11: 8C72 T10670 TARGETID T10670 T10670 TARGNAME Neuropeptide Y receptor type 2 (NPY2R) T10670 INDICATI Investigative Acute diabete complication [ICD-11: 5A2Y] T10670 INDICATI Investigative Metabolic disorder [ICD-11: 5C50-5D2Z] T10670 INDICATI Discontinued in Phase 2 Obesity [ICD-11: 5B80-5B81] T10735 TARGETID T10735 T10735 TARGNAME Histidine decarboxylase (HDC) T10735 INDICATI Phase 2 Heart failure [ICD-11: BD10-BD1Z] T10735 INDICATI Phase 3 Hypo-osmolality/hyponatraemia [ICD-11: 5C72] T10735 INDICATI Phase 1 Pruritus [ICD-11: EC90] T10735 INDICATI Phase 2 Skin and skin-structure infection [ICD-11: 1F28-1G0Z] T10762 TARGETID T10762 T10762 TARGNAME Bone morphogenetic protein 6 (BMP6) T10762 INDICATI Phase 2 Acute disease anaemia [ICD-11: 3A90] T10783 TARGETID T10783 T10783 TARGNAME MERS-CoV spike glycoprotein S2' HR1 region (S S2'HR1) T10783 INDICATI Investigative Middle East Respiratory Syndrome [ICD-11: 1D64] T10783 INDICATI Investigative Severe acute respiratory syndrome [ICD-11: 1D65] T10822 TARGETID T10822 T10822 TARGNAME Cyclin-dependent kinase 8 (CDK8) T10822 INDICATI Phase 1 Acute myeloid leukaemia [ICD-11: 2A60] T10822 INDICATI Preclinical Colorectal cancer [ICD-11: 2B91] T10822 INDICATI Phase 1 Myelodysplastic syndrome [ICD-11: 2A37] T10822 INDICATI Investigative Pain [ICD-11: MG30-MG3Z] T10828 TARGETID T10828 T10828 TARGNAME Alpha-fetoprotein (AFP) T10828 INDICATI Phase 2 Diabetes mellitus [ICD-11: 5A10] T10828 INDICATI Phase 1 Liver cancer [ICD-11: 2C12] T10877 TARGETID T10877 T10877 TARGNAME Cyclic ADP-ribose hydrolase 1 (CD38) T10877 INDICATI Phase 1/2 Acute myeloid leukaemia [ICD-11: 2A60] T10877 INDICATI Phase 1/2 B-cell lymphoma [ICD-11: 2A86] T10877 INDICATI Phase 1/2 Malignant haematopoietic neoplasm [ICD-11: 2B33] T10877 INDICATI Phase 1/2 Mature B-cell lymphoma [ICD-11: 2A85] T10877 INDICATI Approved Multiple myeloma [ICD-11: 2A83] T10877 INDICATI Phase 2 Myasthenia gravis [ICD-11: 8C6Y] T10877 INDICATI Phase 1 Myelodysplastic syndrome [ICD-11: 2A37] T10877 INDICATI Phase 1 Postoperative inflammation [ICD-11: 1A00-CA43] T10877 INDICATI Phase 1 Solid tumour/cancer [ICD-11: 2A00-2F9Z] T10877 INDICATI Phase 2 Thrombocytopenia ICD-11: 3B64 T10877 INDICATI Phase 1 Urinary system clinical sympton [ICD-11: MF8Y] T10897 TARGETID T10897 T10897 TARGNAME Acyl-CoA desaturase (SCD) T10897 INDICATI Investigative Acute diabete complication [ICD-11: 5A2Y] T10897 INDICATI Approved Bacterial infection [ICD-11: 1A00-1C4Z] T10897 INDICATI Phase 2/3 Inborn lipid metabolism error [ICD-11: 5C52] T10897 INDICATI Phase 2 Type 2 diabetes mellitus [ICD-11: 5A11] T10937 TARGETID T10937 T10937 TARGNAME Mdm2 messenger RNA (MDM2 mRNA) T10937 INDICATI Investigative Solid tumour/cancer [ICD-11: 2A00-2F9Z] T10965 TARGETID T10965 T10965 TARGNAME P-selectin (SELP) T10965 INDICATI Discontinued in Phase 1 Allergic/hypersensitivity disorder [ICD-11: 4A80-4A8Z] T10965 INDICATI Phase 1 Arterial occlusive disease [ICD-11: BD40] T10965 INDICATI Phase 3 Asthma [ICD-11: CA23] T10965 INDICATI Approved Circulatory system disease [ICD-11: BE2Z] T10965 INDICATI Phase 2 Graft-versus-host disease [ICD-11: 4B24] T10965 INDICATI Phase 2/3 Hypertension [ICD-11: BA00-BA04] T10965 INDICATI Phase 2 Influenza [ICD-11: 1E30-1E32] T10965 INDICATI Phase 4 Sickle-cell disorder [ICD-11: 3A51] T10965 INDICATI Discontinued in Phase 2 Solid tumour/cancer [ICD-11: 2A00-2F9Z] T10965 INDICATI Phase 1 Thrombosis [ICD-11: DB61-GB90] T10988 TARGETID T10988 T10988 TARGNAME IL-1 receptor-like 2 (IL1RL2) T10988 INDICATI Phase 2 Melanoma [ICD-11: 2C30] T10988 INDICATI Phase 3 Ovarian cancer [ICD-11: 2C73] T10988 INDICATI Approved Psoriasis [ICD-11: EA90] T10988 INDICATI Phase 3 Psoriasis ICD-11: EA90 T11005 TARGETID T11005 T11005 TARGNAME Interferon-omega (IFNW1) T11005 INDICATI Phase 2 Hepatitis virus infection [ICD-11: 1E50-1E51] T11011 TARGETID T11011 T11011 TARGNAME Corticotropin-releasing factor receptor 2 (CRHR2) T11011 INDICATI Terminated Anxiety disorder [ICD-11: 6B00-6B0Z] T11011 INDICATI Phase 1 Binge eating disorder [ICD-11: 6B82] T11011 INDICATI Phase 2 Heart failure [ICD-11: BD10-BD1Z] T11069 TARGETID T11069 T11069 TARGNAME Lyase unspecific (LYA) T11069 INDICATI Phase 1 Solid tumour/cancer [ICD-11: 2A00-2F9Z] T11072 TARGETID T11072 T11072 TARGNAME 5-HT 1D receptor (HTR1D) T11072 INDICATI Phase 2 Alzheimer disease [ICD-11: 8A20] T11072 INDICATI Phase 2 Dementia [ICD-11: 6D80-6D8Z] T11072 INDICATI Terminated Depression [ICD-11: 6A70-6A7Z] T11072 INDICATI Phase 2 Epilepsy/seizure [ICD-11: 8A61-8A6Z] T11072 INDICATI Phase 2 Insomnia [ICD-11: 7A00-7A0Z] T11072 INDICATI Approved Migraine [ICD-11: 8A80] T11072 INDICATI Phase 2 Mood disorder [ICD-11: 6A60-6E23] T11072 INDICATI Approved Pituitary gland disorder [ICD-11: 5A60-5A61] T11164 TARGETID T11164 T11164 TARGNAME Secretory phospholipase A2 (sPLA2) T11164 INDICATI Phase 3 Rheumatoid arthritis [ICD-11: FA20] T11211 TARGETID T11211 T11211 TARGNAME Androgen receptor (AR) T11211 INDICATI Approved Acne vulgaris [ICD-11: ED80] T11211 INDICATI Approved Acute myeloid leukaemia [ICD-11: 2A60] T11211 INDICATI Approved Alcoholic liver disease [ICD-11: DB94] T11211 INDICATI Phase 2 Alopecia [ICD-11: ED70] T11211 INDICATI Investigative Bladder cancer [ICD-11: 2C94] T11211 INDICATI Approved Breast cancer [ICD-11: 2C60-2C6Y] T11211 INDICATI Discontinued in Phase 1 Cachexia [ICD-11: MG20] T11211 INDICATI Phase 4 Cardiovascular disease [ICD-11: BA00-BE2Z] T11211 INDICATI Phase 2 Chronic kidney disease [ICD-11: GB61] T11211 INDICATI Approved Chronic obstructive pulmonary disease [ICD-11: CA22] T11211 INDICATI Phase 1 Contraceptive management [ICD-11: QA21] T11211 INDICATI Discontinued in Phase 2 Cystic fibrosis [ICD-11: CA25] T11211 INDICATI Discontinued in Phase 1 Dissociative neurological symptom disorder [ICD-11: 6B60] T11211 INDICATI Approved Female pelvic pain [ICD-11: GA34] T11211 INDICATI Phase 1 Heart failure [ICD-11: BD10-BD1Z] T11211 INDICATI Approved Hypo-osmolality/hyponatraemia [ICD-11: 5C72] T11211 INDICATI Approved Low bone mass disorder [ICD-11: FB83] T11211 INDICATI Approved Mammary tumour [ICD-11: 2C60-2C6Z] T11211 INDICATI Phase 1 Muscle disorder [ICD-11: FB32-FB3Z] T11211 INDICATI Phase 1 Muscular dystrophy [ICD-11: 8C70] T11211 INDICATI Investigative Oesophagitis [ICD-11: DA24] T11211 INDICATI Discontinued in Phase 2 Pain [ICD-11: MG30-MG3Z] T11211 INDICATI Phase 2 Pituitary gland disorder [ICD-11: 5A60-5A61] T11211 INDICATI Approved Prostate cancer [ICD-11: 2C82] T11211 INDICATI Phase 4 Prostate hyperplasia [ICD-11: GA90] T11211 INDICATI Investigative Solid tumour/cancer [ICD-11: 2A00-2F9Z] T11211 INDICATI Approved Testicular dysfunction [ICD-11: 5A81] T11211 INDICATI Phase 2 Thrombosis [ICD-11: DB61-GB90] T11241 TARGETID T11241 T11241 TARGNAME Sphingosine-1-phosphate receptor 3 (S1PR3) T11241 INDICATI Preclinical Breast cancer [ICD-11: 2C60-2C6Y] T11253 TARGETID T11253 T11253 TARGNAME HSPB1 messenger RNA (HSPB1 mRNA) T11253 INDICATI Investigative Bladder cancer [ICD-11: 2C94] T11253 INDICATI Investigative Breast cancer [ICD-11: 2C60-2C6Y] T11253 INDICATI Investigative Lung cancer [ICD-11: 2C25] T11253 INDICATI Investigative Ovarian cancer [ICD-11: 2C73] T11253 INDICATI Investigative Prostate cancer [ICD-11: 2C82] T11253 INDICATI Discontinued in Phase 1 Rheumatoid arthritis [ICD-11: FA20] T11283 TARGETID T11283 T11283 TARGNAME Mitochondrial matrix protein P1 (HSPD1) T11283 INDICATI Phase 3 Diabetes mellitus [ICD-11: 5A10] T11288 TARGETID T11288 T11288 TARGNAME Multidrug resistance-associated protein 1 (ABCC1) T11288 INDICATI Approved Gout [ICD-11: FA25] T11309 TARGETID T11309 T11309 TARGNAME Monocyte chemotactic and activating factor (CCL2) T11309 INDICATI Phase 2 Acute diabete complication [ICD-11: 5A2Y] T11309 INDICATI Discontinued in Phase 1 Asthma [ICD-11: CA23] T11309 INDICATI Preclinical Chronic obstructive pulmonary disease [ICD-11: CA22] T11309 INDICATI Phase 2 Idiopathic interstitial pneumonitis [ICD-11: CB03] T11309 INDICATI Phase 3 Nephritic syndrome [ICD-11: GB40] T11309 INDICATI Preclinical Rheumatoid arthritis [ICD-11: FA20] T11309 INDICATI Phase 1 Solid tumour/cancer [ICD-11: 2A00-2F9Z] T11388 TARGETID T11388 T11388 TARGNAME Cathepsin K (CTSK) T11388 INDICATI Investigative Asthma [ICD-11: CA23] T11388 INDICATI Patented Bone cancer [ICD-11: 2B5Z] T11388 INDICATI Patented Chronic obstructive pulmonary disease [ICD-11: CA22] T11388 INDICATI Patented Chronic pain [ICD-11: MG30] T11388 INDICATI Patented Digestive system disease [ICD-11: DE2Z] T11388 INDICATI Patented Hepatic fibrosis/cirrhosis [ICD-11: DB93] T11388 INDICATI Phase 3 Low bone mass disorder [ICD-11: FB83] T11388 INDICATI Discontinued in Phase 2 Metastatic tumour [ICD-11: 2D50-2E2Z] T11388 INDICATI Patented Multiple sclerosis [ICD-11: 8A40] T11388 INDICATI Investigative Musculoskeletal system/connective tissue disease [ICD-11: FC0Z] T11388 INDICATI Preclinical Osteoarthritis [ICD-11: FA00-FA05] T11388 INDICATI Phase 1 Pain [ICD-11: MG30-MG3Z] T11388 INDICATI Investigative Postoperative inflammation [ICD-11: 1A00-CA43] T11388 INDICATI Patented Psoriasis [ICD-11: EA90] T11388 INDICATI Phase 1 Rheumatoid arthritis [ICD-11: FA20] T11448 TARGETID T11448 T11448 TARGNAME Adrenergic receptor alpha-2A (ADRA2A) T11448 INDICATI Phase 3 Alzheimer disease [ICD-11: 8A20] T11448 INDICATI Approved Attention deficit hyperactivity disorder [ICD-11: 6A05] T11448 INDICATI Investigative Dementia [ICD-11: 6D80-6D8Z] T11448 INDICATI Phase 1 Depression [ICD-11: 6A70-6A7Z] T11448 INDICATI Terminated Genetic cardiac arrhythmia [ICD-11: BC65] T11448 INDICATI Investigative Obesity [ICD-11: 5B80-5B81] T11448 INDICATI Approved Opioid use disorder [ICD-11: 6C43] T11448 INDICATI Phase 2 Pain [ICD-11: MG30-MG3Z] T11448 INDICATI Discontinued in Phase 2 Sexual dysfunction [ICD-11: HA00-HA01] T11448 INDICATI IND submitted Solid tumour/cancer [ICD-11: 2A00-2F9Z] T11448 INDICATI Approved Substance abuse [ICD-11: 6C40] T11451 TARGETID T11451 T11451 TARGNAME Toll-like receptor 9 (TLR9) T11451 INDICATI Preclinical Allergic/hypersensitivity disorder [ICD-11: 4A80-4A8Z] T11451 INDICATI Phase 2 Asthma [ICD-11: CA23] T11451 INDICATI Phase 1 Autoimmune disease [ICD-11: 4A40-4A45] T11451 INDICATI Phase 1 Brain cancer [ICD-11: 2A00] T11451 INDICATI Phase 3 Colorectal cancer [ICD-11: 2B91] T11451 INDICATI Phase 2 Diabetes mellitus [ICD-11: 5A10] T11451 INDICATI Discontinued in Phase 1/2 Diffuse large B-cell lymphoma [ICD-11: 2A81] T11451 INDICATI Phase 3 Hepatitis virus infection [ICD-11: 1E50-1E51] T11451 INDICATI Phase 2 Human immunodeficiency virus disease [ICD-11: 1C60-1C62] T11451 INDICATI Phase 2 Indeterminate colitis [ICD-11: DD72] T11451 INDICATI Phase 1 Influenza [ICD-11: 1E30-1E32] T11451 INDICATI Phase 2 Leukaemia [ICD-11: 2A60-2B33] T11451 INDICATI Phase 1 Lung cancer [ICD-11: 2C25] T11451 INDICATI Phase 1 Lupus erythematosus [ICD-11: 4A40] T11451 INDICATI Phase 1 Mature B-cell leukaemia [ICD-11: 2A82] T11451 INDICATI Phase 3 Melanoma [ICD-11: 2C30] T11451 INDICATI Phase 1/2 Metastatic lymph node neoplasm [ICD-11: 2D60] T11451 INDICATI Investigative Parkinsonism [ICD-11: 8A00] T11451 INDICATI Investigative Postoperative inflammation [ICD-11: 1A00-CA43] T11451 INDICATI Phase 3 Prostate cancer [ICD-11: 2C82] T11451 INDICATI Phase 2 Psoriasis [ICD-11: EA90] T11451 INDICATI Phase 2 Renal cell carcinoma [ICD-11: 2C90] T11451 INDICATI Investigative Sepsis [ICD-11: 1G40-1G41] T11451 INDICATI Phase 2 Skin disease [ICD-11: EA00-EM0Z] T11451 INDICATI Phase 2 Solid tumour/cancer [ICD-11: 2A00-2F9Z] T11451 INDICATI Investigative Spine/trunk injury [ICD-11: ND51] T11451 INDICATI Phase 1/2 Squamous cell carcinoma [ICD-11: 2B60-2D01] T11451 INDICATI Phase 2 Vasomotor/allergic rhinitis [ICD-11: CA08] T11453 TARGETID T11453 T11453 TARGNAME Gastric inhibitory polypeptide (GIP) T11453 INDICATI Phase 1 Type 2 diabetes mellitus [ICD-11: 5A11] T11487 TARGETID T11487 T11487 TARGNAME Acetoacetyl-CoA thiolase (ACAT1) T11487 INDICATI Phase 1 Adrenal cancer [ICD-11: 2D11] T11487 INDICATI Withdrawn from market Postoperative inflammation [ICD-11: 1A00-CA43] T11562 TARGETID T11562 T11562 TARGNAME SARS-CoV spike glycoprotein (S) T11562 INDICATI Phase 1 Human immunodeficiency virus disease [ICD-11: 1C60-1C62] T11562 INDICATI Preclinical Middle East Respiratory Syndrome [ICD-11: 1D64] T11562 INDICATI Preclinical Severe acute respiratory syndrome [ICD-11: 1D65] T11566 TARGETID T11566 T11566 TARGNAME SARS-CoV envelope small membrane protein (E) T11566 INDICATI Preclinical Severe acute respiratory syndrome [ICD-11: 1D65] T11610 TARGETID T11610 T11610 TARGNAME SARS-CoV spike glycoprotein S2' HR1 region (S S2'HR1) T11610 INDICATI Investigative Middle East Respiratory Syndrome [ICD-11: 1D64] T11610 INDICATI Investigative Severe acute respiratory syndrome [ICD-11: 1D65] T11615 TARGETID T11615 T11615 TARGNAME Cystine/glutamate transporter (SLC7A11) T11615 INDICATI Phase 2 Body-focused behaviour disorder [ICD-11: 6B25] T11701 TARGETID T11701 T11701 TARGNAME Interleukin-31 (IL31) T11701 INDICATI Phase 1 Atopic eczema [ICD-11: EA80] T11701 INDICATI Phase 1 Prurigo [ICD-11: EC91] T11754 TARGETID T11754 T11754 TARGNAME Fatty acid amide hydrolase (FAAH) T11754 INDICATI Phase 2 Anxiety disorder [ICD-11: 6B00-6B0Z] T11754 INDICATI Approved Corneal disease [ICD-11: 9A76-9A78] T11754 INDICATI Phase 2 Depression [ICD-11: 6A70-6A7Z] T11754 INDICATI Investigative General pain disorder [ICD-11: 8E43] T11754 INDICATI Phase 2 Liver disease [ICD-11: DB90-DB9Z] T11754 INDICATI Phase 1 Pain [ICD-11: MG30-MG3Z] T11754 INDICATI Phase 2 Postoperative inflammation [ICD-11: 1A00-CA43] T11754 INDICATI Phase 2 Social anxiety disorder [ICD-11: 6B04] T11822 TARGETID T11822 T11822 TARGNAME Retinoic acid receptor (RAR) T11822 INDICATI Approved Acne vulgaris [ICD-11: ED80] T11822 INDICATI Approved Acute myeloid leukaemia [ICD-11: 2A60] T11822 INDICATI Phase 3 Brain cancer [ICD-11: 2A00] T11822 INDICATI Terminated Breast cancer [ICD-11: 2C60-2C6Y] T11822 INDICATI Investigative Kinetoplastids [ICD-11: 1F61-1G2Z] T11822 INDICATI Approved Light sensitivity impairment [ICD-11: 9D45] T11822 INDICATI Phase 3 Liver cancer [ICD-11: 2C12] T11822 INDICATI Phase 2 Lymphoma [ICD-11: 2A80-2A86] T11822 INDICATI Phase 2 Male infertility [ICD-11: GB04] T11822 INDICATI Phase 2 Mature T-cell lymphoma [ICD-11: 2A90] T11822 INDICATI Discontinued in Phase 3 Psoriasis [ICD-11: EA90] T11822 INDICATI Phase 3 Retinopathy [ICD-11: 9B71] T11822 INDICATI Discontinued in Preregistration Rosacea [ICD-11: ED90] T11822 INDICATI Phase 2 Solid tumour/cancer [ICD-11: 2A00-2F9Z] T11843 TARGETID T11843 T11843 TARGNAME Vitamin K epoxide reductase complex 1 (VKORC1) T11843 INDICATI Approved Bleeding disorder [ICD-11: GA20-GA21] T11843 INDICATI Phase 3 Cerebral ischaemia [ICD-11: 8B1Z] T11843 INDICATI Approved Coagulation defect [ICD-11: 3B10] T11843 INDICATI Approved Pulmonary thromboembolism [ICD-11: BB00] T11843 INDICATI Approved Supraventricular tachyarrhythmia [ICD-11: BC81] T11843 INDICATI Approved Thrombosis [ICD-11: DB61-GB90] T11911 TARGETID T11911 T11911 TARGNAME Calcium-activated potassium channel KCa2.1 (KCNN1) T11911 INDICATI Clinical trial Myelopathy [ICD-11: 8B42] T11947 TARGETID T11947 T11947 TARGNAME Coagulation factor XIII (F13B) T11947 INDICATI Phase 3 Coagulation defect [ICD-11: 3B10] T11947 INDICATI Phase 3 Graft-versus-host disease [ICD-11: 4B24] T11947 INDICATI Terminated Thrombosis [ICD-11: DB61-GB90] T12059 TARGETID T12059 T12059 TARGNAME Alpha-mannosidase (MANA) T12059 INDICATI Phase 3 Lysosomal disease [ICD-11: 5C56] T12091 TARGETID T12091 T12091 TARGNAME Activin receptor-like kinase 2 (ALK-2) T12091 INDICATI Phase 2 Anemia [ICD-11: 3A00-3A9Z] T12091 INDICATI Phase 2 Multiple myeloma [ICD-11: 2A83] T12091 INDICATI Phase 2 Myelodysplastic syndrome [ICD-11: 2A37] T12091 INDICATI Phase 1 Solid tumour/cancer [ICD-11: 2A00-2F9Z] T12097 TARGETID T12097 T12097 TARGNAME Melanoma-associated antigen 4 (MAGEA4) T12097 INDICATI Phase 2 Kaposi sarcoma [ICD-11: 2B57] T12097 INDICATI Phase 1/2 Lung cancer [ICD-11: 2C25] T12097 INDICATI Phase 1 Solid tumour/cancer [ICD-11: 2A00-2F9Z] T12097 INDICATI Phase 2 Synovial sarcoma [ICD-11: 2B5A] T12108 TARGETID T12108 T12108 TARGNAME Cryptochrome circadian clock 1 (CRY1) T12108 INDICATI Preclinical Brain cancer [ICD-11: 2A00] T12108 INDICATI Preclinical Breast cancer [ICD-11: 2C60-2C6Y] T12119 TARGETID T12119 T12119 TARGNAME Voltage-gated sodium channel alpha Nav1.7 (SCN9A) T12119 INDICATI Discontinued in Phase 2 Asthma [ICD-11: CA23] T12119 INDICATI Phase 2 Bipolar disorder [ICD-11: 6A60] T12119 INDICATI Phase 2 Chronic pain [ICD-11: MG30] T12119 INDICATI Discontinued in Phase 2 Dissociative neurological symptom disorder [ICD-11: 6B60] T12119 INDICATI Phase 2 Extremities vasodilatation [ICD-11: EG00] T12119 INDICATI Phase 1 General pain disorder [ICD-11: 8E43] T12119 INDICATI Phase 2 Osteoarthritis [ICD-11: FA00-FA05] T12119 INDICATI Phase 2 Pain [ICD-11: MG30-MG3Z] T12119 INDICATI Phase 2 Radiculopathy [ICD-11: 8B93] T12119 INDICATI Phase 2 Trigeminal nerve disorder [ICD-11: 8B82] T12187 TARGETID T12187 T12187 TARGNAME Mycobacterium D-alanine-D-alanine ligase A (MycB ddl) T12187 INDICATI Approved Bacterial infection [ICD-11: 1A00-1C4Z] T12187 INDICATI Approved HIV-infected patients with tuberculosis [ICD-11: 1B10-1B14] T12187 INDICATI Phase 2 Obsessive-compulsive disorder [ICD-11: 6B20] T12189 TARGETID T12189 T12189 TARGNAME Telomerase messenger RNA (Telomerase mRNA) T12189 INDICATI Discontinued in Phase 2 Chronic obstructive pulmonary disease [ICD-11: CA22] T12279 TARGETID T12279 T12279 TARGNAME Human papillomavirus E2 transactivator messenger RNA (HPV E2 mRNA) T12279 INDICATI Discontinued in Phase 2 Sexually transmitted infection [ICD-11: 1A9Y-1A9Z] T12355 TARGETID T12355 T12355 TARGNAME G1/S-specific cyclin-D1 (CCND1) T12355 INDICATI Phase 2 Mature B-cell leukaemia [ICD-11: 2A82] T12355 INDICATI Phase 3 Myeloproliferative neoplasm [ICD-11: 2A20] T12355 INDICATI Phase 1 Solid tumour/cancer [ICD-11: 2A00-2F9Z] T12427 TARGETID T12427 T12427 TARGNAME Sodium pump (NaP) T12427 INDICATI Approved Cardiovascular disease [ICD-11: BA00-BE2Z] T12475 TARGETID T12475 T12475 TARGNAME Gonadotropin-releasing hormone receptor (GNRHR) T12475 INDICATI Preclinical Coronavirus infection [ICD-11: 1D92] T12475 INDICATI Approved Endometriosis [ICD-11: GA10] T12475 INDICATI Discontinued in Phase 1 Esophageal cancer [ICD-11: 2B70] T12475 INDICATI Phase 3 Female infertility [ICD-11: GA31] T12475 INDICATI Phase 3 Mature B-cell lymphoma [ICD-11: 2A85] T12475 INDICATI Approved Ovarian developmental anomaly [ICD-11: LB45] T12475 INDICATI Approved Ovarian dysfunction [ICD-11: 5A80] T12475 INDICATI Approved Pituitary gland disorder [ICD-11: 5A60-5A61] T12475 INDICATI Approved Prostate cancer [ICD-11: 2C82] T12475 INDICATI Phase 2 Prostate disease [ICD-11: GA91] T12475 INDICATI Discontinued in Phase 2 Prostate hyperplasia [ICD-11: GA90] T12475 INDICATI Approved Solid tumour/cancer [ICD-11: 2A00-2F9Z] T12475 INDICATI Phase 3 Uterine fibroid [ICD-11: 2E86] T12499 TARGETID T12499 T12499 TARGNAME LCK tyrosine protein kinase (LCK) T12499 INDICATI Phase 1 Cardiovascular disease [ICD-11: BA00-BE2Z] T12499 INDICATI Investigative Gram-positive bacterial infection [ICD-11: 1B74-1F40] T12499 INDICATI Phase 2 Multiple myeloma [ICD-11: 2A83] T12499 INDICATI Approved Myeloproliferative neoplasm [ICD-11: 2A20] T12499 INDICATI Phase 1 Postoperative inflammation [ICD-11: 1A00-CA43] T12499 INDICATI Phase 2 Solid tumour/cancer [ICD-11: 2A00-2F9Z] T12541 TARGETID T12541 T12541 TARGNAME Phosphatidylinositol-4-kinase beta (PI4KB) T12541 INDICATI Phase 1 Chronic obstructive pulmonary disease [ICD-11: CA22] T12541 INDICATI Phase 1 Zoonotic viral disease ICD-11: 1D6Y T12646 TARGETID T12646 T12646 TARGNAME Valosin-containing protein p97 (VCP) T12646 INDICATI Phase 1 Acute myeloid leukaemia [ICD-11: 2A60] T12646 INDICATI Phase 1 Multiple myeloma [ICD-11: 2A83] T12646 INDICATI Phase 1 Myelodysplastic syndrome [ICD-11: 2A37] T12646 INDICATI Phase 1 Solid tumour/cancer [ICD-11: 2A00-2F9Z] T12719 TARGETID T12719 T12719 TARGNAME Cytomegalovirus Replication (CMV replication) T12719 INDICATI Discontinued in Phase 2 Virus infection [ICD-11: 1A24-1D9Z] T12808 TARGETID T12808 T12808 TARGNAME Protein kinase C alpha (PRKCA) T12808 INDICATI Investigative Human immunodeficiency virus disease [ICD-11: 1C60-1C62] T12808 INDICATI Approved Muscular atrophy [ICD-11: 8B61] T12808 INDICATI Terminated Nephritic syndrome [ICD-11: GB40] T12808 INDICATI Phase 2 Transplant rejection [ICD-11: NE84] T12909 TARGETID T12909 T12909 TARGNAME Dystrophin (DMD) T12909 INDICATI Phase 3 Muscular dystrophy ICD-11: 8C70 T12909 INDICATI Phase 2/3 Muscular dystrophy [ICD-11: 8C70] T12966 TARGETID T12966 T12966 TARGNAME Troponin C (TN-C) T12966 INDICATI Approved Acquired cutaneous blood vessel malformation [ICD-11: EF20] T12966 INDICATI Phase 3 Cardiomyopathy [ICD-11: BC43] T12966 INDICATI Approved Heart failure [ICD-11: BD10-BD1Z] T12966 INDICATI Phase 2 Pulmonary hypertension [ICD-11: BB01] T13017 TARGETID T13017 T13017 TARGNAME Syndecan-1 (SDC1) T13017 INDICATI Phase 1 Immune system disease [ICD-11: 4A01-4B41] T13017 INDICATI Phase 2 Multiple myeloma [ICD-11: 2A83] T13057 TARGETID T13057 T13057 TARGNAME Protein-tyrosine phosphatase SHP-2 (PTPN11) T13057 INDICATI Phase 1/2 Solid tumour/cancer [ICD-11: 2A00-2F9Z] T13075 TARGETID T13075 T13075 TARGNAME Casein kinase I alpha (CSNK1A1) T13075 INDICATI Phase 1 Malignant haematopoietic neoplasm [ICD-11: 2B33] T13075 INDICATI Preclinical Mature B-cell leukaemia [ICD-11: 2A82] T13075 INDICATI Preclinical Pancreatic cancer [ICD-11: 2C10] T13075 INDICATI Phase 1 Solid tumour/cancer [ICD-11: 2A00-2F9Z] T13127 TARGETID T13127 T13127 TARGNAME Farnesyl protein transferase (Ftase) T13127 INDICATI Phase 3 Acute myeloid leukaemia [ICD-11: 2A60] T13127 INDICATI Phase 1/2 Colorectal cancer [ICD-11: 2B91] T13127 INDICATI Phase 2 Hepatitis virus infection [ICD-11: 1E50-1E51] T13127 INDICATI Phase 1 Lung cancer [ICD-11: 2C25] T13127 INDICATI Phase 1 Lymphoma [ICD-11: 2A80-2A86] T13127 INDICATI Phase 2 Mature T-cell lymphoma [ICD-11: 2A90] T13127 INDICATI Phase 3 Myelodysplastic syndrome [ICD-11: 2A37] T13127 INDICATI Phase 2 Myeloproliferative neoplasm [ICD-11: 2A20] T13127 INDICATI Phase 1/2 Pancreatic cancer [ICD-11: 2C10] T13127 INDICATI Approved Premature ageing appearance [ICD-11: LD2B] T13127 INDICATI Phase 2 Sexually transmitted infection [ICD-11: 1A9Y-1A9Z] T13127 INDICATI Phase 1 Solid tumour/cancer [ICD-11: 2A00-2F9Z] T13176 TARGETID T13176 T13176 TARGNAME PRKR-like endoplasmic reticulum kinase (PERK) T13176 INDICATI Phase 1 Breast cancer [ICD-11: 2C60-2C6Y] T13201 TARGETID T13201 T13201 TARGNAME Carbonic anhydrase I (CA-I) T13201 INDICATI Phase 2 Breast cancer [ICD-11: 2C60-2C6Y] T13201 INDICATI Withdrawn from market Duodenal ulcer [ICD-11: DA63] T13201 INDICATI Approved Glaucoma [ICD-11: 9C61] T13201 INDICATI Phase 3 Rheumatoid arthritis [ICD-11: FA20] T13201 INDICATI Approved Seborrhoeic dermatitis [ICD-11: EA81] T13201 INDICATI Phase 3 Solid tumour/cancer [ICD-11: 2A00-2F9Z] T13209 TARGETID T13209 T13209 TARGNAME Activin receptor type II (ACVR2) T13209 INDICATI Phase 2 Type 2 diabetes mellitus [ICD-11: 5A11] T13251 TARGETID T13251 T13251 TARGNAME Interleukin-12 alpha (IL12A) T13251 INDICATI Phase 2 Crohn disease [ICD-11: DD70] T13251 INDICATI Phase 2/3 Indeterminate colitis [ICD-11: DD72] T13251 INDICATI Investigative Malaria [ICD-11: 1F40-1F45] T13251 INDICATI Approved Psoriasis [ICD-11: EA90] T13251 INDICATI Phase 2 Rheumatoid arthritis [ICD-11: FA20] T13251 INDICATI Approved Ulcerative colitis [ICD-11: DD71] T13259 TARGETID T13259 T13259 TARGNAME Succinate-semialdehyde dehydrogenase (ALDH5A1) T13259 INDICATI Approved Diagnostic imaging [ICD-11: N.A.] T13259 INDICATI Approved Nutritional deficiency [ICD-11: 5B50-5B71] T13260 TARGETID T13260 T13260 TARGNAME Aromatase (CYP19A1) T13260 INDICATI Discontinued in Phase 2 Bladder cancer [ICD-11: 2C94] T13260 INDICATI Approved Breast cancer [ICD-11: 2C60-2C6Y] T13260 INDICATI Approved Cushing syndrome [ICD-11: 5A70] T13260 INDICATI Phase 2 Endometriosis [ICD-11: GA10] T13260 INDICATI Phase 2 Neuropathy [ICD-11: 8C0Z] T13260 INDICATI Phase 2/3 Oesophagitis [ICD-11: DA24] T13260 INDICATI Discontinued in Phase 2 Prostate disease [ICD-11: GA91] T13348 TARGETID T13348 T13348 TARGNAME AP endonuclease 1 (APEX1) T13348 INDICATI Investigative Brain cancer [ICD-11: 2A00] T13348 INDICATI Investigative Melanoma [ICD-11: 2C30] T13348 INDICATI Discontinued in Phase 2 Ocular cancer [ICD-11: 2D00-2D07] T13348 INDICATI Phase 2 Retinopathy [ICD-11: 9B71] T13348 INDICATI Phase 1 Solid tumour/cancer [ICD-11: 2A00-2F9Z] T13409 TARGETID T13409 T13409 TARGNAME Human immunodeficiency virus Matrix p17 (HIV MA) T13409 INDICATI Phase 2 Human immunodeficiency virus disease [ICD-11: 1C60-1C62] T13491 TARGETID T13491 T13491 TARGNAME Solute carrier family 29 member 1 (SLC29A1) T13491 INDICATI Approved Angina pectoris [ICD-11: BA40] T13568 TARGETID T13568 T13568 TARGNAME Methamphetamine (Meth) T13568 INDICATI Phase 2 Stimulants use disorder [ICD-11: 6C46] T13616 TARGETID T13616 T13616 TARGNAME Integrin-linked protein kinase 1 (ILK) T13616 INDICATI Investigative Solid tumour/cancer [ICD-11: 2A00-2F9Z] T13629 TARGETID T13629 T13629 TARGNAME PD-1-PD-L1 interaction (PD-1/PD-L1 PPI) T13629 INDICATI Patented Human immunodeficiency virus disease [ICD-11: 1C60-1C62] T13629 INDICATI Patented Inflammatory liver disease [ICD-11: DB97] T13629 INDICATI Patented Postoperative inflammation [ICD-11: 1A00-CA43] T13629 INDICATI Patented Solid tumour/cancer [ICD-11: 2A00-2F9Z] T13644 TARGETID T13644 T13644 TARGNAME Somatostatin receptor type 3 (SSTR3) T13644 INDICATI Terminated Alzheimer disease [ICD-11: 8A20] T13644 INDICATI Approved Cushing syndrome [ICD-11: 5A70] T13644 INDICATI Investigative Stomach cancer [ICD-11: 2B72] T13712 TARGETID T13712 T13712 TARGNAME Cholesterol synthesis (Chole synth) T13712 INDICATI Phase 3 Cardiovascular disease [ICD-11: BA00-BE2Z] T13712 INDICATI Approved Hyper-lipoproteinaemia [ICD-11: 5C80] T13714 TARGETID T13714 T13714 TARGNAME Oxysterols receptor LXR-beta (NR1H2) T13714 INDICATI Phase 2 Atopic eczema [ICD-11: EA80] T13714 INDICATI Investigative Depression [ICD-11: 6A70-6A7Z] T13726 TARGETID T13726 T13726 TARGNAME Retinoic acid receptor RXR-alpha (RXRA) T13726 INDICATI Approved Kaposi sarcoma [ICD-11: 2B57] T13726 INDICATI Approved Mycosis fungoides [ICD-11: 2B01] T13741 TARGETID T13741 T13741 TARGNAME Opioid receptor zeta (OGFR) T13741 INDICATI Phase 2 Pancreatic cancer [ICD-11: 2C10] T13741 INDICATI Phase 1 Solid tumour/cancer [ICD-11: 2A00-2F9Z] T13852 TARGETID T13852 T13852 TARGNAME Sphingosine-1-phosphate receptor 1 (S1PR1) T13852 INDICATI Phase 1 Acne vulgaris [ICD-11: ED80] T13852 INDICATI Phase 1 Cardiovascular disease [ICD-11: BA00-BE2Z] T13852 INDICATI Phase 2 Crohn disease [ICD-11: DD70] T13852 INDICATI Phase 2 Cutaneous lupus erythematosus [ICD-11: EB50-EB5Z] T13852 INDICATI Phase 2 Diabetes mellitus [ICD-11: 5A10] T13852 INDICATI Phase 1 Immune system disease [ICD-11: 4A01-4B41] T13852 INDICATI Phase 3 Liver cancer [ICD-11: 2C12] T13852 INDICATI Phase 3 Lung cancer [ICD-11: 2C25] T13852 INDICATI Approved Multiple sclerosis [ICD-11: 8A40] T13852 INDICATI Investigative Postoperative inflammation [ICD-11: 1A00-CA43] T13852 INDICATI Phase 2 Psoriasis [ICD-11: EA90] T13852 INDICATI Phase 2 Pyoderma gangrenosum [ICD-11: EB21] T13852 INDICATI Phase 1 Retinopathy [ICD-11: 9B71] T13852 INDICATI Phase 2 Rheumatoid arthritis [ICD-11: FA20] T13852 INDICATI Terminated Solid tumour/cancer [ICD-11: 2A00-2F9Z] T13852 INDICATI Approved Ulcerative colitis [ICD-11: DD71] T13910 TARGETID T13910 T13910 TARGNAME Phosphofructokinase 2 (PFK2) T13910 INDICATI Phase 2 Type-1/2 diabete [ICD-11: 5A10-5A11] T14037 TARGETID T14037 T14037 TARGNAME RAC serine/threonine-protein kinase (AKT) T14037 INDICATI Phase 1 Solid tumour/cancer [ICD-11: 2A00-2F9Z] T14056 TARGETID T14056 T14056 TARGNAME Netrin (NET) T14056 INDICATI Phase 2 Parkinsonism [ICD-11: 8A00] T14065 TARGETID T14065 T14065 TARGNAME Integrin beta-7 (ITGB7) T14065 INDICATI Approved Crohn disease [ICD-11: DD70] T14065 INDICATI Approved Ulcerative colitis [ICD-11: DD71] T14110 TARGETID T14110 T14110 TARGNAME Beta-klotho (KLB) T14110 INDICATI Phase 2 Non-alcoholic fatty liver disease [ICD-11: DB92] T14110 INDICATI Phase 1 Type 2 diabetes mellitus [ICD-11: 5A11] T14143 TARGETID T14143 T14143 TARGNAME Transforming growth factor beta 2 (TGFB2) T14143 INDICATI Phase 3 Colorectal cancer [ICD-11: 2B91] T14231 TARGETID T14231 T14231 TARGNAME Leucine-rich repeat-containing GPCR 5 (LGR5) T14231 INDICATI Phase 1 Colorectal cancer [ICD-11: 2B91] T14231 INDICATI Phase 1 Solid tumour/cancer [ICD-11: 2A00-2F9Z] T14342 TARGETID T14342 T14342 TARGNAME Human immunodeficiency virus Reverse transcriptase (HIV RT) T14342 INDICATI Phase 2 Breast cancer [ICD-11: 2C60-2C6Y] T14342 INDICATI Terminated Cytomegaloviral disease [ICD-11: 1D82] T14342 INDICATI Phase 3 Hepatic fibrosis/cirrhosis [ICD-11: DB93] T14342 INDICATI Approved Hepatitis virus infection [ICD-11: 1E50-1E51] T14342 INDICATI Terminated Herpes simplex infection [ICD-11: 1F00] T14342 INDICATI Approved Human immunodeficiency virus disease [ICD-11: 1C60-1C62] T14342 INDICATI Phase 1 Mycobacterium infection [ICD-11: 1B10-1B21] T14342 INDICATI Investigative Pain [ICD-11: MG30-MG3Z] T14342 INDICATI Phase 3 Sexually transmitted infection [ICD-11: 1A9Y-1A9Z] T14342 INDICATI Phase 1/2 Solid tumour/cancer [ICD-11: 2A00-2F9Z] T14342 INDICATI Phase 2 Unspecific body region injury [ICD-11: ND56] T14342 INDICATI Approved Virus infection [ICD-11: 1A24-1D9Z] T14463 TARGETID T14463 T14463 TARGNAME Sterol O-acyltransferase (SOAT) T14463 INDICATI Phase 1 Adrenal cancer [ICD-11: 2D11] T14463 INDICATI Terminated Arterial occlusive disease [ICD-11: BD40] T14541 TARGETID T14541 T14541 TARGNAME Clostridium difficile Toxin B (CD toxB) T14541 INDICATI Approved Clostridium difficile enterocolitis [ICD-11: 1A04] T14541 INDICATI Phase 3 Malaria [ICD-11: 1F40-1F45] T14557 TARGETID T14557 T14557 TARGNAME Interleukin 10 receptor (IL10RB) T14557 INDICATI Investigative General pain disorder [ICD-11: 8E43] T14557 INDICATI Investigative Indeterminate colitis [ICD-11: DD72] T14557 INDICATI Investigative Postoperative inflammation [ICD-11: 1A00-CA43] T14558 TARGETID T14558 T14558 TARGNAME Tryptase alpha/beta-1 (Tryptase) T14558 INDICATI Discontinued in Phase 2 Asthma [ICD-11: CA23] T14558 INDICATI Approved Fungal infection [ICD-11: 1F29-1F2F] T14558 INDICATI Withdrawn from market Human immunodeficiency virus disease [ICD-11: 1C60-1C62] T14558 INDICATI Discontinued in Phase 2 Indeterminate colitis [ICD-11: DD72] T14558 INDICATI Approved Solid tumour/cancer [ICD-11: 2A00-2F9Z] T14582 TARGETID T14582 T14582 TARGNAME Mycobacterium Biosynthetic alanine racemase (MycB alr) T14582 INDICATI Approved Bacterial infection [ICD-11: 1A00-1C4Z] T14582 INDICATI Approved HIV-infected patients with tuberculosis [ICD-11: 1B10-1B14] T14582 INDICATI Phase 2 Obsessive-compulsive disorder [ICD-11: 6B20] T14592 TARGETID T14592 T14592 TARGNAME Apoptosis mediating surface antigen FAS (FAS) T14592 INDICATI Phase 3 Brain cancer [ICD-11: 2A00] T14592 INDICATI Phase 2 Cerebral ischaemia [ICD-11: 8B1Z] T14592 INDICATI Investigative Mature T-cell lymphoma [ICD-11: 2A90] T14592 INDICATI Phase 1 Multiple myeloma [ICD-11: 2A83] T14592 INDICATI Phase 3 Ovarian cancer [ICD-11: 2C73] T14592 INDICATI Investigative Postoperative inflammation [ICD-11: 1A00-CA43] T14592 INDICATI Phase 2 Rheumatoid arthritis [ICD-11: FA20] T14592 INDICATI Investigative Solid tumour/cancer [ICD-11: 2A00-2F9Z] T14597 TARGETID T14597 T14597 TARGNAME Erbb2 tyrosine kinase receptor (HER2) T14597 INDICATI Phase 1/2 Bladder cancer [ICD-11: 2C94] T14597 INDICATI Phase 2 Brain cancer [ICD-11: 2A00] T14597 INDICATI Approved Breast cancer [ICD-11: 2C60-2C6Y] T14597 INDICATI Phase 2 Colorectal cancer [ICD-11: 2B91] T14597 INDICATI Phase 2 Head and neck cancer [ICD-11: 2D42] T14597 INDICATI Patented Hepatitis virus infection [ICD-11: 1E50-1E51] T14597 INDICATI Approved Lung cancer [ICD-11: 2C25] T14597 INDICATI Phase 2 Lymphoma [ICD-11: 2A80-2A86] T14597 INDICATI Phase 2 Malignant digestive organ neoplasm [ICD-11: 2C11] T14597 INDICATI Phase 3 Malignant haematopoietic neoplasm [ICD-11: 2B33] T14597 INDICATI Phase 1/2 Malignant mesenchymal neoplasm [ICD-11: 2B5D-2B5Y] T14597 INDICATI Phase 2/3 Metastatic biliary tract neoplasms [ICD-11: 2C14-2C17] T14597 INDICATI Phase 1 Metastatic malignant neoplasm [ICD-11: 2D50-2E09] T14597 INDICATI Phase 1/2 Ovarian cancer [ICD-11: 2C73] T14597 INDICATI Phase 2 Pancreatic cancer [ICD-11: 2C10] T14597 INDICATI Approved Prostate cancer [ICD-11: 2C82] T14597 INDICATI Phase 1/2 Retinal vascular occlusion [ICD-11: 9B74] T14597 INDICATI Phase 2 Solid tumour/cancer [ICD-11: 2A00-2F9Z] T14597 INDICATI Phase 1 Spinal cord/cranial nerve neoplasm [ICD-11: 2A02] T14597 INDICATI Phase 3 Stomach cancer [ICD-11: 2B72] T14597 INDICATI Phase 1 Stomach cancer ICD-11: 2B72 T14597 INDICATI Phase 1 Testicular cancer [ICD-11: 2C80] T14597 INDICATI Phase 2 Ureteral cancer [ICD-11: 2C92] T14597 INDICATI Phase 2 Urogenital cancer [ICD-11: 2C95-2C9Z] T14602 TARGETID T14602 T14602 TARGNAME Coagulation factor VIII (F8) T14602 INDICATI Investigative Angina pectoris [ICD-11: BA40] T14602 INDICATI Approved Cerebral ischaemia [ICD-11: 8B1Z] T14602 INDICATI Approved Coagulation defect [ICD-11: 3B10] T14602 INDICATI Phase 3 Ischaemic/haemorrhagic stroke [ICD-11: 8B20] T14602 INDICATI Phase 3 Liposarcoma [ICD-11: 2B59] T14602 INDICATI Approved Sepsis [ICD-11: 1G40-1G41] T14602 INDICATI Phase 2 Supraventricular tachyarrhythmia [ICD-11: BC81] T14602 INDICATI Phase 2 Venous thromboembolism [ICD-11: BD72] T14602 INDICATI Phase 3 Von Willebrand disease [ICD-11: 3B12] T14676 TARGETID T14676 T14676 TARGNAME A proliferation-inducing ligand (APRIL) T14676 INDICATI Phase 2 Lupus erythematosus [ICD-11: 4A40] T14676 INDICATI Phase 3 Lymphoma [ICD-11: 2A80-2A86] T14676 INDICATI Phase 2 Multiple sclerosis [ICD-11: 8A40] T14676 INDICATI Phase 2 Rheumatoid arthritis [ICD-11: FA20] T14705 TARGETID T14705 T14705 TARGNAME Bacterial Beta-glucuronidase (Bact uidA) T14705 INDICATI Preclinical Therapeutic intestinal toxicity [ICD-11: DA94] T14731 TARGETID T14731 T14731 TARGNAME NAD-dependent deacetylase sirtuin-1 (SIRT1) T14731 INDICATI Phase 2 Choreiform disorder [ICD-11: 8A01] T14731 INDICATI Phase 2 Chronic obstructive pulmonary disease [ICD-11: CA22] T14731 INDICATI Discontinued in Phase 2 Colon cancer [ICD-11: 2B90] T14731 INDICATI Discontinued in Phase 2 Colorectal cancer [ICD-11: 2B91] T14731 INDICATI Discontinued in Phase 2 Malignant haematopoietic neoplasm [ICD-11: 2B33] T14731 INDICATI Phase 2 Obesity [ICD-11: 5B80-5B81] T14731 INDICATI Phase 3 Rheumatoid arthritis [ICD-11: FA20] T14731 INDICATI Investigative Solid tumour/cancer [ICD-11: 2A00-2F9Z] T14731 INDICATI Phase 3 Systemic sclerosis [ICD-11: 4A42] T14731 INDICATI Phase 1 Type 2 diabetes mellitus [ICD-11: 5A11] T14731 INDICATI Phase 3 Vasculitis [ICD-11: 4A44] T14755 TARGETID T14755 T14755 TARGNAME TNF related activation protein (CD40LG) T14755 INDICATI Phase 1 B-cell lymphoma [ICD-11: 2A86] T14755 INDICATI Phase 2 Diabetes mellitus [ICD-11: 5A10] T14755 INDICATI Terminated Diffuse large B-cell lymphoma [ICD-11: 2A81] T14755 INDICATI Phase 2 Lupus erythematosus [ICD-11: 4A40] T14755 INDICATI Phase 2 Lymphoma [ICD-11: 2A80-2A86] T14755 INDICATI Terminated Malignant haematopoietic neoplasm [ICD-11: 2B33] T14755 INDICATI Phase 2 Mature B-cell leukaemia [ICD-11: 2A82] T14755 INDICATI Phase 2 Mature B-cell lymphoma [ICD-11: 2A85] T14755 INDICATI Investigative Melanoma [ICD-11: 2C30] T14755 INDICATI Phase 1 Prostate cancer [ICD-11: 2C82] T14755 INDICATI Phase 1 Rheumatoid arthritis [ICD-11: FA20] T14755 INDICATI Phase 1 Sjogren syndrome [ICD-11: 4A43] T14755 INDICATI Phase 1 Solid tumour/cancer [ICD-11: 2A00-2F9Z] T14755 INDICATI Phase 1 Thrombocytopenia [ICD-11: 3B64] T14825 TARGETID T14825 T14825 TARGNAME VEGFR2 messenger RNA (VEGFR2 mRNA) T14825 INDICATI Discontinued in Phase 2 Degenerative high myopia [ICD-11: 9B76] T14834 TARGETID T14834 T14834 TARGNAME Cytosolic phospholipase A2 (GIVA cPLA2) T14834 INDICATI Terminated Asthma [ICD-11: CA23] T14834 INDICATI Phase 1/2 Atopic eczema [ICD-11: EA80] T14853 TARGETID T14853 T14853 TARGNAME Fibroblast growth factor-23 (FGF23) T14853 INDICATI Approved Vitamin/non-protein cofactor absorption/transport disorder [ICD-11: 5C63] T14875 TARGETID T14875 T14875 TARGNAME Ubiquitin carboxyl-terminal hydrolase 14 (USP14) T14875 INDICATI Preclinical Neurodegenerative disorder [ICD-11: 8A20-8A23] T14875 INDICATI Preclinical Solid tumour/cancer [ICD-11: 2A00-2F9Z] T14908 TARGETID T14908 T14908 TARGNAME Ceramide glucosyltransferase (UGCG) T14908 INDICATI Approved Lysosomal disease [ICD-11: 5C56] T14908 INDICATI Approved Metabolic disorder [ICD-11: 5C50-5D2Z] T14908 INDICATI Phase 2 Parkinsonism [ICD-11: 8A00] T14912 TARGETID T14912 T14912 TARGNAME Induced myeloid leukemia cell differentiation protein Mcl-1 (MCL1) T14912 INDICATI Phase 1 Acute myeloid leukaemia [ICD-11: 2A60] T14912 INDICATI Terminated Asthma [ICD-11: CA23] T14912 INDICATI Phase 1 Malignant haematopoietic neoplasm [ICD-11: 2B33] T14912 INDICATI Phase 1 Mature B-cell lymphoma [ICD-11: 2A85] T14912 INDICATI Phase 1 Melanoma [ICD-11: 2C30] T14912 INDICATI Phase 1 Multiple myeloma [ICD-11: 2A83] T14912 INDICATI Investigative Rheumatoid arthritis [ICD-11: FA20] T14912 INDICATI Phase 2 Solid tumour/cancer [ICD-11: 2A00-2F9Z] T14912 INDICATI Withdrawn from market Trematode disease [ICD-11: 1F8Y] T14945 TARGETID T14945 T14945 TARGNAME Centromeric protein E (CENPE) T14945 INDICATI Terminated Solid tumour/cancer [ICD-11: 2A00-2F9Z] T15000 TARGETID T15000 T15000 TARGNAME Cytotoxic T-lymphocyte protein 4 (CTLA-4) T15000 INDICATI Phase 1 Breast cancer [ICD-11: 2C60-2C6Y] T15000 INDICATI Phase 2 Cervical cancer [ICD-11: 2C77] T15000 INDICATI Investigative Diabetes mellitus [ICD-11: 5A10] T15000 INDICATI Phase 3 Epidermal dysplasias [ICD-11: EK90] T15000 INDICATI Approved Liver cancer [ICD-11: 2C12] T15000 INDICATI Phase 3 Lung cancer [ICD-11: 2C25] T15000 INDICATI Approved Melanoma [ICD-11: 2C30] T15000 INDICATI Phase 1 Non-small-cell lung cancer [ICD-11: 2C25] T15000 INDICATI Phase 3 Pleural mesothelioma [ICD-11: 2C26] T15000 INDICATI Phase 2 Prostate cancer [ICD-11: 2C82] T15000 INDICATI Investigative Rheumatoid arthritis [ICD-11: FA20] T15000 INDICATI Phase 3 Solid tumour/cancer [ICD-11: 2A00-2F9Z] T15023 TARGETID T15023 T15023 TARGNAME Neuropilin-1 (NRP1) T15023 INDICATI Approved Retinopathy [ICD-11: 9B71] T15023 INDICATI Phase 1 Solid tumour/cancer [ICD-11: 2A00-2F9Z] T15068 TARGETID T15068 T15068 TARGNAME Focal adhesion kinase 1 (FAK) T15068 INDICATI Phase 1 Metastatic tumour [ICD-11: 2D50-2E2Z] T15068 INDICATI Phase 2 Ovarian cancer [ICD-11: 2C73] T15068 INDICATI Phase 1 Pancreatic cancer [ICD-11: 2C10] T15068 INDICATI Phase 2 Peritoneal cancer [ICD-11: 2C51] T15068 INDICATI Phase 1 Pulmonary hypertension [ICD-11: BB01] T15068 INDICATI Phase 1 Solid tumour/cancer [ICD-11: 2A00-2F9Z] T15107 TARGETID T15107 T15107 TARGNAME Human immunodeficiency virus Nucleocapsid p7 (HIV p7) T15107 INDICATI Phase 2 Human immunodeficiency virus disease [ICD-11: 1C60-1C62] T15117 TARGETID T15117 T15117 TARGNAME Adrenergic receptor (ADR) T15117 INDICATI Discontinued in Phase 1 Allergic/hypersensitivity disorder [ICD-11: 4A80-4A8Z] T15117 INDICATI Phase 2 Attention deficit hyperactivity disorder [ICD-11: 6A05] T15117 INDICATI Withdrawn from market Cardiovascular disease [ICD-11: BA00-BE2Z] T15117 INDICATI Approved Cushing syndrome [ICD-11: 5A70] T15117 INDICATI Approved Diagnostic imaging [ICD-11: N.A.] T15117 INDICATI Approved Glaucoma [ICD-11: 9C61] T15117 INDICATI Approved Hypertension [ICD-11: BA00-BA04] T15117 INDICATI Phase 3 Mild neurocognitive disorder [ICD-11: 6D71] T15117 INDICATI Approved Orthostatic hypotension [ICD-11: BA21] T15117 INDICATI Patented Parkinsonism [ICD-11: 8A00] T15117 INDICATI Patented Tonus and reflex abnormality [ICD-11: MB47] T15167 TARGETID T15167 T15167 TARGNAME Collagen I (COL1A2) T15167 INDICATI Phase 2 Systemic sclerosis [ICD-11: 4A42] T15197 TARGETID T15197 T15197 TARGNAME Potential penetration (PP) T15197 INDICATI Investigative Thyrotoxicosis [ICD-11: 5A02] T15334 TARGETID T15334 T15334 TARGNAME Cholesteryl ester transfer protein (CETP) T15334 INDICATI Phase 3 Arterial occlusive disease [ICD-11: BD40] T15334 INDICATI Phase 3 Cardiovascular disease [ICD-11: BA00-BE2Z] T15334 INDICATI Discontinued in Phase 2 Chronic arterial occlusive disease [ICD-11: BD4Z] T15334 INDICATI Discontinued in Phase 1 Dyslipidemia [ICD-11: 5C80-5C81] T15334 INDICATI Phase 3 Hyper-lipoproteinaemia [ICD-11: 5C80] T15334 INDICATI Phase 2 Inborn lipid metabolism error [ICD-11: 5C52] T15334 INDICATI Phase 3 Myocardial infarction [ICD-11: BA41-BA43] T15344 TARGETID T15344 T15344 TARGNAME Activation-inducible TNFR family receptor (TNFRSF18) T15344 INDICATI Phase 1 Melanoma [ICD-11: 2C30] T15344 INDICATI Phase 1 Metastatic lymph node neoplasm [ICD-11: 2D60] T15344 INDICATI Phase 2 Solid tumour/cancer [ICD-11: 2A00-2F9Z] T15377 TARGETID T15377 T15377 TARGNAME Sarcoplasmic/endoplasmic reticulum calcium ATPase 2 (ATP2A2) T15377 INDICATI Phase 2 Asthma [ICD-11: CA23] T15377 INDICATI Phase 2 Heart failure [ICD-11: BD10-BD1Z] T15377 INDICATI Discontinued in Phase 1 Hypertension [ICD-11: BA00-BA04] T15439 TARGETID T15439 T15439 TARGNAME C5a anaphylatoxin chemotactic receptor (C5AR1) T15439 INDICATI Phase 2 Atopic eczema [ICD-11: EA80] T15439 INDICATI Preclinical Central nervous system disease [ICD-11: 8A04-8D87] T15439 INDICATI Phase 2 Haemolytic anemia [ICD-11: 3A20-3A2Z] T15439 INDICATI Investigative Postoperative inflammation [ICD-11: 1A00-CA43] T15439 INDICATI Discontinued in Phase 2 Rheumatoid arthritis [ICD-11: FA20] T15439 INDICATI Approved Vasculitis [ICD-11: 4A44] T15494 TARGETID T15494 T15494 TARGNAME GHR messenger RNA (GHR mRNA) T15494 INDICATI Phase 1 Pituitary gland disorder [ICD-11: 5A60-5A61] T15497 TARGETID T15497 T15497 TARGNAME Prostaglandin E2 receptor EP1 (PTGER1) T15497 INDICATI Terminated Abnormal micturition [ICD-11: MF50] T15497 INDICATI Discontinued in Phase 2 Pain [ICD-11: MG30-MG3Z] T15497 INDICATI Clinical trial Solid tumour/cancer [ICD-11: 2A00-2F9Z] T15497 INDICATI Phase 3 Thrombosis [ICD-11: DB61-GB90] T15510 TARGETID T15510 T15510 TARGNAME Insulin receptor substrate-1 (IRS1) T15510 INDICATI Phase 1/2 Solid tumour/cancer [ICD-11: 2A00-2F9Z] T15556 TARGETID T15556 T15556 TARGNAME Endothelial plasminogen activator inhibitor (SERPINE1) T15556 INDICATI Phase 2 Asthma [ICD-11: CA23] T15556 INDICATI Terminated Solid tumour/cancer [ICD-11: 2A00-2F9Z] T15556 INDICATI Phase 1 Thrombosis [ICD-11: DB61-GB90] T15569 TARGETID T15569 T15569 TARGNAME Methylmalonyl-CoA mutase (MMUT) T15569 INDICATI Phase 2 Intrathoracic organs injury [ICD-11: NB32] T15569 INDICATI Phase 1/2 Metabolism inborn error [ICD-11: 5C50] T15569 INDICATI Approved Vitamin deficiency [ICD-11: 5B55-5B5F] T15571 TARGETID T15571 T15571 TARGNAME 5-HT 5A receptor (HTR5A) T15571 INDICATI Approved Pituitary gland disorder [ICD-11: 5A60-5A61] T15610 TARGETID T15610 T15610 TARGNAME Puromycin-sensitive aminopeptidase (NPEPPS) T15610 INDICATI Phase 2 Acute myeloid leukaemia [ICD-11: 2A60] T15610 INDICATI Phase 2 Myelodysplastic syndrome [ICD-11: 2A37] T15610 INDICATI Terminated Postoperative inflammation [ICD-11: 1A00-CA43] T15639 TARGETID T15639 T15639 TARGNAME Zinc finger protein (ZNF) T15639 INDICATI Phase 2 Acne vulgaris [ICD-11: ED80] T15700 TARGETID T15700 T15700 TARGNAME Caspase-8 (CASP8) T15700 INDICATI Investigative Diabetes mellitus [ICD-11: 5A10] T15700 INDICATI Investigative Solid tumour/cancer [ICD-11: 2A00-2F9Z] T15739 TARGETID T15739 T15739 TARGNAME Cellular tumor antigen p53 (TP53) T15739 INDICATI Phase 2 Acute myeloid leukaemia [ICD-11: 2A60] T15739 INDICATI Phase 1/2 Arterial occlusive disease [ICD-11: BD40] T15739 INDICATI Phase 2 Bladder cancer [ICD-11: 2C94] T15739 INDICATI Phase 2 Brain cancer [ICD-11: 2A00] T15739 INDICATI Phase 1 Cervical cancer [ICD-11: 2C77] T15739 INDICATI Phase 1/2 Colorectal cancer [ICD-11: 2B91] T15739 INDICATI Phase 1 Endometrial cancer [ICD-11: 2C76] T15739 INDICATI Phase 1 Esophageal cancer [ICD-11: 2B70] T15739 INDICATI Phase 1 Fallopian tube cancer [ICD-11: 2C74] T15739 INDICATI Phase 2 Head and neck cancer [ICD-11: 2D42] T15739 INDICATI Phase 3 Lip/oral cavity/pharynx neoplasm [ICD-11: 2B6E] T15739 INDICATI Phase 1 Liposarcoma [ICD-11: 2B59] T15739 INDICATI Phase 1 Malignant haematopoietic neoplasm [ICD-11: 2B33] T15739 INDICATI Phase 2 Mature B-cell leukaemia [ICD-11: 2A82] T15739 INDICATI Phase 1 Metastatic liver/bile duct neoplasm [ICD-11: 2D80] T15739 INDICATI Phase 1 Myelodysplastic syndrome [ICD-11: 2A37] T15739 INDICATI Phase 2 Ovarian cancer [ICD-11: 2C73] T15739 INDICATI Phase 2/3 Ovarian dysfunction [ICD-11: 5A80] T15739 INDICATI Phase 2 Pancreatic cancer [ICD-11: 2C10] T15739 INDICATI Phase 1 Peritoneal cancer [ICD-11: 2C51] T15739 INDICATI Phase 2 Solid tumour/cancer [ICD-11: 2A00-2F9Z] T15739 INDICATI Phase 1/2 Stomach cancer [ICD-11: 2B72] T15739 INDICATI Terminated Toxicity [ICD-11: N.A.] T15739 INDICATI Phase 3 Transplant rejection [ICD-11: NE84] T15776 TARGETID T15776 T15776 TARGNAME Pyruvate dehydrogenase kinase 1 (PDHK1) T15776 INDICATI Phase 1 Idiopathic interstitial pneumonitis [ICD-11: CB03] T15776 INDICATI Phase 3 Inborn energy metabolism error [ICD-11: 5C53] T15776 INDICATI Phase 4 Insulin-resistance syndrome [ICD-11: 5A44] T15776 INDICATI Patented Metastatic tumour [ICD-11: 2D50-2E2Z] T15776 INDICATI Patented Solid tumour/cancer [ICD-11: 2A00-2F9Z] T15783 TARGETID T15783 T15783 TARGNAME NKG2-A/B-activating NK receptor (NKG2A) T15783 INDICATI Phase 1/2 Head and neck cancer [ICD-11: 2D42] T15783 INDICATI Phase 1/2 Mature B-cell leukaemia [ICD-11: 2A82] T15783 INDICATI Phase 2 Rheumatoid arthritis [ICD-11: FA20] T15783 INDICATI Phase 1/2 Solid tumour/cancer [ICD-11: 2A00-2F9Z] T15784 TARGETID T15784 T15784 TARGNAME Lipid peroxidation (LPO) T15784 INDICATI Phase 2 Alzheimer disease [ICD-11: 8A20] T15784 INDICATI Discontinued in Phase 2 Dissociative neurological symptom disorder [ICD-11: 6B60] T15784 INDICATI Investigative Immune system disease [ICD-11: 4A01-4B41] T15784 INDICATI Phase 2 Ischemia [ICD-11: 8B10-8B11] T15795 TARGETID T15795 T15795 TARGNAME TWIK-related acid-sensitive potassium channel 1 (TASK1) T15795 INDICATI Phase 2 Obstructive sleep apnoea [ICD-11: 7A41] T15797 TARGETID T15797 T15797 TARGNAME SET and MYND domain-containing protein 2 (SMYD2) T15797 INDICATI Preclinical Lung cancer [ICD-11: 2C25] T15797 INDICATI Preclinical Solid tumour/cancer [ICD-11: 2A00-2F9Z] T15803 TARGETID T15803 T15803 TARGNAME Factor XI messenger RNA (F11 mRNA) T15803 INDICATI Clinical trial Alzheimer disease [ICD-11: 8A20] T15803 INDICATI Phase 2 Cerebral ischaemic stroke [ICD-11: 8B11] T15803 INDICATI Phase 2 Coagulation defect [ICD-11: 3B10] T15803 INDICATI Phase 2 Thrombosis [ICD-11: DB61-GB90] T15855 TARGETID T15855 T15855 TARGNAME Dipeptidyl peptidase 8 (DPP-8) T15855 INDICATI Phase 3 Neutropenia [ICD-11: 4B00] T15855 INDICATI Phase 1/2 Prostate cancer [ICD-11: 2C82] T15855 INDICATI Phase 1 Solid tumour/cancer [ICD-11: 2A00-2F9Z] T15867 TARGETID T15867 T15867 TARGNAME Gastric carcinoma-associated antigen MG7 (MG7) T15867 INDICATI Phase 1/2 Acute myeloid leukaemia [ICD-11: 2A60] T15882 TARGETID T15882 T15882 TARGNAME Leukocyte proteinase-3 (PRTN3) T15882 INDICATI Phase 2 Malignant haematopoietic neoplasm [ICD-11: 2B33] T15882 INDICATI Phase 2 Myocardial infarction [ICD-11: BA41-BA43] T15894 TARGETID T15894 T15894 TARGNAME Cerebron E3 ubiquitin ligase complex (CRL4-CRBN E3 ubiquitin ligase) T15894 INDICATI Phase 1 Lupus erythematosus [ICD-11: 4A40] T15894 INDICATI Phase 1 Prostate cancer [ICD-11: 2C82] T16016 TARGETID T16016 T16016 TARGNAME C-C chemokine receptor type 1 (CCR1) T16016 INDICATI Discontinued in Phase 2 Chronic obstructive pulmonary disease [ICD-11: CA22] T16016 INDICATI Phase 2 Diabetes mellitus [ICD-11: 5A10] T16016 INDICATI Phase 2 Rheumatoid arthritis [ICD-11: FA20] T16047 TARGETID T16047 T16047 TARGNAME Onchocerca Glutamate-gated chloride channel (Onchoc GluCl) T16047 INDICATI Approved Onchocerciasis [ICD-11: 1F6A] T16047 INDICATI Approved Strongyloidiasis [ICD-11: 1F6B] T16087 TARGETID T16087 T16087 TARGNAME TMPRSS6 messenger RNA (TMPRSS6 mRNA) T16087 INDICATI Phase 2 Myeloproliferative neoplasm [ICD-11: 2A20] T16087 INDICATI Phase 2 Thalassaemia [ICD-11: 3A50] T16117 TARGETID T16117 T16117 TARGNAME Nitric-oxide synthase brain (NOS1) T16117 INDICATI Phase 2 Headache [ICD-11: 8A80-8A84] T16117 INDICATI Phase 2 Migraine [ICD-11: 8A80] T16128 TARGETID T16128 T16128 TARGNAME Gastrin (GAST) T16128 INDICATI Phase 3 Stomach cancer [ICD-11: 2B72] T16144 TARGETID T16144 T16144 TARGNAME B7-related protein 1 (B7RP1) T16144 INDICATI Phase 2 Lupus erythematosus [ICD-11: 4A40] T16144 INDICATI Phase 2 Sjogren syndrome [ICD-11: 4A43] T16156 TARGETID T16156 T16156 TARGNAME Thrombopoietin receptor (MPL) T16156 INDICATI Investigative Acute myeloid leukaemia [ICD-11: 2A60] T16156 INDICATI Phase 1 Ischaemic/haemorrhagic stroke [ICD-11: 8B20] T16156 INDICATI Phase 3 Liver disease [ICD-11: DB90-DB9Z] T16156 INDICATI Phase 2 Multiple myeloma [ICD-11: 2A83] T16156 INDICATI Phase 2 Myelodysplastic syndrome [ICD-11: 2A37] T16156 INDICATI Phase 1 Myocardial infarction [ICD-11: BA41-BA43] T16156 INDICATI Approved Thrombocytopenia [ICD-11: 3B64] T16156 INDICATI Terminated Transplanted organ/tissue [ICD-11: QB63] T16263 TARGETID T16263 T16263 TARGNAME T-cell-specific protein RANTES (CCL5) T16263 INDICATI Phase 1 Diabetes mellitus [ICD-11: 5A10] T16308 TARGETID T16308 T16308 TARGNAME Rotamase Pin1 (PIN1) T16308 INDICATI Phase 3 Lung cancer [ICD-11: 2C25] T16308 INDICATI Investigative Nasopharyngeal cancer [ICD-11: 2B6B] T16340 TARGETID T16340 T16340 TARGNAME Interleukin-1 alpha (IL1A) T16340 INDICATI Phase 2 Acne vulgaris [ICD-11: ED80] T16340 INDICATI Terminated Arterial occlusive disease [ICD-11: BD40] T16340 INDICATI Phase 2 Atopic eczema [ICD-11: EA80] T16340 INDICATI Phase 2 Chronic arterial occlusive disease [ICD-11: BD4Z] T16340 INDICATI Phase 3 Colorectal cancer [ICD-11: 2B91] T16340 INDICATI Phase 2 Hidradenitis suppurativa [ICD-11: ED92] T16340 INDICATI Phase 3 Influenza [ICD-11: 1E30-1E32] T16340 INDICATI Phase 2 Lung cancer [ICD-11: 2C25] T16340 INDICATI Phase 2 Osteoarthritis [ICD-11: FA00-FA05] T16340 INDICATI Phase 2 Psoriasis [ICD-11: EA90] T16340 INDICATI Phase 2 Pyoderma gangrenosum [ICD-11: EB21] T16340 INDICATI Phase 2 Rheumatoid arthritis [ICD-11: FA20] T16340 INDICATI Phase 2 Type 2 diabetes mellitus [ICD-11: 5A11] T16347 TARGETID T16347 T16347 TARGNAME Protein-tyrosine phosphatase 1B (PTP1B) T16347 INDICATI Phase 1/2 Acute diabete complication [ICD-11: 5A2Y] T16347 INDICATI Phase 1 Breast cancer [ICD-11: 2C60-2C6Y] T16347 INDICATI Phase 1 Obesity [ICD-11: 5B80-5B81] T16347 INDICATI Phase 2 Type 2 diabetes mellitus [ICD-11: 5A11] T16353 TARGETID T16353 T16353 TARGNAME Gap junction alpha-8 protein (Cx50) T16353 INDICATI Investigative Solid tumour/cancer [ICD-11: 2A00-2F9Z] T16422 TARGETID T16422 T16422 TARGNAME Multidrug resistance protein (MDR) T16422 INDICATI Discontinued in Phase 3 Acute myeloid leukaemia [ICD-11: 2A60] T16422 INDICATI Phase 2 Atopic eczema [ICD-11: EA80] T16422 INDICATI Approved Nausea/vomiting [ICD-11: MD90] T16422 INDICATI Phase 3 Solid tumour/cancer [ICD-11: 2A00-2F9Z] T16422 INDICATI Preclinical Transplant rejection [ICD-11: NE84] T16486 TARGETID T16486 T16486 TARGNAME TNFA messenger RNA (TNF mRNA) T16486 INDICATI Discontinued in Phase 2 Crohn disease [ICD-11: DD70] T16486 INDICATI Discontinued in Phase 2 Rheumatoid arthritis [ICD-11: FA20] T16486 INDICATI Terminated Schizophrenia [ICD-11: 6A20] T16514 TARGETID T16514 T16514 TARGNAME Fatty acid synthase (FASN) T16514 INDICATI Phase 2 Brain cancer [ICD-11: 2A00] T16514 INDICATI Phase 2 Colon cancer [ICD-11: 2B90] T16514 INDICATI Approved concerning food/fluid intake symptom [ICD-11: MG43] T16514 INDICATI Preclinical Fungal infection [ICD-11: 1F29-1F2F] T16514 INDICATI Investigative Gram-positive bacterial infection [ICD-11: 1B74-1F40] T16514 INDICATI Phase 3 Hepatic fibrosis/cirrhosis [ICD-11: DB93] T16514 INDICATI Phase 2 Non-alcoholic fatty liver disease [ICD-11: DB92] T16514 INDICATI Investigative Obesity [ICD-11: 5B80-5B81] T16514 INDICATI Phase 1 Solid tumour/cancer [ICD-11: 2A00-2F9Z] T16538 TARGETID T16538 T16538 TARGNAME EGFR T790M mutant (EGFR T790M) T16538 INDICATI Approved Lung cancer [ICD-11: 2C25] T16538 INDICATI Phase 3 Melanoma [ICD-11: 2C30] T16601 TARGETID T16601 T16601 TARGNAME Carcinoembryonic antigen CEA (CD66e) T16601 INDICATI Phase 1 Acute myeloid leukaemia [ICD-11: 2A60] T16601 INDICATI Phase 1 Ascites [ICD-11: ME04] T16601 INDICATI Phase 1 Brain cancer [ICD-11: 2A00] T16601 INDICATI Phase 2 Breast cancer [ICD-11: 2C60-2C6Y] T16601 INDICATI Phase 2 Colorectal cancer [ICD-11: 2B91] T16601 INDICATI Phase 3 Lung cancer [ICD-11: 2C25] T16601 INDICATI Phase 1 Metastatic peritoneum neoplasm [ICD-11: 2D91] T16601 INDICATI Phase 3 Non-small-cell lung cancer [ICD-11: 2C25] T16601 INDICATI Phase 2 Pancreatic cancer [ICD-11: 2C10] T16601 INDICATI Phase 2 Solid tumour/cancer [ICD-11: 2A00-2F9Z] T16601 INDICATI Phase 2 Stomach cancer ICD-11: 2B72 T16601 INDICATI Phase 1 Stomach cancer [ICD-11: 2B72] T16601 INDICATI Phase 2 Thyroid cancer [ICD-11: 2D10] T16605 TARGETID T16605 T16605 TARGNAME Marburg virus NP messenger RNA (MV NP mRNA) T16605 INDICATI Phase 1 Filovirus disease [ICD-11: 1D60] T16633 TARGETID T16633 T16633 TARGNAME Somatostatin receptor type 1 (SSTR1) T16633 INDICATI Terminated Alzheimer disease [ICD-11: 8A20] T16633 INDICATI Approved Cushing syndrome [ICD-11: 5A70] T16633 INDICATI Approved Stomach cancer [ICD-11: 2B72] T16688 TARGETID T16688 T16688 TARGNAME Diacylglycerol acyltransferase 1 (DGAT1) T16688 INDICATI Phase 1 Acute diabete complication [ICD-11: 5A2Y] T16688 INDICATI Phase 3 Hepatitis virus infection [ICD-11: 1E50-1E51] T16688 INDICATI Approved Hyper-lipoproteinaemia [ICD-11: 5C80] T16688 INDICATI Phase 1 Obesity [ICD-11: 5B80-5B81] T16688 INDICATI Terminated Type 2 diabetes mellitus [ICD-11: 5A11] T16691 TARGETID T16691 T16691 TARGNAME 5-HT 6 receptor (HTR6) T16691 INDICATI Phase 3 Alzheimer disease [ICD-11: 8A20] T16691 INDICATI Phase 2 Anxiety disorder [ICD-11: 6B00-6B0Z] T16691 INDICATI Patented Attention deficit hyperactivity disorder [ICD-11: 6A05] T16691 INDICATI Phase 2 Dissociative neurological symptom disorder [ICD-11: 6B60] T16691 INDICATI Investigative Mental/behavioural/neurodevelopmental disorder [ICD-11: 6E20-6E8Z] T16691 INDICATI Phase 2 Mild neurocognitive disorder [ICD-11: 6D71] T16691 INDICATI Investigative Nausea/vomiting [ICD-11: MD90] T16691 INDICATI Phase 1 Neurodegenerative disorder [ICD-11: 8A20-8A23] T16691 INDICATI Phase 1 Obesity [ICD-11: 5B80-5B81] T16691 INDICATI Phase 2 Parkinsonism [ICD-11: 8A00] T16691 INDICATI Phase 3 Schizophrenia [ICD-11: 6A20] T16731 TARGETID T16731 T16731 TARGNAME Vacuolar-type proton ATPase catalytic A (v-ATPase-A) T16731 INDICATI Preclinical Fungal infection [ICD-11: 1F29-1F2F] T16738 TARGETID T16738 T16738 TARGNAME Protein delta homolog 1 (DLK1) T16738 INDICATI Phase 1 Motor neuron disease [ICD-11: 8B60] T16739 TARGETID T16739 T16739 TARGNAME Lysine-specific histone demethylase 1 (LSD) T16739 INDICATI Phase 2 Acute myeloid leukaemia [ICD-11: 2A60] T16739 INDICATI Phase 2 Alzheimer disease [ICD-11: 8A20] T16739 INDICATI Phase 1 Ewing sarcoma [ICD-11: 2B52] T16739 INDICATI Phase 1/2 Lung cancer [ICD-11: 2C25] T16739 INDICATI Phase 2 Lymphoma [ICD-11: 2A80-2A86] T16739 INDICATI Phase 2 Malignant haematopoietic neoplasm [ICD-11: 2B33] T16739 INDICATI Phase 2 Myelodysplastic syndrome [ICD-11: 2A37] T16739 INDICATI Phase 1/2 Myeloproliferative neoplasm [ICD-11: 2A20] T16739 INDICATI Phase 1 Solid tumour/cancer [ICD-11: 2A00-2F9Z] T16761 TARGETID T16761 T16761 TARGNAME Pneumocystis carinii Dihydropteroate synthase (PC DHPS) T16761 INDICATI Approved Pneumonia [ICD-11: CA40] T16769 TARGETID T16769 T16769 TARGNAME X-linked inhibitor of apoptosis protein (XIAP) T16769 INDICATI Phase 1 Acute myeloid leukaemia [ICD-11: 2A60] T16769 INDICATI Phase 2 Lymphoma [ICD-11: 2A80-2A86] T16769 INDICATI Phase 1 Malignant haematopoietic neoplasm [ICD-11: 2B33] T16769 INDICATI Phase 3 Metastatic lymph node neoplasm [ICD-11: 2D60] T16769 INDICATI Investigative Nasopharyngeal cancer [ICD-11: 2B6B] T16769 INDICATI Phase 1 Obesity [ICD-11: 5B80-5B81] T16769 INDICATI Phase 1/2 Ovarian cancer [ICD-11: 2C73] T16769 INDICATI Phase 2 Solid tumour/cancer [ICD-11: 2A00-2F9Z] T16784 TARGETID T16784 T16784 TARGNAME Microtubule polymerization (MicroTu poly) T16784 INDICATI Phase 1/2 Solid tumour/cancer [ICD-11: 2A00-2F9Z] T16792 TARGETID T16792 T16792 TARGNAME Iodothyronine deiodinase type I (DIO1) T16792 INDICATI Approved Thyrotoxicosis [ICD-11: 5A02] T16802 TARGETID T16802 T16802 TARGNAME Human immunodeficiency virus Attachment (HIV att) T16802 INDICATI Phase 2 Human immunodeficiency virus disease [ICD-11: 1C60-1C62] T16808 TARGETID T16808 T16808 TARGNAME Protein arginine methyltransferase 1 (PRMT1) T16808 INDICATI Phase 1 Solid tumour/cancer [ICD-11: 2A00-2F9Z] T16868 TARGETID T16868 T16868 TARGNAME Neural cadherin (CDH2) T16868 INDICATI Phase 2 Solid tumour/cancer [ICD-11: 2A00-2F9Z] T16888 TARGETID T16888 T16888 TARGNAME Small-inducible cytokine A11 (CCL11) T16888 INDICATI Phase 2 Allergic/hypersensitivity disorder [ICD-11: 4A80-4A8Z] T16888 INDICATI Phase 2 Pemphigoid [ICD-11: EB41] T16888 INDICATI Phase 2 Psoriasis [ICD-11: EA90] T16888 INDICATI Phase 2 Ulcerative colitis [ICD-11: DD71] T16987 TARGETID T16987 T16987 TARGNAME Carbonic anhydrase XII (CA-XII) T16987 INDICATI Approved Bacterial infection [ICD-11: 1A00-1C4Z] T16987 INDICATI Phase 2 Breast cancer [ICD-11: 2C60-2C6Y] T16987 INDICATI Approved Seborrhoeic dermatitis [ICD-11: EA81] T16987 INDICATI Phase 3 Solid tumour/cancer [ICD-11: 2A00-2F9Z] T17003 TARGETID T17003 T17003 TARGNAME DNA-directed RNA polymerase (RNAP) T17003 INDICATI Phase 3 Crohn disease [ICD-11: DD70] T17003 INDICATI Approved HIV-infected patients with tuberculosis [ICD-11: 1B10-1B14] T17003 INDICATI Approved Mycobacterium infection [ICD-11: 1B10-1B21] T17003 INDICATI Investigative Retinopathy [ICD-11: 9B71] T17048 TARGETID T17048 T17048 TARGNAME DNA topoisomerase II alpha (TOP2A) T17048 INDICATI Phase 1/2 Acute myeloid leukaemia [ICD-11: 2A60] T17048 INDICATI Phase 2 Kaposi sarcoma [ICD-11: 2B57] T17048 INDICATI Investigative Mature T-cell lymphoma [ICD-11: 2A90] T17048 INDICATI Phase 2 Solid tumour/cancer [ICD-11: 2A00-2F9Z] T17067 TARGETID T17067 T17067 TARGNAME Isopeptidase T (USP5) T17067 INDICATI Preclinical Postoperative inflammation [ICD-11: 1A00-CA43] T17067 INDICATI Preclinical Solid tumour/cancer [ICD-11: 2A00-2F9Z] T17140 TARGETID T17140 T17140 TARGNAME P2X purinoceptor 3 (P2RX3) T17140 INDICATI Phase 3 Cough [ICD-11: MD12] T17140 INDICATI Phase 1 Endometriosis [ICD-11: GA10] T17140 INDICATI Phase 2 Functional bladder disorder [ICD-11: GC50] T17140 INDICATI Phase 1 Hypertension [ICD-11: BA00-BA04] T17140 INDICATI Investigative Pain [ICD-11: MG30-MG3Z] T17163 TARGETID T17163 T17163 TARGNAME Leptin receptor (LEPR) T17163 INDICATI Approved Acute diabete complication [ICD-11: 5A2Y] T17163 INDICATI Investigative Alzheimer disease [ICD-11: 8A20] T17163 INDICATI Investigative Cachexia [ICD-11: MG20] T17163 INDICATI Investigative Obesity [ICD-11: 5B80-5B81] T17163 INDICATI Investigative Solid tumour/cancer [ICD-11: 2A00-2F9Z] T17234 TARGETID T17234 T17234 TARGNAME Cytomegalovirus Ganciclovir kinase (CMV UL97) T17234 INDICATI Approved Cytomegaloviral disease [ICD-11: 1D82] T17248 TARGETID T17248 T17248 TARGNAME Measles virus Fusion glycoprotein (MeV F) T17248 INDICATI Phase 1 Acute diabete complication [ICD-11: 5A2Y] T17248 INDICATI Phase 2 Metastatic tumour [ICD-11: 2D50-2E2Z] T17248 INDICATI Phase 2 Multiple sclerosis [ICD-11: 8A40] T17248 INDICATI Phase 2 Pregnancy/childbirth/puerperium maternal infection [ICD-11: JB63] T17248 INDICATI Phase 1 Type 2 diabetes mellitus [ICD-11: 5A11] T17248 INDICATI Terminated Viral encephalitis [ICD-11: 1C80] T17345 TARGETID T17345 T17345 TARGNAME Dihydrofolate reductase (DHFR) T17345 INDICATI Phase 3 Bacterial infection [ICD-11: 1A00-1C4Z] T17345 INDICATI Phase 2 Bladder cancer [ICD-11: 2C94] T17345 INDICATI Approved Indeterminate colitis [ICD-11: DD72] T17345 INDICATI Phase 2 Pneumonia [ICD-11: CA40] T17345 INDICATI Phase 2 Rheumatoid arthritis [ICD-11: FA20] T17345 INDICATI Approved Solid tumour/cancer [ICD-11: 2A00-2F9Z] T17345 INDICATI Phase 1 Toxoplasmosis [ICD-11: 1F57] T17345 INDICATI Approved Tuberculosis [ICD-11: 1B10-1B12] T17345 INDICATI Approved Urinary tract infection [ICD-11: GC08] T17367 TARGETID T17367 T17367 TARGNAME Sequestosome-1 p62 (SQSTM1) T17367 INDICATI Preclinical Nasopharyngitis [ICD-11: CA00] T17427 TARGETID T17427 T17427 TARGNAME Platelet glycoprotein Ib alpha (CD42b) T17427 INDICATI Phase 1/2 Thrombosis [ICD-11: DB61-GB90] T17448 TARGETID T17448 T17448 TARGNAME Histamine N-methyltransferase (HNMT) T17448 INDICATI Approved Episodic vestibular syndrome [ICD-11: AB31] T17448 INDICATI Approved Malaria [ICD-11: 1F40-1F45] T17448 INDICATI Phase 2 Solid tumour/cancer [ICD-11: 2A00-2F9Z] T17485 TARGETID T17485 T17485 TARGNAME Menin-MLL1 interaction (MEN1-KMT2A PPI) T17485 INDICATI Phase 1/2 Acute myeloid leukaemia [ICD-11: 2A60] T17485 INDICATI Phase 1/2 Malignant haematopoietic neoplasm [ICD-11: 2B33] T17502 TARGETID T17502 T17502 TARGNAME Retinal pigment epithelium protein (RPE65) T17502 INDICATI Phase 3 Herpes simplex infection [ICD-11: 1F00] T17502 INDICATI Phase 1/2 Inherited retinal dystrophy [ICD-11: 9B70] T17502 INDICATI Phase 2/3 Macular degeneration [ICD-11: 9B75] T17502 INDICATI Phase 2 Retinopathy [ICD-11: 9B71] T17502 INDICATI Phase 1/2 Vision impairment [ICD-11: 9D90] T17514 TARGETID T17514 T17514 TARGNAME Activin (ACT) T17514 INDICATI Phase 1 Ovarian cancer [ICD-11: 2C73] T17569 TARGETID T17569 T17569 TARGNAME Voltage-gated potassium channel Kv1.5 (KCNA5) T17569 INDICATI Approved Angina pectoris [ICD-11: BA40] T17569 INDICATI Phase 1 Cardiac arrhythmia [ICD-11: BC9Z] T17569 INDICATI Preclinical Obesity [ICD-11: 5B80-5B81] T17569 INDICATI Phase 1 Pain [ICD-11: MG30-MG3Z] T17569 INDICATI Phase 2 Supraventricular tachyarrhythmia [ICD-11: BC81] T17629 TARGETID T17629 T17629 TARGNAME Tumor associated calcium signal transducer 2 (TACSTD2) T17629 INDICATI Approved Breast cancer [ICD-11: 2C60-2C6Y] T17629 INDICATI Phase 3 Non-small-cell lung cancer [ICD-11: 2C25] T17629 INDICATI Phase 1/2 Solid tumour/cancer [ICD-11: 2A00-2F9Z] T17629 INDICATI Approved Ureteral cancer [ICD-11: 2C92] T17687 TARGETID T17687 T17687 TARGNAME Fibroblast growth factor receptor (FGFR) T17687 INDICATI Approved Bladder cancer [ICD-11: 2C94] T17687 INDICATI Phase 1/2 Breast cancer [ICD-11: 2C60-2C6Y] T17687 INDICATI Approved Liver cancer [ICD-11: 2C12] T17687 INDICATI Phase 4 Lymphoma [ICD-11: 2A80-2A86] T17687 INDICATI Phase 1/2 Multiple myeloma [ICD-11: 2A83] T17687 INDICATI Investigative Nasopharyngeal cancer [ICD-11: 2B6B] T17687 INDICATI Phase 2/3 Solid tumour/cancer [ICD-11: 2A00-2F9Z] T17687 INDICATI Phase 2 Ureteral cancer [ICD-11: 2C92] T17710 TARGETID T17710 T17710 TARGNAME Haptoglobin (HP) T17710 INDICATI Phase 3 Diabetes mellitus [ICD-11: 5A10] T17758 TARGETID T17758 T17758 TARGNAME Urokinase-type plasminogen activator (PLAU) T17758 INDICATI Phase 2 Breast cancer [ICD-11: 2C60-2C6Y] T17758 INDICATI Clinical trial Cardiomegaly [ICD-11: BC45] T17758 INDICATI Phase 1/2 Cerebral ischaemia [ICD-11: 8B1Z] T17758 INDICATI Approved Inherited coagulation factor deficiency [ICD-11: 3B14] T17758 INDICATI Clinical trial Ischaemic heart disease [ICD-11: BA6Z] T17758 INDICATI Approved Myocardial infarction [ICD-11: BA41-BA43] T17758 INDICATI Discontinued in Phase 1/2 Solid tumour/cancer [ICD-11: 2A00-2F9Z] T17758 INDICATI Phase 3 Thrombosis [ICD-11: DB61-GB90] T17758 INDICATI Clinical trial Unspecific body region injury [ICD-11: ND56] T17852 TARGETID T17852 T17852 TARGNAME Phosphodiesterase 9 (PDE9) T17852 INDICATI Phase 2 Alzheimer disease [ICD-11: 8A20] T17852 INDICATI Phase 2 Dementia [ICD-11: 6D80-6D8Z] T17852 INDICATI Phase 2 Genitourinary disease [ICD-11: GA0Z-GC8Z] T17852 INDICATI Phase 2 Heart failure [ICD-11: BD10-BD1Z] T17852 INDICATI Phase 2 Mental/behavioural/neurodevelopmental disorder [ICD-11: 6E20-6E8Z] T17852 INDICATI Investigative Mild neurocognitive disorder [ICD-11: 6D71] T17852 INDICATI Phase 2 Parkinsonism [ICD-11: 8A00] T17852 INDICATI Phase 2 Schizophrenia [ICD-11: 6A20] T17852 INDICATI Phase 2 Sickle-cell disorder [ICD-11: 3A51] T17967 TARGETID T17967 T17967 TARGNAME Pyruvate dehydrogenase kinase 2 (PDHK2) T17967 INDICATI Terminated Acute diabete complication [ICD-11: 5A2Y] T17980 TARGETID T17980 T17980 TARGNAME Fyn tyrosine protein kinase (FYN) T17980 INDICATI Phase 2 Multiple myeloma [ICD-11: 2A83] T17980 INDICATI Approved Myeloproliferative neoplasm [ICD-11: 2A20] T17980 INDICATI Phase 1 Solid tumour/cancer [ICD-11: 2A00-2F9Z] T17986 TARGETID T17986 T17986 TARGNAME Enhancer of zeste homolog 1 (EZH1) T17986 INDICATI Phase 1 Acute myeloid leukaemia [ICD-11: 2A60] T17986 INDICATI Phase 1/2 Lung cancer [ICD-11: 2C25] T17986 INDICATI Phase 1 Malignant haematopoietic neoplasm [ICD-11: 2B33] T17986 INDICATI Phase 1 Mature B-cell lymphoma [ICD-11: 2A85] T17986 INDICATI Phase 2 Mature T-cell lymphoma [ICD-11: 2A90] T17986 INDICATI Phase 1 Renal cell carcinoma [ICD-11: 2C90] T17986 INDICATI Phase 1 Solid tumour/cancer [ICD-11: 2A00-2F9Z] T17986 INDICATI Phase 1 Ureteral cancer [ICD-11: 2C92] T18059 TARGETID T18059 T18059 TARGNAME Complement receptor type 2 (CD21) T18059 INDICATI Phase 1 Diabetes mellitus [ICD-11: 5A10] T18143 TARGETID T18143 T18143 TARGNAME MERS-CoV papain-like proteinase (PL-PRO) T18143 INDICATI Investigative COVID-19 [ICD-11: 1D6Y] T18143 INDICATI Approved Crohn disease [ICD-11: DD70] T18143 INDICATI Approved Malignant haematopoietic neoplasm [ICD-11: 2B33] T18143 INDICATI Preclinical Middle East Respiratory Syndrome [ICD-11: 1D64] T18143 INDICATI Preclinical Severe acute respiratory syndrome [ICD-11: 1D65] T18143 INDICATI Approved Substance abuse [ICD-11: 6C40] T18204 TARGETID T18204 T18204 TARGNAME Alpha-secretase (ASE) T18204 INDICATI Phase 2 Alzheimer disease [ICD-11: 8A20] T18226 TARGETID T18226 T18226 TARGNAME HUMAN clathrin-mediated endocytosis (RME) T18226 INDICATI Phase 3 COVID-19 [ICD-11: 1D6Y] T18226 INDICATI Investigative Middle East Respiratory Syndrome [ICD-11: 1D64] T18226 INDICATI Withdrawn from market Schizophrenia [ICD-11: 6A20] T18226 INDICATI Investigative Severe acute respiratory syndrome [ICD-11: 1D65] T18299 TARGETID T18299 T18299 TARGNAME CaM-kinase II (CAMK2) T18299 INDICATI Investigative Anxiety disorder [ICD-11: 6B00-6B0Z] T18299 INDICATI Phase 2 Rheumatoid arthritis [ICD-11: FA20] T18356 TARGETID T18356 T18356 TARGNAME Lassa virus Pre-glycoprotein polyprotein GP complex (LASV GPC) T18356 INDICATI Phase 1 Arenavirus disease [ICD-11: 1D61] T18477 TARGETID T18477 T18477 TARGNAME Heat shock protein 90 alpha (HSP90A) T18477 INDICATI Approved Acute upper respiratory infection [ICD-11: CA07] T18477 INDICATI Phase 0 Alzheimer disease [ICD-11: 8A20] T18477 INDICATI Approved Asthma [ICD-11: CA23] T18477 INDICATI Phase 2 Breast cancer [ICD-11: 2C60-2C6Y] T18477 INDICATI Discontinued in Phase 3 Diabetes mellitus [ICD-11: 5A10] T18477 INDICATI Phase 1 Encephalopathy [ICD-11: 8E47] T18477 INDICATI Phase 1/2 Lung cancer [ICD-11: 2C25] T18477 INDICATI Phase 1/2 Malignant haematopoietic neoplasm [ICD-11: 2B33] T18477 INDICATI Phase 1 Mature B-cell leukaemia [ICD-11: 2A82] T18477 INDICATI Phase 1 Mature B-cell lymphoma [ICD-11: 2A85] T18477 INDICATI Phase 1 Melanoma [ICD-11: 2C30] T18477 INDICATI Phase 2 Multiple myeloma [ICD-11: 2A83] T18477 INDICATI Phase 1 Neuropathy [ICD-11: 8C0Z] T18477 INDICATI Phase 1 Ovarian cancer [ICD-11: 2C73] T18477 INDICATI Discontinued in Phase 2 Renal cell carcinoma [ICD-11: 2C90] T18477 INDICATI Phase 2 Solid tumour/cancer [ICD-11: 2A00-2F9Z] T18477 INDICATI Phase 1 Stomach cancer [ICD-11: 2B72] T18477 INDICATI Discontinued in Phase 2 Unspecific body region injury [ICD-11: ND56] T18477 INDICATI Terminated Vasomotor/allergic rhinitis [ICD-11: CA08] T18551 TARGETID T18551 T18551 TARGNAME CD80-PD-L1 interaction (CD80/PD-L1 PPI) T18551 INDICATI Patented Human immunodeficiency virus disease [ICD-11: 1C60-1C62] T18551 INDICATI Patented Inflammatory liver disease [ICD-11: DB97] T18551 INDICATI Patented Postoperative inflammation [ICD-11: 1A00-CA43] T18551 INDICATI Patented Solid tumour/cancer [ICD-11: 2A00-2F9Z] T18632 TARGETID T18632 T18632 TARGNAME Cholinergic receptor unspecific (CHR) T18632 INDICATI Phase 3 Hyperhidrosis [ICD-11: EE00] T18632 INDICATI Approved Tonus and reflex abnormality [ICD-11: MB47] T18639 TARGETID T18639 T18639 TARGNAME Heparin-binding growth factor 1 (FGF1) T18639 INDICATI Phase 2 Chronic arterial occlusive disease [ICD-11: BD4Z] T18639 INDICATI Phase 2 Coronary atherosclerosis [ICD-11: BA80] T18664 TARGETID T18664 T18664 TARGNAME Monoglyceride lipase (MAGL) T18664 INDICATI Phase 1 General pain disorder [ICD-11: 8E43] T18664 INDICATI Phase 1 Tic disorder [ICD-11: 8A05] T18779 TARGETID T18779 T18779 TARGNAME Mucin-1 (MUC1) T18779 INDICATI Phase 2 Acute myeloid leukaemia [ICD-11: 2A60] T18779 INDICATI Phase 2/3 Bipolar disorder [ICD-11: 6A60] T18779 INDICATI Phase 1/2 Brain cancer [ICD-11: 2A00] T18779 INDICATI Phase 2 Breast cancer [ICD-11: 2C60-2C6Y] T18779 INDICATI Phase 1/2 Cervical cancer [ICD-11: 2C77] T18779 INDICATI Phase 2 Colorectal cancer [ICD-11: 2B91] T18779 INDICATI Phase 1/2 Esophageal cancer [ICD-11: 2B70] T18779 INDICATI Phase 1/2 Liver cancer [ICD-11: 2C12] T18779 INDICATI Phase 2/3 Lung cancer [ICD-11: 2C25] T18779 INDICATI Phase 1/2 Multiple myeloma [ICD-11: 2A83] T18779 INDICATI Phase 1 Myelodysplastic syndrome [ICD-11: 2A37] T18779 INDICATI Phase 3 Pancreatic cancer [ICD-11: 2C10] T18779 INDICATI Phase 2 Solid tumour/cancer [ICD-11: 2A00-2F9Z] T18779 INDICATI Phase 1/2 Stomach cancer [ICD-11: 2B72] T18872 TARGETID T18872 T18872 TARGNAME Metastasis-suppressor KiSS-1 (KISS1) T18872 INDICATI Phase 2 Prostate cancer [ICD-11: 2C82] T18876 TARGETID T18876 T18876 TARGNAME Prostaglandin E2 receptor EP4 (PTGER4) T18876 INDICATI Phase 2 Asthma [ICD-11: CA23] T18876 INDICATI Investigative Glaucoma [ICD-11: 9C61] T18876 INDICATI Phase 1 Heart failure [ICD-11: BD10-BD1Z] T18876 INDICATI Phase 2 Migraine [ICD-11: 8A80] T18876 INDICATI Phase 1/2 Non-small-cell lung cancer [ICD-11: 2C25] T18876 INDICATI Investigative Osteoarthritis [ICD-11: FA00-FA05] T18876 INDICATI Phase 2 Pain [ICD-11: MG30-MG3Z] T18876 INDICATI Investigative Postoperative inflammation [ICD-11: 1A00-CA43] T18876 INDICATI Phase 1 Rectum cancer [ICD-11: 2B92] T18876 INDICATI Phase 1 Solid tumour/cancer [ICD-11: 2A00-2F9Z] T18876 INDICATI Phase 2 Transplanted organ/tissue [ICD-11: QB63] T18876 INDICATI Investigative Ulcerative colitis [ICD-11: DD71] T18876 INDICATI Discontinued in Phase 2 Unspecific body region injury [ICD-11: ND56] T18950 TARGETID T18950 T18950 TARGNAME Leutinizing-hormone-releasing hormone (GNRH1) T18950 INDICATI Approved Breast cancer [ICD-11: 2C60-2C6Y] T18950 INDICATI Approved Prostate cancer [ICD-11: 2C82] T18950 INDICATI Phase 2 Solid tumour/cancer [ICD-11: 2A00-2F9Z] T18972 TARGETID T18972 T18972 TARGNAME T-cell surface glycoprotein CD3 gamma (CD3G) T18972 INDICATI Phase 2 Breast cancer [ICD-11: 2C60-2C6Y] T18972 INDICATI Phase 1/2 Colorectal cancer [ICD-11: 2B91] T18972 INDICATI Phase 1 Malignant digestive organ neoplasm [ICD-11: 2C11] T18972 INDICATI Phase 1 Prostate cancer [ICD-11: 2C82] T18972 INDICATI Phase 1 Solid tumour/cancer [ICD-11: 2A00-2F9Z] T19011 TARGETID T19011 T19011 TARGNAME M-phase inducer phosphatase 3 (MPIP3) T19011 INDICATI Terminated Solid tumour/cancer [ICD-11: 2A00-2F9Z] T19160 TARGETID T19160 T19160 TARGNAME Group IIA phospholipase A2 (GIIA sPLA2) T19160 INDICATI Clinical trial Breast cancer [ICD-11: 2C60-2C6Y] T19229 TARGETID T19229 T19229 TARGNAME Proton-coupled folate transporter (SLC46A1) T19229 INDICATI Approved Folate deficiency anaemia [ICD-11: 3A02] T19229 INDICATI Approved Leukaemia [ICD-11: 2A60-2B33] T19229 INDICATI Approved Nutritional deficiency [ICD-11: 5B50-5B71] T19229 INDICATI Investigative Prostate cancer [ICD-11: 2C82] T19229 INDICATI Phase 1 Rheumatoid arthritis [ICD-11: FA20] T19229 INDICATI Phase 3 Solid tumour/cancer [ICD-11: 2A00-2F9Z] T19229 INDICATI Phase 3 Vitreoretinopathy [ICD-11: 9B78] T19244 TARGETID T19244 T19244 TARGNAME S-mephenytoin 4-hydroxylase (CYP2C9) T19244 INDICATI Approved Bacterial infection [ICD-11: 1A00-1C4Z] T19334 TARGETID T19334 T19334 TARGNAME Interleukin 21 receptor (IL21R) T19334 INDICATI Phase 1 Crohn disease [ICD-11: DD70] T19334 INDICATI Phase 2 Postoperative inflammation [ICD-11: 1A00-CA43] T19334 INDICATI Phase 1 Solid tumour/cancer [ICD-11: 2A00-2F9Z] T19368 TARGETID T19368 T19368 TARGNAME Endothelial lipase (LIPG) T19368 INDICATI Phase 2 Chronic arterial occlusive disease [ICD-11: BD4Z] T19368 INDICATI Clinical trial Coagulation defect [ICD-11: 3B10] T19368 INDICATI Phase 2 Coronary atherosclerosis [ICD-11: BA80] T19414 TARGETID T19414 T19414 TARGNAME Fibrin (FG) T19414 INDICATI Approved Bleeding disorder [ICD-11: GA20-GA21] T19414 INDICATI Discontinued in Phase 2 Cardiovascular disease [ICD-11: BA00-BE2Z] T19414 INDICATI Phase 3 Chronic arterial occlusive disease [ICD-11: BD4Z] T19414 INDICATI Preclinical Dengue fever [ICD-11: 1D2Z] T19414 INDICATI Phase 3 Injury [ICD-11: NA00-ND5Z] T19414 INDICATI Phase 2 Pregnancy/childbirth/puerperium maternal infection [ICD-11: JB63] T19414 INDICATI Approved Skin postprocedural disorder [ICD-11: EL8Y] T19414 INDICATI Phase 2 Ulcer [ICD-11: CA02-CB40] T19433 TARGETID T19433 T19433 TARGNAME Glutathione-dependent PGD synthase (HPGDS) T19433 INDICATI Phase 2 Alzheimer disease [ICD-11: 8A20] T19433 INDICATI Approved Flatworm infection [ICD-11: 1F70-1F86] T19556 TARGETID T19556 T19556 TARGNAME Oncostatin-M (OSM) T19556 INDICATI Phase 2 Crohn disease [ICD-11: DD70] T19556 INDICATI Investigative Rheumatoid arthritis [ICD-11: FA20] T19556 INDICATI Phase 2 Systemic sclerosis [ICD-11: 4A42] T19567 TARGETID T19567 T19567 TARGNAME Beta-N-acetylhexosaminidase (OGA) T19567 INDICATI Phase 2 Alzheimer disease [ICD-11: 8A20] T19567 INDICATI Phase 1 Parkinsonism [ICD-11: 8A00] T19579 TARGETID T19579 T19579 TARGNAME Interleukin 2 receptor beta (IL2RB) T19579 INDICATI Phase 1/2 Bladder cancer [ICD-11: 2C94] T19579 INDICATI Phase 2 Brain cancer [ICD-11: 2A00] T19579 INDICATI Phase 1/2 Colorectal cancer [ICD-11: 2B91] T19579 INDICATI Phase 1 Head and neck cancer [ICD-11: 2D42] T19579 INDICATI Phase 1 Human immunodeficiency virus disease [ICD-11: 1C60-1C62] T19579 INDICATI Phase 3 Melanoma [ICD-11: 2C30] T19579 INDICATI Phase 1/2 Renal cell carcinoma [ICD-11: 2C90] T19579 INDICATI Phase 2 Sarcoma [ICD-11: 2A60-2C35] T19579 INDICATI Phase 1/2 Solid tumour/cancer [ICD-11: 2A00-2F9Z] T19615 TARGETID T19615 T19615 TARGNAME Granulocyte colony-stimulating factor (CSF3) T19615 INDICATI Approved Aplastic anaemia [ICD-11: 3A70] T19615 INDICATI Approved Neutropenia [ICD-11: 4B00] T19693 TARGETID T19693 T19693 TARGNAME Soluble guanylyl cyclase (GUCY2D) T19693 INDICATI Phase 2 Angina pectoris [ICD-11: BA40] T19693 INDICATI Approved Heart failure [ICD-11: BD10-BD1Z] T19693 INDICATI Approved Pulmonary hypertension [ICD-11: BB01] T19760 TARGETID T19760 T19760 TARGNAME Mixed lineage kinase 1 (MAP3K9) T19760 INDICATI Phase 2/3 Asthma [ICD-11: CA23] T19784 TARGETID T19784 T19784 TARGNAME Somatotropin (GH1) T19784 INDICATI Phase 3 Multiple structural anomalies syndrome [ICD-11: LD2F] T19784 INDICATI Phase 3 Pituitary gland disorder [ICD-11: 5A60-5A61] T19852 TARGETID T19852 T19852 TARGNAME Keratinocyte growth factor (FGF7) T19852 INDICATI Phase 1 Solid tumour/cancer [ICD-11: 2A00-2F9Z] T19947 TARGETID T19947 T19947 TARGNAME Immunoproteasome complex (IP) T19947 INDICATI Phase 2 Idiopathic inflammatory myopathy ICD-11: 4A41 T20017 TARGETID T20017 T20017 TARGNAME CREB-regulated transcription coactivator 1 (TORC1) T20017 INDICATI Phase 2 COVID-19 [ICD-11: 1D6Y] T20017 INDICATI Phase 3 Respiratory infection [ICD-11: CA07-CA4Z] T20059 TARGETID T20059 T20059 TARGNAME TGF-beta receptor (TGFBR) T20059 INDICATI Phase 1 Idiopathic interstitial pneumonitis [ICD-11: CB03] T20059 INDICATI Investigative Pleural effusion [ICD-11: CB27] T20089 TARGETID T20089 T20089 TARGNAME Plasmodium Deoxyribonucleic acid (Malaria DNA) T20089 INDICATI Approved Malaria [ICD-11: 1F40-1F45] T20103 TARGETID T20103 T20103 TARGNAME Vacuolar-type proton ATPase (v-ATPase) T20103 INDICATI Preclinical Arteries/arterioles disorder [ICD-11: BD52] T20103 INDICATI Discontinued in Phase 2 Low bone mass disorder [ICD-11: FB83] T20103 INDICATI Investigative Malignant haematopoietic neoplasm [ICD-11: 2B33] T20103 INDICATI Preclinical Solid tumour/cancer [ICD-11: 2A00-2F9Z] T20178 TARGETID T20178 T20178 TARGNAME Tumor necrosis factor (TNF) T20178 INDICATI Approved Arterial occlusive disease [ICD-11: BD40] T20178 INDICATI Phase 3 Asthma [ICD-11: CA23] T20178 INDICATI Phase 2 Atopic eczema [ICD-11: EA80] T20178 INDICATI Phase 2 Bowel habit change [ICD-11: ME05] T20178 INDICATI Phase 2 Crohn disease [ICD-11: DD70] T20178 INDICATI Phase 2 Cystic fibrosis [ICD-11: CA25] T20178 INDICATI Phase 2 Diabetes mellitus [ICD-11: 5A10] T20178 INDICATI Phase 3 Esophageal cancer [ICD-11: 2B70] T20178 INDICATI Phase 2 Herpes simplex infection [ICD-11: 1F00] T20178 INDICATI Phase 2/3 Indeterminate colitis [ICD-11: DD72] T20178 INDICATI Terminated Infectious gastroenteritis/colitis [ICD-11: 1A40] T20178 INDICATI Phase 2 Influenza [ICD-11: 1E30-1E32] T20178 INDICATI Phase 2 Lupus erythematosus [ICD-11: 4A40] T20178 INDICATI Preclinical Motor neuron disease [ICD-11: 8B60] T20178 INDICATI Approved Multiple myeloma [ICD-11: 2A83] T20178 INDICATI Phase 2 Osteoarthritis [ICD-11: FA00-FA05] T20178 INDICATI Approved Pancreatitis [ICD-11: DC31-DC34] T20178 INDICATI Phase 2 Pemphigus [ICD-11: EB40] T20178 INDICATI Phase 2 Pneumonia [ICD-11: CA40] T20178 INDICATI Phase 1 Postoperative inflammation [ICD-11: 1A00-CA43] T20178 INDICATI Approved Psoriasis [ICD-11: EA90] T20178 INDICATI Phase 2 Psoriatic arthritis [ICD-11: FA21] T20178 INDICATI Approved Rheumatoid arthritis [ICD-11: FA20] T20178 INDICATI Phase 1/2 Sarcoidosis [ICD-11: 4B20] T20178 INDICATI Discontinued in Phase 3 Sepsis [ICD-11: 1G40-1G41] T20178 INDICATI Phase 2 Solid tumour/cancer [ICD-11: 2A00-2F9Z] T20178 INDICATI Phase 3 Spinal pain [ICD-11: ME84] T20178 INDICATI Phase 3 Systemic sclerosis [ICD-11: 4A42] T20178 INDICATI Preclinical Transplant rejection [ICD-11: NE84] T20178 INDICATI Phase 1 Ulcerative colitis [ICD-11: DD71] T20178 INDICATI Discontinued in Phase 1/2 Vasomotor/allergic rhinitis [ICD-11: CA08] T20185 TARGETID T20185 T20185 TARGNAME Fucosyl GM1 (FucGM1) T20185 INDICATI Phase 2 Lung cancer [ICD-11: 2C25] T20185 INDICATI Phase 2 Solid tumour/cancer [ICD-11: 2A00-2F9Z] T20210 TARGETID T20210 T20210 TARGNAME Feto-acinar pancreatic protein (FAPP) T20210 INDICATI Terminated Pancreatic cancer [ICD-11: 2C10] T20251 TARGETID T20251 T20251 TARGNAME Voltage-gated potassium channel Kv11.1 (KCNH2) T20251 INDICATI Terminated Angina pectoris [ICD-11: BA40] T20251 INDICATI Discontinued in Phase 2 Cardiac arrhythmia [ICD-11: BC9Z] T20251 INDICATI Investigative Genetic cardiac arrhythmia [ICD-11: BC65] T20251 INDICATI Approved Heart failure [ICD-11: BD10-BD1Z] T20251 INDICATI Phase 2 Malaria [ICD-11: 1F40-1F45] T20251 INDICATI Phase 2 Multiple sclerosis [ICD-11: 8A40] T20251 INDICATI Investigative Ovarian cancer [ICD-11: 2C73] T20251 INDICATI Phase 2 Pain [ICD-11: MG30-MG3Z] T20251 INDICATI Phase 3 Sleep-wake disorder [ICD-11: 7A00-7B2Z] T20278 TARGETID T20278 T20278 TARGNAME Major histocompatibility complex (MHC) T20278 INDICATI Discontinued in Phase 2 Virus infection [ICD-11: 1A24-1D9Z] T20297 TARGETID T20297 T20297 TARGNAME Serine protease unspecific (SP) T20297 INDICATI Terminated Arteries/arterioles disorder [ICD-11: BD52] T20297 INDICATI Approved Bleeding disorder [ICD-11: GA20-GA21] T20297 INDICATI Phase 2 Cystic fibrosis [ICD-11: CA25] T20297 INDICATI Phase 4 Intrathoracic organs injury [ICD-11: NB32] T20297 INDICATI Phase 2 Myocardial infarction [ICD-11: BA41-BA43] T20297 INDICATI Approved Pancreatitis [ICD-11: DC31-DC34] T20297 INDICATI Phase 2 Pneumonia [ICD-11: CA40] T20297 INDICATI Discontinued in Phase 2 Sepsis [ICD-11: 1G40-1G41] T20297 INDICATI Discontinued in Phase 3 Solid tumour/cancer [ICD-11: 2A00-2F9Z] T20297 INDICATI Terminated Thrombosis [ICD-11: DB61-GB90] T20297 INDICATI Preclinical Transplant rejection [ICD-11: NE84] T20331 TARGETID T20331 T20331 TARGNAME Neuropeptide Y receptor type 5 (NPY5R) T20331 INDICATI Preclinical Acute diabete complication [ICD-11: 5A2Y] T20331 INDICATI Discontinued in Phase 1 Binge eating disorder [ICD-11: 6B82] T20331 INDICATI Investigative Depression [ICD-11: 6A70-6A7Z] T20331 INDICATI Terminated Fungal infection [ICD-11: 1F29-1F2F] T20331 INDICATI Discontinued in Phase 3 Obesity [ICD-11: 5B80-5B81] T20333 TARGETID T20333 T20333 TARGNAME Macrophage colony-stimulating factor 1 receptor (CSF1R) T20333 INDICATI Phase 3 Alzheimer disease [ICD-11: 8A20] T20333 INDICATI Approved Bone/articular cartilage neoplasm [ICD-11: 2F7B] T20333 INDICATI Phase 1/2 Diabetes mellitus [ICD-11: 5A10] T20333 INDICATI Phase 2 Idiopathic interstitial pneumonitis [ICD-11: CB03] T20333 INDICATI Phase 3 Inflammatory arthropathy [ICD-11: FA2Z] T20333 INDICATI Phase 1 Malignant haematopoietic neoplasm [ICD-11: 2B33] T20333 INDICATI Phase 2 Motor neuron disease [ICD-11: 8B60] T20333 INDICATI Phase 2 Pancreatic cancer [ICD-11: 2C10] T20333 INDICATI Phase 1/2 Phakomatoses/hamartoneoplastic syndrome [ICD-11: LD2D] T20333 INDICATI Phase 2 Solid tumour/cancer [ICD-11: 2A00-2F9Z] T20333 INDICATI Phase 3 Stomach cancer [ICD-11: 2B72] T20401 TARGETID T20401 T20401 TARGNAME Carbonic anhydrase II (CA-II) T20401 INDICATI Approved Bacterial infection [ICD-11: 1A00-1C4Z] T20401 INDICATI Phase 2 Breast cancer [ICD-11: 2C60-2C6Y] T20401 INDICATI Withdrawn from market Duodenal ulcer [ICD-11: DA63] T20401 INDICATI Approved Essential hypertension [ICD-11: BA00] T20401 INDICATI Approved Glaucoma [ICD-11: 9C61] T20401 INDICATI Approved Heart failure [ICD-11: BD10-BD1Z] T20401 INDICATI Approved Insomnia [ICD-11: 7A00-7A0Z] T20401 INDICATI Phase 2 Low bone mass disorder [ICD-11: FB83] T20401 INDICATI Phase 3 Rheumatoid arthritis [ICD-11: FA20] T20401 INDICATI Approved Seborrhoeic dermatitis [ICD-11: EA81] T20401 INDICATI Phase 3 Solid tumour/cancer [ICD-11: 2A00-2F9Z] T20474 TARGETID T20474 T20474 TARGNAME DNA topoisomerase (TOP) T20474 INDICATI Phase 2 Fungal infection [ICD-11: 1F29-1F2F] T20474 INDICATI Phase 3 Lung cancer [ICD-11: 2C25] T20474 INDICATI Phase 3 Ovarian cancer [ICD-11: 2C73] T20514 TARGETID T20514 T20514 TARGNAME Delta-aminolevulinic acid dehydratase (ALAD) T20514 INDICATI Approved Acne vulgaris [ICD-11: ED80] T20514 INDICATI Approved Epidermal dysplasias [ICD-11: EK90] T20534 TARGETID T20534 T20534 TARGNAME Pseudomonas Transcriptional activator protein LasR (Pseudo LasR) T20534 INDICATI Preclinical Glanders [ICD-11: 1B92] T20563 TARGETID T20563 T20563 TARGNAME EGFR Exon20ins mutant (EGFR Exon20ins) T20563 INDICATI Approved Non-small-cell lung cancer [ICD-11: 2C25] T20575 TARGETID T20575 T20575 TARGNAME C-C chemokine receptor type 8 (CCR8) T20575 INDICATI Discontinued in Phase 1 Psoriasis [ICD-11: EA90] T20575 INDICATI Phase 1 Solid tumour/cancer [ICD-11: 2A00-2F9Z] T20578 TARGETID T20578 T20578 TARGNAME Phosphodiesterase 7B (PDE7B) T20578 INDICATI Discontinued in Phase 1 Pain [ICD-11: MG30-MG3Z] T20593 TARGETID T20593 T20593 TARGNAME Tumor-associated glycan antigen (TAGA) T20593 INDICATI Phase 1 Solid tumour/cancer [ICD-11: 2A00-2F9Z] T20629 TARGETID T20629 T20629 TARGNAME Adrenomedullin (ADM) T20629 INDICATI Phase 2 Acute respiratory distress syndrome [ICD-11: CB00] T20709 TARGETID T20709 T20709 TARGNAME Muscarinic acetylcholine receptor M4 (CHRM4) T20709 INDICATI Approved Asthma [ICD-11: CA23] T20709 INDICATI Investigative Attention deficit hyperactivity disorder [ICD-11: 6A05] T20709 INDICATI Approved Eye anterior segment structural developmental anomaly [ICD-11: LA11] T20709 INDICATI Approved Glaucoma [ICD-11: 9C61] T20709 INDICATI Approved Nausea/vomiting [ICD-11: MD90] T20709 INDICATI Approved Respiratory system disease [ICD-11: CB40-CB7Z] T20710 TARGETID T20710 T20710 TARGNAME Interleukin 2 receptor (IL2R) T20710 INDICATI Approved Leukaemia [ICD-11: 2A60-2B33] T20710 INDICATI Phase 2 Lung cancer [ICD-11: 2C25] T20710 INDICATI Phase 2 Solid tumour/cancer [ICD-11: 2A00-2F9Z] T20741 TARGETID T20741 T20741 TARGNAME Solute carrier family 6 member 8 (SLC6A8) T20741 INDICATI Phase 1 Malignant digestive organ neoplasm [ICD-11: 2C11] T20761 TARGETID T20761 T20761 TARGNAME Vascular endothelial growth factor A (VEGFA) T20761 INDICATI Patented Bone growth disorder [ICD-11: FB86] T20761 INDICATI Phase 3 Breast cancer [ICD-11: 2C60-2C6Y] T20761 INDICATI Patented Circulatory system disease [ICD-11: BE2Z] T20761 INDICATI Approved Colorectal cancer [ICD-11: 2B91] T20761 INDICATI Patented Corneal disease [ICD-11: 9A76-9A78] T20761 INDICATI Phase 1 Fallopian tube cancer [ICD-11: 2C74] T20761 INDICATI Patented Fibrosis [ICD-11: GA14-GC01] T20761 INDICATI Phase 1/2 Hypopharyngeal cancer [ICD-11: 2B6D] T20761 INDICATI Phase 2 Liver cancer [ICD-11: 2C12] T20761 INDICATI Phase 3 Lung cancer [ICD-11: 2C25] T20761 INDICATI Phase 3 Lymphoma [ICD-11: 2A80-2A86] T20761 INDICATI Patented Macular degeneration [ICD-11: 9B75] T20761 INDICATI Phase 3 Malignant haematopoietic neoplasm [ICD-11: 2B33] T20761 INDICATI Patented Metabolic disorder [ICD-11: 5C50-5D2Z] T20761 INDICATI Phase 2 Metastatic tumour [ICD-11: 2D50-2E2Z] T20761 INDICATI Phase 1/2 Muscular atrophy [ICD-11: 8B61] T20761 INDICATI Investigative Nasopharyngeal cancer [ICD-11: 2B6B] T20761 INDICATI Patented Neurodegenerative disorder [ICD-11: 8A20-8A23] T20761 INDICATI Phase 1 Ovarian cancer [ICD-11: 2C73] T20761 INDICATI Phase 1 Peritoneal cancer [ICD-11: 2C51] T20761 INDICATI Approved Retinopathy [ICD-11: 9B71] T20761 INDICATI Phase 2 Rheumatoid arthritis [ICD-11: FA20] T20761 INDICATI Phase 2 Solid tumour/cancer [ICD-11: 2A00-2F9Z] T20761 INDICATI Patented Stomach cancer [ICD-11: 2B72] T20761 INDICATI Patented Transient ischaemic attack [ICD-11: 8B10] T20761 INDICATI Approved Vascular system developmental anomaly [ICD-11: LA90] T20761 INDICATI Patented Virus infection [ICD-11: 1A24-1D9Z] T20796 TARGETID T20796 T20796 TARGNAME Reactive oxygen species (ROS) T20796 INDICATI Phase 1/2 Asthma [ICD-11: CA23] T20796 INDICATI Phase 2 Hepatitis virus infection [ICD-11: 1E50-1E51] T20796 INDICATI Approved Malaria [ICD-11: 1F40-1F45] T20796 INDICATI Phase 2 Motor neuron disease [ICD-11: 8B60] T20808 TARGETID T20808 T20808 TARGNAME Isocitrate dehydrogenase (IDH) T20808 INDICATI Approved Acute myeloid leukaemia [ICD-11: 2A60] T20808 INDICATI Phase 3 BCR-ABL1-negative chronic myeloid leukaemia [ICD-11: 2A41] T20808 INDICATI Phase 3 Brain cancer [ICD-11: 2A00] T20891 TARGETID T20891 T20891 TARGNAME Phosphoinositide dependent protein kinase-1 (PDPK1) T20891 INDICATI Phase 1 Lymphoma [ICD-11: 2A80-2A86] T20891 INDICATI Investigative Solid tumour/cancer [ICD-11: 2A00-2F9Z] T20973 TARGETID T20973 T20973 TARGNAME Cyclin-dependent kinase 5 (CDK5) T20973 INDICATI Preclinical Obesity [ICD-11: 5B80-5B81] T20978 TARGETID T20978 T20978 TARGNAME T-cell surface glycoprotein CD8 (CD8) T20978 INDICATI Phase 1 Human immunodeficiency virus disease [ICD-11: 1C60-1C62] T20978 INDICATI Phase 2 Influenza [ICD-11: 1E30-1E32] T20978 INDICATI Phase 1/2 Solid tumour/cancer [ICD-11: 2A00-2F9Z] T21112 TARGETID T21112 T21112 TARGNAME DNA replication (DNA repli) T21112 INDICATI Approved Acute myeloid leukaemia [ICD-11: 2A60] T21112 INDICATI Phase 3 Bacterial infection [ICD-11: 1A00-1C4Z] T21112 INDICATI Approved Impetigo [ICD-11: 1B72] T21112 INDICATI Approved Kaposi sarcoma [ICD-11: 2B57] T21112 INDICATI Approved Mature B-cell leukaemia [ICD-11: 2A82] T21112 INDICATI Phase 1/2 Mature B-cell lymphoma [ICD-11: 2A85] T21112 INDICATI Approved Solid tumour/cancer [ICD-11: 2A00-2F9Z] T21123 TARGETID T21123 T21123 TARGNAME Hypoxia-inducible factor 2 alpha (HIF-2A) T21123 INDICATI Approved Adrenomedullary hyperfunction [ICD-11: 5A75] T21123 INDICATI Phase 2 Brain cancer [ICD-11: 2A00] T21123 INDICATI Phase 3 Renal cell carcinoma [ICD-11: 2C90] T21123 INDICATI Phase 1 Solid tumour/cancer [ICD-11: 2A00-2F9Z] T21291 TARGETID T21291 T21291 TARGNAME Plasmodium Apical membrane protein (Malaria AMA-1) T21291 INDICATI Phase 1/2 Malaria [ICD-11: 1F40-1F45] T21307 TARGETID T21307 T21307 TARGNAME MAPK-activated protein kinase 2 (MAPKAPK2) T21307 INDICATI Phase 1 Acute laryngitis/tracheitis [ICD-11: CA05] T21307 INDICATI Investigative Fibrosis [ICD-11: GA14-GC01] T21307 INDICATI Phase 2 Hidradenitis suppurativa [ICD-11: ED92] T21307 INDICATI Phase 2 Monogenic autoinflammatory syndrome ICD-11: 4A60 T21307 INDICATI Phase 1/2 Peritoneal cancer [ICD-11: 2C51] T21307 INDICATI Phase 2 Psoriatic arthritis [ICD-11: FA21] T21307 INDICATI Phase 2 Rheumatoid arthritis [ICD-11: FA20] T21307 INDICATI Phase 1 Solid tumour/cancer [ICD-11: 2A00-2F9Z] T21312 TARGETID T21312 T21312 TARGNAME Immune checkpoint (ICH) T21312 INDICATI Phase 1 Solid tumour/cancer [ICD-11: 2A00-2F9Z] T21324 TARGETID T21324 T21324 TARGNAME Isomerase unspecific (IsoM) T21324 INDICATI Discontinued in Preregistration Angina pectoris [ICD-11: BA40] T21324 INDICATI Discontinued in Phase 2 Asthma [ICD-11: CA23] T21334 TARGETID T21334 T21334 TARGNAME Osteoclast differentiation factor (ODF) T21334 INDICATI Approved Low bone mass disorder [ICD-11: FB83] T21334 INDICATI Phase 1 Metastatic tumour [ICD-11: 2D50-2E2Z] T21334 INDICATI Phase 3 Prostate cancer [ICD-11: 2C82] T21334 INDICATI Phase 2 Rheumatoid arthritis [ICD-11: FA20] T21351 TARGETID T21351 T21351 TARGNAME Nuclear receptor unspecific (NR) T21351 INDICATI Phase 2 Rheumatoid arthritis [ICD-11: FA20] T21395 TARGETID T21395 T21395 TARGNAME Membrane cofactor protein (CD46) T21395 INDICATI Phase 1 Multiple myeloma [ICD-11: 2A83] T21434 TARGETID T21434 T21434 TARGNAME Neuronal acetylcholine receptor alpha-10 (CHRNA10) T21434 INDICATI Phase 1 General pain disorder [ICD-11: 8E43] T21447 TARGETID T21447 T21447 TARGNAME Glutamine receptor (GluR) T21447 INDICATI Approved Nasopharyngitis [ICD-11: CA00] T21617 TARGETID T21617 T21617 TARGNAME Signal transduction unspecific (ST) T21617 INDICATI Phase 3 Lupus erythematosus [ICD-11: 4A40] T21617 INDICATI Phase 1 Solid tumour/cancer [ICD-11: 2A00-2F9Z] T21669 TARGETID T21669 T21669 TARGNAME Glutathione S-transferase P (GSTP1) T21669 INDICATI Phase 2 Myelodysplastic syndrome [ICD-11: 2A37] T21669 INDICATI Phase 3 Solid tumour/cancer [ICD-11: 2A00-2F9Z] T21678 TARGETID T21678 T21678 TARGNAME Alpha-galactosidase A (GLA) T21678 INDICATI Approved Lysosomal disease [ICD-11: 5C56] T21679 TARGETID T21679 T21679 TARGNAME Huntingtin messenger RNA (HTT mRNA) T21679 INDICATI Preclinical Choreiform disorder [ICD-11: 8A01] T21689 TARGETID T21689 T21689 TARGNAME Apolipoprotein E (APOE) T21689 INDICATI Phase 1/2 Alzheimer disease [ICD-11: 8A20] T21689 INDICATI Terminated Glaucoma [ICD-11: 9C61] T21689 INDICATI Phase 2 Hyper-lipoproteinaemia [ICD-11: 5C80] T21689 INDICATI Phase 2 Intracerebral haemorrhage [ICD-11: 8B00] T21701 TARGETID T21701 T21701 TARGNAME Transforming protein Rho (RHO) T21701 INDICATI Phase 2/3 Spine/trunk injury [ICD-11: ND51] T21782 TARGETID T21782 T21782 TARGNAME Proliferating cell nuclear antigen (PCNA) T21782 INDICATI Phase 3 Obesity [ICD-11: 5B80-5B81] T21782 INDICATI Discontinued in Phase 1 Retina disorder [ICD-11: 9B70-9B7Z] T21865 TARGETID T21865 T21865 TARGNAME P-selectin glycoprotein ligand 1 (SELPLG) T21865 INDICATI Phase 2 Allergic/hypersensitivity disorder [ICD-11: 4A80-4A8Z] T21865 INDICATI Phase 2 Asthma [ICD-11: CA23] T21865 INDICATI Phase 2 Chronic obstructive pulmonary disease [ICD-11: CA22] T21865 INDICATI Phase 2 Myocardial infarction [ICD-11: BA41-BA43] T21865 INDICATI Phase 2 Psoriatic arthritis [ICD-11: FA21] T21890 TARGETID T21890 T21890 TARGNAME Carcinoembryonic antigen CGM1 (CD66d) T21890 INDICATI Approved Breast cancer [ICD-11: 2C60-2C6Y] T21945 TARGETID T21945 T21945 TARGNAME Norepinephrine transporter (NET) T21945 INDICATI Approved Acute pain [ICD-11: MG31] T21945 INDICATI Phase 2 Adrenal cancer [ICD-11: 2D11] T21945 INDICATI Application submitted Adrenomedullary hyperfunction [ICD-11: 5A75] T21945 INDICATI Approved Attention deficit hyperactivity disorder [ICD-11: 6A05] T21945 INDICATI Phase 3 Binge eating disorder [ICD-11: 6B82] T21945 INDICATI Approved Chronic pain [ICD-11: MG30] T21945 INDICATI Phase 2 Cocaine use disorder [ICD-11: 6C45] T21945 INDICATI Approved Corneal disease [ICD-11: 9A76-9A78] T21945 INDICATI Approved Depression [ICD-11: 6A70-6A7Z] T21945 INDICATI Discontinued in Phase 1 Dissociative neurological symptom disorder [ICD-11: 6B60] T21945 INDICATI Phase 2 Fatigue [ICD-11: MG22] T21945 INDICATI Phase 3 General pain disorder [ICD-11: 8E43] T21945 INDICATI Approved Glaucoma [ICD-11: 9C61] T21945 INDICATI Phase 2 Heart failure [ICD-11: BD10-BD1Z] T21945 INDICATI Approved Migraine [ICD-11: 8A80] T21945 INDICATI Phase 3 Mild neurocognitive disorder [ICD-11: 6D71] T21945 INDICATI Phase 3 Mood disorder [ICD-11: 6A60-6E23] T21945 INDICATI Approved Nicotine use disorder [ICD-11: 6C4A] T21945 INDICATI Approved Obesity [ICD-11: 5B80-5B81] T21945 INDICATI Phase 1 Orthostatic hypotension [ICD-11: BA21] T21945 INDICATI Approved Pain [ICD-11: MG30-MG3Z] T21945 INDICATI Approved Stomach cancer [ICD-11: 2B72] T21945 INDICATI Phase 2 Stomach disease [ICD-11: DA43-DA4Y] T21945 INDICATI Phase 2 Substance abuse [ICD-11: 6C40] T21960 TARGETID T21960 T21960 TARGNAME Angiopoietin-2 (ANGPT2) T21960 INDICATI Phase 2 Alzheimer disease [ICD-11: 8A20] T21960 INDICATI Discontinued in Phase 2 Asthma [ICD-11: CA23] T21960 INDICATI Phase 3 Breast cancer [ICD-11: 2C60-2C6Y] T21960 INDICATI Phase 2 Colorectal cancer [ICD-11: 2B91] T21960 INDICATI Phase 3 General pain disorder [ICD-11: 8E43] T21960 INDICATI Phase 3 Ovarian cancer [ICD-11: 2C73] T21960 INDICATI Phase 2 Renal cell carcinoma [ICD-11: 2C90] T21960 INDICATI Approved Retinopathy [ICD-11: 9B71] T21960 INDICATI Investigative Sepsis [ICD-11: 1G40-1G41] T21960 INDICATI Preclinical Sexual dysfunction [ICD-11: HA00-HA01] T21960 INDICATI Phase 1/2 Solid tumour/cancer [ICD-11: 2A00-2F9Z] T22032 TARGETID T22032 T22032 TARGNAME Parathyroid hormone receptor (PTH2R) T22032 INDICATI Phase 1 Alopecia [ICD-11: ED70] T22032 INDICATI Investigative Endocrine disease [ICD-11: 5B3Z] T22032 INDICATI Phase 3 Low bone mass disorder [ICD-11: FB83] T22095 TARGETID T22095 T22095 TARGNAME Interleukin-17 (IL17) T22095 INDICATI Phase 2 Acne vulgaris [ICD-11: ED80] T22095 INDICATI Phase 2 Asthma [ICD-11: CA23] T22095 INDICATI Phase 1 Multiple myeloma [ICD-11: 2A83] T22095 INDICATI Approved Psoriasis [ICD-11: EA90] T22095 INDICATI Phase 3 Psoriatic arthritis [ICD-11: FA21] T22095 INDICATI Phase 2 Rheumatoid arthritis [ICD-11: FA20] T22095 INDICATI Phase 1 Solid tumour/cancer [ICD-11: 2A00-2F9Z] T22118 TARGETID T22118 T22118 TARGNAME Dopamine D1 receptor (D1R) T22118 INDICATI Approved Abortion [ICD-11: JA00] T22118 INDICATI Approved Allergic/hypersensitivity disorder [ICD-11: 4A80-4A8Z] T22118 INDICATI Phase 3 Cocaine use disorder [ICD-11: 6C45] T22118 INDICATI Phase 2 Dementia [ICD-11: 6D80-6D8Z] T22118 INDICATI Discontinued in Phase 1 Glaucoma [ICD-11: 9C61] T22118 INDICATI Approved Hypertension [ICD-11: BA00-BA04] T22118 INDICATI Terminated Mental/behavioural/neurodevelopmental disorder [ICD-11: 6E20-6E8Z] T22118 INDICATI Discontinued in Phase 2 Mild neurocognitive disorder [ICD-11: 6D71] T22118 INDICATI Discontinued in Phase 2 Pain [ICD-11: MG30-MG3Z] T22118 INDICATI Approved Parkinsonism [ICD-11: 8A00] T22118 INDICATI Phase 1/2 Psychotic disorder [ICD-11: 6A20-6A25] T22118 INDICATI Phase 3 Schizophrenia [ICD-11: 6A20] T22118 INDICATI Phase 2 Tic disorder [ICD-11: 8A05] T22118 INDICATI Terminated Type 2 diabetes mellitus [ICD-11: 5A11] T22118 INDICATI Terminated Unspecific substance use disorder [ICD-11: 6C4Z] T22128 TARGETID T22128 T22128 TARGNAME Glutamate decarboxylase 2 (GAD2) T22128 INDICATI Phase 3 Diabetes mellitus [ICD-11: 5A10] T22212 TARGETID T22212 T22212 TARGNAME Immunoglobulin gamma Fc receptor IIA (FCGR2A) T22212 INDICATI Preclinical Chronic kidney disease [ICD-11: GB61] T22212 INDICATI Phase 2 Lupus erythematosus [ICD-11: 4A40] T22212 INDICATI Approved (orphan drug) Thrombocytopenia [ICD-11: 3B64] T22274 TARGETID T22274 T22274 TARGNAME Histone deacetylase 6 (HDAC6) T22274 INDICATI Phase 1 Multiple myeloma [ICD-11: 2A83] T22274 INDICATI Phase 1 Solid tumour/cancer [ICD-11: 2A00-2F9Z] T22285 TARGETID T22285 T22285 TARGNAME Glutamate receptor ionotropic NMDA 2A (NMDAR2A) T22285 INDICATI Terminated Alzheimer disease [ICD-11: 8A20] T22285 INDICATI Terminated Cerebral ischaemia [ICD-11: 8B1Z] T22285 INDICATI Phase 1 Dissociative neurological symptom disorder [ICD-11: 6B60] T22285 INDICATI Discontinued in Phase 2 Epilepsy/seizure [ICD-11: 8A61-8A6Z] T22285 INDICATI Terminated Neurodegenerative disorder [ICD-11: 8A20-8A23] T22285 INDICATI Approved Nutritional deficiency [ICD-11: 5B50-5B71] T22295 TARGETID T22295 T22295 TARGNAME Staphylococcus Capsular polysaccharide CP5 (Stap-coc CP5) T22295 INDICATI Phase 2 Depression [ICD-11: 6A70-6A7Z] T22295 INDICATI Phase 2 Staphylococcal/streptococcal disease [ICD-11: 1B5Y] T22302 TARGETID T22302 T22302 TARGNAME Solute carrier family 12 member 5 (SLC12A5) T22302 INDICATI Investigative Epilepsy/seizure [ICD-11: 8A61-8A6Z] T22348 TARGETID T22348 T22348 TARGNAME Bacterial DNA gyrase (Bact gyrase) T22348 INDICATI Phase 2 Acne vulgaris [ICD-11: ED80] T22348 INDICATI Approved Bacterial infection [ICD-11: 1A00-1C4Z] T22348 INDICATI Approved Bronchitis [ICD-11: CA20] T22348 INDICATI Phase 3 Conjunctiva disorder [ICD-11: 9A60] T22348 INDICATI Phase 2 Cystic fibrosis [ICD-11: CA25] T22348 INDICATI Phase 3 Diabetic foot ulcer [ICD-11: BD54] T22348 INDICATI Phase 1 Digestive organ benign neoplasm [ICD-11: 2E92] T22348 INDICATI Phase 2 Escherichia coli intestinal infection [ICD-11: 1A03] T22348 INDICATI Terminated Fungal infection [ICD-11: 1F29-1F2F] T22348 INDICATI Approved Glaucoma [ICD-11: 9C61] T22348 INDICATI Phase 3 Gonococcal infection [ICD-11: 1A70-1A7Z] T22348 INDICATI Approved Gram-positive bacterial infection [ICD-11: 1B74-1F40] T22348 INDICATI Approved Impetigo [ICD-11: 1B72] T22348 INDICATI Phase 1 Joint direct infection [ICD-11: FA10] T22348 INDICATI Phase 3 Otitis media [ICD-11: AA80-AB0Z] T22348 INDICATI Approved Pneumonia [ICD-11: CA40] T22348 INDICATI Discontinued in Phase 2 Postoperative inflammation [ICD-11: 1A00-CA43] T22348 INDICATI Approved Respiratory infection [ICD-11: CA07-CA4Z] T22348 INDICATI Phase 2 Skin and skin-structure infection [ICD-11: 1F28-1G0Z] T22348 INDICATI Terminated Staphylococcal/streptococcal disease [ICD-11: 1B5Y] T22348 INDICATI Approved Urinary tract infection [ICD-11: GC08] T22350 TARGETID T22350 T22350 TARGNAME Endoglin CD105 (ENG) T22350 INDICATI Phase 3 Angiosarcoma [ICD-11: 2B56] T22350 INDICATI Phase 2 Brain cancer [ICD-11: 2A00] T22350 INDICATI Phase 1 Breast cancer [ICD-11: 2C60-2C6Y] T22350 INDICATI Phase 2 Fallopian tube cancer [ICD-11: 2C74] T22350 INDICATI Phase 2 Gynecologic cancer [ICD-11: 2F33-2F76] T22350 INDICATI Phase 2 Kaposi sarcoma [ICD-11: 2B57] T22350 INDICATI Phase 2 Liver cancer [ICD-11: 2C12] T22350 INDICATI Phase 1 Lung cancer [ICD-11: 2C25] T22350 INDICATI Phase 1 Non-small-cell lung cancer [ICD-11: 2C25] T22350 INDICATI Phase 2 Ovarian cancer [ICD-11: 2C73] T22350 INDICATI Phase 2 Peritoneal cancer [ICD-11: 2C51] T22350 INDICATI Phase 2 Renal cell carcinoma [ICD-11: 2C90] T22350 INDICATI Phase 2 Retinopathy [ICD-11: 9B71] T22415 TARGETID T22415 T22415 TARGNAME Pseudomonas PcrV protein type III (Pseudo pcrV) T22415 INDICATI Phase 2 Cystic fibrosis [ICD-11: CA25] T22415 INDICATI Phase 1 Glanders [ICD-11: 1B92] T22415 INDICATI Phase 2 Medical/surgical procedure injury [ICD-11: PK80-PK81] T22415 INDICATI Phase 2 Postoperative inflammation [ICD-11: 1A00-CA43] T22496 TARGETID T22496 T22496 TARGNAME Huntingtin (HTT) T22496 INDICATI Phase 3 Choreiform disorder [ICD-11: 8A01] T22583 TARGETID T22583 T22583 TARGNAME Sodium/glucose cotransporter 2 (SLC5A4) T22583 INDICATI Phase 3 Acute diabete complication [ICD-11: 5A2Y] T22583 INDICATI Discontinued in Phase 3 Gout [ICD-11: FA25] T22583 INDICATI Phase 3 Type 2 diabetes mellitus [ICD-11: 5A11] T22583 INDICATI Phase 2 Type-1/2 diabete [ICD-11: 5A10-5A11] T22608 TARGETID T22608 T22608 TARGNAME TNF alpha production (TNFA produ) T22608 INDICATI Phase 2 Chronic arterial occlusive disease [ICD-11: BD4Z] T22655 TARGETID T22655 T22655 TARGNAME Mucosal addressin cell adhesion molecule 1 (MADCAM1) T22655 INDICATI Phase 2 Chronic obstructive pulmonary disease [ICD-11: CA22] T22655 INDICATI Phase 2 Crohn disease [ICD-11: DD70] T22655 INDICATI Phase 2 Indeterminate colitis [ICD-11: DD72] T22655 INDICATI Phase 1 Solid tumour/cancer [ICD-11: 2A00-2F9Z] T22655 INDICATI Phase 3 Ulcerative colitis [ICD-11: DD71] T22658 TARGETID T22658 T22658 TARGNAME Interleukin-8 (IL8) T22658 INDICATI Phase 2 COVID-19 [ICD-11: 1D6Y] T22658 INDICATI Phase 1 Diabetes mellitus [ICD-11: 5A10] T22658 INDICATI Phase 2 Melanoma [ICD-11: 2C30] T22658 INDICATI Approved Pain [ICD-11: MG30-MG3Z] T22658 INDICATI Phase 2 Solid tumour/cancer [ICD-11: 2A00-2F9Z] T22778 TARGETID T22778 T22778 TARGNAME Intracellular nitroreductase (INR) T22778 INDICATI Phase 1 Diagnostic imaging [ICD-11: N.A.] T22839 TARGETID T22839 T22839 TARGNAME Pancreatic elastase 1 (CELA1) T22839 INDICATI Approved Alpha-1-antitrypsin deficiency [ICD-11: 5C5A] T22839 INDICATI Application submitted Anterior uveitis [ICD-11: 9A96] T22839 INDICATI Approved Bronchitis [ICD-11: CA20] T22839 INDICATI Terminated Chronic obstructive pulmonary disease [ICD-11: CA22] T22839 INDICATI Withdrawn from market Chronic pain [ICD-11: MG30] T22839 INDICATI Phase 3 Crohn disease [ICD-11: DD70] T22839 INDICATI Terminated Cystic fibrosis [ICD-11: CA25] T22839 INDICATI Terminated Emphysema [ICD-11: CA21] T22839 INDICATI Application submitted Inflammatory spondyloarthritis [ICD-11: FA92] T22839 INDICATI Phase 3 Multiple sclerosis [ICD-11: 8A40] T22839 INDICATI Terminated Postoperative inflammation [ICD-11: 1A00-CA43] T22839 INDICATI Phase 3 Psoriatic arthritis [ICD-11: FA21] T22839 INDICATI Phase 3 Pyoderma gangrenosum [ICD-11: EB21] T22839 INDICATI Phase 3 Rheumatoid arthritis [ICD-11: FA20] T22839 INDICATI Phase 3 Ulcerative colitis [ICD-11: DD71] T22939 TARGETID T22939 T22939 TARGNAME Progesterone receptor (PGR) T22939 INDICATI Approved Breast cancer [ICD-11: 2C60-2C6Y] T22939 INDICATI Approved Contraceptive management [ICD-11: QA21] T22939 INDICATI Phase 2 Endometrial cancer [ICD-11: 2C76] T22939 INDICATI Phase 3 Endometriosis [ICD-11: GA10] T22939 INDICATI Investigative Female genital system disease [ICD-11: GA6Z] T22939 INDICATI Phase 3 Female pelvic pain [ICD-11: GA34] T22939 INDICATI Terminated Low bone mass disorder [ICD-11: FB83] T22939 INDICATI Approved Menstrual cycle bleeding disorder [ICD-11: GA20] T22939 INDICATI Approved Preterm labour/delivery [ICD-11: JB00] T22939 INDICATI Approved Solid tumour/cancer [ICD-11: 2A00-2F9Z] T22939 INDICATI Phase 2 Uterine fibroid [ICD-11: 2E86] T22956 TARGETID T22956 T22956 TARGNAME Cyclin-dependent kinase 3 (CDK3) T22956 INDICATI Phase 1 Malignant haematopoietic neoplasm [ICD-11: 2B33] T22976 TARGETID T22976 T22976 TARGNAME Thymidine kinase 2 (Mt-TK2) T22976 INDICATI Phase 3 Inborn purine/pyrimidine/nucleotide metabolism error [ICD-11: 5C55] T22977 TARGETID T22977 T22977 TARGNAME Superoxide dismutase Cu-Zn (SOD Cu-Zn) T22977 INDICATI Terminated Cerebral ischaemia [ICD-11: 8B1Z] T22977 INDICATI Phase 2 Cerebral ischaemic stroke [ICD-11: 8B11] T22977 INDICATI Phase 3 Dissociative neurological symptom disorder [ICD-11: 6B60] T22977 INDICATI Phase 1/2 Eczema [ICD-11: EA80-EA89] T22977 INDICATI Terminated Head injury [ICD-11: NA00-NA0Z] T22977 INDICATI Investigative Motor neuron disease [ICD-11: 8B60] T22977 INDICATI Preclinical Multiple sclerosis [ICD-11: 8A40] T22977 INDICATI Phase 2 Myocardial infarction [ICD-11: BA41-BA43] T22977 INDICATI Terminated Neurodegenerative disorder [ICD-11: 8A20-8A23] T22977 INDICATI Phase 2 Respiratory system disease [ICD-11: CB40-CB7Z] T22977 INDICATI Phase 1 Skin sensation disturbance [ICD-11: ME65] T22977 INDICATI Phase 2 Solid tumour/cancer [ICD-11: 2A00-2F9Z] T22977 INDICATI Phase 2 Spine/trunk injury [ICD-11: ND51] T22978 TARGETID T22978 T22978 TARGNAME Transforming growth factor beta 3 (TGFB3) T22978 INDICATI Phase 3 Sarcoidosis [ICD-11: 4B20] T22995 TARGETID T22995 T22995 TARGNAME Hepcidin (HAMP) T22995 INDICATI Preclinical Acute disease anaemia [ICD-11: 3A90] T22995 INDICATI Phase 2 Anemia [ICD-11: 3A00-3A9Z] T22995 INDICATI Phase 2 Mineral absorption/transport disorder [ICD-11: 5C64] T22995 INDICATI Phase 2 Myeloproliferative neoplasm [ICD-11: 2A20] T22995 INDICATI Phase 2 Thalassaemia [ICD-11: 3A50] T23003 TARGETID T23003 T23003 TARGNAME MAPK/ERK kinase kinase (MAP3K) T23003 INDICATI Phase 2 Breast cancer [ICD-11: 2C60-2C6Y] T23003 INDICATI Phase 2 Colorectal cancer [ICD-11: 2B91] T23003 INDICATI Phase 2 Lung cancer [ICD-11: 2C25] T23003 INDICATI Approved Melanoma [ICD-11: 2C30] T23003 INDICATI Phase 2 Non-small-cell lung cancer [ICD-11: 2C25] T23003 INDICATI Phase 2 Ovarian cancer [ICD-11: 2C73] T23003 INDICATI Phase 2 Psoriasis [ICD-11: EA90] T23003 INDICATI Phase 3 Solid tumour/cancer [ICD-11: 2A00-2F9Z] T23003 INDICATI Phase 3 Thyroid cancer [ICD-11: 2D10] T23036 TARGETID T23036 T23036 TARGNAME Staphylococcus Enoyl ACP reductase (Stap-coc fabI) T23036 INDICATI Preclinical Anaerobic bacterial infection [ICD-11: 1A00-1A09] T23036 INDICATI Phase 2 Bacterial infection [ICD-11: 1A00-1C4Z] T23036 INDICATI Phase 2 Staphylococcal/streptococcal disease [ICD-11: 1B5Y] T23050 TARGETID T23050 T23050 TARGNAME Pseudomonas LPS-assembly protein LptD (Pseudo lptD) T23050 INDICATI Phase 3 Medical/surgical procedure injury [ICD-11: PK80-PK81] T23145 TARGETID T23145 T23145 TARGNAME Cholesterol desmolase (CYP11A1) T23145 INDICATI Approved Cushing syndrome [ICD-11: 5A70] T23145 INDICATI Phase 1/2 Prostate cancer [ICD-11: 2C82] T23172 TARGETID T23172 T23172 TARGNAME Janus kinase 3 (JAK-3) T23172 INDICATI Phase 1 Acquired hypomelanotic disorder [ICD-11: ED63] T23172 INDICATI Approved Alopecia ICD-11: ED70 T23172 INDICATI Phase 2/3 Alopecia [ICD-11: ED70] T23172 INDICATI Phase 2 Asthma [ICD-11: CA23] T23172 INDICATI Approved Atopic eczema [ICD-11: EA80] T23172 INDICATI Phase 2 B-cell lymphoma [ICD-11: 2A86] T23172 INDICATI Phase 1 Crohn disease [ICD-11: DD70] T23172 INDICATI Investigative Diabetes mellitus [ICD-11: 5A10] T23172 INDICATI Investigative Diffuse large B-cell lymphoma [ICD-11: 2A81] T23172 INDICATI Phase 2 Lupus erythematosus [ICD-11: 4A40] T23172 INDICATI Phase 1/2 Malignant haematopoietic neoplasm [ICD-11: 2B33] T23172 INDICATI Terminated Multiple myeloma [ICD-11: 2A83] T23172 INDICATI Approved Myeloproliferative neoplasm [ICD-11: 2A20] T23172 INDICATI Investigative Postoperative inflammation [ICD-11: 1A00-CA43] T23172 INDICATI Phase 1 Pruritus [ICD-11: EC90] T23172 INDICATI Phase 3 Psoriasis [ICD-11: EA90] T23172 INDICATI Approved Rheumatoid arthritis [ICD-11: FA20] T23172 INDICATI Terminated Transplant rejection [ICD-11: NE84] T23178 TARGETID T23178 T23178 TARGNAME Integrin beta-6 (ITGB6) T23178 INDICATI Phase 1 Solid tumour/cancer [ICD-11: 2A00-2F9Z] T23212 TARGETID T23212 T23212 TARGNAME Monocyte differentiation antigen CD14 (CD14) T23212 INDICATI Phase 2 Sepsis [ICD-11: 1G40-1G41] T23276 TARGETID T23276 T23276 TARGNAME Extracellular signal-regulated kinase 1 (ERK1) T23276 INDICATI Phase 1 Arteries/arterioles disorder [ICD-11: BD52] T23276 INDICATI Preclinical Mature T-cell lymphoma [ICD-11: 2A90] T23276 INDICATI Phase 2 Melanoma [ICD-11: 2C30] T23276 INDICATI Phase 1 Pancreatic cancer [ICD-11: 2C10] T23276 INDICATI Phase 1/2 Solid tumour/cancer [ICD-11: 2A00-2F9Z] T23292 TARGETID T23292 T23292 TARGNAME N-acetylgalactosamine 6 sulfatase (GALNS) T23292 INDICATI Approved Lysosomal disease [ICD-11: 5C56] T23343 TARGETID T23343 T23343 TARGNAME Human immunodeficiency virus Capsid p24 (HIV p24) T23343 INDICATI Approved Human immunodeficiency virus disease [ICD-11: 1C60-1C62] T23347 TARGETID T23347 T23347 TARGNAME Interleukin 1 receptor type 2 (IL1R2) T23347 INDICATI Terminated Immune system disease [ICD-11: 4A01-4B41] T23347 INDICATI Phase 1 Rheumatoid arthritis [ICD-11: FA20] T23348 TARGETID T23348 T23348 TARGNAME von Willebrand factor (VWF) T23348 INDICATI Phase 1 Cerebral ischaemic stroke [ICD-11: 8B11] T23348 INDICATI Phase 2 Intracranial embolism [ICD-11: 8B22] T23348 INDICATI Terminated Solid tumour/cancer [ICD-11: 2A00-2F9Z] T23348 INDICATI Approved Thrombocytopenia [ICD-11: 3B64] T23348 INDICATI Phase 1 Thrombosis [ICD-11: DB61-GB90] T23348 INDICATI Approved Von Willebrand disease [ICD-11: 3B12] T23355 TARGETID T23355 T23355 TARGNAME ITGB3 messenger RNA (ITGB3 mRNA) T23355 INDICATI Discontinued in Phase 3 Cardiovascular disease [ICD-11: BA00-BE2Z] T23355 INDICATI Discontinued in Phase 3 Chronic arterial occlusive disease [ICD-11: BD4Z] T23359 TARGETID T23359 T23359 TARGNAME APP messenger RNA (APP mRNA) T23359 INDICATI Phase 1 Alzheimer disease [ICD-11: 8A20] T23389 TARGETID T23389 T23389 TARGNAME Transthyretin messenger RNA (TTR mRNA) T23389 INDICATI Approved Amyloidosis [ICD-11: 5D00] T23389 INDICATI Approved Amyloidosis ICD-11: 5D00 T23459 TARGETID T23459 T23459 TARGNAME Epstein-Barr virus Envelope glycoprotein gp340 (EBV BLLF1) T23459 INDICATI Approved Herpes simplex infection [ICD-11: 1F00] T23471 TARGETID T23471 T23471 TARGNAME Myeloperoxidase (MPO) T23471 INDICATI Phase 2 Chronic obstructive pulmonary disease [ICD-11: CA22] T23471 INDICATI Phase 1 Heart failure [ICD-11: BD10-BD1Z] T23471 INDICATI Phase 2/3 Left ventricular failure ICD-11: BD11 T23471 INDICATI Discontinued in Phase 1 Multiple sclerosis [ICD-11: 8A40] T23471 INDICATI Phase 2 Parkinsonism [ICD-11: 8A00] T23471 INDICATI Phase 3 Postoperative inflammation [ICD-11: 1A00-CA43] T23499 TARGETID T23499 T23499 TARGNAME Endothelin A receptor (EDNRA) T23499 INDICATI Discontinued in Phase 1 Anxiety disorder [ICD-11: 6B00-6B0Z] T23499 INDICATI Discontinued in Phase 2 Cardiac arrhythmia [ICD-11: BC9Z] T23499 INDICATI Approved Cardiovascular disease [ICD-11: BA00-BE2Z] T23499 INDICATI Discontinued in Phase 2 Cerebrovascular disease [ICD-11: 8B22-8B2Z] T23499 INDICATI Phase 3 Chronic kidney disease [ICD-11: GB61] T23499 INDICATI Phase 3 Coronary vasospastic disease [ICD-11: BA85] T23499 INDICATI Discontinued in Phase 1 Depression [ICD-11: 6A70-6A7Z] T23499 INDICATI Terminated Heart disease [ICD-11: BA41-BA42] T23499 INDICATI Phase 2 Hypertension [ICD-11: BA00-BA04] T23499 INDICATI Phase 3 Hypotension [ICD-11: BA20-BA21] T23499 INDICATI Phase 1 Increased intracranial pressure [ICD-11: 8D60] T23499 INDICATI Phase 2 Myocardial infarction [ICD-11: BA41-BA43] T23499 INDICATI Investigative Preterm labour/delivery [ICD-11: JB00] T23499 INDICATI Phase 2 Prostate cancer [ICD-11: 2C82] T23499 INDICATI Approved Pulmonary hypertension [ICD-11: BB01] T23499 INDICATI Discontinued in Phase 3 Retinal vascular occlusion [ICD-11: 9B74] T23499 INDICATI Discontinued in Phase 1 Solid tumour/cancer [ICD-11: 2A00-2F9Z] T23499 INDICATI Discontinued in Phase 1 Unspecific body region injury [ICD-11: ND56] T23499 INDICATI Approved Urinary system clinical sympton [ICD-11: MF8Y] T23519 TARGETID T23519 T23519 TARGNAME G-protein coupled receptor C 5D (GPRC5D) T23519 INDICATI Approved Multiple myeloma [ICD-11: 2A83] T23547 TARGETID T23547 T23547 TARGNAME Opioid receptor (OPR) T23547 INDICATI Phase 2 Alzheimer disease [ICD-11: 8A20] T23547 INDICATI Phase 2 Anxiety disorder [ICD-11: 6B00-6B0Z] T23547 INDICATI Discontinued in Phase 2 Asthma [ICD-11: CA23] T23547 INDICATI Phase 3 Breast cancer [ICD-11: 2C60-2C6Y] T23547 INDICATI Terminated Cerebral ischaemic stroke [ICD-11: 8B11] T23547 INDICATI Phase 4 Chronic pain [ICD-11: MG30] T23547 INDICATI Approved Cough [ICD-11: MD12] T23547 INDICATI Phase 3 General pain disorder [ICD-11: 8E43] T23547 INDICATI Phase 2 Hepatitis virus infection [ICD-11: 1E50-1E51] T23547 INDICATI Phase 4 Human immunodeficiency virus disease [ICD-11: 1C60-1C62] T23547 INDICATI Phase 2 Influenza [ICD-11: 1E30-1E32] T23547 INDICATI Preclinical Irritable bowel syndrome [ICD-11: DD91] T23547 INDICATI Phase 3 Obesity [ICD-11: 5B80-5B81] T23547 INDICATI Approved Opioid use disorder [ICD-11: 6C43] T23547 INDICATI Approved Pain [ICD-11: MG30-MG3Z] T23547 INDICATI Investigative Parkinsonism [ICD-11: 8A00] T23547 INDICATI Terminated Postoperative inflammation [ICD-11: 1A00-CA43] T23547 INDICATI Terminated Psychotic disorder [ICD-11: 6A20-6A25] T23547 INDICATI Approved Sensation disturbance [ICD-11: MB40] T23547 INDICATI Preclinical Sexual dysfunction [ICD-11: HA00-HA01] T23547 INDICATI Approved Substance abuse [ICD-11: 6C40] T23666 TARGETID T23666 T23666 TARGNAME Aryl hydrocarbon receptor (AHR) T23666 INDICATI Phase 2 Atopic eczema [ICD-11: EA80] T23666 INDICATI Preclinical Brain cancer [ICD-11: 2A00] T23666 INDICATI Investigative Eczema [ICD-11: EA80-EA89] T23666 INDICATI Phase 2 Multiple myeloma [ICD-11: 2A83] T23666 INDICATI Phase 2 Myelodysplastic syndrome [ICD-11: 2A37] T23666 INDICATI Approved Psoriasis [ICD-11: EA90] T23666 INDICATI Phase 1 Solid tumour/cancer [ICD-11: 2A00-2F9Z] T23666 INDICATI Approved Thrombocytopenia [ICD-11: 3B64] T23666 INDICATI Clinical trial Ulcerative colitis [ICD-11: DD71] T23666 INDICATI Phase 1 Ureteral cancer [ICD-11: 2C92] T23673 TARGETID T23673 T23673 TARGNAME Proto-oncogene c-RAF (c-RAF) T23673 INDICATI Phase 2 Diabetes mellitus [ICD-11: 5A10] T23673 INDICATI Phase 2 Indeterminate colitis [ICD-11: DD72] T23673 INDICATI Phase 2 Solid tumour/cancer [ICD-11: 2A00-2F9Z] T23714 TARGETID T23714 T23714 TARGNAME B2 bradykinin receptor (BDKRB2) T23714 INDICATI Terminated Asthma [ICD-11: CA23] T23714 INDICATI Discontinued in Phase 2 Brain cancer [ICD-11: 2A00] T23714 INDICATI Phase 2 Cerebral ischaemic stroke [ICD-11: 8B11] T23714 INDICATI Phase 1/2 Chronic kidney disease [ICD-11: GB61] T23714 INDICATI Phase 1/2 Diabetes mellitus [ICD-11: 5A10] T23714 INDICATI Approved Innate/adaptive immunodeficiency [ICD-11: 4A00] T23714 INDICATI Phase 2 Intracranial injury [ICD-11: NA07] T23714 INDICATI Phase 2 Osteoarthritis [ICD-11: FA00-FA05] T23714 INDICATI Terminated Pain [ICD-11: MG30-MG3Z] T23714 INDICATI Terminated Postoperative inflammation [ICD-11: 1A00-CA43] T23714 INDICATI Discontinued in Phase 2 Rheumatoid arthritis [ICD-11: FA20] T23714 INDICATI Phase 2 Sepsis [ICD-11: 1G40-1G41] T23714 INDICATI Investigative Solid tumour/cancer [ICD-11: 2A00-2F9Z] T23761 TARGETID T23761 T23761 TARGNAME Sarcoplasmic/endoplasmic reticulum calcium ATPase (ATP2A) T23761 INDICATI Approved Malaria [ICD-11: 1F40-1F45] T23761 INDICATI Application submitted Psoriasis [ICD-11: EA90] T23761 INDICATI Phase 3 Psoriatic arthritis [ICD-11: FA21] T23761 INDICATI Phase 3 Rheumatoid arthritis [ICD-11: FA20] T23787 TARGETID T23787 T23787 TARGNAME Renal carcinoma antigen NY-REN-56 (PFKFB3) T23787 INDICATI Investigative Idiopathic interstitial pneumonitis [ICD-11: CB03] T23787 INDICATI Phase 1 Solid tumour/cancer [ICD-11: 2A00-2F9Z] T23797 TARGETID T23797 T23797 TARGNAME Interleukin-33 (IL33) T23797 INDICATI Phase 2 Asthma [ICD-11: CA23] T23797 INDICATI Phase 1 Atopic eczema [ICD-11: EA80] T23797 INDICATI Phase 3 Chronic obstructive pulmonary disease [ICD-11: CA22] T23797 INDICATI Phase 3 Respiratory failure ICD-11: CB41 T23953 TARGETID T23953 T23953 TARGNAME Prostate stem cell antigen (PSCA) T23953 INDICATI Phase 1 Non-small-cell lung cancer [ICD-11: 2C25] T23953 INDICATI Phase 2 Pancreatic cancer [ICD-11: 2C10] T23953 INDICATI Phase 1/2 Prostate cancer [ICD-11: 2C82] T23953 INDICATI Phase 1 Solid tumour/cancer [ICD-11: 2A00-2F9Z] T23953 INDICATI Phase 1/2 Stomach cancer [ICD-11: 2B72] T23995 TARGETID T23995 T23995 TARGNAME Protein kinase C theta (PRKCQ) T23995 INDICATI Terminated Postoperative inflammation [ICD-11: 1A00-CA43] T23995 INDICATI Phase 2 Transplant rejection [ICD-11: NE84] T24127 TARGETID T24127 T24127 TARGNAME Peptide tyrosine tyrosine PYY (PYY) T24127 INDICATI Phase 2 Obesity [ICD-11: 5B80-5B81] T24211 TARGETID T24211 T24211 TARGNAME C1 esterase inhibitor (SERPING1) T24211 INDICATI Approved Innate/adaptive immunodeficiency [ICD-11: 4A00] T24211 INDICATI Approved Sexual dysfunction [ICD-11: HA00-HA01] T24373 TARGETID T24373 T24373 TARGNAME Lysosomal acid lipase (LIPA) T24373 INDICATI Approved Enzyme deficiency [ICD-11: 5C51-5C57] T24555 TARGETID T24555 T24555 TARGNAME ADRB2 messenger RNA (ADRB2 mRNA) T24555 INDICATI Phase 2 Glaucoma [ICD-11: 9C61] T24587 TARGETID T24587 T24587 TARGNAME O-6-methylguanine-DNA-alkyltransferase (MGMT) T24587 INDICATI Phase 3 Sarcoma [ICD-11: 2A60-2C35] T24626 TARGETID T24626 T24626 TARGNAME Haemophilus influenzae Acetylglucosamine deacetylase (Hae-influ lpxC) T24626 INDICATI Phase 1 Glanders [ICD-11: 1B92] T24634 TARGETID T24634 T24634 TARGNAME Bacterial UDP-N-acetylglucosamine carboxyvinyltransferase (Bact murA) T24634 INDICATI Approved Bacterial infection [ICD-11: 1A00-1C4Z] T24634 INDICATI Investigative Gram-positive bacterial infection [ICD-11: 1B74-1F40] T24793 TARGETID T24793 T24793 TARGNAME Voltage-gated calcium channel alpha Cav1.3 (CACNA1D) T24793 INDICATI Phase 3 Alzheimer disease [ICD-11: 8A20] T24793 INDICATI Discontinued in Phase 2 Dissociative neurological symptom disorder [ICD-11: 6B60] T24793 INDICATI Terminated Genetic cardiac arrhythmia [ICD-11: BC65] T24793 INDICATI Investigative Heart failure [ICD-11: BD10-BD1Z] T24793 INDICATI Terminated Unspecific body region injury [ICD-11: ND56] T24835 TARGETID T24835 T24835 TARGNAME Mycobacterial lipoarabinomannan (MycB LAM) T24835 INDICATI Preclinical Mycobacterium infection [ICD-11: 1B10-1B21] T24836 TARGETID T24836 T24836 TARGNAME Vitamin K-dependent protein C (PROC) T24836 INDICATI Discontinued in Phase 1 Cardiovascular disease [ICD-11: BA00-BE2Z] T24836 INDICATI Phase 2 Cerebral ischaemia [ICD-11: 8B1Z] T24836 INDICATI Phase 2 Cerebral ischaemic stroke [ICD-11: 8B11] T24836 INDICATI Approved Chronic lower extremities peripheral venous insufficiency [ICD-11: BD74] T24836 INDICATI Approved Hemangioma [ICD-11: 2E81-2F2Y] T24836 INDICATI Phase 3 Pregnancy/childbirth/puerperium maternal infection [ICD-11: JB63] T24982 TARGETID T24982 T24982 TARGNAME Ileal sodium/bile acid cotransporter (SLC10A2) T24982 INDICATI Phase 2 Autoimmune liver disease [ICD-11: DB96] T24982 INDICATI Phase 3 Gallbladder/bile ducts/liver structural developmental anomaly [ICD-11: LB20] T24982 INDICATI Phase 2 Hyper-lipoproteinaemia [ICD-11: 5C80] T24982 INDICATI Phase 3 Inborn lipid metabolism error [ICD-11: 5C52] T24982 INDICATI Phase 3 Inborn porphyrin/heme metabolism error [ICD-11: 5C58] T24982 INDICATI Approved Pruritus [ICD-11: EC90] T24982 INDICATI Phase 2 Type 2 diabetes mellitus [ICD-11: 5A11] T24983 TARGETID T24983 T24983 TARGNAME Dopamine D4 receptor (D4R) T24983 INDICATI Approved Allergic/hypersensitivity disorder [ICD-11: 4A80-4A8Z] T24983 INDICATI Phase 1 Alzheimer disease [ICD-11: 8A20] T24983 INDICATI Phase 1 Attention deficit hyperactivity disorder [ICD-11: 6A05] T24983 INDICATI Phase 1 Bipolar disorder [ICD-11: 6A60] T24983 INDICATI Phase 1 Depression [ICD-11: 6A70-6A7Z] T24983 INDICATI Phase 1 Parkinsonism [ICD-11: 8A00] T24983 INDICATI Phase 2 Psychotic disorder [ICD-11: 6A20-6A25] T24983 INDICATI Approved Schizophrenia [ICD-11: 6A20] T24983 INDICATI Discontinued in Phase 2 Sexual dysfunction [ICD-11: HA00-HA01] T25005 TARGETID T25005 T25005 TARGNAME Tyrosine-protein kinase BTK (ATK) T25005 INDICATI Phase 1/2 Acute myeloid leukaemia [ICD-11: 2A60] T25005 INDICATI Phase 2 Atopic eczema [ICD-11: EA80] T25005 INDICATI Phase 1 Autoimmune disease [ICD-11: 4A40-4A45] T25005 INDICATI Phase 2 B-cell lymphoma [ICD-11: 2A86] T25005 INDICATI Preclinical Diabetes mellitus [ICD-11: 5A10] T25005 INDICATI Phase 3 Diffuse large B-cell lymphoma [ICD-11: 2A81] T25005 INDICATI Phase 3 Follicular lymphoma [ICD-11: 2A80] T25005 INDICATI Phase 1 Lupus erythematosus [ICD-11: 4A40] T25005 INDICATI Approved Malignant haematopoietic neoplasm [ICD-11: 2B33] T25005 INDICATI Phase 3 Mature B-cell leukaemia [ICD-11: 2A82] T25005 INDICATI Approved Mature B-cell lymphoma [ICD-11: 2A85] T25005 INDICATI Phase 3 Multiple sclerosis [ICD-11: 8A40] T25005 INDICATI Phase 3 Pancreatic cancer [ICD-11: 2C10] T25005 INDICATI Phase 2 Pemphigus [ICD-11: EB40] T25005 INDICATI Phase 2 Rheumatoid arthritis [ICD-11: FA20] T25005 INDICATI Phase 2 Solid tumour/cancer [ICD-11: 2A00-2F9Z] T25005 INDICATI Phase 2 Spontaneous urticaria [ICD-11: EB00] T25064 TARGETID T25064 T25064 TARGNAME Neisseria gonorrhoeae Enoyl-[acyl-carrier-protein] reductase (Neisseria fabI) T25064 INDICATI Preclinical Gonococcal infection [ICD-11: 1A70-1A7Z] T25076 TARGETID T25076 T25076 TARGNAME Endothelin-1 (EDN1) T25076 INDICATI Discontinued in Phase 2 Dissociative neurological symptom disorder [ICD-11: 6B60] T25163 TARGETID T25163 T25163 TARGNAME Carbamoyl-phosphate synthetase I (CPS1) T25163 INDICATI Approved Metabolism inborn error [ICD-11: 5C50] T25163 INDICATI Approved Varicose veins [ICD-11: BD74-BD75] T25258 TARGETID T25258 T25258 TARGNAME Multidrug resistance protein 1 (ABCB1) T25258 INDICATI Discontinued in Phase 3 Acute myeloid leukaemia [ICD-11: 2A60] T25258 INDICATI Discontinued in Phase 2 Adrenal cancer [ICD-11: 2D11] T25258 INDICATI Phase 1 Bacterial infection [ICD-11: 1A00-1C4Z] T25258 INDICATI Discontinued in Phase 3 Lung cancer [ICD-11: 2C25] T25258 INDICATI Discontinued in Phase 2 Ovarian cancer [ICD-11: 2C73] T25258 INDICATI Phase 1 Solid tumour/cancer [ICD-11: 2A00-2F9Z] T25265 TARGETID T25265 T25265 TARGNAME Enhancer of zeste homolog 2 (EZH2) T25265 INDICATI Phase 1 Acute myeloid leukaemia [ICD-11: 2A60] T25265 INDICATI Phase 1 B-cell lymphoma [ICD-11: 2A86] T25265 INDICATI Phase 2 Brain cancer [ICD-11: 2A00] T25265 INDICATI Investigative Breast cancer [ICD-11: 2C60-2C6Y] T25265 INDICATI Phase 1/2 Diffuse large B-cell lymphoma [ICD-11: 2A81] T25265 INDICATI Approved Follicular lymphoma [ICD-11: 2A80] T25265 INDICATI Phase 1/2 Lung cancer [ICD-11: 2C25] T25265 INDICATI Phase 1 Malignant haematopoietic neoplasm [ICD-11: 2B33] T25265 INDICATI Phase 1 Mature B-cell lymphoma [ICD-11: 2A85] T25265 INDICATI Phase 2 Mature T-cell lymphoma [ICD-11: 2A90] T25265 INDICATI Phase 2 Peritoneal cancer [ICD-11: 2C51] T25265 INDICATI Phase 1/2 Prostate cancer [ICD-11: 2C82] T25265 INDICATI Phase 1 Renal cell carcinoma [ICD-11: 2C90] T25265 INDICATI Phase 2 Solid tumour/cancer [ICD-11: 2A00-2F9Z] T25265 INDICATI Phase 1 Synovial sarcoma [ICD-11: 2B5A] T25265 INDICATI Phase 1 Ureteral cancer [ICD-11: 2C92] T25307 TARGETID T25307 T25307 TARGNAME Nuclear receptor ROR-gamma (RORG) T25307 INDICATI Preclinical Arterial occlusive disease [ICD-11: BD40] T25307 INDICATI Phase 1 Autoimmune disease [ICD-11: 4A40-4A45] T25307 INDICATI Phase 1 Crohn disease [ICD-11: DD70] T25307 INDICATI Preclinical Liver cancer [ICD-11: 2C12] T25307 INDICATI Phase 2 Lung cancer [ICD-11: 2C25] T25307 INDICATI Phase 1 Multiple sclerosis [ICD-11: 8A40] T25307 INDICATI Phase 2 Psoriasis [ICD-11: EA90] T25307 INDICATI Preclinical Rheumatoid arthritis [ICD-11: FA20] T25307 INDICATI Phase 2 Solid tumour/cancer [ICD-11: 2A00-2F9Z] T25315 TARGETID T25315 T25315 TARGNAME C-X-C chemokine receptor type 3 (CXCR3) T25315 INDICATI Preclinical Hepatic fibrosis/cirrhosis [ICD-11: DB93] T25315 INDICATI Discontinued in Phase 1 Postoperative inflammation [ICD-11: 1A00-CA43] T25315 INDICATI Discontinued in Phase 2 Psoriasis [ICD-11: EA90] T25315 INDICATI Preclinical Solid tumour/cancer [ICD-11: 2A00-2F9Z] T25317 TARGETID T25317 T25317 TARGNAME Cholestenol delta-isomerase (EBP) T25317 INDICATI Phase 2 Rheumatoid arthritis [ICD-11: FA20] T25419 TARGETID T25419 T25419 TARGNAME Tropomyosin receptor kinase (Trk) T25419 INDICATI Phase 2 Non-small-cell lung cancer [ICD-11: 2C25] T25464 TARGETID T25464 T25464 TARGNAME Calcineurin (PPP3CA) T25464 INDICATI Phase 3 Allergic/hypersensitivity disorder [ICD-11: 4A80-4A8Z] T25464 INDICATI Approved Atopic eczema [ICD-11: EA80] T25464 INDICATI Phase 4 Intracranial injury [ICD-11: NA07] T25464 INDICATI Approved Lupus erythematosus [ICD-11: 4A40] T25464 INDICATI Approved Psoriasis [ICD-11: EA90] T25464 INDICATI Approved Transplant rejection [ICD-11: NE84] T25464 INDICATI Phase 2 Urinary system disease [ICD-11: GC2Z] T25464 INDICATI Investigative Vitamin deficiency [ICD-11: 5B55-5B5F] T25537 TARGETID T25537 T25537 TARGNAME Mitogen-activated protein kinase (MAPK) T25537 INDICATI Phase 2 Keratosis pilaris [ICD-11: ED56] T25537 INDICATI Phase 1 Solid tumour/cancer [ICD-11: 2A00-2F9Z] T25608 TARGETID T25608 T25608 TARGNAME Free fatty acid receptor 1 (GPR40) T25608 INDICATI Phase 2 Acute diabete complication [ICD-11: 5A2Y] T25608 INDICATI Phase 2 Idiopathic interstitial pneumonitis [ICD-11: CB03] T25608 INDICATI Phase 3 Type 2 diabetes mellitus [ICD-11: 5A11] T25637 TARGETID T25637 T25637 TARGNAME Lysyl oxidase homolog 2 (LOXL2) T25637 INDICATI Preclinical Cardiac arrest [ICD-11: MC82] T25637 INDICATI Phase 2 Colorectal cancer [ICD-11: 2B91] T25663 TARGETID T25663 T25663 TARGNAME Adenosine receptor (ADOR) T25663 INDICATI Phase 2 Cardiac arrhythmia [ICD-11: BC9Z] T25663 INDICATI Approved Chronic obstructive pulmonary disease [ICD-11: CA22] T25663 INDICATI Terminated Hypertension [ICD-11: BA00-BA04] T25663 INDICATI Phase 2 Malignant haematopoietic neoplasm [ICD-11: 2B33] T25663 INDICATI Phase 2 Solid tumour/cancer [ICD-11: 2A00-2F9Z] T25698 TARGETID T25698 T25698 TARGNAME Pseudomonas Lipopolysaccharide (Pseudo LPS) T25698 INDICATI Phase 1/2 Glanders [ICD-11: 1B92] T25698 INDICATI Phase 2 Medical/surgical procedure injury [ICD-11: PK80-PK81] T25698 INDICATI Phase 2 Pneumonia [ICD-11: CA40] T25703 TARGETID T25703 T25703 TARGNAME Heme oxygenase 1 (HMOX1) T25703 INDICATI Phase 2 Neonatal hyperbilirubinaemia [ICD-11: KA87] T25705 TARGETID T25705 T25705 TARGNAME N-formyl peptide receptor 3 (FPR3) T25705 INDICATI Preclinical Alzheimer disease [ICD-11: 8A20] T25726 TARGETID T25726 T25726 TARGNAME Glypican-3 (GPC3) T25726 INDICATI Phase 2 Liver cancer [ICD-11: 2C12] T25726 INDICATI Phase 1 Lung cancer [ICD-11: 2C25] T25726 INDICATI Phase 2 Metastatic liver/bile duct neoplasm [ICD-11: 2D80] T25726 INDICATI Phase 2 Solid tumour/cancer [ICD-11: 2A00-2F9Z] T25739 TARGETID T25739 T25739 TARGNAME Solute carrier family 39 member 6 (SLC39A6) T25739 INDICATI Phase 1 Breast cancer [ICD-11: 2C60-2C6Y] T25739 INDICATI Phase 2 Lung cancer [ICD-11: 2C25] T25739 INDICATI Phase 2 Non-small-cell lung cancer [ICD-11: 2C25] T25847 TARGETID T25847 T25847 TARGNAME Rotamase B (PPIB) T25847 INDICATI Approved Nutritional deficiency [ICD-11: 5B50-5B71] T25889 TARGETID T25889 T25889 TARGNAME Adenylate cyclase (ADCY) T25889 INDICATI Terminated Heart failure [ICD-11: BD10-BD1Z] T25889 INDICATI Investigative Solid tumour/cancer [ICD-11: 2A00-2F9Z] T25950 TARGETID T25950 T25950 TARGNAME Bone metabolism (Bone metab) T25950 INDICATI Discontinued in Phase 2 Postoperative inflammation [ICD-11: 1A00-CA43] T25956 TARGETID T25956 T25956 TARGNAME Histone acetyltransferase p300 (EP300) T25956 INDICATI Phase 1 Prostate cancer [ICD-11: 2C82] T25956 INDICATI Phase 1/2 Solid tumour/cancer [ICD-11: 2A00-2F9Z] T26170 TARGETID T26170 T26170 TARGNAME Tumor necrosis factor receptor member 25 (TNFRSF25) T26170 INDICATI Phase 1 Solid tumour/cancer [ICD-11: 2A00-2F9Z] T26203 TARGETID T26203 T26203 TARGNAME Intercellular adhesion molecule ICAM-1 (ICAM1) T26203 INDICATI Phase 3 Conjunctiva disorder [ICD-11: 9A60] T26203 INDICATI Phase 2 Crohn disease [ICD-11: DD70] T26203 INDICATI Terminated Indeterminate colitis [ICD-11: DD72] T26203 INDICATI Phase 3 Infectious gastroenteritis/colitis [ICD-11: 1A40] T26203 INDICATI Phase 2 Multiple myeloma [ICD-11: 2A83] T26203 INDICATI Terminated Postoperative inflammation [ICD-11: 1A00-CA43] T26203 INDICATI Phase 2 Prostate cancer [ICD-11: 2C82] T26203 INDICATI Terminated Psoriasis [ICD-11: EA90] T26203 INDICATI Phase 1 Thyroid cancer [ICD-11: 2D10] T26203 INDICATI Phase 2 Ulcerative colitis [ICD-11: DD71] T26203 INDICATI Approved Visual system disease [ICD-11: 9E1Z] T26220 TARGETID T26220 T26220 TARGNAME Somatostatin receptor (SSTR) T26220 INDICATI Phase 2 Alzheimer disease [ICD-11: 8A20] T26220 INDICATI Investigative Duodenal ulcer [ICD-11: DA63] T26220 INDICATI Phase 2 Hepatitis virus infection [ICD-11: 1E50-1E51] T26220 INDICATI Phase 3 Melanoma [ICD-11: 2C30] T26220 INDICATI Discontinued in Phase 2 Mild neurocognitive disorder [ICD-11: 6D71] T26220 INDICATI Discontinued in Phase 2 Pain [ICD-11: MG30-MG3Z] T26220 INDICATI Phase 2 Pituitary gland disorder [ICD-11: 5A60-5A61] T26220 INDICATI Phase 3 Stomach cancer [ICD-11: 2B72] T26226 TARGETID T26226 T26226 TARGNAME Prolactin receptor (PRLR) T26226 INDICATI Phase 1 Fallopian tube cancer [ICD-11: 2C74] T26226 INDICATI Phase 1 Ovarian cancer [ICD-11: 2C73] T26226 INDICATI Phase 1 Peritoneal cancer [ICD-11: 2C51] T26226 INDICATI Phase 2 Solid tumour/cancer [ICD-11: 2A00-2F9Z] T26240 TARGETID T26240 T26240 TARGNAME Estramustine binding protein (EMBP) T26240 INDICATI Approved Prostate cancer [ICD-11: 2C82] T26327 TARGETID T26327 T26327 TARGNAME Superoxide anion (SPA) T26327 INDICATI Phase 1 Dissociative neurological symptom disorder [ICD-11: 6B60] T26368 TARGETID T26368 T26368 TARGNAME GABA(A) receptor alpha-5 (GABRA5) T26368 INDICATI Phase 2 Adaptive immunity immunodeficiency [ICD-11: 4A01] T26368 INDICATI Phase 2 Alzheimer disease [ICD-11: 8A20] T26368 INDICATI Phase 1 Autism spectrum disorder [ICD-11: 6A02] T26368 INDICATI Phase 2 Indeterminate colitis [ICD-11: DD72] T26368 INDICATI Approved Intentional self-harm [ICD-11: PC91] T26368 INDICATI Phase 2 Mild neurocognitive disorder [ICD-11: 6D71] T26368 INDICATI Investigative Postoperative inflammation [ICD-11: 1A00-CA43] T26368 INDICATI Phase 2 Sex development malformative disorder [ICD-11: LD2A] T26428 TARGETID T26428 T26428 TARGNAME Melanin-concentrating hormone receptor (MCHR) T26428 INDICATI Preclinical Obesity [ICD-11: 5B80-5B81] T26463 TARGETID T26463 T26463 TARGNAME DNA polymerase alpha catalytic p180 (POLA1) T26463 INDICATI Discontinued in Phase 1 Virus infection [ICD-11: 1A24-1D9Z] T26470 TARGETID T26470 T26470 TARGNAME B-cell lymphoma/leukemia 11A (BCL11A) T26470 INDICATI Phase 1/2 Sickle-cell disorder [ICD-11: 3A51] T26470 INDICATI Phase 1/2 Thalassaemia [ICD-11: 3A50] T26500 TARGETID T26500 T26500 TARGNAME Histamine H4 receptor (H4R) T26500 INDICATI Phase 1 Asthma [ICD-11: CA23] T26500 INDICATI Phase 2 Atopic eczema [ICD-11: EA80] T26500 INDICATI Terminated Mild neurocognitive disorder [ICD-11: 6D71] T26500 INDICATI Investigative Postoperative inflammation [ICD-11: 1A00-CA43] T26500 INDICATI Phase 2 Psoriasis [ICD-11: EA90] T26500 INDICATI Phase 2 Rheumatoid arthritis [ICD-11: FA20] T26500 INDICATI Phase 2 Vasomotor/allergic rhinitis [ICD-11: CA08] T26623 TARGETID T26623 T26623 TARGNAME Aldose reductase (AKR1B1) T26623 INDICATI Phase 3 Acute diabete complication [ICD-11: 5A2Y] T26623 INDICATI Withdrawn from market Cataract [ICD-11: 9B10] T26623 INDICATI Phase 1 Glaucoma [ICD-11: 9C61] T26623 INDICATI Discontinued in Phase 3 Gout [ICD-11: FA25] T26623 INDICATI Discontinued in Phase 2 Head and neck cancer [ICD-11: 2D42] T26623 INDICATI Approved Neuropathy [ICD-11: 8C0Z] T26623 INDICATI Investigative Pain [ICD-11: MG30-MG3Z] T26623 INDICATI Approved Rheumatoid arthritis [ICD-11: FA20] T26623 INDICATI Phase 1 Schizophrenia [ICD-11: 6A20] T26623 INDICATI Phase 2/3 Thrombosis [ICD-11: DB61-GB90] T26851 TARGETID T26851 T26851 TARGNAME Complement C3 (CO3) T26851 INDICATI Phase 2 Breast cancer [ICD-11: 2C60-2C6Y] T26851 INDICATI Phase 1/2 Colorectal cancer [ICD-11: 2B91] T26851 INDICATI Phase 2 Gingival disease [ICD-11: DA0B] T26851 INDICATI Approved Haemolytic anemia [ICD-11: 3A20-3A2Z] T26851 INDICATI Phase 2 Head and neck cancer [ICD-11: 2D42] T26851 INDICATI Phase 2 Macular degeneration ICD-11: 9B75 T26851 INDICATI Phase 2/3 Malignant haematopoietic neoplasm [ICD-11: 2B33] T26851 INDICATI Phase 1/2 Melanoma [ICD-11: 2C30] T26851 INDICATI Phase 2 Retinopathy [ICD-11: 9B71] T26900 TARGETID T26900 T26900 TARGNAME Glutamic acid decarboxylase 1 (GAD1) T26900 INDICATI Phase 2 Parkinsonism [ICD-11: 8A00] T27021 TARGETID T27021 T27021 TARGNAME Transferase unspecific (TF) T27021 INDICATI Phase 4 Cerebral ischaemia [ICD-11: 8B1Z] T27021 INDICATI Approved Hepatic fibrosis/cirrhosis [ICD-11: DB93] T27021 INDICATI Terminated Rheumatoid arthritis [ICD-11: FA20] T27021 INDICATI Discontinued in Phase 2 Solid tumour/cancer [ICD-11: 2A00-2F9Z] T27106 TARGETID T27106 T27106 TARGNAME FK506-binding protein (FKBP) T27106 INDICATI Phase 2 Inborn purine/pyrimidine/nucleotide metabolism error [ICD-11: 5C55] T27106 INDICATI Phase 2 Psoriasis [ICD-11: EA90] T27106 INDICATI Phase 1/2 Solid tumour/cancer [ICD-11: 2A00-2F9Z] T27137 TARGETID T27137 T27137 TARGNAME Metabotropic glutamate receptor 1 (mGluR1) T27137 INDICATI Discontinued in Phase 3 Alzheimer disease [ICD-11: 8A20] T27137 INDICATI Preclinical Cerebral ischaemia [ICD-11: 8B1Z] T27137 INDICATI Terminated Dissociative neurological symptom disorder [ICD-11: 6B60] T27137 INDICATI Discontinued in Phase 1 General pain disorder [ICD-11: 8E43] T27137 INDICATI Preclinical Pain [ICD-11: MG30-MG3Z] T27137 INDICATI Discontinued in Phase 2 Schizophrenia [ICD-11: 6A20] T27198 TARGETID T27198 T27198 TARGNAME Streptococcus Methionyl-tRNA synthetase (Stre-coc metG) T27198 INDICATI Phase 1 Bacterial infection [ICD-11: 1A00-1C4Z] T27265 TARGETID T27265 T27265 TARGNAME Oxo-5-alpha-steroid 4-dehydrogenase (SRD5A) T27265 INDICATI Approved Acne vulgaris [ICD-11: ED80] T27265 INDICATI Discontinued in Phase 2 Alopecia [ICD-11: ED70] T27265 INDICATI Phase 3 Hirsutism [ICD-11: ED72] T27265 INDICATI Approved Prostate cancer [ICD-11: 2C82] T27265 INDICATI Phase 2 Prostate disease [ICD-11: GA91] T27265 INDICATI Approved Prostate hyperplasia [ICD-11: GA90] T27288 TARGETID T27288 T27288 TARGNAME Food intake (FI) T27288 INDICATI Discontinued in Phase 2 Obesity [ICD-11: 5B80-5B81] T27376 TARGETID T27376 T27376 TARGNAME GABA(A) receptor delta (GABRD) T27376 INDICATI Terminated Anxiety disorder [ICD-11: 6B00-6B0Z] T27376 INDICATI Terminated Corneal disease [ICD-11: 9A76-9A78] T27376 INDICATI Approved Depression [ICD-11: 6A70-6A7Z] T27376 INDICATI Discontinued in Phase 2 General pain disorder [ICD-11: 8E43] T27376 INDICATI Approved Insomnia [ICD-11: 7A00-7A0Z] T27376 INDICATI Approved Mental/behavioural/neurodevelopmental disorder [ICD-11: 6E20-6E8Z] T27376 INDICATI Phase 3 Status epilepticus [ICD-11: 8A66] T27376 INDICATI Phase 2 Tremor-related disorder [ICD-11: 8A04] T27445 TARGETID T27445 T27445 TARGNAME Bacterial Isoleucyl-tRNA synthetase (Bact ileS) T27445 INDICATI Approved Bacterial infection [ICD-11: 1A00-1C4Z] T27495 TARGETID T27495 T27495 TARGNAME Variola virus Envelope phospholipase F13 (VARV p37) T27495 INDICATI Approved Smallpox [ICD-11: 1E70] T27495 INDICATI Phase 3 Virus infection [ICD-11: 1A24-1D9Z] T27602 TARGETID T27602 T27602 TARGNAME Cationic trypsinogen (PRSS1) T27602 INDICATI Discontinued in Phase 1 Asthma [ICD-11: CA23] T27602 INDICATI Discontinued in Phase 2 Atopic eczema [ICD-11: EA80] T27602 INDICATI Phase 2 Coagulation defect [ICD-11: 3B10] T27602 INDICATI Terminated Hypotension [ICD-11: BA20-BA21] T27602 INDICATI Phase 3 Malignant haematopoietic neoplasm [ICD-11: 2B33] T27602 INDICATI Approved Mature B-cell lymphoma [ICD-11: 2A85] T27602 INDICATI Approved Multiple myeloma [ICD-11: 2A83] T27602 INDICATI Phase 3 Preterm labour/delivery [ICD-11: JB00] T27602 INDICATI Phase 1/2 Sepsis [ICD-11: 1G40-1G41] T27602 INDICATI Investigative Solid tumour/cancer [ICD-11: 2A00-2F9Z] T27611 TARGETID T27611 T27611 TARGNAME Growth/differentiation factor 2 (GDF2) T27611 INDICATI Phase 1 Macular degeneration [ICD-11: 9B75] T27736 TARGETID T27736 T27736 TARGNAME Programmed cell death protein 2 (PD-2) T27736 INDICATI Phase 1 Solid tumour/cancer [ICD-11: 2A00-2F9Z] T27770 TARGETID T27770 T27770 TARGNAME Late inward sodium current (LISC) T27770 INDICATI Phase 3 Genetic cardiac arrhythmia [ICD-11: BC65] T27770 INDICATI Phase 3 Ischemic heart disease [ICD-11: BA40-BA6Z] T27812 TARGETID T27812 T27812 TARGNAME Serotonin transporter (SERT) T27812 INDICATI Phase 3 Alzheimer disease [ICD-11: 8A20] T27812 INDICATI Approved Anxiety disorder [ICD-11: 6B00-6B0Z] T27812 INDICATI Approved Attention deficit hyperactivity disorder [ICD-11: 6A05] T27812 INDICATI Phase 3 Binge eating disorder [ICD-11: 6B82] T27812 INDICATI Approved Chronic pain [ICD-11: MG30] T27812 INDICATI Phase 2 Cocaine use disorder [ICD-11: 6C45] T27812 INDICATI Approved concerning food/fluid intake symptom [ICD-11: MG43] T27812 INDICATI Approved Corneal disease [ICD-11: 9A76-9A78] T27812 INDICATI Approved Cough [ICD-11: MD12] T27812 INDICATI Approved Depression [ICD-11: 6A70-6A7Z] T27812 INDICATI Discontinued in Phase 1 Dissociative neurological symptom disorder [ICD-11: 6B60] T27812 INDICATI Phase 2 Ejaculatory dysfunction [ICD-11: HA03] T27812 INDICATI Phase 3 General pain disorder [ICD-11: 8E43] T27812 INDICATI Phase 3 Insomnia [ICD-11: 7A00-7A0Z] T27812 INDICATI Phase 3 Menopausal disorder [ICD-11: GA30] T27812 INDICATI Approved Migraine [ICD-11: 8A80] T27812 INDICATI Phase 3 Mood disorder [ICD-11: 6A60-6E23] T27812 INDICATI Phase 1 Nausea/vomiting [ICD-11: MD90] T27812 INDICATI Phase 2 Neurobehavioral disorder [ICD-11: 8A00-8A0Z] T27812 INDICATI Approved Nicotine use disorder [ICD-11: 6C4A] T27812 INDICATI Approved Obesity [ICD-11: 5B80-5B81] T27812 INDICATI Phase 1 Orthostatic hypotension [ICD-11: BA21] T27812 INDICATI Approved Pain [ICD-11: MG30-MG3Z] T27812 INDICATI Phase 2 Parkinsonism [ICD-11: 8A00] T27812 INDICATI Terminated Postoperative inflammation [ICD-11: 1A00-CA43] T27812 INDICATI Phase 3 Schizophrenia [ICD-11: 6A20] T27812 INDICATI Phase 1 Soft tissue disorder [ICD-11: FB56] T27812 INDICATI Investigative Solid tumour/cancer [ICD-11: 2A00-2F9Z] T27812 INDICATI Phase 2 Substance abuse [ICD-11: 6C40] T27816 TARGETID T27816 T27816 TARGNAME SNCA messenger RNA (SNCA mRNA) T27816 INDICATI Phase 1 Autonomic nervous system disorder [ICD-11: 8D87] T27816 INDICATI Phase 1 Parkinsonism [ICD-11: 8A00] T27826 TARGETID T27826 T27826 TARGNAME Spectrin non-erythroid beta chain 1 (SPTBN1) T27826 INDICATI Phase 1 Solid tumour/cancer [ICD-11: 2A00-2F9Z] T27861 TARGETID T27861 T27861 TARGNAME Protein cereblon (CRBN) T27861 INDICATI Phase 1 Brain cancer [ICD-11: 2A00] T27861 INDICATI Phase 1 Diffuse large B-cell lymphoma [ICD-11: 2A81] T27861 INDICATI Phase 1 Liver cancer [ICD-11: 2C12] T27861 INDICATI Phase 2 Lupus erythematosus [ICD-11: 4A40] T27861 INDICATI Phase 1 Lymphoma [ICD-11: 2A80-2A86] T27861 INDICATI Phase 1 Mature B-cell leukaemia [ICD-11: 2A82] T27861 INDICATI Phase 1 Multiple myeloma [ICD-11: 2A83] T27861 INDICATI Phase 2 Sarcoidosis [ICD-11: 4B20] T27861 INDICATI Phase 1 Solid tumour/cancer [ICD-11: 2A00-2F9Z] T27889 TARGETID T27889 T27889 TARGNAME Angiotensin-converting enzyme 2 (ACE2) T27889 INDICATI Phase 1/2 Acute diabete complication [ICD-11: 5A2Y] T27889 INDICATI Phase 2 Intrathoracic organs injury [ICD-11: NB32] T27889 INDICATI Phase 1 Pulmonary hypertension [ICD-11: BB01] T27889 INDICATI Discontinued in Phase 1 Type 2 diabetes mellitus [ICD-11: 5A11] T27918 TARGETID T27918 T27918 TARGNAME ATP-dependent RNA helicase DDX5 (DDX5) T27918 INDICATI Phase 2 Breast cancer [ICD-11: 2C60-2C6Y] T27918 INDICATI Phase 1 Solid tumour/cancer [ICD-11: 2A00-2F9Z] T27944 TARGETID T27944 T27944 TARGNAME Neuropeptide Y receptor type 4 (NPY4R) T27944 INDICATI Investigative Acute diabete complication [ICD-11: 5A2Y] T27944 INDICATI Discontinued in Phase 2 Obesity [ICD-11: 5B80-5B81] T27944 INDICATI Discontinued in Phase 2 Schizophrenia [ICD-11: 6A20] T27999 TARGETID T27999 T27999 TARGNAME Bacterial Protective antigen (Bact pagA) T27999 INDICATI Approved Anthrax [ICD-11: 1B97] T27999 INDICATI Phase 1 Bacterial infection [ICD-11: 1A00-1C4Z] T27999 INDICATI Phase 1 Sepsis [ICD-11: 1G40-1G41] T28043 TARGETID T28043 T28043 TARGNAME Ribosomal protein S6 kinase alpha-2 (RSK2) T28043 INDICATI Preclinical Mature B-cell leukaemia [ICD-11: 2A82] T28076 TARGETID T28076 T28076 TARGNAME Fibroblast growth factor-4 (FGF4) T28076 INDICATI Phase 3 Angina pectoris [ICD-11: BA40] T28076 INDICATI Approved Chronic pain [ICD-11: MG30] T28076 INDICATI Approved Cystitis [ICD-11: GC00] T28076 INDICATI Phase 3 Heart disease [ICD-11: BA41-BA42] T28093 TARGETID T28093 T28093 TARGNAME FAS-associated factor 1 (FAF1) T28093 INDICATI Phase 1 Parkinsonism [ICD-11: 8A00] T28213 TARGETID T28213 T28213 TARGNAME Free fatty acid receptor 2 (FFAR2) T28213 INDICATI Phase 2 Abortion [ICD-11: JA00] T28213 INDICATI Phase 1 Acute diabete complication [ICD-11: 5A2Y] T28217 TARGETID T28217 T28217 TARGNAME MHC class I NK cell receptor 3DL2 (CD158k) T28217 INDICATI Phase 2 Mature T-cell lymphoma [ICD-11: 2A90] T28226 TARGETID T28226 T28226 TARGNAME GTP cyclohydrolase-I (GCH1) T28226 INDICATI Phase 1/2 Parkinsonism [ICD-11: 8A00] T28265 TARGETID T28265 T28265 TARGNAME Alpha-1-antitrypsin (SERPINA1) T28265 INDICATI Phase 2 Alpha-1-antitrypsin deficiency [ICD-11: 5C5A] T28265 INDICATI Phase 1 Chronic obstructive pulmonary disease [ICD-11: CA22] T28265 INDICATI Phase 1 Cystic fibrosis [ICD-11: CA25] T28265 INDICATI Phase 2 Depression [ICD-11: 6A70-6A7Z] T28265 INDICATI Approved Emphysema [ICD-11: CA21] T28330 TARGETID T28330 T28330 TARGNAME Cholecystokinin receptor type A (CCKAR) T28330 INDICATI Preclinical Binge eating disorder [ICD-11: 6B82] T28330 INDICATI Terminated Bladder disorder [ICD-11: GC01] T28330 INDICATI Discontinued in Phase 2 Digestive system disease [ICD-11: DE2Z] T28330 INDICATI Terminated Dyspepsia [ICD-11: MD92] T28330 INDICATI Phase 2 Influenza [ICD-11: 1E30-1E32] T28330 INDICATI Discontinued in Phase 2 Obesity [ICD-11: 5B80-5B81] T28330 INDICATI Discontinued in Phase 2 Pancreatic cancer [ICD-11: 2C10] T28330 INDICATI Phase 2 Pancreatic malfunction [ICD-11: DC30-DC3Z] T28385 TARGETID T28385 T28385 TARGNAME Osteoblast cadherin (CDH11) T28385 INDICATI Phase 1 Rheumatoid arthritis [ICD-11: FA20] T28413 TARGETID T28413 T28413 TARGNAME Ephrin type-A receptor 3 (EPHA3) T28413 INDICATI Phase 2 Acute myeloid leukaemia [ICD-11: 2A60] T28413 INDICATI Phase 1 Brain cancer [ICD-11: 2A00] T28413 INDICATI Phase 1/2 Malignant haematopoietic neoplasm [ICD-11: 2B33] T28413 INDICATI Phase 2 Myelodysplastic syndrome [ICD-11: 2A37] T28481 TARGETID T28481 T28481 TARGNAME Lysosphingolipid receptor (LSPR) T28481 INDICATI Phase 2 Lupus erythematosus [ICD-11: 4A40] T28484 TARGETID T28484 T28484 TARGNAME Kinesin-like protein KIF11 (KIF11) T28484 INDICATI Phase 2 Acute myeloid leukaemia [ICD-11: 2A60] T28484 INDICATI Phase 2 Head and neck cancer [ICD-11: 2D42] T28484 INDICATI Phase 1 Lymphoma [ICD-11: 2A80-2A86] T28484 INDICATI Phase 1 Malignant haematopoietic neoplasm [ICD-11: 2B33] T28484 INDICATI Phase 2 Multiple myeloma [ICD-11: 2A83] T28484 INDICATI Phase 2 Ovarian cancer [ICD-11: 2C73] T28484 INDICATI Phase 2 Renal cell carcinoma [ICD-11: 2C90] T28484 INDICATI Phase 2 Solid tumour/cancer [ICD-11: 2A00-2F9Z] T28532 TARGETID T28532 T28532 TARGNAME Ribonuclease P protein (RPP) T28532 INDICATI Discontinued in Phase 3 Psoriasis [ICD-11: EA90] T28658 TARGETID T28658 T28658 TARGNAME Plasmodium 80S ribosome (Malaria 80S) T28658 INDICATI Approved Malaria [ICD-11: 1F40-1F45] T28661 TARGETID T28661 T28661 TARGNAME Tubulin beta-2 chain (TUBB2) T28661 INDICATI Approved Solid tumour/cancer [ICD-11: 2A00-2F9Z] T28692 TARGETID T28692 T28692 TARGNAME Lipoprotein lipase (LPL) T28692 INDICATI Approved Hyper-lipoproteinaemia [ICD-11: 5C80] T28692 INDICATI Phase 3 Pregnancy/childbirth/puerperium maternal infection [ICD-11: JB63] T28713 TARGETID T28713 T28713 TARGNAME Serine/threonine-protein kinase Chk2 (RAD53) T28713 INDICATI Phase 2 Solid tumour/cancer [ICD-11: 2A00-2F9Z] T28717 TARGETID T28717 T28717 TARGNAME TNF superfamily receptor 12A (TNFRSF12A) T28717 INDICATI Phase 1 Solid tumour/cancer [ICD-11: 2A00-2F9Z] T28722 TARGETID T28722 T28722 TARGNAME GABA(A) receptor gamma-3 (GABRG3) T28722 INDICATI Terminated Alzheimer disease [ICD-11: 8A20] T28722 INDICATI Approved Anxiety disorder [ICD-11: 6B00-6B0Z] T28722 INDICATI Approved Corneal disease [ICD-11: 9A76-9A78] T28722 INDICATI Approved Depression [ICD-11: 6A70-6A7Z] T28722 INDICATI Approved Epilepsy/seizure [ICD-11: 8A61-8A6Z] T28722 INDICATI Investigative Female pelvic pain [ICD-11: GA34] T28722 INDICATI Phase 3 Fragile X chromosome [ICD-11: LD55] T28722 INDICATI Investigative General pain disorder [ICD-11: 8E43] T28722 INDICATI Approved Insomnia [ICD-11: 7A00-7A0Z] T28722 INDICATI Approved Intentional self-harm [ICD-11: PC91] T28722 INDICATI Phase 3 Ischaemic/haemorrhagic stroke [ICD-11: 8B20] T28722 INDICATI Approved Labour/delivery anaesthesia complication [ICD-11: JB0C] T28722 INDICATI Approved Mental/behavioural/neurodevelopmental disorder [ICD-11: 6E20-6E8Z] T28722 INDICATI Approved Mood/affect symptom [ICD-11: MB24] T28722 INDICATI Phase 2 Neurodegenerative disorder [ICD-11: 8A20-8A23] T28722 INDICATI Discontinued in Phase 1 Pain [ICD-11: MG30-MG3Z] T28722 INDICATI Investigative Panic disorder [ICD-11: 6B01] T28722 INDICATI Phase 2 Parkinsonism [ICD-11: 8A00] T28722 INDICATI Investigative Postoperative inflammation [ICD-11: 1A00-CA43] T28722 INDICATI Phase 3 Status epilepticus [ICD-11: 8A66] T28722 INDICATI Phase 2 Substance abuse [ICD-11: 6C40] T28722 INDICATI Phase 2 Tremor-related disorder [ICD-11: 8A04] T28746 TARGETID T28746 T28746 TARGNAME Protein kinase unspecific (PK) T28746 INDICATI Phase 2 Arterial occlusive disease [ICD-11: BD40] T28746 INDICATI Phase 2 Psoriasis [ICD-11: EA90] T28848 TARGETID T28848 T28848 TARGNAME Virus Deoxyribonucleic acid (Viru DNA) T28848 INDICATI Approved Herpes simplex infection [ICD-11: 1F00] T28869 TARGETID T28869 T28869 TARGNAME Bacterial Urease (Bact ureC) T28869 INDICATI Approved Urinary tract infection [ICD-11: GC08] T28887 TARGETID T28887 T28887 TARGNAME Histone deacetylase 8 (HDAC8) T28887 INDICATI Phase 1 Solid tumour/cancer [ICD-11: 2A00-2F9Z] T28893 TARGETID T28893 T28893 TARGNAME Muscarinic acetylcholine receptor M1 (CHRM1) T28893 INDICATI Approved Abdominal pelvic pain [ICD-11: MD81] T28893 INDICATI Phase 2 Abnormal micturition [ICD-11: MF50] T28893 INDICATI Phase 1 Alzheimer disease [ICD-11: 8A20] T28893 INDICATI Approved Chronic obstructive pulmonary disease [ICD-11: CA22] T28893 INDICATI Approved Corneal disease [ICD-11: 9A76-9A78] T28893 INDICATI Phase 1 Dementia [ICD-11: 6D80-6D8Z] T28893 INDICATI Investigative Dissociative neurological symptom disorder [ICD-11: 6B60] T28893 INDICATI Phase 1 Dyslipidemia [ICD-11: 5C80-5C81] T28893 INDICATI Approved Dystonic disorder [ICD-11: 8A02] T28893 INDICATI Phase 1 Epileptic encephalopathy [ICD-11: 8A62] T28893 INDICATI Phase 1 Frontotemporal dementia ICD-11: 6D83 T28893 INDICATI Approved Functional bladder disorder [ICD-11: GC50] T28893 INDICATI Approved Gastric ulcer [ICD-11: DA60] T28893 INDICATI Phase 1 General pain disorder [ICD-11: 8E43] T28893 INDICATI Approved Glaucoma [ICD-11: 9C61] T28893 INDICATI Approved Hyperhidrosis [ICD-11: EE00] T28893 INDICATI Discontinued in Phase 2 Indeterminate colitis [ICD-11: DD72] T28893 INDICATI Phase 1 Intellectual development disorder [ICD-11: LD90] T28893 INDICATI Approved Irritable bowel syndrome [ICD-11: DD91] T28893 INDICATI Phase 2 Mild neurocognitive disorder [ICD-11: 6D71] T28893 INDICATI Phase 1 Neuropathy [ICD-11: 8C0Z] T28893 INDICATI Investigative Obesity [ICD-11: 5B80-5B81] T28893 INDICATI Approved Parkinsonism [ICD-11: 8A00] T28893 INDICATI Approved Peptic ulcer [ICD-11: DA61] T28893 INDICATI Phase 2 Schizoaffective disorder [ICD-11: 6A21] T28893 INDICATI Phase 2 Schizophrenia [ICD-11: 6A20] T28893 INDICATI Approved Sebaceous gland disorder [ICD-11: ED91] T28893 INDICATI Phase 1 Solid tumour/cancer [ICD-11: 2A00-2F9Z] T28925 TARGETID T28925 T28925 TARGNAME Inosine-5'-monophosphate dehydrogenase (IMPDH) T28925 INDICATI Approved Acute myeloid leukaemia [ICD-11: 2A60] T28925 INDICATI Discontinued in Phase 1 Hepatitis virus infection [ICD-11: 1E50-1E51] T28925 INDICATI Discontinued in Phase 1 Indeterminate colitis [ICD-11: DD72] T28925 INDICATI Phase 2 Solid tumour/cancer [ICD-11: 2A00-2F9Z] T28925 INDICATI Approved Transplant rejection [ICD-11: NE84] T28993 TARGETID T28993 T28993 TARGNAME Iduronate 2-sulfatase (IDS) T28993 INDICATI Approved Lysosomal disease [ICD-11: 5C56] T28993 INDICATI Phase 2/3 Lysosomal disease ICD-11: 5C56 T28993 INDICATI Approved Male infertility [ICD-11: GB04] T29024 TARGETID T29024 T29024 TARGNAME SOD1 messenger RNA (SOD1 mRNA) T29024 INDICATI Approved Motor neuron disease [ICD-11: 8B60] T29036 TARGETID T29036 T29036 TARGNAME CCN2 messenger RNA (CCN2 mRNA) T29036 INDICATI Phase 2 Fibrosis [ICD-11: GA14-GC01] T29036 INDICATI Phase 2 Keloid/hypertrophic scar [ICD-11: EE60] T29064 TARGETID T29064 T29064 TARGNAME Angiogenesis/myeloma cell growth (AMCG) T29064 INDICATI Approved Systemic sclerosis [ICD-11: 4A42] T29075 TARGETID T29075 T29075 TARGNAME TNF-alpha signaling pathway (TNFA pathway) T29075 INDICATI Phase 1 Human immunodeficiency virus disease [ICD-11: 1C60-1C62] T29130 TARGETID T29130 T29130 TARGNAME Signal transducer and activator of transcription 3 (STAT3) T29130 INDICATI Phase 1/2 Brain cancer [ICD-11: 2A00] T29130 INDICATI Phase 3 Colorectal cancer [ICD-11: 2B91] T29130 INDICATI Phase 2 Immune system disease [ICD-11: 4A01-4B41] T29130 INDICATI Phase 1/2 Liver cancer [ICD-11: 2C12] T29130 INDICATI Phase 1/2 Malignant digestive organ neoplasm [ICD-11: 2C11] T29130 INDICATI Phase 1 Malignant haematopoietic neoplasm [ICD-11: 2B33] T29130 INDICATI Phase 1/2 Mature B-cell leukaemia [ICD-11: 2A82] T29130 INDICATI Phase 1/2 Multiple myeloma [ICD-11: 2A83] T29130 INDICATI Phase 1 Mycosis fungoides [ICD-11: 2B01] T29130 INDICATI Phase 3 Pancreatic cancer [ICD-11: 2C10] T29130 INDICATI Discontinued in Phase 2 Postoperative inflammation [ICD-11: 1A00-CA43] T29130 INDICATI Approved Psoriasis [ICD-11: EA90] T29130 INDICATI Phase 1/2 Respiratory infection [ICD-11: CA07-CA4Z] T29130 INDICATI Phase 3 Solid tumour/cancer [ICD-11: 2A00-2F9Z] T29130 INDICATI Phase 1 Ulcerative colitis [ICD-11: DD71] T29143 TARGETID T29143 T29143 TARGNAME Interleukin-13 (IL13) T29143 INDICATI Investigative Allergic/hypersensitivity disorder [ICD-11: 4A80-4A8Z] T29143 INDICATI Phase 3 Asthma [ICD-11: CA23] T29143 INDICATI Approved Atopic eczema [ICD-11: EA80] T29143 INDICATI Phase 2 Chronic obstructive pulmonary disease [ICD-11: CA22] T29143 INDICATI Phase 2 Idiopathic interstitial pneumonitis [ICD-11: CB03] T29143 INDICATI Phase 2 Myeloproliferative neoplasm [ICD-11: 2A20] T29143 INDICATI Phase 3 Oesophagitis [ICD-11: DA24] T29143 INDICATI Phase 3 Pulmonary eosinophilia [ICD-11: CB02] T29143 INDICATI Phase 2 Systemic sclerosis [ICD-11: 4A42] T29143 INDICATI Phase 3 Ulcerative colitis [ICD-11: DD71] T29143 INDICATI Phase 2 Vasomotor/allergic rhinitis [ICD-11: CA08] T29144 TARGETID T29144 T29144 TARGNAME Arginase (ARG) T29144 INDICATI Phase 1/2 Solid tumour/cancer [ICD-11: 2A00-2F9Z] T29303 TARGETID T29303 T29303 TARGNAME Sodium channel unspecific (NaC) T29303 INDICATI Discontinued in Phase 2 Acute diabete complication [ICD-11: 5A2Y] T29303 INDICATI Approved Angina pectoris [ICD-11: BA40] T29303 INDICATI Approved Bacterial infection [ICD-11: 1A00-1C4Z] T29303 INDICATI Discontinued in Phase 3 Bipolar disorder [ICD-11: 6A60] T29303 INDICATI Discontinued in Phase 2 Cardiac arrhythmia [ICD-11: BC9Z] T29303 INDICATI Terminated Cardiovascular disease [ICD-11: BA00-BE2Z] T29303 INDICATI Terminated Cerebral ischaemia [ICD-11: 8B1Z] T29303 INDICATI Terminated Cerebral ischaemic stroke [ICD-11: 8B11] T29303 INDICATI Approved Corneal disease [ICD-11: 9A76-9A78] T29303 INDICATI Phase 2 Cough [ICD-11: MD12] T29303 INDICATI Phase 1/2 Cystic fibrosis [ICD-11: CA25] T29303 INDICATI NDA filed Diabetes mellitus [ICD-11: 5A10] T29303 INDICATI Discontinued in Preregistration Dissociative neurological symptom disorder [ICD-11: 6B60] T29303 INDICATI Phase 3 Dystonic disorder [ICD-11: 8A02] T29303 INDICATI Approved Epilepsy/seizure [ICD-11: 8A61-8A6Z] T29303 INDICATI Approved Epileptic encephalopathy [ICD-11: 8A62] T29303 INDICATI Phase 2 Functional bladder disorder [ICD-11: GC50] T29303 INDICATI Phase 3 General pain disorder [ICD-11: 8E43] T29303 INDICATI Approved Genetic cardiac arrhythmia [ICD-11: BC65] T29303 INDICATI Terminated Heart failure [ICD-11: BD10-BD1Z] T29303 INDICATI Terminated Ischemia [ICD-11: 8B10-8B11] T29303 INDICATI Phase 2 Metabolism inborn error [ICD-11: 5C50] T29303 INDICATI Approved Migraine [ICD-11: 8A80] T29303 INDICATI Phase 1 Neuropathy [ICD-11: 8C0Z] T29303 INDICATI Approved Pain [ICD-11: MG30-MG3Z] T29303 INDICATI Phase 2 Parkinsonism [ICD-11: 8A00] T29303 INDICATI Approved Postpartum haemorrhage [ICD-11: JA43] T29303 INDICATI Approved Scabies [ICD-11: 1G04] T29303 INDICATI Phase 2 Schizophrenia [ICD-11: 6A20] T29303 INDICATI Approved Sensation disturbance [ICD-11: MB40] T29303 INDICATI Phase 3 Stomach cancer [ICD-11: 2B72] T29303 INDICATI Phase 2 Supraventricular tachyarrhythmia [ICD-11: BC81] T29303 INDICATI Discontinued in Phase 2 Tonus and reflex abnormality [ICD-11: MB47] T29303 INDICATI Phase 2 Unspecific body region injury [ICD-11: ND56] T29339 TARGETID T29339 T29339 TARGNAME Retinoic acid-inducible gene-1 (RIG-1) T29339 INDICATI Phase 2 Hepatitis virus infection [ICD-11: 1E50-1E51] T29339 INDICATI Phase 1 Melanoma [ICD-11: 2C30] T29339 INDICATI Phase 1 Solid tumour/cancer [ICD-11: 2A00-2F9Z] T29339 INDICATI Phase 1 Squamous cell carcinoma [ICD-11: 2B60-2D01] T29345 TARGETID T29345 T29345 TARGNAME Mucin-17 (MUC17) T29345 INDICATI Phase 1 Oesophagogastric junction cancer [ICD-11: 2B71] T29345 INDICATI Phase 1 Stomach cancer [ICD-11: 2B72] T29500 TARGETID T29500 T29500 TARGNAME Adrenergic receptor alpha-1B (ADRA1B) T29500 INDICATI Discontinued in Phase 2 Abnormal micturition [ICD-11: MF50] T29500 INDICATI Approved Attention deficit hyperactivity disorder [ICD-11: 6A05] T29500 INDICATI Terminated Genetic cardiac arrhythmia [ICD-11: BC65] T29500 INDICATI Approved Hypertension [ICD-11: BA00-BA04] T29500 INDICATI Approved Mental/behavioural/neurodevelopmental disorder [ICD-11: 6E20-6E8Z] T29500 INDICATI Approved Obesity [ICD-11: 5B80-5B81] T29500 INDICATI Approved Pain [ICD-11: MG30-MG3Z] T29525 TARGETID T29525 T29525 TARGNAME Human immunodeficiency virus Deoxyribonucleic acid (HIV DNA) T29525 INDICATI Phase 2 Human immunodeficiency virus disease [ICD-11: 1C60-1C62] T29649 TARGETID T29649 T29649 TARGNAME Leukotriene receptor (LTR) T29649 INDICATI Terminated Allergic/hypersensitivity disorder [ICD-11: 4A80-4A8Z] T29649 INDICATI Phase 2 Asthma [ICD-11: CA23] T29649 INDICATI Phase 1 Bacterial infection [ICD-11: 1A00-1C4Z] T29649 INDICATI Discontinued in Phase 2 Cardiovascular disease [ICD-11: BA00-BE2Z] T29649 INDICATI Discontinued in Phase 1 Postoperative inflammation [ICD-11: 1A00-CA43] T29683 TARGETID T29683 T29683 TARGNAME Neuromedin-K receptor (TACR3) T29683 INDICATI Investigative Asthma [ICD-11: CA23] T29683 INDICATI Phase 2 Cerebral ischaemic stroke [ICD-11: 8B11] T29683 INDICATI Discontinued in Phase 2 Chronic obstructive pulmonary disease [ICD-11: CA22] T29683 INDICATI Terminated Depression [ICD-11: 6A70-6A7Z] T29683 INDICATI Phase 2 Epilepsy/seizure [ICD-11: 8A61-8A6Z] T29683 INDICATI Discontinued in Phase 2 Irritable bowel syndrome [ICD-11: DD91] T29683 INDICATI Approved Menopausal disorder [ICD-11: GA30] T29683 INDICATI Phase 2 Multiple sclerosis [ICD-11: 8A40] T29683 INDICATI Discontinued in Phase 1 Psychotic disorder [ICD-11: 6A20-6A25] T29683 INDICATI Discontinued in Phase 2b Schizoaffective disorder [ICD-11: 6A21] T29683 INDICATI Phase 2 Schizophrenia [ICD-11: 6A20] T29683 INDICATI Phase 1 Substance abuse [ICD-11: 6C40] T29683 INDICATI Phase 2 #N/A #N/A T29736 TARGETID T29736 T29736 TARGNAME Laminin beta-3 chain (LAMB3) T29736 INDICATI Phase 1 Epidermolysis bullosa [ICD-11: EC3Z] T29741 TARGETID T29741 T29741 TARGNAME NADPH oxidase 4 (NOX4) T29741 INDICATI Phase 2 Fibrosis [ICD-11: GA14-GC01] T29754 TARGETID T29754 T29754 TARGNAME MAPK-activated protein kinase 5 (MAPKAPK5) T29754 INDICATI Discontinued in Phase 2 Rheumatoid arthritis [ICD-11: FA20] T29774 TARGETID T29774 T29774 TARGNAME Leukemia inhibitory factor (LIF) T29774 INDICATI Phase 1 Solid tumour/cancer [ICD-11: 2A00-2F9Z] T29815 TARGETID T29815 T29815 TARGNAME Neoplasm antigen (NA) T29815 INDICATI Phase 2 Colorectal cancer [ICD-11: 2B91] T29815 INDICATI Phase 2 Pancreatic cancer [ICD-11: 2C10] T29879 TARGETID T29879 T29879 TARGNAME Integrin alpha-5 (ITGA5) T29879 INDICATI Discontinued in Phase 1 Allergic/hypersensitivity disorder [ICD-11: 4A80-4A8Z] T29879 INDICATI Discontinued in Phase 1 Asthma [ICD-11: CA23] T29879 INDICATI Discontinued in Phase 1 Multiple sclerosis [ICD-11: 8A40] T29879 INDICATI Phase 1 Retinopathy [ICD-11: 9B71] T29879 INDICATI Discontinued in Phase 2 Vasomotor/allergic rhinitis [ICD-11: CA08] T29960 TARGETID T29960 T29960 TARGNAME Wilms tumor protein (WT1) T29960 INDICATI Phase 2 Acute myeloid leukaemia [ICD-11: 2A60] T29960 INDICATI Phase 2 Leukaemia [ICD-11: 2A60-2B33] T29960 INDICATI Phase 1 Lung cancer [ICD-11: 2C25] T29960 INDICATI Phase 2 Malignant haematopoietic neoplasm [ICD-11: 2B33] T29999 TARGETID T29999 T29999 TARGNAME Vasopressin V1 receptor (V1R) T29999 INDICATI Discontinued in Phase 2 Cardiovascular disease [ICD-11: BA00-BE2Z] T29999 INDICATI Approved Cognition symptoms/signs/clinical sympton [ICD-11: MB21] T29999 INDICATI Approved Hypo-osmolality/hyponatraemia [ICD-11: 5C72] T29999 INDICATI Phase 2 Prostate cancer [ICD-11: 2C82] T29999 INDICATI Approved Vitamin deficiency [ICD-11: 5B55-5B5F] T30014 TARGETID T30014 T30014 TARGNAME Immunoglobulin unspecific (Ig) T30014 INDICATI Approved Vaccination [ICD-11: N.A.] T30028 TARGETID T30028 T30028 TARGNAME Vesicle-associated membrane protein (VAMP) T30028 INDICATI Approved Parkinsonism [ICD-11: 8A00] T30040 TARGETID T30040 T30040 TARGNAME Vascular endothelial growth factor B (VEGFB) T30040 INDICATI Phase 2 Chronic kidney disease [ICD-11: GB61] T30040 INDICATI Approved Colorectal cancer [ICD-11: 2B91] T30081 TARGETID T30081 T30081 TARGNAME Thymidine kinase 1 (TK1) T30081 INDICATI Approved Acute myeloid leukaemia [ICD-11: 2A60] T30081 INDICATI Phase 1 Arterial occlusive disease [ICD-11: BD40] T30081 INDICATI Discontinued in Phase 3 Brain cancer [ICD-11: 2A00] T30081 INDICATI Phase 1 Cardiovascular disease [ICD-11: BA00-BE2Z] T30081 INDICATI Preregistration Graft-versus-host disease [ICD-11: 4B24] T30081 INDICATI Approved Human immunodeficiency virus disease [ICD-11: 1C60-1C62] T30081 INDICATI Phase 3 Pancreatic cancer [ICD-11: 2C10] T30081 INDICATI Phase 2/3 Postoperative inflammation [ICD-11: 1A00-CA43] T30081 INDICATI Phase 1 Prostate cancer [ICD-11: 2C82] T30081 INDICATI Phase 2 Solid tumour/cancer [ICD-11: 2A00-2F9Z] T30081 INDICATI Phase 3 Zoster [ICD-11: 1E91] T30082 TARGETID T30082 T30082 TARGNAME Acetylcholinesterase (AChE) T30082 INDICATI Approved Alzheimer disease [ICD-11: 8A20] T30082 INDICATI Phase 1/2 Dementia [ICD-11: 6D80-6D8Z] T30082 INDICATI Approved Glaucoma [ICD-11: 9C61] T30082 INDICATI Discontinued in Phase 2 Lips/oral mucosa miscellaneous disorder [ICD-11: DA02] T30082 INDICATI Phase 3 Mild neurocognitive disorder [ICD-11: 6D71] T30082 INDICATI Approved Myasthenia gravis [ICD-11: 8C6Y] T30082 INDICATI Investigative Neurodegenerative disorder [ICD-11: 8A20-8A23] T30082 INDICATI Approved Oesophageal/gastroduodenal disorder [ICD-11: DD90] T30082 INDICATI Phase 1 Pain [ICD-11: MG30-MG3Z] T30082 INDICATI Phase 3 Parasitic worm infestation [ICD-11: 1F90] T30082 INDICATI Phase 1 Parkinsonism [ICD-11: 8A00] T30082 INDICATI Approved Pediculosis [ICD-11: 1G00] T30082 INDICATI Discontinued in Phase 2 Solid tumour/cancer [ICD-11: 2A00-2F9Z] T30082 INDICATI Phase 1 Substance abuse [ICD-11: 6C40] T30082 INDICATI Approved Unspecific substance harmful effect [ICD-11: NE6Z] T30082 INDICATI Discontinued in Phase 2 Urinary system disease [ICD-11: GC2Z] T30085 TARGETID T30085 T30085 TARGNAME Sodium/glucose cotransporter 2 (SGLT2) T30085 INDICATI Phase 2 Acute diabete complication [ICD-11: 5A2Y] T30085 INDICATI Phase 3 Cardiovascular disease [ICD-11: BA00-BE2Z] T30085 INDICATI Phase 3 Chronic kidney disease [ICD-11: GB61] T30085 INDICATI Approved Diabetes mellitus [ICD-11: 5A10] T30085 INDICATI Approved Heart failure [ICD-11: BD10-BD1Z] T30085 INDICATI Phase 3 Liver disease [ICD-11: DB90-DB9Z] T30085 INDICATI Approved Type 2 diabetes mellitus [ICD-11: 5A11] T30085 INDICATI Phase 2 Type-1/2 diabete [ICD-11: 5A10-5A11] T30208 TARGETID T30208 T30208 TARGNAME Growth hormone secretion (GH secr) T30208 INDICATI Phase 1 Cerebral ischaemia [ICD-11: 8B1Z] T30284 TARGETID T30284 T30284 TARGNAME Interferon gamma receptor (IFNGR2) T30284 INDICATI Approved Innate/adaptive immunodeficiency [ICD-11: 4A00] T30284 INDICATI Approved Lupus erythematosus [ICD-11: 4A40] T30356 TARGETID T30356 T30356 TARGNAME Blood group Rh(D) polypeptide (RHD) T30356 INDICATI Phase 2/3 Anemia [ICD-11: 3A00-3A9Z] T30372 TARGETID T30372 T30372 TARGNAME Trypanosoma Cruzipain (Trypano CYSP) T30372 INDICATI Investigative Malaria [ICD-11: 1F40-1F45] T30372 INDICATI Approved Parasitic worm infestation [ICD-11: 1F90] T30374 TARGETID T30374 T30374 TARGNAME Gamma-aminobutyric acid uptake (GABAU) T30374 INDICATI Phase 2 Anxiety disorder [ICD-11: 6B00-6B0Z] T30374 INDICATI Approved Epilepsy/seizure [ICD-11: 8A61-8A6Z] T30383 TARGETID T30383 T30383 TARGNAME Endogenous gut peptide (EGP) T30383 INDICATI Phase 2 Obesity [ICD-11: 5B80-5B81] T30418 TARGETID T30418 T30418 TARGNAME DNA synthesis (DNA synth) T30418 INDICATI Phase 1 Alzheimer disease [ICD-11: 8A20] T30418 INDICATI Phase 3 Biliary tract cancer [ICD-11: 2C17] T30418 INDICATI Phase 1 Bladder cancer [ICD-11: 2C94] T30418 INDICATI Approved Leukaemia [ICD-11: 2A60-2B33] T30418 INDICATI Phase 1 Lymphoma [ICD-11: 2A80-2A86] T30418 INDICATI Phase 2 Ovarian cancer [ICD-11: 2C73] T30418 INDICATI Phase 3 Pancreatic cancer [ICD-11: 2C10] T30418 INDICATI Phase 1 Solid tumour/cancer [ICD-11: 2A00-2F9Z] T30420 TARGETID T30420 T30420 TARGNAME SET domain containing 8 (KMT5A) T30420 INDICATI Preclinical Liver cancer [ICD-11: 2C12] T30420 INDICATI Preclinical Solid tumour/cancer [ICD-11: 2A00-2F9Z] T30495 TARGETID T30495 T30495 TARGNAME Salt-inducible kinase 2 (SIK2) T30495 INDICATI Phase 1 Ovarian cancer [ICD-11: 2C73] T30520 TARGETID T30520 T30520 TARGNAME Bacterial RNA polymerase switch region (Bact RNAP-SR) T30520 INDICATI Phase 3 Bacterial infection [ICD-11: 1A00-1C4Z] T30520 INDICATI Approved Clostridium difficile enterocolitis [ICD-11: 1A04] T30520 INDICATI Approved HIV-infected patients with tuberculosis [ICD-11: 1B10-1B14] T30563 TARGETID T30563 T30563 TARGNAME Leukotriene B4 receptor 2 (LTB4R2) T30563 INDICATI Terminated Asthma [ICD-11: CA23] T30563 INDICATI Phase 2 Human immunodeficiency virus disease [ICD-11: 1C60-1C62] T30563 INDICATI Discontinued in Phase 2 Indeterminate colitis [ICD-11: DD72] T30563 INDICATI Phase 1 Renal cell carcinoma [ICD-11: 2C90] T30578 TARGETID T30578 T30578 TARGNAME Mycobacterium Arabinosyltransferase C (MycB embC) T30578 INDICATI Approved Tuberculosis [ICD-11: 1B10-1B12] T30635 TARGETID T30635 T30635 TARGNAME C-X-C motif chemokine 10 (CXCL10) T30635 INDICATI Phase 2 Crohn disease [ICD-11: DD70] T30635 INDICATI Phase 2 Diabetes mellitus [ICD-11: 5A10] T30635 INDICATI Phase 2 Immune system disease [ICD-11: 4A01-4B41] T30635 INDICATI Phase 2 Indeterminate colitis [ICD-11: DD72] T30635 INDICATI Phase 1 Solid tumour/cancer [ICD-11: 2A00-2F9Z] T30635 INDICATI Phase 2 Ulcerative colitis [ICD-11: DD71] T30653 TARGETID T30653 T30653 TARGNAME Acetyl-CoA:lyso-PAF acetyltransferase (PCAT) T30653 INDICATI Approved Bacterial infection [ICD-11: 1A00-1C4Z] T30653 INDICATI Approved Obesity [ICD-11: 5B80-5B81] T30687 TARGETID T30687 T30687 TARGNAME Glucocorticoid receptor messenger RNA (GCR mRNA) T30687 INDICATI Phase 2 Acute diabete complication [ICD-11: 5A2Y] T30687 INDICATI Phase 1 Indeterminate colitis [ICD-11: DD72] T30687 INDICATI Phase 1 Multiple sclerosis [ICD-11: 8A40] T30687 INDICATI Approved Muscular dystrophy ICD-11: 8C70 T30687 INDICATI Phase 2 Muscular dystrophy [ICD-11: 8C70] T30687 INDICATI Phase 2 Prostate cancer [ICD-11: 2C82] T30687 INDICATI Phase 1 Rheumatoid arthritis [ICD-11: FA20] T30687 INDICATI Phase 1 Solid tumour/cancer [ICD-11: 2A00-2F9Z] T30687 INDICATI Phase 1 Type 2 diabetes mellitus [ICD-11: 5A11] T30731 TARGETID T30731 T30731 TARGNAME Kininogen (KNG1) T30731 INDICATI Phase 2/3 Innate/adaptive immunodeficiency [ICD-11: 4A00] T30784 TARGETID T30784 T30784 TARGNAME Thrombospondin-1 (THBS1) T30784 INDICATI Phase 2 Solid tumour/cancer [ICD-11: 2A00-2F9Z] T30790 TARGETID T30790 T30790 TARGNAME Calcium-release activated calcium channel (CRACM) T30790 INDICATI Phase 1 Malignant haematopoietic neoplasm [ICD-11: 2B33] T30802 TARGETID T30802 T30802 TARGNAME Neuron-specific vesicular protein calcyon (CALY) T30802 INDICATI Discontinued in Phase 2 Pain [ICD-11: MG30-MG3Z] T30803 TARGETID T30803 T30803 TARGNAME Glutathione reductase (GR) T30803 INDICATI Investigative Asthma [ICD-11: CA23] T30803 INDICATI Investigative Bacterial infection [ICD-11: 1A00-1C4Z] T30803 INDICATI Approved Breast cancer [ICD-11: 2C60-2C6Y] T30803 INDICATI Investigative Circulatory system disease [ICD-11: BE2Z] T30803 INDICATI Investigative Indeterminate colitis [ICD-11: DD72] T30817 TARGETID T30817 T30817 TARGNAME Serine palmitoyltransferase (SPTC) T30817 INDICATI Preclinical Hepatitis virus infection [ICD-11: 1E50-1E51] T30823 TARGETID T30823 T30823 TARGNAME M-phase inducer phosphatase 1 (MPIP1) T30823 INDICATI Terminated Asthma [ICD-11: CA23] T30823 INDICATI Terminated Solid tumour/cancer [ICD-11: 2A00-2F9Z] T30827 TARGETID T30827 T30827 TARGNAME Platelet factor 4 (PF4) T30827 INDICATI Phase 3 Acute myeloid leukaemia [ICD-11: 2A60] T30834 TARGETID T30834 T30834 TARGNAME Amylin receptor (IAPPR) T30834 INDICATI Discontinued in Phase 1 Hypertension [ICD-11: BA00-BA04] T30834 INDICATI Discontinued in Phase 2 Obesity [ICD-11: 5B80-5B81] T30834 INDICATI Phase 1 Type 2 diabetes mellitus [ICD-11: 5A11] T30846 TARGETID T30846 T30846 TARGNAME Leukocyte immunoglobulin-like receptor B4 (LILRB4) T30846 INDICATI Phase 1 Acute myeloid leukaemia [ICD-11: 2A60] T30846 INDICATI Phase 1 Chronic myelomonocytic leukaemia [ICD-11: 2A40] T30926 TARGETID T30926 T30926 TARGNAME GRB2 messenger RNA (GRB2 mRNA) T30926 INDICATI Phase 2 Acute myeloid leukaemia [ICD-11: 2A60] T30926 INDICATI Phase 2 Malignant haematopoietic neoplasm [ICD-11: 2B33] T30926 INDICATI Phase 2 Mature B-cell lymphoma [ICD-11: 2A85] T30926 INDICATI Phase 2 Myelodysplastic syndrome [ICD-11: 2A37] T30926 INDICATI Phase 2 Myeloproliferative neoplasm [ICD-11: 2A20] T30938 TARGETID T30938 T30938 TARGNAME Mycobacterium RNA polymerase (MycB RNAP) T30938 INDICATI Approved Bowel habit change [ICD-11: ME05] T30938 INDICATI Phase 2 Head and neck cancer [ICD-11: 2D42] T30938 INDICATI Discontinued in Phase 2 Hepatitis virus infection [ICD-11: 1E50-1E51] T30938 INDICATI Registered Influenza [ICD-11: 1E30-1E32] T30938 INDICATI Phase 3 Postoperative inflammation [ICD-11: 1A00-CA43] T30940 TARGETID T30940 T30940 TARGNAME Mitochondrial 10kDa heat shock protein (HSPE1) T30940 INDICATI Phase 1/2 Diabetes mellitus [ICD-11: 5A10] T30956 TARGETID T30956 T30956 TARGNAME Bacillus anthracis Protective antigen (Anthrax PA) T30956 INDICATI Approved Anthrax [ICD-11: 1B97] T30956 INDICATI Phase 1/2 Neuropathy [ICD-11: 8C0Z] T30985 TARGETID T30985 T30985 TARGNAME Histamine H2 receptor (H2R) T30985 INDICATI Withdrawn from market Duodenal ulcer [ICD-11: DA63] T30985 INDICATI Discontinued in Phase 1 Gastric ulcer [ICD-11: DA60] T30985 INDICATI Approved Gastro-oesophageal reflux disease [ICD-11: DA22] T30985 INDICATI Approved Oesophageal/gastroduodenal disorder [ICD-11: DD90] T30985 INDICATI Terminated Pain [ICD-11: MG30-MG3Z] T30985 INDICATI Approved Peptic ulcer [ICD-11: DA61] T30985 INDICATI Discontinued in Phase 3 Ulcerative colitis [ICD-11: DD71] T31072 TARGETID T31072 T31072 TARGNAME Interleukine 12 (IL-12) T31072 INDICATI Phase 2 Brain cancer [ICD-11: 2A00] T31072 INDICATI Phase 2 Breast cancer [ICD-11: 2C60-2C6Y] T31072 INDICATI Phase 2 Melanoma [ICD-11: 2C30] T31072 INDICATI Phase 2 Ovarian cancer [ICD-11: 2C73] T31072 INDICATI Phase 1 Pancreatic cancer [ICD-11: 2C10] T31072 INDICATI Phase 3 Psoriasis [ICD-11: EA90] T31072 INDICATI Phase 3 Psoriatic arthritis [ICD-11: FA21] T31072 INDICATI Phase 1 Solid tumour/cancer [ICD-11: 2A00-2F9Z] T31133 TARGETID T31133 T31133 TARGNAME Potassium (K) T31133 INDICATI Approved Hyperkalaemia [ICD-11: 5C76] T31204 TARGETID T31204 T31204 TARGNAME 5-HT 2B receptor (HTR2B) T31204 INDICATI Discontinued in Phase 3 Anxiety disorder [ICD-11: 6B00-6B0Z] T31204 INDICATI Phase 4 Attention deficit hyperactivity disorder [ICD-11: 6A05] T31204 INDICATI Withdrawn from market Coronary atherosclerosis [ICD-11: BA80] T31204 INDICATI Approved Depression [ICD-11: 6A70-6A7Z] T31204 INDICATI Investigative Irritable bowel syndrome [ICD-11: DD91] T31204 INDICATI Discontinued in Phase 1 Migraine [ICD-11: 8A80] T31204 INDICATI Approved Pituitary gland disorder [ICD-11: 5A60-5A61] T31204 INDICATI Approved Psychotic disorder [ICD-11: 6A20-6A25] T31204 INDICATI Phase 2 Pulmonary hypertension [ICD-11: BB01] T31230 TARGETID T31230 T31230 TARGNAME Bacterial Fumarate reductase flavoprotein (Bact frdA) T31230 INDICATI Approved Hydrocephalus [ICD-11: 8D64] T31230 INDICATI Approved Nematode disease [ICD-11: 1F6Y] T31230 INDICATI Approved Parasitic worm infestation [ICD-11: 1F90] T31230 INDICATI Approved Trichuriasis [ICD-11: 1F6G] T31299 TARGETID T31299 T31299 TARGNAME HLA-A02/AFP complex (HLA-A02/AFP) T31299 INDICATI Phase 1 Liver cancer [ICD-11: 2C12] T31309 TARGETID T31309 T31309 TARGNAME Apoptosis regulator Bcl-2 (BCL-2) T31309 INDICATI Phase 1 Acute myeloid leukaemia [ICD-11: 2A60] T31309 INDICATI Approved Breast cancer [ICD-11: 2C60-2C6Y] T31309 INDICATI Phase 1 Chronic myelomonocytic leukaemia [ICD-11: 2A40] T31309 INDICATI Phase 1 Follicular lymphoma [ICD-11: 2A80] T31309 INDICATI Phase 1/2 Lung cancer [ICD-11: 2C25] T31309 INDICATI Phase 1/2 Malignant haematopoietic neoplasm [ICD-11: 2B33] T31309 INDICATI Approved Mature B-cell leukaemia [ICD-11: 2A82] T31309 INDICATI Phase 1 Mature B-cell lymphoma [ICD-11: 2A85] T31309 INDICATI Phase 3 Melanoma [ICD-11: 2C30] T31309 INDICATI Approved Motor neuron disease [ICD-11: 8B60] T31309 INDICATI Phase 3 Multiple myeloma [ICD-11: 2A83] T31309 INDICATI Phase 1 Myelodysplastic syndrome [ICD-11: 2A37] T31309 INDICATI Phase 3 Myeloproliferative neoplasm [ICD-11: 2A20] T31309 INDICATI Phase 2 Ovarian cancer [ICD-11: 2C73] T31309 INDICATI Phase 2/3 Ovarian dysfunction [ICD-11: 5A80] T31309 INDICATI Phase 3 Pancreatic cancer [ICD-11: 2C10] T31309 INDICATI Phase 2 Prostate cancer [ICD-11: 2C82] T31309 INDICATI Phase 1 Psoriasis [ICD-11: EA90] T31309 INDICATI Approved Solid tumour/cancer [ICD-11: 2A00-2F9Z] T31309 INDICATI Phase 2 Stomach cancer [ICD-11: 2B72] T31329 TARGETID T31329 T31329 TARGNAME Leishmania DNA topoisomerase I (Leishm TOP1) T31329 INDICATI Phase 2 Solid tumour/cancer [ICD-11: 2A00-2F9Z] T31391 TARGETID T31391 T31391 TARGNAME Dipeptidyl peptidase 4 (DPP-4) T31391 INDICATI Approved Acute diabete complication [ICD-11: 5A2Y] T31391 INDICATI Phase 2 Autism spectrum disorder [ICD-11: 6A02] T31391 INDICATI Phase 1/2 Chronic arterial occlusive disease [ICD-11: BD4Z] T31391 INDICATI Preclinical Colon cancer [ICD-11: 2B90] T31391 INDICATI Phase 3 Diabetes mellitus [ICD-11: 5A10] T31391 INDICATI Investigative Hypo-glycaemia [ICD-11: 5A41] T31391 INDICATI Preclinical Lung cancer [ICD-11: 2C25] T31391 INDICATI Phase 1/2 Malignant haematopoietic neoplasm [ICD-11: 2B33] T31391 INDICATI Phase 3 Metabolic disorder [ICD-11: 5C50-5D2Z] T31391 INDICATI Phase 1 Myocardial infarction [ICD-11: BA41-BA43] T31391 INDICATI Phase 2 Psoriasis [ICD-11: EA90] T31391 INDICATI Investigative Transplanted organ/tissue [ICD-11: QB63] T31391 INDICATI Approved Type 2 diabetes mellitus [ICD-11: 5A11] T31406 TARGETID T31406 T31406 TARGNAME Hematopoietic cell kinase (HCK) T31406 INDICATI Discontinued in Phase 2 Indeterminate colitis [ICD-11: DD72] T31424 TARGETID T31424 T31424 TARGNAME Adrenergic receptor Alpha-2 (ADRA2) T31424 INDICATI Phase 2 Acute myeloid leukaemia [ICD-11: 2A60] T31424 INDICATI Discontinued in Phase 3 Angina pectoris [ICD-11: BA40] T31424 INDICATI Approved Attention deficit hyperactivity disorder [ICD-11: 6A05] T31424 INDICATI Approved Breathing abnormality [ICD-11: MD11] T31424 INDICATI Approved Cerebral ischaemia [ICD-11: 8B1Z] T31424 INDICATI Approved Dementia [ICD-11: 6D80-6D8Z] T31424 INDICATI Approved Essential hypertension [ICD-11: BA00] T31424 INDICATI Approved Eyelid inflammatory disorder [ICD-11: 9A02] T31424 INDICATI Phase 2 General pain disorder [ICD-11: 8E43] T31424 INDICATI Approved Glaucoma [ICD-11: 9C61] T31424 INDICATI Approved Hypertension [ICD-11: BA00-BA04] T31424 INDICATI Approved Mood/affect symptom [ICD-11: MB24] T31424 INDICATI Approved Muscle disorder [ICD-11: FB32-FB3Z] T31424 INDICATI Phase 3 Neuropathy [ICD-11: 8C0Z] T31424 INDICATI Approved Opioid use disorder [ICD-11: 6C43] T31424 INDICATI Approved Optic nerve disorder [ICD-11: 9C40] T31424 INDICATI Discontinued in Phase 2 Orgasmic dysfunction [ICD-11: HA02] T31424 INDICATI Approved Pain [ICD-11: MG30-MG3Z] T31424 INDICATI Approved Sexual dysfunction [ICD-11: HA00-HA01] T31424 INDICATI Approved Skin sensation disturbance [ICD-11: ME65] T31424 INDICATI Approved Tonus and reflex abnormality [ICD-11: MB47] T31458 TARGETID T31458 T31458 TARGNAME Pyruvate kinase (PK) T31458 INDICATI Phase 1 Innate/adaptive immunodeficiency [ICD-11: 4A00] T31458 INDICATI Phase 2/3 Sickle-cell disorder [ICD-11: 3A51] T31479 TARGETID T31479 T31479 TARGNAME Phospholipase A2 (PLA2G1B) T31479 INDICATI Phase 2b Allergic/hypersensitivity disorder [ICD-11: 4A80-4A8Z] T31479 INDICATI Phase 1 Arterial occlusive disease [ICD-11: BD40] T31479 INDICATI Discontinued in Phase 2 Asthma [ICD-11: CA23] T31479 INDICATI Phase 1 Cardiovascular disease [ICD-11: BA00-BE2Z] T31479 INDICATI Phase 2 Contact dermatitis [ICD-11: EK00-EK0Z] T31479 INDICATI Approved Leishmaniasis [ICD-11: 1F54] T31479 INDICATI Phase 2 Lichen planus [ICD-11: EA91] T31479 INDICATI Phase 2 Metabolic disorder [ICD-11: 5C50-5D2Z] T31479 INDICATI Approved Peroxisomal disease [ICD-11: 5C57] T31479 INDICATI Investigative Postoperative inflammation [ICD-11: 1A00-CA43] T31479 INDICATI Discontinued in Phase 2 Pruritus [ICD-11: EC90] T31479 INDICATI Phase 2 Rheumatoid arthritis [ICD-11: FA20] T31479 INDICATI Approved Rosacea [ICD-11: ED90] T31479 INDICATI Phase 2 Snakebite ICD-11: N.A. T31479 INDICATI Approved Synthesis disorder [ICD-11: 5C52-5C59] T31479 INDICATI Discontinued in Phase 2 Unspecific body region injury [ICD-11: ND56] T31479 INDICATI Phase 2 Vasomotor/allergic rhinitis [ICD-11: CA08] T31514 TARGETID T31514 T31514 TARGNAME Lysosomal alpha-glucosidase (GAA) T31514 INDICATI Approved Inborn carbohydrate metabolism error [ICD-11: 5C51] T31514 INDICATI Phase 1/2 Inborn carbohydrate metabolism error ICD-11: 5C51 T31595 TARGETID T31595 T31595 TARGNAME Influenza Neuraminidase (Influ NA) T31595 INDICATI Phase 3 Idiopathic inflammatory myopathy [ICD-11: 4A41] T31595 INDICATI Approved Influenza [ICD-11: 1E30-1E32] T31595 INDICATI Phase 2 Muscle disorder [ICD-11: FB32-FB3Z] T31600 TARGETID T31600 T31600 TARGNAME Protein kinase N3 (PKN3) T31600 INDICATI Phase 1 Solid tumour/cancer [ICD-11: 2A00-2F9Z] T31621 TARGETID T31621 T31621 TARGNAME Fibroblast growth factor-2 (FGF2) T31621 INDICATI Approved Acne vulgaris [ICD-11: ED80] T31621 INDICATI Phase 2 Arterial occlusive disease [ICD-11: BD40] T31621 INDICATI Phase 1 Bladder cancer [ICD-11: 2C94] T31621 INDICATI Investigative Multiple myeloma [ICD-11: 2A83] T31621 INDICATI Discontinued in Phase 2 Neurodegenerative disorder [ICD-11: 8A20-8A23] T31621 INDICATI Phase 2 Retinopathy [ICD-11: 9B71] T31621 INDICATI Phase 3 Solid tumour/cancer [ICD-11: 2A00-2F9Z] T31621 INDICATI Phase 2 Stomach cancer [ICD-11: 2B72] T31751 TARGETID T31751 T31751 TARGNAME Plasmodium DOXP reductoisomerase (Malaria DXR) T31751 INDICATI Approved Malaria [ICD-11: 1F40-1F45] T31818 TARGETID T31818 T31818 TARGNAME Integrin alpha-1 (VLA-1) T31818 INDICATI Phase 2 Rheumatoid arthritis [ICD-11: FA20] T31825 TARGETID T31825 T31825 TARGNAME Hemoglobin subunit beta (HBB) T31825 INDICATI Phase 1 Sickle-cell disorder [ICD-11: 3A51] T31825 INDICATI Phase 3 Thalassaemia [ICD-11: 3A50] T31902 TARGETID T31902 T31902 TARGNAME Mammalian disintegrin-metalloprotease (ADAM10) T31902 INDICATI Phase 1/2 Breast cancer [ICD-11: 2C60-2C6Y] T31902 INDICATI Investigative Solid tumour/cancer [ICD-11: 2A00-2F9Z] T31946 TARGETID T31946 T31946 TARGNAME Vascular endothelial growth factor receptor (VEGFR) T31946 INDICATI Terminated Angina pectoris [ICD-11: BA40] T31946 INDICATI Phase 1/2 Basal cell carcinoma [ICD-11: 2C32] T31946 INDICATI Approved Colorectal cancer [ICD-11: 2B91] T31946 INDICATI Phase 2 General pain disorder [ICD-11: 8E43] T31946 INDICATI Approved Idiopathic interstitial pneumonitis [ICD-11: CB03] T31946 INDICATI Phase 3 Lung cancer [ICD-11: 2C25] T31946 INDICATI Phase 2 Macular degeneration [ICD-11: 9B75] T31946 INDICATI Phase 2 Non-small-cell lung cancer [ICD-11: 2C25] T31946 INDICATI Phase 2 Ovarian cancer [ICD-11: 2C73] T31946 INDICATI Phase 3 Peritoneal cancer [ICD-11: 2C51] T31946 INDICATI Phase 2 Psoriasis [ICD-11: EA90] T31946 INDICATI Phase 3 Retinopathy [ICD-11: 9B71] T31946 INDICATI Phase 3 Solid tumour/cancer [ICD-11: 2A00-2F9Z] T31946 INDICATI Phase 3 Stomach cancer [ICD-11: 2B72] T31956 TARGETID T31956 T31956 TARGNAME Glutamyl aminopeptidase (ENPEP) T31956 INDICATI Phase 2 Hypertension [ICD-11: BA00-BA04] T31989 TARGETID T31989 T31989 TARGNAME Sphingosine kinase 2 (SPHK2) T31989 INDICATI Phase 2 Liver cancer [ICD-11: 2C12] T31989 INDICATI Phase 1/2 Multiple myeloma [ICD-11: 2A83] T31989 INDICATI Phase 3 Solid tumour/cancer [ICD-11: 2A00-2F9Z] T31992 TARGETID T31992 T31992 TARGNAME Carbonic anhydrase XIV (CA-XIV) T31992 INDICATI Approved Bacterial infection [ICD-11: 1A00-1C4Z] T31992 INDICATI Phase 2 Breast cancer [ICD-11: 2C60-2C6Y] T31992 INDICATI Approved Inborn metabolism deficiency [ICD-11: 5C50-5C59] T31992 INDICATI Phase 3 Solid tumour/cancer [ICD-11: 2A00-2F9Z] T32060 TARGETID T32060 T32060 TARGNAME 5-HT 2A receptor (HTR2A) T32060 INDICATI Approved Acute diabete complication [ICD-11: 5A2Y] T32060 INDICATI Withdrawn from market Addictive disorder [ICD-11: 6C50-6C5Z] T32060 INDICATI Phase 2 Alzheimer disease [ICD-11: 8A20] T32060 INDICATI Approved Anxiety disorder [ICD-11: 6B00-6B0Z] T32060 INDICATI Phase 1 Attention deficit hyperactivity disorder [ICD-11: 6A05] T32060 INDICATI Phase 1 Bipolar disorder [ICD-11: 6A60] T32060 INDICATI Phase 1 Cardiovascular disease [ICD-11: BA00-BE2Z] T32060 INDICATI Investigative Central nervous system disease [ICD-11: 8A04-8D87] T32060 INDICATI Approved Cerebral ischaemia [ICD-11: 8B1Z] T32060 INDICATI Phase 3 Chronic insomnia [ICD-11: 7A00] T32060 INDICATI Phase 1b Chronic kidney disease [ICD-11: GB61] T32060 INDICATI Phase 3 Chronic pain [ICD-11: MG30] T32060 INDICATI Phase 2 Dementia [ICD-11: 6D80-6D8Z] T32060 INDICATI Phase 3 Depression [ICD-11: 6A70-6A7Z] T32060 INDICATI Phase 2 Glaucoma [ICD-11: 9C61] T32060 INDICATI Discontinued in Phase 3 Haemorrhoids [ICD-11: DB60] T32060 INDICATI Discontinued in Phase 2 Hypertension [ICD-11: BA00-BA04] T32060 INDICATI Phase 2 Idiopathic interstitial pneumonitis [ICD-11: CB03] T32060 INDICATI Phase 3 Insomnia [ICD-11: 7A00-7A0Z] T32060 INDICATI Investigative Mental/behavioural/neurodevelopmental disorder [ICD-11: 6E20-6E8Z] T32060 INDICATI Discontinued in Phase 2 Migraine [ICD-11: 8A80] T32060 INDICATI Approved Mood disorder [ICD-11: 6A60-6E23] T32060 INDICATI Phase 2 Pancreatic cancer [ICD-11: 2C10] T32060 INDICATI Terminated Pancreatitis [ICD-11: DC31-DC34] T32060 INDICATI Approved Parkinsonism [ICD-11: 8A00] T32060 INDICATI Approved Pituitary gland disorder [ICD-11: 5A60-5A61] T32060 INDICATI Phase 3 Post-traumatic stress disorder [ICD-11: 6B40] T32060 INDICATI Patented Prostate hyperplasia [ICD-11: GA90] T32060 INDICATI Phase 1 Psychotic disorder [ICD-11: 6A20-6A25] T32060 INDICATI Phase 2 Schizoaffective disorder [ICD-11: 6A21] T32060 INDICATI Approved Schizophrenia [ICD-11: 6A20] T32060 INDICATI Phase 3 Sexual dysfunction [ICD-11: HA00-HA01] T32060 INDICATI Phase 3 Sleep-wake disorder [ICD-11: 7A00-7B2Z] T32060 INDICATI Phase 2 Social anxiety disorder [ICD-11: 6B04] T32060 INDICATI Terminated Substance abuse [ICD-11: 6C40] T32060 INDICATI Phase 2 Type 2 diabetes mellitus [ICD-11: 5A11] T32137 TARGETID T32137 T32137 TARGNAME NADPH oxidase (NOX) T32137 INDICATI Phase 2 Fibrosis [ICD-11: GA14-GC01] T32137 INDICATI Discontinued in Phase 2 Rheumatoid arthritis [ICD-11: FA20] T32227 TARGETID T32227 T32227 TARGNAME Cyclic nucleotide-gated channel beta-3 (CNGB3) T32227 INDICATI Phase 1/2 Inherited retinal dystrophy [ICD-11: 9B70] T32240 TARGETID T32240 T32240 TARGNAME Interleukin-15 (IL15) T32240 INDICATI Phase 2 Coeliac disease [ICD-11: DA95] T32240 INDICATI Phase 1 Human immunodeficiency virus disease [ICD-11: 1C60-1C62] T32240 INDICATI Phase 2 Mature T-cell lymphoma [ICD-11: 2A90] T32240 INDICATI Phase 2 Mycosis fungoides [ICD-11: 2B01] T32240 INDICATI Discontinued in Phase 1 Rheumatoid arthritis [ICD-11: FA20] T32240 INDICATI Phase 2 Solid tumour/cancer [ICD-11: 2A00-2F9Z] T32247 TARGETID T32247 T32247 TARGNAME Calcitonin receptor (CALCR) T32247 INDICATI Approved Bone paget disease [ICD-11: FB85] T32247 INDICATI Terminated Hypertension [ICD-11: BA00-BA04] T32247 INDICATI Approved Low bone mass disorder [ICD-11: FB83] T32247 INDICATI Phase 1 Obesity [ICD-11: 5B80-5B81] T32247 INDICATI Phase 3 Pain [ICD-11: MG30-MG3Z] T32247 INDICATI Phase 1 Type 2 diabetes mellitus [ICD-11: 5A11] T32262 TARGETID T32262 T32262 TARGNAME Calcitonin gene-related peptide receptor (CGRPR) T32262 INDICATI Phase 2 COVID-19 [ICD-11: 1D6Y] T32262 INDICATI Approved Migraine [ICD-11: 8A80] T32262 INDICATI Approved Pituitary gland disorder [ICD-11: 5A60-5A61] T32262 INDICATI Phase 2 Tension-type headache [ICD-11: 8A81] T32282 TARGETID T32282 T32282 TARGNAME Prolactin (PRL) T32282 INDICATI Discontinued in Phase 2 Multiple sclerosis [ICD-11: 8A40] T32335 TARGETID T32335 T32335 TARGNAME Inhibitor of nuclear factor kappa-B kinase (IKK) T32335 INDICATI Investigative Multiple myeloma [ICD-11: 2A83] T32335 INDICATI Investigative Rheumatoid arthritis [ICD-11: FA20] T32348 TARGETID T32348 T32348 TARGNAME Early growth response protein 1 (EGR-1) T32348 INDICATI Phase 2 Pain [ICD-11: MG30-MG3Z] T32369 TARGETID T32369 T32369 TARGNAME Influenza Polymerase acidic endonuclease (Influ PA) T32369 INDICATI Approved Influenza [ICD-11: 1E30-1E32] T32387 TARGETID T32387 T32387 TARGNAME Endothelium of blood vessels (Endothelium) T32387 INDICATI Approved Acquired cutaneous blood vessel malformation [ICD-11: EF20] T32456 TARGETID T32456 T32456 TARGNAME Second phase insulin secretion (SPI secr) T32456 INDICATI Phase 3 Arteries/arterioles disorder [ICD-11: BD52] T32468 TARGETID T32468 T32468 TARGNAME Bacterial Beta-ketoacyl-ACP synthase I (Bact fabB) T32468 INDICATI Investigative Malaria [ICD-11: 1F40-1F45] T32468 INDICATI Investigative Urinary tract infection [ICD-11: GC08] T32578 TARGETID T32578 T32578 TARGNAME Interleukin-6 (IL6) T32578 INDICATI Approved Anemia [ICD-11: 3A00-3A9Z] T32578 INDICATI Phase 2 Crohn disease [ICD-11: DD70] T32578 INDICATI Phase 3 Cutaneous lupus erythematosus [ICD-11: EB50-EB5Z] T32578 INDICATI Phase 2 Depression [ICD-11: 6A70-6A7Z] T32578 INDICATI Phase 3 Heart failure [ICD-11: BD10-BD1Z] T32578 INDICATI Phase 2 Lupus erythematosus [ICD-11: 4A40] T32578 INDICATI Phase 1 Malignant haematopoietic neoplasm [ICD-11: 2B33] T32578 INDICATI Phase 2 Multiple myeloma [ICD-11: 2A83] T32578 INDICATI Phase 1 Postoperative inflammation [ICD-11: 1A00-CA43] T32578 INDICATI Phase 2 Psoriatic arthritis [ICD-11: FA21] T32578 INDICATI Phase 3 Rheumatoid arthritis [ICD-11: FA20] T32578 INDICATI Phase 3 Vasculitis [ICD-11: 4A44] T32578 INDICATI Phase 3 Vitreoretinopathy ICD-11: 9B78 T32720 TARGETID T32720 T32720 TARGNAME MHC class I NK cell receptor 2DS1 (CD158h) T32720 INDICATI Phase 2 Multiple myeloma [ICD-11: 2A83] T32764 TARGETID T32764 T32764 TARGNAME Adaptor-associated kinase 1 (AAK1) T32764 INDICATI Phase 1 General pain disorder [ICD-11: 8E43] T32780 TARGETID T32780 T32780 TARGNAME Asialoglycoprotein receptor 1 (ASGR1) T32780 INDICATI Phase 1 Cardiovascular disease [ICD-11: BA00-BE2Z] T32790 TARGETID T32790 T32790 TARGNAME LDHA messenger RNA (LDHA mRNA) T32790 INDICATI Approved Inborn carbohydrate metabolism error ICD-11: 5C51 T32790 INDICATI Phase 2 Inborn carbohydrate metabolism error [ICD-11: 5C51] T32855 TARGETID T32855 T32855 TARGNAME Neurotrophin-3 (NTF3) T32855 INDICATI Terminated Central nervous system disease [ICD-11: 8A04-8D87] T32855 INDICATI Discontinued in Phase 2 Irritable bowel syndrome [ICD-11: DD91] T32862 TARGETID T32862 T32862 TARGNAME Fungal Cell membrane ergosterol (Fung CME) T32862 INDICATI Approved Bacterial infection [ICD-11: 1A00-1C4Z] T32862 INDICATI Approved Fungal infection [ICD-11: 1F29-1F2F] T32862 INDICATI Investigative Mycose [ICD-11: 1F2Z] T32880 TARGETID T32880 T32880 TARGNAME HIF-prolyl hydroxylase 2 (HPH-2) T32880 INDICATI Phase 3 Acute disease anaemia [ICD-11: 3A90] T32880 INDICATI Investigative Solid tumour/cancer [ICD-11: 2A00-2F9Z] T32880 INDICATI Phase 3 Urinary system disease [ICD-11: GC2Z] T32938 TARGETID T32938 T32938 TARGNAME Solute carrier family 36 member 2 (SLC36A2) T32938 INDICATI Terminated Rheumatoid arthritis [ICD-11: FA20] T32972 TARGETID T32972 T32972 TARGNAME Lanosterol 14-alpha demethylase (CYP51A1) T32972 INDICATI Phase 1 Infectious meningitis [ICD-11: 1D01] T32972 INDICATI Phase 2 Nail/perionychium infection [ICD-11: EE12] T32972 INDICATI Phase 2 Onchocerciasis [ICD-11: 1F6A] T32973 TARGETID T32973 T32973 TARGNAME Legumain (LGMN) T32973 INDICATI Phase 2/3 Solid tumour/cancer [ICD-11: 2A00-2F9Z] T32984 TARGETID T32984 T32984 TARGNAME Microtubule (MicroTu) T32984 INDICATI Phase 1 Alzheimer disease [ICD-11: 8A20] T32984 INDICATI Phase 2 Brain cancer [ICD-11: 2A00] T32984 INDICATI Phase 2 Breast cancer [ICD-11: 2C60-2C6Y] T32984 INDICATI Phase 1 Parkinsonism [ICD-11: 8A00] T33124 TARGETID T33124 T33124 TARGNAME D-amino acid oxidase (DAO) T33124 INDICATI Phase 2 Ataxic disorder [ICD-11: 8A03] T33124 INDICATI Terminated Mild neurocognitive disorder [ICD-11: 6D71] T33124 INDICATI Phase 1 Schizophrenia [ICD-11: 6A20] T33193 TARGETID T33193 T33193 TARGNAME Bacterial Penicillin binding protein 3 (Bact mrcA) T33193 INDICATI Approved Bacterial infection [ICD-11: 1A00-1C4Z] T33193 INDICATI Approved Respiratory infection [ICD-11: CA07-CA4Z] T33193 INDICATI Approved Urinary tract infection [ICD-11: GC08] T33245 TARGETID T33245 T33245 TARGNAME Growth/differentiation factor 15 (GDF15) T33245 INDICATI Phase 2 Cachexia ICD-11: MG20 T33245 INDICATI Phase 2 Heart failure [ICD-11: BD10-BD1Z] T33245 INDICATI Phase 1 Obesity [ICD-11: 5B80-5B81] T33275 TARGETID T33275 T33275 TARGNAME Tuftsin receptor (TR) T33275 INDICATI Phase 2 Diagnostic imaging [ICD-11: N.A.] T33425 TARGETID T33425 T33425 TARGNAME Epidermal growth factor (EGF) T33425 INDICATI Investigative Oral mucositis [ICD-11: DA01] T33425 INDICATI Phase 2 Skin postprocedural disorder [ICD-11: EL8Y] T33425 INDICATI Approved Unspecific body region injury [ICD-11: ND56] T33455 TARGETID T33455 T33455 TARGNAME Insulin-like growth factor-binding protein 3 (IGFBP3) T33455 INDICATI Phase 2 Dementia [ICD-11: 6D80-6D8Z] T33489 TARGETID T33489 T33489 TARGNAME Steryl-sulfatase (STS) T33489 INDICATI Approved Allergic/hypersensitivity disorder [ICD-11: 4A80-4A8Z] T33489 INDICATI Phase 2 Breast cancer [ICD-11: 2C60-2C6Y] T33489 INDICATI Phase 2 Endometriosis [ICD-11: GA10] T33489 INDICATI Phase 2 Low bone mass disorder [ICD-11: FB83] T33489 INDICATI Phase 1 Prostate cancer [ICD-11: 2C82] T33491 TARGETID T33491 T33491 TARGNAME Bacterial Sporulation kinase A (Bact kinA) T33491 INDICATI Investigative Binge eating disorder [ICD-11: 6B82] T33491 INDICATI Terminated Fungal infection [ICD-11: 1F29-1F2F] T33491 INDICATI Investigative Obesity [ICD-11: 5B80-5B81] T33584 TARGETID T33584 T33584 TARGNAME Glutamate receptor AMPA 1 (GRIA1) T33584 INDICATI Terminated Alzheimer disease [ICD-11: 8A20] T33584 INDICATI Discontinued in Phase 1 Depression [ICD-11: 6A70-6A7Z] T33584 INDICATI Phase 1 Dissociative neurological symptom disorder [ICD-11: 6B60] T33584 INDICATI Discontinued in Phase 2 Epilepsy/seizure [ICD-11: 8A61-8A6Z] T33584 INDICATI Approved Neuropathy [ICD-11: 8C0Z] T33584 INDICATI Discontinued in Phase 3 Parkinsonism [ICD-11: 8A00] T33584 INDICATI Discontinued in Phase 1 Schizophrenia [ICD-11: 6A20] T33629 TARGETID T33629 T33629 TARGNAME Prostate cance cell (PCC) T33629 INDICATI Phase 2 Breast cancer [ICD-11: 2C60-2C6Y] T33636 TARGETID T33636 T33636 TARGNAME Epstein-Barr virus Latent membrane protein 2 (EBV LMP2) T33636 INDICATI Phase 1 Lymphoma [ICD-11: 2A80-2A86] T33636 INDICATI Investigative Nasopharyngeal cancer [ICD-11: 2B6B] T33641 TARGETID T33641 T33641 TARGNAME Cholesterol 24-hydroxylase (CYP46A1) T33641 INDICATI Phase 1 Acidosis [ICD-11: 5C73] T33641 INDICATI Phase 2 Epilepsy/seizure [ICD-11: 8A61-8A6Z] T33641 INDICATI Phase 2 Epileptic encephalopathy [ICD-11: 8A62] T33641 INDICATI Phase 2 Phakomatoses/hamartoneoplastic syndrome [ICD-11: LD2D] T33754 TARGETID T33754 T33754 TARGNAME Phosphodiesterase 3 (PDE3) T33754 INDICATI Terminated Allergic/hypersensitivity disorder [ICD-11: 4A80-4A8Z] T33754 INDICATI Approved Arterial occlusive disease [ICD-11: BD40] T33754 INDICATI Phase 2 Asthma [ICD-11: CA23] T33754 INDICATI Approved Cardiovascular disease [ICD-11: BA00-BE2Z] T33754 INDICATI Approved Castlemans disease [ICD-11: 4B2Y] T33754 INDICATI Discontinued in Phase 2 Chronic obstructive pulmonary disease [ICD-11: CA22] T33754 INDICATI Approved Cough [ICD-11: MD12] T33754 INDICATI Approved Heart failure [ICD-11: BD10-BD1Z] T33754 INDICATI Phase 2 Idiopathic interstitial pneumonitis [ICD-11: CB03] T33754 INDICATI Phase 2 Inborn purine/pyrimidine/nucleotide metabolism error [ICD-11: 5C55] T33754 INDICATI Phase 2 Irritable bowel syndrome [ICD-11: DD91] T33754 INDICATI Phase 2 Motor neuron disease [ICD-11: 8B60] T33754 INDICATI Phase 2 Multiple sclerosis [ICD-11: 8A40] T33754 INDICATI Phase 2 Opioid use disorder [ICD-11: 6C43] T33754 INDICATI Terminated Sepsis [ICD-11: 1G40-1G41] T33754 INDICATI Phase 2 Stimulants use disorder [ICD-11: 6C46] T33754 INDICATI Phase 2 Substance abuse [ICD-11: 6C40] T33754 INDICATI Phase 2 Vasomotor/allergic rhinitis [ICD-11: CA08] T33765 TARGETID T33765 T33765 TARGNAME Mcl-1 messenger RNA (MCL-1 mRNA) T33765 INDICATI Phase 2 Lung cancer [ICD-11: 2C25] T33765 INDICATI Phase 3 Malignant intestine neoplasm [ICD-11: 2C0Z] T33765 INDICATI Investigative Mastocytosis [ICD-11: 2A21] T33765 INDICATI Approved Mature B-cell lymphoma [ICD-11: 2A85] T33765 INDICATI Approved Myeloproliferative neoplasm [ICD-11: 2A20] T33846 TARGETID T33846 T33846 TARGNAME Interleukin 17 receptor (IL17R) T33846 INDICATI Phase 2 Asthma [ICD-11: CA23] T33846 INDICATI Investigative Diabetes mellitus [ICD-11: 5A10] T33846 INDICATI Approved Psoriasis [ICD-11: EA90] T33846 INDICATI Phase 2 Rheumatoid arthritis [ICD-11: FA20] T33901 TARGETID T33901 T33901 TARGNAME Niemann-Pick C1-like protein 1 (NPC1L1) T33901 INDICATI Approved Hyper-lipoproteinaemia [ICD-11: 5C80] T33917 TARGETID T33917 T33917 TARGNAME Hydroxy radical elimination (HYRE) T33917 INDICATI Phase 2 Urinary system disease [ICD-11: GC2Z] T33976 TARGETID T33976 T33976 TARGNAME Transferrin receptor protein 1 (TFRC) T33976 INDICATI Phase 1/2 Diffuse large B-cell lymphoma [ICD-11: 2A81] T33976 INDICATI Phase 1 Malignant haematopoietic neoplasm [ICD-11: 2B33] T33976 INDICATI Phase 1/2 Solid tumour/cancer [ICD-11: 2A00-2F9Z] T33990 TARGETID T33990 T33990 TARGNAME Macrophage colony-stimulating factor 1 (CSF1) T33990 INDICATI Phase 1 Inflammatory arthropathy [ICD-11: FA2Z] T33990 INDICATI Phase 2 Solid tumour/cancer [ICD-11: 2A00-2F9Z] T34123 TARGETID T34123 T34123 TARGNAME Voltage-gated sodium channel alpha Nav1.9 (SCN11A) T34123 INDICATI Approved Bipolar disorder [ICD-11: 6A60] T34123 INDICATI Approved Corneal disease [ICD-11: 9A76-9A78] T34123 INDICATI Approved Epilepsy/seizure [ICD-11: 8A61-8A6Z] T34123 INDICATI Phase 2 Female pelvic pain [ICD-11: GA34] T34123 INDICATI Phase 1 Follicular lymphoma [ICD-11: 2A80] T34123 INDICATI Phase 1 Malignant haematopoietic neoplasm [ICD-11: 2B33] T34123 INDICATI Approved Motor neuron disease [ICD-11: 8B60] T34123 INDICATI Phase 2 Multiple sclerosis [ICD-11: 8A40] T34123 INDICATI Phase 3 Neuropathy [ICD-11: 8C0Z] T34123 INDICATI Terminated Pain [ICD-11: MG30-MG3Z] T34123 INDICATI Investigative Supraventricular tachyarrhythmia [ICD-11: BC81] T34123 INDICATI Approved Tonus and reflex abnormality [ICD-11: MB47] T34204 TARGETID T34204 T34204 TARGNAME Cyclic nucleotide-gated channel alpha-2 (CNGA2) T34204 INDICATI Clinical trial Myelopathy [ICD-11: 8B42] T34234 TARGETID T34234 T34234 TARGNAME Vitamin D3 receptor (VDR) T34234 INDICATI Discontinued in Phase 2 Abnormal micturition [ICD-11: MF50] T34234 INDICATI Terminated Acne vulgaris [ICD-11: ED80] T34234 INDICATI Phase 2 Acute myeloid leukaemia [ICD-11: 2A60] T34234 INDICATI Approved Chronic kidney disease [ICD-11: GB61] T34234 INDICATI Approved Hair/hair growth developmental defect [ICD-11: LC30] T34234 INDICATI Approved Hyper-parathyroidism [ICD-11: 5A51] T34234 INDICATI Approved Hypo-parathyroidism [ICD-11: 5A50] T34234 INDICATI Phase 3 Low bone mass disorder [ICD-11: FB83] T34234 INDICATI Approved Mineral deficiency [ICD-11: 5B5K] T34234 INDICATI Discontinued in Phase 1 Postoperative inflammation [ICD-11: 1A00-CA43] T34234 INDICATI Phase 2 Prostate cancer [ICD-11: 2C82] T34234 INDICATI Phase 1 Prostate disease [ICD-11: GA91] T34234 INDICATI Approved Psoriasis [ICD-11: EA90] T34234 INDICATI Discontinued in Phase 2 Solid tumour/cancer [ICD-11: 2A00-2F9Z] T34234 INDICATI Approved Vitamin deficiency [ICD-11: 5B55-5B5F] T34239 TARGETID T34239 T34239 TARGNAME Protoporphyrinogen oxidase (PPOX) T34239 INDICATI Approved Epidermal dysplasias [ICD-11: EK90] T34287 TARGETID T34287 T34287 TARGNAME Candida Mannose-6-phosphate isomerase (Candi PMI1) T34287 INDICATI Approved Acne vulgaris [ICD-11: ED80] T34287 INDICATI Approved Dermatitis herpetiformis [ICD-11: EB44] T34296 TARGETID T34296 T34296 TARGNAME Matrix metalloproteinase-13 (MMP-13) T34296 INDICATI Discontinued in Phase 2 Corneal disease [ICD-11: 9A76-9A78] T34296 INDICATI Discontinued in Phase 2 Hepatitis virus infection [ICD-11: 1E50-1E51] T34296 INDICATI Clinical trial Pain [ICD-11: MG30-MG3Z] T34296 INDICATI Investigative Postoperative inflammation [ICD-11: 1A00-CA43] T34296 INDICATI Phase 2 Rheumatoid arthritis [ICD-11: FA20] T34296 INDICATI Phase 3 Solid tumour/cancer [ICD-11: 2A00-2F9Z] T34318 TARGETID T34318 T34318 TARGNAME Cathelicidin antimicrobial peptide (CAMP) T34318 INDICATI Approved Asthma [ICD-11: CA23] T34429 TARGETID T34429 T34429 TARGNAME Neuronal acetylcholine receptor alpha-7 (CHRNA7) T34429 INDICATI Phase 1 Adaptive immunity immunodeficiency [ICD-11: 4A01] T34429 INDICATI Phase 3 Alzheimer disease [ICD-11: 8A20] T34429 INDICATI Phase 2 Asthma [ICD-11: CA23] T34429 INDICATI Discontinued in Phase 1 Attention deficit hyperactivity disorder [ICD-11: 6A05] T34429 INDICATI Phase 3 Breast cancer [ICD-11: 2C60-2C6Y] T34429 INDICATI Investigative Central nervous system disease [ICD-11: 8A04-8D87] T34429 INDICATI Approved Corneal disease [ICD-11: 9A76-9A78] T34429 INDICATI Phase 2 Cough ICD-11: MD12 T34429 INDICATI Phase 2 Depression [ICD-11: 6A70-6A7Z] T34429 INDICATI Phase 1 Dissociative neurological symptom disorder [ICD-11: 6B60] T34429 INDICATI Phase 3 General pain disorder [ICD-11: 8E43] T34429 INDICATI Phase 1 Mental/behavioural/neurodevelopmental disorder [ICD-11: 6E20-6E8Z] T34429 INDICATI Phase 1 Mild neurocognitive disorder [ICD-11: 6D71] T34429 INDICATI Phase 3 Nicotine use disorder [ICD-11: 6C4A] T34429 INDICATI Phase 2 Parkinsonism [ICD-11: 8A00] T34429 INDICATI Approved Schizophrenia [ICD-11: 6A20] T34429 INDICATI Phase 1 Sex development malformative disorder [ICD-11: LD2A] T34429 INDICATI Preclinical Sexual dysfunction [ICD-11: HA00-HA01] T34429 INDICATI Discontinued in Phase 2 Thrombosis [ICD-11: DB61-GB90] T34596 TARGETID T34596 T34596 TARGNAME Haemophilus influenzae DNA gyrase A (Hae-influ gyrA) T34596 INDICATI Investigative Bacterial infection [ICD-11: 1A00-1C4Z] T34596 INDICATI Phase 3 Otitis externa [ICD-11: AA00-AA13] T34601 TARGETID T34601 T34601 TARGNAME Dysferlin (DYSF) T34601 INDICATI Phase 1 Muscular dystrophy ICD-11: 8C70 T34624 TARGETID T34624 T34624 TARGNAME Stress-activated protein kinase (p38) T34624 INDICATI Phase 2 Alzheimer disease [ICD-11: 8A20] T34624 INDICATI Phase 2 Arterial occlusive disease [ICD-11: BD40] T34624 INDICATI Phase 2 Asthma [ICD-11: CA23] T34624 INDICATI Phase 3 Cardiomyopathy [ICD-11: BC43] T34624 INDICATI Phase 2 Chronic obstructive pulmonary disease [ICD-11: CA22] T34624 INDICATI Discontinued in Phase 1 Myelodysplastic syndrome [ICD-11: 2A37] T34624 INDICATI Phase 2 Osteoarthritis [ICD-11: FA00-FA05] T34624 INDICATI Phase 2 Pain [ICD-11: MG30-MG3Z] T34624 INDICATI Discontinued in Phase 1 Postoperative inflammation [ICD-11: 1A00-CA43] T34624 INDICATI Phase 2 Psoriasis [ICD-11: EA90] T34624 INDICATI Phase 2 Rheumatoid arthritis [ICD-11: FA20] T34624 INDICATI Phase 1/2 Solid tumour/cancer [ICD-11: 2A00-2F9Z] T34743 TARGETID T34743 T34743 TARGNAME Bacterial Penicillin binding protein (Bact PBP) T34743 INDICATI Approved Acute bronchitis [ICD-11: CA42] T34743 INDICATI Approved Anaerobic bacterial infection [ICD-11: 1A00-1A09] T34743 INDICATI Approved Bacterial infection [ICD-11: 1A00-1C4Z] T34743 INDICATI Approved Bronchitis [ICD-11: CA20] T34743 INDICATI Phase 2 Cystic fibrosis [ICD-11: CA25] T34743 INDICATI Phase 1 Digestive organ benign neoplasm [ICD-11: 2E92] T34743 INDICATI Investigative Dissociative neurological symptom disorder [ICD-11: 6B60] T34743 INDICATI Approved Glanders [ICD-11: 1B92] T34743 INDICATI Approved Gram-positive bacterial infection [ICD-11: 1B74-1F40] T34743 INDICATI Approved Mature B-cell lymphoma [ICD-11: 2A85] T34743 INDICATI Approved Myelodysplastic syndrome [ICD-11: 2A37] T34743 INDICATI Phase 3 Pneumonia [ICD-11: CA40] T34743 INDICATI Approved Respiratory infection [ICD-11: CA07-CA4Z] T34743 INDICATI Approved Rheumatoid arthritis [ICD-11: FA20] T34743 INDICATI Approved Sepsis [ICD-11: 1G40-1G41] T34743 INDICATI Phase 3 Skin and skin-structure infection [ICD-11: 1F28-1G0Z] T34743 INDICATI Approved Urinary tract infection [ICD-11: GC08] T34772 TARGETID T34772 T34772 TARGNAME Endopeptidase (ENP) T34772 INDICATI Approved Bowel habit change [ICD-11: ME05] T34843 TARGETID T34843 T34843 TARGNAME Glucagon-like peptide 2 receptor (GLP2R) T34843 INDICATI Phase 2 Bowel habit change [ICD-11: ME05] T34843 INDICATI Investigative Digestive system disease [ICD-11: DE2Z] T34843 INDICATI Phase 1 Indeterminate colitis [ICD-11: DD72] T34843 INDICATI Phase 1 Low bone mass disorder [ICD-11: FB83] T34843 INDICATI Approved Neonatal malabsorption syndrome [ICD-11: KB89] T34867 TARGETID T34867 T34867 TARGNAME Poly [ADP-ribose] polymerase (PARP) T34867 INDICATI Phase 3 Brain cancer [ICD-11: 2A00] T34867 INDICATI Approved Breast cancer [ICD-11: 2C60-2C6Y] T34867 INDICATI Phase 1/2 Cerebral ischaemia [ICD-11: 8B1Z] T34867 INDICATI Phase 1 Cerebral ischaemic stroke [ICD-11: 8B11] T34867 INDICATI Phase 1 Ewing sarcoma [ICD-11: 2B52] T34867 INDICATI Phase 1 Ischaemic/haemorrhagic stroke [ICD-11: 8B20] T34867 INDICATI Phase 3 Lung cancer [ICD-11: 2C25] T34867 INDICATI Phase 3 Malignant mesenchymal neoplasm [ICD-11: 2B5D-2B5Y] T34867 INDICATI Phase 2 Melanoma [ICD-11: 2C30] T34867 INDICATI Approved Ovarian cancer [ICD-11: 2C73] T34867 INDICATI Phase 3 Pancreatic cancer [ICD-11: 2C10] T34867 INDICATI Phase 3 Prostate cancer [ICD-11: 2C82] T34867 INDICATI Phase 3 Psoriatic arthritis [ICD-11: FA21] T34867 INDICATI Phase 3 Solid tumour/cancer [ICD-11: 2A00-2F9Z] T34867 INDICATI Phase 2 Type 2 diabetes mellitus [ICD-11: 5A11] T34949 TARGETID T34949 T34949 TARGNAME Voltage-gated calcium channel alpha Cav2.1 (CACNA1A) T34949 INDICATI Investigative Heart failure [ICD-11: BD10-BD1Z] T34949 INDICATI Approved Migraine [ICD-11: 8A80] T34949 INDICATI Terminated Unspecific body region injury [ICD-11: ND56] T34997 TARGETID T34997 T34997 TARGNAME Hepatitis C virus Serine protease NS4A (HCV NS4A) T34997 INDICATI Phase 2 Hepatitis virus infection [ICD-11: 1E50-1E51] T35040 TARGETID T35040 T35040 TARGNAME Basigin (BSG) T35040 INDICATI Phase 2/3 Graft-versus-host disease [ICD-11: 4B24] T35040 INDICATI Phase 2 Liver cancer [ICD-11: 2C12] T35063 TARGETID T35063 T35063 TARGNAME RAS-like protein KIR (GEM) T35063 INDICATI Phase 2 Acute myeloid leukaemia [ICD-11: 2A60] T35063 INDICATI Phase 2 Mature B-cell leukaemia [ICD-11: 2A82] T35063 INDICATI Phase 2 Myelodysplastic syndrome [ICD-11: 2A37] T35063 INDICATI Phase 1/2 Solid tumour/cancer [ICD-11: 2A00-2F9Z] T35173 TARGETID T35173 T35173 TARGNAME Cellular inhibitor of apoptosis 2 (BIRC3) T35173 INDICATI Phase 1 Acute myeloid leukaemia [ICD-11: 2A60] T35173 INDICATI Phase 1/2 Lymphoma [ICD-11: 2A80-2A86] T35173 INDICATI Phase 3 Metastatic lymph node neoplasm [ICD-11: 2D60] T35173 INDICATI Phase 2 Solid tumour/cancer [ICD-11: 2A00-2F9Z] T35194 TARGETID T35194 T35194 TARGNAME Dual specificity protein phosphatase 1 (DUSP1) T35194 INDICATI Phase 3 Lung cancer [ICD-11: 2C25] T35194 INDICATI Investigative Nasopharyngeal cancer [ICD-11: 2B6B] T35212 TARGETID T35212 T35212 TARGNAME Vascular endothelial cell growth inhibitor (TNFSF15) T35212 INDICATI Phase 2 Crohn disease [ICD-11: DD70] T35212 INDICATI Phase 1 Indeterminate colitis [ICD-11: DD72] T35212 INDICATI Phase 2 Ulcerative colitis [ICD-11: DD71] T35232 TARGETID T35232 T35232 TARGNAME Interleukin-7 (IL7) T35232 INDICATI Phase 1 Multiple sclerosis [ICD-11: 8A40] T35232 INDICATI Phase 1 Sjogren syndrome [ICD-11: 4A43] T35232 INDICATI Phase 1 Solid tumour/cancer [ICD-11: 2A00-2F9Z] T35265 TARGETID T35265 T35265 TARGNAME S100 calcium-binding protein A4 (S100A4) T35265 INDICATI Preclinical Breast cancer [ICD-11: 2C60-2C6Y] T35289 TARGETID T35289 T35289 TARGNAME NKG2 D activating NK receptor (KLRK1) T35289 INDICATI Phase 1 Acute myeloid leukaemia [ICD-11: 2A60] T35289 INDICATI Phase 1 Colorectal cancer [ICD-11: 2B91] T35289 INDICATI Phase 2 Crohn disease [ICD-11: DD70] T35289 INDICATI Phase 1 Multiple myeloma [ICD-11: 2A83] T35289 INDICATI Phase 1 Myelodysplastic syndrome [ICD-11: 2A37] T35289 INDICATI Discontinued in Phase 2 Rheumatoid arthritis [ICD-11: FA20] T35303 TARGETID T35303 T35303 TARGNAME Pancreatic hormone (PH) T35303 INDICATI Phase 1/2 Obesity [ICD-11: 5B80-5B81] T35423 TARGETID T35423 T35423 TARGNAME Immune costimulatory protein B7H4 (VTCN1) T35423 INDICATI Phase 1 Breast cancer [ICD-11: 2C60-2C6Y] T35423 INDICATI Phase 2 Solid tumour/cancer [ICD-11: 2A00-2F9Z] T35445 TARGETID T35445 T35445 TARGNAME Mothers against decapentaplegic homolog 3 (SMAD3) T35445 INDICATI Preclinical Kidney fibrosis [ICD-11: GC01] T35465 TARGETID T35465 T35465 TARGNAME Solute carrier family 19 member 1 (SLC19A1) T35465 INDICATI Approved Folate deficiency anaemia [ICD-11: 3A02] T35465 INDICATI Approved Leukaemia [ICD-11: 2A60-2B33] T35465 INDICATI Approved Nutritional deficiency [ICD-11: 5B50-5B71] T35465 INDICATI Investigative Prostate cancer [ICD-11: 2C82] T35465 INDICATI Phase 1 Rheumatoid arthritis [ICD-11: FA20] T35465 INDICATI Phase 3 Solid tumour/cancer [ICD-11: 2A00-2F9Z] T35465 INDICATI Phase 3 Vitreoretinopathy [ICD-11: 9B78] T35474 TARGETID T35474 T35474 TARGNAME KRAS messenger RNA (KRAS mRNA) T35474 INDICATI Investigative Solid tumour/cancer [ICD-11: 2A00-2F9Z] T35486 TARGETID T35486 T35486 TARGNAME GTPase NRas (NRAS) T35486 INDICATI Phase 2 Colorectal cancer [ICD-11: 2B91] T35486 INDICATI Phase 2 Head and neck cancer [ICD-11: 2D42] T35486 INDICATI Phase 2 Lung cancer [ICD-11: 2C25] T35486 INDICATI Phase 2 Pancreatic cancer [ICD-11: 2C10] T35486 INDICATI Investigative Prostate cancer [ICD-11: 2C82] T35486 INDICATI Phase 2 Solid tumour/cancer [ICD-11: 2A00-2F9Z] T35591 TARGETID T35591 T35591 TARGNAME Nectin cell adhesion molecule 4 (NECTIN4) T35591 INDICATI Phase 3 Bladder cancer [ICD-11: 2C94] T35591 INDICATI Phase 1/2 Solid tumour/cancer [ICD-11: 2A00-2F9Z] T35591 INDICATI Approved Ureteral cancer [ICD-11: 2C92] T35640 TARGETID T35640 T35640 TARGNAME Integrin alpha-L (ITGAL) T35640 INDICATI Phase 3 Conjunctiva disorder [ICD-11: 9A60] T35640 INDICATI Investigative Diabetes mellitus [ICD-11: 5A10] T35640 INDICATI Preclinical Human immunodeficiency virus disease [ICD-11: 1C60-1C62] T35640 INDICATI Approved Psoriasis [ICD-11: EA90] T35640 INDICATI Phase 2 Transplant rejection [ICD-11: NE84] T35640 INDICATI Approved Visual system disease [ICD-11: 9E1Z] T35734 TARGETID T35734 T35734 TARGNAME Soluble epoxide hydrolase (EPHX2) T35734 INDICATI Phase 1 Chronic obstructive pulmonary disease [ICD-11: CA22] T35734 INDICATI Phase 2 Hypertension [ICD-11: BA00-BA04] T35792 TARGETID T35792 T35792 TARGNAME Histone-lysine N-methyltransferase SMYD3 (SMYD3) T35792 INDICATI Preclinical Colon cancer [ICD-11: 2B90] T35792 INDICATI Preclinical Solid tumour/cancer [ICD-11: 2A00-2F9Z] T35842 TARGETID T35842 T35842 TARGNAME Melanocortin receptor 1 (MC1R) T35842 INDICATI Phase 2 Acquired hypomelanotic disorder [ICD-11: ED63] T35842 INDICATI Investigative Atopic eczema [ICD-11: EA80] T35842 INDICATI Approved Hypoactive sexual desire dysfunction [ICD-11: HA00] T35842 INDICATI Approved Inborn porphyrin/heme metabolism error [ICD-11: 5C58] T35842 INDICATI Phase 3 Inborn porphyrin/heme metabolism error ICD-11: 5C58 T35842 INDICATI Phase 1/2 Metabolic disorder [ICD-11: 5C50-5D2Z] T35842 INDICATI Phase 3 Sexual dysfunction [ICD-11: HA00-HA01] T35842 INDICATI Phase 2 Ulcerative colitis [ICD-11: DD71] T35940 TARGETID T35940 T35940 TARGNAME ERK activator kinase 1 (MEK1) T35940 INDICATI Investigative Cardiac arrest [ICD-11: MC82] T35940 INDICATI Phase 2 Lung cancer [ICD-11: 2C25] T35940 INDICATI Phase 3 Melanoma [ICD-11: 2C30] T35940 INDICATI Discontinued in Phase 1 Solid tumour/cancer [ICD-11: 2A00-2F9Z] T35940 INDICATI Phase 3 Thyroid cancer [ICD-11: 2D10] T36053 TARGETID T36053 T36053 TARGNAME Organic anion transporter M1 (SLCO4C1) T36053 INDICATI Approved Cardiac arrhythmia [ICD-11: BC9Z] T36053 INDICATI Approved Heart failure [ICD-11: BD10-BD1Z] T36059 TARGETID T36059 T36059 TARGNAME Adenosine A3 receptor (ADORA3) T36059 INDICATI Terminated Cerebral ischaemia [ICD-11: 8B1Z] T36059 INDICATI Investigative Glaucoma [ICD-11: 9C61] T36059 INDICATI Phase 2 Heart failure [ICD-11: BD10-BD1Z] T36059 INDICATI Phase 1/2 Hepatitis virus infection [ICD-11: 1E50-1E51] T36059 INDICATI Preclinical Ischaemic heart disease [ICD-11: BA6Z] T36059 INDICATI Phase 1 Ischaemic/haemorrhagic stroke [ICD-11: 8B20] T36059 INDICATI Investigative Ischemia [ICD-11: 8B10-8B11] T36059 INDICATI Phase 2 Liver cancer [ICD-11: 2C12] T36059 INDICATI Phase 2 Malaria [ICD-11: 1F40-1F45] T36059 INDICATI Terminated Multiple sclerosis [ICD-11: 8A40] T36059 INDICATI Preclinical Postoperative inflammation [ICD-11: 1A00-CA43] T36059 INDICATI Phase 3 Psoriasis [ICD-11: EA90] T36059 INDICATI Phase 2 Rheumatoid arthritis [ICD-11: FA20] T36059 INDICATI Phase 3 Solid tumour/cancer [ICD-11: 2A00-2F9Z] T36075 TARGETID T36075 T36075 TARGNAME Glucagon-like peptide 1 receptor (GLP1R) T36075 INDICATI Phase 3 Acute diabete complication [ICD-11: 5A2Y] T36075 INDICATI Phase 2 Alzheimer disease [ICD-11: 8A20] T36075 INDICATI Phase 3 Cardiovascular disease [ICD-11: BA00-BE2Z] T36075 INDICATI Phase 3 Diabetes mellitus [ICD-11: 5A10] T36075 INDICATI Phase 2 Dyspepsia [ICD-11: MD92] T36075 INDICATI Phase 2 Hypo-glycaemia [ICD-11: 5A41] T36075 INDICATI Discontinued in Phase 1/2 Intracranial injury [ICD-11: NA07] T36075 INDICATI Phase 2 Irritable bowel syndrome [ICD-11: DD91] T36075 INDICATI Phase 2 Non-alcoholic fatty liver disease [ICD-11: DB92] T36075 INDICATI Phase 3 Obesity [ICD-11: 5B80-5B81] T36075 INDICATI Phase 2 Pancreatic internal secretion disorder [ICD-11: 5A4Y] T36075 INDICATI Phase 2 Parkinsonism [ICD-11: 8A00] T36075 INDICATI Approved Type 2 diabetes mellitus [ICD-11: 5A11] T36075 INDICATI Approved Type-1/2 diabete [ICD-11: 5A10-5A11] T36467 TARGETID T36467 T36467 TARGNAME Cytosine deaminase (AICDA) T36467 INDICATI Phase 1 Solid tumour/cancer [ICD-11: 2A00-2F9Z] T36479 TARGETID T36479 T36479 TARGNAME T-cell surface protein tactile (CD96) T36479 INDICATI Phase 1 Solid tumour/cancer [ICD-11: 2A00-2F9Z] T36483 TARGETID T36483 T36483 TARGNAME Proteinase activated receptor 1 (F2R) T36483 INDICATI Investigative Arterial occlusive disease [ICD-11: BD40] T36483 INDICATI Terminated Arteries/arterioles disorder [ICD-11: BD52] T36483 INDICATI Phase 2 Chronic arterial occlusive disease [ICD-11: BD4Z] T36483 INDICATI Approved Myocardial infarction [ICD-11: BA41-BA43] T36483 INDICATI Terminated Thrombosis [ICD-11: DB61-GB90] T36557 TARGETID T36557 T36557 TARGNAME Peroxisome proliferator-activated receptor delta (PPARD) T36557 INDICATI Phase 2 Alzheimer disease [ICD-11: 8A20] T36557 INDICATI Phase 2 Autoimmune liver disease [ICD-11: DB96] T36557 INDICATI Investigative Central nervous system disease [ICD-11: 8A04-8D87] T36557 INDICATI Discontinued in Phase 4 Diabetes mellitus [ICD-11: 5A10] T36557 INDICATI Phase 1 Dyslipidemia [ICD-11: 5C80-5C81] T36557 INDICATI Phase 2 Hyper-lipoproteinaemia [ICD-11: 5C80] T36557 INDICATI Phase 1 Metabolic disorder [ICD-11: 5C50-5D2Z] T36557 INDICATI Phase 3 Non-alcoholic fatty liver disease [ICD-11: DB92] T36557 INDICATI Phase 2/3 Obesity [ICD-11: 5B80-5B81] T36557 INDICATI Phase 2 Type 2 diabetes mellitus [ICD-11: 5A11] T36658 TARGETID T36658 T36658 TARGNAME Oxidative stress (OS) T36658 INDICATI Discontinued in Phase 1 Arterial occlusive disease [ICD-11: BD40] T36658 INDICATI Phase 1 Cerebral ischaemic stroke [ICD-11: 8B11] T36741 TARGETID T36741 T36741 TARGNAME p53-binding protein Mdm4 (MDM4) T36741 INDICATI Phase 1 Acute myeloid leukaemia [ICD-11: 2A60] T36741 INDICATI Phase 2 Malignant haematopoietic neoplasm [ICD-11: 2B33] T36741 INDICATI Phase 1 Myelodysplastic syndrome [ICD-11: 2A37] T36741 INDICATI Phase 1 Solid tumour/cancer [ICD-11: 2A00-2F9Z] T36846 TARGETID T36846 T36846 TARGNAME Mitochondrial function (MF) T36846 INDICATI Phase 3 Motor neuron disease [ICD-11: 8B60] T36935 TARGETID T36935 T36935 TARGNAME Prostate specific antigen (KLK3) T36935 INDICATI Phase 3 Arteries/arterioles disorder [ICD-11: BD52] T36935 INDICATI Phase 3 Prostate cancer [ICD-11: 2C82] T36935 INDICATI Phase 3 Prostate hyperplasia [ICD-11: GA90] T36958 TARGETID T36958 T36958 TARGNAME FOXP3 messenger RNA (FOXP3 mRNA) T36958 INDICATI Phase 1 Solid tumour/cancer [ICD-11: 2A00-2F9Z] T36959 TARGETID T36959 T36959 TARGNAME Activin receptor-like kinase-1 (ACVRL1) T36959 INDICATI Phase 2 Solid tumour/cancer [ICD-11: 2A00-2F9Z] T37012 TARGETID T37012 T37012 TARGNAME GDNF family receptor alpha-like (GFRAL) T37012 INDICATI Phase 1 Solid tumour/cancer [ICD-11: 2A00-2F9Z] T37046 TARGETID T37046 T37046 TARGNAME Biliverdin reductase A (BLVRA) T37046 INDICATI Approved Autoimmune liver disease [ICD-11: DB96] T37048 TARGETID T37048 T37048 TARGNAME Staphylococcus IgG binding protein A (Stap-coc SpA) T37048 INDICATI Phase 1/2 Staphylococcal/streptococcal disease [ICD-11: 1B5Y] T37154 TARGETID T37154 T37154 TARGNAME Cathepsin A (CTSA) T37154 INDICATI Phase 1 Acute diabete complication [ICD-11: 5A2Y] T37245 TARGETID T37245 T37245 TARGNAME RTP801 messenger RNA (RTP801 mRNA) T37245 INDICATI Phase 2 Macular degeneration [ICD-11: 9B75] T37245 INDICATI Phase 2 Retinopathy [ICD-11: 9B71] T37298 TARGETID T37298 T37298 TARGNAME MYCBP messenger RNA (MYCBP mRNA) T37298 INDICATI Phase 1/2 Liver cancer [ICD-11: 2C12] T37308 TARGETID T37308 T37308 TARGNAME Immunoglobulin E (IgE) T37308 INDICATI Discontinued in Phase 2 Allergic/hypersensitivity disorder [ICD-11: 4A80-4A8Z] T37308 INDICATI Phase 2 Asthma [ICD-11: CA23] T37308 INDICATI Investigative Myasthenia gravis [ICD-11: 8C6Y] T37308 INDICATI Phase 1 Rheumatoid arthritis [ICD-11: FA20] T37308 INDICATI Phase 3 Spontaneous urticaria [ICD-11: EB00] T37308 INDICATI Phase 2 Vasomotor/allergic rhinitis [ICD-11: CA08] T37382 TARGETID T37382 T37382 TARGNAME Solute carrier family 23 member 1 (SLC23A1) T37382 INDICATI Phase 2 Urinary tract infection [ICD-11: GC08] T37382 INDICATI Approved Vitamin deficiency [ICD-11: 5B55-5B5F] T37434 TARGETID T37434 T37434 TARGNAME Prominin-1 (PROM1) T37434 INDICATI Preclinical Acute myeloid leukaemia [ICD-11: 2A60] T37434 INDICATI Phase 1 Brain cancer [ICD-11: 2A00] T37434 INDICATI Phase 1 Colorectal cancer [ICD-11: 2B91] T37434 INDICATI Phase 1 Liver cancer [ICD-11: 2C12] T37434 INDICATI Phase 1 Ovarian cancer [ICD-11: 2C73] T37434 INDICATI Phase 1 Pancreatic cancer [ICD-11: 2C10] T37434 INDICATI Phase 1 Solid tumour/cancer [ICD-11: 2A00-2F9Z] T37510 TARGETID T37510 T37510 TARGNAME Coagulation factor Va (F5) T37510 INDICATI Approved Cerebral ischaemia [ICD-11: 8B1Z] T37510 INDICATI Approved Sepsis [ICD-11: 1G40-1G41] T37539 TARGETID T37539 T37539 TARGNAME B-cell receptor CD22 (CD22) T37539 INDICATI Phase 1 Acute myeloid leukaemia [ICD-11: 2A60] T37539 INDICATI Phase 1/2 B-cell lymphoma [ICD-11: 2A86] T37539 INDICATI Investigative Diabetes mellitus [ICD-11: 5A10] T37539 INDICATI Phase 1/2 Diffuse large B-cell lymphoma [ICD-11: 2A81] T37539 INDICATI Phase 1/2 Follicular lymphoma [ICD-11: 2A80] T37539 INDICATI Phase 1/2 Leukaemia [ICD-11: 2A60-2B33] T37539 INDICATI Phase 3 Lupus erythematosus [ICD-11: 4A40] T37539 INDICATI Approved Lyme borreliosis [ICD-11: 1C1G] T37539 INDICATI Phase 1/2 Lymphoma [ICD-11: 2A80-2A86] T37539 INDICATI Approved Malignant haematopoietic neoplasm [ICD-11: 2B33] T37539 INDICATI Approved Mature B-cell leukaemia [ICD-11: 2A82] T37539 INDICATI Approved Mature B-cell lymphoma [ICD-11: 2A85] T37539 INDICATI Phase 1/2 Multiple myeloma [ICD-11: 2A83] T37539 INDICATI Phase 3 Transplant rejection [ICD-11: NE84] T37693 TARGETID T37693 T37693 TARGNAME Cannabinoid receptor 2 (CB2) T37693 INDICATI Phase 1 Alzheimer disease [ICD-11: 8A20] T37693 INDICATI Phase 2 Atopic eczema [ICD-11: EA80] T37693 INDICATI Approved Attention deficit hyperactivity disorder [ICD-11: 6A05] T37693 INDICATI Discontinued in Phase 1 Cerebral ischaemia [ICD-11: 8B1Z] T37693 INDICATI Phase 2 Crohn disease [ICD-11: DD70] T37693 INDICATI Patented Endometriosis [ICD-11: GA10] T37693 INDICATI Phase 2 General pain disorder [ICD-11: 8E43] T37693 INDICATI Investigative Immune system disease [ICD-11: 4A01-4B41] T37693 INDICATI Phase 2 Inborn lipid metabolism error [ICD-11: 5C52] T37693 INDICATI Investigative Indeterminate colitis [ICD-11: DD72] T37693 INDICATI Approved Insomnia [ICD-11: 7A00-7A0Z] T37693 INDICATI Discontinued in Phase 2 Ischemia [ICD-11: 8B10-8B11] T37693 INDICATI Patented Low bone mass disorder [ICD-11: FB83] T37693 INDICATI Investigative Ovarian cancer [ICD-11: 2C73] T37693 INDICATI Phase 2 Pain [ICD-11: MG30-MG3Z] T37693 INDICATI Investigative Postoperative inflammation [ICD-11: 1A00-CA43] T37693 INDICATI Patented Prostate cancer [ICD-11: 2C82] T37693 INDICATI Phase 2 Retinopathy [ICD-11: 9B71] T37693 INDICATI Terminated Rheumatoid arthritis [ICD-11: FA20] T37693 INDICATI Patented Transplant rejection [ICD-11: NE84] T37735 TARGETID T37735 T37735 TARGNAME Glutamate decarboxylase (GLUL) T37735 INDICATI Discontinued in Phase 2 Parkinsonism [ICD-11: 8A00] T37742 TARGETID T37742 T37742 TARGNAME Serum amyloid P-component (APCS) T37742 INDICATI Phase 1 Amyloidosis [ICD-11: 5D00] T37742 INDICATI Phase 3 Idiopathic interstitial pneumonitis [ICD-11: CB03] T37742 INDICATI Phase 1/2 Parkinsonism [ICD-11: 8A00] T37847 TARGETID T37847 T37847 TARGNAME Herpes simplex virus DNA polymerase UL30 (HSV UL30) T37847 INDICATI Approved Cytomegaloviral disease [ICD-11: 1D82] T37847 INDICATI Phase 2 Hepatitis virus infection [ICD-11: 1E50-1E51] T37847 INDICATI Approved Herpes simplex infection [ICD-11: 1F00] T37847 INDICATI Approved Human immunodeficiency virus disease [ICD-11: 1C60-1C62] T37847 INDICATI Approved Mature B-cell lymphoma [ICD-11: 2A85] T37847 INDICATI Phase 1 Melanoma [ICD-11: 2C30] T37847 INDICATI Phase 2 Metabolic disorder [ICD-11: 5C50-5D2Z] T37847 INDICATI Approved Retinal inflammation [ICD-11: 9B72] T37847 INDICATI Phase 1/2 Solid tumour/cancer [ICD-11: 2A00-2F9Z] T37847 INDICATI Approved Virus infection [ICD-11: 1A24-1D9Z] T37847 INDICATI Phase 2 Zoster [ICD-11: 1E91] T37848 TARGETID T37848 T37848 TARGNAME Albendazole monooxygenase (CYP3A4) T37848 INDICATI Phase 2 Atopic eczema [ICD-11: EA80] T37848 INDICATI Phase 3 Solid tumour/cancer [ICD-11: 2A00-2F9Z] T37876 TARGETID T37876 T37876 TARGNAME Rhinovirus Capsid protein (HRV VP) T37876 INDICATI Phase 2 Acute upper respiratory infection [ICD-11: CA07] T37876 INDICATI Discontinued in Phase 2 Virus infection [ICD-11: 1A24-1D9Z] T37952 TARGETID T37952 T37952 TARGNAME SYK messenger RNA (SYK mRNA) T37952 INDICATI Phase 2 Eczema [ICD-11: EA80-EA89] T37952 INDICATI Phase 1/2 Lymphoma [ICD-11: 2A80-2A86] T37952 INDICATI Phase 1/2 Solid tumour/cancer [ICD-11: 2A00-2F9Z] T38052 TARGETID T38052 T38052 TARGNAME Cryptosporidium Pyruvate:ferredoxin oxidoreductase (Crypto CpPNO) T38052 INDICATI Approved Bowel habit change [ICD-11: ME05] T38087 TARGETID T38087 T38087 TARGNAME Tankyrase-2 (TNKS-2) T38087 INDICATI Phase 2 Ovarian cancer [ICD-11: 2C73] T38143 TARGETID T38143 T38143 TARGNAME Phosphodiesterase 5 (PDE5) T38143 INDICATI Phase 3 Alzheimer disease [ICD-11: 8A20] T38159 TARGETID T38159 T38159 TARGNAME Trefoil factor-1 (TFF1) T38159 INDICATI Phase 2/3 Oral mucositis [ICD-11: DA01] T38161 TARGETID T38161 T38161 TARGNAME Phospholipase A2 inhibitory protein (PA2IP) T38161 INDICATI Approved Ocular pain [ICD-11: MC18] T38179 TARGETID T38179 T38179 TARGNAME Staphylococcus Beta-lactamase (Stap-coc blaZ) T38179 INDICATI Phase 2 Anaerobic bacterial infection [ICD-11: 1A00-1A09] T38179 INDICATI Terminated Antimicrobial drug resistance [ICD-11: MG50-MG52] T38179 INDICATI Approved Bacterial infection [ICD-11: 1A00-1C4Z] T38179 INDICATI Phase 1 Gram-negative bacterial infection [ICD-11: 1F41-1G40] T38179 INDICATI Discontinued in Phase 3 Gram-positive bacterial infection [ICD-11: 1B74-1F40] T38179 INDICATI Approved Infectious gastroenteritis/colitis [ICD-11: 1A40] T38179 INDICATI Phase 1 Infectious meningitis [ICD-11: 1D01] T38179 INDICATI Discontinued in Phase 3 Otitis media [ICD-11: AA80-AB0Z] T38179 INDICATI Investigative Postoperative inflammation [ICD-11: 1A00-CA43] T38179 INDICATI Discontinued in Phase 2 Toxicity [ICD-11: N.A.] T38179 INDICATI Phase 3 Unspecific infection [ICD-11: 1H0Z] T38179 INDICATI Approved Urinary tract infection [ICD-11: GC08] T38200 TARGETID T38200 T38200 TARGNAME GABA transporter-3 (SLC6A11) T38200 INDICATI Phase 2 Indeterminate colitis [ICD-11: DD72] T38201 TARGETID T38201 T38201 TARGNAME Protein mono-ADP-ribosyltransferase TIPARP (TIPARP) T38201 INDICATI Phase 1 Solid tumour/cancer [ICD-11: 2A00-2F9Z] T38284 TARGETID T38284 T38284 TARGNAME Fusion protein Bcr-Abl (Bcr-Abl) T38284 INDICATI Investigative Gram-positive bacterial infection [ICD-11: 1B74-1F40] T38284 INDICATI Phase 3 Leukaemia [ICD-11: 2A60-2B33] T38284 INDICATI Phase 2 Lung cancer [ICD-11: 2C25] T38284 INDICATI Phase 3 Malignant intestine neoplasm [ICD-11: 2C0Z] T38284 INDICATI Investigative Mastocytosis [ICD-11: 2A21] T38284 INDICATI Phase 2 Mature B-cell leukaemia [ICD-11: 2A82] T38284 INDICATI Approved Mature B-cell lymphoma [ICD-11: 2A85] T38284 INDICATI Phase 2 Multiple myeloma [ICD-11: 2A83] T38284 INDICATI Phase 2 Musculoskeletal system/connective tissue disease [ICD-11: FC0Z] T38284 INDICATI Approved Myeloproliferative neoplasm [ICD-11: 2A20] T38301 TARGETID T38301 T38301 TARGNAME Ribonucleoside-diphosphate reductase M2 (RRM2) T38301 INDICATI Discontinued in Phase 2 Human immunodeficiency virus disease [ICD-11: 1C60-1C62] T38301 INDICATI Approved Myeloproliferative neoplasm [ICD-11: 2A20] T38301 INDICATI Phase 2 Pancreatic cancer [ICD-11: 2C10] T38301 INDICATI Approved Solid tumour/cancer [ICD-11: 2A00-2F9Z] T38301 INDICATI Discontinued in Phase 2 Stomach cancer [ICD-11: 2B72] T38301 INDICATI Phase 2 Unspecific body region injury [ICD-11: ND56] T38338 TARGETID T38338 T38338 TARGNAME Voltage-gated calcium channel alpha Cav2.2 (CACNA1B) T38338 INDICATI Discontinued in Phase 3 Anxiety disorder [ICD-11: 6B00-6B0Z] T38338 INDICATI Phase 3 Essential hypertension [ICD-11: BA00] T38338 INDICATI Phase 3 General pain disorder [ICD-11: 8E43] T38338 INDICATI Investigative Heart failure [ICD-11: BD10-BD1Z] T38338 INDICATI Phase 1/2 Intracranial injury [ICD-11: NA07] T38338 INDICATI Approved Migraine [ICD-11: 8A80] T38338 INDICATI Approved Non-thrombocytopenic purpura [ICD-11: 3B60] T38338 INDICATI Approved Pain [ICD-11: MG30-MG3Z] T38338 INDICATI Terminated Unspecific body region injury [ICD-11: ND56] T38431 TARGETID T38431 T38431 TARGNAME Calgranulin B (S100A9) T38431 INDICATI Phase 2 Lupus erythematosus [ICD-11: 4A40] T38431 INDICATI Phase 3 Prostate cancer [ICD-11: 2C82] T38509 TARGETID T38509 T38509 TARGNAME Coagulation factor XII (F12) T38509 INDICATI Phase 3 Innate/adaptive immunodeficiency [ICD-11: 4A00] T38509 INDICATI Phase 1 Thrombosis [ICD-11: DB61-GB90] T38528 TARGETID T38528 T38528 TARGNAME AdoHcy hydrolase (SAHase) T38528 INDICATI Terminated Rheumatoid arthritis [ICD-11: FA20] T38529 TARGETID T38529 T38529 TARGNAME Prostaglandin E2 receptor EP2 (PTGER2) T38529 INDICATI Approved Abortion [ICD-11: JA00] T38529 INDICATI Discontinued in Phase 3 Arterial occlusive disease [ICD-11: BD40] T38529 INDICATI Phase 4 Coronary atherosclerosis [ICD-11: BA80] T38529 INDICATI Approved Diabetic foot ulcer [ICD-11: BD54] T38529 INDICATI Phase 1 Endometriosis [ICD-11: GA10] T38529 INDICATI Approved Glaucoma [ICD-11: 9C61] T38529 INDICATI Investigative Immune system disease [ICD-11: 4A01-4B41] T38529 INDICATI Phase 2 Low bone mass disorder [ICD-11: FB83] T38529 INDICATI Phase 3 Pemphigus [ICD-11: EB40] T38529 INDICATI Approved Pulmonary hypertension [ICD-11: BB01] T38529 INDICATI Approved Sexual dysfunction [ICD-11: HA00-HA01] T38529 INDICATI Phase 1 Solid tumour/cancer [ICD-11: 2A00-2F9Z] T38529 INDICATI Approved Transplant rejection [ICD-11: NE84] T38529 INDICATI Phase 2 Transplanted organ/tissue [ICD-11: QB63] T38763 TARGETID T38763 T38763 TARGNAME Hepatitis C virus Non-structural 5 (HCV NS5) T38763 INDICATI Phase 1/2 Hepatitis virus infection [ICD-11: 1E50-1E51] T38810 TARGETID T38810 T38810 TARGNAME Apolipoprotein A messenger RNA (LPA mRNA) T38810 INDICATI Phase 3 Cardiovascular disease [ICD-11: BA00-BE2Z] T38810 INDICATI Phase 2 Coronary atherosclerosis [ICD-11: BA80] T38810 INDICATI Phase 2 Hyperlipidemia [ICD-11: 5C80] T38810 INDICATI Phase 3 Hyper-lipoproteinaemia [ICD-11: 5C80] T38810 INDICATI Phase 2 Hyper-lipoproteinaemia ICD-11: 5C80 T38810 INDICATI Phase 2 Liver vascular disorder [ICD-11: DB98] T38875 TARGETID T38875 T38875 TARGNAME AMP-activated protein kinase (AMPK) T38875 INDICATI Phase 3 Acute diabete complication [ICD-11: 5A2Y] T38875 INDICATI Phase 2 Alopecia [ICD-11: ED70] T38875 INDICATI Investigative Breast cancer [ICD-11: 2C60-2C6Y] T38875 INDICATI Investigative Metabolic disorder [ICD-11: 5C50-5D2Z] T38875 INDICATI Phase 2 Non-alcoholic fatty liver disease [ICD-11: DB92] T38875 INDICATI Investigative Obesity [ICD-11: 5B80-5B81] T38875 INDICATI Phase 1 Solid tumour/cancer [ICD-11: 2A00-2F9Z] T38875 INDICATI Phase 2 Type 2 diabetes mellitus [ICD-11: 5A11] T38950 TARGETID T38950 T38950 TARGNAME Myeloid cell surface antigen CD33 (CD33) T38950 INDICATI Approved Acute myeloid leukaemia [ICD-11: 2A60] T38950 INDICATI Phase 1 Alzheimer disease [ICD-11: 8A20] T38950 INDICATI Phase 1/2 BCR-ABL1-negative chronic myeloid leukaemia [ICD-11: 2A41] T38950 INDICATI Phase 1 Leukaemia [ICD-11: 2A60-2B33] T38950 INDICATI Phase 1/2 Malignant haematopoietic neoplasm [ICD-11: 2B33] T38950 INDICATI Phase 1/2 Mastocytosis [ICD-11: 2A21] T38950 INDICATI Phase 1 Multiple myeloma [ICD-11: 2A83] T38950 INDICATI Phase 2 Myelodysplastic syndrome [ICD-11: 2A37] T39031 TARGETID T39031 T39031 TARGNAME Tumor antigen NGcGM3 (NGcGM3) T39031 INDICATI Phase 2 Breast cancer [ICD-11: 2C60-2C6Y] T39047 TARGETID T39047 T39047 TARGNAME Leukocyte-associated Ig-like receptor 1 (LAIR1) T39047 INDICATI Phase 1/2 Solid tumour/cancer [ICD-11: 2A00-2F9Z] T39054 TARGETID T39054 T39054 TARGNAME dUTP pyrophosphatase (DUT) T39054 INDICATI Phase 2 Lung cancer [ICD-11: 2C25] T39054 INDICATI Phase 1 Solid tumour/cancer [ICD-11: 2A00-2F9Z] T39078 TARGETID T39078 T39078 TARGNAME Calcium-activated potassium channel (KCN) T39078 INDICATI Approved Acute pain [ICD-11: MG31] T39078 INDICATI Phase 2 Alzheimer disease [ICD-11: 8A20] T39078 INDICATI Investigative Conjunctiva disorder [ICD-11: 9A60] T39078 INDICATI Approved Neurological toxicity disorder [ICD-11: 8D43] T39078 INDICATI Discontinued in Phase 2 Neutropenia [ICD-11: 4B00] T39087 TARGETID T39087 T39087 TARGNAME Human immunodeficiency virus Integrase (HIV IN) T39087 INDICATI Approved Human immunodeficiency virus disease [ICD-11: 1C60-1C62] T39123 TARGETID T39123 T39123 TARGNAME G-protein coupled receptor 54 (KISS1R) T39123 INDICATI Terminated Allergic/hypersensitivity disorder [ICD-11: 4A80-4A8Z] T39123 INDICATI Discontinued in Phase 1 Prostate cancer [ICD-11: 2C82] T39147 TARGETID T39147 T39147 TARGNAME Cytomegalovirus Terminase (CMV TRM) T39147 INDICATI Approved Cytomegaloviral disease [ICD-11: 1D82] T39147 INDICATI Terminated Virus infection [ICD-11: 1A24-1D9Z] T39231 TARGETID T39231 T39231 TARGNAME Tankyrase-1 (TNKS-1) T39231 INDICATI Phase 2 Ovarian cancer [ICD-11: 2C73] T39321 TARGETID T39321 T39321 TARGNAME Glyceraldehyde-3-phosphate dehydrogenase (GAPDH) T39321 INDICATI Phase 2 Muscular atrophy [ICD-11: 8B61] T39321 INDICATI Phase 1 Muscular dystrophy [ICD-11: 8C70] T39523 TARGETID T39523 T39523 TARGNAME Phosphodiesterase 7A (PDE7A) T39523 INDICATI Discontinued in Phase 1 Pain [ICD-11: MG30-MG3Z] T39554 TARGETID T39554 T39554 TARGNAME MAPK/ERK signaling pathway (MAPK pathway) T39554 INDICATI Phase 2 Mild neurocognitive disorder [ICD-11: 6D71] T39610 TARGETID T39610 T39610 TARGNAME Calmodulin (CALM) T39610 INDICATI Approved Cardiac arrhythmia [ICD-11: BC9Z] T39610 INDICATI Investigative Choreiform disorder [ICD-11: 8A01] T39610 INDICATI Approved Malaria [ICD-11: 1F40-1F45] T39610 INDICATI Approved Schizophrenia [ICD-11: 6A20] T39664 TARGETID T39664 T39664 TARGNAME Estradiol 17 beta-dehydrogenase (17-beta-HSD) T39664 INDICATI Terminated Low bone mass disorder [ICD-11: FB83] T39676 TARGETID T39676 T39676 TARGNAME Solute carrier family 47 member 1 (SLC47A1) T39676 INDICATI Approved Type 2 diabetes mellitus [ICD-11: 5A11] T39677 TARGETID T39677 T39677 TARGNAME Bile-salt-activated lipase (CEL) T39677 INDICATI Terminated Hyper-lipoproteinaemia [ICD-11: 5C80] T39677 INDICATI Phase 3 Pancreas disease [ICD-11: DC35-DC3Z] T39677 INDICATI Investigative Pancreatic malfunction [ICD-11: DC30-DC3Z] T39677 INDICATI Phase 1/2 Type 2 diabetes mellitus [ICD-11: 5A11] T39716 TARGETID T39716 T39716 TARGNAME Voltage-gated sodium channel alpha Nav1.5 (SCN5A) T39716 INDICATI Withdrawn from market Abnormal micturition [ICD-11: MF50] T39716 INDICATI Phase 1 Angina pectoris [ICD-11: BA40] T39716 INDICATI Approved Bacterial infection [ICD-11: 1A00-1C4Z] T39716 INDICATI Approved Cardiac arrhythmia [ICD-11: BC9Z] T39716 INDICATI Approved Corneal disease [ICD-11: 9A76-9A78] T39716 INDICATI Approved Cough [ICD-11: MD12] T39716 INDICATI Discontinued in Preregistration Dissociative neurological symptom disorder [ICD-11: 6B60] T39716 INDICATI Approved Epilepsy/seizure [ICD-11: 8A61-8A6Z] T39716 INDICATI Withdrawn from market Genetic cardiac arrhythmia [ICD-11: BC65] T39716 INDICATI Approved Migraine [ICD-11: 8A80] T39716 INDICATI Approved Pain [ICD-11: MG30-MG3Z] T39716 INDICATI Discontinued in Phase 3 Solid tumour/cancer [ICD-11: 2A00-2F9Z] T39716 INDICATI Approved Ventricular tachyarrhythmia [ICD-11: BC71] T39797 TARGETID T39797 T39797 TARGNAME Frizzled-7 receptor (FZD7) T39797 INDICATI Phase 1 Solid tumour/cancer [ICD-11: 2A00-2F9Z] T39921 TARGETID T39921 T39921 TARGNAME Heat shock protein 20 (HSP20) T39921 INDICATI Phase 2 Asthma [ICD-11: CA23] T39977 TARGETID T39977 T39977 TARGNAME Macrophage migration inhibitory factor (MIF) T39977 INDICATI Investigative Autoimmune disease [ICD-11: 4A40-4A45] T39977 INDICATI Phase 4 Diabetes mellitus [ICD-11: 5A10] T39977 INDICATI Preclinical Postoperative inflammation [ICD-11: 1A00-CA43] T39977 INDICATI Phase 4 Thrombocytopenia [ICD-11: 3B64] T39996 TARGETID T39996 T39996 TARGNAME Euchromatic histone-lysine N-methyltransferase 1 (EHMT1) T39996 INDICATI Preclinical Breast cancer [ICD-11: 2C60-2C6Y] T39996 INDICATI Preclinical Solid tumour/cancer [ICD-11: 2A00-2F9Z] T40000 TARGETID T40000 T40000 TARGNAME Tissue kallikrein (KLK1) T40000 INDICATI Investigative Respiratory system disease [ICD-11: CB40-CB7Z] T40010 TARGETID T40010 T40010 TARGNAME Epidermal growth factor-like protein 7 (EGFL7) T40010 INDICATI Phase 2 Colorectal cancer [ICD-11: 2B91] T40010 INDICATI Phase 2 Lung cancer [ICD-11: 2C25] T40016 TARGETID T40016 T40016 TARGNAME Glucocorticoid receptor (NR3C1) T40016 INDICATI Approved Adaptive immunity immunodeficiency [ICD-11: 4A01] T40016 INDICATI Phase 2 Adrenogenital disorder [ICD-11: 5A71] T40016 INDICATI Approved Allergic/hypersensitivity disorder [ICD-11: 4A80-4A8Z] T40016 INDICATI Terminated Anxiety disorder [ICD-11: 6B00-6B0Z] T40016 INDICATI Approved Asthma [ICD-11: CA23] T40016 INDICATI Phase 2 Atopic eczema [ICD-11: EA80] T40016 INDICATI Phase 2 Breast cancer [ICD-11: 2C60-2C6Y] T40016 INDICATI Approved Chronic obstructive pulmonary disease [ICD-11: CA22] T40016 INDICATI Approved Cushing syndrome [ICD-11: 5A70] T40016 INDICATI Phase 2 Depression [ICD-11: 6A70-6A7Z] T40016 INDICATI Phase 2 Eczema [ICD-11: EA80-EA89] T40016 INDICATI Phase 3 Herpes simplex infection [ICD-11: 1F00] T40016 INDICATI Phase 3 Knee osteoarthritis [ICD-11: FA01] T40016 INDICATI Phase 2 Mood disorder [ICD-11: 6A60-6E23] T40016 INDICATI Phase 2 Motor neuron disease [ICD-11: 8B60] T40016 INDICATI Phase 3 Multiple sclerosis [ICD-11: 8A40] T40016 INDICATI Approved Muscular dystrophy [ICD-11: 8C70] T40016 INDICATI Approved Oesophagitis [ICD-11: DA24] T40016 INDICATI Phase 3 Otitis externa [ICD-11: AA00-AA13] T40016 INDICATI Approved Postoperative inflammation [ICD-11: 1A00-CA43] T40016 INDICATI Phase 1 Retinopathy [ICD-11: 9B71] T40016 INDICATI Approved Rheumatoid arthritis [ICD-11: FA20] T40016 INDICATI Approved Solid tumour/cancer [ICD-11: 2A00-2F9Z] T40016 INDICATI Investigative Spine/trunk injury [ICD-11: ND51] T40016 INDICATI Phase 1 Substance abuse ICD-11: 6C40 T40016 INDICATI Clinical trial Substance abuse [ICD-11: 6C40] T40016 INDICATI Phase 2 Type 2 diabetes mellitus [ICD-11: 5A11] T40016 INDICATI Approved Vasomotor/allergic rhinitis [ICD-11: CA08] T40016 INDICATI Phase 2 Vitamin deficiency [ICD-11: 5B55-5B5F] T40045 TARGETID T40045 T40045 TARGNAME RRM1 messenger RNA (RRM1 mRNA) T40045 INDICATI Discontinued in Phase 1 Solid tumour/cancer [ICD-11: 2A00-2F9Z] T40097 TARGETID T40097 T40097 TARGNAME Stress-activated protein kinase JNK1 (JNK1) T40097 INDICATI Investigative Intracranial injury [ICD-11: NA07] T40097 INDICATI Preclinical Mature T-cell lymphoma [ICD-11: 2A90] T40097 INDICATI Phase 1 Solid tumour/cancer [ICD-11: 2A00-2F9Z] T40111 TARGETID T40111 T40111 TARGNAME Inosine-5'-monophosphate dehydrogenase 1 (IMPDH1) T40111 INDICATI Approved Breast cancer [ICD-11: 2C60-2C6Y] T40111 INDICATI Phase 4 Crohn disease [ICD-11: DD70] T40111 INDICATI Phase 2 Head and neck cancer [ICD-11: 2D42] T40111 INDICATI Approved Hepatitis virus infection [ICD-11: 1E50-1E51] T40111 INDICATI Approved Mature B-cell lymphoma [ICD-11: 2A85] T40111 INDICATI Patented Psoriasis [ICD-11: EA90] T40111 INDICATI Withdrawn from market Sensation disturbance [ICD-11: MB40] T40111 INDICATI Approved Solid tumour/cancer [ICD-11: 2A00-2F9Z] T40111 INDICATI Phase 3 Stomach cancer [ICD-11: 2B72] T40111 INDICATI Approved Transplant rejection [ICD-11: NE84] T40126 TARGETID T40126 T40126 TARGNAME Pseudomonas Kynureninase (Pseudo kynU) T40126 INDICATI Preclinical Bacterial infection [ICD-11: 1A00-1C4Z] T40149 TARGETID T40149 T40149 TARGNAME PKC-eta messenger RNA (PRKCH mRNA) T40149 INDICATI Investigative Human immunodeficiency virus disease [ICD-11: 1C60-1C62] T40160 TARGETID T40160 T40160 TARGNAME Aryl hydrocarbon receptor signaling pathway (AhR pathway) T40160 INDICATI Phase 2 Breast cancer [ICD-11: 2C60-2C6Y] T40192 TARGETID T40192 T40192 TARGNAME DNA-binding factor KBF1 (p105) T40192 INDICATI Phase 2 Muscular dystrophy [ICD-11: 8C70] T40192 INDICATI Phase 2 Solid tumour/cancer [ICD-11: 2A00-2F9Z] T40192 INDICATI Phase 1 Type 2 diabetes mellitus [ICD-11: 5A11] T40276 TARGETID T40276 T40276 TARGNAME Protein kinase C beta (PRKCB) T40276 INDICATI Phase 2 Brain cancer [ICD-11: 2A00] T40276 INDICATI Phase 1 Central nervous system disease [ICD-11: 8A04-8D87] T40276 INDICATI Phase 3 Diffuse large B-cell lymphoma [ICD-11: 2A81] T40276 INDICATI Investigative Human immunodeficiency virus disease [ICD-11: 1C60-1C62] T40276 INDICATI Phase 3 Lymphoma [ICD-11: 2A80-2A86] T40276 INDICATI Phase 3 Malignant haematopoietic neoplasm [ICD-11: 2B33] T40276 INDICATI Phase 1 Mature B-cell leukaemia [ICD-11: 2A82] T40276 INDICATI Discontinued in Phase 2 Rheumatoid arthritis [ICD-11: FA20] T40276 INDICATI Phase 2 Solid tumour/cancer [ICD-11: 2A00-2F9Z] T40276 INDICATI Phase 2 Transplant rejection [ICD-11: NE84] T40332 TARGETID T40332 T40332 TARGNAME Neutrophil elastase (NE) T40332 INDICATI Investigative Acute respiratory distress syndrome [ICD-11: CB00] T40332 INDICATI Application submitted Anterior uveitis [ICD-11: 9A96] T40332 INDICATI Discontinued in Phase 2 Atopic eczema [ICD-11: EA80] T40332 INDICATI Phase 2 Bronchiectasis [ICD-11: CA24] T40332 INDICATI Phase 2 Chronic obstructive pulmonary disease [ICD-11: CA22] T40332 INDICATI Phase 3 Crohn disease [ICD-11: DD70] T40332 INDICATI Phase 2 Cystic fibrosis [ICD-11: CA25] T40332 INDICATI Discontinued in Phase 2 Emphysema [ICD-11: CA21] T40332 INDICATI Phase 3 Hepatic fibrosis/cirrhosis [ICD-11: DB93] T40332 INDICATI Application submitted Inflammatory spondyloarthritis [ICD-11: FA92] T40332 INDICATI Investigative Injury [ICD-11: NA00-ND5Z] T40332 INDICATI Phase 4 Intrathoracic organs injury [ICD-11: NB32] T40332 INDICATI Phase 3 Multiple sclerosis [ICD-11: 8A40] T40332 INDICATI Phase 2 Myocardial infarction [ICD-11: BA41-BA43] T40332 INDICATI Discontinued in Phase 3 Phlegmy cough [ICD-11: SA80-SA8Z] T40332 INDICATI Phase 2 Pneumonia [ICD-11: CA40] T40332 INDICATI Terminated Postoperative inflammation [ICD-11: 1A00-CA43] T40332 INDICATI Phase 3 Psoriatic arthritis [ICD-11: FA21] T40332 INDICATI Investigative Pulmonary disease [ICD-11: 1B10-1F85] T40332 INDICATI Phase 3 Pyoderma gangrenosum [ICD-11: EB21] T40332 INDICATI Phase 3 Rheumatoid arthritis [ICD-11: FA20] T40332 INDICATI Investigative Sepsis [ICD-11: 1G40-1G41] T40332 INDICATI Phase 3 Ulcerative colitis [ICD-11: DD71] T40459 TARGETID T40459 T40459 TARGNAME Interleukin 13 receptor alpha-2 (IL13RA2) T40459 INDICATI Phase 1 Asthma [ICD-11: CA23] T40459 INDICATI Phase 3 Brain cancer [ICD-11: 2A00] T40459 INDICATI Phase 2 Oesophagitis [ICD-11: DA24] T40474 TARGETID T40474 T40474 TARGNAME Proto-oncogene c-Met (MET) T40474 INDICATI Phase 1/2 Alzheimer disease [ICD-11: 8A20] T40474 INDICATI Phase 2 Biliary tract cancer [ICD-11: 2C17] T40474 INDICATI Phase 1 Brain cancer [ICD-11: 2A00] T40474 INDICATI Phase 2 Breast cancer [ICD-11: 2C60-2C6Y] T40474 INDICATI Phase 2 Cardiovascular disease [ICD-11: BA00-BE2Z] T40474 INDICATI Phase 3 Chronic arterial occlusive disease [ICD-11: BD4Z] T40474 INDICATI Phase 1/2 Colorectal cancer [ICD-11: 2B91] T40474 INDICATI Phase 1/2 Fibrosis [ICD-11: GA14-GC01] T40474 INDICATI Discontinued in Phase 2 Glaucoma [ICD-11: 9C61] T40474 INDICATI Phase 1 Head and neck cancer [ICD-11: 2D42] T40474 INDICATI Phase 3 Heart disease [ICD-11: BA41-BA42] T40474 INDICATI Phase 2 Injury [ICD-11: NA00-ND5Z] T40474 INDICATI Phase 3 Liver cancer [ICD-11: 2C12] T40474 INDICATI Phase 1 Liver disease [ICD-11: DB90-DB9Z] T40474 INDICATI Approved Lung cancer [ICD-11: 2C25] T40474 INDICATI Phase 1 Melanoma [ICD-11: 2C30] T40474 INDICATI Phase 2 Metastatic lymph node neoplasm [ICD-11: 2D60] T40474 INDICATI Preclinical Nasopharyngitis [ICD-11: CA00] T40474 INDICATI Approved Non-small-cell lung cancer [ICD-11: 2C25] T40474 INDICATI Phase 2 Ovarian cancer [ICD-11: 2C73] T40474 INDICATI Phase 3 Renal cell carcinoma [ICD-11: 2C90] T40474 INDICATI Phase 2 Sarcoma [ICD-11: 2A60-2C35] T40474 INDICATI Phase 3 Solid tumour/cancer [ICD-11: 2A00-2F9Z] T40474 INDICATI Phase 3 Stomach cancer [ICD-11: 2B72] T40474 INDICATI Approved Thyroid cancer [ICD-11: 2D10] T40490 TARGETID T40490 T40490 TARGNAME Natural cytotoxic triggering receptor 1 (NCR1) T40490 INDICATI Phase 1 Acute myeloid leukaemia [ICD-11: 2A60] T40491 TARGETID T40491 T40491 TARGNAME Serine/threonine PP2A-alpha (PPP2CA) T40491 INDICATI Phase 2 Brain cancer [ICD-11: 2A00] T40491 INDICATI Phase 2 Common warts [ICD-11: 1E80] T40491 INDICATI Phase 3 Molluscum contagiosum [ICD-11: 1E76] T40491 INDICATI Phase 1 Solid tumour/cancer [ICD-11: 2A00-2F9Z] T40492 TARGETID T40492 T40492 TARGNAME Hepatitis C virus NS3 helicase (HCV NS3) T40492 INDICATI Approved Hepatitis virus infection [ICD-11: 1E50-1E51] T40492 INDICATI Investigative Human immunodeficiency virus disease [ICD-11: 1C60-1C62] T40555 TARGETID T40555 T40555 TARGNAME Hepatitis C virus Non-structural 5A (HCV NS5A) T40555 INDICATI Approved Hepatitis virus infection [ICD-11: 1E50-1E51] T40556 TARGETID T40556 T40556 TARGNAME Bromodomain-containing protein 4 (BRD4) T40556 INDICATI Phase 1/2 Acute myeloid leukaemia [ICD-11: 2A60] T40556 INDICATI Phase 1/2 Alzheimer disease [ICD-11: 8A20] T40556 INDICATI Phase 1 Malignant haematopoietic neoplasm [ICD-11: 2B33] T40556 INDICATI Phase 1 Myelodysplastic syndrome [ICD-11: 2A37] T40556 INDICATI Phase 3 Myeloproliferative neoplasm [ICD-11: 2A20] T40556 INDICATI Phase 1 Prostate cancer [ICD-11: 2C82] T40556 INDICATI Phase 1/2 Solid tumour/cancer [ICD-11: 2A00-2F9Z] T40556 INDICATI Phase 1 Testicular cancer [ICD-11: 2C80] T40628 TARGETID T40628 T40628 TARGNAME Hydroxysteroid dehydrogenase 3-beta (HSD3B) T40628 INDICATI Investigative Abortion [ICD-11: JA00] T40663 TARGETID T40663 T40663 TARGNAME Regulatory protein unspecific (RGP) T40663 INDICATI Phase 1/2 Diabetes mellitus [ICD-11: 5A10] T40663 INDICATI Phase 3 Graft-versus-host disease [ICD-11: 4B24] T40663 INDICATI Terminated Transplanted organ/tissue [ICD-11: QB63] T40694 TARGETID T40694 T40694 TARGNAME Polo-like kinase 1 (PLK1) T40694 INDICATI Phase 3 Acute myeloid leukaemia [ICD-11: 2A60] T40694 INDICATI Investigative Lymphoma [ICD-11: 2A80-2A86] T40694 INDICATI Phase 1 Malignant haematopoietic neoplasm [ICD-11: 2B33] T40694 INDICATI Phase 3 Myelodysplastic syndrome [ICD-11: 2A37] T40694 INDICATI Investigative Nasopharyngeal cancer [ICD-11: 2B6B] T40694 INDICATI Discontinued in Phase 1 Pancreatic cancer [ICD-11: 2C10] T40694 INDICATI Phase 2 Prostate cancer [ICD-11: 2C82] T40694 INDICATI Phase 3 Solid tumour/cancer [ICD-11: 2A00-2F9Z] T40696 TARGETID T40696 T40696 TARGNAME Staphylococcus Topoisomerase IV (Stap-coc parC) T40696 INDICATI Phase 1 Acute upper respiratory infection [ICD-11: CA07] T40696 INDICATI Phase 3 Anaerobic bacterial infection [ICD-11: 1A00-1A09] T40696 INDICATI Approved Bacterial infection [ICD-11: 1A00-1C4Z] T40696 INDICATI Phase 2 Cystic fibrosis [ICD-11: CA25] T40696 INDICATI Phase 1 Digestive organ benign neoplasm [ICD-11: 2E92] T40696 INDICATI Approved Glaucoma [ICD-11: 9C61] T40696 INDICATI Approved Gram-positive bacterial infection [ICD-11: 1B74-1F40] T40696 INDICATI Approved Impetigo [ICD-11: 1B72] T40696 INDICATI Phase 2 Infectious meningitis [ICD-11: 1D01] T40696 INDICATI Phase 3 Pneumonia [ICD-11: CA40] T40696 INDICATI Approved Respiratory infection [ICD-11: CA07-CA4Z] T40696 INDICATI Approved Skin and skin-structure infection [ICD-11: 1F28-1G0Z] T40696 INDICATI Approved Urinary tract infection [ICD-11: GC08] T40730 TARGETID T40730 T40730 TARGNAME Bacterial Dihydroneopterinaldolase (Bact folB) T40730 INDICATI Discontinued in Phase 3 Virus infection [ICD-11: 1A24-1D9Z] T40785 TARGETID T40785 T40785 TARGNAME Fungal Papulacandin B resistance protein 1 (Fung FKS1) T40785 INDICATI Terminated Candidosis [ICD-11: 1F23] T40785 INDICATI Phase 3 Fungal infection [ICD-11: 1F29-1F2F] T40787 TARGETID T40787 T40787 TARGNAME S-methyl-5'-thioadenosine phosphorylase (MTAP) T40787 INDICATI Terminated Multiple sclerosis [ICD-11: 8A40] T40800 TARGETID T40800 T40800 TARGNAME Sodium pump subunit alpha-1 (ATP1A1) T40800 INDICATI Approved Cardiac arrhythmia [ICD-11: BC9Z] T40800 INDICATI Approved Chronic obstructive pulmonary disease [ICD-11: CA22] T40800 INDICATI Approved Corneal disease [ICD-11: 9A76-9A78] T40800 INDICATI Approved Heart failure [ICD-11: BD10-BD1Z] T40800 INDICATI Approved Hyperhidrosis [ICD-11: EE00] T40800 INDICATI Approved Malaria [ICD-11: 1F40-1F45] T40800 INDICATI Phase 1 Solid tumour/cancer [ICD-11: 2A00-2F9Z] T40800 INDICATI Approved Supraventricular tachyarrhythmia [ICD-11: BC81] T40812 TARGETID T40812 T40812 TARGNAME Poly [ADP-ribose] polymerase 2 (PARP2) T40812 INDICATI Phase 2 Ovarian cancer [ICD-11: 2C73] T40812 INDICATI Phase 1/2 Solid tumour/cancer [ICD-11: 2A00-2F9Z] T40874 TARGETID T40874 T40874 TARGNAME V-set and immunoglobulin domain-containing protein 9 (TIGIT) T40874 INDICATI Phase 2 Cervical cancer [ICD-11: 2C77] T40874 INDICATI Phase 3 Lung cancer [ICD-11: 2C25] T40874 INDICATI Phase 3 Non-small-cell lung cancer [ICD-11: 2C25] T40874 INDICATI Phase 2 Solid tumour/cancer [ICD-11: 2A00-2F9Z] T40909 TARGETID T40909 T40909 TARGNAME Rhinovirus Protease 3C (HRV P3C) T40909 INDICATI Phase 2 Virus infection [ICD-11: 1A24-1D9Z] T40954 TARGETID T40954 T40954 TARGNAME Xanthine dehydrogenase/oxidase (XDH) T40954 INDICATI Phase 2 Chronic kidney disease [ICD-11: GB61] T40954 INDICATI Phase 2 Encephalopathy [ICD-11: 8E47] T40954 INDICATI Phase 2 Gout [ICD-11: FA25] T40954 INDICATI Phase 2/3 Heart failure [ICD-11: BD10-BD1Z] T40954 INDICATI Approved Inborn purine/pyrimidine/nucleotide metabolism error [ICD-11: 5C55] T40954 INDICATI Phase 2 Influenza [ICD-11: 1E30-1E32] T40954 INDICATI Approved Mineral deficiency [ICD-11: 5B5K] T40954 INDICATI Phase 3 Solid tumour/cancer [ICD-11: 2A00-2F9Z] T41003 TARGETID T41003 T41003 TARGNAME HIF2-alpha messenger RNA (EPAS1 mRNA) T41003 INDICATI Phase 2 Adrenomedullary hyperfunction [ICD-11: 5A75] T41003 INDICATI Phase 2 Brain cancer [ICD-11: 2A00] T41003 INDICATI Phase 1 Renal cell carcinoma [ICD-11: 2C90] T41141 TARGETID T41141 T41141 TARGNAME Cathepsin L (CTSL) T41141 INDICATI Patented Alopecia [ICD-11: ED70] T41141 INDICATI Preclinical Alzheimer disease [ICD-11: 8A20] T41141 INDICATI Patented Aneurysm/dissection [ICD-11: BD50] T41141 INDICATI Investigative Asthma [ICD-11: CA23] T41141 INDICATI Patented Bone cancer [ICD-11: 2B5Z] T41141 INDICATI Patented Brain cancer [ICD-11: 2A00] T41141 INDICATI Patented Chronic obstructive pulmonary disease [ICD-11: CA22] T41141 INDICATI Patented Chronic pain [ICD-11: MG30] T41141 INDICATI Clinical trial Coagulation defect [ICD-11: 3B10] T41141 INDICATI Patented Coronavirus infection [ICD-11: 1D92] T41141 INDICATI Patented Digestive system disease [ICD-11: DE2Z] T41141 INDICATI Patented Henipavirus encephalitis [ICD-11: 1D63] T41141 INDICATI Patented Hepatic fibrosis/cirrhosis [ICD-11: DB93] T41141 INDICATI Patented Multiple sclerosis [ICD-11: 8A40] T41141 INDICATI Preclinical Osteoarthritis [ICD-11: FA00-FA05] T41141 INDICATI Patented Psoriasis [ICD-11: EA90] T41141 INDICATI Patented Rheumatoid arthritis [ICD-11: FA20] T41141 INDICATI Patented Solid tumour/cancer [ICD-11: 2A00-2F9Z] T41171 TARGETID T41171 T41171 TARGNAME Interleukin-27 (IL27) T41171 INDICATI Phase 1 Liver cancer [ICD-11: 2C12] T41171 INDICATI Phase 1 Solid tumour/cancer [ICD-11: 2A00-2F9Z] T41201 TARGETID T41201 T41201 TARGNAME Dehydropeptidase I (DPEP1) T41201 INDICATI Approved Bacterial infection [ICD-11: 1A00-1C4Z] T41202 TARGETID T41202 T41202 TARGNAME microRNA hsa-miR-29b (MIR29b) T41202 INDICATI Phase 2 Keloid/hypertrophic scar [ICD-11: EE60] T41239 TARGETID T41239 T41239 TARGNAME Hydroxyapatite (HA) T41239 INDICATI Phase 3 Calcific uremic arteriolopathy [ICD-11: EB90] T41263 TARGETID T41263 T41263 TARGNAME Taste receptor (TASR) T41263 INDICATI Approved Cholera [ICD-11: 1A00] T41380 TARGETID T41380 T41380 TARGNAME Transforming growth factor beta activator LRRC32 (LRRC32) T41380 INDICATI Phase 1 Solid tumour/cancer [ICD-11: 2A00-2F9Z] T41515 TARGETID T41515 T41515 TARGNAME FGFR4 messenger RNA (FGFR4 mRNA) T41515 INDICATI Phase 1/2 Liver cancer [ICD-11: 2C12] T41515 INDICATI Phase 2 Obesity [ICD-11: 5B80-5B81] T41515 INDICATI Terminated Retina cancer [ICD-11: 2D02] T41515 INDICATI Phase 1/2 Solid tumour/cancer [ICD-11: 2A00-2F9Z] T41560 TARGETID T41560 T41560 TARGNAME EGFR messenger RNA (EGFR mRNA) T41560 INDICATI Phase 1/2 Head and neck cancer [ICD-11: 2D42] T41560 INDICATI Phase 3 Lung cancer [ICD-11: 2C25] T41560 INDICATI Phase 1 Solid tumour/cancer [ICD-11: 2A00-2F9Z] T41580 TARGETID T41580 T41580 TARGNAME Adrenergic receptor alpha-2B (ADRA2B) T41580 INDICATI Phase 2 General pain disorder [ICD-11: 8E43] T41580 INDICATI Terminated Genetic cardiac arrhythmia [ICD-11: BC65] T41580 INDICATI Withdrawn from market Hypertension [ICD-11: BA00-BA04] T41580 INDICATI Phase 2 Pain [ICD-11: MG30-MG3Z] T41580 INDICATI Approved Substance abuse [ICD-11: 6C40] T41597 TARGETID T41597 T41597 TARGNAME DGAT2 messenger RNA (DGAT2 mRNA) T41597 INDICATI Phase 1 Non-alcoholic fatty liver disease [ICD-11: DB92] T41750 TARGETID T41750 T41750 TARGNAME Gastric inhibitory polypeptide receptor (GIPR) T41750 INDICATI Phase 3 Obesity [ICD-11: 5B80-5B81] T41750 INDICATI Approved Type 2 diabetes mellitus [ICD-11: 5A11] T41756 TARGETID T41756 T41756 TARGNAME BV virus Major capsid protein VP1 (BKV VP1) T41756 INDICATI Phase 1 Viral encephalitis [ICD-11: 1C80] T41820 TARGETID T41820 T41820 TARGNAME Fungal Isoleucyl t-RNA synthetase (Fung ILS1) T41820 INDICATI Terminated Bacterial infection [ICD-11: 1A00-1C4Z] T41820 INDICATI Phase 2 Fungal infection [ICD-11: 1F29-1F2F] T41955 TARGETID T41955 T41955 TARGNAME Long transient receptor potential channel 8 (TRPM8) T41955 INDICATI Investigative General pain disorder [ICD-11: 8E43] T41955 INDICATI Phase 1 Pain [ICD-11: MG30-MG3Z] T41955 INDICATI Phase 1 Solid tumour/cancer [ICD-11: 2A00-2F9Z] T41955 INDICATI Approved Upper respiratory tract disorder [ICD-11: CA0Z] T41963 TARGETID T41963 T41963 TARGNAME Toll-like receptor (TLR) T41963 INDICATI Phase 1 Autoimmune disease [ICD-11: 4A40-4A45] T41963 INDICATI Phase 1/2 Diffuse large B-cell lymphoma [ICD-11: 2A81] T41963 INDICATI Discontinued in Phase 2 Immune system disease [ICD-11: 4A01-4B41] T41963 INDICATI Phase 2 Lung cancer [ICD-11: 2C25] T41963 INDICATI Patented Malaria [ICD-11: 1F40-1F45] T41963 INDICATI Phase 1/2 Mature B-cell lymphoma [ICD-11: 2A85] T41963 INDICATI Phase 1 Prostate cancer [ICD-11: 2C82] T41963 INDICATI Phase 2 Rheumatoid arthritis [ICD-11: FA20] T41963 INDICATI Phase 2 Solid tumour/cancer [ICD-11: 2A00-2F9Z] T42000 TARGETID T42000 T42000 TARGNAME Interleukin-1 beta (IL1B) T42000 INDICATI Phase 1 Alzheimer disease [ICD-11: 8A20] T42000 INDICATI Phase 2 Cardiovascular disease [ICD-11: BA00-BE2Z] T42000 INDICATI Phase 3 Gout [ICD-11: FA25] T42000 INDICATI Discontinued in Phase 1/2 Immune system disease [ICD-11: 4A01-4B41] T42000 INDICATI Approved Mineral excesses [ICD-11: 5B91] T42000 INDICATI Approved Monogenic autoinflammatory syndrome [ICD-11: 4A60] T42000 INDICATI Preclinical Motor neuron disease [ICD-11: 8B60] T42000 INDICATI Approved Osteoarthritis [ICD-11: FA00-FA05] T42000 INDICATI Phase 1 Postoperative inflammation [ICD-11: 1A00-CA43] T42000 INDICATI Approved Rheumatoid arthritis [ICD-11: FA20] T42000 INDICATI Investigative Solid tumour/cancer [ICD-11: 2A00-2F9Z] T42000 INDICATI Phase 3 Type 2 diabetes mellitus [ICD-11: 5A11] T42000 INDICATI Phase 2 Urticaria [ICD-11: EB00-EB05] T42000 INDICATI Phase 2 Vasculitis [ICD-11: 4A44] T42048 TARGETID T42048 T42048 TARGNAME Bromodomain-containing protein 3 (BRD3) T42048 INDICATI Phase 1 Acute myeloid leukaemia [ICD-11: 2A60] T42048 INDICATI Phase 1 Prostate cancer [ICD-11: 2C82] T42065 TARGETID T42065 T42065 TARGNAME N-acetylmannosamine kinase (GNE) T42065 INDICATI Phase 1 Muscle disorder [ICD-11: FB32-FB3Z] T42157 TARGETID T42157 T42157 TARGNAME SPS1/STE20-related protein kinase YSK4 (YSK4) T42157 INDICATI Phase 1 Breast cancer [ICD-11: 2C60-2C6Y] T42354 TARGETID T42354 T42354 TARGNAME Bacterial RNA polymerase sigma factor SigA (Bact sigA) T42354 INDICATI Approved Bowel habit change [ICD-11: ME05] T42354 INDICATI Phase 3 Postoperative inflammation [ICD-11: 1A00-CA43] T42392 TARGETID T42392 T42392 TARGNAME Glutamate receptor AMPA 2 (GRIA2) T42392 INDICATI Approved Neuropathy [ICD-11: 8C0Z] T42392 INDICATI Phase 2 Parkinsonism [ICD-11: 8A00] T42446 TARGETID T42446 T42446 TARGNAME Gamma-aminobutyric acid B receptor (GABBR) T42446 INDICATI Investigative Anxiety disorder [ICD-11: 6B00-6B0Z] T42446 INDICATI Phase 2 Autism spectrum disorder [ICD-11: 6A02] T42446 INDICATI Phase 2 Chronic pain [ICD-11: MG30] T42446 INDICATI Approved Depression [ICD-11: 6A70-6A7Z] T42446 INDICATI Approved Epilepsy/seizure [ICD-11: 8A61-8A6Z] T42446 INDICATI Phase 3 Fragile X chromosome [ICD-11: LD55] T42446 INDICATI Discontinued in Phase 2 Gastro-oesophageal reflux disease [ICD-11: DA22] T42446 INDICATI Phase 2 Indeterminate colitis [ICD-11: DD72] T42446 INDICATI Approved Multiple sclerosis [ICD-11: 8A40] T42446 INDICATI Approved Narcolepsy [ICD-11: 7A20] T42446 INDICATI Discontinued in Phase 3 Newborn muscle tone disorder [ICD-11: KB08] T42446 INDICATI Investigative Nicotine use disorder [ICD-11: 6C4A] T42446 INDICATI Investigative Pain [ICD-11: MG30-MG3Z] T42446 INDICATI Investigative Psychoactive substances use disorder [ICD-11: 6C4G] T42446 INDICATI Phase 2 Schizophrenia [ICD-11: 6A20] T42446 INDICATI Phase 3 Solid tumour/cancer [ICD-11: 2A00-2F9Z] T42446 INDICATI Phase 2 Substance abuse [ICD-11: 6C40] T42521 TARGETID T42521 T42521 TARGNAME Bacterial Shiga toxin 2 subunit B (Bact stxII) T42521 INDICATI Phase 3 Bacterial infection [ICD-11: 1A00-1C4Z] T42521 INDICATI Phase 2 Haemolytic anemia [ICD-11: 3A20-3A2Z] T42658 TARGETID T42658 T42658 TARGNAME Herpesvirus ubiquitin-specific protease (HAUSP) T42658 INDICATI Preclinical Postoperative inflammation [ICD-11: 1A00-CA43] T42658 INDICATI Preclinical Solid tumour/cancer [ICD-11: 2A00-2F9Z] T42724 TARGETID T42724 T42724 TARGNAME Calcium-activated potassium channel KCa3.1 (KCNN4) T42724 INDICATI Phase 2 Alzheimer disease [ICD-11: 8A20] T42724 INDICATI Phase 2 Chronic pain [ICD-11: MG30] T42724 INDICATI Investigative Conjunctiva disorder [ICD-11: 9A60] T42724 INDICATI Discontinued in Phase 2 Neutropenia [ICD-11: 4B00] T42748 TARGETID T42748 T42748 TARGNAME Serotoninnorepinephrinedopamine reuptake (SNDR) T42748 INDICATI Phase 1 Alzheimer disease [ICD-11: 8A20] T42748 INDICATI Approved Attention deficit hyperactivity disorder [ICD-11: 6A05] T42748 INDICATI Phase 3 Binge eating disorder [ICD-11: 6B82] T42748 INDICATI Phase 1 Bipolar disorder [ICD-11: 6A60] T42748 INDICATI Approved Depression [ICD-11: 6A70-6A7Z] T42748 INDICATI Phase 1 Idiopathic interstitial pneumonitis [ICD-11: CB03] T42748 INDICATI Phase 3 Mood disorder [ICD-11: 6A60-6E23] T42748 INDICATI Phase 1 Parkinsonism [ICD-11: 8A00] T42748 INDICATI Phase 1 Pulmonary hypertension [ICD-11: BB01] T42748 INDICATI Phase 2 Schizophrenia [ICD-11: 6A20] T42760 TARGETID T42760 T42760 TARGNAME Ribosomal protein S6 kinase beta-2 (RPS6KB2) T42760 INDICATI Phase 1 Breast cancer [ICD-11: 2C60-2C6Y] T42822 TARGETID T42822 T42822 TARGNAME Ferrochelatase (FECH) T42822 INDICATI Approved Acne vulgaris [ICD-11: ED80] T42822 INDICATI Approved Peroxisomal disease [ICD-11: 5C57] T42822 INDICATI Approved Synthesis disorder [ICD-11: 5C52-5C59] T42854 TARGETID T42854 T42854 TARGNAME Melanoma-associated antigen 1 (MAGEA1) T42854 INDICATI Phase 1/2 Lung cancer [ICD-11: 2C25] T42854 INDICATI Discontinued in Phase 2 Melanoma [ICD-11: 2C30] T42882 TARGETID T42882 T42882 TARGNAME Pseudomonas Psl exopolysaccharide (Pseudo pslG) T42882 INDICATI Phase 1 Glanders [ICD-11: 1B92] T42882 INDICATI Phase 2 Medical/surgical procedure injury [ICD-11: PK80-PK81] T42928 TARGETID T42928 T42928 TARGNAME Fibroblast growth factor-21 (FGF21) T42928 INDICATI Phase 3 Hyper-lipoproteinaemia [ICD-11: 5C80] T42928 INDICATI Phase 2 Type 2 diabetes mellitus [ICD-11: 5A11] T42974 TARGETID T42974 T42974 TARGNAME AXL receptor tyrosine kinase ligand (GAS6) T42974 INDICATI Phase 3 Ovarian cancer [ICD-11: 2C73] T42974 INDICATI Phase 2 Urinary system clinical sympton [ICD-11: MF8Y] T43025 TARGETID T43025 T43025 TARGNAME Alpha-crystallin (CRYA) T43025 INDICATI Preclinical Mycobacterium infection [ICD-11: 1B10-1B21] T43115 TARGETID T43115 T43115 TARGNAME Leukocyte common antigen (PTPRC) T43115 INDICATI Phase 3 Acute myeloid leukaemia [ICD-11: 2A60] T43115 INDICATI Phase 1 Diffuse large B-cell lymphoma [ICD-11: 2A81] T43115 INDICATI Phase 2 Leukaemia [ICD-11: 2A60-2B33] T43115 INDICATI Phase 1 Lymphoma [ICD-11: 2A80-2A86] T43115 INDICATI Phase 1 Malignant haematopoietic neoplasm [ICD-11: 2B33] T43115 INDICATI Terminated Pain [ICD-11: MG30-MG3Z] T43115 INDICATI Phase 1 Transplant rejection [ICD-11: NE84] T43115 INDICATI Phase 3 Transplanted organ/tissue [ICD-11: QB63] T43189 TARGETID T43189 T43189 TARGNAME Tubulin (TUB) T43189 INDICATI Discontinued in Phase 3 Bladder cancer [ICD-11: 2C94] T43189 INDICATI Phase 1 Brain cancer [ICD-11: 2A00] T43189 INDICATI Approved Breast cancer [ICD-11: 2C60-2C6Y] T43189 INDICATI Investigative Central nervous system disease [ICD-11: 8A04-8D87] T43189 INDICATI Phase 1 Epidermal dysplasias [ICD-11: EK90] T43189 INDICATI Approved Gout [ICD-11: FA25] T43189 INDICATI Discontinued in Phase 1 Immune system disease [ICD-11: 4A01-4B41] T43189 INDICATI Phase 3 Ovarian cancer [ICD-11: 2C73] T43189 INDICATI Discontinued in Phase 3 Pancreatic cancer [ICD-11: 2C10] T43189 INDICATI Phase 2 Sarcoma [ICD-11: 2A60-2C35] T43189 INDICATI Approved Solid tumour/cancer [ICD-11: 2A00-2F9Z] T43206 TARGETID T43206 T43206 TARGNAME Nuclear receptor ROR-alpha (RORA) T43206 INDICATI Preclinical Liver cancer [ICD-11: 2C12] T43206 INDICATI Preclinical Type 2 diabetes mellitus [ICD-11: 5A11] T43332 TARGETID T43332 T43332 TARGNAME Coagulation factor VII (F7) T43332 INDICATI Phase 3 Bleeding disorder [ICD-11: GA20-GA21] T43332 INDICATI Investigative Christmas disease [ICD-11: 3B11] T43332 INDICATI Approved Coagulation defect [ICD-11: 3B10] T43332 INDICATI Discontinued in Phase 2 Colorectal cancer [ICD-11: 2B91] T43332 INDICATI Phase 1/2 Inherited coagulation factor deficiency [ICD-11: 3B14] T43415 TARGETID T43415 T43415 TARGNAME Tyrosine-protein kinase (PTK) T43415 INDICATI Phase 2 Acquired hypomelanotic disorder [ICD-11: ED63] T43415 INDICATI Terminated Acute diabete complication [ICD-11: 5A2Y] T43415 INDICATI Phase 2 Asthma [ICD-11: CA23] T43415 INDICATI Phase 2 Atopic eczema [ICD-11: EA80] T43415 INDICATI Phase 2 Brain cancer [ICD-11: 2A00] T43415 INDICATI Phase 2 Cystic/dysplastic kidney disease [ICD-11: GB8Y] T43415 INDICATI Phase 2 Eczema [ICD-11: EA80-EA89] T43415 INDICATI Phase 3 Gastrointestinal stromal tumour [ICD-11: 2B5B] T43415 INDICATI Discontinued in Phase 1 Human immunodeficiency virus disease [ICD-11: 1C60-1C62] T43415 INDICATI Terminated Low bone mass disorder [ICD-11: FB83] T43415 INDICATI Phase 2 Lung cancer [ICD-11: 2C25] T43415 INDICATI Phase 3 Metastatic digestive system neoplasm [ICD-11: 2D8Y] T43415 INDICATI Phase 2 Metastatic meninges neoplasm [ICD-11: 2D51] T43415 INDICATI Phase 2 Metastatic tumour [ICD-11: 2D50-2E2Z] T43415 INDICATI Phase 3 Motor neuron disease [ICD-11: 8B60] T43415 INDICATI Phase 3 Multiple sclerosis [ICD-11: 8A40] T43415 INDICATI Phase 3 Ovarian cancer [ICD-11: 2C73] T43415 INDICATI Phase 3 Pancreatic cancer [ICD-11: 2C10] T43415 INDICATI Phase 3 Psoriasis [ICD-11: EA90] T43415 INDICATI Approved Rheumatoid arthritis [ICD-11: FA20] T43415 INDICATI Phase 1 Ulcerative colitis [ICD-11: DD71] T43658 TARGETID T43658 T43658 TARGNAME HAO1 messenger RNA (HAO1 mRNA) T43658 INDICATI Approved Inborn carbohydrate metabolism error [ICD-11: 5C51] T43718 TARGETID T43718 T43718 TARGNAME Toll-like receptor 5 (TLR5) T43718 INDICATI Phase 1 Colorectal cancer [ICD-11: 2B91] T43718 INDICATI Phase 2 Radiation effect [ICD-11: NF00] T43718 INDICATI Phase 1 Solid tumour/cancer [ICD-11: 2A00-2F9Z] T43721 TARGETID T43721 T43721 TARGNAME Corticosteroid 11-beta-dehydrogenase 2 (HSD11B2) T43721 INDICATI Phase 2 Type 2 diabetes mellitus [ICD-11: 5A11] T43739 TARGETID T43739 T43739 TARGNAME Voltage-gated sodium channel alpha Nav1.8 (SCN10A) T43739 INDICATI Discontinued in Phase 2 Asthma [ICD-11: CA23] T43739 INDICATI Phase 2 Colorectal cancer [ICD-11: 2B91] T43739 INDICATI Approved Corneal disease [ICD-11: 9A76-9A78] T43739 INDICATI Discontinued in Phase 2 Dissociative neurological symptom disorder [ICD-11: 6B60] T43739 INDICATI Phase 2 General pain disorder [ICD-11: 8E43] T43739 INDICATI Approved Human immunodeficiency virus disease [ICD-11: 1C60-1C62] T43739 INDICATI Phase 2 Pain [ICD-11: MG30-MG3Z] T43739 INDICATI Approved Sensation disturbance [ICD-11: MB40] T43739 INDICATI Approved Substance abuse [ICD-11: 6C40] T43760 TARGETID T43760 T43760 TARGNAME Thyroid hormone receptor (THR) T43760 INDICATI Phase 1 Dementia [ICD-11: 6D80-6D8Z] T43760 INDICATI Phase 1 Dyslipidemia [ICD-11: 5C80-5C81] T43760 INDICATI Terminated Inborn lipid metabolism error [ICD-11: 5C52] T43760 INDICATI Phase 1 Schizophrenia [ICD-11: 6A20] T43760 INDICATI Phase 1 Solid tumour/cancer [ICD-11: 2A00-2F9Z] T43902 TARGETID T43902 T43902 TARGNAME Histamine release (His rele) T43902 INDICATI Phase 1 Asthma [ICD-11: CA23] T43920 TARGETID T43920 T43920 TARGNAME Carbonic anhydrase (CA) T43920 INDICATI Approved Bacterial infection [ICD-11: 1A00-1C4Z] T43920 INDICATI Phase 2 Breast cancer [ICD-11: 2C60-2C6Y] T43920 INDICATI Patented Cas mediated disorder [ICD-11: N.A.] T43920 INDICATI Approved Hypertension [ICD-11: BA00-BA04] T43920 INDICATI Phase 3 Obesity [ICD-11: 5B80-5B81] T43920 INDICATI Approved Seborrhoeic dermatitis [ICD-11: EA81] T43920 INDICATI Phase 3 Solid tumour/cancer [ICD-11: 2A00-2F9Z] T43980 TARGETID T43980 T43980 TARGNAME Ig-like domain-containing receptor 2 (ILDR2) T43980 INDICATI Phase 1 Solid tumour/cancer [ICD-11: 2A00-2F9Z] T44008 TARGETID T44008 T44008 TARGNAME cAMP formation (cAMP form) T44008 INDICATI Phase 2 Mild neurocognitive disorder [ICD-11: 6D71] T44057 TARGETID T44057 T44057 TARGNAME Aquaporin-1 (AQP1) T44057 INDICATI Phase 1/2 Lips/oral mucosa miscellaneous disorder [ICD-11: DA02] T44068 TARGETID T44068 T44068 TARGNAME Adrenergic receptor beta-1 (ADRB1) T44068 INDICATI Phase 2 Acute diabete complication [ICD-11: 5A2Y] T44068 INDICATI Approved Allergic/hypersensitivity disorder [ICD-11: 4A80-4A8Z] T44068 INDICATI Terminated Angina pectoris [ICD-11: BA40] T44068 INDICATI Approved Asthma [ICD-11: CA23] T44068 INDICATI Approved Cardiac arrhythmia [ICD-11: BC9Z] T44068 INDICATI Approved Central and peripheral nervous disease [ICD-11: 8A04-8E7Z] T44068 INDICATI Approved Circulatory system disease [ICD-11: BE2Z] T44068 INDICATI Approved Conduction disorder [ICD-11: BC63] T44068 INDICATI Approved Coronary atherosclerosis [ICD-11: BA80] T44068 INDICATI Phase 1/2 Diabetic foot ulcer [ICD-11: BD54] T44068 INDICATI Approved Essential hypertension [ICD-11: BA00] T44068 INDICATI Withdrawn from market Genetic cardiac arrhythmia [ICD-11: BC65] T44068 INDICATI Approved Glaucoma [ICD-11: 9C61] T44068 INDICATI Approved Heart failure [ICD-11: BD10-BD1Z] T44068 INDICATI Approved Hypertension [ICD-11: BA00-BA04] T44068 INDICATI Phase 1 Melanoma [ICD-11: 2C30] T44068 INDICATI Approved Migraine [ICD-11: 8A80] T44068 INDICATI Phase 1 Obesity [ICD-11: 5B80-5B81] T44068 INDICATI Approved Sepsis [ICD-11: 1G40-1G41] T44068 INDICATI Approved Supraventricular tachyarrhythmia [ICD-11: BC81] T44068 INDICATI Approved Ventricular tachyarrhythmia [ICD-11: BC71] T44141 TARGETID T44141 T44141 TARGNAME Angiopoietin-1 (ANGPT1) T44141 INDICATI Phase 2 Alzheimer disease [ICD-11: 8A20] T44141 INDICATI Discontinued in Phase 2 Asthma [ICD-11: CA23] T44141 INDICATI Phase 3 Breast cancer [ICD-11: 2C60-2C6Y] T44141 INDICATI Phase 3 General pain disorder [ICD-11: 8E43] T44141 INDICATI Phase 3 Ovarian cancer [ICD-11: 2C73] T44141 INDICATI Phase 2 Renal cell carcinoma [ICD-11: 2C90] T44141 INDICATI Preclinical Sexual dysfunction [ICD-11: HA00-HA01] T44141 INDICATI Phase 1 Solid tumour/cancer [ICD-11: 2A00-2F9Z] T44282 TARGETID T44282 T44282 TARGNAME Mitochondrial aldehyde dehydrogenase (ALDH2) T44282 INDICATI Phase 1 Cardiovascular disease [ICD-11: BA00-BE2Z] T44282 INDICATI Phase 2 Cerebral ischaemia [ICD-11: 8B1Z] T44282 INDICATI Investigative Substance abuse [ICD-11: 6C40] T44282 INDICATI Phase 1 Unspecific substance use disorder [ICD-11: 6C4Z] T44351 TARGETID T44351 T44351 TARGNAME Cannabinoid receptor (CB) T44351 INDICATI Approved Epilepsy/seizure [ICD-11: 8A61-8A6Z] T44351 INDICATI Approved Epileptic encephalopathy [ICD-11: 8A62] T44351 INDICATI Phase 3 Tic disorder [ICD-11: 8A05] T44458 TARGETID T44458 T44458 TARGNAME Cyclin-dependent kinase 9 (CDK9) T44458 INDICATI Phase 2 Acute myeloid leukaemia [ICD-11: 2A60] T44458 INDICATI Discontinued in Phase 2 Lung cancer [ICD-11: 2C25] T44458 INDICATI Phase 1 Lymphoma [ICD-11: 2A80-2A86] T44458 INDICATI Phase 1 Malignant haematopoietic neoplasm [ICD-11: 2B33] T44458 INDICATI Phase 1 Mature B-cell leukaemia [ICD-11: 2A82] T44458 INDICATI Phase 2 Mature B-cell lymphoma [ICD-11: 2A85] T44458 INDICATI Phase 1 Non-alcoholic fatty liver disease [ICD-11: DB92] T44458 INDICATI Phase 1 Solid tumour/cancer [ICD-11: 2A00-2F9Z] T44479 TARGETID T44479 T44479 TARGNAME Gap junction alpha-1 protein (GJA1) T44479 INDICATI Phase 3 Diabetic foot ulcer [ICD-11: BD54] T44479 INDICATI Phase 1/2 Osteosarcoma [ICD-11: 2B51] T44479 INDICATI Phase 3 Radiation effect [ICD-11: NF00] T44479 INDICATI Phase 2 Retinopathy [ICD-11: 9B71] T44479 INDICATI Phase 3 Skin postprocedural disorder [ICD-11: EL8Y] T44479 INDICATI Phase 2 Skin surgical scar [ICD-11: EL50] T44479 INDICATI Phase 1 Spine/trunk injury [ICD-11: ND51] T44513 TARGETID T44513 T44513 TARGNAME Normal cross-reacting antigen (CD66c) T44513 INDICATI Phase 1 Solid tumour/cancer [ICD-11: 2A00-2F9Z] T44589 TARGETID T44589 T44589 TARGNAME Interleukin 3 receptor (CSF2RB) T44589 INDICATI Phase 1/2 Acute myeloid leukaemia [ICD-11: 2A60] T44589 INDICATI Phase 2 Asthma [ICD-11: CA23] T44589 INDICATI Phase 2 Immune system disease [ICD-11: 4A01-4B41] T44589 INDICATI Phase 1/2 Multiple myeloma [ICD-11: 2A83] T44589 INDICATI Phase 1/2 Myeloproliferative neoplasm [ICD-11: 2A20] T44614 TARGETID T44614 T44614 TARGNAME Plasmodium Cysteine protease falcipain-2 (Malaria CPF2) T44614 INDICATI Terminated Malaria [ICD-11: 1F40-1F45] T44682 TARGETID T44682 T44682 TARGNAME Interleukin-22 (IL22) T44682 INDICATI Phase 2 Diabetic foot ulcer [ICD-11: BD54] T44682 INDICATI Phase 2 Graft-versus-host disease [ICD-11: 4B24] T44682 INDICATI Phase 2 Psoriasis [ICD-11: EA90] T44682 INDICATI Phase 1 Ulcerative colitis [ICD-11: DD71] T44684 TARGETID T44684 T44684 TARGNAME Notch-3 receptor (NOTCH3) T44684 INDICATI Phase 2 Lung cancer [ICD-11: 2C25] T44684 INDICATI Phase 2 Pancreatic cancer [ICD-11: 2C10] T44771 TARGETID T44771 T44771 TARGNAME TGF beta-2 messenger RNA (TGFB2 mRNA) T44771 INDICATI Phase 2/3 Brain cancer [ICD-11: 2A00] T44771 INDICATI Phase 2 COVID-19 [ICD-11: 1D6Y] T44771 INDICATI Phase 3 Lung cancer [ICD-11: 2C25] T44771 INDICATI Phase 2/3 Melanoma [ICD-11: 2C30] T44771 INDICATI Phase 2/3 Neuroendocrine carcinoma [ICD-11: 2C34] T44771 INDICATI Phase 2/3 Pancreatic cancer [ICD-11: 2C10] T44818 TARGETID T44818 T44818 TARGNAME Tryptophan 2,3-dioxygenase (TDO) T44818 INDICATI Phase 1 Solid tumour/cancer [ICD-11: 2A00-2F9Z] T44861 TARGETID T44861 T44861 TARGNAME Protein kinase C delta (PRKCD) T44861 INDICATI Investigative Human immunodeficiency virus disease [ICD-11: 1C60-1C62] T44861 INDICATI Phase 1/2 Myocardial infarction [ICD-11: BA41-BA43] T44862 TARGETID T44862 T44862 TARGNAME Cytomegalovirus 65kDa phosphoprotein (HCV UL83) T44862 INDICATI Phase 2 Cytomegaloviral disease [ICD-11: 1D82] T44916 TARGETID T44916 T44916 TARGNAME Embryonic ectoderm development protein (EED) T44916 INDICATI Phase 1/2 Diffuse large B-cell lymphoma [ICD-11: 2A81] T44916 INDICATI Phase 1 Prostate cancer [ICD-11: 2C82] T44919 TARGETID T44919 T44919 TARGNAME Glucagon (GCG) T44919 INDICATI Phase 1 Acute diabete complication [ICD-11: 5A2Y] T44919 INDICATI Phase 1 Diabetes mellitus [ICD-11: 5A10] T44919 INDICATI Phase 2 Obesity [ICD-11: 5B80-5B81] T44919 INDICATI Phase 2 Parkinsonism [ICD-11: 8A00] T44919 INDICATI Phase 2 Type 2 diabetes mellitus [ICD-11: 5A11] T45074 TARGETID T45074 T45074 TARGNAME Carnitine acyltransferase (CRAT) T45074 INDICATI Discontinued in Phase 2 Acute diabete complication [ICD-11: 5A2Y] T45074 INDICATI Terminated Ischemia [ICD-11: 8B10-8B11] T45083 TARGETID T45083 T45083 TARGNAME Tryptophan 5-hydroxylase (TPH) T45083 INDICATI Phase 2 Irritable bowel syndrome [ICD-11: DD91] T45086 TARGETID T45086 T45086 TARGNAME Triggering receptor expressed on monocytes 2 (TREM2) T45086 INDICATI Phase 2 Alzheimer disease [ICD-11: 8A20] T45151 TARGETID T45151 T45151 TARGNAME Plasminogen activator inhibitor (PAI) T45151 INDICATI Phase 1 Alzheimer disease [ICD-11: 8A20] T45151 INDICATI Terminated Arterial occlusive disease [ICD-11: BD40] T45151 INDICATI Terminated Thrombosis [ICD-11: DB61-GB90] T45182 TARGETID T45182 T45182 TARGNAME Progranulin (PGRN) T45182 INDICATI Phase 1/2 Frontotemporal dementia ICD-11: 6D83 T45196 TARGETID T45196 T45196 TARGNAME Angiogenesis (AGG) T45196 INDICATI Phase 1 Lymphoma [ICD-11: 2A80-2A86] T45196 INDICATI Phase 1 Solid tumour/cancer [ICD-11: 2A00-2F9Z] T45228 TARGETID T45228 T45228 TARGNAME Ghrelin O acyltransferase (GOAT) T45228 INDICATI Patented Obesity [ICD-11: 5B80-5B81] T45228 INDICATI Patented Type 2 diabetes mellitus [ICD-11: 5A11] T45262 TARGETID T45262 T45262 TARGNAME Corticotropin-releasing factor receptor 1 (CRHR1) T45262 INDICATI Phase 2 Adrenogenital disorder [ICD-11: 5A71] T45262 INDICATI Phase 2/3 Anxiety disorder [ICD-11: 6B00-6B0Z] T45262 INDICATI Phase 2 Depression [ICD-11: 6A70-6A7Z] T45262 INDICATI Discontinued in Phase 2 Irritable bowel syndrome [ICD-11: DD91] T45262 INDICATI Discontinued in Phase 2 Mood disorder [ICD-11: 6A60-6E23] T45262 INDICATI Approved Staphylococcal/streptococcal disease [ICD-11: 1B5Y] T45262 INDICATI Phase 2 Substance abuse [ICD-11: 6C40] T45287 TARGETID T45287 T45287 TARGNAME Aspartyl aminopeptidase (DNPEP) T45287 INDICATI Phase 2 Hypertension [ICD-11: BA00-BA04] T45299 TARGETID T45299 T45299 TARGNAME Tissue-type plasminogen activator (PLAT) T45299 INDICATI Approved Bleeding disorder [ICD-11: GA20-GA21] T45299 INDICATI Approved Procedure injury [ICD-11: NE81] T45457 TARGETID T45457 T45457 TARGNAME Melanocortin receptor (MCR) T45457 INDICATI Investigative Sexual dysfunction [ICD-11: HA00-HA01] T45457 INDICATI Phase 2 Ulcerative colitis [ICD-11: DD71] T45516 TARGETID T45516 T45516 TARGNAME Cyclin D1 synthesis (CCND1 synthesis) T45516 INDICATI Phase 2 Neutropenia [ICD-11: 4B00] T45591 TARGETID T45591 T45591 TARGNAME Nucleophosmin (NPM1) T45591 INDICATI Phase 1/2 Solid tumour/cancer [ICD-11: 2A00-2F9Z] T45593 TARGETID T45593 T45593 TARGNAME Microtubule-associated protein tau (MAPT) T45593 INDICATI Phase 3 Acute myeloid leukaemia [ICD-11: 2A60] T45593 INDICATI Phase 3 Alzheimer disease [ICD-11: 8A20] T45593 INDICATI Investigative Central nervous system disease [ICD-11: 8A04-8D87] T45593 INDICATI Phase 2 Choreiform disorder [ICD-11: 8A01] T45593 INDICATI Phase 3 Mild neurocognitive disorder [ICD-11: 6D71] T45593 INDICATI Investigative Neurodegenerative disorder [ICD-11: 8A20-8A23] T45593 INDICATI Phase 2 Parkinsonism [ICD-11: 8A00] T45596 TARGETID T45596 T45596 TARGNAME JNK signaling pathway (JNK pathway) T45596 INDICATI Phase 2 Mild neurocognitive disorder [ICD-11: 6D71] T45597 TARGETID T45597 T45597 TARGNAME Ribosomal protein S6 kinase (S6K) T45597 INDICATI Phase 1 Solid tumour/cancer [ICD-11: 2A00-2F9Z] T45598 TARGETID T45598 T45598 TARGNAME Interferon alpha (IFNA) T45598 INDICATI Phase 2 Behcet disease [ICD-11: 4A62] T45598 INDICATI Phase 1 Bladder cancer [ICD-11: 2C94] T45598 INDICATI Phase 2 Chronic obstructive pulmonary disease [ICD-11: CA22] T45598 INDICATI Phase 2 Chronic pain [ICD-11: MG30] T45598 INDICATI Terminated Head and neck cancer [ICD-11: 2D42] T45598 INDICATI Phase 2 Hepatitis virus infection [ICD-11: 1E50-1E51] T45598 INDICATI Approved Human immunodeficiency virus disease [ICD-11: 1C60-1C62] T45598 INDICATI Phase 2 Liver cancer [ICD-11: 2C12] T45598 INDICATI Phase 2 Lupus erythematosus [ICD-11: 4A40] T45598 INDICATI Approved Mature B-cell leukaemia [ICD-11: 2A82] T45598 INDICATI Phase 3 Myeloproliferative neoplasm [ICD-11: 2A20] T45598 INDICATI Phase 1 Solid tumour/cancer [ICD-11: 2A00-2F9Z] T45612 TARGETID T45612 T45612 TARGNAME B7 homolog 3 (CD276) T45612 INDICATI Phase 2/3 Adrenal cancer [ICD-11: 2D11] T45612 INDICATI Phase 2/3 Brain cancer [ICD-11: 2A00] T45612 INDICATI Phase 1 Metastatic tumour [ICD-11: 2D50-2E2Z] T45612 INDICATI Phase 1/2 Myeloproliferative neoplasm [ICD-11: 2A20] T45612 INDICATI Phase 2 Prostate cancer [ICD-11: 2C82] T45612 INDICATI Phase 2 Solid tumour/cancer [ICD-11: 2A00-2F9Z] T45674 TARGETID T45674 T45674 TARGNAME Sigma intracellular receptor 2 (TMEM97) T45674 INDICATI Phase 2 Alzheimer disease [ICD-11: 8A20] T45674 INDICATI Preclinical Melanoma [ICD-11: 2C30] T45674 INDICATI Preclinical Pancreatic cancer [ICD-11: 2C10] T45674 INDICATI Preclinical Prostate cancer [ICD-11: 2C82] T45674 INDICATI Phase 3 Schizophrenia [ICD-11: 6A20] T45737 TARGETID T45737 T45737 TARGNAME Immunoglobulin alpha Fc receptor (FCAR) T45737 INDICATI Discontinued in Phase 1/2 Diabetes mellitus [ICD-11: 5A10] T45758 TARGETID T45758 T45758 TARGNAME CD40L receptor (CD40) T45758 INDICATI Phase 1 Brain cancer [ICD-11: 2A00] T45758 INDICATI Phase 1 Crohn disease [ICD-11: DD70] T45758 INDICATI Phase 2 Diabetes mellitus [ICD-11: 5A10] T45758 INDICATI Phase 2 Lupus erythematosus [ICD-11: 4A40] T45758 INDICATI Investigative Mature B-cell leukaemia [ICD-11: 2A82] T45758 INDICATI Phase 2 Melanoma [ICD-11: 2C30] T45758 INDICATI Phase 2 Motor neuron disease [ICD-11: 8B60] T45758 INDICATI Phase 2 Multiple sclerosis [ICD-11: 8A40] T45758 INDICATI Phase 2 Myasthenia gravis [ICD-11: 8C6Y] T45758 INDICATI Phase 1 Ovarian cancer [ICD-11: 2C73] T45758 INDICATI Phase 2 Rheumatoid arthritis [ICD-11: FA20] T45758 INDICATI Phase 2 Sjogren syndrome [ICD-11: 4A43] T45758 INDICATI Phase 1 Solid tumour/cancer [ICD-11: 2A00-2F9Z] T45758 INDICATI Phase 1 Thrombocytopenia [ICD-11: 3B64] T45758 INDICATI Phase 2 Thyrotoxicosis [ICD-11: 5A02] T45758 INDICATI Phase 2 Transplant rejection [ICD-11: NE84] T45760 TARGETID T45760 T45760 TARGNAME HRSV RNA-directed RNA polymerase L (HRSV L) T45760 INDICATI Phase 1 Viral encephalitis [ICD-11: 1C80] T45968 TARGETID T45968 T45968 TARGNAME RING finger protein 43 (RNF43) T45968 INDICATI Phase 2 Colorectal cancer [ICD-11: 2B91] T45993 TARGETID T45993 T45993 TARGNAME Calcium channel unspecific (CaC) T45993 INDICATI Terminated Allergic/hypersensitivity disorder [ICD-11: 4A80-4A8Z] T45993 INDICATI Terminated Alzheimer disease [ICD-11: 8A20] T45993 INDICATI Approved Angina pectoris [ICD-11: BA40] T45993 INDICATI Phase 1 Bipolar disorder [ICD-11: 6A60] T45993 INDICATI Discontinued in Phase 2 Cardiac arrhythmia [ICD-11: BC9Z] T45993 INDICATI Terminated Cardiovascular disease [ICD-11: BA00-BE2Z] T45993 INDICATI Terminated Cerebral ischaemia [ICD-11: 8B1Z] T45993 INDICATI Discontinued in Phase 3 Colorectal cancer [ICD-11: 2B91] T45993 INDICATI Approved Coronary vasospastic disease [ICD-11: BA85] T45993 INDICATI Phase 1 Epilepsy/seizure [ICD-11: 8A61-8A6Z] T45993 INDICATI Approved Essential hypertension [ICD-11: BA00] T45993 INDICATI Phase 2 Genetic cardiac arrhythmia [ICD-11: BC65] T45993 INDICATI Discontinued in Phase 1 Glaucoma [ICD-11: 9C61] T45993 INDICATI Preclinical Heart failure [ICD-11: BD10-BD1Z] T45993 INDICATI Phase 3 Herpes simplex infection [ICD-11: 1F00] T45993 INDICATI Approved Hypertension [ICD-11: BA00-BA04] T45993 INDICATI Phase 2 Irritable bowel syndrome [ICD-11: DD91] T45993 INDICATI Discontinued in Phase 2 Mild neurocognitive disorder [ICD-11: 6D71] T45993 INDICATI Discontinued in Phase 2 Pain [ICD-11: MG30-MG3Z] T45993 INDICATI Terminated Pancreatic internal secretion disorder [ICD-11: 5A4Y] T45993 INDICATI Phase 1 Psoriasis [ICD-11: EA90] T45993 INDICATI Phase 1 Sarcoma [ICD-11: 2A60-2C35] T45993 INDICATI Phase 2 Supraventricular tachyarrhythmia [ICD-11: BC81] T45993 INDICATI Discontinued in Phase 2 Unspecific body region injury [ICD-11: ND56] T46040 TARGETID T46040 T46040 TARGNAME Coagulation factor XI (F11) T46040 INDICATI Phase 3 Cerebral ischaemic stroke [ICD-11: 8B11] T46040 INDICATI Phase 1 Chronic kidney disease [ICD-11: GB61] T46040 INDICATI IND submitted Clotting disorder ICD-11: 3B4Z T46040 INDICATI Phase 2 Supraventricular tachyarrhythmia [ICD-11: BC81] T46040 INDICATI Phase 2 Thrombosis [ICD-11: DB61-GB90] T46052 TARGETID T46052 T46052 TARGNAME Lysosome-associated membrane glycoprotein 2 (LAMP2) T46052 INDICATI Phase 1 Inborn carbohydrate metabolism error [ICD-11: 5C51] T46084 TARGETID T46084 T46084 TARGNAME TNF related apoptosis inducing ligand (TNFSF10) T46084 INDICATI Phase 1 Brain cancer [ICD-11: 2A00] T46084 INDICATI Terminated Colorectal cancer [ICD-11: 2B91] T46084 INDICATI Terminated Lung cancer [ICD-11: 2C25] T46084 INDICATI Phase 1 Malignant haematopoietic neoplasm [ICD-11: 2B33] T46084 INDICATI Phase 1 Prostate cancer [ICD-11: 2C82] T46084 INDICATI Phase 1 Solid tumour/cancer [ICD-11: 2A00-2F9Z] T46128 TARGETID T46128 T46128 TARGNAME Melanocytes lineage-specific antigen GP100 (PMEL) T46128 INDICATI Phase 3 Melanoma [ICD-11: 2C30] T46128 INDICATI Approved Stomach cancer ICD-11: 2B72 T46185 TARGETID T46185 T46185 TARGNAME Muscarinic acetylcholine receptor M2 (CHRM2) T46185 INDICATI Phase 2 Abnormal micturition [ICD-11: MF50] T46185 INDICATI Terminated Alzheimer disease [ICD-11: 8A20] T46185 INDICATI Approved Asthma [ICD-11: CA23] T46185 INDICATI Terminated Cardiovascular disease [ICD-11: BA00-BE2Z] T46185 INDICATI Discontinued in Phase 2 Functional bladder disorder [ICD-11: GC50] T46185 INDICATI Approved Glaucoma [ICD-11: 9C61] T46185 INDICATI Discontinued in Phase 2 Heart failure [ICD-11: BD10-BD1Z] T46185 INDICATI Approved Muscle disorder [ICD-11: FB32-FB3Z] T46185 INDICATI Discontinued in Phase 1 Parkinsonism [ICD-11: 8A00] T46185 INDICATI Approved Peptic ulcer [ICD-11: DA61] T46185 INDICATI Approved Respiratory system disease [ICD-11: CB40-CB7Z] T46185 INDICATI Approved Sebaceous gland disorder [ICD-11: ED91] T46208 TARGETID T46208 T46208 TARGNAME Gp100[209-217] peptide (PMEL) T46208 INDICATI Phase 1 Melanoma [ICD-11: 2C30] T46216 TARGETID T46216 T46216 TARGNAME Bromodomain-containing protein 9 (BRD9) T46216 INDICATI Investigative Acute myeloid leukaemia [ICD-11: 2A60] T46245 TARGETID T46245 T46245 TARGNAME Glutaminyl cyclase (QPCT) T46245 INDICATI Phase 2 Dementia [ICD-11: 6D80-6D8Z] T46263 TARGETID T46263 T46263 TARGNAME Lymphocyte activation antigen 4F2 (SLC3A2) T46263 INDICATI Phase 1 Acute myeloid leukaemia [ICD-11: 2A60] T46360 TARGETID T46360 T46360 TARGNAME Opioid receptor sigma 1 (OPRS1) T46360 INDICATI Terminated Abnormal micturition [ICD-11: MF50] T46360 INDICATI Phase 3 Alzheimer disease [ICD-11: 8A20] T46360 INDICATI Terminated Anxiety disorder [ICD-11: 6B00-6B0Z] T46360 INDICATI Phase 2 Bulimia nervosa [ICD-11: 6B81] T46360 INDICATI Withdrawn from market Cataract [ICD-11: 9B10] T46360 INDICATI Phase 1 Central nervous system disease [ICD-11: 8A04-8D87] T46360 INDICATI Phase 1 Chronic obstructive pulmonary disease [ICD-11: CA22] T46360 INDICATI Approved Cough [ICD-11: MD12] T46360 INDICATI Phase 1 Cystic fibrosis [ICD-11: CA25] T46360 INDICATI Phase 2 Depression [ICD-11: 6A70-6A7Z] T46360 INDICATI Terminated Dermal/subcutaneous connective tissue atrophy/degeneration [ICD-11: EE40] T46360 INDICATI Phase 1 Epileptic encephalopathy [ICD-11: 8A62] T46360 INDICATI Phase 1 Frontotemporal dementia ICD-11: 6D83 T46360 INDICATI Phase 1 Immune system disease [ICD-11: 4A01-4B41] T46360 INDICATI Phase 1 Intellectual development disorder [ICD-11: LD90] T46360 INDICATI Investigative Intracranial injury [ICD-11: NA07] T46360 INDICATI Preclinical Melanoma [ICD-11: 2C30] T46360 INDICATI Phase 1 Mild neurocognitive disorder [ICD-11: 6D71] T46360 INDICATI Phase 3 Mood disorder [ICD-11: 6A60-6E23] T46360 INDICATI Phase 2 Neurobehavioral disorder [ICD-11: 8A00-8A0Z] T46360 INDICATI Phase 1 Pain [ICD-11: MG30-MG3Z] T46360 INDICATI Preclinical Pancreatic cancer [ICD-11: 2C10] T46360 INDICATI Phase 1 Parkinsonism [ICD-11: 8A00] T46360 INDICATI Discontinued in Phase 2 Peptic ulcer [ICD-11: DA61] T46360 INDICATI Preclinical Prostate cancer [ICD-11: 2C82] T46360 INDICATI Investigative Psychoactive substances use disorder [ICD-11: 6C4G] T46360 INDICATI Discontinued in Phase 3 Psychotic disorder [ICD-11: 6A20-6A25] T46360 INDICATI Phase 3 Schizophrenia [ICD-11: 6A20] T46360 INDICATI Phase 1 Sexual dysfunction [ICD-11: HA00-HA01] T46360 INDICATI Phase 2 Somnolence [ICD-11: MG42] T46365 TARGETID T46365 T46365 TARGNAME M-phase inducer phosphatase 2 (MPIP2) T46365 INDICATI Phase 3 Lung cancer [ICD-11: 2C25] T46365 INDICATI Investigative Nasopharyngeal cancer [ICD-11: 2B6B] T46365 INDICATI Terminated Solid tumour/cancer [ICD-11: 2A00-2F9Z] T46456 TARGETID T46456 T46456 TARGNAME Retinoic acid receptor RXR-gamma (RXRG) T46456 INDICATI Phase 2 Acute diabete complication [ICD-11: 5A2Y] T46456 INDICATI Phase 1 Breast cancer [ICD-11: 2C60-2C6Y] T46456 INDICATI Approved Kaposi sarcoma [ICD-11: 2B57] T46456 INDICATI Investigative Kinetoplastids [ICD-11: 1F61-1G2Z] T46456 INDICATI Approved Light sensitivity impairment [ICD-11: 9D45] T46456 INDICATI Phase 1 Lung cancer [ICD-11: 2C25] T46456 INDICATI Phase 1 Pancreatic cancer [ICD-11: 2C10] T46456 INDICATI Phase 1 Prostate cancer [ICD-11: 2C82] T46456 INDICATI Phase 1 Solid tumour/cancer [ICD-11: 2A00-2F9Z] T46465 TARGETID T46465 T46465 TARGNAME Plasmodium Plasmepsin 2 (Malaria PLA2) T46465 INDICATI Terminated Malaria [ICD-11: 1F40-1F45] T46482 TARGETID T46482 T46482 TARGNAME Toll-like receptor 7 (TLR7) T46482 INDICATI Phase 2 Asthma [ICD-11: CA23] T46482 INDICATI Phase 1 Autoimmune disease [ICD-11: 4A40-4A45] T46482 INDICATI Investigative Bladder cancer [ICD-11: 2C94] T46482 INDICATI Phase 1 Diabetes mellitus [ICD-11: 5A10] T46482 INDICATI Discontinued in Phase 1/2 Diffuse large B-cell lymphoma [ICD-11: 2A81] T46482 INDICATI Phase 2 Epidermal dysplasias [ICD-11: EK90] T46482 INDICATI Phase 2a Hepatitis virus infection [ICD-11: 1E50-1E51] T46482 INDICATI Phase 1/2 Herpes simplex infection [ICD-11: 1F00] T46482 INDICATI Phase 1 Human immunodeficiency virus disease [ICD-11: 1C60-1C62] T46482 INDICATI Phase 2 Immune system disease [ICD-11: 4A01-4B41] T46482 INDICATI Phase 1 Liver cancer [ICD-11: 2C12] T46482 INDICATI Phase 1/2 Lung cancer [ICD-11: 2C25] T46482 INDICATI Phase 2 Lupus erythematosus [ICD-11: 4A40] T46482 INDICATI Approved Malaria [ICD-11: 1F40-1F45] T46482 INDICATI Phase 2 Melanoma [ICD-11: 2C30] T46482 INDICATI Phase 2 Mycosis fungoides [ICD-11: 2B01] T46482 INDICATI Phase 2 Psoriasis [ICD-11: EA90] T46482 INDICATI Approved Skin cancer [ICD-11: 2C30-2C37] T46482 INDICATI Phase 1/2 Solid tumour/cancer [ICD-11: 2A00-2F9Z] T46482 INDICATI Phase 1 Squamous cell carcinoma [ICD-11: 2B60-2D01] T46482 INDICATI Phase 2 Vasomotor/allergic rhinitis [ICD-11: CA08] T46521 TARGETID T46521 T46521 TARGNAME Androgen receptor messenger RNA (AR mRNA) T46521 INDICATI Discontinued in Phase 1 Acne vulgaris [ICD-11: ED80] T46521 INDICATI Phase 2 Breast cancer [ICD-11: 2C60-2C6Y] T46521 INDICATI Phase 1/2 Prostate cancer [ICD-11: 2C82] T46521 INDICATI Phase 4 Prostate hyperplasia [ICD-11: GA90] T46521 INDICATI Investigative Solid tumour/cancer [ICD-11: 2A00-2F9Z] T46524 TARGETID T46524 T46524 TARGNAME TNF-related weak inducer of apoptosis (TWEAK) T46524 INDICATI Phase 2 Rheumatoid arthritis [ICD-11: FA20] T46524 INDICATI Phase 1 Solid tumour/cancer [ICD-11: 2A00-2F9Z] T46526 TARGETID T46526 T46526 TARGNAME Bacterial Fimbrin D-mannose adhesin (Bact FimH) T46526 INDICATI Phase 2 Crohn disease [ICD-11: DD70] T46526 INDICATI Patented Ulcerative colitis [ICD-11: DD71] T46526 INDICATI Phase 1 Urinary tract infection [ICD-11: GC08] T46616 TARGETID T46616 T46616 TARGNAME Bacterial Botulinum toxin A (Bact botA) T46616 INDICATI Phase 2 Acne vulgaris [ICD-11: ED80] T46616 INDICATI Phase 1/2 Ataxic disorder [ICD-11: 8A03] T46616 INDICATI Phase 1 Clostridium difficile enterocolitis [ICD-11: 1A04] T46628 TARGETID T46628 T46628 TARGNAME Microsomal triglyceride transfer protein (MTTP) T46628 INDICATI Phase 2 Acute diabete complication [ICD-11: 5A2Y] T46628 INDICATI Discontinued in Phase 1 Arterial occlusive disease [ICD-11: BD40] T46628 INDICATI Phase 2 Dyslipidemia [ICD-11: 5C80-5C81] T46628 INDICATI Approved Hyper-lipoproteinaemia [ICD-11: 5C80] T46628 INDICATI Phase 2 Type 2 diabetes mellitus [ICD-11: 5A11] T46628 INDICATI Phase 1/2 Urinary system disease [ICD-11: GC2Z] T46642 TARGETID T46642 T46642 TARGNAME Arachidonate 5-lipoxygenase activating protein (FLAP) T46642 INDICATI Terminated Allergic/hypersensitivity disorder [ICD-11: 4A80-4A8Z] T46642 INDICATI Discontinued in Phase 3 Asthma [ICD-11: CA23] T46642 INDICATI Discontinued in Phase 2 Cardiovascular disease [ICD-11: BA00-BE2Z] T46642 INDICATI Discontinued in Phase 1 Solid tumour/cancer [ICD-11: 2A00-2F9Z] T46658 TARGETID T46658 T46658 TARGNAME Eosinophil/lymphocyte-rich accumulation (ELR accum) T46658 INDICATI Phase 2 Asthma [ICD-11: CA23] T46781 TARGETID T46781 T46781 TARGNAME Aurora kinase B (AURKB) T46781 INDICATI Phase 3 Acute diabete complication [ICD-11: 5A2Y] T46781 INDICATI Phase 1 Acute myeloid leukaemia [ICD-11: 2A60] T46781 INDICATI Phase 2 Malignant haematopoietic neoplasm [ICD-11: 2B33] T46781 INDICATI Investigative Oral cavity/oesophagus/stomach in situ carcinoma [ICD-11: 2E60] T46781 INDICATI Phase 2 Prostate cancer [ICD-11: 2C82] T46781 INDICATI Phase 3 Solid tumour/cancer [ICD-11: 2A00-2F9Z] T46789 TARGETID T46789 T46789 TARGNAME Inhibitory receptor SHPS-1 (SIRPA) T46789 INDICATI Phase 1 Malignant haematopoietic neoplasm [ICD-11: 2B33] T46789 INDICATI Phase 1 Solid tumour/cancer [ICD-11: 2A00-2F9Z] T46828 TARGETID T46828 T46828 TARGNAME Dopamine D5 receptor (D5R) T46828 INDICATI Approved Allergic/hypersensitivity disorder [ICD-11: 4A80-4A8Z] T46828 INDICATI Preclinical Schizophrenia [ICD-11: 6A20] T46871 TARGETID T46871 T46871 TARGNAME SH2 domain inositol 5'-phosphatase 1 (INPP5D) T46871 INDICATI Phase 2 Chronic obstructive pulmonary disease [ICD-11: CA22] T46904 TARGETID T46904 T46904 TARGNAME Secretin receptor (SCT) T46904 INDICATI Approved Pancreas disease [ICD-11: DC35-DC3Z] T46904 INDICATI Approved Pancreatic cancer [ICD-11: 2C10] T46937 TARGETID T46937 T46937 TARGNAME P2Y purinoceptor 12 (P2RY12) T46937 INDICATI Phase 3 Arterial thrombosis [ICD-11: DB61-DD30] T46937 INDICATI Phase 2 Cardiovascular disease [ICD-11: BA00-BE2Z] T46937 INDICATI Approved Myocardial infarction [ICD-11: BA41-BA43] T46937 INDICATI Approved Thrombosis [ICD-11: DB61-GB90] T47077 TARGETID T47077 T47077 TARGNAME Prostaglandin receptor (PTGR) T47077 INDICATI Discontinued in Phase 2 Acute diabete complication [ICD-11: 5A2Y] T47077 INDICATI Approved Alopecia [ICD-11: ED70] T47077 INDICATI Phase 3 Bacterial infection [ICD-11: 1A00-1C4Z] T47077 INDICATI Approved Glaucoma [ICD-11: 9C61] T47077 INDICATI Discontinued in Phase 2 Pain [ICD-11: MG30-MG3Z] T47077 INDICATI Phase 2 Pneumonia [ICD-11: CA40] T47077 INDICATI Terminated Psoriasis [ICD-11: EA90] T47077 INDICATI Discontinued in Phase 2 Sarcoidosis [ICD-11: 4B20] T47077 INDICATI Investigative Sexual dysfunction [ICD-11: HA00-HA01] T47077 INDICATI Phase 2 Skin and skin-structure infection [ICD-11: 1F28-1G0Z] T47077 INDICATI Terminated Solid tumour/cancer [ICD-11: 2A00-2F9Z] T47077 INDICATI Discontinued in Phase 3 Thrombosis [ICD-11: DB61-GB90] T47081 TARGETID T47081 T47081 TARGNAME Rotamase A (PPIA) T47081 INDICATI Approved Nutritional deficiency [ICD-11: 5B50-5B71] T47087 TARGETID T47087 T47087 TARGNAME Human papillomavirus E1 region messenger RNA (HPV E1 mRNA) T47087 INDICATI Discontinued in Phase 1 Solid tumour/cancer [ICD-11: 2A00-2F9Z] T47094 TARGETID T47094 T47094 TARGNAME Substance-P receptor (TACR1) T47094 INDICATI Phase 2 Abnormal micturition [ICD-11: MF50] T47094 INDICATI Phase 1 Acute diabete complication [ICD-11: 5A2Y] T47094 INDICATI Terminated Acute upper respiratory infection [ICD-11: CA07] T47094 INDICATI Phase 2 Anxiety disorder [ICD-11: 6B00-6B0Z] T47094 INDICATI Discontinued in Phase 2 Asthma [ICD-11: CA23] T47094 INDICATI Phase 3 Atopic eczema [ICD-11: EA80] T47094 INDICATI Discontinued in Phase 2 Chronic obstructive pulmonary disease [ICD-11: CA22] T47094 INDICATI Investigative Chronic pain [ICD-11: MG30] T47094 INDICATI Phase 2 Cough [ICD-11: MD12] T47094 INDICATI Approved Depression [ICD-11: 6A70-6A7Z] T47094 INDICATI Phase 1 Eczema [ICD-11: EA80-EA89] T47094 INDICATI Discontinued in Phase 2 Functional bladder disorder [ICD-11: GC50] T47094 INDICATI Phase 2 Hypertension [ICD-11: BA00-BA04] T47094 INDICATI Investigative Influenza [ICD-11: 1E30-1E32] T47094 INDICATI Investigative Intracranial injury [ICD-11: NA07] T47094 INDICATI Discontinued in Phase 2 Irritable bowel syndrome [ICD-11: DD91] T47094 INDICATI Phase 3 Menopausal disorder [ICD-11: GA30] T47094 INDICATI Phase 2 Migraine [ICD-11: 8A80] T47094 INDICATI Phase 2 Mood disorder [ICD-11: 6A60-6E23] T47094 INDICATI Approved Nausea/vomiting [ICD-11: MD90] T47094 INDICATI Discontinued in Phase 1 Oesophagus motility disorder [ICD-11: DA21] T47094 INDICATI Phase 2 Pain [ICD-11: MG30-MG3Z] T47094 INDICATI Phase 3 Prurigo [ICD-11: EC91] T47094 INDICATI Phase 2 Psoriasis [ICD-11: EA90] T47094 INDICATI Phase 1 Schizophrenia [ICD-11: 6A20] T47094 INDICATI Patented Skin tag/polyp [ICD-11: EK71] T47094 INDICATI Phase 3 Solid tumour/cancer [ICD-11: 2A00-2F9Z] T47094 INDICATI Phase 2 Substance abuse [ICD-11: 6C40] T47101 TARGETID T47101 T47101 TARGNAME Fibroblast growth factor receptor 1 (FGFR1) T47101 INDICATI Phase 3 Acute diabete complication [ICD-11: 5A2Y] T47101 INDICATI Phase 1 Acute myeloid leukaemia [ICD-11: 2A60] T47101 INDICATI Phase 1/2 Alzheimer disease [ICD-11: 8A20] T47101 INDICATI Phase 2 Bladder cancer [ICD-11: 2C94] T47101 INDICATI Phase 1/2 Breast cancer [ICD-11: 2C60-2C6Y] T47101 INDICATI Investigative Chronic arterial occlusive disease [ICD-11: BD4Z] T47101 INDICATI Approved Colorectal cancer [ICD-11: 2B91] T47101 INDICATI Phase 2 Coronary atherosclerosis [ICD-11: BA80] T47101 INDICATI Phase 2 Endometrial cancer [ICD-11: 2C76] T47101 INDICATI Phase 2 Epidermal dysplasias [ICD-11: EK90] T47101 INDICATI Investigative Gram-positive bacterial infection [ICD-11: 1B74-1F40] T47101 INDICATI Approved Idiopathic interstitial pneumonitis [ICD-11: CB03] T47101 INDICATI Approved Liver cancer [ICD-11: 2C12] T47101 INDICATI Phase 3 Lung cancer [ICD-11: 2C25] T47101 INDICATI Phase 2 Multiple myeloma [ICD-11: 2A83] T47101 INDICATI Phase 2 Myelodysplastic syndrome [ICD-11: 2A37] T47101 INDICATI Phase 2 Myeloproliferative neoplasm [ICD-11: 2A20] T47101 INDICATI Phase 2 Non-alcoholic fatty liver disease [ICD-11: DB92] T47101 INDICATI Phase 2 Oesophagitis [ICD-11: DA24] T47101 INDICATI Phase 2 Ovarian cancer [ICD-11: 2C73] T47101 INDICATI Phase 3 Peritoneal cancer [ICD-11: 2C51] T47101 INDICATI Terminated Retina cancer [ICD-11: 2D02] T47101 INDICATI Phase 3 Solid tumour/cancer [ICD-11: 2A00-2F9Z] T47101 INDICATI Phase 3 Stomach cancer [ICD-11: 2B72] T47101 INDICATI Approved Thrombocytopenia [ICD-11: 3B64] T47101 INDICATI Phase 1 Type 2 diabetes mellitus [ICD-11: 5A11] T47107 TARGETID T47107 T47107 TARGNAME Protein kinase C gamma (PRKCG) T47107 INDICATI Approved Acute myeloid leukaemia [ICD-11: 2A60] T47107 INDICATI Phase 2 Chronic myelomonocytic leukaemia [ICD-11: 2A40] T47107 INDICATI Phase 1 Colorectal cancer [ICD-11: 2B91] T47107 INDICATI Investigative Human immunodeficiency virus disease [ICD-11: 1C60-1C62] T47107 INDICATI Approved Mastocytosis [ICD-11: 2A21] T47164 TARGETID T47164 T47164 TARGNAME MST-1 protein kinase (STK4) T47164 INDICATI Investigative Ischemic heart disease [ICD-11: BA40-BA6Z] T47165 TARGETID T47165 T47165 TARGNAME Neural cell adhesion molecule (NCAM) T47165 INDICATI Phase 1 Alzheimer disease [ICD-11: 8A20] T47165 INDICATI Phase 2 Solid tumour/cancer [ICD-11: 2A00-2F9Z] T47215 TARGETID T47215 T47215 TARGNAME Cholecystokinin receptor (CCKR) T47215 INDICATI Terminated Obesity [ICD-11: 5B80-5B81] T47366 TARGETID T47366 T47366 TARGNAME Activin receptor type IIA (ACVR2A) T47366 INDICATI Phase 2/3 Acute myeloid leukaemia [ICD-11: 2A60] T47366 INDICATI Phase 3 Idiopathic inflammatory myopathy [ICD-11: 4A41] T47366 INDICATI Phase 2 Muscle disorder [ICD-11: FB32-FB3Z] T47381 TARGETID T47381 T47381 TARGNAME GSTP1 messenger RNA (GSTP1 mRNA) T47381 INDICATI Phase 1 Colorectal cancer [ICD-11: 2B91] T47381 INDICATI Phase 1 Lung cancer [ICD-11: 2C25] T47381 INDICATI Phase 1 Pancreatic cancer [ICD-11: 2C10] T47387 TARGETID T47387 T47387 TARGNAME BCL-2 messenger RNA (BCL2 mRNA) T47387 INDICATI Investigative Acute myeloid leukaemia [ICD-11: 2A60] T47387 INDICATI Investigative Colorectal cancer [ICD-11: 2B91] T47387 INDICATI Phase 2 Diffuse large B-cell lymphoma [ICD-11: 2A81] T47387 INDICATI Phase 1/2 Leukaemia [ICD-11: 2A60-2B33] T47387 INDICATI Investigative Lung cancer [ICD-11: 2C25] T47387 INDICATI Investigative Lymphoma [ICD-11: 2A80-2A86] T47387 INDICATI Phase 1 Malignant haematopoietic neoplasm [ICD-11: 2B33] T47387 INDICATI Investigative Melanoma [ICD-11: 2C30] T47387 INDICATI Investigative Multiple myeloma [ICD-11: 2A83] T47387 INDICATI Phase 2 Solid tumour/cancer [ICD-11: 2A00-2F9Z] T47415 TARGETID T47415 T47415 TARGNAME HLA class I antigen B-7 (HLA-B) T47415 INDICATI Phase 3 Melanoma [ICD-11: 2C30] T47466 TARGETID T47466 T47466 TARGNAME Porphobilinogen deaminase (HMBS) T47466 INDICATI Phase 2 Inborn porphyrin/heme metabolism error [ICD-11: 5C58] T47583 TARGETID T47583 T47583 TARGNAME Werner syndrome ATP-dependent helicase (WRN) T47583 INDICATI Investigative Mature T-cell lymphoma [ICD-11: 2A90] T47610 TARGETID T47610 T47610 TARGNAME Interleukin 11 receptor alpha (IL11RA) T47610 INDICATI Phase 1 Prostate cancer [ICD-11: 2C82] T47610 INDICATI Approved Thrombocytopenia [ICD-11: 3B64] T47623 TARGETID T47623 T47623 TARGNAME Heparanase (HPSE) T47623 INDICATI Phase 1 African trypanosomiasis [ICD-11: 1F51] T47623 INDICATI Discontinued in Phase 3 Circulatory system disease [ICD-11: BE2Z] T47623 INDICATI Phase 1 Herpes simplex infection [ICD-11: 1F00] T47768 TARGETID T47768 T47768 TARGNAME Opioid receptor mu (MOP) T47768 INDICATI Discontinued in Phase 1 Abnormal micturition [ICD-11: MF50] T47768 INDICATI Approved Acute pain [ICD-11: MG31] T47768 INDICATI Terminated Asthma [ICD-11: CA23] T47768 INDICATI Phase 2 Binge eating disorder [ICD-11: 6B82] T47768 INDICATI Approved Bowel habit change [ICD-11: ME05] T47768 INDICATI Phase 3 Breathing abnormality [ICD-11: MD11] T47768 INDICATI Approved Chronic pain [ICD-11: MG30] T47768 INDICATI Approved Corneal disease [ICD-11: 9A76-9A78] T47768 INDICATI Phase 1 Coronary vasospastic disease [ICD-11: BA85] T47768 INDICATI Approved Cough [ICD-11: MD12] T47768 INDICATI Approved Depression [ICD-11: 6A70-6A7Z] T47768 INDICATI Approved Digestive system disease [ICD-11: DE2Z] T47768 INDICATI Phase 3 General pain disorder [ICD-11: 8E43] T47768 INDICATI Phase 1 Headache [ICD-11: 8A80-8A84] T47768 INDICATI Approved Irritable bowel syndrome [ICD-11: DD91] T47768 INDICATI Approved Large intestine motility disorder [ICD-11: DB32] T47768 INDICATI Investigative Lung cancer [ICD-11: 2C25] T47768 INDICATI Phase 3 Mental/behavioural/neurodevelopmental disorder [ICD-11: 6E20-6E8Z] T47768 INDICATI Phase 2 Migraine [ICD-11: 8A80] T47768 INDICATI Investigative Movement disorder [ICD-11: 8A07-8A0Z] T47768 INDICATI Phase 3 Neuropathy [ICD-11: 8C0Z] T47768 INDICATI Phase 1 Obesity [ICD-11: 5B80-5B81] T47768 INDICATI Approved Opioid use disorder [ICD-11: 6C43] T47768 INDICATI Approved Pain [ICD-11: MG30-MG3Z] T47768 INDICATI Investigative Postoperative inflammation [ICD-11: 1A00-CA43] T47768 INDICATI Approved Pruritus [ICD-11: EC90] T47768 INDICATI Approved Sensation disturbance [ICD-11: MB40] T47768 INDICATI Phase 3 Spinal pain [ICD-11: ME84] T47768 INDICATI Phase 2 Substance abuse [ICD-11: 6C40] T47768 INDICATI Discontinued in Phase 1 Unspecific substance use disorder [ICD-11: 6C4Z] T47818 TARGETID T47818 T47818 TARGNAME Amino acid transporter ATB0+ (SLC6A14) T47818 INDICATI Terminated Rheumatoid arthritis [ICD-11: FA20] T47863 TARGETID T47863 T47863 TARGNAME Tumor-associated calcium signal transducer 1 (EPCAM) T47863 INDICATI Phase 3 Bladder cancer [ICD-11: 2C94] T47863 INDICATI Phase 1 Breast cancer [ICD-11: 2C60-2C6Y] T47863 INDICATI Phase 1/2 Colon cancer [ICD-11: 2B90] T47863 INDICATI Discontinued in Phase 2 Colorectal cancer [ICD-11: 2B91] T47863 INDICATI Phase 1/2 Esophageal cancer [ICD-11: 2B70] T47863 INDICATI Phase 2/3 Head and neck cancer [ICD-11: 2D42] T47863 INDICATI Phase 1/2 Liver cancer [ICD-11: 2C12] T47863 INDICATI Phase 1 Lung cancer [ICD-11: 2C25] T47863 INDICATI Phase 1 Melanoma [ICD-11: 2C30] T47863 INDICATI Phase 1 Metastatic tumour [ICD-11: 2D50-2E2Z] T47863 INDICATI Phase 1/2 Pancreatic cancer [ICD-11: 2C10] T47863 INDICATI Phase 1/2 Prostate cancer [ICD-11: 2C82] T47863 INDICATI Phase 1 Solid tumour/cancer [ICD-11: 2A00-2F9Z] T47863 INDICATI Phase 1/2 Stomach cancer [ICD-11: 2B72] T47864 TARGETID T47864 T47864 TARGNAME Teratocarcinoma-derived growth factor 1 (TDGF1) T47864 INDICATI Phase 1 Solid tumour/cancer [ICD-11: 2A00-2F9Z] T47885 TARGETID T47885 T47885 TARGNAME Protein kinase D (PRKD1) T47885 INDICATI Investigative Solid tumour/cancer [ICD-11: 2A00-2F9Z] T47885 INDICATI Investigative Urinary system disease [ICD-11: GC2Z] T47888 TARGETID T47888 T47888 TARGNAME Sphingosine-1-phosphate receptor 2 (S1PR2) T47888 INDICATI Phase 2 Ulcerative colitis [ICD-11: DD71] T47891 TARGETID T47891 T47891 TARGNAME Natural killer cell receptor (NKCR) T47891 INDICATI Phase 3 Hepatitis virus infection [ICD-11: 1E50-1E51] T47941 TARGETID T47941 T47941 TARGNAME Phosphodiesterase 4 (PDE4) T47941 INDICATI Approved Asthma [ICD-11: CA23] T47941 INDICATI Approved Atopic eczema [ICD-11: EA80] T47941 INDICATI Discontinued in Phase 3 Bronchitis [ICD-11: CA20] T47941 INDICATI Approved Castlemans disease [ICD-11: 4B2Y] T47941 INDICATI Phase 3 Chronic obstructive pulmonary disease [ICD-11: CA22] T47941 INDICATI Approved Cough [ICD-11: MD12] T47941 INDICATI Discontinued in Phase 3 Emphysema [ICD-11: CA21] T47941 INDICATI Phase 2 Gram-positive bacterial infection [ICD-11: 1B74-1F40] T47941 INDICATI Phase 2 Motor neuron disease [ICD-11: 8B60] T47941 INDICATI Phase 2 Multiple sclerosis [ICD-11: 8A40] T47941 INDICATI Phase 2 Non-alcoholic fatty liver disease [ICD-11: DB92] T47941 INDICATI Phase 2 Opioid use disorder [ICD-11: 6C43] T47941 INDICATI Approved Psoriasis [ICD-11: EA90] T47941 INDICATI Phase 2 Psoriasis ICD-11: EA90 T47941 INDICATI Phase 2 Stimulants use disorder [ICD-11: 6C46] T47941 INDICATI Phase 2 Substance abuse [ICD-11: 6C40] T47941 INDICATI Phase 1 Type 2 diabetes mellitus [ICD-11: 5A11] T48069 TARGETID T48069 T48069 TARGNAME Insulin-like growth factor I receptor (IGF1R) T48069 INDICATI Discontinued in Phase 1 Adrenal cancer [ICD-11: 2D11] T48069 INDICATI Phase 2 Breast cancer [ICD-11: 2C60-2C6Y] T48069 INDICATI Phase 2 Chronic kidney disease [ICD-11: GB61] T48069 INDICATI Phase 1 Colorectal cancer [ICD-11: 2B91] T48069 INDICATI Phase 2 Extraocular muscle disorder [ICD-11: 9C82] T48069 INDICATI Phase 2 Liver cancer [ICD-11: 2C12] T48069 INDICATI Phase 2 Lung cancer [ICD-11: 2C25] T48069 INDICATI Phase 1 Motor neuron disease [ICD-11: 8B60] T48069 INDICATI Phase 1 Multiple myeloma [ICD-11: 2A83] T48069 INDICATI Approved Multiple structural anomalies syndrome [ICD-11: LD2F] T48069 INDICATI Phase 1 Pain [ICD-11: MG30-MG3Z] T48069 INDICATI Phase 2 Pancreatic cancer [ICD-11: 2C10] T48069 INDICATI Phase 1 Parkinsonism [ICD-11: 8A00] T48069 INDICATI Approved Pituitary gland disorder [ICD-11: 5A60-5A61] T48069 INDICATI Phase 1 Retinopathy [ICD-11: 9B71] T48069 INDICATI Phase 3 Solid tumour/cancer [ICD-11: 2A00-2F9Z] T48069 INDICATI Approved Thyrotoxicosis [ICD-11: 5A02] T48268 TARGETID T48268 T48268 TARGNAME Melatonin receptor type 1B (MTNR1B) T48268 INDICATI Terminated Circadian rhythm sleep disorder [ICD-11: 7A60-7A65] T48268 INDICATI Phase 3 Epilepsy/seizure [ICD-11: 8A61-8A6Z] T48268 INDICATI Approved Insomnia [ICD-11: 7A00-7A0Z] T48429 TARGETID T48429 T48429 TARGNAME Interleukin 15 receptor alpha (IL15RA) T48429 INDICATI Phase 2 Acute myeloid leukaemia [ICD-11: 2A60] T48429 INDICATI Phase 2 Bladder cancer [ICD-11: 2C94] T48429 INDICATI Phase 1/2 Colorectal cancer [ICD-11: 2B91] T48429 INDICATI Phase 1/2 Head and neck cancer [ICD-11: 2D42] T48429 INDICATI Phase 1 Human immunodeficiency virus disease [ICD-11: 1C60-1C62] T48429 INDICATI Phase 1/2 Lung cancer [ICD-11: 2C25] T48429 INDICATI Phase 1/2 Malignant haematopoietic neoplasm [ICD-11: 2B33] T48429 INDICATI Phase 1 Multiple myeloma [ICD-11: 2A83] T48429 INDICATI Phase 1 Pancreatic cancer [ICD-11: 2C10] T48429 INDICATI Phase 1/2 Solid tumour/cancer [ICD-11: 2A00-2F9Z] T48457 TARGETID T48457 T48457 TARGNAME Complement receptor type 1 (CR1) T48457 INDICATI Phase 1 Retinopathy [ICD-11: 9B71] T48470 TARGETID T48470 T48470 TARGNAME Hormone unspecific (HOM) T48470 INDICATI Phase 1 Cardiovascular disease [ICD-11: BA00-BE2Z] T48470 INDICATI Investigative Indeterminate colitis [ICD-11: DD72] T48472 TARGETID T48472 T48472 TARGNAME Bacterial 70S ribosomal RNA (Bact 70S rRNA) T48472 INDICATI Approved Bacterial infection [ICD-11: 1A00-1C4Z] T48472 INDICATI Approved HIV-infected patients with tuberculosis [ICD-11: 1B10-1B14] T48472 INDICATI Phase 2 Mycobacterium infection [ICD-11: 1B10-1B21] T48598 TARGETID T48598 T48598 TARGNAME GTPase KRas (KRAS) T48598 INDICATI Phase 1 Solid tumour/cancer [ICD-11: 2A00-2F9Z] T48703 TARGETID T48703 T48703 TARGNAME Toll-like receptor 8 (TLR8) T48703 INDICATI Discontinued in Phase 2 Allergic/hypersensitivity disorder [ICD-11: 4A80-4A8Z] T48703 INDICATI Investigative Diabetes mellitus [ICD-11: 5A10] T48703 INDICATI Discontinued in Phase 1/2 Diffuse large B-cell lymphoma [ICD-11: 2A81] T48703 INDICATI Phase 2 Epidermal dysplasias [ICD-11: EK90] T48703 INDICATI Phase 2 Hepatitis virus infection [ICD-11: 1E50-1E51] T48703 INDICATI Phase 1/2 Herpes simplex infection [ICD-11: 1F00] T48703 INDICATI Phase 2 Lupus erythematosus [ICD-11: 4A40] T48703 INDICATI Phase 1 Melanoma [ICD-11: 2C30] T48703 INDICATI Phase 2 Mycosis fungoides [ICD-11: 2B01] T48703 INDICATI Investigative Rheumatoid arthritis [ICD-11: FA20] T48703 INDICATI Phase 1/2 Solid tumour/cancer [ICD-11: 2A00-2F9Z] T48703 INDICATI Phase 1 Squamous cell carcinoma [ICD-11: 2B60-2D01] T48703 INDICATI Phase 1 Vasomotor/allergic rhinitis [ICD-11: CA08] T48873 TARGETID T48873 T48873 TARGNAME Synaptic vesicle amine transporter (SLC18A2) T48873 INDICATI Phase 3 Alzheimer disease [ICD-11: 8A20] T48873 INDICATI Approved Choreiform disorder [ICD-11: 8A01] T48873 INDICATI Approved Dissociative neurological symptom disorder [ICD-11: 6B60] T48873 INDICATI Approved Dystonic disorder [ICD-11: 8A02] T48873 INDICATI Approved Essential hypertension [ICD-11: BA00] T48873 INDICATI Approved Hypertension [ICD-11: BA00-BA04] T48873 INDICATI Phase 3 Movement disorder [ICD-11: 8A07-8A0Z] T48873 INDICATI Phase 2 Tic disorder [ICD-11: 8A05] T48873 INDICATI Phase 2 Unspecific substance use disorder [ICD-11: 6C4Z] T48881 TARGETID T48881 T48881 TARGNAME Herpes virus entry mediator ligand (CD258) T48881 INDICATI Phase 2 Asthma ICD-11: CA23 T48940 TARGETID T48940 T48940 TARGNAME HIF-prolyl hydroxylase (HPH) T48940 INDICATI Phase 3 Acute disease anaemia [ICD-11: 3A90] T48940 INDICATI Phase 1 Anemia [ICD-11: 3A00-3A9Z] T48940 INDICATI Approved Fungal infection [ICD-11: 1F29-1F2F] T48940 INDICATI Preclinical Mineral deficiency [ICD-11: 5B5K] T48940 INDICATI Phase 2 Urinary system disease [ICD-11: GC2Z] T48945 TARGETID T48945 T48945 TARGNAME TERT messenger RNA (TERT mRNA) T48945 INDICATI Phase 2 Breast cancer [ICD-11: 2C60-2C6Y] T48945 INDICATI Investigative Colorectal cancer [ICD-11: 2B91] T48945 INDICATI Phase 3 Liver cancer [ICD-11: 2C12] T48945 INDICATI Approved Solid tumour/cancer [ICD-11: 2A00-2F9Z] T49040 TARGETID T49040 T49040 TARGNAME Glucose metabolism (Glucose metab) T49040 INDICATI Phase 2 Metabolic disorder [ICD-11: 5C50-5D2Z] T49049 TARGETID T49049 T49049 TARGNAME Immunoglobulin Fc receptor (FCR) T49049 INDICATI Investigative Ischemic heart disease [ICD-11: BA40-BA6Z] T49049 INDICATI Approved Myasthenia gravis ICD-11: 8C60 T49049 INDICATI Phase 3 Myasthenia gravis [ICD-11: 8C6Y] T49049 INDICATI Phase 2 Rheumatoid arthritis [ICD-11: FA20] T49064 TARGETID T49064 T49064 TARGNAME Gastric triacylglycerol lipase (LIPF) T49064 INDICATI Phase 3 Acute diabete complication [ICD-11: 5A2Y] T49064 INDICATI Phase 3 Obesity [ICD-11: 5B80-5B81] T49072 TARGETID T49072 T49072 TARGNAME Urotensin II receptor (UTS2R) T49072 INDICATI Phase 1 Asthma [ICD-11: CA23] T49072 INDICATI Discontinued in Phase 1 Chronic kidney disease [ICD-11: GB61] T49072 INDICATI Discontinued in Phase 2 Kidney failure [ICD-11: GB60-GB6Z] T49105 TARGETID T49105 T49105 TARGNAME Transmembrane protein PVRIG (PVRIG) T49105 INDICATI Phase 1 Solid tumour/cancer [ICD-11: 2A00-2F9Z] T49146 TARGETID T49146 T49146 TARGNAME MHC class II antigen DR (HLA-DR) T49146 INDICATI Phase 1 Influenza [ICD-11: 1E30-1E32] T49146 INDICATI Phase 1 Leukaemia [ICD-11: 2A60-2B33] T49146 INDICATI Phase 1 Malignant haematopoietic neoplasm [ICD-11: 2B33] T49146 INDICATI Phase 2 Solid tumour/cancer [ICD-11: 2A00-2F9Z] T49156 TARGETID T49156 T49156 TARGNAME Tyrosine-protein phosphatase non-receptor type 2 (PTPN2) T49156 INDICATI Phase 1 Solid tumour/cancer [ICD-11: 2A00-2F9Z] T49327 TARGETID T49327 T49327 TARGNAME ATP-binding cassette transporter A4 (ABCA4) T49327 INDICATI Phase 1/2 Inherited retinal dystrophy [ICD-11: 9B70] T49368 TARGETID T49368 T49368 TARGNAME PKC-delta messenger RNA (PRKCD mRNA) T49368 INDICATI Investigative Human immunodeficiency virus disease [ICD-11: 1C60-1C62] T49453 TARGETID T49453 T49453 TARGNAME Notch-4 receptor (NOTCH4) T49453 INDICATI Phase 1 Lymphoma [ICD-11: 2A80-2A86] T49453 INDICATI Phase 1/2 Mature T-cell lymphoma [ICD-11: 2A90] T49453 INDICATI Phase 1/2 Solid tumour/cancer [ICD-11: 2A00-2F9Z] T49493 TARGETID T49493 T49493 TARGNAME Hemoglobin (HB) T49493 INDICATI Terminated Alopecia [ICD-11: ED70] T49493 INDICATI Phase 2/3 Anemia [ICD-11: 3A00-3A9Z] T49493 INDICATI Phase 1/2 Cardiovascular disease [ICD-11: BA00-BE2Z] T49493 INDICATI Terminated Cerebral ischaemia [ICD-11: 8B1Z] T49493 INDICATI Discontinued in Phase 3 Hypotension [ICD-11: BA20-BA21] T49493 INDICATI Approved Iron deficiency anaemia [ICD-11: 3A00] T49493 INDICATI Terminated Liver cancer [ICD-11: 2C12] T49493 INDICATI Phase 3 Lung cancer [ICD-11: 2C25] T49493 INDICATI Phase 1/2 Malignant haematopoietic neoplasm [ICD-11: 2B33] T49493 INDICATI Phase 2 Mineral absorption/transport disorder [ICD-11: 5C64] T49493 INDICATI Discontinued in Phase 1 Myeloproliferative neoplasm [ICD-11: 2A20] T49493 INDICATI Discontinued in Phase 2 Neutropenia [ICD-11: 4B00] T49493 INDICATI Phase 3 Pregnancy/childbirth/puerperium maternal infection [ICD-11: JB63] T49493 INDICATI Approved Sickle-cell disorder [ICD-11: 3A51] T49493 INDICATI Phase 2 Thalassaemia [ICD-11: 3A50] T49493 INDICATI Terminated Undiagnosed blood transfusion [ICD-11: QB98] T49493 INDICATI Terminated Unspecific body region injury [ICD-11: ND56] T49507 TARGETID T49507 T49507 TARGNAME Ephrin type-B receptor 4 (EPHB4) T49507 INDICATI Phase 2 Brain cancer [ICD-11: 2A00] T49507 INDICATI Phase 2 Cystic/dysplastic kidney disease [ICD-11: GB8Y] T49507 INDICATI Phase 2 Lung cancer [ICD-11: 2C25] T49507 INDICATI Phase 2 Metastatic meninges neoplasm [ICD-11: 2D51] T49507 INDICATI Phase 2 Metastatic tumour [ICD-11: 2D50-2E2Z] T49507 INDICATI Investigative Solid tumour/cancer [ICD-11: 2A00-2F9Z] T49526 TARGETID T49526 T49526 TARGNAME Voltage-gated potassium channel Kv7.1 (KCNQ1) T49526 INDICATI Approved Hypertension [ICD-11: BA00-BA04] T49571 TARGETID T49571 T49571 TARGNAME Aminotransferase (AT) T49571 INDICATI Phase 2 Liver disease [ICD-11: DB90-DB9Z] T49578 TARGETID T49578 T49578 TARGNAME Transient receptor potential channel (TRP channel) T49578 INDICATI Phase 2 Motor neuron disease [ICD-11: 8B60] T49578 INDICATI Phase 2 Multiple sclerosis [ICD-11: 8A40] T49578 INDICATI Investigative Postoperative inflammation [ICD-11: 1A00-CA43] T49578 INDICATI Phase 2 Tonus and reflex abnormality [ICD-11: MB47] T49630 TARGETID T49630 T49630 TARGNAME Lectin-like oxidized LDL receptor (OLR1) T49630 INDICATI Discontinued in Phase 1 Arterial occlusive disease [ICD-11: BD40] T49630 INDICATI Phase 2 Cardiovascular disease [ICD-11: BA00-BE2Z] T49630 INDICATI Phase 2 Coronary atherosclerosis [ICD-11: BA80] T49639 TARGETID T49639 T49639 TARGNAME Heat shock protein 70 (HSP70) T49639 INDICATI Discontinued in Phase 2 Acute diabete complication [ICD-11: 5A2Y] T49639 INDICATI Phase 1 Diabetic foot ulcer [ICD-11: BD54] T49639 INDICATI Investigative Heart failure [ICD-11: BD10-BD1Z] T49639 INDICATI Phase 1 Herpes simplex infection [ICD-11: 1F00] T49639 INDICATI Phase 2 Leukaemia [ICD-11: 2A60-2B33] T49639 INDICATI Phase 1 Malignant digestive organ neoplasm [ICD-11: 2C11] T49639 INDICATI Phase 1 Metastatic malignant neoplasm [ICD-11: 2D50-2E09] T49639 INDICATI Discontinued in Phase 2 Motor neuron disease [ICD-11: 8B60] T49639 INDICATI Phase 2 Neuropathy [ICD-11: 8C0Z] T49639 INDICATI Phase 1 Solid tumour/cancer [ICD-11: 2A00-2F9Z] T49639 INDICATI Phase 1 Stomach cancer [ICD-11: 2B72] T49639 INDICATI Discontinued in Phase 2 Supraventricular tachyarrhythmia [ICD-11: BC81] T49689 TARGETID T49689 T49689 TARGNAME Immunoglobulin G1k (IgG1k) T49689 INDICATI Phase 1 Sickle-cell disorder [ICD-11: 3A51] T49736 TARGETID T49736 T49736 TARGNAME T-cell differentiation antigen CD6 (TP120) T49736 INDICATI Phase 3 Diabetes mellitus [ICD-11: 5A10] T49755 TARGETID T49755 T49755 TARGNAME LDL receptor related protein-6 (LRP-6) T49755 INDICATI Phase 1 Solid tumour/cancer [ICD-11: 2A00-2F9Z] T49814 TARGETID T49814 T49814 TARGNAME Bacterial Deoxyribonucleic acid (Bact DNA) T49814 INDICATI Approved Amoebiasis [ICD-11: 1A36] T49814 INDICATI Approved Blastomycosis [ICD-11: 1F22] T49814 INDICATI Approved Bowel habit change [ICD-11: ME05] T49814 INDICATI Phase 2 Clostridium difficile enterocolitis [ICD-11: 1A04] T49814 INDICATI Approved Crohn disease [ICD-11: DD70] T49814 INDICATI Investigative Mycobacterium infection [ICD-11: 1B10-1B21] T49814 INDICATI Approved Sepsis [ICD-11: 1G40-1G41] T49814 INDICATI Approved Urinary tract infection [ICD-11: GC08] T49833 TARGETID T49833 T49833 TARGNAME TNF/IL-10 release (TNF/IL10 rele) T49833 INDICATI Phase 2 Postoperative inflammation [ICD-11: 1A00-CA43] T49898 TARGETID T49898 T49898 TARGNAME Cyclin-dependent kinase 1 (CDK1) T49898 INDICATI Patented Allergic/hypersensitivity disorder [ICD-11: 4A80-4A8Z] T49898 INDICATI Phase 2 Breast cancer [ICD-11: 2C60-2C6Y] T49898 INDICATI Phase 2 Lung cancer [ICD-11: 2C25] T49898 INDICATI Phase 1 Malignant haematopoietic neoplasm [ICD-11: 2B33] T49898 INDICATI Phase 2 Mature B-cell lymphoma [ICD-11: 2A85] T49898 INDICATI Investigative Nasopharyngeal cancer [ICD-11: 2B6B] T49898 INDICATI Preclinical Obesity [ICD-11: 5B80-5B81] T49898 INDICATI Investigative Pain [ICD-11: MG30-MG3Z] T49898 INDICATI Phase 2 Solid tumour/cancer [ICD-11: 2A00-2F9Z] T49898 INDICATI Patented Transplant rejection [ICD-11: NE84] T49989 TARGETID T49989 T49989 TARGNAME TGF-beta receptor type II (TGFBR2) T49989 INDICATI Phase 1 Solid tumour/cancer [ICD-11: 2A00-2F9Z] T50066 TARGETID T50066 T50066 TARGNAME Chloride channel protein 2 (CLC-2) T50066 INDICATI Phase 2 Alopecia [ICD-11: ED70] T50066 INDICATI Approved Chronic pancreatitis [ICD-11: DC32] T50089 TARGETID T50089 T50089 TARGNAME Sphingosine-1-phosphate receptor 5 (S1PR5) T50089 INDICATI Phase 1 Multiple sclerosis [ICD-11: 8A40] T50261 TARGETID T50261 T50261 TARGNAME PI3-kinase (PIK3C) T50261 INDICATI Investigative Breast cancer [ICD-11: 2C60-2C6Y] T50269 TARGETID T50269 T50269 TARGNAME Strychnine-binding glycine receptor (GLRA1) T50269 INDICATI Terminated Sepsis [ICD-11: 1G40-1G41] T50269 INDICATI Approved Tonus and reflex abnormality [ICD-11: MB47] T50289 TARGETID T50289 T50289 TARGNAME Bone morphogenetic protein 7 (BMP7) T50289 INDICATI Phase 2 Kidney fibrosis [ICD-11: GC01] T50444 TARGETID T50444 T50444 TARGNAME Connective tissue growth factor (CTGF) T50444 INDICATI Phase 1b Chronic kidney disease [ICD-11: GB61] T50444 INDICATI Phase 2 Idiopathic interstitial pneumonitis [ICD-11: CB03] T50444 INDICATI Phase 2 Pancreatic cancer [ICD-11: 2C10] T50444 INDICATI Phase 2 Schizoaffective disorder [ICD-11: 6A21] T50444 INDICATI Phase 2 Schizophrenia [ICD-11: 6A20] T50444 INDICATI Phase 2 Type 2 diabetes mellitus [ICD-11: 5A11] T50445 TARGETID T50445 T50445 TARGNAME CD40 messenger RNA (CD40 mRNA) T50445 INDICATI Phase 1 Graft-versus-host disease [ICD-11: 4B24] T50461 TARGETID T50461 T50461 TARGNAME Ribonuclease (RNase) T50461 INDICATI Phase 2 Cervical cancer [ICD-11: 2C77] T50461 INDICATI Phase 1 Human immunodeficiency virus disease [ICD-11: 1C60-1C62] T50461 INDICATI Phase 2 Lung cancer [ICD-11: 2C25] T50461 INDICATI Terminated Solid tumour/cancer [ICD-11: 2A00-2F9Z] T50547 TARGETID T50547 T50547 TARGNAME Plasmodium Plasmepsin 1 (Malaria PLA1) T50547 INDICATI Terminated Malaria [ICD-11: 1F40-1F45] T50584 TARGETID T50584 T50584 TARGNAME Protein bactericidal permeability-increasing (BPI) T50584 INDICATI Phase 2 Acne vulgaris [ICD-11: ED80] T50594 TARGETID T50594 T50594 TARGNAME Serine/threonine-protein kinase pim-1 (PIM1) T50594 INDICATI Phase 1/2 Acute myeloid leukaemia [ICD-11: 2A60] T50594 INDICATI Investigative Non-small-cell lung cancer [ICD-11: 2C25] T50594 INDICATI Phase 1 Solid tumour/cancer [ICD-11: 2A00-2F9Z] T50688 TARGETID T50688 T50688 TARGNAME Glycoprotein IIb/IIIa receptor (GPIIb/IIIa) T50688 INDICATI Approved Acquired hypermelanosis [ICD-11: ED60] T50688 INDICATI Approved Angina pectoris [ICD-11: BA40] T50688 INDICATI Discontinued in Phase 2 Arterial occlusive disease [ICD-11: BD40] T50688 INDICATI Terminated Arterial thrombosis [ICD-11: DB61-DD30] T50688 INDICATI Discontinued in Phase 2 Arteries/arterioles disorder [ICD-11: BD52] T50688 INDICATI Discontinued in Phase 3 Cardiovascular disease [ICD-11: BA00-BE2Z] T50688 INDICATI Discontinued in Phase 3 Chronic arterial occlusive disease [ICD-11: BD4Z] T50688 INDICATI Discontinued in Phase 2 Circulatory system disease [ICD-11: BE2Z] T50688 INDICATI Phase 3 Coronary atherosclerosis [ICD-11: BA80] T50688 INDICATI Approved Myocardial infarction [ICD-11: BA41-BA43] T50688 INDICATI Phase 1/2 Obstetric embolism [ICD-11: JB42] T50688 INDICATI Phase 1 Thrombosis [ICD-11: DB61-GB90] T50699 TARGETID T50699 T50699 TARGNAME Lymphotoxin beta receptor (LTBR) T50699 INDICATI Phase 2 Rheumatoid arthritis [ICD-11: FA20] T50699 INDICATI Phase 1 Solid tumour/cancer [ICD-11: 2A00-2F9Z] T50823 TARGETID T50823 T50823 TARGNAME Semaphorin-4D (SEMA4D) T50823 INDICATI Phase 2 Choreiform disorder [ICD-11: 8A01] T50823 INDICATI Phase 1 Lung cancer [ICD-11: 2C25] T50823 INDICATI Phase 1/2 Metastatic lymph node neoplasm [ICD-11: 2D60] T50823 INDICATI Phase 1 Multiple sclerosis [ICD-11: 8A40] T50912 TARGETID T50912 T50912 TARGNAME T-lymphocyte activation antigen CD86 (FUN1) T50912 INDICATI Phase 1 Diabetes mellitus [ICD-11: 5A10] T50912 INDICATI Approved Rheumatoid arthritis [ICD-11: FA20] T50912 INDICATI Terminated Transplant rejection [ICD-11: NE84] T50942 TARGETID T50942 T50942 TARGNAME Low-affinity nerve growth factor receptor (NGFR) T50942 INDICATI Phase 1/2 Alzheimer disease [ICD-11: 8A20] T50942 INDICATI Investigative Cerebral ischaemia [ICD-11: 8B1Z] T50942 INDICATI Phase 3 Chronic pain [ICD-11: MG30] T50942 INDICATI Terminated Cystitis [ICD-11: GC00] T50942 INDICATI Phase 3 Joint pain [ICD-11: ME82] T50942 INDICATI Discontinued in Phase 3 Mild neurocognitive disorder [ICD-11: 6D71] T50942 INDICATI Investigative Motor neuron disease [ICD-11: 8B60] T50942 INDICATI Investigative Neurodegenerative disorder [ICD-11: 8A20-8A23] T50942 INDICATI Approved Neurotrophic keratitis [ICD-11: 9A74] T50942 INDICATI Investigative Pain [ICD-11: MG30-MG3Z] T50942 INDICATI Phase 2 Parkinsonism [ICD-11: 8A00] T50942 INDICATI Phase 3 Spinal pain [ICD-11: ME84] T50973 TARGETID T50973 T50973 TARGNAME Kynurenine 3-hydroxylase (KMO) T50973 INDICATI Preclinical Choreiform disorder [ICD-11: 8A01] T50973 INDICATI Preclinical Neurodegenerative disorder [ICD-11: 8A20-8A23] T50973 INDICATI Phase 1 Pancreatitis [ICD-11: DC31-DC34] T51038 TARGETID T51038 T51038 TARGNAME Hyaluronic acid (HA) T51038 INDICATI Approved Resorption of radiopaque agents [ICD-11: N.A.] T51038 INDICATI Approved Solid tumour/cancer [ICD-11: 2A00-2F9Z] T51076 TARGETID T51076 T51076 TARGNAME NT-3 growth factor receptor (TrkC) T51076 INDICATI Phase 1 Adrenal cancer [ICD-11: 2D11] T51076 INDICATI Phase 1/2 Alzheimer disease [ICD-11: 8A20] T51076 INDICATI Phase 1 Breast cancer [ICD-11: 2C60-2C6Y] T51076 INDICATI Patented Chronic pain [ICD-11: MG30] T51076 INDICATI Phase 2 Colorectal cancer [ICD-11: 2B91] T51076 INDICATI Patented General pain disorder [ICD-11: 8E43] T51076 INDICATI Approved Non-small-cell lung cancer [ICD-11: 2C25] T51076 INDICATI Patented Pruritus [ICD-11: EC90] T51076 INDICATI Approved Solid tumour/cancer [ICD-11: 2A00-2F9Z] T51076 INDICATI Patented Thymoma [ICD-11: 2C27] T51115 TARGETID T51115 T51115 TARGNAME Voltage-gated calcium channel alpha Cav1.2 (CACNA1C) T51115 INDICATI Phase 3 Alzheimer disease [ICD-11: 8A20] T51115 INDICATI Terminated Angina pectoris [ICD-11: BA40] T51115 INDICATI Terminated Genetic cardiac arrhythmia [ICD-11: BC65] T51115 INDICATI Investigative Heart failure [ICD-11: BD10-BD1Z] T51115 INDICATI Terminated Unspecific body region injury [ICD-11: ND56] T51120 TARGETID T51120 T51120 TARGNAME Thyroid peroxidase (TPO) T51120 INDICATI Investigative Thrombocytopenia [ICD-11: 3B64] T51120 INDICATI Approved Thyrotoxicosis [ICD-11: 5A02] T51146 TARGETID T51146 T51146 TARGNAME Fucosyltransferase IV (CD15) T51146 INDICATI Approved Appendicitis [ICD-11: DB10] T51191 TARGETID T51191 T51191 TARGNAME Histone deacetylase 2 (HDAC2) T51191 INDICATI Investigative Eczema [ICD-11: EA80-EA89] T51191 INDICATI Phase 1/2 Lymphoma [ICD-11: 2A80-2A86] T51191 INDICATI Phase 1 Solid tumour/cancer [ICD-11: 2A00-2F9Z] T51223 TARGETID T51223 T51223 TARGNAME Interleukin-21 (IL21) T51223 INDICATI Phase 2 Colorectal cancer [ICD-11: 2B91] T51223 INDICATI Phase 1 Diabetes mellitus [ICD-11: 5A10] T51282 TARGETID T51282 T51282 TARGNAME Rho-associated protein kinase 1 (ROCK1) T51282 INDICATI Phase 2 Chronic kidney disease [ICD-11: GB61] T51282 INDICATI Investigative Chronic obstructive pulmonary disease [ICD-11: CA22] T51282 INDICATI Phase 2 Coronary microvascular disease [ICD-11: BA86] T51282 INDICATI Approved Glaucoma [ICD-11: 9C61] T51282 INDICATI Investigative Pain [ICD-11: MG30-MG3Z] T51282 INDICATI Clinical trial Postoperative inflammation [ICD-11: 1A00-CA43] T51282 INDICATI Phase 2 Pulmonary hypertension [ICD-11: BB01] T51282 INDICATI Investigative Solid tumour/cancer [ICD-11: 2A00-2F9Z] T51407 TARGETID T51407 T51407 TARGNAME Exportin-1 (XPO1) T51407 INDICATI Phase 2 Acute myeloid leukaemia [ICD-11: 2A60] T51407 INDICATI Phase 2 Brain cancer [ICD-11: 2A00] T51407 INDICATI Phase 1/2 Colorectal cancer [ICD-11: 2B91] T51407 INDICATI Phase 2 Diffuse large B-cell lymphoma [ICD-11: 2A81] T51407 INDICATI Phase 3 Liposarcoma [ICD-11: 2B59] T51407 INDICATI Phase 3 Multiple myeloma [ICD-11: 2A83] T51407 INDICATI Phase 1/2 Myelodysplastic syndrome [ICD-11: 2A37] T51407 INDICATI Phase 1/2 Prostate cancer [ICD-11: 2C82] T51407 INDICATI Phase 2 Solid tumour/cancer [ICD-11: 2A00-2F9Z] T51407 INDICATI Phase 3 Stomach cancer [ICD-11: 2B72] T51408 TARGETID T51408 T51408 TARGNAME Adrenergic receptor beta-3 (ADRB3) T51408 INDICATI Phase 2 Abnormal micturition [ICD-11: MF50] T51408 INDICATI Phase 2 Acute diabete complication [ICD-11: 5A2Y] T51408 INDICATI Approved Angina pectoris [ICD-11: BA40] T51408 INDICATI Approved Asthma [ICD-11: CA23] T51408 INDICATI Phase 1 Bladder disorder [ICD-11: GC01] T51408 INDICATI Approved Chronic obstructive pulmonary disease [ICD-11: CA22] T51408 INDICATI Discontinued in Phase 3 Depression [ICD-11: 6A70-6A7Z] T51408 INDICATI Terminated Digestive system disease [ICD-11: DE2Z] T51408 INDICATI Approved Dystonic disorder [ICD-11: 8A02] T51408 INDICATI Approved Functional bladder disorder [ICD-11: GC50] T51408 INDICATI Phase 1/2 Glaucoma [ICD-11: 9C61] T51408 INDICATI Approved Hypertension [ICD-11: BA00-BA04] T51408 INDICATI Terminated Irritable bowel syndrome [ICD-11: DD91] T51408 INDICATI Phase 2/3 Ischaemic/haemorrhagic stroke [ICD-11: 8B20] T51408 INDICATI Phase 2 Left ventricular failure ICD-11: BD11 T51408 INDICATI Discontinued in Phase 3 Mood disorder [ICD-11: 6A60-6E23] T51408 INDICATI Phase 2 Obesity [ICD-11: 5B80-5B81] T51408 INDICATI Approved Parkinsonism [ICD-11: 8A00] T51408 INDICATI Phase 2 Type 2 diabetes mellitus [ICD-11: 5A11] T51425 TARGETID T51425 T51425 TARGNAME Vascular endothelial growth factor C (VEGFC) T51425 INDICATI Phase 2 Retinopathy [ICD-11: 9B71] T51425 INDICATI Phase 1 Solid tumour/cancer [ICD-11: 2A00-2F9Z] T51426 TARGETID T51426 T51426 TARGNAME Farnesoid X-activated receptor (FXR) T51426 INDICATI Approved Autoimmune liver disease [ICD-11: DB96] T51426 INDICATI Phase 3 Breast cancer [ICD-11: 2C60-2C6Y] T51426 INDICATI Approved Cholelithiasis [ICD-11: DC11] T51426 INDICATI Phase 2 Chronic kidney disease [ICD-11: GB61] T51426 INDICATI Phase 1 Hepatic fibrosis/cirrhosis [ICD-11: DB93] T51426 INDICATI Phase 1 Hyper-lipoproteinaemia [ICD-11: 5C80] T51426 INDICATI Clinical trial Insomnia [ICD-11: 7A00-7A0Z] T51426 INDICATI Phase 2 Non-alcoholic fatty liver disease [ICD-11: DB92] T51426 INDICATI Approved Osteoarthritis [ICD-11: FA00-FA05] T51426 INDICATI Phase 2 Skeletal anomaly [ICD-11: LD24] T51426 INDICATI Discontinued in Phase 2 Type 2 diabetes mellitus [ICD-11: 5A11] T51452 TARGETID T51452 T51452 TARGNAME GABA(A) receptor alpha-2 (GABRA2) T51452 INDICATI Discontinued in Phase 2 General pain disorder [ICD-11: 8E43] T51452 INDICATI Phase 2 Indeterminate colitis [ICD-11: DD72] T51452 INDICATI Approved Intentional self-harm [ICD-11: PC91] T51452 INDICATI Investigative Postoperative inflammation [ICD-11: 1A00-CA43] T51452 INDICATI Terminated Substance abuse [ICD-11: 6C40] T51468 TARGETID T51468 T51468 TARGNAME Cdc-like kinase (CLK) T51468 INDICATI Phase 1 Malignant haematopoietic neoplasm [ICD-11: 2B33] T51487 TARGETID T51487 T51487 TARGNAME GABA(A) receptor alpha-1 (GABRA1) T51487 INDICATI Approved Acute respiratory distress syndrome [ICD-11: CB00] T51487 INDICATI Approved Anxiety disorder [ICD-11: 6B00-6B0Z] T51487 INDICATI Approved Chronic insomnia [ICD-11: 7A00] T51487 INDICATI Approved Chronic pain [ICD-11: MG30] T51487 INDICATI Approved Corneal disease [ICD-11: 9A76-9A78] T51487 INDICATI Approved Cystitis [ICD-11: GC00] T51487 INDICATI Approved Depression [ICD-11: 6A70-6A7Z] T51487 INDICATI Approved Epilepsy/seizure [ICD-11: 8A61-8A6Z] T51487 INDICATI Discontinued in Phase 3 Female pelvic pain [ICD-11: GA34] T51487 INDICATI Approved Headache [ICD-11: 8A80-8A84] T51487 INDICATI Phase 2 Indeterminate colitis [ICD-11: DD72] T51487 INDICATI Approved Insomnia [ICD-11: 7A00-7A0Z] T51487 INDICATI Discontinued in Phase 1 Liver vascular disorder [ICD-11: DB98] T51487 INDICATI Approved Malaria [ICD-11: 1F40-1F45] T51487 INDICATI Approved Mental/behavioural/neurodevelopmental disorder [ICD-11: 6E20-6E8Z] T51487 INDICATI Investigative Postoperative inflammation [ICD-11: 1A00-CA43] T51487 INDICATI Phase 3 Status epilepticus [ICD-11: 8A66] T51487 INDICATI Approved Tonus and reflex abnormality [ICD-11: MB47] T51487 INDICATI Phase 2 Tremor-related disorder [ICD-11: 8A04] T51499 TARGETID T51499 T51499 TARGNAME Ganglioside GM2 activator (GM2A) T51499 INDICATI Phase 1/2 Multiple myeloma [ICD-11: 2A83] T51565 TARGETID T51565 T51565 TARGNAME Casein kinase II alpha (CSNK2A1) T51565 INDICATI Phase 2 Coronavirus infection [ICD-11: 1D92] T51565 INDICATI Phase 1/2 Liver cancer [ICD-11: 2C12] T51565 INDICATI Phase 1 Solid tumour/cancer [ICD-11: 2A00-2F9Z] T51593 TARGETID T51593 T51593 TARGNAME Tryptophan hydroxylase (TPH) T51593 INDICATI Approved Carcinoid syndrome [ICD-11: 5B10] T51593 INDICATI Approved Small intestine developmental anomaly [ICD-11: DA90] T51666 TARGETID T51666 T51666 TARGNAME Gastric H(+)/K(+) ATPase alpha (ATP4A) T51666 INDICATI Approved Bacterial infection [ICD-11: 1A00-1C4Z] T51666 INDICATI Investigative Cardiovascular disease [ICD-11: BA00-BE2Z] T51666 INDICATI Investigative Colorectal cancer [ICD-11: 2B91] T51666 INDICATI Phase 3 Gastric ulcer [ICD-11: DA60] T51666 INDICATI Approved Gastro-oesophageal reflux disease [ICD-11: DA22] T51666 INDICATI Investigative Helicobacter infection [ICD-11: DA42-DA63] T51666 INDICATI Approved Oesophageal ulcer [ICD-11: DA25] T51666 INDICATI Approved Peptic ulcer [ICD-11: DA61] T51666 INDICATI Preclinical Solid tumour/cancer [ICD-11: 2A00-2F9Z] T51666 INDICATI Phase 3 Ulcerative colitis [ICD-11: DD71] T51672 TARGETID T51672 T51672 TARGNAME NF-kappa-B inhibitor alpha (NFKBIA) T51672 INDICATI Phase 3 Breast cancer [ICD-11: 2C60-2C6Y] T51672 INDICATI Phase 2 Metabolic disorder [ICD-11: 5C50-5D2Z] T51693 TARGETID T51693 T51693 TARGNAME Melanoma-associated antigen 3 (MAGEA3) T51693 INDICATI Phase 2 Colorectal cancer [ICD-11: 2B91] T51693 INDICATI Phase 2 Head and neck cancer [ICD-11: 2D42] T51693 INDICATI Phase 2 Lip/oral cavity/pharynx neoplasm [ICD-11: 2B6E] T51693 INDICATI Phase 3 Lung cancer [ICD-11: 2C25] T51693 INDICATI Phase 2 Melanoma [ICD-11: 2C30] T51693 INDICATI Phase 2 Multiple myeloma [ICD-11: 2A83] T51693 INDICATI Phase 1 Solid tumour/cancer [ICD-11: 2A00-2F9Z] T51693 INDICATI Phase 2 Squamous cell carcinoma [ICD-11: 2B60-2D01] T51694 TARGETID T51694 T51694 TARGNAME Histone synthesis (Histone synth) T51694 INDICATI Discontinued in Phase 2 Solid tumour/cancer [ICD-11: 2A00-2F9Z] T51748 TARGETID T51748 T51748 TARGNAME HIF1-alpha messenger RNA (HIF1A mRNA) T51748 INDICATI Phase 2 Adrenomedullary hyperfunction [ICD-11: 5A75] T51748 INDICATI Phase 2 Brain cancer [ICD-11: 2A00] T51803 TARGETID T51803 T51803 TARGNAME microRNA hsa-miR-34 (MIR34) T51803 INDICATI Phase 1 Liver cancer [ICD-11: 2C12] T51843 TARGETID T51843 T51843 TARGNAME Virus RNA-dependent RNA polymerase (Viru RdRP) T51843 INDICATI Phase 2 COVID-19 [ICD-11: 1D6Y] T51843 INDICATI Investigative Virus infection [ICD-11: 1A24-1D9Z] T51883 TARGETID T51883 T51883 TARGNAME Serine/threonine-protein kinase Raf (RAF) T51883 INDICATI Phase 1 Melanoma [ICD-11: 2C30] T51883 INDICATI Phase 2 Non-small-cell lung cancer [ICD-11: 2C25] T51883 INDICATI Phase 2 Ovarian cancer [ICD-11: 2C73] T51883 INDICATI Phase 2 Solid tumour/cancer [ICD-11: 2A00-2F9Z] T51908 TARGETID T51908 T51908 TARGNAME Cryptochrome-2 (CRY2) T51908 INDICATI Preclinical Brain cancer [ICD-11: 2A00] T51908 INDICATI Preclinical Breast cancer [ICD-11: 2C60-2C6Y] T52007 TARGETID T52007 T52007 TARGNAME Peripheral carotid chemoreceptor (PCC) T52007 INDICATI Approved Respiratory system disease [ICD-11: CB40-CB7Z] T52034 TARGETID T52034 T52034 TARGNAME SERPINH1 messenger RNA (SERPINH1 mRNA) T52034 INDICATI Phase 2 Hepatic fibrosis/cirrhosis [ICD-11: DB93] T52036 TARGETID T52036 T52036 TARGNAME Ubiquitin carboxyl-terminal hydrolase 20 (USP20) T52036 INDICATI Preclinical Solid tumour/cancer [ICD-11: 2A00-2F9Z] T52037 TARGETID T52037 T52037 TARGNAME Toll-like receptor 6 (TLR6) T52037 INDICATI Phase 1/2 Pancreatic cancer [ICD-11: 2C10] T52098 TARGETID T52098 T52098 TARGNAME Ornithine transcarbamylase (OTC) T52098 INDICATI Phase 3 Metabolism inborn error [ICD-11: 5C50] T52110 TARGETID T52110 T52110 TARGNAME Lipopolysaccharide-binding protein (LBP) T52110 INDICATI Discontinued in Phase 2 Sepsis [ICD-11: 1G40-1G41] T52138 TARGETID T52138 T52138 TARGNAME Hepatitis B virus Large envelope protein messenger RNA (HBV S mRNA) T52138 INDICATI Phase 2 Hepatitis virus infection [ICD-11: 1E50-1E51] T52173 TARGETID T52173 T52173 TARGNAME Amiloride-sensitive sodium channel (ENaC) T52173 INDICATI Phase 2 Cystic fibrosis [ICD-11: CA25] T52173 INDICATI Approved Heart failure [ICD-11: BD10-BD1Z] T52173 INDICATI Approved Hypertension [ICD-11: BA00-BA04] T52173 INDICATI Phase 2 Lung structural developmental anomaly [ICD-11: LA75] T52173 INDICATI Approved Oedema [ICD-11: MG29] T52188 TARGETID T52188 T52188 TARGNAME Plasmodium Acetyl-CoA carboxylase 1 (Malaria ACC1) T52188 INDICATI Investigative Parkinsonism [ICD-11: 8A00] T52189 TARGETID T52189 T52189 TARGNAME ATP-citrate synthase (ACLY) T52189 INDICATI Phase 3 Cardiovascular disease [ICD-11: BA00-BE2Z] T52189 INDICATI Approved Hyper-lipoproteinaemia [ICD-11: 5C80] T52227 TARGETID T52227 T52227 TARGNAME Candida Thymidylate synthase (Candi TMP1) T52227 INDICATI Approved Bacterial infection [ICD-11: 1A00-1C4Z] T52227 INDICATI Phase 3 Breast cancer [ICD-11: 2C60-2C6Y] T52227 INDICATI Approved Colon cancer [ICD-11: 2B90] T52227 INDICATI Approved Colorectal cancer [ICD-11: 2B91] T52227 INDICATI Phase 2 Cystic fibrosis [ICD-11: CA25] T52227 INDICATI Phase 1 Digestive organ benign neoplasm [ICD-11: 2E92] T52227 INDICATI Approved Endocarditis [ICD-11: BB40-BA42] T52227 INDICATI Approved Gram-positive bacterial infection [ICD-11: 1B74-1F40] T52227 INDICATI Terminated Keratosis pilaris [ICD-11: ED56] T52227 INDICATI Approved Pleural mesothelioma [ICD-11: 2C26] T52227 INDICATI Approved Rectum cancer [ICD-11: 2B92] T52227 INDICATI Approved Solid tumour/cancer [ICD-11: 2A00-2F9Z] T52227 INDICATI Phase 2 Stomach cancer [ICD-11: 2B72] T52227 INDICATI Approved Virus infection [ICD-11: 1A24-1D9Z] T52258 TARGETID T52258 T52258 TARGNAME Hepatitis B virus messenger RNA (HBV mRNA) T52258 INDICATI Phase 2 Hepatitis virus infection [ICD-11: 1E50-1E51] T52297 TARGETID T52297 T52297 TARGNAME Oxysterols receptor LXR-alpha (NR1H3) T52297 INDICATI Investigative Depression [ICD-11: 6A70-6A7Z] T52316 TARGETID T52316 T52316 TARGNAME Raf messenger RNA (Raf mRNA) T52316 INDICATI Investigative Diabetes mellitus [ICD-11: 5A10] T52316 INDICATI Phase 1 Lung cancer [ICD-11: 2C25] T52316 INDICATI Phase 1 Melanoma [ICD-11: 2C30] T52316 INDICATI Phase 1 Parkinsonism [ICD-11: 8A00] T52316 INDICATI Phase 1 Retinopathy [ICD-11: 9B71] T52316 INDICATI Phase 2 Solid tumour/cancer [ICD-11: 2A00-2F9Z] T52349 TARGETID T52349 T52349 TARGNAME Enterococcus fsrC (Ente-cocc fsrC) T52349 INDICATI Preclinical Infectious meningitis [ICD-11: 1D01] T52389 TARGETID T52389 T52389 TARGNAME Quinone reductase 1 (NQO1) T52389 INDICATI Phase 2 Choreiform disorder [ICD-11: 8A01] T52389 INDICATI Phase 2 CNS anomalies syndrome [ICD-11: LD20] T52389 INDICATI Phase 2 Inborn energy metabolism error [ICD-11: 5C53] T52389 INDICATI Phase 2 Intellectual development disorder [ICD-11: LD90] T52389 INDICATI Phase 2 Pancreatic cancer [ICD-11: 2C10] T52389 INDICATI Phase 1 Solid tumour/cancer [ICD-11: 2A00-2F9Z] T52450 TARGETID T52450 T52450 TARGNAME Matrix metalloproteinase-1 (MMP-1) T52450 INDICATI Discontinued in Phase 3 Brain cancer [ICD-11: 2A00] T52450 INDICATI Discontinued in Phase 2 Chronic kidney disease [ICD-11: GB61] T52450 INDICATI Discontinued in Phase 2 Corneal disease [ICD-11: 9A76-9A78] T52450 INDICATI Discontinued in Phase 2 Hepatitis virus infection [ICD-11: 1E50-1E51] T52450 INDICATI Discontinued in Phase 3 Kaposi sarcoma [ICD-11: 2B57] T52450 INDICATI Approved Lung cancer [ICD-11: 2C25] T52450 INDICATI Terminated Multiple sclerosis [ICD-11: 8A40] T52450 INDICATI Phase 3 Pancreatic cancer [ICD-11: 2C10] T52450 INDICATI Discontinued in Phase 3 Prostate cancer [ICD-11: 2C82] T52450 INDICATI Phase 3 Rheumatoid arthritis [ICD-11: FA20] T52450 INDICATI Terminated Solid tumour/cancer [ICD-11: 2A00-2F9Z] T52489 TARGETID T52489 T52489 TARGNAME Rap guanine nucleotide exchange factor 3 (RAPGEF3) T52489 INDICATI Phase 2 Epidermal dysplasias [ICD-11: EK90] T52522 TARGETID T52522 T52522 TARGNAME Adrenergic receptor beta-2 (ADRB2) T52522 INDICATI Approved Asthma [ICD-11: CA23] T52522 INDICATI Phase 1 Bladder disorder [ICD-11: GC01] T52522 INDICATI Phase 3 Breast cancer [ICD-11: 2C60-2C6Y] T52522 INDICATI Phase 2 Cachexia [ICD-11: MG20] T52522 INDICATI Terminated Cardiovascular disease [ICD-11: BA00-BE2Z] T52522 INDICATI Approved Chronic obstructive pulmonary disease [ICD-11: CA22] T52522 INDICATI Approved Conduction disorder [ICD-11: BC63] T52522 INDICATI Phase 2 Dermal/subcutaneous connective tissue atrophy/degeneration [ICD-11: EE40] T52522 INDICATI Discontinued in Preregistration Ejaculatory dysfunction [ICD-11: HA03] T52522 INDICATI Phase 2 Hypertension [ICD-11: BA00-BA04] T52522 INDICATI Phase 1 Melanoma [ICD-11: 2C30] T52522 INDICATI Phase 1 Obesity [ICD-11: 5B80-5B81] T52522 INDICATI Approved Preterm labour/delivery [ICD-11: JB00] T52522 INDICATI Phase 2 Skin and skin-structure infection [ICD-11: 1F28-1G0Z] T52522 INDICATI Approved Sleep-related breathing disorder [ICD-11: 7A4Z] T52522 INDICATI Phase 3 Stomach cancer [ICD-11: 2B72] T52522 INDICATI Phase 2/3 Supraventricular tachyarrhythmia [ICD-11: BC81] T52534 TARGETID T52534 T52534 TARGNAME Bacterial Protein synthesis (Bact PROS) T52534 INDICATI Phase 2 Acne vulgaris [ICD-11: ED80] T52534 INDICATI Phase 2 Bacterial infection [ICD-11: 1A00-1C4Z] T52534 INDICATI Phase 2 HIV-infected patients with tuberculosis [ICD-11: 1B10-1B14] T52534 INDICATI Phase 2 Pneumonia [ICD-11: CA40] T52624 TARGETID T52624 T52624 TARGNAME Platelet-derived growth factor receptor (PDGFR) T52624 INDICATI Phase 3 Acute diabete complication [ICD-11: 5A2Y] T52624 INDICATI Phase 2 Breast cancer [ICD-11: 2C60-2C6Y] T52624 INDICATI Approved Colorectal cancer [ICD-11: 2B91] T52624 INDICATI Phase 4 Coronary atherosclerosis [ICD-11: BA80] T52624 INDICATI Approved Diabetic foot ulcer [ICD-11: BD54] T52624 INDICATI Phase 2 Endometrial cancer [ICD-11: 2C76] T52624 INDICATI Approved Idiopathic interstitial pneumonitis [ICD-11: CB03] T52624 INDICATI Phase 3 Lung cancer [ICD-11: 2C25] T52624 INDICATI Phase 2 Macular degeneration [ICD-11: 9B75] T52624 INDICATI Phase 3 Malignant intestine neoplasm [ICD-11: 2C0Z] T52624 INDICATI Investigative Mastocytosis [ICD-11: 2A21] T52624 INDICATI Approved Mature B-cell lymphoma [ICD-11: 2A85] T52624 INDICATI Investigative Multiple myeloma [ICD-11: 2A83] T52624 INDICATI Approved Myeloproliferative neoplasm [ICD-11: 2A20] T52624 INDICATI Phase 4 Myocardial infarction [ICD-11: BA41-BA43] T52624 INDICATI Phase 2 Non-small-cell lung cancer [ICD-11: 2C25] T52624 INDICATI Phase 2 Ovarian cancer [ICD-11: 2C73] T52624 INDICATI Phase 3 Peritoneal cancer [ICD-11: 2C51] T52624 INDICATI Patented Pulmonary hypertension [ICD-11: BB01] T52624 INDICATI Approved Renal cell carcinoma [ICD-11: 2C90] T52624 INDICATI Phase 1 Retinopathy [ICD-11: 9B71] T52624 INDICATI Phase 2 Solid tumour/cancer [ICD-11: 2A00-2F9Z] T52624 INDICATI Phase 2 Stomach cancer [ICD-11: 2B72] T52671 TARGETID T52671 T52671 TARGNAME Apolipoprotein(a) (LPA) T52671 INDICATI Phase 2 Cardiovascular disease [ICD-11: BA00-BE2Z] T52671 INDICATI Phase 1 Solid tumour/cancer [ICD-11: 2A00-2F9Z] T52771 TARGETID T52771 T52771 TARGNAME Mycobacterium Proton pump (MycB Prop) T52771 INDICATI Approved Antimicrobial drug resistance [ICD-11: MG50-MG52] T52790 TARGETID T52790 T52790 TARGNAME Substance-K receptor (TACR2) T52790 INDICATI Discontinued in Phase 1 Abnormal micturition [ICD-11: MF50] T52790 INDICATI Discontinued in Phase 1 Acute/chronic pain [ICD-11: MG30-MG31] T52790 INDICATI Discontinued in Phase 3 Anxiety disorder [ICD-11: 6B00-6B0Z] T52790 INDICATI Discontinued in Phase 2 Asthma [ICD-11: CA23] T52790 INDICATI Phase 2 Atopic eczema [ICD-11: EA80] T52790 INDICATI Discontinued in Phase 2 Chronic obstructive pulmonary disease [ICD-11: CA22] T52790 INDICATI Discontinued in Phase 3 Depression [ICD-11: 6A70-6A7Z] T52790 INDICATI Phase 1/2 Infants/toddlers/children functional digestive disorder [ICD-11: DD93] T52790 INDICATI Phase 3 Irritable bowel syndrome [ICD-11: DD91] T52790 INDICATI Terminated Pain [ICD-11: MG30-MG3Z] T52790 INDICATI Phase 1/2 Postoperative ileus [ICD-11: DA91-DB30] T52790 INDICATI Phase 2 Psoriasis [ICD-11: EA90] T52873 TARGETID T52873 T52873 TARGNAME 3-oxo-dodecanoyl-homoserine lactone (C12) T52873 INDICATI Preclinical Glanders [ICD-11: 1B92] T52910 TARGETID T52910 T52910 TARGNAME Ubiquitin carboxyl-terminal hydrolase 30 (USP30) T52910 INDICATI Preclinical Neurodegenerative disorder [ICD-11: 8A20-8A23] T52921 TARGETID T52921 T52921 TARGNAME Nociceptin receptor (OPRL1) T52921 INDICATI Investigative Anxiety disorder [ICD-11: 6B00-6B0Z] T52921 INDICATI Phase 2 Atopic eczema [ICD-11: EA80] T52921 INDICATI Investigative Central nervous system disease [ICD-11: 8A04-8D87] T52921 INDICATI Phase 2 Depression [ICD-11: 6A70-6A7Z] T52921 INDICATI Phase 1 Headache [ICD-11: 8A80-8A84] T52921 INDICATI Phase 2 Heart failure [ICD-11: BD10-BD1Z] T52921 INDICATI Preclinical Irritable bowel syndrome [ICD-11: DD91] T52921 INDICATI Discontinued in Phase 2 Pain [ICD-11: MG30-MG3Z] T52921 INDICATI Investigative Postoperative inflammation [ICD-11: 1A00-CA43] T52921 INDICATI Investigative Stress [ICD-11: 6B40-6B45] T52937 TARGETID T52937 T52937 TARGNAME Agouti-related protein (AGRP) T52937 INDICATI Phase 2 Obesity [ICD-11: 5B80-5B81] T52953 TARGETID T52953 T52953 TARGNAME CRP messenger RNA (CRP mRNA) T52953 INDICATI Phase 1 Cardiovascular disease [ICD-11: BA00-BE2Z] T52953 INDICATI Phase 2 Coronary atherosclerosis [ICD-11: BA80] T52953 INDICATI Phase 1 Postoperative inflammation [ICD-11: 1A00-CA43] T52969 TARGETID T52969 T52969 TARGNAME CAP-dependent endonuclease (CDE) T52969 INDICATI Discontinued in Phase 2 Colon cancer [ICD-11: 2B90] T52969 INDICATI Discontinued in Phase 2 Malignant haematopoietic neoplasm [ICD-11: 2B33] T52969 INDICATI Discontinued in Phase 2 Type 2 diabetes mellitus [ICD-11: 5A11] T53024 TARGETID T53024 T53024 TARGNAME Somatostatin receptor type 2 (SSTR2) T53024 INDICATI Terminated Alzheimer disease [ICD-11: 8A20] T53024 INDICATI Approved Cushing syndrome [ICD-11: 5A70] T53024 INDICATI Approved Diagnostic imaging [ICD-11: N.A.] T53024 INDICATI Phase 2 Endocrine gland neoplasm [ICD-11: 2F37] T53024 INDICATI Phase 1/2 Lung cancer [ICD-11: 2C25] T53024 INDICATI Approved Pituitary gland disorder [ICD-11: 5A60-5A61] T53024 INDICATI Phase 1/2 Stomach cancer [ICD-11: 2B72] T53103 TARGETID T53103 T53103 TARGNAME Alpha-N-acetylglucosaminidase (NAGLU) T53103 INDICATI Approved Diabetes mellitus [ICD-11: 5A10] T53103 INDICATI Phase 1/2 Lysosomal disease [ICD-11: 5C56] T53103 INDICATI Phase 1/2 Lysosomal disease ICD-11: 5C56 T53139 TARGETID T53139 T53139 TARGNAME Angiopoietin-related protein 3 (ANGPTL3) T53139 INDICATI Phase 2 Blood/blood-forming organ sympton [ICD-11: MA14] T53139 INDICATI Phase 2 Cardiovascular disease [ICD-11: BA00-BE2Z] T53139 INDICATI Approved Hyper-lipoproteinaemia [ICD-11: 5C80] T53139 INDICATI Phase 2 Knee osteoarthritis [ICD-11: FA01] T53242 TARGETID T53242 T53242 TARGNAME Mycobacterium Mycolic acid synthase (MycB cma) T53242 INDICATI Approved HIV-infected patients with tuberculosis [ICD-11: 1B10-1B14] T53242 INDICATI Phase 3 Mycobacterium infection [ICD-11: 1B10-1B21] T53251 TARGETID T53251 T53251 TARGNAME Histone-lysine N-methyltransferase EHMT2 (EHMT2) T53251 INDICATI Preclinical Breast cancer [ICD-11: 2C60-2C6Y] T53251 INDICATI Preclinical Postoperative inflammation [ICD-11: 1A00-CA43] T53251 INDICATI Preclinical Solid tumour/cancer [ICD-11: 2A00-2F9Z] T53378 TARGETID T53378 T53378 TARGNAME Carbonic anhydrase IV (CA-IV) T53378 INDICATI Phase 1/2 Asthma [ICD-11: CA23] T53378 INDICATI Approved Bacterial infection [ICD-11: 1A00-1C4Z] T53378 INDICATI Phase 2 Breast cancer [ICD-11: 2C60-2C6Y] T53378 INDICATI Approved Glaucoma [ICD-11: 9C61] T53378 INDICATI Approved Seborrhoeic dermatitis [ICD-11: EA81] T53378 INDICATI Phase 3 Solid tumour/cancer [ICD-11: 2A00-2F9Z] T53381 TARGETID T53381 T53381 TARGNAME Adrenergic receptor alpha-1D (ADRA1D) T53381 INDICATI Discontinued in Phase 2 Abnormal micturition [ICD-11: MF50] T53381 INDICATI Discontinued in Phase 2 Acute diabete complication [ICD-11: 5A2Y] T53381 INDICATI Discontinued in Phase 2 Chronic arterial occlusive disease [ICD-11: BD4Z] T53381 INDICATI Terminated Genetic cardiac arrhythmia [ICD-11: BC65] T53381 INDICATI Approved Glaucoma [ICD-11: 9C61] T53381 INDICATI Approved Heart failure [ICD-11: BD10-BD1Z] T53381 INDICATI Approved Hypertension [ICD-11: BA00-BA04] T53381 INDICATI Phase 2 Pain [ICD-11: MG30-MG3Z] T53381 INDICATI Discontinued in Phase 2 Prostate disease [ICD-11: GA91] T53381 INDICATI Approved Prostate hyperplasia [ICD-11: GA90] T53381 INDICATI Approved Sexual dysfunction [ICD-11: HA00-HA01] T53381 INDICATI Approved Solid tumour/cancer [ICD-11: 2A00-2F9Z] T53389 TARGETID T53389 T53389 TARGNAME TGF-beta receptor type I (TGFBR1) T53389 INDICATI Phase 2/3 Arterial occlusive disease [ICD-11: BD40] T53389 INDICATI Phase 1/2 Brain cancer [ICD-11: 2A00] T53389 INDICATI Investigative Cachexia [ICD-11: MG20] T53389 INDICATI Terminated Fibrosis [ICD-11: GA14-GC01] T53389 INDICATI Preclinical Idiopathic interstitial pneumonitis [ICD-11: CB03] T53389 INDICATI Phase 2 Liver cancer [ICD-11: 2C12] T53389 INDICATI Phase 2/3 Lung cancer [ICD-11: 2C25] T53389 INDICATI Phase 1/2 Myelodysplastic syndrome [ICD-11: 2A37] T53389 INDICATI Phase 2 Myeloproliferative neoplasm [ICD-11: 2A20] T53389 INDICATI Phase 1 Pancreatic cancer [ICD-11: 2C10] T53389 INDICATI Investigative Pulmonary disease [ICD-11: 1B10-1F85] T53389 INDICATI Phase 1/2 Solid tumour/cancer [ICD-11: 2A00-2F9Z] T53389 INDICATI Phase 1/2 Systemic sclerosis [ICD-11: 4A42] T53389 INDICATI Phase 2 Ureteral cancer [ICD-11: 2C92] T53472 TARGETID T53472 T53472 TARGNAME MHC class I NK cell receptor 2DL3 (CD158b2) T53472 INDICATI Phase 2 Acute myeloid leukaemia [ICD-11: 2A60] T53472 INDICATI Phase 2 Multiple myeloma [ICD-11: 2A83] T53524 TARGETID T53524 T53524 TARGNAME Platelet-derived growth factor receptor alpha (PDGFRA) T53524 INDICATI Phase 2 Acute myeloid leukaemia [ICD-11: 2A60] T53524 INDICATI Phase 2 BCR-ABL1-negative chronic myeloid leukaemia [ICD-11: 2A41] T53524 INDICATI Phase 2 Brain cancer [ICD-11: 2A00] T53524 INDICATI Patented Breast cancer [ICD-11: 2C60-2C6Y] T53524 INDICATI Patented Colon cancer [ICD-11: 2B90] T53524 INDICATI Patented Colorectal cancer [ICD-11: 2B91] T53524 INDICATI Approved Gastrointestinal stromal tumour [ICD-11: 2B5B] T53524 INDICATI Investigative Gram-positive bacterial infection [ICD-11: 1B74-1F40] T53524 INDICATI Approved Kaposi sarcoma [ICD-11: 2B57] T53524 INDICATI Phase 1 Lung cancer [ICD-11: 2C25] T53524 INDICATI Phase 3 Malignant digestive organ neoplasm [ICD-11: 2C11] T53524 INDICATI Phase 1 Mastocytosis [ICD-11: 2A21] T53524 INDICATI Phase 2 Multiple myeloma [ICD-11: 2A83] T53524 INDICATI Phase 2 Myelodysplastic syndrome [ICD-11: 2A37] T53524 INDICATI Patented Pancreatic cancer [ICD-11: 2C10] T53524 INDICATI Patented Prostate cancer [ICD-11: 2C82] T53524 INDICATI Phase 3 Solid tumour/cancer [ICD-11: 2A00-2F9Z] T53524 INDICATI Patented Stomach cancer [ICD-11: 2B72] T53524 INDICATI Approved Thrombocytopenia [ICD-11: 3B64] T53549 TARGETID T53549 T53549 TARGNAME Protein thiol group (PTG) T53549 INDICATI Discontinued in Phase 1 Indeterminate colitis [ICD-11: DD72] T53585 TARGETID T53585 T53585 TARGNAME HMG-CoA reductase (HMGCR) T53585 INDICATI Discontinued in Phase 3 Arterial occlusive disease [ICD-11: BD40] T53585 INDICATI Phase 3 Blood/blood-forming organ sympton [ICD-11: MA14] T53585 INDICATI Approved Cardiovascular disease [ICD-11: BA00-BE2Z] T53585 INDICATI Phase 4 Coronary atherosclerosis [ICD-11: BA80] T53585 INDICATI Approved Dyslipidemia [ICD-11: 5C80-5C81] T53585 INDICATI Phase 1 Hepatitis virus infection [ICD-11: 1E50-1E51] T53585 INDICATI Approved Hyper-lipoproteinaemia [ICD-11: 5C80] T53585 INDICATI Phase 1/2 Multiple myeloma [ICD-11: 2A83] T53585 INDICATI Approved Multiple sclerosis [ICD-11: 8A40] T53585 INDICATI Approved Myocardial infarction [ICD-11: BA41-BA43] T53585 INDICATI Approved Pain [ICD-11: MG30-MG3Z] T53585 INDICATI Phase 3 Rheumatoid arthritis [ICD-11: FA20] T53585 INDICATI Discontinued in Phase 2 Thrombosis [ICD-11: DB61-GB90] T53588 TARGETID T53588 T53588 TARGNAME Bacterial NADH-dependent enoyl-ACP reductase (Bact fabI) T53588 INDICATI Preclinical Anaerobic bacterial infection [ICD-11: 1A00-1A09] T53601 TARGETID T53601 T53601 TARGNAME Bacterial 50S ribosomal RNA (Bact 50S rRNA) T53601 INDICATI Approved Acne vulgaris [ICD-11: ED80] T53601 INDICATI Approved Bacterial infection [ICD-11: 1A00-1C4Z] T53601 INDICATI Approved Gram-positive bacterial infection [ICD-11: 1B74-1F40] T53601 INDICATI Approved Impetigo [ICD-11: 1B72] T53601 INDICATI Phase 2 Indeterminate colitis [ICD-11: DD72] T53601 INDICATI Phase 1 Respiratory infection [ICD-11: CA07-CA4Z] T53601 INDICATI Phase 3 Sepsis [ICD-11: 1G40-1G41] T53601 INDICATI Approved Skin and skin-structure infection [ICD-11: 1F28-1G0Z] T53601 INDICATI Approved Syphilis [ICD-11: 1A61-1A6Z] T53601 INDICATI Phase 3 Vaginal discharge [ICD-11: MF3A] T53640 TARGETID T53640 T53640 TARGNAME Hepatitis B virus Large envelope protein (HBV S) T53640 INDICATI Approved Hepatitis virus infection [ICD-11: 1E50-1E51] T53669 TARGETID T53669 T53669 TARGNAME Thymic stromal lymphoprotein receptor (CRLF2) T53669 INDICATI Phase 1 Asthma [ICD-11: CA23] T53684 TARGETID T53684 T53684 TARGNAME Inflammation pathogenesis (IP) T53684 INDICATI Phase 3 Indeterminate colitis [ICD-11: DD72] T53748 TARGETID T53748 T53748 TARGNAME Plasmodium Enoyl-ACP reductase (Malaria fabI) T53748 INDICATI Phase 3 Hepatic fibrosis/cirrhosis [ICD-11: DB93] T53748 INDICATI Approved Malaria [ICD-11: 1F40-1F45] T53748 INDICATI Investigative Trypanosomiasis [ICD-11: 1D51-1F53] T53748 INDICATI Investigative Urinary tract infection [ICD-11: GC08] T53764 TARGETID T53764 T53764 TARGNAME Prolyl endopeptidase FAP (FAP) T53764 INDICATI Preclinical Colon cancer [ICD-11: 2B90] T53764 INDICATI Phase 2 Colorectal cancer [ICD-11: 2B91] T53764 INDICATI Investigative Indeterminate colitis [ICD-11: DD72] T53764 INDICATI Preclinical Lung cancer [ICD-11: 2C25] T53764 INDICATI Phase 3 Neutropenia [ICD-11: 4B00] T53764 INDICATI Phase 2 Solid tumour/cancer [ICD-11: 2A00-2F9Z] T53811 TARGETID T53811 T53811 TARGNAME Human papillomavirus protein E6 (HPV E6) T53811 INDICATI Phase 3 Cervical intraepithelial neoplasia [ICD-11: 2E66] T53811 INDICATI Phase 3 Dysplasia [ICD-11: LB30-LD2F] T53811 INDICATI Phase 2 Genital organ in situ carcinoma [ICD-11: 2E67] T53811 INDICATI Phase 2 Sexually transmitted infection [ICD-11: 1A9Y-1A9Z] T53903 TARGETID T53903 T53903 TARGNAME Hepatitis C virus NS3 helicase messenger RNA (HCV NS3 mRNA) T53903 INDICATI Discontinued in Phase 1/2 Hepatitis virus infection [ICD-11: 1E50-1E51] T53904 TARGETID T53904 T53904 TARGNAME HIF-prolyl hydroxylase 1 (HPH-1) T53904 INDICATI Approved Acute disease anaemia [ICD-11: 3A90] T53904 INDICATI Phase 2 Anemia [ICD-11: 3A00-3A9Z] T53904 INDICATI Phase 2 Autism spectrum disorder [ICD-11: 6A02] T53904 INDICATI Phase 1 Diabetic foot ulcer [ICD-11: BD54] T53904 INDICATI Phase 3 Urinary system disease [ICD-11: GC2Z] T54031 TARGETID T54031 T54031 TARGNAME Retinoschisin (RS1) T54031 INDICATI Phase 1/2 Retinal detachment [ICD-11: 9B73] T54055 TARGETID T54055 T54055 TARGNAME Hyaluronic acid receptor (LYVE1) T54055 INDICATI Investigative Aplastic anaemia [ICD-11: 3A70] T54055 INDICATI Phase 3 Enthesopathy [ICD-11: FB53-FB55] T54055 INDICATI Approved Joint lubricant [ICD-11: FA30-FA38] T54055 INDICATI Discontinued in Phase 1 Malignant haematopoietic neoplasm [ICD-11: 2B33] T54065 TARGETID T54065 T54065 TARGNAME Bacterial Phosphoshikimate1-carboxyvinyltransferase (Bact aroA) T54065 INDICATI Investigative Malaria [ICD-11: 1F40-1F45] T54093 TARGETID T54093 T54093 TARGNAME T-box transcription factor T (TBXT) T54093 INDICATI Phase 2 Pituitary gland disorder [ICD-11: 5A60-5A61] T54093 INDICATI Phase 1 Solid tumour/cancer [ICD-11: 2A00-2F9Z] T54128 TARGETID T54128 T54128 TARGNAME Glutamate receptor AMPA (GRIA) T54128 INDICATI Approved Alzheimer disease [ICD-11: 8A20] T54128 INDICATI Approved Anxiety disorder [ICD-11: 6B00-6B0Z] T54128 INDICATI Approved Appearance/behaviour symptom [ICD-11: MB23] T54128 INDICATI Phase 2 Attention deficit hyperactivity disorder [ICD-11: 6A05] T54128 INDICATI Discontinued in Phase 1 Cerebral ischaemia [ICD-11: 8B1Z] T54128 INDICATI Approved Corneal disease [ICD-11: 9A76-9A78] T54128 INDICATI Phase 1 Coronary atherosclerosis [ICD-11: BA80] T54128 INDICATI Approved Depression [ICD-11: 6A70-6A7Z] T54128 INDICATI Phase 1 Dissociative neurological symptom disorder [ICD-11: 6B60] T54128 INDICATI Phase 2 Epilepsy/seizure [ICD-11: 8A61-8A6Z] T54128 INDICATI Approved Insomnia [ICD-11: 7A00-7A0Z] T54128 INDICATI Approved Malaria [ICD-11: 1F40-1F45] T54128 INDICATI Phase 1 Mental/behavioural/neurodevelopmental disorder [ICD-11: 6E20-6E8Z] T54128 INDICATI Phase 3 Mild neurocognitive disorder [ICD-11: 6D71] T54128 INDICATI Approved Monitored anaesthesia care [ICD-11: N.A.] T54128 INDICATI Approved Neuropathy [ICD-11: 8C0Z] T54128 INDICATI Phase 2 Obstructive sleep apnoea [ICD-11: 7A41] T54128 INDICATI Terminated Pain [ICD-11: MG30-MG3Z] T54128 INDICATI Phase 2 Parkinsonism [ICD-11: 8A00] T54128 INDICATI Approved Pediculosis [ICD-11: 1G00] T54128 INDICATI Phase 2/3 Pervasive developmental disorder [ICD-11: 6A00-6A0Z] T54128 INDICATI Phase 2/3 Schizophrenia [ICD-11: 6A20] T54128 INDICATI Phase 2 Spine/trunk injury [ICD-11: ND51] T54128 INDICATI Approved Substance abuse [ICD-11: 6C40] T54132 TARGETID T54132 T54132 TARGNAME Voltage-gated potassium channel Kv7.3 (KCNQ3) T54132 INDICATI Approved Behcet disease [ICD-11: 4A62] T54132 INDICATI Phase 2 Epilepsy/seizure [ICD-11: 8A61-8A6Z] T54132 INDICATI Phase 3 Mild neurocognitive disorder [ICD-11: 6D71] T54132 INDICATI Preclinical Pain [ICD-11: MG30-MG3Z] T54156 TARGETID T54156 T54156 TARGNAME Matrix metalloproteinase-9 (MMP-9) T54156 INDICATI Phase 1/2 Brain cancer [ICD-11: 2A00] T54156 INDICATI Terminated Colorectal cancer [ICD-11: 2B91] T54156 INDICATI Discontinued in Phase 2 Corneal disease [ICD-11: 9A76-9A78] T54156 INDICATI Phase 2 Crohn disease [ICD-11: DD70] T54156 INDICATI Discontinued in Phase 2 Hepatitis virus infection [ICD-11: 1E50-1E51] T54156 INDICATI Phase 3 Ischaemic/haemorrhagic stroke [ICD-11: 8B20] T54156 INDICATI Phase 1 Lung cancer [ICD-11: 2C25] T54156 INDICATI Phase 1 Renal cell carcinoma [ICD-11: 2C90] T54156 INDICATI Phase 1 Rheumatoid arthritis [ICD-11: FA20] T54156 INDICATI Phase 3 Solid tumour/cancer [ICD-11: 2A00-2F9Z] T54156 INDICATI Phase 3 Stomach cancer [ICD-11: 2B72] T54156 INDICATI Phase 3 Ulcerative colitis [ICD-11: DD71] T54347 TARGETID T54347 T54347 TARGNAME Candida Chitin synthase 3 (Candi CHS3) T54347 INDICATI Phase 1/2 Candidosis [ICD-11: 1F23] T54379 TARGETID T54379 T54379 TARGNAME Wnt signaling pathway (Wnt pathway) T54379 INDICATI Phase 1/2 Acute myeloid leukaemia [ICD-11: 2A60] T54379 INDICATI Phase 2/3 Alopecia [ICD-11: ED70] T54379 INDICATI Phase 1 Liver cancer [ICD-11: 2C12] T54379 INDICATI Phase 1 Multiple myeloma [ICD-11: 2A83] T54379 INDICATI Phase 2 Osteoarthritis [ICD-11: FA00-FA05] T54379 INDICATI Phase 1 Psoriasis [ICD-11: EA90] T54379 INDICATI Phase 1 Solid tumour/cancer [ICD-11: 2A00-2F9Z] T54447 TARGETID T54447 T54447 TARGNAME Pigment epithelium-derived factor (SERPINF1) T54447 INDICATI Phase 2 Retinopathy [ICD-11: 9B71] T54519 TARGETID T54519 T54519 TARGNAME Schistosoma Purine nucleoside phosphorylase (sch PNP) T54519 INDICATI Phase 1 Prostate cancer [ICD-11: 2C82] T54582 TARGETID T54582 T54582 TARGNAME Nicotinamide phosphoribosyltransferase (NAMPT) T54582 INDICATI Phase 2 Leukaemia [ICD-11: 2A60-2B33] T54582 INDICATI Phase 1 Lymphoma [ICD-11: 2A80-2A86] T54582 INDICATI Phase 1/2 Solid tumour/cancer [ICD-11: 2A00-2F9Z] T54606 TARGETID T54606 T54606 TARGNAME Staphylococcus Five leukocidin toxins (Stap-coc lukF) T54606 INDICATI Phase 2 Medical/surgical procedure injury [ICD-11: PK80-PK81] T54606 INDICATI Phase 2 Pneumonia [ICD-11: CA40] T54644 TARGETID T54644 T54644 TARGNAME Voltage-gated calcium channel alpha Cav3.2 (CACNA1H) T54644 INDICATI Approved Acidosis [ICD-11: 5C73] T54644 INDICATI Investigative Angina pectoris [ICD-11: BA40] T54644 INDICATI Phase 1 Brain cancer [ICD-11: 2A00] T54644 INDICATI Preclinical Insomnia [ICD-11: 7A00-7A0Z] T54644 INDICATI Approved Migraine [ICD-11: 8A80] T54644 INDICATI Withdrawn from market Ovarian cancer [ICD-11: 2C73] T54644 INDICATI Phase 2 Pain [ICD-11: MG30-MG3Z] T54644 INDICATI Investigative Solid tumour/cancer [ICD-11: 2A00-2F9Z] T54761 TARGETID T54761 T54761 TARGNAME Myelin basic protein (MBP) T54761 INDICATI Phase 2 Multiple sclerosis [ICD-11: 8A40] T54771 TARGETID T54771 T54771 TARGNAME Sodium/glucose cotransporter 1 (SGLT1) T54771 INDICATI Discontinued in Phase 2 Acute diabete complication [ICD-11: 5A2Y] T54771 INDICATI Phase 2 Diabetes mellitus [ICD-11: 5A10] T54771 INDICATI Phase 2 Heart failure [ICD-11: BD10-BD1Z] T54771 INDICATI Phase 2 Type 2 diabetes mellitus [ICD-11: 5A11] T54789 TARGETID T54789 T54789 TARGNAME X-linked retinitis pigmentosa GTPase regulator (RPGR) T54789 INDICATI Phase 3 Inherited retinal dystrophy ICD-11: 9B70 T54789 INDICATI Phase 2/3 Inherited retinal dystrophy [ICD-11: 9B70] T54902 TARGETID T54902 T54902 TARGNAME MHC class I NK cell receptor 2DL2 (CD158b1) T54902 INDICATI Phase 2 Acute myeloid leukaemia [ICD-11: 2A60] T54902 INDICATI Phase 2 Multiple myeloma [ICD-11: 2A83] T54931 TARGETID T54931 T54931 TARGNAME Neuronal acetylcholine receptor alpha-2/alpha-3 (CHRNA2/A3) T54931 INDICATI Investigative Psychoactive substances use disorder [ICD-11: 6C4G] T54931 INDICATI Discontinued in Phase 2 Thrombosis [ICD-11: DB61-GB90] T54940 TARGETID T54940 T54940 TARGNAME Plasmodium Cysteine protease falcipain (Malaria CPF) T54940 INDICATI Terminated Malaria [ICD-11: 1F40-1F45] T55012 TARGETID T55012 T55012 TARGNAME Ion channel unspecific (IC) T55012 INDICATI Phase 2 Bipolar disorder [ICD-11: 6A60] T55012 INDICATI Terminated Chronic obstructive pulmonary disease [ICD-11: CA22] T55012 INDICATI Discontinued in Phase 1 Dissociative neurological symptom disorder [ICD-11: 6B60] T55012 INDICATI Terminated Rheumatoid arthritis [ICD-11: FA20] T55012 INDICATI Phase 2 Supraventricular tachyarrhythmia [ICD-11: BC81] T55094 TARGETID T55094 T55094 TARGNAME Acid-sensing ion channel 1 (ASIC1) T55094 INDICATI Approved Heart failure [ICD-11: BD10-BD1Z] T55094 INDICATI Phase 1 Pain [ICD-11: MG30-MG3Z] T55260 TARGETID T55260 T55260 TARGNAME Protein phosphatase 1A (PPM1A) T55260 INDICATI Phase 2 Common warts [ICD-11: 1E80] T55260 INDICATI Phase 3 Molluscum contagiosum [ICD-11: 1E76] T55269 TARGETID T55269 T55269 TARGNAME Nucleoside transporter (SLC) T55269 INDICATI Discontinued in Phase 2 Cardiac arrhythmia [ICD-11: BC9Z] T55273 TARGETID T55273 T55273 TARGNAME Delta-like protein 4 (DLL4) T55273 INDICATI Phase 1 Colorectal cancer [ICD-11: 2B91] T55273 INDICATI Phase 1 Fallopian tube cancer [ICD-11: 2C74] T55273 INDICATI Phase 1 Ovarian cancer [ICD-11: 2C73] T55273 INDICATI Phase 1 Peritoneal cancer [ICD-11: 2C51] T55273 INDICATI Phase 2 Solid tumour/cancer [ICD-11: 2A00-2F9Z] T55285 TARGETID T55285 T55285 TARGNAME Glycine receptor (GlyR) T55285 INDICATI Phase 1 Cerebral ischaemia [ICD-11: 8B1Z] T55285 INDICATI Phase 1 Epilepsy/seizure [ICD-11: 8A61-8A6Z] T55285 INDICATI Discontinued in Phase 2 Migraine [ICD-11: 8A80] T55285 INDICATI Discontinued in Phase 2 Nicotine use disorder [ICD-11: 6C4A] T55285 INDICATI Terminated Sepsis [ICD-11: 1G40-1G41] T55285 INDICATI Approved Tonus and reflex abnormality [ICD-11: MB47] T55285 INDICATI Phase 1 Unspecific body region injury [ICD-11: ND56] T55293 TARGETID T55293 T55293 TARGNAME Integrin alpha-2 (ITGA2) T55293 INDICATI Phase 2 Colorectal cancer [ICD-11: 2B91] T55293 INDICATI Phase 2 Solid tumour/cancer [ICD-11: 2A00-2F9Z] T55302 TARGETID T55302 T55302 TARGNAME B-type natriuretic peptide (BNP) T55302 INDICATI Investigative Hypertension [ICD-11: BA00-BA04] T55352 TARGETID T55352 T55352 TARGNAME Amyloid precursor protein (APP) T55352 INDICATI Phase 1 Alzheimer disease [ICD-11: 8A20] T55398 TARGETID T55398 T55398 TARGNAME Renal carcinoma antigen NY-REN-64 (IRAK-4) T55398 INDICATI Phase 2 Atopic eczema [ICD-11: EA80] T55398 INDICATI Phase 1 Cutaneous lupus erythematosus [ICD-11: EB50-EB5Z] T55398 INDICATI Phase 1 Lymphoma [ICD-11: 2A80-2A86] T55398 INDICATI Phase 1 Postoperative inflammation [ICD-11: 1A00-CA43] T55398 INDICATI Phase 1 Psoriasis [ICD-11: EA90] T55398 INDICATI Phase 2 Rheumatoid arthritis [ICD-11: FA20] T55610 TARGETID T55610 T55610 TARGNAME Hypoxia-inducible factor 1 alpha (HIF-1A) T55610 INDICATI Phase 4 Lymphoma [ICD-11: 2A80-2A86] T55610 INDICATI Phase 2 Pulmonary hypertension [ICD-11: BB01] T55610 INDICATI Phase 3 Solid tumour/cancer [ICD-11: 2A00-2F9Z] T55643 TARGETID T55643 T55643 TARGNAME Heat shock protein (HSP) T55643 INDICATI Phase 2/3 Cerebral ischaemia [ICD-11: 8B1Z] T55643 INDICATI Phase 2/3 Idiopathic inflammatory myopathy [ICD-11: 4A41] T55643 INDICATI Phase 2 Meningococcal disease [ICD-11: 1C1C] T55654 TARGETID T55654 T55654 TARGNAME cAMP-dependent chloride channel (CFTR) T55654 INDICATI Phase 2 Bowel habit change [ICD-11: ME05] T55654 INDICATI Phase 2 Chronic obstructive pulmonary disease [ICD-11: CA22] T55654 INDICATI Approved Cystic fibrosis [ICD-11: CA25] T55654 INDICATI Approved Intrathoracic organs injury [ICD-11: NB32] T55654 INDICATI Approved Viral intestinal infection [ICD-11: 1A2Z] T55689 TARGETID T55689 T55689 TARGNAME Hormone sensitive lipase (LIPE) T55689 INDICATI Investigative Obesity [ICD-11: 5B80-5B81] T55689 INDICATI Clinical trial Pancreatitis [ICD-11: DC31-DC34] T55689 INDICATI Approved Pediculosis [ICD-11: 1G00] T55703 TARGETID T55703 T55703 TARGNAME Plasma retinol-binding protein (RBP4) T55703 INDICATI Phase 3 Inherited retinal dystrophy [ICD-11: 9B70] T55709 TARGETID T55709 T55709 TARGNAME Choline kinase (CHKA) T55709 INDICATI Phase 1 Solid tumour/cancer [ICD-11: 2A00-2F9Z] T55729 TARGETID T55729 T55729 TARGNAME Stress-activated protein kinase 2b (p38 beta) T55729 INDICATI Phase 2 Alzheimer disease [ICD-11: 8A20] T55729 INDICATI Discontinued in Phase 1 Psoriasis [ICD-11: EA90] T55729 INDICATI Phase 2 Rheumatoid arthritis [ICD-11: FA20] T55781 TARGETID T55781 T55781 TARGNAME Tyrosine-protein kinase Mer (MERTK) T55781 INDICATI Phase 1/2 Acute myeloid leukaemia [ICD-11: 2A60] T55781 INDICATI Phase 1/2 Alzheimer disease [ICD-11: 8A20] T55781 INDICATI Investigative Brain cancer [ICD-11: 2A00] T55781 INDICATI Investigative Mature B-cell lymphoma [ICD-11: 2A85] T55781 INDICATI Phase 1/2 Myelodysplastic syndrome [ICD-11: 2A37] T55781 INDICATI Phase 1 Solid tumour/cancer [ICD-11: 2A00-2F9Z] T55815 TARGETID T55815 T55815 TARGNAME Neuronal acetylcholine receptor alpha-2 (CHRNA2) T55815 INDICATI Approved Corneal disease [ICD-11: 9A76-9A78] T55815 INDICATI Approved Depression [ICD-11: 6A70-6A7Z] T55815 INDICATI Approved Glaucoma [ICD-11: 9C61] T55815 INDICATI Approved Nicotine use disorder [ICD-11: 6C4A] T55815 INDICATI Approved Tonus and reflex abnormality [ICD-11: MB47] T55860 TARGETID T55860 T55860 TARGNAME TAX transcriptionally-activated glycoprotein 1 (OX40) T55860 INDICATI Phase 2 Alzheimer disease [ICD-11: 8A20] T55860 INDICATI Phase 2 Asthma [ICD-11: CA23] T55860 INDICATI Phase 2 Atopic eczema [ICD-11: EA80] T55860 INDICATI Phase 3 Breast cancer [ICD-11: 2C60-2C6Y] T55860 INDICATI Phase 3 General pain disorder [ICD-11: 8E43] T55860 INDICATI Phase 1 Lymphoma [ICD-11: 2A80-2A86] T55860 INDICATI Phase 1 Ovarian cancer [ICD-11: 2C73] T55860 INDICATI Phase 1 Postoperative inflammation [ICD-11: 1A00-CA43] T55860 INDICATI Preclinical Sexual dysfunction [ICD-11: HA00-HA01] T55860 INDICATI Phase 2 Solid tumour/cancer [ICD-11: 2A00-2F9Z] T55860 INDICATI Phase 2 Ureteral cancer [ICD-11: 2C92] T55922 TARGETID T55922 T55922 TARGNAME S-adenosylmethionine decarboxylase proenzyme (AMD1) T55922 INDICATI Approved Acidosis [ICD-11: 5C73] T55922 INDICATI Discontinued in Phase 2 Burn and burn infection [ICD-11: ND90-NE2Z] T55922 INDICATI Terminated Head and neck cancer [ICD-11: 2D42] T55922 INDICATI Phase 2 Mood disorder [ICD-11: 6A60-6E23] T55922 INDICATI Terminated Pneumonia [ICD-11: CA40] T55922 INDICATI Phase 2 Solid tumour/cancer [ICD-11: 2A00-2F9Z] T55936 TARGETID T55936 T55936 TARGNAME Mycobacterium CDP-diacylglycerol-inositol phosphatidyltransferase (MycB pssA) T55936 INDICATI Phase 2 Alzheimer disease [ICD-11: 8A20] T55959 TARGETID T55959 T55959 TARGNAME Dopamine transporter (DAT) T55959 INDICATI Approved Attention deficit hyperactivity disorder [ICD-11: 6A05] T55959 INDICATI Phase 3 Binge eating disorder [ICD-11: 6B82] T55959 INDICATI Phase 4 Bipolar disorder [ICD-11: 6A60] T55959 INDICATI Phase 2 Cocaine use disorder [ICD-11: 6C45] T55959 INDICATI Approved Corneal disease [ICD-11: 9A76-9A78] T55959 INDICATI Phase 3 Dementia [ICD-11: 6D80-6D8Z] T55959 INDICATI Phase 2 Depression [ICD-11: 6A70-6A7Z] T55959 INDICATI Discontinued in Phase 1 Dissociative neurological symptom disorder [ICD-11: 6B60] T55959 INDICATI Discontinued in Phase 1 General pain disorder [ICD-11: 8E43] T55959 INDICATI Phase 4 Intracranial injury [ICD-11: NA07] T55959 INDICATI Phase 3 Mood disorder [ICD-11: 6A60-6E23] T55959 INDICATI Approved Narcolepsy [ICD-11: 7A20] T55959 INDICATI Approved Obesity [ICD-11: 5B80-5B81] T55959 INDICATI Approved Parkinsonism [ICD-11: 8A00] T55959 INDICATI Phase 2 Stomach disease [ICD-11: DA43-DA4Y] T55959 INDICATI Phase 2 Substance abuse [ICD-11: 6C40] T56051 TARGETID T56051 T56051 TARGNAME Ubiquitin thioesterase L1 (UCHL1) T56051 INDICATI Preclinical Solid tumour/cancer [ICD-11: 2A00-2F9Z] T56175 TARGETID T56175 T56175 TARGNAME Lanosterol synthase (LSS) T56175 INDICATI Terminated Arterial occlusive disease [ICD-11: BD40] T56262 TARGETID T56262 T56262 TARGNAME Tripeptidyl-peptidase I (TPP1) T56262 INDICATI Approved Lysosomal disease [ICD-11: 5C56] T56262 INDICATI Phase 1/2 Lysosomal disease ICD-11: 5C56 T56262 INDICATI Approved Metabolism inborn error [ICD-11: 5C50] T56269 TARGETID T56269 T56269 TARGNAME Islet amyloid polypeptide (IAPP) T56269 INDICATI Phase 1 Obesity [ICD-11: 5B80-5B81] T56308 TARGETID T56308 T56308 TARGNAME Interleukin-11 (IL11) T56308 INDICATI Phase 3 Thrombocytopenia [ICD-11: 3B64] T56349 TARGETID T56349 T56349 TARGNAME C-X-C motif chemokine 9 (CXCL9) T56349 INDICATI Phase 1 Solid tumour/cancer [ICD-11: 2A00-2F9Z] T56362 TARGETID T56362 T56362 TARGNAME Choline transporter-like protein 4 (SLC44A4) T56362 INDICATI Phase 1 Pancreatic cancer [ICD-11: 2C10] T56362 INDICATI Phase 1 Prostate cancer [ICD-11: 2C82] T56365 TARGETID T56365 T56365 TARGNAME B-lymphocyte surface antigen B4 (CD19) T56365 INDICATI Phase 1/2 Acute myeloid leukaemia [ICD-11: 2A60] T56365 INDICATI Phase 2/3 B-cell lymphoma [ICD-11: 2A86] T56365 INDICATI Phase 2 Diabetes mellitus [ICD-11: 5A10] T56365 INDICATI Approved Diffuse large B-cell lymphoma [ICD-11: 2A81] T56365 INDICATI Phase 1/2 Diffuse large B-cell lymphoma ICD-11: 2A81 T56365 INDICATI Phase 2 Encephalopathy [ICD-11: 8E47] T56365 INDICATI Phase 2/3 Follicular lymphoma [ICD-11: 2A80] T56365 INDICATI Phase 0 Hodgkin lymphoma [ICD-11: 2B30] T56365 INDICATI Phase 1 Immune system disease [ICD-11: 4A01-4B41] T56365 INDICATI Phase 1 Immunoproliferative disorder [ICD-11: 2B32] T56365 INDICATI Phase 2 Leukaemia [ICD-11: 2A60-2B33] T56365 INDICATI Phase 2 Lupus erythematosus [ICD-11: 4A40] T56365 INDICATI Phase 2 Lymphoma [ICD-11: 2A80-2A86] T56365 INDICATI Phase 2 Malignant haematopoietic neoplasm [ICD-11: 2B33] T56365 INDICATI Phase 3 Mature B-cell leukaemia [ICD-11: 2A82] T56365 INDICATI Approved Mature B-cell lymphoma [ICD-11: 2A85] T56365 INDICATI Phase 2 Multiple myeloma [ICD-11: 2A83] T56365 INDICATI Approved Nervous system paraneoplastic/autoimmune disorder [ICD-11: 8E4A] T56365 INDICATI Phase 2 Neuromyelitis optica [ICD-11: 8A43] T56365 INDICATI Phase 1 Pancreatic cancer [ICD-11: 2C10] T56365 INDICATI Phase 2 Precursor B-lymphoblastic neoplasm [ICD-11: 2A70] T56365 INDICATI Phase 1/2 Rheumatoid arthritis [ICD-11: FA20] T56365 INDICATI Phase 3 Sjogren syndrome [ICD-11: 4A43] T56365 INDICATI Phase 1 Systemic sclerosis [ICD-11: 4A42] T56367 TARGETID T56367 T56367 TARGNAME Phosphodiesterase 1 (PDE1) T56367 INDICATI Phase 1 Adaptive immunity immunodeficiency [ICD-11: 4A01] T56367 INDICATI Approved Cerebral ischaemic stroke [ICD-11: 8B11] T56367 INDICATI Phase 1/2 Parkinsonism [ICD-11: 8A00] T56367 INDICATI Phase 1 Schizophrenia [ICD-11: 6A20] T56367 INDICATI Phase 1 Sex development malformative disorder [ICD-11: LD2A] T56367 INDICATI Terminated Solid tumour/cancer [ICD-11: 2A00-2F9Z] T56418 TARGETID T56418 T56418 TARGNAME ALK tyrosine kinase receptor (ALK) T56418 INDICATI Phase 1 Adrenal cancer [ICD-11: 2D11] T56418 INDICATI Phase 1 Breast cancer [ICD-11: 2C60-2C6Y] T56418 INDICATI Phase 2 Colorectal cancer [ICD-11: 2B91] T56418 INDICATI Phase 1 Diffuse large B-cell lymphoma [ICD-11: 2A81] T56418 INDICATI Approved Lung cancer [ICD-11: 2C25] T56418 INDICATI Investigative Lymphoma [ICD-11: 2A80-2A86] T56418 INDICATI Approved Mature T-cell lymphoma [ICD-11: 2A90] T56418 INDICATI Patented Metastatic tumour [ICD-11: 2D50-2E2Z] T56418 INDICATI Approved Non-small-cell lung cancer [ICD-11: 2C25] T56418 INDICATI Phase 2 Solid tumour/cancer [ICD-11: 2A00-2F9Z] T56510 TARGETID T56510 T56510 TARGNAME Apoptosis regulator Bcl-xL (BCL-xL) T56510 INDICATI Phase 1/2 Lung cancer [ICD-11: 2C25] T56510 INDICATI Phase 1/2 Malignant haematopoietic neoplasm [ICD-11: 2B33] T56510 INDICATI Phase 2 Mature B-cell leukaemia [ICD-11: 2A82] T56510 INDICATI Investigative Mature T-cell lymphoma [ICD-11: 2A90] T56510 INDICATI Phase 3 Myeloproliferative neoplasm [ICD-11: 2A20] T56510 INDICATI Phase 2 Solid tumour/cancer [ICD-11: 2A00-2F9Z] T56518 TARGETID T56518 T56518 TARGNAME Hepatitis B virus Reverse transcriptase (HBV RT) T56518 INDICATI Approved Hepatitis virus infection [ICD-11: 1E50-1E51] T56545 TARGETID T56545 T56545 TARGNAME Apolipoprotein A-I (APOA1) T56545 INDICATI Phase 1 Aortic valve stenosis [ICD-11: BB70] T56545 INDICATI Phase 2 Arterial occlusive disease [ICD-11: BD40] T56545 INDICATI Phase 2 Cardiovascular disease [ICD-11: BA00-BE2Z] T56545 INDICATI Discontinued in Phase 2 Hyper-lipoproteinaemia [ICD-11: 5C80] T56545 INDICATI Terminated Lipidaemia [ICD-11: 5C8Z] T56545 INDICATI Phase 2 Myocardial infarction [ICD-11: BA41-BA43] T56556 TARGETID T56556 T56556 TARGNAME ATP-binding cassette transporter G2 (ABCG2) T56556 INDICATI Approved Irritable bowel syndrome [ICD-11: DD91] T56556 INDICATI Approved Rheumatoid arthritis [ICD-11: FA20] T56588 TARGETID T56588 T56588 TARGNAME Glutamate receptor ionotropic NMDA 2D (GluN2D) T56588 INDICATI Terminated Neurodegenerative disorder [ICD-11: 8A20-8A23] T56625 TARGETID T56625 T56625 TARGNAME Tripeptidyl-peptidase II (TPP2) T56625 INDICATI Discontinued in Phase 1 Obesity [ICD-11: 5B80-5B81] T56697 TARGETID T56697 T56697 TARGNAME Dickkopf-related protein 1 (DKK1) T56697 INDICATI Phase 2 Biliary tract cancer [ICD-11: 2C17] T56697 INDICATI Phase 2 Endometrial cancer [ICD-11: 2C76] T56697 INDICATI Phase 2 Esophageal cancer [ICD-11: 2B70] T56697 INDICATI Phase 1/2 Liver cancer [ICD-11: 2C12] T56697 INDICATI Phase 1 Low bone mass disorder [ICD-11: FB83] T56697 INDICATI Phase 2 Multiple myeloma [ICD-11: 2A83] T56697 INDICATI Phase 1/2 Oesophagogastric junction cancer [ICD-11: 2B71] T56697 INDICATI Phase 2 Ovarian cancer [ICD-11: 2C73] T56697 INDICATI Phase 1/2 Prostate cancer [ICD-11: 2C82] T56824 TARGETID T56824 T56824 TARGNAME Vibrio TCP pilus virulence regulatory protein (Vibrio tcpN) T56824 INDICATI Preclinical Pneumonia [ICD-11: CA40] T56915 TARGETID T56915 T56915 TARGNAME Human immunodeficiency virus Protease (HIV PR) T56915 INDICATI Phase 3 Hepatitis virus infection [ICD-11: 1E50-1E51] T56915 INDICATI Approved Human immunodeficiency virus disease [ICD-11: 1C60-1C62] T56915 INDICATI Discontinued in Phase 2 Virus infection [ICD-11: 1A24-1D9Z] T56923 TARGETID T56923 T56923 TARGNAME C-X-C chemokine receptor type 2 (CXCR2) T56923 INDICATI Phase 2 Asthma [ICD-11: CA23] T56923 INDICATI Phase 2 Chronic obstructive pulmonary disease [ICD-11: CA22] T56923 INDICATI Phase 2 Cystic fibrosis [ICD-11: CA25] T56923 INDICATI Approved Fungal infection [ICD-11: 1F29-1F2F] T56923 INDICATI Withdrawn from market Gout [ICD-11: FA25] T56923 INDICATI Phase 2 Hidradenitis suppurativa [ICD-11: ED92] T56923 INDICATI Phase 2 Indeterminate colitis [ICD-11: DD72] T56923 INDICATI Phase 2 Liver vascular disorder [ICD-11: DB98] T56923 INDICATI Phase 2 Medical/surgical procedure injury [ICD-11: PK80-PK81] T56923 INDICATI Phase 1 Melanoma [ICD-11: 2C30] T56923 INDICATI Phase 1 Myelodysplastic syndrome [ICD-11: 2A37] T56923 INDICATI Approved Pain [ICD-11: MG30-MG3Z] T56923 INDICATI Phase 2 Psoriasis [ICD-11: EA90] T56923 INDICATI Preclinical Schizophrenia [ICD-11: 6A20] T56923 INDICATI Phase 1 Solid tumour/cancer [ICD-11: 2A00-2F9Z] T56923 INDICATI Phase 3 Transplant rejection [ICD-11: NE84] T56923 INDICATI Phase 2 Ulcerative colitis [ICD-11: DD71] T57001 TARGETID T57001 T57001 TARGNAME Cell surface A33 antigen (GPA33) T57001 INDICATI Phase 1/2 Colorectal cancer [ICD-11: 2B91] T57011 TARGETID T57011 T57011 TARGNAME ICAM1 messenger RNA (ICAM1 mRNA) T57011 INDICATI Phase 2 Crohn disease [ICD-11: DD70] T57011 INDICATI Approved Infectious gastroenteritis/colitis [ICD-11: 1A40] T57011 INDICATI Terminated Transplant rejection [ICD-11: NE84] T57011 INDICATI Phase 2 Ulcerative colitis [ICD-11: DD71] T57034 TARGETID T57034 T57034 TARGNAME Protein tyrosine phosphatase beta (PTPRB) T57034 INDICATI Phase 2 Chronic arterial occlusive disease [ICD-11: BD4Z] T57034 INDICATI Phase 2 Retinopathy [ICD-11: 9B71] T57059 TARGETID T57059 T57059 TARGNAME E2F transcription factor 1 (E2F1) T57059 INDICATI Phase 1 Solid tumour/cancer [ICD-11: 2A00-2F9Z] T57211 TARGETID T57211 T57211 TARGNAME Cytomegalovirus DNA polymerase messenger RNA (CMV DNA polymerase mRNA) T57211 INDICATI Withdrawn from market Cytomegaloviral disease [ICD-11: 1D82] T57278 TARGETID T57278 T57278 TARGNAME Ephrin type-A receptor 2 (EPHA2) T57278 INDICATI Phase 1/2 Brain cancer [ICD-11: 2A00] T57278 INDICATI Phase 1/2 Solid tumour/cancer [ICD-11: 2A00-2F9Z] T57361 TARGETID T57361 T57361 TARGNAME Kallikrein-related peptidase (KLK) T57361 INDICATI Phase 2 Congenital ichthyosis [ICD-11: EC20] T57361 INDICATI Phase 3 Malignant haematopoietic neoplasm [ICD-11: 2B33] T57361 INDICATI Approved Mature B-cell lymphoma [ICD-11: 2A85] T57361 INDICATI Approved Multiple myeloma [ICD-11: 2A83] T57361 INDICATI Approved Peptic ulcer [ICD-11: DA61] T57361 INDICATI Approved Retinal vascular occlusion [ICD-11: 9B74] T57364 TARGETID T57364 T57364 TARGNAME Human immunodeficiency virus Rev messenger RNA (HIV rev mRNA) T57364 INDICATI Phase 2 Human immunodeficiency virus disease [ICD-11: 1C60-1C62] T57392 TARGETID T57392 T57392 TARGNAME Debrisoquine 4-hydroxylase (CYP2D6) T57392 INDICATI Approved Insomnia [ICD-11: 7A00-7A0Z] T57392 INDICATI Phase 1 Malaria [ICD-11: 1F40-1F45] T57392 INDICATI Investigative Migraine [ICD-11: 8A80] T57585 TARGETID T57585 T57585 TARGNAME Chloride channel unspecific (ClC) T57585 INDICATI Phase 2 Brain cancer [ICD-11: 2A00] T57585 INDICATI Phase 2 Chronic obstructive pulmonary disease [ICD-11: CA22] T57585 INDICATI Discontinued in Phase 2 Cystic fibrosis [ICD-11: CA25] T57585 INDICATI Phase 2 Solid tumour/cancer [ICD-11: 2A00-2F9Z] T57654 TARGETID T57654 T57654 TARGNAME Influenza Polymerase basic protein 2 (Influ PB2) T57654 INDICATI Phase 3 Influenza [ICD-11: 1E30-1E32] T57680 TARGETID T57680 T57680 TARGNAME Soluble guanylate cyclase (GCS) T57680 INDICATI Phase 2 Alzheimer disease [ICD-11: 8A20] T57680 INDICATI Approved Angina pectoris [ICD-11: BA40] T57680 INDICATI Phase 2 Ataxic disorder [ICD-11: 8A03] T57680 INDICATI Phase 2 Chronic kidney disease [ICD-11: GB61] T57680 INDICATI Discontinued in Phase 2 Dermatophytosis [ICD-11: 1F28] T57680 INDICATI Approved Diabetic foot ulcer [ICD-11: BD54] T57680 INDICATI Phase 2 Heart failure [ICD-11: BD10-BD1Z] T57680 INDICATI Approved Hypertension [ICD-11: BA00-BA04] T57680 INDICATI Phase 2 Pulmonary hypertension [ICD-11: BB01] T57680 INDICATI Approved Respiratory failure [ICD-11: CB41] T57680 INDICATI Phase 2 Retinopathy ICD-11: 9B71 T57680 INDICATI Phase 3 Solid tumour/cancer [ICD-11: 2A00-2F9Z] T57700 TARGETID T57700 T57700 TARGNAME Tyrosine-protein kinase Kit (KIT) T57700 INDICATI Phase 1 Acute myeloid leukaemia [ICD-11: 2A60] T57700 INDICATI Phase 3 Alzheimer disease [ICD-11: 8A20] T57700 INDICATI Approved Bone/articular cartilage neoplasm [ICD-11: 2F7B] T57700 INDICATI Phase 1 Brain cancer [ICD-11: 2A00] T57700 INDICATI Approved Colorectal cancer [ICD-11: 2B91] T57700 INDICATI Approved Gastrointestinal stromal tumour [ICD-11: 2B5B] T57700 INDICATI Phase 3 Inflammatory arthropathy [ICD-11: FA2Z] T57700 INDICATI Phase 3 Liver cancer [ICD-11: 2C12] T57700 INDICATI Phase 2 Lung cancer [ICD-11: 2C25] T57700 INDICATI Phase 3 Malignant intestine neoplasm [ICD-11: 2C0Z] T57700 INDICATI Phase 1 Mastocytosis [ICD-11: 2A21] T57700 INDICATI Approved Mature B-cell lymphoma [ICD-11: 2A85] T57700 INDICATI Phase 2 Multiple myeloma [ICD-11: 2A83] T57700 INDICATI Phase 2 Myelodysplastic syndrome [ICD-11: 2A37] T57700 INDICATI Approved Myeloproliferative neoplasm [ICD-11: 2A20] T57700 INDICATI Phase 1/2 Phakomatoses/hamartoneoplastic syndrome [ICD-11: LD2D] T57700 INDICATI Phase 1 Postoperative inflammation [ICD-11: 1A00-CA43] T57700 INDICATI Approved Renal cell carcinoma [ICD-11: 2C90] T57700 INDICATI Phase 2 Solid tumour/cancer [ICD-11: 2A00-2F9Z] T57700 INDICATI Approved Thrombocytopenia [ICD-11: 3B64] T57700 INDICATI Phase 1/2 Transplanted organ/tissue [ICD-11: QB63] T57718 TARGETID T57718 T57718 TARGNAME Melanoma-associated antigen C2 (MAGEC2) T57718 INDICATI Phase 1/2 Lung cancer [ICD-11: 2C25] T57941 TARGETID T57941 T57941 TARGNAME Melanoma-associated antigen 6 (MAGEA6) T57941 INDICATI Phase 1 Solid tumour/cancer [ICD-11: 2A00-2F9Z] T57943 TARGETID T57943 T57943 TARGNAME Caspase-3 (CASP3) T57943 INDICATI Phase 1 Brain cancer [ICD-11: 2A00] T57943 INDICATI Investigative Solid tumour/cancer [ICD-11: 2A00-2F9Z] T58093 TARGETID T58093 T58093 TARGNAME Staphylococcus Peptide deformylase (Stap-coc def) T58093 INDICATI Phase 2 Bacterial infection [ICD-11: 1A00-1C4Z] T58184 TARGETID T58184 T58184 TARGNAME Ribosome (hRBS) T58184 INDICATI Phase 2 Cystic fibrosis [ICD-11: CA25] T58184 INDICATI Phase 1 Solid tumour/cancer [ICD-11: 2A00-2F9Z] T58238 TARGETID T58238 T58238 TARGNAME Activation B7-1 antigen (CD80) T58238 INDICATI Phase 1 Diabetes mellitus [ICD-11: 5A10] T58238 INDICATI Phase 2 Lung cancer [ICD-11: 2C25] T58238 INDICATI Phase 2 Lymphoma [ICD-11: 2A80-2A86] T58238 INDICATI Approved Rheumatoid arthritis [ICD-11: FA20] T58238 INDICATI Phase 1 Solid tumour/cancer [ICD-11: 2A00-2F9Z] T58238 INDICATI Terminated Transplant rejection [ICD-11: NE84] T58298 TARGETID T58298 T58298 TARGNAME Ectonucleoside triphosphate diphosphohydrolase 1 (CD39) T58298 INDICATI Phase 1 Lymphoma [ICD-11: 2A80-2A86] T58298 INDICATI Phase 1 Solid tumour/cancer [ICD-11: 2A00-2F9Z] T58449 TARGETID T58449 T58449 TARGNAME Cyclin-dependent kinase 7 (CDK7) T58449 INDICATI Phase 1/2 Breast cancer [ICD-11: 2C60-2C6Y] T58449 INDICATI Phase 2 Lung cancer [ICD-11: 2C25] T58449 INDICATI Phase 1 Malignant haematopoietic neoplasm [ICD-11: 2B33] T58449 INDICATI Investigative Nasopharyngeal cancer [ICD-11: 2B6B] T58449 INDICATI Phase 2 Solid tumour/cancer [ICD-11: 2A00-2F9Z] T58454 TARGETID T58454 T58454 TARGNAME Fibroblast growth factor receptor 2 (FGFR2) T58454 INDICATI Phase 1/2 Alzheimer disease [ICD-11: 8A20] T58454 INDICATI Phase 2 Bladder cancer [ICD-11: 2C94] T58454 INDICATI Phase 1/2 Breast cancer [ICD-11: 2C60-2C6Y] T58454 INDICATI Approved Hepatitis virus infection [ICD-11: 1E50-1E51] T58454 INDICATI Approved Liver cancer [ICD-11: 2C12] T58454 INDICATI Phase 2 Myeloproliferative neoplasm [ICD-11: 2A20] T58454 INDICATI Approved Oral mucositis [ICD-11: DA01] T58454 INDICATI Phase 3 Periodontal disease [ICD-11: DA0C] T58454 INDICATI Terminated Retina cancer [ICD-11: 2D02] T58454 INDICATI Phase 3 Solid tumour/cancer [ICD-11: 2A00-2F9Z] T58454 INDICATI Phase 1 Stomach cancer [ICD-11: 2B72] T58470 TARGETID T58470 T58470 TARGNAME Cyclin A2 (CCNA2) T58470 INDICATI Terminated Retina cancer [ICD-11: 2D02] T58479 TARGETID T58479 T58479 TARGNAME VEGF messenger RNA (VEGF mRNA) T58479 INDICATI Terminated Retinopathy [ICD-11: 9B71] T58496 TARGETID T58496 T58496 TARGNAME Transient receptor potential cation channel V3 (TRPV3) T58496 INDICATI Investigative Depression [ICD-11: 6A70-6A7Z] T58496 INDICATI Investigative Diabetes mellitus [ICD-11: 5A10] T58496 INDICATI Phase 2 Pain [ICD-11: MG30-MG3Z] T58589 TARGETID T58589 T58589 TARGNAME B1 bradykinin receptor (BDKRB1) T58589 INDICATI Investigative Depression [ICD-11: 6A70-6A7Z] T58589 INDICATI Phase 1 Osteoarthritis [ICD-11: FA00-FA05] T58589 INDICATI Investigative Pain [ICD-11: MG30-MG3Z] T58589 INDICATI Phase 2 Retinopathy [ICD-11: 9B71] T58589 INDICATI Phase 2 Rheumatoid arthritis [ICD-11: FA20] T58679 TARGETID T58679 T58679 TARGNAME Polyadenylate-binding protein 1 (PABPC1) T58679 INDICATI Phase 1 Solid tumour/cancer [ICD-11: 2A00-2F9Z] T58716 TARGETID T58716 T58716 TARGNAME Sphingomyelin phosphodiesterase 4 (SMPD4) T58716 INDICATI Discontinued in Phase 1 Depression [ICD-11: 6A70-6A7Z] T58741 TARGETID T58741 T58741 TARGNAME Voltage-gated sodium channel alpha Nav1.6 (SCN8A) T58741 INDICATI Phase 1 Epilepsy/seizure [ICD-11: 8A61-8A6Z] T58741 INDICATI Phase 2 Epileptic encephalopathy ICD-11: 8A62 T58772 TARGETID T58772 T58772 TARGNAME Mammalian target of rapamycin complex 1 (mTORC1) T58772 INDICATI Phase 1/2 Breast cancer [ICD-11: 2C60-2C6Y] T58772 INDICATI Phase 1 Depression [ICD-11: 6A70-6A7Z] T58772 INDICATI Phase 2 Heart failure [ICD-11: BD10-BD1Z] T58772 INDICATI Investigative Influenza [ICD-11: 1E30-1E32] T58772 INDICATI Phase 1 Pleural mesothelioma [ICD-11: 2C26] T58772 INDICATI Phase 3 Respiratory infection [ICD-11: CA07-CA4Z] T58772 INDICATI Phase 1 Retinopathy [ICD-11: 9B71] T58772 INDICATI Phase 2 Solid tumour/cancer [ICD-11: 2A00-2F9Z] T58902 TARGETID T58902 T58902 TARGNAME Tau protein aggregation (TauA) T58902 INDICATI Phase 3 Acute myeloid leukaemia [ICD-11: 2A60] T58902 INDICATI Phase 3 Alzheimer disease [ICD-11: 8A20] T58920 TARGETID T58920 T58920 TARGNAME Thyrotropin-releasing hormone (TRH) T58920 INDICATI Discontinued in Phase 2 Dementia [ICD-11: 6D80-6D8Z] T58920 INDICATI Phase 3 Parkinsonism [ICD-11: 8A00] T58921 TARGETID T58921 T58921 TARGNAME Peroxisome proliferator-activated receptor gamma (PPAR-gamma) T58921 INDICATI Approved Acute diabete complication [ICD-11: 5A2Y] T58921 INDICATI Approved Alzheimer disease [ICD-11: 8A20] T58921 INDICATI Phase 3 Diabetes mellitus [ICD-11: 5A10] T58921 INDICATI Phase 3 Glaucoma [ICD-11: 9C61] T58921 INDICATI Phase 2/3 Gout [ICD-11: FA25] T58921 INDICATI Phase 1 Hyper-lipoproteinaemia [ICD-11: 5C80] T58921 INDICATI Preclinical Idiopathic interstitial pneumonitis [ICD-11: CB03] T58921 INDICATI Phase 3 Inborn lipid metabolism error [ICD-11: 5C52] T58921 INDICATI Phase 2 Indeterminate colitis [ICD-11: DD72] T58921 INDICATI Preclinical Metabolic disorder [ICD-11: 5C50-5D2Z] T58921 INDICATI Phase 2 Multiple sclerosis [ICD-11: 8A40] T58921 INDICATI Phase 2 Nicotine use disorder [ICD-11: 6C4A] T58921 INDICATI Phase 2 Non-alcoholic fatty liver disease [ICD-11: DB92] T58921 INDICATI Investigative Obesity [ICD-11: 5B80-5B81] T58921 INDICATI Phase 2 Opioid use disorder [ICD-11: 6C43] T58921 INDICATI Phase 3 Peroxisomal disease ICD-11: 5C57 T58921 INDICATI Phase 1 Solid tumour/cancer [ICD-11: 2A00-2F9Z] T58921 INDICATI Approved Type 2 diabetes mellitus [ICD-11: 5A11] T58970 TARGETID T58970 T58970 TARGNAME Extracellular signal-regulated kinase 2 (ERK2) T58970 INDICATI Patented Allergic/hypersensitivity disorder [ICD-11: 4A80-4A8Z] T58970 INDICATI Phase 1 Arteries/arterioles disorder [ICD-11: BD52] T58970 INDICATI Preclinical Mature T-cell lymphoma [ICD-11: 2A90] T58970 INDICATI Phase 2 Melanoma [ICD-11: 2C30] T58970 INDICATI Phase 1 Pancreatic cancer [ICD-11: 2C10] T58970 INDICATI Terminated Rheumatoid arthritis [ICD-11: FA20] T58970 INDICATI Phase 1/2 Solid tumour/cancer [ICD-11: 2A00-2F9Z] T58970 INDICATI Patented Transplant rejection [ICD-11: NE84] T58992 TARGETID T58992 T58992 TARGNAME Opioid receptor delta (OPRD1) T58992 INDICATI Investigative Abnormal micturition [ICD-11: MF50] T58992 INDICATI Phase 2 Anxiety disorder [ICD-11: 6B00-6B0Z] T58992 INDICATI Investigative Bladder disorder [ICD-11: GC01] T58992 INDICATI Approved Bowel habit change [ICD-11: ME05] T58992 INDICATI Phase 3 Chronic pain [ICD-11: MG30] T58992 INDICATI Phase 1 Coronary vasospastic disease [ICD-11: BA85] T58992 INDICATI Phase 1 Cough [ICD-11: MD12] T58992 INDICATI Investigative Depression [ICD-11: 6A70-6A7Z] T58992 INDICATI Investigative Ejaculatory dysfunction [ICD-11: HA03] T58992 INDICATI Phase 1 Functional bladder disorder [ICD-11: GC50] T58992 INDICATI Approved Irritable bowel syndrome [ICD-11: DD91] T58992 INDICATI Investigative Ischemic heart disease [ICD-11: BA40-BA6Z] T58992 INDICATI Phase 1 Migraine [ICD-11: 8A80] T58992 INDICATI Preclinical Obesity [ICD-11: 5B80-5B81] T58992 INDICATI Phase 1 Opioid use disorder [ICD-11: 6C43] T58992 INDICATI Approved Pain [ICD-11: MG30-MG3Z] T58992 INDICATI Phase 2 Rheumatoid arthritis [ICD-11: FA20] T58992 INDICATI Phase 3 Spinal pain [ICD-11: ME84] T58992 INDICATI Preclinical Substance abuse [ICD-11: 6C40] T58992 INDICATI Discontinued in Phase 1 Unspecific substance use disorder [ICD-11: 6C4Z] T58998 TARGETID T58998 T58998 TARGNAME Bromodomain and extraterminal domain protein (BET) T58998 INDICATI Phase 1/2 Acute myeloid leukaemia [ICD-11: 2A60] T58998 INDICATI Phase 1 Brain cancer [ICD-11: 2A00] T58998 INDICATI Phase 1 Malignant haematopoietic neoplasm [ICD-11: 2B33] T58998 INDICATI Phase 1/2 Mature B-cell lymphoma [ICD-11: 2A85] T58998 INDICATI Phase 1 Multiple myeloma [ICD-11: 2A83] T58998 INDICATI Phase 1 Myelodysplastic syndrome [ICD-11: 2A37] T58998 INDICATI Phase 3 Myeloproliferative neoplasm [ICD-11: 2A20] T58998 INDICATI Phase 2 Prostate cancer [ICD-11: 2C82] T58998 INDICATI Phase 1/2 Solid tumour/cancer [ICD-11: 2A00-2F9Z] T58998 INDICATI Phase 1 Testicular cancer [ICD-11: 2C80] T59001 TARGETID T59001 T59001 TARGNAME Immunoglobulin gamma Fc receptor IIIA (FCGR3A) T59001 INDICATI Phase 2 Hodgkin lymphoma [ICD-11: 2B30] T59001 INDICATI Phase 1/2 Lymphoma [ICD-11: 2A80-2A86] T59001 INDICATI Phase 2 Mature T-cell lymphoma [ICD-11: 2A90] T59001 INDICATI Phase 1 Multiple myeloma [ICD-11: 2A83] T59001 INDICATI Phase 2 Mycosis fungoides [ICD-11: 2B01] T59001 INDICATI Phase 1/2 Solid tumour/cancer [ICD-11: 2A00-2F9Z] T59045 TARGETID T59045 T59045 TARGNAME GABA transaminase (ABAT) T59045 INDICATI Approved Brain cancer [ICD-11: 2A00] T59045 INDICATI Phase 2 Dementia [ICD-11: 6D80-6D8Z] T59045 INDICATI Approved Epilepsy/seizure [ICD-11: 8A61-8A6Z] T59045 INDICATI Approved Epileptic encephalopathy [ICD-11: 8A62] T59045 INDICATI Approved Mineral deficiency [ICD-11: 5B5K] T59045 INDICATI Approved Nutritional deficiency [ICD-11: 5B50-5B71] T59045 INDICATI Phase 2 Tic disorder [ICD-11: 8A05] T59045 INDICATI Phase 1 Unspecific substance use disorder [ICD-11: 6C4Z] T59056 TARGETID T59056 T59056 TARGNAME Aldosterone synthase (CYP11B2) T59056 INDICATI Phase 2 Hypertension [ICD-11: BA00-BA04] T59102 TARGETID T59102 T59102 TARGNAME Platelet-derived growth factor receptor beta (PDGFRB) T59102 INDICATI Approved Acute diabete complication [ICD-11: 5A2Y] T59102 INDICATI Phase 1/2 Alzheimer disease [ICD-11: 8A20] T59102 INDICATI Investigative Gram-positive bacterial infection [ICD-11: 1B74-1F40] T59102 INDICATI Phase 1/2 Intracranial injury [ICD-11: NA07] T59102 INDICATI Phase 3 Liver cancer [ICD-11: 2C12] T59102 INDICATI Investigative Lung cancer [ICD-11: 2C25] T59102 INDICATI Phase 2 Multiple myeloma [ICD-11: 2A83] T59102 INDICATI Phase 2 Myelodysplastic syndrome [ICD-11: 2A37] T59102 INDICATI Approved Renal cell carcinoma [ICD-11: 2C90] T59102 INDICATI Phase 3 Solid tumour/cancer [ICD-11: 2A00-2F9Z] T59102 INDICATI Approved Thrombocytopenia [ICD-11: 3B64] T59122 TARGETID T59122 T59122 TARGNAME Surface glycoprotein LFA-3 (CD58) T59122 INDICATI Approved Pain [ICD-11: MG30-MG3Z] T59174 TARGETID T59174 T59174 TARGNAME Sodium/hydrogen exchanger (SLC) T59174 INDICATI Terminated Hypertension [ICD-11: BA00-BA04] T59174 INDICATI Investigative Myocardial infarction [ICD-11: BA41-BA43] T59190 TARGETID T59190 T59190 TARGNAME Protein kinase C zeta (PRKCZ) T59190 INDICATI Investigative Solid tumour/cancer [ICD-11: 2A00-2F9Z] T59273 TARGETID T59273 T59273 TARGNAME PLK1 messenger RNA (PLK1 mRNA) T59273 INDICATI Phase 1/2 Solid tumour/cancer [ICD-11: 2A00-2F9Z] T59328 TARGETID T59328 T59328 TARGNAME Epidermal growth factor receptor (EGFR) T59328 INDICATI Approved Angina pectoris [ICD-11: BA40] T59328 INDICATI Phase 3 Brain cancer [ICD-11: 2A00] T59328 INDICATI Approved Breast cancer [ICD-11: 2C60-2C6Y] T59328 INDICATI Investigative Cerebral ischaemia [ICD-11: 8B1Z] T59328 INDICATI Phase 2 Chronic pain [ICD-11: MG30] T59328 INDICATI Phase 2 Colon cancer [ICD-11: 2B90] T59328 INDICATI Approved Colorectal cancer [ICD-11: 2B91] T59328 INDICATI Investigative Cryptosporidiosis [ICD-11: 1A32] T59328 INDICATI Approved Diabetic foot ulcer [ICD-11: BD54] T59328 INDICATI Investigative Diffuse large B-cell lymphoma [ICD-11: 2A81] T59328 INDICATI Terminated Digestive system disease [ICD-11: DE2Z] T59328 INDICATI Discontinued in Phase 2 Esophageal cancer [ICD-11: 2B70] T59328 INDICATI Investigative Gram-positive bacterial infection [ICD-11: 1B74-1F40] T59328 INDICATI Phase 3 Head and neck cancer [ICD-11: 2D42] T59328 INDICATI Patented Hepatitis virus infection [ICD-11: 1E50-1E51] T59328 INDICATI Phase 1/2 Hypopharyngeal cancer [ICD-11: 2B6D] T59328 INDICATI Phase 1 Intracerebral haemorrhage [ICD-11: 8B00] T59328 INDICATI Approved Ischemia [ICD-11: 8B10-8B11] T59328 INDICATI Phase 3 Liver cancer [ICD-11: 2C12] T59328 INDICATI Approved Lung cancer [ICD-11: 2C25] T59328 INDICATI Phase 2 Lymphoma [ICD-11: 2A80-2A86] T59328 INDICATI Phase 1/2 Malignant mesenchymal neoplasm [ICD-11: 2B5D-2B5Y] T59328 INDICATI Phase 1 Mature B-cell leukaemia [ICD-11: 2A82] T59328 INDICATI Phase 3 Melanoma [ICD-11: 2C30] T59328 INDICATI Phase 2/3 Metastatic biliary tract neoplasms [ICD-11: 2C14-2C17] T59328 INDICATI Phase 1 Metastatic lymph node neoplasm [ICD-11: 2D60] T59328 INDICATI Phase 2 Myelodysplastic syndrome [ICD-11: 2A37] T59328 INDICATI Investigative Nasopharyngeal cancer [ICD-11: 2B6B] T59328 INDICATI Approved Non-small-cell lung cancer [ICD-11: 2C25] T59328 INDICATI Phase 3 Pancreatic cancer [ICD-11: 2C10] T59328 INDICATI Discontinued in Phase 1 Psoriasis [ICD-11: EA90] T59328 INDICATI Approved Renal cell carcinoma [ICD-11: 2C90] T59328 INDICATI Phase 2 Skin postprocedural disorder [ICD-11: EL8Y] T59328 INDICATI Approved Solid tumour/cancer [ICD-11: 2A00-2F9Z] T59328 INDICATI Phase 1 Spinal cord/cranial nerve neoplasm [ICD-11: 2A02] T59328 INDICATI Phase 3 Stomach cancer [ICD-11: 2B72] T59328 INDICATI Phase 1 Testicular cancer [ICD-11: 2C80] T59328 INDICATI Approved Unspecific body region injury [ICD-11: ND56] T59328 INDICATI Phase 2 Urethral cancer [ICD-11: 2C93] T59382 TARGETID T59382 T59382 TARGNAME Beta-sarcoglycan (SGCB) T59382 INDICATI Phase 1/2 Muscular dystrophy [ICD-11: 8C70] T59463 TARGETID T59463 T59463 TARGNAME KRAS G12D mutant messenger RNA (KRAS mRNA) T59463 INDICATI Phase 2 Pancreatic cancer [ICD-11: 2C10] T59480 TARGETID T59480 T59480 TARGNAME KRAS G12C mutant (KRAS G12C) T59480 INDICATI Phase 3 Lung cancer [ICD-11: 2C25] T59480 INDICATI Approved Non-small-cell lung cancer [ICD-11: 2C25] T59480 INDICATI Phase 1/2 Solid tumour/cancer [ICD-11: 2A00-2F9Z] T59550 TARGETID T59550 T59550 TARGNAME CI Man-6-P receptor (IGF2R) T59550 INDICATI Phase 1 Fibrosis [ICD-11: GA14-GC01] T59550 INDICATI Phase 2 Sarcoidosis [ICD-11: 4B20] T59550 INDICATI Preclinical Solid tumour/cancer [ICD-11: 2A00-2F9Z] T59554 TARGETID T59554 T59554 TARGNAME Mycobacterium Decaprenylphosphoryl-beta-D-ribose oxidase (McyB dprE1) T59554 INDICATI Phase 2 HIV-infected patients with tuberculosis [ICD-11: 1B10-1B14] T59554 INDICATI Phase 1 Mycobacterium infection [ICD-11: 1B10-1B21] T59604 TARGETID T59604 T59604 TARGNAME Growth hormone secretagogue receptor 1 (GHSR) T59604 INDICATI Terminated Anorexia nervosa [ICD-11: 6B80] T59604 INDICATI Investigative Cachexia [ICD-11: MG20] T59604 INDICATI Approved Chronic pain [ICD-11: MG30] T59604 INDICATI Phase 2b Digestive system disease [ICD-11: DE2Z] T59604 INDICATI Phase 2b Gastroduodenal motor/secretory disorder [ICD-11: DA41] T59604 INDICATI Phase 3 Inborn carbohydrate metabolism error [ICD-11: 5C51] T59604 INDICATI Phase 1 Irritable bowel syndrome [ICD-11: DD91] T59604 INDICATI Preclinical Metabolic disorder [ICD-11: 5C50-5D2Z] T59604 INDICATI Discontinued in Phase 1/2 Obesity [ICD-11: 5B80-5B81] T59604 INDICATI Investigative Oesophagus motility disorder [ICD-11: DA21] T59604 INDICATI Phase 2 Old age [ICD-11: MG2A] T59604 INDICATI Approved Pituitary gland disorder [ICD-11: 5A60-5A61] T59604 INDICATI Phase 1/2 Postoperative ileus [ICD-11: DA91-DB30] T59604 INDICATI Phase 2b Small intestine motility disorder [ICD-11: DA93] T59604 INDICATI Phase 2 Solid tumour/cancer [ICD-11: 2A00-2F9Z] T59604 INDICATI Preclinical Substance abuse [ICD-11: 6C40] T59604 INDICATI Phase 1 Type 2 diabetes mellitus [ICD-11: 5A11] T59626 TARGETID T59626 T59626 TARGNAME Leukotriene B4 receptor 1 (LTB4R) T59626 INDICATI Terminated Allergic/hypersensitivity disorder [ICD-11: 4A80-4A8Z] T59626 INDICATI Discontinued in Phase 2 Asthma [ICD-11: CA23] T59626 INDICATI Discontinued in Phase 2 Cystic fibrosis [ICD-11: CA25] T59626 INDICATI Phase 2 Human immunodeficiency virus disease [ICD-11: 1C60-1C62] T59626 INDICATI Discontinued in Phase 2 Indeterminate colitis [ICD-11: DD72] T59626 INDICATI Terminated Low bone mass disorder [ICD-11: FB83] T59626 INDICATI Discontinued in Phase 2 Pancreatic cancer [ICD-11: 2C10] T59626 INDICATI Terminated Postoperative inflammation [ICD-11: 1A00-CA43] T59626 INDICATI Discontinued in Phase 1 Prostate cancer [ICD-11: 2C82] T59626 INDICATI Discontinued in Phase 2 Psoriasis [ICD-11: EA90] T59626 INDICATI Phase 2 Pulmonary disease [ICD-11: 1B10-1F85] T59626 INDICATI Phase 1 Renal cell carcinoma [ICD-11: 2C90] T59626 INDICATI Discontinued in Phase 2 Rheumatoid arthritis [ICD-11: FA20] T59631 TARGETID T59631 T59631 TARGNAME Programmed cell death protein 1 (PD-1) T59631 INDICATI Phase 3 Bladder cancer [ICD-11: 2C94] T59631 INDICATI Phase 3 Brain cancer [ICD-11: 2A00] T59631 INDICATI Phase 3 Breast cancer [ICD-11: 2C60-2C6Y] T59631 INDICATI Phase 3 Cervical cancer [ICD-11: 2C77] T59631 INDICATI Phase 3 Colorectal cancer [ICD-11: 2B91] T59631 INDICATI Phase 2 Diffuse large B-cell lymphoma [ICD-11: 2A81] T59631 INDICATI Approved Endometrial cancer [ICD-11: 2C76] T59631 INDICATI Phase 3 Epidermal dysplasias [ICD-11: EK90] T59631 INDICATI Phase 3 Esophageal cancer [ICD-11: 2B70] T59631 INDICATI Phase 2 Follicular lymphoma [ICD-11: 2A80] T59631 INDICATI Approved Hodgkin lymphoma [ICD-11: 2B30] T59631 INDICATI Patented Human immunodeficiency virus disease [ICD-11: 1C60-1C62] T59631 INDICATI Patented Inflammatory liver disease [ICD-11: DB97] T59631 INDICATI Phase 3 Liver cancer [ICD-11: 2C12] T59631 INDICATI Approved Lung cancer [ICD-11: 2C25] T59631 INDICATI Phase 1 Lymphoma [ICD-11: 2A80-2A86] T59631 INDICATI Phase 2 Malignant haematopoietic neoplasm [ICD-11: 2B33] T59631 INDICATI Approved Melanoma [ICD-11: 2C30] T59631 INDICATI Phase 1 Metastatic tumour [ICD-11: 2D50-2E2Z] T59631 INDICATI Phase 3 Multiple myeloma [ICD-11: 2A83] T59631 INDICATI Phase 1 Myeloproliferative neoplasm [ICD-11: 2A20] T59631 INDICATI Approved in China Nasopharyngeal cancer ICD-11: 2B6B T59631 INDICATI Phase 2 Neuroendocrine carcinoma [ICD-11: 2C34] T59631 INDICATI Phase 2 Non-small-cell lung cancer [ICD-11: 2C25] T59631 INDICATI Phase 3 Oral cavity/oesophagus/stomach in situ carcinoma [ICD-11: 2E60] T59631 INDICATI Phase 2 Ovarian cancer [ICD-11: 2C73] T59631 INDICATI Phase 1/2 Pancreatic cancer [ICD-11: 2C10] T59631 INDICATI Phase 1 Penile cancer [ICD-11: 2C81] T59631 INDICATI Phase 3 Pleural mesothelioma [ICD-11: 2C26] T59631 INDICATI Patented Postoperative inflammation [ICD-11: 1A00-CA43] T59631 INDICATI Phase 2 Prostate cancer [ICD-11: 2C82] T59631 INDICATI Phase 1 Psoriasis [ICD-11: EA90] T59631 INDICATI Phase 3 Renal cell carcinoma [ICD-11: 2C90] T59631 INDICATI Phase 2 Rheumatoid arthritis [ICD-11: FA20] T59631 INDICATI Phase 3 Solid tumour/cancer [ICD-11: 2A00-2F9Z] T59631 INDICATI Phase 3 Squamous cell carcinoma [ICD-11: 2B60-2D01] T59631 INDICATI Approved Stomach cancer [ICD-11: 2B72] T59631 INDICATI Phase 2 Ulcerative colitis [ICD-11: DD71] T59631 INDICATI Approved in China Ureteral cancer [ICD-11: 2C92] T59631 INDICATI Phase 1 Uterine ligament/parametrium/uterine adnexa neoplasm [ICD-11: 2C72] T59654 TARGETID T59654 T59654 TARGNAME Polo-like kinase 2 (PLK2) T59654 INDICATI Investigative Solid tumour/cancer [ICD-11: 2A00-2F9Z] T59679 TARGETID T59679 T59679 TARGNAME 5-HT 4 receptor (HTR4) T59679 INDICATI Investigative Abnormal micturition [ICD-11: MF50] T59679 INDICATI Phase 2 Alzheimer disease [ICD-11: 8A20] T59679 INDICATI Phase 2 Digestive system disease [ICD-11: DE2Z] T59679 INDICATI Withdrawn from market Dyspepsia [ICD-11: MD92] T59679 INDICATI Phase 2 Gastroduodenal motor/secretory disorder [ICD-11: DA41] T59679 INDICATI Approved Gastro-oesophageal reflux disease [ICD-11: DA22] T59679 INDICATI Investigative General pain disorder [ICD-11: 8E43] T59679 INDICATI Phase 1 Heart failure [ICD-11: BD10-BD1Z] T59679 INDICATI Terminated Indeterminate colitis [ICD-11: DD72] T59679 INDICATI Approved Irritable bowel syndrome [ICD-11: DD91] T59679 INDICATI Phase 1 Mild neurocognitive disorder [ICD-11: 6D71] T59679 INDICATI Phase 2 Nausea/vomiting [ICD-11: MD90] T59679 INDICATI Investigative Neurodegenerative disorder [ICD-11: 8A20-8A23] T59679 INDICATI Discontinued in Phase 2 Oesophagus motility disorder [ICD-11: DA21] T59679 INDICATI Investigative Pain [ICD-11: MG30-MG3Z] T59679 INDICATI Discontinued in Phase 2 Parkinsonism [ICD-11: 8A00] T59679 INDICATI Phase 2 Post-traumatic stress disorder [ICD-11: 6B40] T59679 INDICATI Phase 2 Supraventricular tachyarrhythmia [ICD-11: BC81] T59686 TARGETID T59686 T59686 TARGNAME Methyl cpg binding protein 2 (MECP2) T59686 INDICATI Phase 1 Intellectual development disorder [ICD-11: LD90] T59702 TARGETID T59702 T59702 TARGNAME Frizzled-10 (FZD10) T59702 INDICATI Phase 1 Synovial sarcoma [ICD-11: 2B5A] T59720 TARGETID T59720 T59720 TARGNAME Fragile histidine triad protein (FHIT) T59720 INDICATI Approved Nausea/vomiting [ICD-11: MD90] T59735 TARGETID T59735 T59735 TARGNAME Interferon receptor (IFNR) T59735 INDICATI Phase 2 Hepatitis virus infection [ICD-11: 1E50-1E51] T59735 INDICATI Phase 1 Human immunodeficiency virus disease [ICD-11: 1C60-1C62] T59735 INDICATI Terminated Solid tumour/cancer [ICD-11: 2A00-2F9Z] T59735 INDICATI Discontinued in Phase 3 Virus infection [ICD-11: 1A24-1D9Z] T59845 TARGETID T59845 T59845 TARGNAME Serine/threonine PP1-alpha (PPP1CA) T59845 INDICATI Approved Molluscum contagiosum [ICD-11: 1E76] T59870 TARGETID T59870 T59870 TARGNAME Cholesterol absorption (Chole absorp) T59870 INDICATI Phase 2 Hyper-lipoproteinaemia [ICD-11: 5C80] T59881 TARGETID T59881 T59881 TARGNAME Vasopressin V1b receptor (V1BR) T59881 INDICATI Approved Acute diabete complication [ICD-11: 5A2Y] T59881 INDICATI Phase 2 Anxiety disorder [ICD-11: 6B00-6B0Z] T59881 INDICATI Approved Autism spectrum disorder [ICD-11: 6A02] T59881 INDICATI Phase 3 Childbirth associated breast/lactation disorder [ICD-11: JB46] T59881 INDICATI Phase 2 Depression [ICD-11: 6A70-6A7Z] T59881 INDICATI Approved Hypo-osmolality/hyponatraemia [ICD-11: 5C72] T59909 TARGETID T59909 T59909 TARGNAME Protein prenyl transferase (PPTF) T59909 INDICATI Terminated Solid tumour/cancer [ICD-11: 2A00-2F9Z] T59929 TARGETID T59929 T59929 TARGNAME Thymidine phosphorylase (TYMP) T59929 INDICATI Approved Depression [ICD-11: 6A70-6A7Z] T59955 TARGETID T59955 T59955 TARGNAME Progesterone (PG) T59955 INDICATI Phase 2 Breast cancer [ICD-11: 2C60-2C6Y] T59955 INDICATI Discontinued in Phase 2 Contraceptive management [ICD-11: QA21] T60077 TARGETID T60077 T60077 TARGNAME Retinoic acid receptor RXR-beta (RXRB) T60077 INDICATI Approved Kaposi sarcoma [ICD-11: 2B57] T60136 TARGETID T60136 T60136 TARGNAME Trigeminal ganglion stimulation-induced response (TGSR) T60136 INDICATI Phase 2 Epilepsy/seizure [ICD-11: 8A61-8A6Z] T60182 TARGETID T60182 T60182 TARGNAME Glucagon receptor (GCGR) T60182 INDICATI Phase 2 Acute diabete complication [ICD-11: 5A2Y] T60182 INDICATI Phase 2 Diabetes mellitus [ICD-11: 5A10] T60182 INDICATI Approved Hypo-glycaemia [ICD-11: 5A41] T60182 INDICATI Phase 2 Non-alcoholic fatty liver disease [ICD-11: DB92] T60182 INDICATI Phase 3 Obesity [ICD-11: 5B80-5B81] T60182 INDICATI Phase 2 Pancreatic internal secretion disorder [ICD-11: 5A4Y] T60182 INDICATI Phase 2 Type 2 diabetes mellitus [ICD-11: 5A11] T60213 TARGETID T60213 T60213 TARGNAME Bone morphogenetic protein receptor (BMPR2) T60213 INDICATI Investigative Joint derangement [ICD-11: FA34] T60213 INDICATI Investigative Prostate cancer [ICD-11: 2C82] T60213 INDICATI Investigative Urinary system disease [ICD-11: GC2Z] T60213 INDICATI Investigative Urinary/pelvic organs injury [ICD-11: NB92] T60345 TARGETID T60345 T60345 TARGNAME T-cell surface glycoprotein CD3 (CD3) T60345 INDICATI Phase 1/2 Acute myeloid leukaemia [ICD-11: 2A60] T60345 INDICATI Phase 1 B-cell lymphoma [ICD-11: 2A86] T60345 INDICATI Phase 1 BCR-ABL1-negative chronic myeloid leukaemia [ICD-11: 2A41] T60345 INDICATI Phase 1 Brain cancer [ICD-11: 2A00] T60345 INDICATI Phase 1 Brain cancer ICD-11: 2A00 T60345 INDICATI Phase 1/2 Breast cancer [ICD-11: 2C60-2C6Y] T60345 INDICATI Phase 1 Colorectal cancer [ICD-11: 2B91] T60345 INDICATI Approved Diabetes mellitus [ICD-11: 5A10] T60345 INDICATI Approved Diffuse large B-cell lymphoma [ICD-11: 2A81] T60345 INDICATI Approved Follicular lymphoma [ICD-11: 2A80] T60345 INDICATI Phase 1 Human immunodeficiency virus disease [ICD-11: 1C60-1C62] T60345 INDICATI Phase 1/2 Leukaemia [ICD-11: 2A60-2B33] T60345 INDICATI Phase 2 Lung cancer [ICD-11: 2C25] T60345 INDICATI Phase 2 Malignant haematopoietic neoplasm [ICD-11: 2B33] T60345 INDICATI Phase 1 Mature B-cell leukaemia [ICD-11: 2A82] T60345 INDICATI Approved Mature B-cell lymphoma [ICD-11: 2A85] T60345 INDICATI Phase 3 Melanoma [ICD-11: 2C30] T60345 INDICATI Approved Multiple myeloma [ICD-11: 2A83] T60345 INDICATI Phase 1 Myelodysplastic syndrome [ICD-11: 2A37] T60345 INDICATI Phase 1 Non-small-cell lung cancer [ICD-11: 2C25] T60345 INDICATI Phase 1 Oesophagogastric junction cancer [ICD-11: 2B71] T60345 INDICATI Phase 1/2 Ovarian cancer [ICD-11: 2C73] T60345 INDICATI Phase 1/2 Prostate cancer [ICD-11: 2C82] T60345 INDICATI Phase 2 Solid tumour/cancer [ICD-11: 2A00-2F9Z] T60345 INDICATI Phase 1 Stomach cancer ICD-11: 2B72 T60345 INDICATI Phase 1 Stomach cancer [ICD-11: 2B72] T60348 TARGETID T60348 T60348 TARGNAME Voltage-dependent anion channel (VDAC) T60348 INDICATI Phase 2 Epidermal dysplasias [ICD-11: EK90] T60366 TARGETID T60366 T60366 TARGNAME Ornithine decarboxylase (ODC1) T60366 INDICATI Approved African trypanosomiasis [ICD-11: 1F51] T60366 INDICATI Discontinued in Phase 2 Burn and burn infection [ICD-11: ND90-NE2Z] T60366 INDICATI Investigative Head and neck cancer [ICD-11: 2D42] T60366 INDICATI Phase 2 Trypanosomiasis [ICD-11: 1D51-1F53] T60433 TARGETID T60433 T60433 TARGNAME T-cell surface glycoprotein CD1a (CD1A) T60433 INDICATI Approved Aplastic anaemia [ICD-11: 3A70] T60433 INDICATI Phase 1 Atopic eczema [ICD-11: EA80] T60514 TARGETID T60514 T60514 TARGNAME Platelet glycoprotein VI (GP6) T60514 INDICATI Phase 2 Arterial occlusive disease [ICD-11: BD40] T60514 INDICATI Phase 1/2 Cerebral ischaemic stroke [ICD-11: 8B11] T60526 TARGETID T60526 T60526 TARGNAME L-selectin (SELL) T60526 INDICATI Phase 3 Asthma [ICD-11: CA23] T60526 INDICATI Phase 3 Circulatory system disease [ICD-11: BE2Z] T60526 INDICATI Phase 2 Influenza [ICD-11: 1E30-1E32] T60526 INDICATI Investigative Postoperative inflammation [ICD-11: 1A00-CA43] T60526 INDICATI Terminated Psoriasis [ICD-11: EA90] T60529 TARGETID T60529 T60529 TARGNAME Prostaglandin G/H synthase 1 (COX-1) T60529 INDICATI Phase 3 Alzheimer disease [ICD-11: 8A20] T60529 INDICATI Phase 1/2 Ataxic disorder [ICD-11: 8A03] T60529 INDICATI Discontinued in Phase 2 Colorectal cancer [ICD-11: 2B91] T60529 INDICATI Investigative Endometriosis [ICD-11: GA10] T60529 INDICATI Approved Eye anterior segment structural developmental anomaly [ICD-11: LA11] T60529 INDICATI Approved Female pelvic pain [ICD-11: GA34] T60529 INDICATI Withdrawn from market Fever [ICD-11: MG26] T60529 INDICATI Investigative General pain disorder [ICD-11: 8E43] T60529 INDICATI Withdrawn from market Gout [ICD-11: FA25] T60529 INDICATI Approved Hyper-lipoproteinaemia [ICD-11: 5C80] T60529 INDICATI Approved Indeterminate colitis [ICD-11: DD72] T60529 INDICATI Phase 1/2 Muscular dystrophy [ICD-11: 8C70] T60529 INDICATI Phase 1/2 Neuropathy [ICD-11: 8C0Z] T60529 INDICATI Approved Nutritional deficiency [ICD-11: 5B50-5B71] T60529 INDICATI Approved Osteoarthritis [ICD-11: FA00-FA05] T60529 INDICATI Approved Pain [ICD-11: MG30-MG3Z] T60529 INDICATI Approved Postoperative inflammation [ICD-11: 1A00-CA43] T60529 INDICATI Approved Rheumatoid arthritis [ICD-11: FA20] T60529 INDICATI Approved Seborrhoeic dermatitis [ICD-11: EA81] T60529 INDICATI Withdrawn from market Sensation disturbance [ICD-11: MB40] T60529 INDICATI Preregistration Shoulder lesion [ICD-11: FB53] T60529 INDICATI Preregistration Soft tissue disorder [ICD-11: FB56] T60529 INDICATI Phase 3 Solid tumour/cancer [ICD-11: 2A00-2F9Z] T60529 INDICATI Phase 3 Systemic sclerosis [ICD-11: 4A42] T60529 INDICATI Approved Tuberculosis [ICD-11: 1B10-1B12] T60529 INDICATI Discontinued in Phase 2 Type 2 diabetes mellitus [ICD-11: 5A11] T60529 INDICATI Approved Ulcerative colitis [ICD-11: DD71] T60529 INDICATI Phase 3 Vasculitis [ICD-11: 4A44] T60568 TARGETID T60568 T60568 TARGNAME Human immunodeficiency virus Tat messenger RNA (HIV tat mRNA) T60568 INDICATI Phase 2 Human immunodeficiency virus disease [ICD-11: 1C60-1C62] T60606 TARGETID T60606 T60606 TARGNAME Thyrotropin receptor (TSHR) T60606 INDICATI Approved Hypo-thyroidism [ICD-11: 5A00] T60606 INDICATI Approved Thyroid cancer [ICD-11: 2D10] T60628 TARGETID T60628 T60628 TARGNAME Kappa myeloma antigen (KMA) T60628 INDICATI Phase 2 Malignant haematopoietic neoplasm [ICD-11: 2B33] T60631 TARGETID T60631 T60631 TARGNAME Proto-oncogene c-Ret (RET) T60631 INDICATI Phase 2 Breast cancer [ICD-11: 2C60-2C6Y] T60631 INDICATI Phase 1/2 Colon cancer [ICD-11: 2B90] T60631 INDICATI Approved Colorectal cancer [ICD-11: 2B91] T60631 INDICATI Phase 1 Indeterminate colitis [ICD-11: DD72] T60631 INDICATI Approved Lung cancer [ICD-11: 2C25] T60631 INDICATI Approved Mature B-cell lymphoma [ICD-11: 2A85] T60631 INDICATI Phase 2 Multiple myeloma [ICD-11: 2A83] T60631 INDICATI Phase 2 Myelodysplastic syndrome [ICD-11: 2A37] T60631 INDICATI Terminated Neurodegenerative disorder [ICD-11: 8A20-8A23] T60631 INDICATI Approved Solid tumour/cancer [ICD-11: 2A00-2F9Z] T60631 INDICATI Approved Thrombocytopenia [ICD-11: 3B64] T60631 INDICATI Approved Thyroid cancer [ICD-11: 2D10] T60636 TARGETID T60636 T60636 TARGNAME Alpha-ketoglutarate dehydrogenase (OGDH) T60636 INDICATI Phase 3 Acute myeloid leukaemia [ICD-11: 2A60] T60636 INDICATI Phase 2 B-cell lymphoma [ICD-11: 2A86] T60636 INDICATI Phase 1 Colorectal cancer [ICD-11: 2B91] T60636 INDICATI Phase 2 Mature B-cell lymphoma [ICD-11: 2A85] T60636 INDICATI Phase 1 Mature T-cell lymphoma [ICD-11: 2A90] T60636 INDICATI Phase 2 Myelodysplastic syndrome [ICD-11: 2A37] T60636 INDICATI Phase 3 Pancreatic cancer [ICD-11: 2C10] T60693 TARGETID T60693 T60693 TARGNAME Opioid receptor kappa (OPRK1) T60693 INDICATI Phase 1 Bipolar disorder [ICD-11: 6A60] T60693 INDICATI Phase 2 Chronic pain [ICD-11: MG30] T60693 INDICATI Phase 1 Coronary vasospastic disease [ICD-11: BA85] T60693 INDICATI Phase 3 Depression [ICD-11: 6A70-6A7Z] T60693 INDICATI Terminated Indeterminate colitis [ICD-11: DD72] T60693 INDICATI Phase 3 Irritable bowel syndrome [ICD-11: DD91] T60693 INDICATI Terminated Neurodegenerative disorder [ICD-11: 8A20-8A23] T60693 INDICATI Approved Non-specific cutaneous vascular sympton [ICD-11: ME64] T60693 INDICATI Preclinical Obesity [ICD-11: 5B80-5B81] T60693 INDICATI Phase 1 Opioid use disorder [ICD-11: 6C43] T60693 INDICATI Approved Pain [ICD-11: MG30-MG3Z] T60693 INDICATI Phase 2/3 Prurigo [ICD-11: EC91] T60693 INDICATI Approved Pruritus [ICD-11: EC90] T60693 INDICATI Phase 2 Substance abuse [ICD-11: 6C40] T60693 INDICATI Discontinued in Phase 1 Unspecific substance use disorder [ICD-11: 6C4Z] T60708 TARGETID T60708 T60708 TARGNAME Complement C5 (CO5) T60708 INDICATI Preclinical Amyloidosis [ICD-11: 5D00] T60708 INDICATI Discontinued in Phase 3 Cardiovascular disease [ICD-11: BA00-BE2Z] T60708 INDICATI Phase 1 Chronic obstructive pulmonary disease [ICD-11: CA22] T60708 INDICATI Phase 1 Diabetes mellitus [ICD-11: 5A10] T60708 INDICATI Approved Diffuse large B-cell lymphoma ICD-11: 2A81 T60708 INDICATI Approved Haemolytic anemia [ICD-11: 3A20-3A2Z] T60708 INDICATI Phase 2 Hidradenitis suppurativa [ICD-11: ED92] T60708 INDICATI Approved Macular degeneration ICD-11: 9B75 T60708 INDICATI Phase 2 Macular degeneration [ICD-11: 9B75] T60708 INDICATI Approved Myasthenia gravis ICD-11: 8C60 T60708 INDICATI Phase 3 Myasthenia gravis [ICD-11: 8C6Y] T60708 INDICATI Phase 3 Pemphigoid [ICD-11: EB41] T60708 INDICATI Terminated Postoperative inflammation [ICD-11: 1A00-CA43] T60708 INDICATI Phase 3 Retinopathy [ICD-11: 9B71] T60708 INDICATI Phase 2 Rheumatoid arthritis [ICD-11: FA20] T60708 INDICATI Phase 3 Thrombotic microangiopathy [ICD-11: 3B65] T60724 TARGETID T60724 T60724 TARGNAME Sclerostin (SOST) T60724 INDICATI Approved Low bone mass disorder [ICD-11: FB83] T60724 INDICATI Phase 2 Osteopathy/chondropathy [ICD-11: FB8Y] T60724 INDICATI Phase 3 Skeletal anomaly [ICD-11: LD24] T60810 TARGETID T60810 T60810 TARGNAME Cell mediated immunity response (CMIR) T60810 INDICATI Approved Acute viral hepatitis [ICD-11: 1E50] T60810 INDICATI Approved Hepatitis virus infection [ICD-11: 1E50-1E51] T60810 INDICATI Approved Human immunodeficiency virus disease [ICD-11: 1C60-1C62] T60810 INDICATI Approved Influenza [ICD-11: 1E30-1E32] T60810 INDICATI Phase 2 Leishmaniasis [ICD-11: 1F54] T60810 INDICATI Phase 1 Malaria [ICD-11: 1F40-1F45] T60810 INDICATI Approved Postoperative inflammation [ICD-11: 1A00-CA43] T60810 INDICATI Phase 1 Vaccination [ICD-11: N.A.] T60810 INDICATI Approved Whooping cough [ICD-11: 1C12] T60857 TARGETID T60857 T60857 TARGNAME Dihydrodiol dehydrogenase type I (AKR1C3) T60857 INDICATI Approved Female pelvic pain [ICD-11: GA34] T60857 INDICATI Phase 1/2 Prostate cancer [ICD-11: 2C82] T60930 TARGETID T60930 T60930 TARGNAME Insulin-like growth factor-I (IGF1) T60930 INDICATI Phase 2 Breast cancer [ICD-11: 2C60-2C6Y] T60930 INDICATI Phase 1/2 Prostate cancer [ICD-11: 2C82] T60930 INDICATI Phase 1 Solid tumour/cancer [ICD-11: 2A00-2F9Z] T61033 TARGETID T61033 T61033 TARGNAME Ciliary neurotrophic factor receptor alpha (CNTFR) T61033 INDICATI Phase 2/3 Glaucoma [ICD-11: 9C61] T61033 INDICATI Phase 2/3 Inherited retinal dystrophy [ICD-11: 9B70] T61033 INDICATI Phase 2 Macular degeneration [ICD-11: 9B75] T61033 INDICATI Phase 1 Obesity [ICD-11: 5B80-5B81] T61052 TARGETID T61052 T61052 TARGNAME Neuroepithelial receptor (NR) T61052 INDICATI Phase 3 Female pelvic pain [ICD-11: GA34] T61317 TARGETID T61317 T61317 TARGNAME Plasmodium Oxoacyl-[acyl-carrier protein] reductase (Malaria fabG) T61317 INDICATI Phase 3 Hepatic fibrosis/cirrhosis [ICD-11: DB93] T61339 TARGETID T61339 T61339 TARGNAME Alpha-glucosidase (GLA) T61339 INDICATI Approved in EU Inborn carbohydrate metabolism error ICD-11: 5C51 T61339 INDICATI Approved Inborn carbohydrate metabolism error [ICD-11: 5C51] T61339 INDICATI Investigative Solid tumour/cancer [ICD-11: 2A00-2F9Z] T61400 TARGETID T61400 T61400 TARGNAME Dihydroorotate dehydrogenase (DHODH) T61400 INDICATI Phase 1/2 Acute myeloid leukaemia [ICD-11: 2A60] T61400 INDICATI Phase 2 COVID-19 [ICD-11: 1D6Y] T61400 INDICATI Phase 1 Hepatitis virus infection [ICD-11: 1E50-1E51] T61400 INDICATI Approved Hyper-lipoproteinaemia [ICD-11: 5C80] T61400 INDICATI Phase 2 Indeterminate colitis [ICD-11: DD72] T61400 INDICATI Phase 1 Malignant haematopoietic neoplasm [ICD-11: 2B33] T61400 INDICATI Approved Multiple sclerosis [ICD-11: 8A40] T61400 INDICATI Phase 3 Rheumatoid arthritis [ICD-11: FA20] T61400 INDICATI Discontinued in Phase 2 Transplant rejection [ICD-11: NE84] T61484 TARGETID T61484 T61484 TARGNAME Chymotrypsin (CTR) T61484 INDICATI Phase 3 Attention deficit hyperactivity disorder [ICD-11: 6A05] T61484 INDICATI Phase 3 Autism spectrum disorder [ICD-11: 6A02] T61484 INDICATI Phase 3 Cystic fibrosis [ICD-11: CA25] T61484 INDICATI NDA filed Pancreatic malfunction [ICD-11: DC30-DC3Z] T61484 INDICATI Investigative Solid tumour/cancer [ICD-11: 2A00-2F9Z] T61518 TARGETID T61518 T61518 TARGNAME Tyrosine-protein kinase MELK (MELK) T61518 INDICATI Phase 1 Acute myeloid leukaemia [ICD-11: 2A60] T61518 INDICATI Phase 1 Breast cancer [ICD-11: 2C60-2C6Y] T61518 INDICATI Phase 1 Mature B-cell leukaemia [ICD-11: 2A82] T61518 INDICATI Phase 1 Mature B-cell lymphoma [ICD-11: 2A85] T61518 INDICATI Phase 1 Myelodysplastic syndrome [ICD-11: 2A37] T61518 INDICATI Phase 1 Myeloproliferative neoplasm [ICD-11: 2A20] T61544 TARGETID T61544 T61544 TARGNAME Transcription factor Sp1 (SP1) T61544 INDICATI Phase 2 Solid tumour/cancer [ICD-11: 2A00-2F9Z] T61547 TARGETID T61547 T61547 TARGNAME Staphylococcus Manganese transporter C (Stap-coc MntC) T61547 INDICATI Phase 2 Depression [ICD-11: 6A70-6A7Z] T61547 INDICATI Phase 2 Staphylococcal/streptococcal disease [ICD-11: 1B5Y] T61581 TARGETID T61581 T61581 TARGNAME Guanylate cyclase soluble beta-1 (GUCY1B1) T61581 INDICATI Phase 2 Heart failure [ICD-11: BD10-BD1Z] T61581 INDICATI Discontinued in Phase 1 Hypertension [ICD-11: BA00-BA04] T61622 TARGETID T61622 T61622 TARGNAME Angiotensinogenase renin (REN) T61622 INDICATI Phase 1 Cardiovascular disease [ICD-11: BA00-BE2Z] T61622 INDICATI Phase 2 Glaucoma [ICD-11: 9C61] T61622 INDICATI Approved Hypertension [ICD-11: BA00-BA04] T61622 INDICATI Phase 2 Type 2 diabetes mellitus [ICD-11: 5A11] T61622 INDICATI Phase 2 Ulcerative colitis [ICD-11: DD71] T61657 TARGETID T61657 T61657 TARGNAME Retinoic acid receptor beta (RARB) T61657 INDICATI Phase 2/3 Alzheimer disease [ICD-11: 8A20] T61657 INDICATI Approved Kaposi sarcoma [ICD-11: 2B57] T61657 INDICATI Phase 3 Mature T-cell lymphoma [ICD-11: 2A90] T61683 TARGETID T61683 T61683 TARGNAME Inhibitor of apoptosis protein (hIAP) T61683 INDICATI Phase 1 Acute myeloid leukaemia [ICD-11: 2A60] T61683 INDICATI Phase 1 Breast cancer [ICD-11: 2C60-2C6Y] T61683 INDICATI Phase 1/2 Lymphoma [ICD-11: 2A80-2A86] T61683 INDICATI Phase 1 Malignant haematopoietic neoplasm [ICD-11: 2B33] T61683 INDICATI Phase 3 Metastatic lymph node neoplasm [ICD-11: 2D60] T61683 INDICATI Phase 2 Multiple myeloma [ICD-11: 2A83] T61683 INDICATI Phase 2 Myeloproliferative neoplasm [ICD-11: 2A20] T61683 INDICATI Investigative Nasopharyngeal cancer [ICD-11: 2B6B] T61683 INDICATI Phase 2 Solid tumour/cancer [ICD-11: 2A00-2F9Z] T61698 TARGETID T61698 T61698 TARGNAME Interleukin-2 (IL2) T61698 INDICATI Phase 3 Acute diabete complication [ICD-11: 5A2Y] T61698 INDICATI Phase 2 Adrenal cancer [ICD-11: 2D11] T61698 INDICATI Phase 2/3 Bipolar disorder [ICD-11: 6A60] T61698 INDICATI Phase 2 Brain cancer [ICD-11: 2A00] T61698 INDICATI Phase 2 Immune system disease [ICD-11: 4A01-4B41] T61698 INDICATI Phase 2/3 Lung cancer [ICD-11: 2C25] T61698 INDICATI Discontinued in Phase 3 Lupus erythematosus [ICD-11: 4A40] T61698 INDICATI Phase 2 Lymphoma [ICD-11: 2A80-2A86] T61698 INDICATI Phase 2 Malignant haematopoietic neoplasm [ICD-11: 2B33] T61698 INDICATI Phase 2 Mature B-cell leukaemia [ICD-11: 2A82] T61698 INDICATI Phase 2 Mature T-cell lymphoma [ICD-11: 2A90] T61698 INDICATI Phase 2 Melanoma [ICD-11: 2C30] T61698 INDICATI Approved Multiple sclerosis [ICD-11: 8A40] T61698 INDICATI Phase 2 Mycosis fungoides [ICD-11: 2B01] T61698 INDICATI Phase 1/2 Ovarian cancer [ICD-11: 2C73] T61698 INDICATI Preclinical Prostate cancer [ICD-11: 2C82] T61698 INDICATI Approved Renal cell carcinoma [ICD-11: 2C90] T61698 INDICATI Discontinued in Phase 1 Rheumatoid arthritis [ICD-11: FA20] T61698 INDICATI Phase 1/2 Solid tumour/cancer [ICD-11: 2A00-2F9Z] T61722 TARGETID T61722 T61722 TARGNAME Prostaglandin D2 receptor 2 (PTGDR2) T61722 INDICATI Phase 2 Allergic/hypersensitivity disorder [ICD-11: 4A80-4A8Z] T61722 INDICATI Phase 2 Alopecia [ICD-11: ED70] T61722 INDICATI Discontinued in Phase 3 Arterial occlusive disease [ICD-11: BD40] T61722 INDICATI Phase 3 Asthma [ICD-11: CA23] T61722 INDICATI Phase 2 Chronic obstructive pulmonary disease [ICD-11: CA22] T61722 INDICATI Phase 4 Coronary atherosclerosis [ICD-11: BA80] T61722 INDICATI Phase 1 Respiratory system disease [ICD-11: CB40-CB7Z] T61722 INDICATI Clinical trial Solid tumour/cancer [ICD-11: 2A00-2F9Z] T61722 INDICATI Phase 2/3 Vasomotor/allergic rhinitis [ICD-11: CA08] T61729 TARGETID T61729 T61729 TARGNAME Prolyl 4-hydroxylasesubunit alpha-1 (P4HA1) T61729 INDICATI Phase 2 Hepatic fibrosis/cirrhosis [ICD-11: DB93] T61729 INDICATI Phase 1 Transplant rejection [ICD-11: NE84] T61744 TARGETID T61744 T61744 TARGNAME Phosphodiesterase 4A (PDE4A) T61744 INDICATI Investigative Acute upper respiratory infection [ICD-11: CA07] T61744 INDICATI Terminated Allergic/hypersensitivity disorder [ICD-11: 4A80-4A8Z] T61744 INDICATI Terminated Amyloidosis [ICD-11: 5D00] T61744 INDICATI Approved Asthma [ICD-11: CA23] T61744 INDICATI Phase 2 Atopic eczema [ICD-11: EA80] T61744 INDICATI Discontinued in Phase 3 Bronchitis [ICD-11: CA20] T61744 INDICATI Phase 1 Choreiform disorder [ICD-11: 8A01] T61744 INDICATI Terminated Chronic arterial occlusive disease [ICD-11: BD4Z] T61744 INDICATI Phase 2 Chronic obstructive pulmonary disease [ICD-11: CA22] T61744 INDICATI Phase 2 Crohn disease [ICD-11: DD70] T61744 INDICATI Discontinued in Phase 3 Emphysema [ICD-11: CA21] T61744 INDICATI Phase 2 Inborn purine/pyrimidine/nucleotide metabolism error [ICD-11: 5C55] T61744 INDICATI Phase 2 Irritable bowel syndrome [ICD-11: DD91] T61744 INDICATI Investigative Mature B-cell leukaemia [ICD-11: 2A82] T61744 INDICATI Phase 3 Mild neurocognitive disorder [ICD-11: 6D71] T61744 INDICATI Phase 1 Mood disorder [ICD-11: 6A60-6E23] T61744 INDICATI Discontinued in Phase 2 Multiple sclerosis [ICD-11: 8A40] T61744 INDICATI Discontinued in Phase 1 Mycosis fungoides [ICD-11: 2B01] T61744 INDICATI Phase 1 Parkinsonism [ICD-11: 8A00] T61744 INDICATI Investigative Pneumonia [ICD-11: CA40] T61744 INDICATI Investigative Postoperative inflammation [ICD-11: 1A00-CA43] T61744 INDICATI Phase 2 Psoriasis [ICD-11: EA90] T61744 INDICATI Phase 2 Rheumatoid arthritis [ICD-11: FA20] T61744 INDICATI Investigative Vitamin deficiency [ICD-11: 5B55-5B5F] T61746 TARGETID T61746 T61746 TARGNAME Cathepsin B (CTSB) T61746 INDICATI Patented Alopecia [ICD-11: ED70] T61746 INDICATI Patented Alzheimer disease [ICD-11: 8A20] T61746 INDICATI Investigative Asthma [ICD-11: CA23] T61746 INDICATI Patented Bone cancer [ICD-11: 2B5Z] T61746 INDICATI Patented Brain cancer [ICD-11: 2A00] T61746 INDICATI Preclinical Cardiac arrest [ICD-11: MC82] T61746 INDICATI Patented Cerebral ischaemic stroke [ICD-11: 8B11] T61746 INDICATI Patented Chronic obstructive pulmonary disease [ICD-11: CA22] T61746 INDICATI Patented Chronic pain [ICD-11: MG30] T61746 INDICATI Preclinical Cystic fibrosis [ICD-11: CA25] T61746 INDICATI Patented Digestive system disease [ICD-11: DE2Z] T61746 INDICATI Patented Hepatic fibrosis/cirrhosis [ICD-11: DB93] T61746 INDICATI Preclinical Idiopathic interstitial pneumonitis [ICD-11: CB03] T61746 INDICATI Patented Meningioma [ICD-11: 2A01] T61746 INDICATI Patented Metastatic tumour [ICD-11: 2D50-2E2Z] T61746 INDICATI Patented Multiple sclerosis [ICD-11: 8A40] T61746 INDICATI Patented Neurodegenerative disorder [ICD-11: 8A20-8A23] T61746 INDICATI Patented Osteoarthritis [ICD-11: FA00-FA05] T61746 INDICATI Patented Pancreatitis [ICD-11: DC31-DC34] T61746 INDICATI Patented Psoriasis [ICD-11: EA90] T61746 INDICATI Patented Rheumatoid arthritis [ICD-11: FA20] T62047 TARGETID T62047 T62047 TARGNAME Hepatitis B virus Large envelope protein (HBV S) T62047 INDICATI Phase 2 Hepatitis virus infection [ICD-11: 1E50-1E51] T62094 TARGETID T62094 T62094 TARGNAME Bacterial 30S ribosomal RNA (Bact 30S rRNA) T62094 INDICATI Approved Acne vulgaris [ICD-11: ED80] T62094 INDICATI Phase 1 Antimicrobial drug resistance [ICD-11: MG50-MG52] T62094 INDICATI Approved Bacterial infection [ICD-11: 1A00-1C4Z] T62094 INDICATI Phase 2 Diabetic foot ulcer [ICD-11: BD54] T62094 INDICATI Approved Gingival/edentulous alveolar ridge disorder [ICD-11: DA0D] T62094 INDICATI Approved Infectious gastroenteritis/colitis [ICD-11: 1A40] T62094 INDICATI Phase 2 Influenza [ICD-11: 1E30-1E32] T62094 INDICATI Approved Periodontal disease [ICD-11: DA0C] T62094 INDICATI Approved Pneumonia [ICD-11: CA40] T62094 INDICATI Discontinued in Phase 1 Postoperative inflammation [ICD-11: 1A00-CA43] T62094 INDICATI Phase 1 Respiratory infection [ICD-11: CA07-CA4Z] T62094 INDICATI Approved Skin sensation disturbance [ICD-11: ME65] T62151 TARGETID T62151 T62151 TARGNAME Monoamine oxidase (MAO) T62151 INDICATI Approved Acquired methaemoglobinaemia [ICD-11: 3A93] T62151 INDICATI Patented Alopecia [ICD-11: ED70] T62151 INDICATI Approved Alzheimer disease [ICD-11: 8A20] T62151 INDICATI Approved Depression [ICD-11: 6A70-6A7Z] T62151 INDICATI Approved Hypertension [ICD-11: BA00-BA04] T62151 INDICATI Discontinued in Phase 3 Mild neurocognitive disorder [ICD-11: 6D71] T62151 INDICATI Patented Muscular dystrophy [ICD-11: 8C70] T62151 INDICATI Discontinued in Phase 3 Nausea/vomiting [ICD-11: MD90] T62151 INDICATI Approved Parkinsonism [ICD-11: 8A00] T62151 INDICATI Patented Prostate cancer [ICD-11: 2C82] T62151 INDICATI Patented Skin tag/polyp [ICD-11: EK71] T62166 TARGETID T62166 T62166 TARGNAME Adenine synthesis (Adeni synth) T62166 INDICATI Phase 2 Brain cancer [ICD-11: 2A00] T62184 TARGETID T62184 T62184 TARGNAME GABA transporter GAT-1 (SLC6A1) T62184 INDICATI Phase 2 Anxiety disorder [ICD-11: 6B00-6B0Z] T62184 INDICATI Approved Epilepsy/seizure [ICD-11: 8A61-8A6Z] T62184 INDICATI Phase 2 Indeterminate colitis [ICD-11: DD72] T62184 INDICATI Approved Multiple myeloma [ICD-11: 2A83] T62187 TARGETID T62187 T62187 TARGNAME Herpes simplex virus Helicase-primase (HSV UL8) T62187 INDICATI Phase 3 Herpes simplex infection [ICD-11: 1F00] T62193 TARGETID T62193 T62193 TARGNAME Aromatic-L-amino-acid decarboxylase (DDC) T62193 INDICATI Phase 2 Neurotransmitter metabolic error [ICD-11: 5C59] T62193 INDICATI Approved Parkinsonism [ICD-11: 8A00] T62193 INDICATI Approved Vitamin deficiency [ICD-11: 5B55-5B5F] T62206 TARGETID T62206 T62206 TARGNAME Proprotein convertase subtilisin/kexin type 9 (PCSK9) T62206 INDICATI Phase 2 Cardiovascular disease [ICD-11: BA00-BE2Z] T62206 INDICATI Phase 3 Chronic obstructive pulmonary disease [ICD-11: CA22] T62206 INDICATI Investigative Coronary atherosclerosis [ICD-11: BA80] T62206 INDICATI Approved Hyper-lipoproteinaemia [ICD-11: 5C80] T62206 INDICATI Approved Hyper-lipoproteinaemia ICD-11: 5C80 T62241 TARGETID T62241 T62241 TARGNAME Interleukin-25 (IL25) T62241 INDICATI Phase 1 Psoriasis [ICD-11: EA90] T62276 TARGETID T62276 T62276 TARGNAME Glutamate receptor ionotropic NMDA 1 (NMDAR1) T62276 INDICATI Terminated Alzheimer disease [ICD-11: 8A20] T62276 INDICATI Approved Bacterial infection [ICD-11: 1A00-1C4Z] T62276 INDICATI Terminated Cerebral ischaemia [ICD-11: 8B1Z] T62276 INDICATI Phase 1 Dissociative neurological symptom disorder [ICD-11: 6B60] T62276 INDICATI Discontinued in Phase 2 Epilepsy/seizure [ICD-11: 8A61-8A6Z] T62276 INDICATI Approved HIV-infected patients with tuberculosis [ICD-11: 1B10-1B14] T62276 INDICATI Phase 2 Multiple sclerosis [ICD-11: 8A40] T62276 INDICATI Terminated Neurodegenerative disorder [ICD-11: 8A20-8A23] T62276 INDICATI Phase 2 Obsessive-compulsive disorder [ICD-11: 6B20] T62292 TARGETID T62292 T62292 TARGNAME GABA(A) receptor alpha-3 (GABRA3) T62292 INDICATI Phase 2 Anxiety disorder [ICD-11: 6B00-6B0Z] T62292 INDICATI Phase 2 Indeterminate colitis [ICD-11: DD72] T62292 INDICATI Approved Intentional self-harm [ICD-11: PC91] T62292 INDICATI Investigative Postoperative inflammation [ICD-11: 1A00-CA43] T62292 INDICATI Discontinued in Phase 1 Schizophrenia [ICD-11: 6A20] T62292 INDICATI Phase 2 Sleep-wake disorder [ICD-11: 7A00-7B2Z] T62306 TARGETID T62306 T62306 TARGNAME Motilin receptor (MLNR) T62306 INDICATI Investigative Bowel habit change [ICD-11: ME05] T62306 INDICATI Phase 1 Digestive system disease [ICD-11: DE2Z] T62306 INDICATI Preclinical Dyspepsia [ICD-11: MD92] T62306 INDICATI Phase 2 Gastroduodenal motor/secretory disorder [ICD-11: DA41] T62306 INDICATI Phase 1 Gastro-oesophageal reflux disease [ICD-11: DA22] T62306 INDICATI Phase 1 Irritable bowel syndrome [ICD-11: DD91] T62306 INDICATI Discontinued in Phase 2 Oesophagus motility disorder [ICD-11: DA21] T62306 INDICATI Phase 2 Pain [ICD-11: MG30-MG3Z] T62390 TARGETID T62390 T62390 TARGNAME Tyrosine 3-monooxygenase (TH) T62390 INDICATI Approved Adrenomedullary hyperfunction [ICD-11: 5A75] T62390 INDICATI Phase 2 Autism spectrum disorder [ICD-11: 6A02] T62390 INDICATI Approved Nutritional deficiency [ICD-11: 5B50-5B71] T62390 INDICATI Phase 1/2 Parkinsonism [ICD-11: 8A00] T62391 TARGETID T62391 T62391 TARGNAME Glutamate receptor AMPA 3 (GRIA3) T62391 INDICATI Approved Neuropathy [ICD-11: 8C0Z] T62391 INDICATI Discontinued in Phase 3 Parkinsonism [ICD-11: 8A00] T62431 TARGETID T62431 T62431 TARGNAME Tyrosine-protein kinase SYK (SYK) T62431 INDICATI Phase 1 Acquired hypomelanotic disorder [ICD-11: ED63] T62431 INDICATI Phase 2 Acute myeloid leukaemia [ICD-11: 2A60] T62431 INDICATI Investigative Allergic/hypersensitivity disorder [ICD-11: 4A80-4A8Z] T62431 INDICATI Phase 1 Asthma [ICD-11: CA23] T62431 INDICATI Phase 1 Atopic eczema [ICD-11: EA80] T62431 INDICATI Phase 2 B-cell lymphoma [ICD-11: 2A86] T62431 INDICATI Phase 1 Chronic obstructive pulmonary disease [ICD-11: CA22] T62431 INDICATI Phase 2 Cutaneous lupus erythematosus [ICD-11: EB50-EB5Z] T62431 INDICATI Investigative Diabetes mellitus [ICD-11: 5A10] T62431 INDICATI Phase 2 Diffuse large B-cell lymphoma [ICD-11: 2A81] T62431 INDICATI Phase 2 Malignant haematopoietic neoplasm [ICD-11: 2B33] T62431 INDICATI Phase 1 Mature B-cell leukaemia [ICD-11: 2A82] T62431 INDICATI Phase 3 Rheumatoid arthritis [ICD-11: FA20] T62431 INDICATI Phase 1 Solid tumour/cancer [ICD-11: 2A00-2F9Z] T62431 INDICATI Approved Thrombocytopenia [ICD-11: 3B64] T62431 INDICATI Investigative Thrombosis [ICD-11: DB61-GB90] T62431 INDICATI Phase 1 Urticaria [ICD-11: EB00-EB05] T62449 TARGETID T62449 T62449 TARGNAME Checkpoint kinase-1 (CHK1) T62449 INDICATI Phase 1 Anal cancer [ICD-11: 2C00] T62449 INDICATI Investigative Breast cancer [ICD-11: 2C60-2C6Y] T62449 INDICATI Phase 1 Head and neck cancer [ICD-11: 2D42] T62449 INDICATI Phase 1 Hodgkin lymphoma [ICD-11: 2B30] T62449 INDICATI Phase 2 Lung cancer [ICD-11: 2C25] T62449 INDICATI Phase 1 Lymphoma [ICD-11: 2A80-2A86] T62449 INDICATI Phase 2 Ovarian cancer [ICD-11: 2C73] T62449 INDICATI Phase 2 Pancreatic cancer [ICD-11: 2C10] T62449 INDICATI Phase 2 Solid tumour/cancer [ICD-11: 2A00-2F9Z] T62460 TARGETID T62460 T62460 TARGNAME Janus kinase 1 (JAK-1) T62460 INDICATI Phase 1/2 Acquired hypomelanotic disorder [ICD-11: ED63] T62460 INDICATI Phase 2 Alopecia [ICD-11: ED70] T62460 INDICATI Phase 2 Asthma [ICD-11: CA23] T62460 INDICATI Approved Atopic eczema [ICD-11: EA80] T62460 INDICATI Phase 2 B-cell lymphoma [ICD-11: 2A86] T62460 INDICATI Phase 2 Crohn disease [ICD-11: DD70] T62460 INDICATI Phase 2 Cutaneous lupus erythematosus [ICD-11: EB50-EB5Z] T62460 INDICATI Investigative Diffuse large B-cell lymphoma [ICD-11: 2A81] T62460 INDICATI Phase 2 Hidradenitis suppurativa [ICD-11: ED92] T62460 INDICATI Phase 2 Lung cancer [ICD-11: 2C25] T62460 INDICATI Phase 2 Lupus erythematosus [ICD-11: 4A40] T62460 INDICATI Phase 1/2 Malignant haematopoietic neoplasm [ICD-11: 2B33] T62460 INDICATI Approved Myeloproliferative neoplasm [ICD-11: 2A20] T62460 INDICATI Phase 3 Pancreatic cancer [ICD-11: 2C10] T62460 INDICATI Phase 3 Psoriasis [ICD-11: EA90] T62460 INDICATI Phase 3 Psoriatic arthritis [ICD-11: FA21] T62460 INDICATI Approved Rheumatoid arthritis [ICD-11: FA20] T62460 INDICATI Phase 2 Solid tumour/cancer [ICD-11: 2A00-2F9Z] T62460 INDICATI Approved Thrombocytosis [ICD-11: 3B63] T62460 INDICATI Phase 3 Ulcerative colitis [ICD-11: DD71] T62501 TARGETID T62501 T62501 TARGNAME Toxic methotrexate (TM) T62501 INDICATI Approved Delayed methotrexate clearance [ICD-11: N.A.] T62553 TARGETID T62553 T62553 TARGNAME Herpes simplex virus Ribonucleoside-diphosphate reductase (HSV RIR1) T62553 INDICATI Terminated Herpes simplex infection [ICD-11: 1F00] T62705 TARGETID T62705 T62705 TARGNAME Inducible T-cell costimulator (ICOS) T62705 INDICATI Phase 1 Lupus erythematosus [ICD-11: 4A40] T62705 INDICATI Phase 2 Solid tumour/cancer [ICD-11: 2A00-2F9Z] T62739 TARGETID T62739 T62739 TARGNAME STMN1 messenger RNA (STMN1 mRNA) T62739 INDICATI Investigative Breast cancer [ICD-11: 2C60-2C6Y] T62739 INDICATI Phase 1 Solid tumour/cancer [ICD-11: 2A00-2F9Z] T62753 TARGETID T62753 T62753 TARGNAME Phosphorylated protein kinase B (pAKT) T62753 INDICATI Phase 2 Brain cancer [ICD-11: 2A00] T62753 INDICATI Phase 2 Solid tumour/cancer [ICD-11: 2A00-2F9Z] T62763 TARGETID T62763 T62763 TARGNAME Fibroblast growth factor-10 (FGF10) T62763 INDICATI Discontinued in Phase 2 Oral mucositis [ICD-11: DA01] T62820 TARGETID T62820 T62820 TARGNAME Metabotropic glutamate receptor 2 (mGluR2) T62820 INDICATI Phase 2 Alzheimer disease [ICD-11: 8A20] T62820 INDICATI Discontinued in Phase 3 Anxiety disorder [ICD-11: 6B00-6B0Z] T62820 INDICATI Phase 1 Bipolar disorder [ICD-11: 6A60] T62820 INDICATI Phase 2 Dengue fever [ICD-11: 1D2Z] T62820 INDICATI Phase 2 Depression [ICD-11: 6A70-6A7Z] T62820 INDICATI Phase 1 Epilepsy/seizure [ICD-11: 8A61-8A6Z] T62820 INDICATI Phase 1 Mental/behavioural/neurodevelopmental disorder [ICD-11: 6E20-6E8Z] T62820 INDICATI Discontinued in Phase 2 Migraine [ICD-11: 8A80] T62820 INDICATI Discontinued in Phase 2 Mood disorder [ICD-11: 6A60-6E23] T62820 INDICATI Phase 2 Obesity [ICD-11: 5B80-5B81] T62820 INDICATI Phase 2 Psychotic disorder [ICD-11: 6A20-6A25] T62820 INDICATI Phase 1 Schizophrenia [ICD-11: 6A20] T62841 TARGETID T62841 T62841 TARGNAME Proteinase activated receptor 2 (PAR2) T62841 INDICATI Patented Acquired cutaneous blood vessel malformation [ICD-11: EF20] T62841 INDICATI Patented Arterial occlusive disease [ICD-11: BD40] T62841 INDICATI Patented Atopic eczema [ICD-11: EA80] T62841 INDICATI Patented Chronic obstructive pulmonary disease [ICD-11: CA22] T62841 INDICATI Phase 1 Chronic pain [ICD-11: MG30] T62841 INDICATI Patented Digestive system disease [ICD-11: DE2Z] T62841 INDICATI Patented Gastric ulcer [ICD-11: DA60] T62841 INDICATI Patented Hepatic fibrosis/cirrhosis [ICD-11: DB93] T62841 INDICATI Patented Metabolic disorder [ICD-11: 5C50-5D2Z] T62841 INDICATI Patented Multiple sclerosis [ICD-11: 8A40] T62841 INDICATI Patented Pain [ICD-11: MG30-MG3Z] T62841 INDICATI Patented Postoperative inflammation [ICD-11: 1A00-CA43] T62841 INDICATI Patented Psoriasis [ICD-11: EA90] T62841 INDICATI Patented Solid tumour/cancer [ICD-11: 2A00-2F9Z] T62841 INDICATI Patented Type 2 diabetes mellitus [ICD-11: 5A11] T62905 TARGETID T62905 T62905 TARGNAME Sodium-dependent multivitamin transporter (SLC5A6) T62905 INDICATI Phase 2 Substance abuse [ICD-11: 6C40] T62945 TARGETID T62945 T62945 TARGNAME Voltage-gated calcium channel (Cav) T62945 INDICATI Phase 1 Parkinsonism [ICD-11: 8A00] T62945 INDICATI Approved Tonus and reflex abnormality [ICD-11: MB47] T62974 TARGETID T62974 T62974 TARGNAME Somatostatin receptor type 4 (SSTR4) T62974 INDICATI Terminated Alzheimer disease [ICD-11: 8A20] T62974 INDICATI Phase 2 Chronic pain ICD-11: MG30 T62974 INDICATI Phase 1 Chronic pain [ICD-11: MG30] T62974 INDICATI Phase 2 Hepatitis virus infection [ICD-11: 1E50-1E51] T62974 INDICATI Investigative Stomach cancer [ICD-11: 2B72] T63068 TARGETID T63068 T63068 TARGNAME Serum albumin (ALB) T63068 INDICATI Approved Aneurysm/dissection [ICD-11: BD50] T63068 INDICATI Approved Bowel habit change [ICD-11: ME05] T63068 INDICATI Approved Cholelithiasis [ICD-11: DC11] T63068 INDICATI Phase 2/3 Coagulation defect [ICD-11: 3B10] T63068 INDICATI Approved Inborn energy metabolism error [ICD-11: 5C53] T63068 INDICATI Approved Irritable bowel syndrome [ICD-11: DD91] T63068 INDICATI Phase 2 Lupus erythematosus [ICD-11: 4A40] T63068 INDICATI Approved Preprocedural examination [ICD-11: QA0B] T63068 INDICATI Approved Rheumatoid arthritis [ICD-11: FA20] T63068 INDICATI Approved Schizophrenia [ICD-11: 6A20] T63068 INDICATI Approved Unspecific body region injury [ICD-11: ND56] T63068 INDICATI Phase 1/2 Vitamin deficiency [ICD-11: 5B55-5B5F] T63083 TARGETID T63083 T63083 TARGNAME DNA repair protein RAD51 homolog 1 (RAD51) T63083 INDICATI Phase 1/2 B-cell lymphoma [ICD-11: 2A86] T63083 INDICATI Phase 1/2 Solid tumour/cancer [ICD-11: 2A00-2F9Z] T63140 TARGETID T63140 T63140 TARGNAME Bacterial Integral membrane LmrP (Bact lmrP) T63140 INDICATI Approved Bacterial infection [ICD-11: 1A00-1C4Z] T63155 TARGETID T63155 T63155 TARGNAME Pyruvate kinase PKLR (PKLR) T63155 INDICATI Approved Haemolytic anemia [ICD-11: 3A20-3A2Z] T63155 INDICATI Phase 2 Inborn energy metabolism error [ICD-11: 5C53] T63155 INDICATI Approved Lysosomal disease [ICD-11: 5C56] T63156 TARGETID T63156 T63156 TARGNAME Lysosomal alpha-mannosidase (MAN2B1) T63156 INDICATI Approved Lysosomal disease [ICD-11: 5C56] T63158 TARGETID T63158 T63158 TARGNAME Sphingomyelin phosphodiesterase (SMPD1) T63158 INDICATI Approved Lysosomal disease [ICD-11: 5C56] T63160 TARGETID T63160 T63160 TARGNAME Apolipoprotein L1 messenger RNA (APOL1 mRNA) T63160 INDICATI Phase 1 Chronic kidney disease [ICD-11: GB61] T63160 INDICATI Phase 1 Urinary system disease [ICD-11: GC2Z] T63161 TARGETID T63161 T63161 TARGNAME Ataxin-3 messenger RNA (ATXN3 mRNA) T63161 INDICATI Phase 1 Ataxic disorder ICD-11: 8A03 T63163 TARGETID T63163 T63163 TARGNAME [3-methyl-2-oxobutanoate dehydrogenase] kinase (BCKDK) T63163 INDICATI Phase 1 Left ventricular failure ICD-11: BD11 T63164 TARGETID T63164 T63164 TARGNAME Cadherin-6 (CDH6) T63164 INDICATI Phase 1 Ovarian cancer [ICD-11: 2C73] T63165 TARGETID T63165 T63165 TARGNAME C-C chemokine receptor type 6 (CCR6) T63165 INDICATI Phase 1 Indeterminate colitis [ICD-11: DD72] T63166 TARGETID T63166 T63166 TARGNAME Claudin-6 (CLDN6) T63166 INDICATI Phase 1 Solid tumour/cancer [ICD-11: 2A00-2F9Z] T63168 TARGETID T63168 T63168 TARGNAME Ectonucleoside triphosphate diphosphohydrolase 3 (ENTPD3) T63168 INDICATI Phase 1 Cardiovascular disease [ICD-11: BA00-BE2Z] T63169 TARGETID T63169 T63169 TARGNAME Glucose-6-phosphatase catalytic subunit 1 messenger RNA (G6PC1 mRNA) T63169 INDICATI Phase 1 Inborn carbohydrate metabolism error ICD-11: 5C51 T63170 TARGETID T63170 T63170 TARGNAME 2-Hydroxyacid oxidase 1 (HAO1) T63170 INDICATI Phase 1 Inborn carbohydrate metabolism error ICD-11: 5C51 T63173 TARGETID T63173 T63173 TARGNAME Zinc finger protein Aiolos (IKZF3) T63173 INDICATI Phase 1 Malignant haematopoietic neoplasm [ICD-11: 2B33] T63173 INDICATI Phase 1 Mature B-cell leukaemia [ICD-11: 2A82] T63174 TARGETID T63174 T63174 TARGNAME Interleukin-1 receptor antagonist protein (IL1RN) T63174 INDICATI Phase 1 Osteoarthritis [ICD-11: FA00-FA05] T63175 TARGETID T63175 T63175 TARGNAME Histone acetyltransferase KAT6A (KAT6A) T63175 INDICATI Phase 1 Breast cancer [ICD-11: 2C60-2C6Y] T63176 TARGETID T63176 T63176 TARGNAME CD85k-Fibronectin interaction (LILRB4-FN1 PPI) T63176 INDICATI Phase 1 Solid tumour/cancer [ICD-11: 2A00-2F9Z] T63177 TARGETID T63177 T63177 TARGNAME Leucine-rich repeat serine/threonine-protein kinase 2 messenger RNA (LRRK2 mRNA) T63177 INDICATI Phase 1 Parkinsonism [ICD-11: 8A00] T63178 TARGETID T63178 T63178 TARGNAME Melanoma-associated antigen 10 (MAGEA10) T63178 INDICATI Phase 1 Bladder cancer [ICD-11: 2C94] T63178 INDICATI Phase 1 Head and neck cancer [ICD-11: 2D42] T63178 INDICATI Phase 1 Melanoma [ICD-11: 2C30] T63178 INDICATI Phase 1 Non-small-cell lung cancer [ICD-11: 2C25] T63180 TARGETID T63180 T63180 TARGNAME Mucin-5AC messenger RNA (MUC5AC mRNA) T63180 INDICATI Phase 1 Asthma [ICD-11: CA23] T63182 TARGETID T63182 T63182 TARGNAME Nucleoprotein (N) T63182 INDICATI Phase 1 Viral encephalitis [ICD-11: 1C80] T63183 TARGETID T63183 T63183 TARGNAME Pantothenate kinase 3 (PANK3) T63183 INDICATI Phase 1 Metabolism inborn error [ICD-11: 5C50] T63183 INDICATI Phase 1 Metabolism inborn error ICD-11: 5C50 T63184 TARGETID T63184 T63184 TARGNAME Advanced glycosylation end product-specific receptor messenger RNA (AGER mRNA) T63184 INDICATI Phase 1 Asthma [ICD-11: CA23] T63185 TARGETID T63185 T63185 TARGNAME KRas D816V mutant (KRAS D816V) T63185 INDICATI Phase 1 Solid tumour/cancer [ICD-11: 2A00-2F9Z] T63187 TARGETID T63187 T63187 TARGNAME F-box-like/WD repeat-containing protein TBL1X (TBL1X) T63187 INDICATI Phase 1 Acute myeloid leukaemia [ICD-11: 2A60] T63187 INDICATI Phase 1 Desmoid tumour [ICD-11: 2F7C] T63188 TARGETID T63188 T63188 TARGNAME Aspartoacylase (ASPA) T63188 INDICATI Phase 1/2 Metabolism inborn error ICD-11: 5C50 T63189 TARGETID T63189 T63189 TARGNAME Cell division cycle protein 123 (CDC123) T63189 INDICATI Phase 1 Acute myeloid leukaemia [ICD-11: 2A60] T63190 TARGETID T63190 T63190 TARGNAME Battenin (CLN3) T63190 INDICATI Phase 1/2 Lysosomal disease ICD-11: 5C56 T63191 TARGETID T63191 T63191 TARGNAME Ceroid-lipofuscinosis neuronal protein 6 (CLN6) T63191 INDICATI Phase 1/2 Lysosomal disease ICD-11: 5C56 T63192 TARGETID T63192 T63192 TARGNAME Steroid 21-hydroxylase (CYP21A2) T63192 INDICATI Phase 1/2 Adrenogenital disorder [ICD-11: 5A71] T63193 TARGETID T63193 T63193 TARGNAME Diacylglycerol kinase zeta (DGKZ) T63193 INDICATI Phase 1/2 Solid tumour/cancer [ICD-11: 2A00-2F9Z] T63194 TARGETID T63194 T63194 TARGNAME Ectonucleotide pyrophosphatase/phosphodiesterase family member 1 (ENPP1) T63194 INDICATI Phase 1/2 Pseudoxanthoma elasticum ICD-11: EC40 T63194 INDICATI Phase 1/2 Vitamin/non-protein cofactor absorption/transport disorder ICD-11: 5C63 T63195 TARGETID T63195 T63195 TARGNAME Gigaxonin (GAN) T63195 INDICATI Phase 1/2 Giant axonal neuropathy ICD-11: 8C2Y T63196 TARGETID T63196 T63196 TARGNAME Beta-hexosaminidase subunit alpha (HEXA) T63196 INDICATI Phase 1/2 Lysosomal disease ICD-11: 5C56 T63197 TARGETID T63197 T63197 TARGNAME Beta-hexosaminidase subunit beta (HEXB) T63197 INDICATI Phase 1/2 Lysosomal disease ICD-11: 5C56 T63198 TARGETID T63198 T63198 TARGNAME Rhodopsin P23H mutant messenger RNA (RHO P23H mRNA) T63198 INDICATI Phase 1/2 Inherited retinal dystrophy [ICD-11: 9B70] T63200 TARGETID T63200 T63200 TARGNAME Xanthine dehydrogenase/oxidase messenger RNA (XDH mRNA) T63200 INDICATI Phase 1/2 Gout [ICD-11: FA25] T63201 TARGETID T63201 T63201 TARGNAME Angiotensinogen messenger RNA (AGT mRNA) T63201 INDICATI Phase 2 Hypertension [ICD-11: BA00-BA04] T63202 TARGETID T63202 T63202 TARGNAME Copper-transporting ATPase 2 (ATP7B) T63202 INDICATI Phase 2 Mineral absorption/transport disorder [ICD-11: 5C64] T63203 TARGETID T63203 T63203 TARGNAME Ataxin-2 messenger RNA (ATXN2 mRNA) T63203 INDICATI Phase 2 Motor neuron disease [ICD-11: 8B60] T63204 TARGETID T63204 T63204 TARGNAME CD47-SHPS1 interaction (CD47-SHPS1 PPI) T63204 INDICATI Phase 2 Diffuse large B-cell lymphoma [ICD-11: 2A81] T63204 INDICATI Phase 1/2 Ovarian cancer [ICD-11: 2C73] T63206 TARGETID T63206 T63206 TARGNAME Integrin alpha-5/beta-1 (ITGA5/B1) T63206 INDICATI Phase 2 Autoimmune liver disease [ICD-11: DB96] T63206 INDICATI Phase 2 Idiopathic interstitial pneumonitis [ICD-11: CB03] T63207 TARGETID T63207 T63207 TARGNAME LanC-like protein 2 (LANCL2) T63207 INDICATI Phase 1 Rheumatoid arthritis [ICD-11: FA20] T63207 INDICATI Phase 2 Ulcerative colitis [ICD-11: DD71] T63208 TARGETID T63208 T63208 TARGNAME Leukocyte immunoglobulin-like receptor subfamily A member 4 (LILRA4) T63208 INDICATI Phase 2 Alopecia ICD-11: ED70 T63208 INDICATI Phase 2 Cutaneous lupus erythematosus [ICD-11: EB50-EB5Z] T63208 INDICATI Phase 2 Idiopathic inflammatory myopathy ICD-11: 4A41 T63208 INDICATI Phase 2 Lupus erythematosus [ICD-11: 4A40] T63209 TARGETID T63209 T63209 TARGNAME Leukocyte immunoglobulin-like receptor subfamily B member 1 (LILRB1) T63209 INDICATI Phase 2 Solid tumour/cancer [ICD-11: 2A00-2F9Z] T63210 TARGETID T63210 T63210 TARGNAME Arachidonate 12-lipoxygenase, 12R-type (ALOX12B) T63210 INDICATI Phase 2 Thrombocytopenia [ICD-11: 3B64] T63211 TARGETID T63211 T63211 TARGNAME NLR family member X1 (NLRX1) T63211 INDICATI Phase 2 Ulcerative colitis [ICD-11: DD71] T63212 TARGETID T63212 T63212 TARGNAME Propionyl-CoA carboxylase alpha chain, mitochondrial messenger RNA (PCCA mRNA) T63212 INDICATI Phase 2 Metabolism inborn error ICD-11: 5C50 T63213 TARGETID T63213 T63213 TARGNAME Propionyl-CoA carboxylase beta chain, mitochondrial messenger RNA (PCCB mRNA) T63213 INDICATI Phase 2 Metabolism inborn error ICD-11: 5C50 T63214 TARGETID T63214 T63214 TARGNAME 1-acylglycerol-3-phosphate O-acyltransferase PNPLA3 messenger RNA (PNPLA3 mRNA) T63214 INDICATI Phase 2 Non-alcoholic fatty liver disease [ICD-11: DB92] T63215 TARGETID T63215 T63215 TARGNAME Semaphorin-3A (SEMA3A) T63215 INDICATI Phase 2 Retinopathy [ICD-11: 9B71] T63216 TARGETID T63216 T63216 TARGNAME Slit homolog 2 protein (SLIT2) T63216 INDICATI Phase 2 Urinary system clinical sympton [ICD-11: MF8Y] T63217 TARGETID T63217 T63217 TARGNAME Protein-glutamine gamma-glutamyltransferase K (TGM1) T63217 INDICATI Phase 2 Autosomal Recessive Ichthyosis ICD-11: ED20 T63218 TARGETID T63218 T63218 TARGNAME 3-ketoacyl-CoA thiolase, mitochondrial (ACAA2) T63218 INDICATI Phase 2 Coronary atherosclerosis [ICD-11: BA80] T63221 TARGETID T63221 T63221 TARGNAME Killer cell lectin-like receptor subfamily G member 1 (KLRG1) T63221 INDICATI Phase 2/3 Idiopathic inflammatory myopathy [ICD-11: 4A41] T63222 TARGETID T63222 T63222 TARGNAME Usherin messenger RNA (USH2A mRNA) T63222 INDICATI Phase 2/3 Inherited retinal dystrophy [ICD-11: 9B70] T63224 TARGETID T63224 T63224 TARGNAME Arginase-1 (ARG1) T63224 INDICATI Phase 3 Metabolism inborn error [ICD-11: 5C50] T63225 TARGETID T63225 T63225 TARGNAME A disintegrin and metalloproteinase with thrombospondin motifs 13 (ADAMTS13) T63225 INDICATI Phase 3 Thrombocytopenia [ICD-11: 3B64] T63225 INDICATI Phase 3 Thrombocytopenia ICD-11: 3B64 T63226 TARGETID T63226 T63226 TARGNAME C-type lectin domain family 4 member C (CLEC4C) T63226 INDICATI Phase 3 Cutaneous lupus erythematosus [ICD-11: EB50-EB5Z] T63226 INDICATI Phase 3 Lupus erythematosus [ICD-11: 4A40] T63227 TARGETID T63227 T63227 TARGNAME RNA-binding protein FUS messenger RNA (FUS mRNA) T63227 INDICATI Phase 3 Motor neuron disease [ICD-11: 8B60] T63228 TARGETID T63228 T63228 TARGNAME Glial fibrillary acidic protein messenger RNA (GFAP mRNA) T63228 INDICATI Phase 3 Leukodystrophy ICD-11: 8A44 T63229 TARGETID T63229 T63229 TARGNAME Interleukin-1 receptor-like 1 (IL1RL1) T63229 INDICATI Phase 2 Asthma [ICD-11: CA23] T63229 INDICATI Phase 3 Chronic obstructive pulmonary disease [ICD-11: CA22] T63230 TARGETID T63230 T63230 TARGNAME Inhibin beta A chain (INHBA) T63230 INDICATI Phase 3 Muscle calcification/ossification [ICD-11: FB31] T63231 TARGETID T63231 T63231 TARGNAME KIT D816V mutant (KIT D816V) T63231 INDICATI Phase 3 Gastrointestinal stromal tumour [ICD-11: 2B5B] T63233 TARGETID T63233 T63233 TARGNAME Sortilin (SORT1) T63233 INDICATI Phase 3 Frontotemporal dementia ICD-11: 6D83 T63233 INDICATI Phase 2 Motor neuron disease [ICD-11: 8B60] T63233 INDICATI Phase 1 Neurodegenerative disorder [ICD-11: 8A20-8A23] T63234 TARGETID T63234 T63234 TARGNAME Cytochrome bc1 complex cytochrome b subunit (qcrB) T63234 INDICATI Preclinical HIV-infected patients with tuberculosis [ICD-11: 1B10-1B14] T63235 TARGETID T63235 T63235 TARGNAME BRAF V600E mutant (BRAF V600E) T63235 INDICATI Phase 1 Solid tumour/cancer [ICD-11: 2A00-2F9Z] T63236 TARGETID T63236 T63236 TARGNAME C-C motif chemokine 17 (CCL17) T63236 INDICATI Phase 2 Chronic pain [ICD-11: MG30] T63237 TARGETID T63237 T63237 TARGNAME 17-beta-hydroxysteroid dehydrogenase 13 (HSD17B13) T63237 INDICATI Phase 2 Non-alcoholic fatty liver disease [ICD-11: DB92] T63238 TARGETID T63238 T63238 TARGNAME G-protein coupled receptor 6 (GPR6) T63238 INDICATI Phase 2 Parkinsonism [ICD-11: 8A00] T63239 TARGETID T63239 T63239 TARGNAME HLA class I histocompatibility antigen, A alpha chain (HLA-A) T63239 INDICATI Phase 1 Acute myeloid leukaemia [ICD-11: 2A60] T63240 TARGETID T63240 T63240 TARGNAME Signal peptidase I (lepB) T63240 INDICATI Phase 1 Urinary tract infection [ICD-11: GC08] T63241 TARGETID T63241 T63241 TARGNAME Terminal nucleotidyltransferase 4B (TENT4B) T63241 INDICATI Phase 1 Hepatitis virus infection [ICD-11: 1E50-1E51] T63242 TARGETID T63242 T63242 TARGNAME Terminal nucleotidyltransferase 4A (TENT4A) T63242 INDICATI Phase 1 Hepatitis virus infection [ICD-11: 1E50-1E51] T63243 TARGETID T63243 T63243 TARGNAME Lysosomal acid glucosylceramidase (GBA1) T63243 INDICATI Phase 2/3 Lysosomal disease [ICD-11: 5C56] T63243 INDICATI Phase 1/2 Parkinsonism [ICD-11: 8A00] T63244 TARGETID T63244 T63244 TARGNAME Fibroblast growth factor 19 (FGF19) T63244 INDICATI Phase 2 Non-alcoholic fatty liver disease [ICD-11: DB92] T63245 TARGETID T63245 T63245 TARGNAME 2-acylglycerol O-acyltransferase 2 (MOGAT2) T63245 INDICATI Phase 1 Obesity [ICD-11: 5B80-5B81] T63246 TARGETID T63246 T63246 TARGNAME Cystinosin (CTNS) T63246 INDICATI Clinical trial Amino acid absorption/transport disorder ICD-11: 5C60 T63414 TARGETID T63414 T63414 TARGNAME P2X purinoceptor 7 (P2RX7) T63414 INDICATI Phase 1/2 Alzheimer disease [ICD-11: 8A20] T63414 INDICATI Phase 2 Chronic obstructive pulmonary disease [ICD-11: CA22] T63414 INDICATI Phase 1 CNS non-viral infection [ICD-11: 1D0Y] T63414 INDICATI Phase 1 Depression [ICD-11: 6A70-6A7Z] T63414 INDICATI Investigative Diabetes mellitus [ICD-11: 5A10] T63414 INDICATI Phase 1 Indeterminate colitis [ICD-11: DD72] T63414 INDICATI Phase 2/3 Joint pain [ICD-11: ME82] T63414 INDICATI Phase 1 Mood disorder [ICD-11: 6A60-6E23] T63414 INDICATI Phase 1 Mood/affect symptom [ICD-11: MB24] T63414 INDICATI Phase 2 Pain [ICD-11: MG30-MG3Z] T63414 INDICATI Investigative Postoperative inflammation [ICD-11: 1A00-CA43] T63414 INDICATI Phase 1 Rheumatoid arthritis [ICD-11: FA20] T63414 INDICATI Phase 1/2 Solid tumour/cancer [ICD-11: 2A00-2F9Z] T63484 TARGETID T63484 T63484 TARGNAME Glucose-6-phosphate dehydrogenase (G6PD) T63484 INDICATI Phase 4 Cardiovascular disease [ICD-11: BA00-BE2Z] T63484 INDICATI Approved Chronic obstructive pulmonary disease [ICD-11: CA22] T63484 INDICATI Discontinued in Phase 2 Rheumatoid arthritis [ICD-11: FA20] T63505 TARGETID T63505 T63505 TARGNAME Tyrosine-protein kinase ABL1 (ABL) T63505 INDICATI Phase 1 Acute myeloid leukaemia [ICD-11: 2A60] T63505 INDICATI Approved Breast cancer [ICD-11: 2C60-2C6Y] T63505 INDICATI Phase 1 Cardiovascular disease [ICD-11: BA00-BE2Z] T63505 INDICATI Discontinued in Phase 2 Heart beat abnormality [ICD-11: MC81] T63505 INDICATI Phase 2 Heart disease [ICD-11: BA41-BA42] T63505 INDICATI Approved Ischemia [ICD-11: 8B10-8B11] T63505 INDICATI Preclinical Leukaemia [ICD-11: 2A60-2B33] T63505 INDICATI Phase 2 Malignant haematopoietic neoplasm [ICD-11: 2B33] T63505 INDICATI Approved Mature B-cell lymphoma [ICD-11: 2A85] T63505 INDICATI Phase 2 Myeloproliferative neoplasm [ICD-11: 2A20] T63505 INDICATI Approved Nutritional deficiency [ICD-11: 5B50-5B71] T63505 INDICATI Phase 2 Osteosarcoma [ICD-11: 2B51] T63505 INDICATI Phase 1 Parkinsonism [ICD-11: 8A00] T63505 INDICATI Phase 1 Postoperative inflammation [ICD-11: 1A00-CA43] T63505 INDICATI Phase 2 Solid tumour/cancer [ICD-11: 2A00-2F9Z] T63512 TARGETID T63512 T63512 TARGNAME Extracellular lysophospholipase D (E-NPP2) T63512 INDICATI Patented Fibrosis [ICD-11: GA14-GC01] T63512 INDICATI Phase 2 Idiopathic interstitial pneumonitis [ICD-11: CB03] T63512 INDICATI Patented Pain [ICD-11: MG30-MG3Z] T63512 INDICATI Patented Postoperative inflammation [ICD-11: 1A00-CA43] T63512 INDICATI Patented Solid tumour/cancer [ICD-11: 2A00-2F9Z] T63551 TARGETID T63551 T63551 TARGNAME Integrin (ITG) T63551 INDICATI Phase 1 Retinopathy [ICD-11: 9B71] T63598 TARGETID T63598 T63598 TARGNAME Pediculus humanus Nicotinic acetylcholine receptor (Pedhc nAChR) T63598 INDICATI Approved Pediculosis [ICD-11: 1G00] T63609 TARGETID T63609 T63609 TARGNAME Adenylate cyclase type 1 (ADCY1) T63609 INDICATI Approved Nutritional deficiency [ICD-11: 5B50-5B71] T63803 TARGETID T63803 T63803 TARGNAME Vascular endothelial growth factor D (VEGFD) T63803 INDICATI Discontinued in Phase 1/2 Angina pectoris [ICD-11: BA40] T63803 INDICATI Discontinued in Phase 1/2 Chronic arterial occlusive disease [ICD-11: BD4Z] T63803 INDICATI Phase 2 Retinopathy [ICD-11: 9B71] T63816 TARGETID T63816 T63816 TARGNAME Histone deacetylase 4 (HDAC4) T63816 INDICATI Investigative Solid tumour/cancer [ICD-11: 2A00-2F9Z] T63934 TARGETID T63934 T63934 TARGNAME Interferon-alpha 2 (IFNA2) T63934 INDICATI Phase 1 Basal cell carcinoma [ICD-11: 2C32] T63934 INDICATI Phase 2 Bladder cancer [ICD-11: 2C94] T63934 INDICATI Phase 2 Colorectal cancer [ICD-11: 2B91] T63934 INDICATI Approved Hepatitis virus infection [ICD-11: 1E50-1E51] T63934 INDICATI Approved Mature B-cell leukaemia [ICD-11: 2A82] T63934 INDICATI Approved Melanoma [ICD-11: 2C30] T63934 INDICATI Phase 2 Myeloproliferative neoplasm [ICD-11: 2A20] T63934 INDICATI Phase 1 Peritoneal cancer [ICD-11: 2C51] T63934 INDICATI Phase 3 Thrombocytosis [ICD-11: 3B63] T63934 INDICATI Phase 3 Virus infection [ICD-11: 1A24-1D9Z] T63966 TARGETID T63966 T63966 TARGNAME Vascular endothelial growth factor receptor 1 (FLT-1) T63966 INDICATI Phase 2 Arterial occlusive disease [ICD-11: BD40] T63966 INDICATI Phase 2 Bladder cancer [ICD-11: 2C94] T63966 INDICATI Phase 1 Chronic arterial occlusive disease [ICD-11: BD4Z] T63966 INDICATI Phase 1/2 Colorectal cancer [ICD-11: 2B91] T63966 INDICATI Discontinued in Phase 2 Diabetic foot ulcer [ICD-11: BD54] T63966 INDICATI Phase 2 Macular degeneration [ICD-11: 9B75] T63966 INDICATI Phase 2 Pancreatic cancer [ICD-11: 2C10] T63966 INDICATI Approved Renal cell carcinoma [ICD-11: 2C90] T63966 INDICATI Phase 1 Retinopathy [ICD-11: 9B71] T63966 INDICATI Phase 3 Solid tumour/cancer [ICD-11: 2A00-2F9Z] T63966 INDICATI Phase 3 Stomach cancer [ICD-11: 2B72] T63967 TARGETID T63967 T63967 TARGNAME Neuronal acetylcholine receptor alpha-4/beta-2 (CHRNA4/B2) T63967 INDICATI Phase 2 Alzheimer disease [ICD-11: 8A20] T63967 INDICATI Discontinued in Phase 2 Anxiety disorder [ICD-11: 6B00-6B0Z] T63967 INDICATI Phase 2 Attention deficit hyperactivity disorder [ICD-11: 6A05] T63967 INDICATI Approved Corneal disease [ICD-11: 9A76-9A78] T63967 INDICATI Discontinued in Phase 2 Dementia [ICD-11: 6D80-6D8Z] T63967 INDICATI Phase 1 Depression [ICD-11: 6A70-6A7Z] T63967 INDICATI Phase 2 Digestive system disease [ICD-11: DE2Z] T63967 INDICATI Phase 2 Irritable bowel syndrome [ICD-11: DD91] T63967 INDICATI Phase 1 Mood disorder [ICD-11: 6A60-6E23] T63967 INDICATI Approved Nicotine use disorder [ICD-11: 6C4A] T63967 INDICATI Discontinued in Phase 2 Pain [ICD-11: MG30-MG3Z] T63967 INDICATI Terminated Parkinsonism [ICD-11: 8A00] T63967 INDICATI Discontinued in Phase 2 Schizophrenia [ICD-11: 6A20] T63986 TARGETID T63986 T63986 TARGNAME Kinesin spindle messenger RNA (KIF11 mRNA) T63986 INDICATI Phase 1 Liver cancer [ICD-11: 2C12] T63986 INDICATI Phase 1 Malignant haematopoietic neoplasm [ICD-11: 2B33] T64074 TARGETID T64074 T64074 TARGNAME Scavenger decapping enzyme DcpS (DCPS) T64074 INDICATI Phase 1 Muscular atrophy [ICD-11: 8B61] T64205 TARGETID T64205 T64205 TARGNAME Signal transducer and activator of transcription 1 (STAT1) T64205 INDICATI Discontinued in Phase 2 Skin and skin-structure infection [ICD-11: 1F28-1G0Z] T64213 TARGETID T64213 T64213 TARGNAME Transient receptor potential cation channel V4 (TRPV4) T64213 INDICATI Phase 2 Acute myeloid leukaemia [ICD-11: 2A60] T64213 INDICATI Phase 2 Heart failure [ICD-11: BD10-BD1Z] T64213 INDICATI Phase 2 Hodgkin lymphoma [ICD-11: 2B30] T64242 TARGETID T64242 T64242 TARGNAME Cholesterol 24-monooxygenase (CYP46A1) T64242 INDICATI Discontinued in Phase 1 Solid tumour/cancer [ICD-11: 2A00-2F9Z] T64258 TARGETID T64258 T64258 TARGNAME Microtubule-associated protein (MAP) T64258 INDICATI Approved Solid tumour/cancer [ICD-11: 2A00-2F9Z] T64376 TARGETID T64376 T64376 TARGNAME Fibroblast growth factor (FGF) T64376 INDICATI Phase 3 Skin sensation disturbance [ICD-11: ME65] T64376 INDICATI Phase 1 Solid tumour/cancer [ICD-11: 2A00-2F9Z] T64382 TARGETID T64382 T64382 TARGNAME Gamma-aminobutyric acid receptor (GAR) T64382 INDICATI Approved Anxiety disorder [ICD-11: 6B00-6B0Z] T64382 INDICATI Approved Ascariasis [ICD-11: 1F62] T64382 INDICATI Approved Bipolar disorder [ICD-11: 6A60] T64382 INDICATI Approved Depression [ICD-11: 6A70-6A7Z] T64382 INDICATI Approved Enterobiasis [ICD-11: 1F65] T64382 INDICATI Approved Epilepsy/seizure [ICD-11: 8A61-8A6Z] T64382 INDICATI Discontinued in Phase 3 Female pelvic pain [ICD-11: GA34] T64382 INDICATI Phase 2 Indeterminate colitis [ICD-11: DD72] T64382 INDICATI Phase 2 Irritable bowel syndrome [ICD-11: DD91] T64382 INDICATI Approved Mental/behavioural/neurodevelopmental disorder [ICD-11: 6E20-6E8Z] T64382 INDICATI Phase 2 Metabolism inborn error [ICD-11: 5C50] T64382 INDICATI Phase 3 Obesity [ICD-11: 5B80-5B81] T64382 INDICATI Approved Onchocerciasis [ICD-11: 1F6A] T64382 INDICATI Investigative Postoperative inflammation [ICD-11: 1A00-CA43] T64382 INDICATI Phase 2 Schizophrenia [ICD-11: 6A20] T64382 INDICATI Phase 3 Status epilepticus [ICD-11: 8A66] T64382 INDICATI Terminated Substance abuse [ICD-11: 6C40] T64382 INDICATI Approved Tonus and reflex abnormality [ICD-11: MB47] T64382 INDICATI Phase 2 Tremor-related disorder [ICD-11: 8A04] T64410 TARGETID T64410 T64410 TARGNAME Bacterial DD-carboxypeptidase (Bact vanYB) T64410 INDICATI Approved Bacterial infection [ICD-11: 1A00-1C4Z] T64410 INDICATI Phase 2 Gram-positive bacterial infection [ICD-11: 1B74-1F40] T64410 INDICATI Phase 3 Skin and skin-structure infection [ICD-11: 1F28-1G0Z] T64526 TARGETID T64526 T64526 TARGNAME Staphylococcus Clumping factor A (Stap-coc ClfA) T64526 INDICATI Phase 2 Depression [ICD-11: 6A70-6A7Z] T64526 INDICATI Phase 2 Staphylococcal/streptococcal disease [ICD-11: 1B5Y] T64567 TARGETID T64567 T64567 TARGNAME Carbonic anhydrase IX (CA-IX) T64567 INDICATI Phase 2 Breast cancer [ICD-11: 2C60-2C6Y] T64567 INDICATI Phase 2 Lymphoma [ICD-11: 2A80-2A86] T64567 INDICATI Phase 2 Renal cell carcinoma [ICD-11: 2C90] T64567 INDICATI Phase 3 Solid tumour/cancer [ICD-11: 2A00-2F9Z] T64591 TARGETID T64591 T64591 TARGNAME 5-HT 3A receptor (HTR3A) T64591 INDICATI Approved Chronic pain [ICD-11: MG30] T64591 INDICATI Approved Corneal disease [ICD-11: 9A76-9A78] T64591 INDICATI Approved Epilepsy/seizure [ICD-11: 8A61-8A6Z] T64591 INDICATI Discontinued in Phase 2 Gastro-oesophageal reflux disease [ICD-11: DA22] T64591 INDICATI Approved Irritable bowel syndrome [ICD-11: DD91] T64591 INDICATI Approved Nausea/vomiting [ICD-11: MD90] T64591 INDICATI Terminated Schizophrenia [ICD-11: 6A20] T64597 TARGETID T64597 T64597 TARGNAME Integrin beta-8 (ITGB8) T64597 INDICATI Phase 1 Chronic kidney disease [ICD-11: GB61] T64645 TARGETID T64645 T64645 TARGNAME N-sulphoglucosamine sulphohydrolase (SGSH) T64645 INDICATI Phase 2/3 Lysosomal disease [ICD-11: 5C56] T64682 TARGETID T64682 T64682 TARGNAME Serine/threonine-protein kinase Sgk1 (SGK1) T64682 INDICATI Investigative Prostate cancer [ICD-11: 2C82] T64721 TARGETID T64721 T64721 TARGNAME Cancer stemness kinase (CSK) T64721 INDICATI Phase 2 Liver cancer [ICD-11: 2C12] T64721 INDICATI Phase 2 Ovarian cancer [ICD-11: 2C73] T64721 INDICATI Phase 2 Solid tumour/cancer [ICD-11: 2A00-2F9Z] T64765 TARGETID T64765 T64765 TARGNAME Histamine H3 receptor (H3R) T64765 INDICATI Phase 2 Alzheimer disease [ICD-11: 8A20] T64765 INDICATI Terminated Anxiety disorder [ICD-11: 6B00-6B0Z] T64765 INDICATI Phase 2 Attention deficit hyperactivity disorder [ICD-11: 6A05] T64765 INDICATI Terminated Binge eating disorder [ICD-11: 6B82] T64765 INDICATI Patented Central nervous system disease [ICD-11: 8A04-8D87] T64765 INDICATI Phase 2 Chronic pain [ICD-11: MG30] T64765 INDICATI Phase 2 Dementia [ICD-11: 6D80-6D8Z] T64765 INDICATI Investigative Dissociative neurological symptom disorder [ICD-11: 6B60] T64765 INDICATI Patented Eexposure to noxious substances harmful effect [ICD-11: NE61] T64765 INDICATI Terminated Epilepsy/seizure [ICD-11: 8A61-8A6Z] T64765 INDICATI Patented General pain disorder [ICD-11: 8E43] T64765 INDICATI Clinical trial Insulin-resistance syndrome [ICD-11: 5A44] T64765 INDICATI Investigative Metabolic disorder [ICD-11: 5C50-5D2Z] T64765 INDICATI Phase 3 Mild neurocognitive disorder [ICD-11: 6D71] T64765 INDICATI Phase 2 Narcolepsy [ICD-11: 7A20] T64765 INDICATI Phase 2 Neuropathy [ICD-11: 8C0Z] T64765 INDICATI Investigative Obesity [ICD-11: 5B80-5B81] T64765 INDICATI Discontinued in Phase 2 Pain [ICD-11: MG30-MG3Z] T64765 INDICATI Patented Parkinsonism [ICD-11: 8A00] T64765 INDICATI Phase 3 Schizophrenia [ICD-11: 6A20] T64765 INDICATI Phase 1 Sleep-wake disorder [ICD-11: 7A00-7B2Z] T64765 INDICATI Approved Somnolence [ICD-11: MG42] T64765 INDICATI Phase 2 Substance abuse [ICD-11: 6C40] T64765 INDICATI Phase 1 Vasomotor/allergic rhinitis [ICD-11: CA08] T64774 TARGETID T64774 T64774 TARGNAME Voltage-dependent anion-selective channel 3 (VDAC3) T64774 INDICATI Phase 1/2 Solid tumour/cancer [ICD-11: 2A00-2F9Z] T64795 TARGETID T64795 T64795 TARGNAME Voltage-gated calcium channel alpha Cav3.1 (CACNA1G) T64795 INDICATI Approved Epilepsy/seizure [ICD-11: 8A61-8A6Z] T64795 INDICATI Approved Hypertension [ICD-11: BA00-BA04] T64795 INDICATI Phase 2 Insomnia [ICD-11: 7A00-7A0Z] T64795 INDICATI Approved Multiple structural anomalies syndrome [ICD-11: LD2F] T64795 INDICATI Approved Pancreatic cancer [ICD-11: 2C10] T64795 INDICATI Approved Schizophrenia [ICD-11: 6A20] T64795 INDICATI Investigative Solid tumour/cancer [ICD-11: 2A00-2F9Z] T64830 TARGETID T64830 T64830 TARGNAME Somatostatin receptor type 5 (SSTR5) T64830 INDICATI Terminated Alzheimer disease [ICD-11: 8A20] T64830 INDICATI Approved Cushing syndrome [ICD-11: 5A70] T64830 INDICATI Investigative Stomach cancer [ICD-11: 2B72] T64969 TARGETID T64969 T64969 TARGNAME Epidermal growth factor receptor variant III (EGFR vIII) T64969 INDICATI Phase 1/2 Brain cancer [ICD-11: 2A00] T64969 INDICATI Phase 1 Brain cancer ICD-11: 2A00 T64969 INDICATI Phase 1/2 Liver cancer [ICD-11: 2C12] T64969 INDICATI Phase 1/2 Lung cancer [ICD-11: 2C25] T64969 INDICATI Phase 1 Pancreatic cancer [ICD-11: 2C10] T64977 TARGETID T64977 T64977 TARGNAME IGF1R messenger RNA (IGF1R mRNA) T64977 INDICATI Preclinical Psoriasis [ICD-11: EA90] T64987 TARGETID T64987 T64987 TARGNAME Epstein-Barr virus Latent membrane protein 1 (EBV LMP1) T64987 INDICATI Phase 1 Lymphoma [ICD-11: 2A80-2A86] T64987 INDICATI Phase 1/2 Nasopharyngeal cancer [ICD-11: 2B6B] T65019 TARGETID T65019 T65019 TARGNAME Matrix metalloproteinase-14 (MMP-14) T65019 INDICATI Discontinued in Phase 2 Corneal disease [ICD-11: 9A76-9A78] T65019 INDICATI Phase 3 Hepatic fibrosis/cirrhosis [ICD-11: DB93] T65019 INDICATI Phase 1/2a Solid tumour/cancer [ICD-11: 2A00-2F9Z] T65054 TARGETID T65054 T65054 TARGNAME Actin (ACT) T65054 INDICATI Phase 2 Vaginitis [ICD-11: GA02] T65074 TARGETID T65074 T65074 TARGNAME microRNA hsa-miR-92 (MIR92) T65074 INDICATI Phase 1 Heart failure [ICD-11: BD10-BD1Z] T65116 TARGETID T65116 T65116 TARGNAME Ecto-5'-nucleotidase (CD73) T65116 INDICATI Phase 2 Ovarian cancer [ICD-11: 2C73] T65116 INDICATI Phase 1 Pancreatic cancer [ICD-11: 2C10] T65116 INDICATI Phase 1 Solid tumour/cancer [ICD-11: 2A00-2F9Z] T65197 TARGETID T65197 T65197 TARGNAME Erythropoietin Receptor (EPOR) T65197 INDICATI Approved Anemia [ICD-11: 3A00-3A9Z] T65197 INDICATI Phase 2 Depression [ICD-11: 6A70-6A7Z] T65197 INDICATI Phase 2 General pain disorder [ICD-11: 8E43] T65197 INDICATI Phase 1 Neuropathy [ICD-11: 8C0Z] T65197 INDICATI Phase 1 Retinopathy [ICD-11: 9B71] T65197 INDICATI Phase 2 Sarcoidosis [ICD-11: 4B20] T65197 INDICATI Approved Solid tumour/cancer [ICD-11: 2A00-2F9Z] T65197 INDICATI Approved Transplant rejection [ICD-11: NE84] T65198 TARGETID T65198 T65198 TARGNAME Pro-neuregulin-1 (Pro-NRG1) T65198 INDICATI Phase 3 Heart failure [ICD-11: BD10-BD1Z] T65200 TARGETID T65200 T65200 TARGNAME Corticosteroid 11-beta-dehydrogenase 1 (HSD11B1) T65200 INDICATI Phase 2 Acute diabete complication [ICD-11: 5A2Y] T65200 INDICATI Phase 2 Alzheimer disease [ICD-11: 8A20] T65200 INDICATI Phase 2 Glaucoma [ICD-11: 9C61] T65200 INDICATI Phase 2 Hyper-lipoproteinaemia [ICD-11: 5C80] T65200 INDICATI Phase 1 Inborn lipid metabolism error [ICD-11: 5C52] T65200 INDICATI Phase 3 Influenza [ICD-11: 1E30-1E32] T65200 INDICATI Phase 3 Lupus erythematosus [ICD-11: 4A40] T65200 INDICATI Phase 2 Metabolic disorder [ICD-11: 5C50-5D2Z] T65200 INDICATI Phase 2 Myasthenia gravis [ICD-11: 8C6Y] T65200 INDICATI Phase 1 Obesity [ICD-11: 5B80-5B81] T65200 INDICATI Phase 2a Type 2 diabetes mellitus [ICD-11: 5A11] T65236 TARGETID T65236 T65236 TARGNAME G-protein coupled estrogen receptor 1 (GPER1) T65236 INDICATI Approved Contraceptive management [ICD-11: QA21] T65236 INDICATI Phase 1/2 Lymphoma [ICD-11: 2A80-2A86] T65236 INDICATI Phase 1/2 Solid tumour/cancer [ICD-11: 2A00-2F9Z] T65291 TARGETID T65291 T65291 TARGNAME Fatty aldehyde dehydrogenase (ALDH3A2) T65291 INDICATI Discontinued in Phase 2 Epilepsy/seizure [ICD-11: 8A61-8A6Z] T65291 INDICATI Approved Substance abuse [ICD-11: 6C40] T65414 TARGETID T65414 T65414 TARGNAME Human immunodeficiency virus Envelope messenger RNA (HIV env mRNA) T65414 INDICATI Approved Coronavirus infection [ICD-11: 1D92] T65414 INDICATI Approved Human immunodeficiency virus disease [ICD-11: 1C60-1C62] T65429 TARGETID T65429 T65429 TARGNAME G-protein coupled receptor 20 (GPR20) T65429 INDICATI Phase 1 Gastrointestinal stromal tumour [ICD-11: 2B5B] T65501 TARGETID T65501 T65501 TARGNAME DNA [cytosine-5]-methyltransferase 3B (DNMT3B) T65501 INDICATI Phase 3 Solid tumour/cancer [ICD-11: 2A00-2F9Z] T65570 TARGETID T65570 T65570 TARGNAME Alcohol dehydrogenase 1A (ADH1A) T65570 INDICATI Approved Eexposure to noxious substances harmful effect [ICD-11: NE61] T65667 TARGETID T65667 T65667 TARGNAME PMN apoptosis and chemotaxis (PMNAC) T65667 INDICATI Phase 1 Rheumatoid arthritis [ICD-11: FA20] T65731 TARGETID T65731 T65731 TARGNAME Nitric oxide elimination (NOE) T65731 INDICATI Phase 1 Type 2 diabetes mellitus [ICD-11: 5A11] T65755 TARGETID T65755 T65755 TARGNAME Histone deacetylase (HDAC) T65755 INDICATI Phase 3 Acute myeloid leukaemia [ICD-11: 2A60] T65755 INDICATI Phase 1 Acute upper respiratory infection [ICD-11: CA07] T65755 INDICATI Phase 1 Adrenal cancer [ICD-11: 2D11] T65755 INDICATI Phase 2 Basal cell carcinoma [ICD-11: 2C32] T65755 INDICATI Phase 1/2 BCR-ABL1-negative chronic myeloid leukaemia [ICD-11: 2A41] T65755 INDICATI Phase 3 Breast cancer [ICD-11: 2C60-2C6Y] T65755 INDICATI Phase 2 Colorectal cancer [ICD-11: 2B91] T65755 INDICATI Phase 1/2 Diabetes mellitus [ICD-11: 5A10] T65755 INDICATI Phase 2 Diffuse large B-cell lymphoma [ICD-11: 2A81] T65755 INDICATI Approved Epilepsy/seizure [ICD-11: 8A61-8A6Z] T65755 INDICATI Phase 3 Follicular lymphoma [ICD-11: 2A80] T65755 INDICATI Phase 2 Gynecologic cancer [ICD-11: 2F33-2F76] T65755 INDICATI Phase 2 Human immunodeficiency virus disease [ICD-11: 1C60-1C62] T65755 INDICATI Phase 2 Keratosis pilaris [ICD-11: ED56] T65755 INDICATI Discontinued in Phase 1/2 Leukaemia [ICD-11: 2A60-2B33] T65755 INDICATI Registered Lung cancer [ICD-11: 2C25] T65755 INDICATI Phase 1/2 Lymphoma [ICD-11: 2A80-2A86] T65755 INDICATI Phase 1 Malignant haematopoietic neoplasm [ICD-11: 2B33] T65755 INDICATI Phase 2 Mature T-cell lymphoma [ICD-11: 2A90] T65755 INDICATI Phase 2 Melanoma [ICD-11: 2C30] T65755 INDICATI Phase 3 Mood disorder [ICD-11: 6A60-6E23] T65755 INDICATI Phase 2 Multiple myeloma [ICD-11: 2A83] T65755 INDICATI Approved Muscular atrophy [ICD-11: 8B61] T65755 INDICATI Phase 3 Muscular dystrophy [ICD-11: 8C70] T65755 INDICATI Phase 2 Mycosis fungoides [ICD-11: 2B01] T65755 INDICATI Phase 2 Myelodysplastic syndrome [ICD-11: 2A37] T65755 INDICATI Phase 2 Myeloproliferative neoplasm [ICD-11: 2A20] T65755 INDICATI Phase 1/2 Neuroendocrine carcinoma [ICD-11: 2C34] T65755 INDICATI Phase 2 Ovarian cancer [ICD-11: 2C73] T65755 INDICATI Phase 3 Renal cell carcinoma [ICD-11: 2C90] T65755 INDICATI Phase 1 Rheumatoid arthritis [ICD-11: FA20] T65755 INDICATI Registered Solid tumour/cancer [ICD-11: 2A00-2F9Z] T65755 INDICATI Phase 2 Substance abuse [ICD-11: 6C40] T65755 INDICATI Phase 2 Thrombocytosis [ICD-11: 3B63] T65783 TARGETID T65783 T65783 TARGNAME Apelin receptor (APLNR) T65783 INDICATI Phase 1 Heart failure [ICD-11: BD10-BD1Z] T65864 TARGETID T65864 T65864 TARGNAME Stress-activated protein kinase 2a (p38 alpha) T65864 INDICATI Phase 2 Alzheimer disease [ICD-11: 8A20] T65864 INDICATI Phase 1 Chronic obstructive pulmonary disease [ICD-11: CA22] T65864 INDICATI Phase 2a Coronary atherosclerosis [ICD-11: BA80] T65864 INDICATI Phase 2 Intrathoracic organs injury [ICD-11: NB32] T65864 INDICATI Phase 3 Myocardial infarction [ICD-11: BA41-BA43] T65864 INDICATI Investigative Pain [ICD-11: MG30-MG3Z] T65864 INDICATI Phase 1 Postoperative inflammation [ICD-11: 1A00-CA43] T65864 INDICATI Discontinued in Phase 1 Psoriasis [ICD-11: EA90] T65864 INDICATI Investigative Retinopathy [ICD-11: 9B71] T65864 INDICATI Phase 2a Rheumatoid arthritis [ICD-11: FA20] T65864 INDICATI Terminated Solid tumour/cancer [ICD-11: 2A00-2F9Z] T65864 INDICATI Phase 4 Vitamin deficiency [ICD-11: 5B55-5B5F] T65868 TARGETID T65868 T65868 TARGNAME RNA synthesis (hRNA synth) T65868 INDICATI Investigative Lung cancer [ICD-11: 2C25] T65868 INDICATI Approved Mineral excesses [ICD-11: 5B91] T65868 INDICATI Investigative Ovarian cancer [ICD-11: 2C73] T65868 INDICATI Withdrawn from market Solid tumour/cancer [ICD-11: 2A00-2F9Z] T65868 INDICATI Approved Testicular cancer [ICD-11: 2C80] T65879 TARGETID T65879 T65879 TARGNAME Inhibitor of nuclear factor kappa-B kinase alpha (IKKA) T65879 INDICATI Investigative Solid tumour/cancer [ICD-11: 2A00-2F9Z] T65883 TARGETID T65883 T65883 TARGNAME Claudin-18 (CLDN18) T65883 INDICATI Clinical trial Adenocarcinoma [ICD-11: 2D40] T65883 INDICATI Phase 2 Esophageal cancer [ICD-11: 2B70] T65883 INDICATI Phase 3 Oesophagogastric junction cancer [ICD-11: 2B71] T65883 INDICATI Phase 2 Pancreatic cancer [ICD-11: 2C10] T65883 INDICATI Phase 1/2 Solid tumour/cancer [ICD-11: 2A00-2F9Z] T65883 INDICATI Phase 3 Stomach cancer [ICD-11: 2B72] T65883 INDICATI Phase 1/2 Stomach cancer ICD-11: 2B72 T65889 TARGETID T65889 T65889 TARGNAME Pyruvate kinase M2 (PKM) T65889 INDICATI Phase 2 Pain [ICD-11: MG30-MG3Z] T65889 INDICATI Phase 2a Renal cell carcinoma [ICD-11: 2C90] T65889 INDICATI Phase 1 Solid tumour/cancer [ICD-11: 2A00-2F9Z] T65941 TARGETID T65941 T65941 TARGNAME SERPINA1 messenger RNA (SERPINA1 mRNA) T65941 INDICATI Phase 2 Alopecia [ICD-11: ED70] T65941 INDICATI Phase 3 Alpha-1-antitrypsin deficiency [ICD-11: 5C5A] T65978 TARGETID T65978 T65978 TARGNAME Pseudomonas Multiple virulence factor regulator MvfR (Pseudo MvfR) T65978 INDICATI Preclinical Glanders [ICD-11: 1B92] T66011 TARGETID T66011 T66011 TARGNAME Complement factor B (CFB) T66011 INDICATI Investigative Asthma [ICD-11: CA23] T66011 INDICATI Discontinued in Phase 1 Coronary atherosclerosis [ICD-11: BA80] T66011 INDICATI Approved Haemolytic anemia [ICD-11: 3A20-3A2Z] T66011 INDICATI Phase 2 Macular degeneration ICD-11: 9B75 T66011 INDICATI Investigative Macular degeneration [ICD-11: 9B75] T66011 INDICATI Phase 3 Urinary system clinical sympton [ICD-11: MF8Y] T66023 TARGETID T66023 T66023 TARGNAME Schistosoma Deoxyribonucleic acid (Schist DNA) T66023 INDICATI Approved Schistosomiasis [ICD-11: 1F86] T66030 TARGETID T66030 T66030 TARGNAME Natural killer cell activation (NKA) T66030 INDICATI Approved Breast cancer [ICD-11: 2C60-2C6Y] T66040 TARGETID T66040 T66040 TARGNAME Bacterial Penicillin binding protein 2 (Bact mrdA) T66040 INDICATI Approved Bacterial infection [ICD-11: 1A00-1C4Z] T66093 TARGETID T66093 T66093 TARGNAME Hepatitis C virus microRNA miR-122 (HCV MIR122) T66093 INDICATI Phase 2 Hepatitis virus infection [ICD-11: 1E50-1E51] T66120 TARGETID T66120 T66120 TARGNAME Bacterial Deoxy-manno-octulosonate cytidylyltransferase (Bact kdsB) T66120 INDICATI Phase 3 Idiopathic inflammatory myopathy [ICD-11: 4A41] T66120 INDICATI Phase 2 Muscle disorder [ICD-11: FB32-FB3Z] T66161 TARGETID T66161 T66161 TARGNAME Filamin A (FLNA) T66161 INDICATI Phase 2 Alzheimer disease [ICD-11: 8A20] T66237 TARGETID T66237 T66237 TARGNAME Vasopressin V2 receptor (V2R) T66237 INDICATI Discontinued in Phase 1 Abnormal micturition [ICD-11: MF50] T66237 INDICATI Approved Acute diabete complication [ICD-11: 5A2Y] T66237 INDICATI Phase 2 Anxiety disorder [ICD-11: 6B00-6B0Z] T66237 INDICATI Approved Autism spectrum disorder [ICD-11: 6A02] T66237 INDICATI Phase 3 Childbirth associated breast/lactation disorder [ICD-11: JB46] T66237 INDICATI Phase 2 Depression [ICD-11: 6A70-6A7Z] T66237 INDICATI Approved Enuresis [ICD-11: 6C00] T66237 INDICATI Terminated Female pelvic pain [ICD-11: GA34] T66237 INDICATI Phase 3 Heart failure [ICD-11: BD10-BD1Z] T66237 INDICATI Approved Hypo-osmolality/hyponatraemia [ICD-11: 5C72] T66237 INDICATI Approved Pituitary gland disorder [ICD-11: 5A60-5A61] T66237 INDICATI Approved Polyuria [ICD-11: MF55] T66237 INDICATI Phase 2 Skin and skin-structure infection [ICD-11: 1F28-1G0Z] T66252 TARGETID T66252 T66252 TARGNAME Dipeptidyl peptidase 9 (DPP-9) T66252 INDICATI Phase 3 Neutropenia [ICD-11: 4B00] T66252 INDICATI Phase 1/2 Prostate cancer [ICD-11: 2C82] T66252 INDICATI Phase 1 Solid tumour/cancer [ICD-11: 2A00-2F9Z] T66266 TARGETID T66266 T66266 TARGNAME T-cell antigen CD7 (CD7) T66266 INDICATI Phase 1 Leukaemia [ICD-11: 2A60-2B33] T66266 INDICATI Phase 1 Lymphoma [ICD-11: 2A80-2A86] T66266 INDICATI Phase 1 Malignant haematopoietic neoplasm [ICD-11: 2B33] T66266 INDICATI Phase 1 Mycosis fungoides [ICD-11: 2B01] T66350 TARGETID T66350 T66350 TARGNAME Ras-related protein Rab-9A (RAB9A) T66350 INDICATI Approved Fungal infection [ICD-11: 1F29-1F2F] T66383 TARGETID T66383 T66383 TARGNAME Complement factor D (CFD) T66383 INDICATI Phase 2 Acute disease anaemia [ICD-11: 3A90] T66383 INDICATI Phase 1 Amyloidosis [ICD-11: 5D00] T66383 INDICATI Investigative Diabetes mellitus [ICD-11: 5A10] T66383 INDICATI Phase 3 Haemolytic anemia [ICD-11: 3A20-3A2Z] T66383 INDICATI Phase 2 Lupus erythematosus ICD-11: 4A40 T66383 INDICATI Phase 1/2 Macular degeneration [ICD-11: 9B75] T66383 INDICATI Phase 2 Myasthenia gravis ICD-11: 8C60 T66383 INDICATI Phase 3 Retinopathy [ICD-11: 9B71] T66383 INDICATI Phase 2 Urinary system clinical sympton [ICD-11: MF8Y] T66426 TARGETID T66426 T66426 TARGNAME Hematopoietic progenitor cell antigen CD34 (CD34) T66426 INDICATI Phase 1 Acute myeloid leukaemia [ICD-11: 2A60] T66426 INDICATI Phase 2 Heart failure [ICD-11: BD10-BD1Z] T66426 INDICATI Phase 1 Myelodysplastic syndrome [ICD-11: 2A37] T66505 TARGETID T66505 T66505 TARGNAME Smoothened homolog (SMO) T66505 INDICATI Approved Basal cell carcinoma [ICD-11: 2C32] T66505 INDICATI Phase 2 Brain cancer [ICD-11: 2A00] T66505 INDICATI Approved Chronic myelomonocytic leukaemia [ICD-11: 2A40] T66505 INDICATI Phase 1 Ovarian cancer [ICD-11: 2C73] T66505 INDICATI Phase 2 Skin cancer [ICD-11: 2C30-2C37] T66505 INDICATI Approved Solid tumour/cancer [ICD-11: 2A00-2F9Z] T66514 TARGETID T66514 T66514 TARGNAME Carbohydrate antigen Lewis-Y (Lewis-Y) T66514 INDICATI Phase 1 Solid tumour/cancer [ICD-11: 2A00-2F9Z] T66538 TARGETID T66538 T66538 TARGNAME Calcium-activated potassium channel KCa1.1 (KCNMA1) T66538 INDICATI Phase 2 Asthma [ICD-11: CA23] T66538 INDICATI Phase 2 Functional bladder disorder [ICD-11: GC50] T66540 TARGETID T66540 T66540 TARGNAME TRPV1 messenger RNA (TRPV1 mRNA) T66540 INDICATI Phase 3 Visual system disease [ICD-11: 9E1Z] T66665 TARGETID T66665 T66665 TARGNAME Prostaglandin G/H synthase 2 (COX-2) T66665 INDICATI Phase 3 Alzheimer disease [ICD-11: 8A20] T66665 INDICATI Phase 2/3 Asthma [ICD-11: CA23] T66665 INDICATI Approved Chronic pain [ICD-11: MG30] T66665 INDICATI Terminated Colorectal cancer [ICD-11: 2B91] T66665 INDICATI Terminated Endometriosis [ICD-11: GA10] T66665 INDICATI Approved Female pelvic pain [ICD-11: GA34] T66665 INDICATI Terminated Fever [ICD-11: MG26] T66665 INDICATI Discontinued in Phase 3 General pain disorder [ICD-11: 8E43] T66665 INDICATI Withdrawn from market Gout [ICD-11: FA25] T66665 INDICATI Approved Hyper-lipoproteinaemia [ICD-11: 5C80] T66665 INDICATI Approved Indeterminate colitis [ICD-11: DD72] T66665 INDICATI Approved Knee osteoarthritis [ICD-11: FA01] T66665 INDICATI Discontinued in Phase 2 Large intestine polyp [ICD-11: DB35] T66665 INDICATI Discontinued in Phase 2 Lung cancer [ICD-11: 2C25] T66665 INDICATI Discontinued in Phase 3 Lupus erythematosus [ICD-11: 4A40] T66665 INDICATI Terminated Malignant haematopoietic neoplasm [ICD-11: 2B33] T66665 INDICATI Phase 2 Migraine [ICD-11: 8A80] T66665 INDICATI Approved Osteoarthritis [ICD-11: FA00-FA05] T66665 INDICATI Approved Pain [ICD-11: MG30-MG3Z] T66665 INDICATI Discontinued in Phase 2 Pancreatic cancer [ICD-11: 2C10] T66665 INDICATI Discontinued in Phase 3 Postoperative inflammation [ICD-11: 1A00-CA43] T66665 INDICATI Approved Rheumatoid arthritis [ICD-11: FA20] T66665 INDICATI Preregistration Shoulder lesion [ICD-11: FB53] T66665 INDICATI Preregistration Soft tissue disorder [ICD-11: FB56] T66665 INDICATI Phase 3 Solid tumour/cancer [ICD-11: 2A00-2F9Z] T66665 INDICATI Approved Tuberculosis [ICD-11: 1B10-1B12] T66665 INDICATI Discontinued in Phase 2 Type 2 diabetes mellitus [ICD-11: 5A11] T66693 TARGETID T66693 T66693 TARGNAME B-cell maturation protein (TNFRSF17) T66693 INDICATI Clinical trial Follicular lymphoma [ICD-11: 2A80] T66693 INDICATI Phase 1/2 Leukaemia [ICD-11: 2A60-2B33] T66693 INDICATI Phase 1/2 Lymphoma [ICD-11: 2A80-2A86] T66693 INDICATI Clinical trial Malignant haematopoietic neoplasm [ICD-11: 2B33] T66693 INDICATI Clinical trial Mature B-cell leukaemia [ICD-11: 2A82] T66693 INDICATI Clinical trial Mature B-cell lymphoma [ICD-11: 2A85] T66693 INDICATI Approved Multiple myeloma [ICD-11: 2A83] T66693 INDICATI Phase 1 Prostate cancer [ICD-11: 2C82] T66903 TARGETID T66903 T66903 TARGNAME Fascin (FSCN1) T66903 INDICATI Phase 1 Solid tumour/cancer [ICD-11: 2A00-2F9Z] T67022 TARGETID T67022 T67022 TARGNAME Caspase (CASP) T67022 INDICATI Phase 2 Cardiovascular disease [ICD-11: BA00-BE2Z] T67022 INDICATI Preclinical Hepatic fibrosis/cirrhosis [ICD-11: DB93] T67022 INDICATI Preclinical Idiopathic interstitial pneumonitis [ICD-11: CB03] T67022 INDICATI Investigative Mature T-cell lymphoma [ICD-11: 2A90] T67022 INDICATI Terminated Solid tumour/cancer [ICD-11: 2A00-2F9Z] T67046 TARGETID T67046 T67046 TARGNAME Platelet activating factor (PAF) T67046 INDICATI Preclinical Fungal infection [ICD-11: 1F29-1F2F] T67054 TARGETID T67054 T67054 TARGNAME 5-HT 1 receptor (5HT1R) T67054 INDICATI Terminated Anxiety disorder [ICD-11: 6B00-6B0Z] T67054 INDICATI Terminated Depression [ICD-11: 6A70-6A7Z] T67054 INDICATI Terminated Migraine [ICD-11: 8A80] T67058 TARGETID T67058 T67058 TARGNAME Staphylococcus Capsular polysaccharide CP8 (Stap-coc CP8) T67058 INDICATI Phase 2 Depression [ICD-11: 6A70-6A7Z] T67058 INDICATI Phase 2 Staphylococcal/streptococcal disease [ICD-11: 1B5Y] T67063 TARGETID T67063 T67063 TARGNAME Charybdotoxin receptor beta-4 (BKbeta4) T67063 INDICATI Terminated Asthma [ICD-11: CA23] T67063 INDICATI Terminated Cerebral ischaemia [ICD-11: 8B1Z] T67063 INDICATI Phase 2 Sexual dysfunction [ICD-11: HA00-HA01] T67079 TARGETID T67079 T67079 TARGNAME Interleukin-9 (IL9) T67079 INDICATI Phase 2 Asthma [ICD-11: CA23] T67079 INDICATI Phase 2 Mature T-cell lymphoma [ICD-11: 2A90] T67079 INDICATI Phase 2 Mycosis fungoides [ICD-11: 2B01] T67084 TARGETID T67084 T67084 TARGNAME Glucosidase unspecific (GAN) T67084 INDICATI Discontinued in Phase 2 Acute diabete complication [ICD-11: 5A2Y] T67089 TARGETID T67089 T67089 TARGNAME SERPINC1 messenger RNA (SERPINC1 mRNA) T67089 INDICATI Phase 3 Coagulation defect [ICD-11: 3B10] T67102 TARGETID T67102 T67102 TARGNAME Cathepsin D (CTSD) T67102 INDICATI Terminated Hypertension [ICD-11: BA00-BA04] T67102 INDICATI Clinical trial Multiple sclerosis [ICD-11: 8A40] T67103 TARGETID T67103 T67103 TARGNAME Integrin alpha-V (ITGAV) T67103 INDICATI Phase 2 Colorectal cancer [ICD-11: 2B91] T67103 INDICATI Phase 1 Solid tumour/cancer [ICD-11: 2A00-2F9Z] T67162 TARGETID T67162 T67162 TARGNAME Dopamine D2 receptor (D2R) T67162 INDICATI Approved Allergic/hypersensitivity disorder [ICD-11: 4A80-4A8Z] T67162 INDICATI Approved Alzheimer disease [ICD-11: 8A20] T67162 INDICATI Phase 1 Anxiety disorder [ICD-11: 6B00-6B0Z] T67162 INDICATI Approved Asthma [ICD-11: CA23] T67162 INDICATI Approved Attention deficit hyperactivity disorder [ICD-11: 6A05] T67162 INDICATI Discontinued in Phase 3 Bacterial infection [ICD-11: 1A00-1C4Z] T67162 INDICATI Approved Bipolar disorder [ICD-11: 6A60] T67162 INDICATI Phase 2 Brain cancer [ICD-11: 2A00] T67162 INDICATI Withdrawn from market Breast cancer [ICD-11: 2C60-2C6Y] T67162 INDICATI Approved Breathing abnormality [ICD-11: MD11] T67162 INDICATI Phase 2 Carcinoid syndrome [ICD-11: 5B10] T67162 INDICATI Approved Cardiovascular disease [ICD-11: BA00-BE2Z] T67162 INDICATI Approved Cerebral ischaemia [ICD-11: 8B1Z] T67162 INDICATI Phase 3 Choreiform disorder [ICD-11: 8A01] T67162 INDICATI Phase 1b Chronic kidney disease [ICD-11: GB61] T67162 INDICATI Discontinued in Phase 3 Chronic obstructive pulmonary disease [ICD-11: CA22] T67162 INDICATI Approved Depression [ICD-11: 6A70-6A7Z] T67162 INDICATI Approved Digestive system disease [ICD-11: DE2Z] T67162 INDICATI Phase 2 Endocrine gland neoplasm [ICD-11: 2F37] T67162 INDICATI Phase 2 Endometrial cancer [ICD-11: 2C76] T67162 INDICATI Approved Essential hypertension [ICD-11: BA00] T67162 INDICATI Approved Faecal incontinence [ICD-11: ME07] T67162 INDICATI Withdrawn from market Fatigue [ICD-11: MG22] T67162 INDICATI Phase 3 Fibrosis [ICD-11: GA14-GC01] T67162 INDICATI Approved Gangrene [ICD-11: MC85] T67162 INDICATI Phase 2 Gastroduodenal motor/secretory disorder [ICD-11: DA41] T67162 INDICATI Phase 1 General pain disorder [ICD-11: 8E43] T67162 INDICATI Approved Glaucoma [ICD-11: 9C61] T67162 INDICATI Approved Heart failure [ICD-11: BD10-BD1Z] T67162 INDICATI Approved Hyperaemia [ICD-11: 9A61-9B7Y] T67162 INDICATI Approved Hypertension [ICD-11: BA00-BA04] T67162 INDICATI Approved Hypotension [ICD-11: BA20-BA21] T67162 INDICATI Phase 2 Idiopathic interstitial pneumonitis [ICD-11: CB03] T67162 INDICATI Approved Inborn porphyrin/heme metabolism error [ICD-11: 5C58] T67162 INDICATI Discontinued in Phase 2 Indeterminate colitis [ICD-11: DD72] T67162 INDICATI Approved Insomnia [ICD-11: 7A00-7A0Z] T67162 INDICATI Phase 2/3 Intellectual development disorder [ICD-11: LD90] T67162 INDICATI Approved Itching [ICD-11: 1F28-1G07] T67162 INDICATI Phase 1/2 Leukaemia [ICD-11: 2A60-2B33] T67162 INDICATI Phase 3 Lung cancer [ICD-11: 2C25] T67162 INDICATI Phase 1/2 Lymphoma [ICD-11: 2A80-2A86] T67162 INDICATI Investigative Mental/behavioural/neurodevelopmental disorder [ICD-11: 6E20-6E8Z] T67162 INDICATI Approved Migraine [ICD-11: 8A80] T67162 INDICATI Phase 2 Multiple myeloma [ICD-11: 2A83] T67162 INDICATI Approved Nausea/vomiting [ICD-11: MD90] T67162 INDICATI Terminated Nicotine use disorder [ICD-11: 6C4A] T67162 INDICATI Approved Pain [ICD-11: MG30-MG3Z] T67162 INDICATI Phase 2 Pancreatic cancer [ICD-11: 2C10] T67162 INDICATI Approved Parkinsonism [ICD-11: 8A00] T67162 INDICATI Approved Pituitary gland disorder [ICD-11: 5A60-5A61] T67162 INDICATI Terminated Postoperative inflammation [ICD-11: 1A00-CA43] T67162 INDICATI Approved Postpartum haemorrhage [ICD-11: JA43] T67162 INDICATI Discontinued in Phase 3 Psoriasis [ICD-11: EA90] T67162 INDICATI Approved Psychotic disorder [ICD-11: 6A20-6A25] T67162 INDICATI Approved Pulmonary hypertension [ICD-11: BB01] T67162 INDICATI Phase 2 Respiratory infection [ICD-11: CA07-CA4Z] T67162 INDICATI Phase 3 Restless legs syndrome [ICD-11: 7A80] T67162 INDICATI Phase 2 Schizoaffective disorder [ICD-11: 6A21] T67162 INDICATI Approved Schizophrenia [ICD-11: 6A20] T67162 INDICATI Phase 2 Sexual dysfunction [ICD-11: HA00-HA01] T67162 INDICATI Phase 1 Solid tumour/cancer [ICD-11: 2A00-2F9Z] T67162 INDICATI Phase 2 Stomach cancer [ICD-11: 2B72] T67162 INDICATI Approved Substance abuse [ICD-11: 6C40] T67162 INDICATI Investigative Thrombocytopenia [ICD-11: 3B64] T67162 INDICATI Approved Thyrotoxicosis [ICD-11: 5A02] T67162 INDICATI Patented Tonus and reflex abnormality [ICD-11: MB47] T67162 INDICATI Approved Type 2 diabetes mellitus [ICD-11: 5A11] T67162 INDICATI Terminated Unspecific substance use disorder [ICD-11: 6C4Z] T67207 TARGETID T67207 T67207 TARGNAME Lymphocyte IgE receptor (CD23) T67207 INDICATI Phase 2 Leukaemia [ICD-11: 2A60-2B33] T67233 TARGETID T67233 T67233 TARGNAME Cholesterol uptake (Chole uptake) T67233 INDICATI Phase 3 Hyper-lipoproteinaemia [ICD-11: 5C80] T67272 TARGETID T67272 T67272 TARGNAME Aminopeptidase N (ANPEP) T67272 INDICATI Phase 2 Psoriasis [ICD-11: EA90] T67282 TARGETID T67282 T67282 TARGNAME Staphylococcus Leucyl-tRNA synthetase (Stap-coc leuS) T67282 INDICATI Phase 1 Fungal infection [ICD-11: 1F29-1F2F] T67282 INDICATI Approved Nail/perionychium infection [ICD-11: EE12] T67282 INDICATI Phase 2 Urinary tract infection [ICD-11: GC08] T67310 TARGETID T67310 T67310 TARGNAME Glutamate receptor ionotropic (GRI) T67310 INDICATI Terminated Cerebral ischaemia [ICD-11: 8B1Z] T67310 INDICATI Phase 2 General pain disorder [ICD-11: 8E43] T67363 TARGETID T67363 T67363 TARGNAME Integrin alpha-V/beta-3 (ITGAV/B3) T67363 INDICATI Phase 2 Chronic arterial occlusive disease [ICD-11: BD4Z] T67363 INDICATI Terminated Herpes simplex infection [ICD-11: 1F00] T67363 INDICATI Discontinued in Phase 1 Low bone mass disorder [ICD-11: FB83] T67363 INDICATI Phase 1 Melanoma [ICD-11: 2C30] T67363 INDICATI Phase 2 Prostate cancer [ICD-11: 2C82] T67363 INDICATI Phase 2 Renal cell carcinoma [ICD-11: 2C90] T67363 INDICATI Phase 1/2 Retinopathy [ICD-11: 9B71] T67363 INDICATI Phase 3 Rheumatoid arthritis [ICD-11: FA20] T67363 INDICATI Phase 2 Solid tumour/cancer [ICD-11: 2A00-2F9Z] T67364 TARGETID T67364 T67364 TARGNAME Streptococcus Streptokinase (Stre-coc skc) T67364 INDICATI Phase 3 Haemorrhoids [ICD-11: DB60] T67416 TARGETID T67416 T67416 TARGNAME Bifunctional aminoacyl-tRNA synthetase (EPRS) T67416 INDICATI Phase 2 Muscular dystrophy [ICD-11: 8C70] T67619 TARGETID T67619 T67619 TARGNAME RAC-alpha serine/threonine-protein kinase (AKT1) T67619 INDICATI Phase 1 Acute myeloid leukaemia [ICD-11: 2A60] T67619 INDICATI Terminated Arterial occlusive disease [ICD-11: BD40] T67619 INDICATI Phase 2 Brain cancer [ICD-11: 2A00] T67619 INDICATI Approved Breast cancer [ICD-11: 2C60-2C6Y] T67619 INDICATI Phase 2 Cardiovascular disease [ICD-11: BA00-BE2Z] T67619 INDICATI Phase 1 Central nervous system disease [ICD-11: 8A04-8D87] T67619 INDICATI Phase 3 Colorectal cancer [ICD-11: 2B91] T67619 INDICATI Phase 3 Diffuse large B-cell lymphoma [ICD-11: 2A81] T67619 INDICATI Phase 2 Injury [ICD-11: NA00-ND5Z] T67619 INDICATI Phase 2 Leukaemia [ICD-11: 2A60-2B33] T67619 INDICATI Phase 2 Lymphoma [ICD-11: 2A80-2A86] T67619 INDICATI Phase 3 Malignant haematopoietic neoplasm [ICD-11: 2B33] T67619 INDICATI Phase 1 Multiple myeloma [ICD-11: 2A83] T67619 INDICATI Phase 1 Ovarian cancer [ICD-11: 2C73] T67619 INDICATI Phase 2 Overgrowth syndrome [ICD-11: LD2C] T67619 INDICATI Phase 2 Pancreatic cancer [ICD-11: 2C10] T67619 INDICATI Phase 2 Parkinsonism [ICD-11: 8A00] T67619 INDICATI Phase 3 Prostate cancer [ICD-11: 2C82] T67619 INDICATI Phase 2 Renal cell carcinoma [ICD-11: 2C90] T67619 INDICATI Phase 2 Solid tumour/cancer [ICD-11: 2A00-2F9Z] T67619 INDICATI Phase 2 Stomach cancer [ICD-11: 2B72] T67658 TARGETID T67658 T67658 TARGNAME Glucose transporter type 4 (SLC2A4) T67658 INDICATI Phase 1 Type 2 diabetes mellitus [ICD-11: 5A11] T67684 TARGETID T67684 T67684 TARGNAME Muscarinic acetylcholine receptor M3 (CHRM3) T67684 INDICATI Discontinued in Phase 3 Abnormal micturition [ICD-11: MF50] T67684 INDICATI Terminated Alzheimer disease [ICD-11: 8A20] T67684 INDICATI Approved Asthma [ICD-11: CA23] T67684 INDICATI Approved Chronic obstructive pulmonary disease [ICD-11: CA22] T67684 INDICATI Approved Functional bladder disorder [ICD-11: GC50] T67684 INDICATI Approved Glaucoma [ICD-11: 9C61] T67684 INDICATI Approved Nausea/vomiting [ICD-11: MD90] T67684 INDICATI Approved Peptic ulcer [ICD-11: DA61] T67684 INDICATI Approved Respiratory system disease [ICD-11: CB40-CB7Z] T67684 INDICATI Approved Sebaceous gland disorder [ICD-11: ED91] T67684 INDICATI Approved Sjogren syndrome [ICD-11: 4A43] T67684 INDICATI Approved Tonus and reflex abnormality [ICD-11: MB47] T67710 TARGETID T67710 T67710 TARGNAME Parathyroid hormone 1 receptor (PTH1R) T67710 INDICATI Phase 1 Hypo-parathyroidism [ICD-11: 5A50] T67710 INDICATI Approved Low bone mass disorder [ICD-11: FB83] T67801 TARGETID T67801 T67801 TARGNAME Lactotransferrin (LTF) T67801 INDICATI Phase 1/2 Bacterial infection [ICD-11: 1A00-1C4Z] T67801 INDICATI Phase 1/2 Candidosis [ICD-11: 1F23] T67801 INDICATI Terminated Colorectal cancer [ICD-11: 2B91] T67801 INDICATI Phase 3 Diabetic foot ulcer [ICD-11: BD54] T67801 INDICATI Phase 1/2 Gonococcal infection [ICD-11: 1A70-1A7Z] T67801 INDICATI Terminated Lung cancer [ICD-11: 2C25] T67801 INDICATI Terminated Malignant haematopoietic neoplasm [ICD-11: 2B33] T67805 TARGETID T67805 T67805 TARGNAME CD70 antigen (CD27-L) T67805 INDICATI Phase 1 Acute myeloid leukaemia [ICD-11: 2A60] T67805 INDICATI Phase 1/2 B-cell lymphoma [ICD-11: 2A86] T67805 INDICATI Phase 1 Diabetes mellitus [ICD-11: 5A10] T67805 INDICATI Phase 1 Malignant haematopoietic neoplasm [ICD-11: 2B33] T67805 INDICATI Phase 1 Mature T-cell lymphoma [ICD-11: 2A90] T67805 INDICATI Investigative Melanoma [ICD-11: 2C30] T67805 INDICATI Phase 2 Myelodysplastic syndrome [ICD-11: 2A37] T67805 INDICATI Phase 1 Ovarian cancer [ICD-11: 2C73] T67805 INDICATI Phase 1 Pancreatic cancer [ICD-11: 2C10] T67805 INDICATI Phase 1 Renal cell carcinoma [ICD-11: 2C90] T67805 INDICATI Phase 1 Solid tumour/cancer [ICD-11: 2A00-2F9Z] T67849 TARGETID T67849 T67849 TARGNAME PI3-kinase delta (PIK3CD) T67849 INDICATI Phase 2 Asthma [ICD-11: CA23] T67849 INDICATI Phase 1 B-cell lymphoma [ICD-11: 2A86] T67849 INDICATI Phase 3 Breast cancer [ICD-11: 2C60-2C6Y] T67849 INDICATI Phase 1/2 Colorectal cancer [ICD-11: 2B91] T67849 INDICATI Phase 2/3 Diffuse large B-cell lymphoma [ICD-11: 2A81] T67849 INDICATI Approved Follicular lymphoma [ICD-11: 2A80] T67849 INDICATI Phase 1/2 Lymphoma [ICD-11: 2A80-2A86] T67849 INDICATI Approved Malignant haematopoietic neoplasm [ICD-11: 2B33] T67849 INDICATI Approved Mature B-cell leukaemia [ICD-11: 2A82] T67849 INDICATI Approved Mature B-cell lymphoma [ICD-11: 2A85] T67849 INDICATI Phase 1 Mycosis fungoides [ICD-11: 2B01] T67849 INDICATI Phase 3 Rheumatoid arthritis [ICD-11: FA20] T67849 INDICATI Phase 2 Sjogren syndrome [ICD-11: 4A43] T67849 INDICATI Phase 1 Solid tumour/cancer [ICD-11: 2A00-2F9Z] T67849 INDICATI Approved Stomach cancer ICD-11: 2B72 T67894 TARGETID T67894 T67894 TARGNAME Toll-like receptor 3 (TLR3) T67894 INDICATI Phase 2 Brain cancer [ICD-11: 2A00] T67894 INDICATI Investigative Diabetes mellitus [ICD-11: 5A10] T67894 INDICATI Discontinued in Phase 3 Digestive organ benign neoplasm [ICD-11: 2E92] T67894 INDICATI Phase 3 Human immunodeficiency virus disease [ICD-11: 1C60-1C62] T67894 INDICATI Investigative Keratosis pilaris [ICD-11: ED56] T67894 INDICATI Discontinued in Phase 3 Sexually transmitted infection [ICD-11: 1A9Y-1A9Z] T67894 INDICATI Phase 2 Solid tumour/cancer [ICD-11: 2A00-2F9Z] T67908 TARGETID T67908 T67908 TARGNAME Globohexaosylceramide (Globo H) T67908 INDICATI Phase 1/2 Solid tumour/cancer [ICD-11: 2A00-2F9Z] T67942 TARGETID T67942 T67942 TARGNAME Bacterial Cystathionine gamma-synthase (Bact metB) T67942 INDICATI Preclinical Chronic obstructive pulmonary disease [ICD-11: CA22] T67952 TARGETID T67952 T67952 TARGNAME Potassium channel unspecific (KC) T67952 INDICATI Phase 1 Abnormal micturition [ICD-11: MF50] T67952 INDICATI Approved Acute diabete complication [ICD-11: 5A2Y] T67952 INDICATI Terminated Alopecia [ICD-11: ED70] T67952 INDICATI Approved Angina pectoris [ICD-11: BA40] T67952 INDICATI Terminated Arterial occlusive disease [ICD-11: BD40] T67952 INDICATI Discontinued in Phase 1 Asthma [ICD-11: CA23] T67952 INDICATI Phase 2 Atopic eczema [ICD-11: EA80] T67952 INDICATI Approved Cardiac arrhythmia [ICD-11: BC9Z] T67952 INDICATI Terminated Cerebral ischaemia [ICD-11: 8B1Z] T67952 INDICATI Discontinued in Preregistration Chronic obstructive pulmonary disease [ICD-11: CA22] T67952 INDICATI Terminated Depression [ICD-11: 6A70-6A7Z] T67952 INDICATI Approved Essential hypertension [ICD-11: BA00] T67952 INDICATI Discontinued in Phase 2 Functional bladder disorder [ICD-11: GC50] T67952 INDICATI Phase 2 Genetic cardiac arrhythmia [ICD-11: BC65] T67952 INDICATI Phase 2 Glaucoma [ICD-11: 9C61] T67952 INDICATI Approved Hypertension [ICD-11: BA00-BA04] T67952 INDICATI Approved Lambert-Eaton syndrome [ICD-11: 8C62] T67952 INDICATI Approved Multiple sclerosis [ICD-11: 8A40] T67952 INDICATI Phase 1 Obstructive sleep apnoea [ICD-11: 7A41] T67952 INDICATI Phase 3 Rheumatoid arthritis [ICD-11: FA20] T67952 INDICATI Discontinued in Phase 3 Solid tumour/cancer [ICD-11: 2A00-2F9Z] T67952 INDICATI Approved Supraventricular tachyarrhythmia [ICD-11: BC81] T67952 INDICATI Discontinued in Phase 3 Unspecific body region injury [ICD-11: ND56] T67952 INDICATI Approved Ventricular tachyarrhythmia [ICD-11: BC71] T67977 TARGETID T67977 T67977 TARGNAME Cytochrome P450 3A (CYP3A) T67977 INDICATI Approved Human immunodeficiency virus disease [ICD-11: 1C60-1C62] T68001 TARGETID T68001 T68001 TARGNAME B- and T-lymphocyte attenuator (BTLA) T68001 INDICATI Phase 2 Lupus erythematosus [ICD-11: 4A40] T68001 INDICATI Phase 2 Sjogren syndrome [ICD-11: 4A43] T68001 INDICATI Phase 1 Solid tumour/cancer [ICD-11: 2A00-2F9Z] T68039 TARGETID T68039 T68039 TARGNAME Cell adhesion molecule (CADM) T68039 INDICATI Terminated Cerebrovascular disease [ICD-11: 8B22-8B2Z] T68039 INDICATI Terminated Deep vein thrombosis [ICD-11: BD71] T68039 INDICATI Terminated Graft-versus-host disease [ICD-11: 4B24] T68039 INDICATI Discontinued in Phase 1 Melanoma [ICD-11: 2C30] T68039 INDICATI Terminated Neurodegenerative disorder [ICD-11: 8A20-8A23] T68039 INDICATI Terminated Postoperative inflammation [ICD-11: 1A00-CA43] T68039 INDICATI Phase 1 Psoriasis [ICD-11: EA90] T68039 INDICATI Terminated Rheumatoid arthritis [ICD-11: FA20] T68066 TARGETID T68066 T68066 TARGNAME Steroid hormone receptor ERR (ESRR) T68066 INDICATI Approved Asthma [ICD-11: CA23] T68066 INDICATI Approved Atopic eczema [ICD-11: EA80] T68066 INDICATI Approved Contact dermatitis [ICD-11: EK00-EK0Z] T68066 INDICATI Approved Eyelid inflammatory disorder [ICD-11: 9A02] T68066 INDICATI Discontinued in Phase 2 Indeterminate colitis [ICD-11: DD72] T68066 INDICATI Approved Inflammatory arthropathy [ICD-11: FA2Z] T68066 INDICATI Approved Postoperative inflammation [ICD-11: 1A00-CA43] T68066 INDICATI Phase 3 Psoriasis [ICD-11: EA90] T68066 INDICATI Approved Skin disease [ICD-11: EA00-EM0Z] T68066 INDICATI Approved Solid tumour/cancer [ICD-11: 2A00-2F9Z] T68066 INDICATI Approved Vasomotor/allergic rhinitis [ICD-11: CA08] T68163 TARGETID T68163 T68163 TARGNAME Tyrosine-protein kinase Lyn (JTK8) T68163 INDICATI Phase 2 Musculoskeletal system/connective tissue disease [ICD-11: FC0Z] T68163 INDICATI Phase 1 Solid tumour/cancer [ICD-11: 2A00-2F9Z] T68230 TARGETID T68230 T68230 TARGNAME Clostridium difficile Toxin A (CD toxA) T68230 INDICATI Phase 3 Clostridium difficile enterocolitis [ICD-11: 1A04] T68230 INDICATI Phase 3 Malaria [ICD-11: 1F40-1F45] T68251 TARGETID T68251 T68251 TARGNAME Matrix metalloproteinase-2 (MMP-2) T68251 INDICATI Phase 1 Acne vulgaris [ICD-11: ED80] T68251 INDICATI Discontinued in Phase 3 Brain cancer [ICD-11: 2A00] T68251 INDICATI Discontinued in Phase 2 Corneal disease [ICD-11: 9A76-9A78] T68251 INDICATI Phase 3 Hepatic fibrosis/cirrhosis [ICD-11: DB93] T68251 INDICATI Discontinued in Phase 2 Hepatitis virus infection [ICD-11: 1E50-1E51] T68251 INDICATI Discontinued in Phase 3 Kaposi sarcoma [ICD-11: 2B57] T68251 INDICATI Approved Lung cancer [ICD-11: 2C25] T68251 INDICATI Terminated Multiple sclerosis [ICD-11: 8A40] T68251 INDICATI Discontinued in Phase 3 Osteoarthritis [ICD-11: FA00-FA05] T68251 INDICATI Discontinued in Phase 3 Ovarian cancer [ICD-11: 2C73] T68251 INDICATI Phase 3 Pancreatic cancer [ICD-11: 2C10] T68251 INDICATI Discontinued in Phase 3 Prostate cancer [ICD-11: 2C82] T68251 INDICATI Phase 1 Renal cell carcinoma [ICD-11: 2C90] T68251 INDICATI Discontinued in Phase 2 Solid tumour/cancer [ICD-11: 2A00-2F9Z] T68290 TARGETID T68290 T68290 TARGNAME Cathepsin S (CTSS) T68290 INDICATI Patented Alopecia [ICD-11: ED70] T68290 INDICATI Patented Aneurysm/dissection [ICD-11: BD50] T68290 INDICATI Investigative Asthma [ICD-11: CA23] T68290 INDICATI Phase 2 Autoimmune disease [ICD-11: 4A40-4A45] T68290 INDICATI Patented Bone cancer [ICD-11: 2B5Z] T68290 INDICATI Patented Brain cancer [ICD-11: 2A00] T68290 INDICATI Discontinued in Phase 1 Cardiovascular disease [ICD-11: BA00-BE2Z] T68290 INDICATI Patented Chronic obstructive pulmonary disease [ICD-11: CA22] T68290 INDICATI Patented Chronic pain [ICD-11: MG30] T68290 INDICATI Phase 1 Coeliac disease [ICD-11: DA95] T68290 INDICATI Phase 1 Crohn disease [ICD-11: DD70] T68290 INDICATI Phase 1 Diabetes mellitus [ICD-11: 5A10] T68290 INDICATI Patented Digestive system disease [ICD-11: DE2Z] T68290 INDICATI Phase 1 General pain disorder [ICD-11: 8E43] T68290 INDICATI Patented Hepatic fibrosis/cirrhosis [ICD-11: DB93] T68290 INDICATI Preclinical Lupus erythematosus [ICD-11: 4A40] T68290 INDICATI Patented Multiple sclerosis [ICD-11: 8A40] T68290 INDICATI Preclinical Osteoarthritis [ICD-11: FA00-FA05] T68290 INDICATI Phase 1 Pain [ICD-11: MG30-MG3Z] T68290 INDICATI Investigative Postoperative inflammation [ICD-11: 1A00-CA43] T68290 INDICATI Patented Psoriasis [ICD-11: EA90] T68290 INDICATI Patented Rheumatoid arthritis [ICD-11: FA20] T68290 INDICATI Phase 2 Sjogren syndrome [ICD-11: 4A43] T68290 INDICATI Investigative Solid tumour/cancer [ICD-11: 2A00-2F9Z] T68315 TARGETID T68315 T68315 TARGNAME Endothelin receptor (EDNR) T68315 INDICATI Phase 3 Coronary vasospastic disease [ICD-11: BA85] T68315 INDICATI Phase 2 Hypertension [ICD-11: BA00-BA04] T68315 INDICATI Discontinued in Phase 2 Kidney failure [ICD-11: GB60-GB6Z] T68315 INDICATI Discontinued in Phase 3 Retinal vascular occlusion [ICD-11: 9B74] T68334 TARGETID T68334 T68334 TARGNAME Follicle-stimulating hormone receptor (FSHR) T68334 INDICATI Phase 1 African trypanosomiasis [ICD-11: 1F51] T68334 INDICATI Investigative Contraceptive management [ICD-11: QA21] T68334 INDICATI Approved Female infertility [ICD-11: GA31] T68383 TARGETID T68383 T68383 TARGNAME Bone morphogenetic protein 2 (BMP2) T68383 INDICATI Phase 3 Bone growth disorder [ICD-11: FB86] T68443 TARGETID T68443 T68443 TARGNAME Matrix metalloproteinase-21 (MMP-21) T68443 INDICATI Discontinued in Phase 2 Corneal disease [ICD-11: 9A76-9A78] T68461 TARGETID T68461 T68461 TARGNAME Adenine nucleotide translocator 1 (SLC25A4) T68461 INDICATI Approved Mineral excesses [ICD-11: 5B91] T68470 TARGETID T68470 T68470 TARGNAME Deubiquitinating enzyme 1 (USP1) T68470 INDICATI Preclinical Solid tumour/cancer [ICD-11: 2A00-2F9Z] T68517 TARGETID T68517 T68517 TARGNAME Heat shock protein 27 (HSP27) T68517 INDICATI Phase 2 Bladder cancer [ICD-11: 2C94] T68517 INDICATI Phase 2 Breast cancer [ICD-11: 2C60-2C6Y] T68517 INDICATI Phase 2 Lung cancer [ICD-11: 2C25] T68517 INDICATI Phase 2 Ovarian cancer [ICD-11: 2C73] T68517 INDICATI Phase 2 Prostate cancer [ICD-11: 2C82] T68517 INDICATI Discontinued in Phase 2 Supraventricular tachyarrhythmia [ICD-11: BC81] T68525 TARGETID T68525 T68525 TARGNAME Inactive tyrosine-protein kinase 7 (PTK7) T68525 INDICATI Phase 1 Solid tumour/cancer [ICD-11: 2A00-2F9Z] T68536 TARGETID T68536 T68536 TARGNAME Tubulin beta (TUBB) T68536 INDICATI Phase 2 Brain cancer [ICD-11: 2A00] T68536 INDICATI Approved Breast cancer [ICD-11: 2C60-2C6Y] T68536 INDICATI Phase 3 Lung cancer [ICD-11: 2C25] T68536 INDICATI Phase 1 Lymphoma [ICD-11: 2A80-2A86] T68536 INDICATI Approved Mature B-cell lymphoma [ICD-11: 2A85] T68536 INDICATI Phase 2 Metastatic tumour [ICD-11: 2D50-2E2Z] T68536 INDICATI Phase 2 Ovarian cancer [ICD-11: 2C73] T68536 INDICATI Phase 3 Pancreatic cancer [ICD-11: 2C10] T68536 INDICATI Approved Parasitic worm infestation [ICD-11: 1F90] T68536 INDICATI Phase 2 Peritoneal cancer [ICD-11: 2C51] T68536 INDICATI Approved Solid tumour/cancer [ICD-11: 2A00-2F9Z] T68536 INDICATI Phase 2 Stomach cancer [ICD-11: 2B72] T68547 TARGETID T68547 T68547 TARGNAME Histone deacetylase 1 (HDAC1) T68547 INDICATI Phase 2 Acute myeloid leukaemia [ICD-11: 2A60] T68547 INDICATI Phase 1 Ataxic disorder [ICD-11: 8A03] T68547 INDICATI Phase 3 Breast cancer [ICD-11: 2C60-2C6Y] T68547 INDICATI Phase 2 Cerebral ischaemia [ICD-11: 8B1Z] T68547 INDICATI Phase 2 Cerebral ischaemic stroke [ICD-11: 8B11] T68547 INDICATI Phase 2 Colorectal cancer [ICD-11: 2B91] T68547 INDICATI Phase 1/2 Diffuse large B-cell lymphoma [ICD-11: 2A81] T68547 INDICATI Phase 2 Intracranial injury [ICD-11: NA07] T68547 INDICATI Phase 2 Ischaemic/haemorrhagic stroke [ICD-11: 8B20] T68547 INDICATI Discontinued in Phase 1/2 Leukaemia [ICD-11: 2A60-2B33] T68547 INDICATI Phase 2 Liver cancer [ICD-11: 2C12] T68547 INDICATI Registered Lung cancer [ICD-11: 2C25] T68547 INDICATI Phase 1/2 Lymphoma [ICD-11: 2A80-2A86] T68547 INDICATI Phase 3 Mature T-cell lymphoma [ICD-11: 2A90] T68547 INDICATI Phase 2 Melanoma [ICD-11: 2C30] T68547 INDICATI Phase 2 Metabolism inborn error [ICD-11: 5C50] T68547 INDICATI Phase 3 Mood disorder [ICD-11: 6A60-6E23] T68547 INDICATI Approved Multiple myeloma [ICD-11: 2A83] T68547 INDICATI Phase 3 Muscular dystrophy [ICD-11: 8C70] T68547 INDICATI Approved Mycosis fungoides [ICD-11: 2B01] T68547 INDICATI Phase 2 Myeloproliferative neoplasm [ICD-11: 2A20] T68547 INDICATI Phase 1/2 Neuroendocrine carcinoma [ICD-11: 2C34] T68547 INDICATI Phase 2 Ovarian cancer [ICD-11: 2C73] T68547 INDICATI Phase 3 Renal cell carcinoma [ICD-11: 2C90] T68547 INDICATI Phase 2 Sickle-cell disorder [ICD-11: 3A51] T68547 INDICATI Registered Solid tumour/cancer [ICD-11: 2A00-2F9Z] T68547 INDICATI Phase 2 Thrombocytosis [ICD-11: 3B63] T68547 INDICATI Phase 3 Type 2 diabetes mellitus [ICD-11: 5A11] T68668 TARGETID T68668 T68668 TARGNAME Golgi alpha-mannosidase II (MAN2A1) T68668 INDICATI Discontinued in Phase 2 Solid tumour/cancer [ICD-11: 2A00-2F9Z] T68706 TARGETID T68706 T68706 TARGNAME Dibasic-processing enzyme (Furin) T68706 INDICATI Preclinical Coronavirus infection [ICD-11: 1D92] T68766 TARGETID T68766 T68766 TARGNAME DMPK messenger RNA (DMPK mRNA) T68766 INDICATI Phase 1/2 Myotonic disorder [ICD-11: 8C71] T68782 TARGETID T68782 T68782 TARGNAME Prostaglandin D2 receptor (PTGDR) T68782 INDICATI Phase 2 Allergic/hypersensitivity disorder [ICD-11: 4A80-4A8Z] T68782 INDICATI Discontinued in Phase 3 Arterial occlusive disease [ICD-11: BD40] T68782 INDICATI Phase 3 Asthma [ICD-11: CA23] T68782 INDICATI Phase 2 Atopic eczema [ICD-11: EA80] T68782 INDICATI Phase 4 Coronary atherosclerosis [ICD-11: BA80] T68782 INDICATI Phase 1 Diabetes mellitus [ICD-11: 5A10] T68782 INDICATI Discontinued in Phase 3 Dyslipidemia [ICD-11: 5C80-5C81] T68782 INDICATI Investigative Pain [ICD-11: MG30-MG3Z] T68782 INDICATI Discontinued in Phase 2 Rheumatoid arthritis [ICD-11: FA20] T68782 INDICATI Clinical trial Solid tumour/cancer [ICD-11: 2A00-2F9Z] T68782 INDICATI Phase 1 Thrombosis [ICD-11: DB61-GB90] T68782 INDICATI Phase 2 Vasomotor/allergic rhinitis [ICD-11: CA08] T68887 TARGETID T68887 T68887 TARGNAME Bombesin receptor (BS) T68887 INDICATI Phase 1 Breast cancer [ICD-11: 2C60-2C6Y] T68887 INDICATI Phase 1 Solid tumour/cancer [ICD-11: 2A00-2F9Z] T68934 TARGETID T68934 T68934 TARGNAME Collagen (CO) T68934 INDICATI Approved Amoebiasis [ICD-11: 1A36] T68934 INDICATI Phase 2 Keloid/hypertrophic scar [ICD-11: EE60] T68934 INDICATI Approved Skin sensation disturbance [ICD-11: ME65] T68934 INDICATI Phase 1 Systemic sclerosis [ICD-11: 4A42] T68934 INDICATI Phase 2 Urinary tract infection [ICD-11: GC08] T68934 INDICATI Approved Vitamin deficiency [ICD-11: 5B55-5B5F] T68967 TARGETID T68967 T68967 TARGNAME Sphingomyelin synthase (SMS) T68967 INDICATI Phase 1/2 Hypertension [ICD-11: BA00-BA04] T69085 TARGETID T69085 T69085 TARGNAME Transcription factor AP-1 (JUN) T69085 INDICATI Discontinued in Phase 2 Rheumatoid arthritis [ICD-11: FA20] T69128 TARGETID T69128 T69128 TARGNAME Proto-oncogene c-Ros (ROS1) T69128 INDICATI Phase 1 Adrenal cancer [ICD-11: 2D11] T69128 INDICATI Phase 1 Breast cancer [ICD-11: 2C60-2C6Y] T69128 INDICATI Phase 2 Colorectal cancer [ICD-11: 2B91] T69128 INDICATI Approved Lung cancer [ICD-11: 2C25] T69128 INDICATI Patented Metastatic tumour [ICD-11: 2D50-2E2Z] T69128 INDICATI Approved Non-small-cell lung cancer [ICD-11: 2C25] T69128 INDICATI Phase 2 Solid tumour/cancer [ICD-11: 2A00-2F9Z] T69146 TARGETID T69146 T69146 TARGNAME Mitochondrial uncoupling protein 3 (UCP3) T69146 INDICATI Phase 2 Obesity [ICD-11: 5B80-5B81] T69189 TARGETID T69189 T69189 TARGNAME Hedgehog signaling pathway (HS pathway) T69189 INDICATI Phase 2 Basal cell carcinoma [ICD-11: 2C32] T69189 INDICATI Discontinued in Phase 2 Chondrosarcoma [ICD-11: 2B50] T69189 INDICATI Approved Chronic myelomonocytic leukaemia [ICD-11: 2A40] T69189 INDICATI Approved Fungal infection [ICD-11: 1F29-1F2F] T69189 INDICATI Phase 2 Idiopathic interstitial pneumonitis [ICD-11: CB03] T69189 INDICATI Approved Solid tumour/cancer [ICD-11: 2A00-2F9Z] T69375 TARGETID T69375 T69375 TARGNAME Stress-activated protein kinase JNK2 (JNK2) T69375 INDICATI Preclinical Mature T-cell lymphoma [ICD-11: 2A90] T69485 TARGETID T69485 T69485 TARGNAME Orexin receptor type 2 (HCRTR2) T69485 INDICATI Phase 2 Depression [ICD-11: 6A70-6A7Z] T69485 INDICATI Approved Insomnia [ICD-11: 7A00-7A0Z] T69485 INDICATI Phase 2 Narcolepsy ICD-11: 7A20 T69485 INDICATI Phase 1 Narcolepsy [ICD-11: 7A20] T69494 TARGETID T69494 T69494 TARGNAME N-methyl-D-aspartate receptor (NMDAR) T69494 INDICATI Approved Acute pain [ICD-11: MG31] T69494 INDICATI Approved Alzheimer disease [ICD-11: 8A20] T69494 INDICATI Approved Anxiety disorder [ICD-11: 6B00-6B0Z] T69494 INDICATI Phase 2 Autism spectrum disorder [ICD-11: 6A02] T69494 INDICATI Approved Bacterial infection [ICD-11: 1A00-1C4Z] T69494 INDICATI Discontinued in Phase 3 Cerebral ischaemia [ICD-11: 8B1Z] T69494 INDICATI Approved Cerebral ischaemic stroke [ICD-11: 8B11] T69494 INDICATI Phase 2 Chronic pain [ICD-11: MG30] T69494 INDICATI Phase 2 Clostridium difficile enterocolitis [ICD-11: 1A04] T69494 INDICATI Approved Corneal disease [ICD-11: 9A76-9A78] T69494 INDICATI Terminated Dementia [ICD-11: 6D80-6D8Z] T69494 INDICATI Phase 3 Depression [ICD-11: 6A70-6A7Z] T69494 INDICATI Phase 2 Dissociative neurological symptom disorder [ICD-11: 6B60] T69494 INDICATI Approved Epilepsy/seizure [ICD-11: 8A61-8A6Z] T69494 INDICATI Phase 3 General pain disorder [ICD-11: 8E43] T69494 INDICATI Approved HIV-infected patients with tuberculosis [ICD-11: 1B10-1B14] T69494 INDICATI Phase 1 Intellectual development disorder [ICD-11: LD90] T69494 INDICATI Phase 3 Intracranial injury [ICD-11: NA07] T69494 INDICATI Discontinued in Phase 3 Mild neurocognitive disorder [ICD-11: 6D71] T69494 INDICATI Terminated Nervous system disease [ICD-11: 8A00-8E7Z] T69494 INDICATI Terminated Neurodegenerative disorder [ICD-11: 8A20-8A23] T69494 INDICATI Phase 2 Neuropathy [ICD-11: 8C0Z] T69494 INDICATI Approved Obesity [ICD-11: 5B80-5B81] T69494 INDICATI Phase 2 Obsessive-compulsive disorder [ICD-11: 6B20] T69494 INDICATI Approved Pain [ICD-11: MG30-MG3Z] T69494 INDICATI Phase 1 Panic disorder [ICD-11: 6B01] T69494 INDICATI Approved Parkinsonism [ICD-11: 8A00] T69494 INDICATI Phase 2/3 Post-traumatic stress disorder [ICD-11: 6B40] T69494 INDICATI Approved Schizophrenia [ICD-11: 6A20] T69494 INDICATI Phase 1 Thought content symptom [ICD-11: MB26] T69494 INDICATI Phase 2 Zoster [ICD-11: 1E91] T69506 TARGETID T69506 T69506 TARGNAME Orphan nuclear receptor NR1I3 (NR1I3) T69506 INDICATI Approved Dizziness and giddiness [ICD-11: MB48] T69563 TARGETID T69563 T69563 TARGNAME Oxalosuccinate decarboxylase (IDH1) T69563 INDICATI Approved Acute myeloid leukaemia [ICD-11: 2A60] T69563 INDICATI Phase 1/2 Brain cancer [ICD-11: 2A00] T69563 INDICATI Phase 3 Liver cancer [ICD-11: 2C12] T69563 INDICATI Phase 1 Malignant haematopoietic neoplasm [ICD-11: 2B33] T69563 INDICATI Phase 1 Myelodysplastic syndrome [ICD-11: 2A37] T69563 INDICATI Phase 1 Solid tumour/cancer [ICD-11: 2A00-2F9Z] T69619 TARGETID T69619 T69619 TARGNAME Membrane copper amine oxidase (AOC3) T69619 INDICATI Investigative Acute diabete complication [ICD-11: 5A2Y] T69619 INDICATI Investigative Asthma [ICD-11: CA23] T69619 INDICATI Investigative Atopic eczema [ICD-11: EA80] T69619 INDICATI Investigative Cerebral ischaemia [ICD-11: 8B1Z] T69619 INDICATI Phase 1 Chronic kidney disease [ICD-11: GB61] T69619 INDICATI Investigative Circulatory system disease [ICD-11: BE2Z] T69619 INDICATI Approved Hypertension [ICD-11: BA00-BA04] T69619 INDICATI Phase 3 Neuropathy [ICD-11: 8C0Z] T69619 INDICATI Terminated Postoperative inflammation [ICD-11: 1A00-CA43] T69619 INDICATI Phase 2 Psoriasis [ICD-11: EA90] T69619 INDICATI Investigative Pulmonary disease [ICD-11: 1B10-1F85] T69619 INDICATI Phase 2 Retinopathy [ICD-11: 9B71] T69685 TARGETID T69685 T69685 TARGNAME Glycine transporter GlyT-1 (SLC6A9) T69685 INDICATI Investigative Dementia [ICD-11: 6D80-6D8Z] T69685 INDICATI Phase 2 Psychotic disorder [ICD-11: 6A20-6A25] T69685 INDICATI Phase 3 Schizophrenia [ICD-11: 6A20] T69707 TARGETID T69707 T69707 TARGNAME Proteasome (PS) T69707 INDICATI Approved Amyloidosis [ICD-11: 5D00] T69707 INDICATI Phase 3 Brain cancer [ICD-11: 2A00] T69707 INDICATI Phase 2 Hodgkin lymphoma [ICD-11: 2B30] T69707 INDICATI Phase 1 Leishmaniasis [ICD-11: 1F54] T69707 INDICATI Terminated Liver vascular disorder [ICD-11: DB98] T69707 INDICATI Phase 1/2 Lung cancer [ICD-11: 2C25] T69707 INDICATI Phase 3 Malignant haematopoietic neoplasm [ICD-11: 2B33] T69707 INDICATI Approved Mature B-cell lymphoma [ICD-11: 2A85] T69707 INDICATI Approved Multiple myeloma [ICD-11: 2A83] T69707 INDICATI Phase 1 Solid tumour/cancer [ICD-11: 2A00-2F9Z] T69823 TARGETID T69823 T69823 TARGNAME P53 Y220C mutant (TP53 Y220C) T69823 INDICATI Phase 1/2 Solid tumour/cancer [ICD-11: 2A00-2F9Z] T69912 TARGETID T69912 T69912 TARGNAME Platelet-activating factor acetylhydrolase (PLA2G7) T69912 INDICATI Phase 1 Alzheimer disease [ICD-11: 8A20] T69912 INDICATI Phase 1 Arterial occlusive disease [ICD-11: BD40] T69912 INDICATI Phase 1 Cardiovascular disease [ICD-11: BA00-BE2Z] T69912 INDICATI Discontinued in Phase 3 Sepsis [ICD-11: 1G40-1G41] T69991 TARGETID T69991 T69991 TARGNAME Wee1-like protein kinase (WEE1) T69991 INDICATI Phase 2 Ovarian cancer [ICD-11: 2C73] T69991 INDICATI Phase 1 Solid tumour/cancer [ICD-11: 2A00-2F9Z] T69991 INDICATI Phase 2 Uterine ligament/parametrium/uterine adnexa neoplasm [ICD-11: 2C72] T70062 TARGETID T70062 T70062 TARGNAME Reticulon-4 (RTN4) T70062 INDICATI Phase 1 Unspecific body region injury [ICD-11: ND56] T70067 TARGETID T70067 T70067 TARGNAME TRAIL receptor 2 (TRAIL-R2) T70067 INDICATI Phase 2 Colorectal cancer [ICD-11: 2B91] T70067 INDICATI Phase 1/2 Liver cancer [ICD-11: 2C12] T70067 INDICATI Phase 1 Malignant haematopoietic neoplasm [ICD-11: 2B33] T70067 INDICATI Discontinued in Phase 2 Pain [ICD-11: MG30-MG3Z] T70067 INDICATI Phase 2 Solid tumour/cancer [ICD-11: 2A00-2F9Z] T70071 TARGETID T70071 T70071 TARGNAME Endothelin-converting enzyme (ECE) T70071 INDICATI Phase 1 Cardiovascular disease [ICD-11: BA00-BE2Z] T70071 INDICATI Phase 2 Heart failure [ICD-11: BD10-BD1Z] T70071 INDICATI Terminated Hypertension [ICD-11: BA00-BA04] T70071 INDICATI Phase 2 Intracranial injury [ICD-11: NA07] T70101 TARGETID T70101 T70101 TARGNAME CTP synthase (CTPS1) T70101 INDICATI Phase 1 Solid tumour/cancer [ICD-11: 2A00-2F9Z] T70134 TARGETID T70134 T70134 TARGNAME C9orf72 messenger RNA (C9orf72 mRNA) T70134 INDICATI Phase 2 Motor neuron disease [ICD-11: 8B60] T70176 TARGETID T70176 T70176 TARGNAME Cyclin-dependent kinase 2 (CDK2) T70176 INDICATI Phase 1/2 Brain cancer [ICD-11: 2A00] T70176 INDICATI Phase 1 Breast cancer [ICD-11: 2C60-2C6Y] T70176 INDICATI Phase 2 Lung cancer [ICD-11: 2C25] T70176 INDICATI Phase 1 Lymphoma [ICD-11: 2A80-2A86] T70176 INDICATI Phase 1 Malignant haematopoietic neoplasm [ICD-11: 2B33] T70176 INDICATI Discontinued in Phase 3 Mature B-cell lymphoma [ICD-11: 2A85] T70176 INDICATI Investigative Nasopharyngeal cancer [ICD-11: 2B6B] T70176 INDICATI Phase 1 Non-small-cell lung cancer [ICD-11: 2C25] T70176 INDICATI Preclinical Obesity [ICD-11: 5B80-5B81] T70176 INDICATI Terminated Retina cancer [ICD-11: 2D02] T70176 INDICATI Phase 2 Solid tumour/cancer [ICD-11: 2A00-2F9Z] T70176 INDICATI Phase 2 Thymoma [ICD-11: 2C27] T70201 TARGETID T70201 T70201 TARGNAME Glioma pathogenesis-related protein 1 (GLIPR1) T70201 INDICATI Phase 1 Prostate cancer [ICD-11: 2C82] T70227 TARGETID T70227 T70227 TARGNAME Transcription factor unspecific (TF) T70227 INDICATI Phase 1 Psoriasis [ICD-11: EA90] T70234 TARGETID T70234 T70234 TARGNAME Ephrin type-A receptor 4 (EPHA4) T70234 INDICATI Terminated Solid tumour/cancer [ICD-11: 2A00-2F9Z] T70309 TARGETID T70309 T70309 TARGNAME Steroid 5-alpha-reductase 1 (SRD5A1) T70309 INDICATI Discontinued in Phase 2 Acne vulgaris [ICD-11: ED80] T70309 INDICATI Phase 2 Prostate disease [ICD-11: GA91] T70449 TARGETID T70449 T70449 TARGNAME Growth hormone-releasing hormone receptor (GHRHR) T70449 INDICATI Approved Bone growth disorder [ICD-11: FB86] T70449 INDICATI Approved Human immunodeficiency virus disease [ICD-11: 1C60-1C62] T70449 INDICATI Discontinued in Phase 2 Lipoatrophy/lipodystrophy [ICD-11: EF01] T70449 INDICATI Discontinued in Phase 2 Pituitary gland disorder [ICD-11: 5A60-5A61] T70490 TARGETID T70490 T70490 TARGNAME Dipeptidyl peptidase I (CTSC) T70490 INDICATI Phase 2 Bronchiectasis [ICD-11: CA24] T70508 TARGETID T70508 T70508 TARGNAME Cyclin-dependent kinase (CDK) T70508 INDICATI Phase 2 Acute myeloid leukaemia [ICD-11: 2A60] T70508 INDICATI Phase 1/2 Brain cancer [ICD-11: 2A00] T70508 INDICATI Phase 1 Breast cancer [ICD-11: 2C60-2C6Y] T70508 INDICATI Phase 2 Lung cancer [ICD-11: 2C25] T70508 INDICATI Discontinued in Phase 3 Mature B-cell leukaemia [ICD-11: 2A82] T70508 INDICATI Investigative Nasopharyngeal cancer [ICD-11: 2B6B] T70508 INDICATI Phase 2 Solid tumour/cancer [ICD-11: 2A00-2F9Z] T70518 TARGETID T70518 T70518 TARGNAME S-nitrosoglutathione reductase (CBR1) T70518 INDICATI Phase 2 Asthma [ICD-11: CA23] T70532 TARGETID T70532 T70532 TARGNAME NCK adaptor protein 1 (NCK1) T70532 INDICATI Phase 1 Multiple sclerosis [ICD-11: 8A40] T70680 TARGETID T70680 T70680 TARGNAME Solute carrier family 22 member 8 (SLC22A8) T70680 INDICATI Approved Gout [ICD-11: FA25] T70680 INDICATI Approved Herpes simplex infection [ICD-11: 1F00] T70680 INDICATI Approved Inborn purine/pyrimidine/nucleotide metabolism error [ICD-11: 5C55] T70680 INDICATI Phase 2 Obesity [ICD-11: 5B80-5B81] T70792 TARGETID T70792 T70792 TARGNAME Placenta growth factor (PlGF) T70792 INDICATI Phase 2 Brain cancer [ICD-11: 2A00] T70792 INDICATI Approved Colorectal cancer [ICD-11: 2B91] T70792 INDICATI Phase 1 Retinopathy [ICD-11: 9B71] T70792 INDICATI Phase 2 Solid tumour/cancer [ICD-11: 2A00-2F9Z] T70888 TARGETID T70888 T70888 TARGNAME TNF receptor (TNFR) T70888 INDICATI Discontinued in Phase 3 Asthma [ICD-11: CA23] T70888 INDICATI Phase 1 Crohn disease [ICD-11: DD70] T70888 INDICATI Terminated Human immunodeficiency virus disease [ICD-11: 1C60-1C62] T70967 TARGETID T70967 T70967 TARGNAME Neuronal acetylcholine receptor alpha-4 (CHRNA4) T70967 INDICATI Discontinued in Phase 2 Alzheimer disease [ICD-11: 8A20] T70967 INDICATI Approved Aneurysm/dissection [ICD-11: BD50] T70967 INDICATI Approved Hypertensive crisis [ICD-11: BA03] T70967 INDICATI Approved Hypotension [ICD-11: BA20-BA21] T70967 INDICATI Phase 3 Nicotine use disorder [ICD-11: 6C4A] T70977 TARGETID T70977 T70977 TARGNAME Glycogen synthase kinase-3 beta (GSK-3B) T70977 INDICATI Investigative Acute diabete complication [ICD-11: 5A2Y] T70977 INDICATI Phase 2 Acute myeloid leukaemia [ICD-11: 2A60] T70977 INDICATI Patented Allergic/hypersensitivity disorder [ICD-11: 4A80-4A8Z] T70977 INDICATI Discontinued in Phase 1 Alzheimer disease [ICD-11: 8A20] T70977 INDICATI Patented Brain cancer [ICD-11: 2A00] T70977 INDICATI Phase 2 Fragile X chromosome [ICD-11: LD55] T70977 INDICATI Phase 2 Myeloproliferative neoplasm [ICD-11: 2A20] T70977 INDICATI Phase 2/3 Myotonic disorder [ICD-11: 8C71] T70977 INDICATI Phase 2 Osteosarcoma [ICD-11: 2B51] T70977 INDICATI Patented Ovarian cancer [ICD-11: 2C73] T70977 INDICATI Phase 1/2 Parkinsonism [ICD-11: 8A00] T70977 INDICATI Phase 1 Solid tumour/cancer [ICD-11: 2A00-2F9Z] T70977 INDICATI Patented Transplant rejection [ICD-11: NE84] T71011 TARGETID T71011 T71011 TARGNAME Enterobacteria Shiga-like toxin 2B (EntBac stxB2) T71011 INDICATI Discontinued in Phase 2 Escherichia coli intestinal infection [ICD-11: 1A03] T71023 TARGETID T71023 T71023 TARGNAME Synaptosomal-associated protein 25 (SNAP25) T71023 INDICATI Approved Eyelid inflammatory/movement disorder [ICD-11: 9A05] T71039 TARGETID T71039 T71039 TARGNAME Carbohydrate antigen 19-9 (CA 19-9) T71039 INDICATI Phase 2 Pancreatic cancer [ICD-11: 2C10] T71054 TARGETID T71054 T71054 TARGNAME C-C chemokine receptor (CCR) T71054 INDICATI Investigative Postoperative inflammation [ICD-11: 1A00-CA43] T71086 TARGETID T71086 T71086 TARGNAME Complement factor H (CFH) T71086 INDICATI Phase 1 Diabetes mellitus [ICD-11: 5A10] T71086 INDICATI Approved Infectious meningitis [ICD-11: 1D01] T71086 INDICATI Phase 1 Lung cancer [ICD-11: 2C25] T71141 TARGETID T71141 T71141 TARGNAME Integrin alpha-V/beta-6 (ITGAV/B6) T71141 INDICATI Phase 2 Autoimmune liver disease [ICD-11: DB96] T71141 INDICATI Preclinical Hepatic fibrosis/cirrhosis [ICD-11: DB93] T71141 INDICATI Phase 2 Idiopathic interstitial pneumonitis [ICD-11: CB03] T71164 TARGETID T71164 T71164 TARGNAME Ganglioside GD2 (GD2) T71164 INDICATI Phase 2 Adrenal cancer [ICD-11: 2D11] T71164 INDICATI Phase 1/2 Brain cancer [ICD-11: 2A00] T71164 INDICATI Phase 1/2 Cervical cancer [ICD-11: 2C77] T71164 INDICATI Phase 1 Colorectal cancer [ICD-11: 2B91] T71164 INDICATI Phase 2 Lung cancer [ICD-11: 2C25] T71164 INDICATI Phase 2 Osteosarcoma [ICD-11: 2B51] T71164 INDICATI Phase 1 Pancreatic cancer [ICD-11: 2C10] T71164 INDICATI Phase 1 Prostate cancer [ICD-11: 2C82] T71164 INDICATI Phase 1 Sarcoma [ICD-11: 2A60-2C35] T71164 INDICATI Phase 1/2 Solid tumour/cancer [ICD-11: 2A00-2F9Z] T71167 TARGETID T71167 T71167 TARGNAME Oxysterols receptor LXR (NR1H) T71167 INDICATI Phase 1 Arterial occlusive disease [ICD-11: BD40] T71167 INDICATI Phase 2 Atopic eczema [ICD-11: EA80] T71167 INDICATI Phase 1 Cardiovascular disease [ICD-11: BA00-BE2Z] T71167 INDICATI Phase 1/2 Lung cancer [ICD-11: 2C25] T71167 INDICATI Phase 1 Lymphoma [ICD-11: 2A80-2A86] T71167 INDICATI Phase 1 Metabolic disorder [ICD-11: 5C50-5D2Z] T71167 INDICATI Phase 1 Solid tumour/cancer [ICD-11: 2A00-2F9Z] T71192 TARGETID T71192 T71192 TARGNAME Leukotriene CysLT1 receptor (CYSLTR1) T71192 INDICATI Phase 1 Allergic/hypersensitivity disorder [ICD-11: 4A80-4A8Z] T71192 INDICATI Approved Asthma [ICD-11: CA23] T71192 INDICATI Discontinued in Phase 2 Migraine [ICD-11: 8A80] T71192 INDICATI Phase 3 Vasomotor/allergic rhinitis [ICD-11: CA08] T71205 TARGETID T71205 T71205 TARGNAME Myeloid inhibitory C-type lectin-like receptor (CD371) T71205 INDICATI Phase 2/3 Acute myeloid leukaemia [ICD-11: 2A60] T71205 INDICATI Phase 1 BCR-ABL1-negative chronic myeloid leukaemia [ICD-11: 2A41] T71205 INDICATI Phase 1/2 Leukaemia [ICD-11: 2A60-2B33] T71205 INDICATI Phase 1/2 Lymphoma [ICD-11: 2A80-2A86] T71205 INDICATI Phase 1/2 Multiple myeloma [ICD-11: 2A83] T71230 TARGETID T71230 T71230 TARGNAME Atrial natriuretic peptide receptor A (NPR1) T71230 INDICATI Phase 2 Asthma [ICD-11: CA23] T71230 INDICATI Phase 2 General pain disorder [ICD-11: 8E43] T71230 INDICATI Phase 2 Heart disease [ICD-11: BA41-BA42] T71230 INDICATI Approved Heart failure [ICD-11: BD10-BD1Z] T71230 INDICATI Phase 2 Hypertension [ICD-11: BA00-BA04] T71266 TARGETID T71266 T71266 TARGNAME RAC-gamma serine/threonine-protein kinase (AKT3) T71266 INDICATI Phase 1 Acute myeloid leukaemia [ICD-11: 2A60] T71266 INDICATI Approved Breast cancer [ICD-11: 2C60-2C6Y] T71266 INDICATI Phase 2 Colorectal cancer [ICD-11: 2B91] T71266 INDICATI Phase 2 Lymphoma [ICD-11: 2A80-2A86] T71266 INDICATI Phase 1 Malignant haematopoietic neoplasm [ICD-11: 2B33] T71266 INDICATI Investigative Nasopharyngeal cancer [ICD-11: 2B6B] T71266 INDICATI Phase 2 Overgrowth syndrome [ICD-11: LD2C] T71266 INDICATI Phase 2 Rectum cancer [ICD-11: 2B92] T71266 INDICATI Phase 2 Solid tumour/cancer [ICD-11: 2A00-2F9Z] T71369 TARGETID T71369 T71369 TARGNAME BCL11A messenger RNA (BCL11A mRNA) T71369 INDICATI Phase 1 Sickle-cell disorder [ICD-11: 3A51] T71374 TARGETID T71374 T71374 TARGNAME Polo-like kinase 4 (PLK4) T71374 INDICATI Phase 2 Breast cancer [ICD-11: 2C60-2C6Y] T71377 TARGETID T71377 T71377 TARGNAME Interleukin 3 receptor alpha (IL3RA) T71377 INDICATI Approved Acute myeloid leukaemia [ICD-11: 2A60] T71377 INDICATI Phase 1 Asthma [ICD-11: CA23] T71377 INDICATI Phase 1/2 B-cell lymphoma [ICD-11: 2A86] T71377 INDICATI Phase 1 Follicular lymphoma [ICD-11: 2A80] T71377 INDICATI Phase 2 Kidney failure [ICD-11: GB60-GB6Z] T71377 INDICATI Phase 1/2 Leukaemia [ICD-11: 2A60-2B33] T71377 INDICATI Terminated Low bone mass disorder [ICD-11: FB83] T71377 INDICATI Phase 1 Lymphoma [ICD-11: 2A80-2A86] T71377 INDICATI Phase 2 Malignant haematopoietic neoplasm [ICD-11: 2B33] T71377 INDICATI Phase 1 Mature B-cell lymphoma [ICD-11: 2A85] T71377 INDICATI Phase 1 Myelodysplastic syndrome [ICD-11: 2A37] T71390 TARGETID T71390 T71390 TARGNAME Steroid 5-alpha-reductase 2 (SRD5A2) T71390 INDICATI Approved Prostate hyperplasia [ICD-11: GA90] T71398 TARGETID T71398 T71398 TARGNAME Guanylate cyclase (GC) T71398 INDICATI Approved Acquired methaemoglobinaemia [ICD-11: 3A93] T71398 INDICATI Approved Anal fissure/fistula [ICD-11: DB50] T71398 INDICATI Approved Angina pectoris [ICD-11: BA40] T71398 INDICATI Discontinued in Phase 2 Dermatophytosis [ICD-11: 1F28] T71398 INDICATI Approved Hydrocephalus [ICD-11: 8D64] T71398 INDICATI Approved Respiratory failure [ICD-11: CB41] T71398 INDICATI Phase 2 Sickle-cell disorder [ICD-11: 3A51] T71398 INDICATI Phase 3 Solid tumour/cancer [ICD-11: 2A00-2F9Z] T71446 TARGETID T71446 T71446 TARGNAME Transporter unspecfic (TP) T71446 INDICATI Investigative Toxicity [ICD-11: N.A.] T71479 TARGETID T71479 T71479 TARGNAME JAK-STAT signaling pathway (JAK-STAT pathway) T71479 INDICATI Phase 1/2 Brain cancer [ICD-11: 2A00] T71479 INDICATI Phase 1 Solid tumour/cancer [ICD-11: 2A00-2F9Z] T71484 TARGETID T71484 T71484 TARGNAME Fungal Microtubule (Fung MicroTU) T71484 INDICATI Approved Dermatophytosis [ICD-11: 1F28] T71501 TARGETID T71501 T71501 TARGNAME Hepatitis B virus Polymerase (HBV P) T71501 INDICATI Approved Hepatitis virus infection [ICD-11: 1E50-1E51] T71536 TARGETID T71536 T71536 TARGNAME Human Deoxyribonucleic acid minor groove (hDNA min) T71536 INDICATI Phase 2 Breast cancer [ICD-11: 2C60-2C6Y] T71536 INDICATI Phase 2 Endometrial cancer [ICD-11: 2C76] T71536 INDICATI Phase 3 Leukaemia [ICD-11: 2A60-2B33] T71536 INDICATI Approved Lung cancer [ICD-11: 2C25] T71536 INDICATI Phase 3 Ovarian cancer [ICD-11: 2C73] T71536 INDICATI Phase 2 Solid tumour/cancer [ICD-11: 2A00-2F9Z] T71556 TARGETID T71556 T71556 TARGNAME Lymphoid cell adhesion molecule expression (LCDME) T71556 INDICATI Approved Atopic eczema [ICD-11: EA80] T71690 TARGETID T71690 T71690 TARGNAME Bacterial Pyruvate decarboxylase (Bact aceE) T71690 INDICATI Approved Vitamin deficiency [ICD-11: 5B55-5B5F] T71905 TARGETID T71905 T71905 TARGNAME Bacterial 16S ribosomal RNA (Bact 16S rRNA) T71905 INDICATI Approved Acute/subacute hepatic failure [ICD-11: DB91] T71905 INDICATI Approved Alcoholic liver disease [ICD-11: DB94] T71905 INDICATI Approved Bacterial infection [ICD-11: 1A00-1C4Z] T71905 INDICATI Phase 1 Gram-negative bacterial infection [ICD-11: 1F41-1G40] T71905 INDICATI Phase 2 Gram-positive bacterial infection [ICD-11: 1B74-1F40] T71907 TARGETID T71907 T71907 TARGNAME Survival motor neuron protein (SMN1) T71907 INDICATI Approved Muscular atrophy [ICD-11: 8B61] T71928 TARGETID T71928 T71928 TARGNAME MHC class I NK cell receptor 2DL1 (CD158A) T71928 INDICATI Phase 2 Acute myeloid leukaemia [ICD-11: 2A60] T71928 INDICATI Phase 2 Multiple myeloma [ICD-11: 2A83] T72024 TARGETID T72024 T72024 TARGNAME Galactocerebrosidase (GALC) T72024 INDICATI Phase 1/2 Leukodystrophy ICD-11: 8A44 T72032 TARGETID T72032 T72032 TARGNAME G-protein coupled receptor GPCR33 (GPRC6A) T72032 INDICATI Phase 3 Intrathoracic organs injury [ICD-11: NB32] T72038 TARGETID T72038 T72038 TARGNAME Galectin-3 (LGALS3) T72038 INDICATI Phase 2 Hypertension [ICD-11: BA00-BA04] T72038 INDICATI Phase 2 Idiopathic interstitial pneumonitis [ICD-11: CB03] T72038 INDICATI Phase 2 Melanoma [ICD-11: 2C30] T72038 INDICATI Phase 1 Non-alcoholic fatty liver disease [ICD-11: DB92] T72038 INDICATI Phase 2 Psoriasis [ICD-11: EA90] T72042 TARGETID T72042 T72042 TARGNAME GAR transformylase (GART) T72042 INDICATI Phase 1 Solid tumour/cancer [ICD-11: 2A00-2F9Z] T72065 TARGETID T72065 T72065 TARGNAME Voltage-gated sodium channel (Nav) T72065 INDICATI Approved Bacterial infection [ICD-11: 1A00-1C4Z] T72065 INDICATI Approved Epilepsy/seizure [ICD-11: 8A61-8A6Z] T72065 INDICATI Terminated Genetic cardiac arrhythmia [ICD-11: BC65] T72065 INDICATI Phase 3 Neuropathy [ICD-11: 8C0Z] T72065 INDICATI Phase 2 Schizophrenia [ICD-11: 6A20] T72065 INDICATI Phase 1 Supraventricular tachyarrhythmia [ICD-11: BC81] T72065 INDICATI Approved Ventricular tachyarrhythmia [ICD-11: BC71] T72120 TARGETID T72120 T72120 TARGNAME Utrophin (UTRN) T72120 INDICATI Phase 2 Muscular dystrophy [ICD-11: 8C70] T72168 TARGETID T72168 T72168 TARGNAME Mineralocorticoid receptor (MR) T72168 INDICATI Approved Adrenocortical insufficiency [ICD-11: 5A74] T72168 INDICATI Phase 2 Cardiovascular disease [ICD-11: BA00-BE2Z] T72168 INDICATI Approved Chronic kidney disease [ICD-11: GB61] T72168 INDICATI Approved Contraceptive management [ICD-11: QA21] T72168 INDICATI Approved Heart failure [ICD-11: BD10-BD1Z] T72168 INDICATI Investigative Human immunodeficiency virus disease [ICD-11: 1C60-1C62] T72168 INDICATI Approved Hypertension [ICD-11: BA00-BA04] T72168 INDICATI Approved Hypo-osmolality/hyponatraemia [ICD-11: 5C72] T72168 INDICATI Investigative Solid tumour/cancer [ICD-11: 2A00-2F9Z] T72168 INDICATI Phase 1 Type 2 diabetes mellitus [ICD-11: 5A11] T72171 TARGETID T72171 T72171 TARGNAME CCR5 messenger RNA (CCR5 mRNA) T72171 INDICATI Phase 3 Chronic obstructive pulmonary disease [ICD-11: CA22] T72171 INDICATI Approved Human immunodeficiency virus disease [ICD-11: 1C60-1C62] T72182 TARGETID T72182 T72182 TARGNAME TNF-alpha/IL-1 beta production (TNFA/IL1B produ) T72182 INDICATI Phase 3 Rheumatoid arthritis [ICD-11: FA20] T72195 TARGETID T72195 T72195 TARGNAME Annexin A5 (ANXA5) T72195 INDICATI Phase 2 Injury [ICD-11: NA00-ND5Z] T72252 TARGETID T72252 T72252 TARGNAME Caspase-7 (CASP7) T72252 INDICATI Clinical trial Cystic fibrosis [ICD-11: CA25] T72269 TARGETID T72269 T72269 TARGNAME Elongation factor 1A (EF1A) T72269 INDICATI Investigative Melanoma [ICD-11: 2C30] T72295 TARGETID T72295 T72295 TARGNAME PKC-theta messenger RNA (PRKCQ mRNA) T72295 INDICATI Investigative Human immunodeficiency virus disease [ICD-11: 1C60-1C62] T72335 TARGETID T72335 T72335 TARGNAME Bacterial Lethal factor (Bact lef) T72335 INDICATI Discontinued in Phase 2 Corneal disease [ICD-11: 9A76-9A78] T72335 INDICATI Phase 1 Sepsis [ICD-11: 1G40-1G41] T72437 TARGETID T72437 T72437 TARGNAME VWF-dependent platelet-collagen conversion (VDDPCC) T72437 INDICATI Phase 2 Postoperative inflammation [ICD-11: 1A00-CA43] T72444 TARGETID T72444 T72444 TARGNAME Bacterial Beta-ketoacyl-ACP synthase III (Bact fabH) T72444 INDICATI Investigative Malaria [ICD-11: 1F40-1F45] T72444 INDICATI Investigative Urinary tract infection [ICD-11: GC08] T72458 TARGETID T72458 T72458 TARGNAME Melanocortin receptor 4 (MC4R) T72458 INDICATI Preclinical Acute diabete complication [ICD-11: 5A2Y] T72458 INDICATI Phase 2 Alzheimer disease [ICD-11: 8A20] T72458 INDICATI Investigative Anorexia nervosa [ICD-11: 6B80] T72458 INDICATI Discontinued in Phase 2 Asthma [ICD-11: CA23] T72458 INDICATI Phase 2 Atopic eczema [ICD-11: EA80] T72458 INDICATI Phase 3 Breast cancer [ICD-11: 2C60-2C6Y] T72458 INDICATI Investigative Cachexia [ICD-11: MG20] T72458 INDICATI Phase 3 General pain disorder [ICD-11: 8E43] T72458 INDICATI Approved Hypoactive sexual desire dysfunction [ICD-11: HA00] T72458 INDICATI Phase 2 Intellectual development disorder [ICD-11: LD90] T72458 INDICATI Approved Large intestine motility disorder [ICD-11: DB32] T72458 INDICATI Phase 1/2 Metabolic disorder [ICD-11: 5C50-5D2Z] T72458 INDICATI Phase 1 Nutritional deficiency [ICD-11: 5B50-5B71] T72458 INDICATI Approved Obesity [ICD-11: 5B80-5B81] T72458 INDICATI Phase 3 Pituitary hypofunction [ICD-11: 5A61] T72458 INDICATI Phase 3 Sexual dysfunction [ICD-11: HA00-HA01] T72458 INDICATI Preclinical Type 2 diabetes mellitus [ICD-11: 5A11] T72478 TARGETID T72478 T72478 TARGNAME Sodium/calcium exchanger (SLC) T72478 INDICATI Phase 2 Cardiovascular disease [ICD-11: BA00-BE2Z] T72478 INDICATI Investigative Cerebral ischaemia [ICD-11: 8B1Z] T72514 TARGETID T72514 T72514 TARGNAME Interleukin-36 gamma (IL36G) T72514 INDICATI Phase 1 Solid tumour/cancer [ICD-11: 2A00-2F9Z] T72515 TARGETID T72515 T72515 TARGNAME Interleukin 1 receptor type 1 (IL1R1) T72515 INDICATI Approved Rheumatoid arthritis [ICD-11: FA20] T72545 TARGETID T72545 T72545 TARGNAME Bacterial DNA topoisomerase 4A (Bact parC) T72545 INDICATI Phase 2 Acne vulgaris [ICD-11: ED80] T72545 INDICATI Phase 3 Conjunctiva disorder [ICD-11: 9A60] T72545 INDICATI Phase 2 Escherichia coli intestinal infection [ICD-11: 1A03] T72545 INDICATI Phase 1 Joint direct infection [ICD-11: FA10] T72545 INDICATI Phase 2 Pneumonia [ICD-11: CA40] T72545 INDICATI Phase 2 Skin and skin-structure infection [ICD-11: 1F28-1G0Z] T72545 INDICATI Approved Urinary tract infection [ICD-11: GC08] T72595 TARGETID T72595 T72595 TARGNAME Glutamate receptor ionotropic NMDA 2C (GluN2C) T72595 INDICATI Terminated Neurodegenerative disorder [ICD-11: 8A20-8A23] T72657 TARGETID T72657 T72657 TARGNAME Staphylococcus 30S ribosomal subunit (Stap-coc pbp2) T72657 INDICATI Approved Acne vulgaris [ICD-11: ED80] T72657 INDICATI Approved Acute/subacute hepatic failure [ICD-11: DB91] T72657 INDICATI Approved Alcoholic liver disease [ICD-11: DB94] T72657 INDICATI Approved Amoebiasis [ICD-11: 1A36] T72657 INDICATI Approved Bacterial infection [ICD-11: 1A00-1C4Z] T72657 INDICATI Approved Bronchitis [ICD-11: CA20] T72657 INDICATI Investigative HIV-infected patients with tuberculosis [ICD-11: 1B10-1B14] T72657 INDICATI Approved Lyme borreliosis [ICD-11: 1C1G] T72657 INDICATI Phase 2 Rosacea [ICD-11: ED90] T72657 INDICATI Approved Skin and skin-structure infection [ICD-11: 1F28-1G0Z] T72702 TARGETID T72702 T72702 TARGNAME Tissue factor (F3) T72702 INDICATI Phase 2 Acute respiratory distress syndrome [ICD-11: CB00] T72702 INDICATI Phase 2 Bleeding disorder [ICD-11: GA20-GA21] T72702 INDICATI Approved Cervical cancer [ICD-11: 2C77] T72702 INDICATI Phase 2 Ovarian cancer [ICD-11: 2C73] T72702 INDICATI Phase 1 Pancreatic cancer [ICD-11: 2C10] T72702 INDICATI Phase 2 Solid tumour/cancer [ICD-11: 2A00-2F9Z] T72737 TARGETID T72737 T72737 TARGNAME Cytomegalovirus Deoxyribonucleic acid (CMV DNA) T72737 INDICATI Phase 3 Cytomegaloviral disease [ICD-11: 1D82] T72835 TARGETID T72835 T72835 TARGNAME E-selectin (SELE) T72835 INDICATI Phase 3 Acute myeloid leukaemia [ICD-11: 2A60] T72835 INDICATI Phase 3 Asthma [ICD-11: CA23] T72835 INDICATI Phase 2a Atopic eczema [ICD-11: EA80] T72835 INDICATI Phase 1 Breast cancer [ICD-11: 2C60-2C6Y] T72835 INDICATI Phase 2a Chronic obstructive pulmonary disease [ICD-11: CA22] T72835 INDICATI Phase 3 Circulatory system disease [ICD-11: BE2Z] T72835 INDICATI Phase 2/3 Hypertension [ICD-11: BA00-BA04] T72835 INDICATI Terminated Indeterminate colitis [ICD-11: DD72] T72835 INDICATI Phase 1 Multiple myeloma [ICD-11: 2A83] T72835 INDICATI Phase 2a Psoriasis [ICD-11: EA90] T72835 INDICATI Phase 1 Sickle-cell disorder [ICD-11: 3A51] T72835 INDICATI Phase 1 Solid tumour/cancer [ICD-11: 2A00-2F9Z] T72841 TARGETID T72841 T72841 TARGNAME Estrogen-related receptor-alpha (ESRRA) T72841 INDICATI Phase 3 Asthma [ICD-11: CA23] T72841 INDICATI Terminated Cachexia [ICD-11: MG20] T72841 INDICATI Phase 1/2 Degenerative high myopia [ICD-11: 9B76] T72841 INDICATI Investigative Eczema [ICD-11: EA80-EA89] T72841 INDICATI Investigative Oesophagitis [ICD-11: DA24] T72841 INDICATI Approved Rheumatoid arthritis [ICD-11: FA20] T72841 INDICATI Phase 4 Schizophrenia [ICD-11: 6A20] T72841 INDICATI Discontinued in Phase 2 Vasomotor/allergic rhinitis [ICD-11: CA08] T72850 TARGETID T72850 T72850 TARGNAME Forkhead box protein O1A (FOXO1) T72850 INDICATI Investigative Hyper-lipoproteinaemia [ICD-11: 5C80] T72915 TARGETID T72915 T72915 TARGNAME Casein kinase 1 (CK1) T72915 INDICATI Preclinical Mood disorder [ICD-11: 6A60-6E23] T72957 TARGETID T72957 T72957 TARGNAME Chemokine receptor (CHR) T72957 INDICATI Discontinued in Phase 2 Asthma [ICD-11: CA23] T72957 INDICATI Discontinued in Phase 1 Chronic obstructive pulmonary disease [ICD-11: CA22] T72957 INDICATI Discontinued in Phase 1 Multiple sclerosis [ICD-11: 8A40] T72957 INDICATI Discontinued in Phase 1 Rheumatoid arthritis [ICD-11: FA20] T73019 TARGETID T73019 T73019 TARGNAME Phosphodiesterase 7 (PDE7) T73019 INDICATI Phase 1 Unspecific substance use disorder [ICD-11: 6C4Z] T73075 TARGETID T73075 T73075 TARGNAME Perlecan (HSPG) T73075 INDICATI Discontinued in Phase 1 Arterial occlusive disease [ICD-11: BD40] T73097 TARGETID T73097 T73097 TARGNAME GMCSFR-alpha (CSF2RA) T73097 INDICATI Phase 2 Acute myeloid leukaemia [ICD-11: 2A60] T73097 INDICATI Phase 2 Brain cancer [ICD-11: 2A00] T73097 INDICATI Preregistration Follicular lymphoma [ICD-11: 2A80] T73097 INDICATI Phase 3 Human immunodeficiency virus disease [ICD-11: 1C60-1C62] T73097 INDICATI Phase 3 Infancy/childhood primary interstitial lung disease [ICD-11: CB04] T73097 INDICATI Phase 2 Multiple myeloma [ICD-11: 2A83] T73097 INDICATI Phase 1/2 Multiple sclerosis [ICD-11: 8A40] T73097 INDICATI Investigative Neutropenia [ICD-11: 4B00] T73097 INDICATI Phase 2 Rheumatoid arthritis [ICD-11: FA20] T73097 INDICATI Phase 1 Skin postprocedural disorder [ICD-11: EL8Y] T73097 INDICATI Phase 2 Solid tumour/cancer [ICD-11: 2A00-2F9Z] T73097 INDICATI Approved Transplanted organ/tissue [ICD-11: QB63] T73134 TARGETID T73134 T73134 TARGNAME Beta-galactosidase (GLB1) T73134 INDICATI Phase 1/2 Lysosomal disease [ICD-11: 5C56] T73184 TARGETID T73184 T73184 TARGNAME Histone-lysine N-methyltransferase SETD7 (SETD7) T73184 INDICATI Preclinical Breast cancer [ICD-11: 2C60-2C6Y] T73189 TARGETID T73189 T73189 TARGNAME Fungal 1,3-beta-glucan synthase (Fung GSC2) T73189 INDICATI Terminated Aspergillosis [ICD-11: 1F20] T73189 INDICATI Approved Candidosis [ICD-11: 1F23] T73189 INDICATI Approved Epilepsy/seizure [ICD-11: 8A61-8A6Z] T73189 INDICATI Approved Fungal infection [ICD-11: 1F29-1F2F] T73215 TARGETID T73215 T73215 TARGNAME Leukocyte surface antigen Leu-16 (CD20) T73215 INDICATI Application submitted Acute myeloid leukaemia [ICD-11: 2A60] T73215 INDICATI Phase 2 Bacterial infection [ICD-11: 1A00-1C4Z] T73215 INDICATI Phase 1/2 B-cell lymphoma [ICD-11: 2A86] T73215 INDICATI Investigative Diabetes mellitus [ICD-11: 5A10] T73215 INDICATI Approved Diffuse large B-cell lymphoma [ICD-11: 2A81] T73215 INDICATI Approved Follicular lymphoma [ICD-11: 2A80] T73215 INDICATI Phase 1/2 Leukaemia [ICD-11: 2A60-2B33] T73215 INDICATI Phase 2 Lupus erythematosus [ICD-11: 4A40] T73215 INDICATI Phase 3 Lymphoma [ICD-11: 2A80-2A86] T73215 INDICATI Approved Malignant haematopoietic neoplasm [ICD-11: 2B33] T73215 INDICATI Approved Mature B-cell leukaemia [ICD-11: 2A82] T73215 INDICATI Approved Mature B-cell lymphoma [ICD-11: 2A85] T73215 INDICATI Approved Multiple sclerosis [ICD-11: 8A40] T73215 INDICATI Phase 1 Pancreatic cancer [ICD-11: 2C10] T73215 INDICATI Phase 3 Pemphigus [ICD-11: EB40] T73215 INDICATI Phase 2 Rheumatoid arthritis [ICD-11: FA20] T73215 INDICATI Phase 2 Solid tumour/cancer [ICD-11: 2A00-2F9Z] T73215 INDICATI Investigative Supraventricular tachyarrhythmia [ICD-11: BC81] T73215 INDICATI Phase 3 Tension-type headache [ICD-11: 8A81] T73215 INDICATI Phase 1/2 Thrombocytopenia [ICD-11: 3B64] T73342 TARGETID T73342 T73342 TARGNAME Ribonucleotide reductase (RIR) T73342 INDICATI Phase 2 Bladder cancer [ICD-11: 2C94] T73342 INDICATI Phase 1/2 Brain cancer [ICD-11: 2A00] T73342 INDICATI Approved Mature B-cell lymphoma [ICD-11: 2A85] T73342 INDICATI Approved Myelodysplastic syndrome [ICD-11: 2A37] T73342 INDICATI Phase 1 Solid tumour/cancer [ICD-11: 2A00-2F9Z] T73404 TARGETID T73404 T73404 TARGNAME Activated leukocyte cell adhesionmolecule (ALCAM) T73404 INDICATI Phase 2 Solid tumour/cancer [ICD-11: 2A00-2F9Z] T73475 TARGETID T73475 T73475 TARGNAME Matrix metalloproteinase-7 (MMP-7) T73475 INDICATI Discontinued in Phase 3 Brain cancer [ICD-11: 2A00] T73475 INDICATI Discontinued in Phase 3 Kaposi sarcoma [ICD-11: 2B57] T73475 INDICATI Approved Lung cancer [ICD-11: 2C25] T73475 INDICATI Phase 3 Pancreatic cancer [ICD-11: 2C10] T73475 INDICATI Discontinued in Phase 3 Prostate cancer [ICD-11: 2C82] T73475 INDICATI Terminated Solid tumour/cancer [ICD-11: 2A00-2F9Z] T73476 TARGETID T73476 T73476 TARGNAME Antithrombin-III (ATIII) T73476 INDICATI Phase 1 Asthma [ICD-11: CA23] T73476 INDICATI Phase 2 Chronic obstructive pulmonary disease [ICD-11: CA22] T73476 INDICATI Approved Coagulation defect [ICD-11: 3B10] T73476 INDICATI Approved Coronary thrombosis [ICD-11: BA43] T73476 INDICATI Approved Deep vein thrombosis [ICD-11: BD71] T73476 INDICATI Phase 1 kidney/ureter disorder [ICD-11: GB90] T73476 INDICATI Phase 2 Myocardial infarction [ICD-11: BA41-BA43] T73476 INDICATI Investigative Solid tumour/cancer [ICD-11: 2A00-2F9Z] T73476 INDICATI Phase 3 Thrombosis [ICD-11: DB61-GB90] T73476 INDICATI Approved Tinnitus [ICD-11: MC41] T73476 INDICATI Discontinued in Phase 3 Ulcerative colitis [ICD-11: DD71] T73476 INDICATI Phase 3 Venous thromboembolism [ICD-11: BD72] T73482 TARGETID T73482 T73482 TARGNAME Orexin receptor type 1 (HCRTR1) T73482 INDICATI Phase 2 Depression [ICD-11: 6A70-6A7Z] T73482 INDICATI Phase 2 Insomnia [ICD-11: 7A00-7A0Z] T73482 INDICATI Phase 1 Opioid use disorder ICD-11: 6C43 T73482 INDICATI Terminated Sleep-wake disorder [ICD-11: 7A00-7B2Z] T73495 TARGETID T73495 T73495 TARGNAME Glutamate receptor ionotropic kainate 1 (GRIK1) T73495 INDICATI Phase 1 Dissociative neurological symptom disorder [ICD-11: 6B60] T73495 INDICATI Approved Epilepsy/seizure [ICD-11: 8A61-8A6Z] T73495 INDICATI Phase 2 General pain disorder [ICD-11: 8E43] T73495 INDICATI Phase 2 Pain [ICD-11: MG30-MG3Z] T73495 INDICATI Approved Substance abuse [ICD-11: 6C40] T73582 TARGETID T73582 T73582 TARGNAME Ubiquitin carboxyl-terminal hydrolase 10 (USP10) T73582 INDICATI Preclinical Postoperative inflammation [ICD-11: 1A00-CA43] T73671 TARGETID T73671 T73671 TARGNAME Interferon (IFN) T73671 INDICATI Phase 2 Hepatitis virus infection [ICD-11: 1E50-1E51] T73671 INDICATI Investigative Sexually transmitted infection [ICD-11: 1A9Y-1A9Z] T73676 TARGETID T73676 T73676 TARGNAME Synaptic vesicle glycoprotein 2A (SV2A) T73676 INDICATI Approved Chronic pain [ICD-11: MG30] T73676 INDICATI Approved Epilepsy/seizure [ICD-11: 8A61-8A6Z] T73676 INDICATI Phase 3 Pain [ICD-11: MG30-MG3Z] T73694 TARGETID T73694 T73694 TARGNAME Tyrosine-protein kinase BRK (PTK6) T73694 INDICATI Phase 1 Cardiovascular disease [ICD-11: BA00-BE2Z] T73694 INDICATI Phase 1 Postoperative inflammation [ICD-11: 1A00-CA43] T73696 TARGETID T73696 T73696 TARGNAME Relaxin receptor 1 (RXFP1) T73696 INDICATI Phase 1 Cardiovascular disease [ICD-11: BA00-BE2Z] T73696 INDICATI Approval submitted Heart failure [ICD-11: BD10-BD1Z] T73708 TARGETID T73708 T73708 TARGNAME Neuropilin-2 (NRP2) T73708 INDICATI Phase 3 Sarcoidosis [ICD-11: 4B20] T73712 TARGETID T73712 T73712 TARGNAME Fatty acid-binding protein 1 (FABP1) T73712 INDICATI Approved Cardiovascular disease [ICD-11: BA00-BE2Z] T73712 INDICATI Withdrawn from market Gout [ICD-11: FA25] T73724 TARGETID T73724 T73724 TARGNAME Neuronal acetylcholine receptor beta-4 (CHRNB4) T73724 INDICATI Discontinued in Phase 2 Alzheimer disease [ICD-11: 8A20] T73724 INDICATI Phase 3 Nicotine use disorder [ICD-11: 6C4A] T73726 TARGETID T73726 T73726 TARGNAME Candida Cytochrome P450 51 (Candi ERG11) T73726 INDICATI Approved Aspergillosis [ICD-11: 1F20] T73726 INDICATI Approved Candidosis [ICD-11: 1F23] T73726 INDICATI Phase 1 Coccidioidomycosis ICD-11: 1F25 T73726 INDICATI Approved Dermatophytosis [ICD-11: 1F28] T73726 INDICATI Approved Fungal infection [ICD-11: 1F29-1F2F] T73726 INDICATI Discontinued in Phase 2 Hyper-lipoproteinaemia [ICD-11: 5C80] T73726 INDICATI Approved Nail/perionychium infection [ICD-11: EE12] T73726 INDICATI Approved Non-dermatophyte superficial dermatomycose [ICD-11: 1F2D] T73726 INDICATI Phase 2 Oesophagitis [ICD-11: DA24] T73726 INDICATI Phase 3 Solid tumour/cancer [ICD-11: 2A00-2F9Z] T73726 INDICATI Phase 2/3 Visual system disease [ICD-11: 9E1Z] T73756 TARGETID T73756 T73756 TARGNAME Ephrin type-B receptor 2 (EPHB2) T73756 INDICATI Phase 2 Kaposi sarcoma [ICD-11: 2B57] T73756 INDICATI Phase 2 Melanoma [ICD-11: 2C30] T73756 INDICATI Phase 1 Pancreatic cancer [ICD-11: 2C10] T73756 INDICATI Phase 1/2 Solid tumour/cancer [ICD-11: 2A00-2F9Z] T73760 TARGETID T73760 T73760 TARGNAME T(H2) cytokine production (TH2 produ) T73760 INDICATI Approved Allergic/hypersensitivity disorder [ICD-11: 4A80-4A8Z] T73977 TARGETID T73977 T73977 TARGNAME Voltage-gated calcium channel alpha Cav2.3 (CACNA1E) T73977 INDICATI Investigative Heart failure [ICD-11: BD10-BD1Z] T73977 INDICATI Terminated Unspecific body region injury [ICD-11: ND56] T73992 TARGETID T73992 T73992 TARGNAME Beta-secretase (BACE) T73992 INDICATI Clinical trial Acute diabete complication [ICD-11: 5A2Y] T73992 INDICATI Phase 3 Alzheimer disease [ICD-11: 8A20] T73992 INDICATI Clinical trial Cardiovascular disease [ICD-11: BA00-BE2Z] T73992 INDICATI Clinical trial Chronic kidney disease [ICD-11: GB61] T73992 INDICATI Preregistration Osteoarthritis [ICD-11: FA00-FA05] T73992 INDICATI Clinical trial Rheumatoid arthritis [ICD-11: FA20] T73992 INDICATI Preregistration Shoulder lesion [ICD-11: FB53] T73992 INDICATI Preregistration Soft tissue disorder [ICD-11: FB56] T73992 INDICATI Clinical trial Solid tumour/cancer [ICD-11: 2A00-2F9Z] T74002 TARGETID T74002 T74002 TARGNAME Granulocyte-macrophage colony-stimulating factor (CSF2) T74002 INDICATI Phase 2 Asthma [ICD-11: CA23] T74002 INDICATI Phase 2 Colorectal cancer [ICD-11: 2B91] T74002 INDICATI Phase 2 COVID-19 [ICD-11: 1D6Y] T74002 INDICATI Phase 1 Diabetes mellitus [ICD-11: 5A10] T74002 INDICATI Phase 3 Liver cancer [ICD-11: 2C12] T74002 INDICATI Approved Melanoma [ICD-11: 2C30] T74002 INDICATI Phase 1 Myeloproliferative neoplasm [ICD-11: 2A20] T74002 INDICATI Phase 2 Pancreatic cancer [ICD-11: 2C10] T74002 INDICATI Phase 1 Prostate cancer [ICD-11: 2C82] T74002 INDICATI Phase 2 Psoriasis [ICD-11: EA90] T74002 INDICATI Phase 2 Rheumatoid arthritis [ICD-11: FA20] T74002 INDICATI Phase 2 Solid tumour/cancer [ICD-11: 2A00-2F9Z] T74034 TARGETID T74034 T74034 TARGNAME Hepatitis C virus Deoxyribonucleic acid (HCV DNA) T74034 INDICATI Phase 1/2 Hepatitis virus infection [ICD-11: 1E50-1E51] T74066 TARGETID T74066 T74066 TARGNAME Polycomb complex protein BMI-1 (BMI1) T74066 INDICATI Phase 2/3 Leiomyosarcoma [ICD-11: 2B58] T74073 TARGETID T74073 T74073 TARGNAME Serine/threonine-protein kinase pim (PIM) T74073 INDICATI Phase 1/2 Acute myeloid leukaemia [ICD-11: 2A60] T74073 INDICATI Phase 1 Myeloproliferative neoplasm [ICD-11: 2A20] T74073 INDICATI Phase 1/2 Solid tumour/cancer [ICD-11: 2A00-2F9Z] T74166 TARGETID T74166 T74166 TARGNAME Neuronal acetylcholine receptor alpha-3/beta-4 (CHRNA3/B4) T74166 INDICATI Approved Cough [ICD-11: MD12] T74166 INDICATI Phase 2 Hyperhidrosis [ICD-11: EE00] T74166 INDICATI Phase 1 Unspecific substance use disorder [ICD-11: 6C4Z] T74203 TARGETID T74203 T74203 TARGNAME Mycobacterium Antigen complex 85A (MycB fbpA) T74203 INDICATI Phase 2 Mycobacterium infection [ICD-11: 1B10-1B21] T74225 TARGETID T74225 T74225 TARGNAME GPCR secretin protein unspecific (GPCRB) T74225 INDICATI Discontinued in Phase 2 Bacterial infection [ICD-11: 1A00-1C4Z] T74238 TARGETID T74238 T74238 TARGNAME Leukotriene CysLT2 receptor (CYSLTR2) T74238 INDICATI Phase 2 Asthma [ICD-11: CA23] T74312 TARGETID T74312 T74312 TARGNAME Fms-like tyrosine kinase 3 (FLT-3) T74312 INDICATI Terminated Acute laryngitis/tracheitis [ICD-11: CA05] T74312 INDICATI Approved (orphan drug) Acute myeloid leukaemia [ICD-11: 2A60] T74312 INDICATI Phase 3 Alzheimer disease [ICD-11: 8A20] T74312 INDICATI Approved Bone/articular cartilage neoplasm [ICD-11: 2F7B] T74312 INDICATI Discontinued in Phase 2 Brain cancer [ICD-11: 2A00] T74312 INDICATI Phase 2 Chronic myelomonocytic leukaemia [ICD-11: 2A40] T74312 INDICATI Phase 2 Chronic pain [ICD-11: MG30] T74312 INDICATI Approved Colorectal cancer [ICD-11: 2B91] T74312 INDICATI Phase 2 Diffuse large B-cell lymphoma [ICD-11: 2A81] T74312 INDICATI Approved Human immunodeficiency virus disease [ICD-11: 1C60-1C62] T74312 INDICATI Approved Idiopathic interstitial pneumonitis [ICD-11: CB03] T74312 INDICATI Phase 3 Inflammatory arthropathy [ICD-11: FA2Z] T74312 INDICATI Phase 3 Leukaemia [ICD-11: 2A60-2B33] T74312 INDICATI Phase 3 Lung cancer [ICD-11: 2C25] T74312 INDICATI Phase 3 Malignant haematopoietic neoplasm [ICD-11: 2B33] T74312 INDICATI Approved Mastocytosis [ICD-11: 2A21] T74312 INDICATI Approved Mature B-cell lymphoma [ICD-11: 2A85] T74312 INDICATI Phase 1 Multiple myeloma [ICD-11: 2A83] T74312 INDICATI Approved Myeloproliferative neoplasm [ICD-11: 2A20] T74312 INDICATI Phase 2 Ovarian cancer [ICD-11: 2C73] T74312 INDICATI Phase 3 Peritoneal cancer [ICD-11: 2C51] T74312 INDICATI Phase 1/2 Phakomatoses/hamartoneoplastic syndrome [ICD-11: LD2D] T74312 INDICATI Phase 2/3 Psoriasis [ICD-11: EA90] T74312 INDICATI Phase 2 Solid tumour/cancer [ICD-11: 2A00-2F9Z] T74312 INDICATI Phase 2 Transplanted organ/tissue [ICD-11: QB63] T74312 INDICATI Investigative Virus infection [ICD-11: 1A24-1D9Z] T74363 TARGETID T74363 T74363 TARGNAME Urokinase plasminogen activator surface receptor (PLAUR) T74363 INDICATI Phase 1/2 Acquired hypomelanotic disorder [ICD-11: ED63] T74363 INDICATI Phase 1/2 Atopic eczema [ICD-11: EA80] T74363 INDICATI Approved Myeloproliferative neoplasm [ICD-11: 2A20] T74363 INDICATI Phase 3 Pancreatic cancer [ICD-11: 2C10] T74363 INDICATI Approved Thrombocytosis [ICD-11: 3B63] T74381 TARGETID T74381 T74381 TARGNAME Cancer/testis antigen MAGE-C1/CT7 (MAGEC1) T74381 INDICATI Phase 1/2 Lung cancer [ICD-11: 2C25] T74402 TARGETID T74402 T74402 TARGNAME NF-kappa-B-p38 signaling pathway (NFKB-p38 pathway) T74402 INDICATI Phase 1 Rheumatoid arthritis [ICD-11: FA20] T74429 TARGETID T74429 T74429 TARGNAME Calcium (Ca) T74429 INDICATI Approved Abnormal urine serum electrolytes level [ICD-11: MF98] T74429 INDICATI Approved Low bone mass disorder [ICD-11: FB83] T74437 TARGETID T74437 T74437 TARGNAME Actin polymerization (Actin poly) T74437 INDICATI Phase 2 Arteries/arterioles disorder [ICD-11: BD52] T74456 TARGETID T74456 T74456 TARGNAME Angiotensin II receptor type-1 (AGTR1) T74456 INDICATI Terminated Alzheimer disease [ICD-11: 8A20] T74456 INDICATI Investigative Arteries/arterioles disorder [ICD-11: BD52] T74456 INDICATI Approved Essential hypertension [ICD-11: BA00] T74456 INDICATI Phase 2 Heart failure [ICD-11: BD10-BD1Z] T74456 INDICATI Approved Hypertension [ICD-11: BA00-BA04] T74456 INDICATI Discontinued in Phase 2 Hypotension [ICD-11: BA20-BA21] T74456 INDICATI Phase 3 Metabolic disorder [ICD-11: 5C50-5D2Z] T74456 INDICATI Phase 2 Myocardial infarction [ICD-11: BA41-BA43] T74456 INDICATI Approved Secondary hypertension [ICD-11: BA04] T74456 INDICATI Approved Urinary system clinical sympton [ICD-11: MF8Y] T74483 TARGETID T74483 T74483 TARGNAME Voltage-gated potassium channel Kv7.2 (KCNQ2) T74483 INDICATI Preclinical Pain [ICD-11: MG30-MG3Z] T74500 TARGETID T74500 T74500 TARGNAME Voltage-gated potassium channel Kv4.3 (KCND3) T74500 INDICATI Approved Acidosis [ICD-11: 5C73] T74500 INDICATI Terminated Genetic cardiac arrhythmia [ICD-11: BC65] T74654 TARGETID T74654 T74654 TARGNAME Adrenergic neuron (AD neuro) T74654 INDICATI Approved Essential hypertension [ICD-11: BA00] T74654 INDICATI Approved Hypertension [ICD-11: BA00-BA04] T74839 TARGETID T74839 T74839 TARGNAME Cyclin-dependent kinase 13 (CDK13) T74839 INDICATI Investigative Solid tumour/cancer [ICD-11: 2A00-2F9Z] T74891 TARGETID T74891 T74891 TARGNAME Entamoeba Cysteine proteinase CP4 (Eh CP4) T74891 INDICATI Investigative Amoebiasis [ICD-11: 1A36] T74937 TARGETID T74937 T74937 TARGNAME Dopamine beta hydroxylase (DBH) T74937 INDICATI Phase 2 Heart failure [ICD-11: BD10-BD1Z] T74937 INDICATI Phase 2 Post-traumatic stress disorder [ICD-11: 6B40] T74977 TARGETID T74977 T74977 TARGNAME Dual specificity protein kinase TTK (MPS1) T74977 INDICATI Phase 1 Solid tumour/cancer [ICD-11: 2A00-2F9Z] T75041 TARGETID T75041 T75041 TARGNAME Tumor-associated glycoprotein 72 (TAG-72) T75041 INDICATI Approved Breast cancer [ICD-11: 2C60-2C6Y] T75243 TARGETID T75243 T75243 TARGNAME Serine/threonine-protein kinase mTOR (mTOR) T75243 INDICATI Approved Arteries/arterioles disorder [ICD-11: BD52] T75243 INDICATI Phase 1/2 Bladder cancer [ICD-11: 2C94] T75243 INDICATI Phase 2 Breast cancer [ICD-11: 2C60-2C6Y] T75243 INDICATI Approved Chronic myelomonocytic leukaemia [ICD-11: 2A40] T75243 INDICATI Phase 2 Endometrial cancer [ICD-11: 2C76] T75243 INDICATI Phase 2 Head and neck cancer [ICD-11: 2D42] T75243 INDICATI Phase 1/2 Hydrocephalus [ICD-11: 8D64] T75243 INDICATI Phase 1 Liver cancer [ICD-11: 2C12] T75243 INDICATI Phase 2 Lung cancer [ICD-11: 2C25] T75243 INDICATI Phase 1 Lymphangioleiomyomatosis [ICD-11: CB07] T75243 INDICATI Phase 1 Lymphoma [ICD-11: 2A80-2A86] T75243 INDICATI Phase 2 Malignant haematopoietic neoplasm [ICD-11: 2B33] T75243 INDICATI Phase 2 Malignant mesenchymal neoplasm [ICD-11: 2B5D-2B5Y] T75243 INDICATI Investigative Mature T-cell lymphoma [ICD-11: 2A90] T75243 INDICATI Phase 2 Metastatic lymph node neoplasm [ICD-11: 2D60] T75243 INDICATI Approved Multiple myeloma [ICD-11: 2A83] T75243 INDICATI Phase 1 Pain [ICD-11: MG30-MG3Z] T75243 INDICATI Phase 2 Pancreatic cancer [ICD-11: 2C10] T75243 INDICATI Phase 1 Pleural mesothelioma [ICD-11: 2C26] T75243 INDICATI Investigative Postoperative inflammation [ICD-11: 1A00-CA43] T75243 INDICATI Phase 2 Prostate cancer [ICD-11: 2C82] T75243 INDICATI Phase 1 Pulmonary hypertension [ICD-11: BB01] T75243 INDICATI Approved Renal cell carcinoma [ICD-11: 2C90] T75243 INDICATI Phase 3 Sarcoma [ICD-11: 2A60-2C35] T75243 INDICATI Approved Solid tumour/cancer [ICD-11: 2A00-2F9Z] T75243 INDICATI Approved Transplant rejection [ICD-11: NE84] T75243 INDICATI Investigative Ulcerative colitis [ICD-11: DD71] T75243 INDICATI Phase 1 Vascular system developmental anomaly ICD-11: LA90 T75251 TARGETID T75251 T75251 TARGNAME Tubulin receptor (TUBR) T75251 INDICATI Phase 1 Retinopathy [ICD-11: 9B71] T75256 TARGETID T75256 T75256 TARGNAME MART-1 melanoma antigen (MLANA) T75256 INDICATI Phase 3 Melanoma [ICD-11: 2C30] T75273 TARGETID T75273 T75273 TARGNAME Staphylococcus DNA gyrase A (Stap-coc gyrA) T75273 INDICATI Phase 3 Bacterial infection [ICD-11: 1A00-1C4Z] T75273 INDICATI Approved Impetigo [ICD-11: 1B72] T75440 TARGETID T75440 T75440 TARGNAME Translocator protein (TSPO) T75440 INDICATI Phase 1 Alzheimer disease [ICD-11: 8A20] T75440 INDICATI Approved Anxiety disorder [ICD-11: 6B00-6B0Z] T75440 INDICATI Phase 2 Brain disease [ICD-11: 8C70-8E61] T75440 INDICATI Approved Epilepsy/seizure [ICD-11: 8A61-8A6Z] T75440 INDICATI Investigative Gram-positive bacterial infection [ICD-11: 1B74-1F40] T75440 INDICATI Approved Insomnia [ICD-11: 7A00-7A0Z] T75440 INDICATI Approved Intentional self-harm [ICD-11: PC91] T75440 INDICATI Phase 2 Irritable bowel syndrome [ICD-11: DD91] T75440 INDICATI Discontinued in Phase 2 Mild neurocognitive disorder [ICD-11: 6D71] T75440 INDICATI Approved Mood/affect symptom [ICD-11: MB24] T75440 INDICATI Discontinued in Phase 2 Muscular atrophy [ICD-11: 8B61] T75440 INDICATI Terminated Pain [ICD-11: MG30-MG3Z] T75440 INDICATI Phase 2 Rheumatoid arthritis [ICD-11: FA20] T75440 INDICATI Phase 2 Solid tumour/cancer [ICD-11: 2A00-2F9Z] T75440 INDICATI Approved Tonus and reflex abnormality [ICD-11: MB47] T75498 TARGETID T75498 T75498 TARGNAME Quinone reductase 2 (NQO2) T75498 INDICATI Phase 2 Breast cancer [ICD-11: 2C60-2C6Y] T75498 INDICATI Approved Insomnia [ICD-11: 7A00-7A0Z] T75498 INDICATI Phase 2 Solid tumour/cancer [ICD-11: 2A00-2F9Z] T75499 TARGETID T75499 T75499 TARGNAME Human Deoxyribonucleic acid major groove (hDNA maj) T75499 INDICATI Approved Solid tumour/cancer [ICD-11: 2A00-2F9Z] T75570 TARGETID T75570 T75570 TARGNAME Yes tyrosine kinase (YES) T75570 INDICATI Phase 1 Solid tumour/cancer [ICD-11: 2A00-2F9Z] T75596 TARGETID T75596 T75596 TARGNAME Methionine aminopeptidase 2 (METAP2) T75596 INDICATI Phase 1 Diabetes mellitus [ICD-11: 5A10] T75596 INDICATI Phase 1 Obesity [ICD-11: 5B80-5B81] T75596 INDICATI Phase 3 Solid tumour/cancer [ICD-11: 2A00-2F9Z] T75596 INDICATI Phase 2 Type 2 diabetes mellitus [ICD-11: 5A11] T75613 TARGETID T75613 T75613 TARGNAME Laminin gamma-2 subunit (LAMC2) T75613 INDICATI Preclinical Solid tumour/cancer [ICD-11: 2A00-2F9Z] T75643 TARGETID T75643 T75643 TARGNAME Pattern recognition receptor NOD2 (NOD2) T75643 INDICATI Phase 2 Diabetes mellitus [ICD-11: 5A10] T75643 INDICATI Phase 2 Hepatitis virus infection [ICD-11: 1E50-1E51] T75643 INDICATI Investigative Sepsis [ICD-11: 1G40-1G41] T75716 TARGETID T75716 T75716 TARGNAME Delta-like protein 3 (DLL3) T75716 INDICATI Phase 3 Lung cancer [ICD-11: 2C25] T75716 INDICATI Phase 1 Solid tumour/cancer [ICD-11: 2A00-2F9Z] T75716 INDICATI Phase 1 Stomach cancer [ICD-11: 2B72] T75788 TARGETID T75788 T75788 TARGNAME Endostatin (COL18A1) T75788 INDICATI Phase 2 Retinopathy [ICD-11: 9B71] T75797 TARGETID T75797 T75797 TARGNAME Prostaglandin F2-alpha receptor (PTGFR) T75797 INDICATI Approved Abortion [ICD-11: JA00] T75797 INDICATI Clinical trial Alzheimer disease [ICD-11: 8A20] T75797 INDICATI Discontinued in Phase 3 Arterial occlusive disease [ICD-11: BD40] T75797 INDICATI Phase 4 Coronary atherosclerosis [ICD-11: BA80] T75797 INDICATI Phase 1 Female pelvic pain [ICD-11: GA34] T75797 INDICATI Approved Glaucoma [ICD-11: 9C61] T75797 INDICATI Investigative Herpes simplex infection [ICD-11: 1F00] T75797 INDICATI Phase 3 Renal cell carcinoma [ICD-11: 2C90] T75797 INDICATI Clinical trial Solid tumour/cancer [ICD-11: 2A00-2F9Z] T75819 TARGETID T75819 T75819 TARGNAME F-box only protein 3 (FBXO3) T75819 INDICATI Preclinical Postoperative inflammation [ICD-11: 1A00-CA43] T75888 TARGETID T75888 T75888 TARGNAME Carnitine O-palmitoyltransferase I (CPT1B) T75888 INDICATI Discontinued in Phase 1 Acute diabete complication [ICD-11: 5A2Y] T75888 INDICATI Approved Angina pectoris [ICD-11: BA40] T75888 INDICATI Terminated Heart failure [ICD-11: BD10-BD1Z] T75888 INDICATI Approved Mild neurocognitive disorder [ICD-11: 6D71] T75888 INDICATI Approved Nutritional deficiency [ICD-11: 5B50-5B71] T75888 INDICATI Investigative Obesity [ICD-11: 5B80-5B81] T75888 INDICATI Terminated Psoriasis [ICD-11: EA90] T75890 TARGETID T75890 T75890 TARGNAME Dihydrothymine dehydrogenase (DPYD) T75890 INDICATI Investigative Colorectal cancer [ICD-11: 2B91] T75890 INDICATI Phase 2 Hyper-lipoproteinaemia [ICD-11: 5C80] T75890 INDICATI Approved Solid tumour/cancer [ICD-11: 2A00-2F9Z] T75907 TARGETID T75907 T75907 TARGNAME ATP synthase (ATPS) T75907 INDICATI Phase 1 Alzheimer disease [ICD-11: 8A20] T75984 TARGETID T75984 T75984 TARGNAME 5-HT 2 receptor (5HT2R) T75984 INDICATI Phase 2 Anxiety disorder [ICD-11: 6B00-6B0Z] T75984 INDICATI Terminated Cerebral ischaemia [ICD-11: 8B1Z] T75984 INDICATI Discontinued in Phase 2 Chronic arterial occlusive disease [ICD-11: BD4Z] T75984 INDICATI Approved Depression [ICD-11: 6A70-6A7Z] T75984 INDICATI Approved Hypertension [ICD-11: BA00-BA04] T75984 INDICATI Terminated Migraine [ICD-11: 8A80] T75984 INDICATI Approved Psychotic disorder [ICD-11: 6A20-6A25] T75984 INDICATI Phase 1 Rheumatoid arthritis [ICD-11: FA20] T75984 INDICATI Phase 2 Schizophrenia [ICD-11: 6A20] T75984 INDICATI Phase 2 Social anxiety disorder [ICD-11: 6B04] T75984 INDICATI Terminated Thrombosis [ICD-11: DB61-GB90] T76024 TARGETID T76024 T76024 TARGNAME Complement C1s component (C1S) T76024 INDICATI Phase 1 Acquired haemolytic anaemia ICD-11: 3A20 T76024 INDICATI Approved Haemolytic anemia [ICD-11: 3A20-3A2Z] T76024 INDICATI Phase 2 Inflammatory polyneuropathy [ICD-11: 8C01] T76024 INDICATI Approved Innate/adaptive immunodeficiency [ICD-11: 4A00] T76024 INDICATI Phase 1 Ischaemic/haemorrhagic stroke [ICD-11: 8B20] T76024 INDICATI Phase 1 Neurodegenerative disorder [ICD-11: 8A20-8A23] T76024 INDICATI Phase 1 Neuromyelitis optica [ICD-11: 8A43] T76024 INDICATI Phase 1 Pemphigoid [ICD-11: EB41] T76024 INDICATI Phase 2 Thrombocytopenia ICD-11: 3B64 T76059 TARGETID T76059 T76059 TARGNAME FK506-binding protein 1A (FKBP1A) T76059 INDICATI Phase 2 Parkinsonism [ICD-11: 8A00] T76059 INDICATI Phase 2 Pruritus [ICD-11: EC90] T76059 INDICATI Phase 1/2 Transplant rejection [ICD-11: NE84] T76093 TARGETID T76093 T76093 TARGNAME Proheparin-binding EGF-like growth factor (HBEGF) T76093 INDICATI Phase 1 Chronic tympanic membrane perforation ICD-11: AB13 T76093 INDICATI Phase 1 Ovarian cancer [ICD-11: 2C73] T76093 INDICATI Phase 1 Solid tumour/cancer [ICD-11: 2A00-2F9Z] T76198 TARGETID T76198 T76198 TARGNAME Thromboxane A2 receptor (TBXA2R) T76198 INDICATI Phase 2 Angina pectoris [ICD-11: BA40] T76198 INDICATI Discontinued in Phase 3 Arterial occlusive disease [ICD-11: BD40] T76198 INDICATI Phase 2 Asthma ICD-11: CA23 T76198 INDICATI Phase 2 Asthma [ICD-11: CA23] T76198 INDICATI Terminated Cardiovascular disease [ICD-11: BA00-BE2Z] T76198 INDICATI Phase 1 Chronic arterial occlusive disease [ICD-11: BD4Z] T76198 INDICATI Phase 4 Coronary atherosclerosis [ICD-11: BA80] T76198 INDICATI Approved Diabetic foot ulcer [ICD-11: BD54] T76198 INDICATI Approved Myocardial infarction [ICD-11: BA41-BA43] T76198 INDICATI Phase 2 Neuropathy [ICD-11: 8C0Z] T76198 INDICATI Approved Sexual dysfunction [ICD-11: HA00-HA01] T76198 INDICATI Clinical trial Solid tumour/cancer [ICD-11: 2A00-2F9Z] T76198 INDICATI Phase 2 Thrombosis [ICD-11: DB61-GB90] T76198 INDICATI Phase 2/3 Vasomotor/allergic rhinitis [ICD-11: CA08] T76213 TARGETID T76213 T76213 TARGNAME Phenylalanine hydroxylase (PAH) T76213 INDICATI Phase 2 Diabetes mellitus [ICD-11: 5A10] T76213 INDICATI Investigative Genetic prion disease [ICD-11: 8E02] T76213 INDICATI Phase 2 Liver disease [ICD-11: DB90-DB9Z] T76213 INDICATI Approved Metabolism inborn error [ICD-11: 5C50] T76233 TARGETID T76233 T76233 TARGNAME Hepatitis A virus cellular receptor 2 (TIM3) T76233 INDICATI Phase 2 Alzheimer disease [ICD-11: 8A20] T76233 INDICATI Phase 2 Hodgkin lymphoma [ICD-11: 2B30] T76233 INDICATI Phase 1 Lymphoma [ICD-11: 2A80-2A86] T76233 INDICATI Phase 3 Myelodysplastic syndrome [ICD-11: 2A37] T76233 INDICATI Phase 2 Non-small-cell lung cancer [ICD-11: 2C25] T76233 INDICATI Phase 2 Oral cavity/oesophagus/stomach in situ carcinoma [ICD-11: 2E60] T76233 INDICATI Phase 1/2 Solid tumour/cancer [ICD-11: 2A00-2F9Z] T76285 TARGETID T76285 T76285 TARGNAME Phosphodiesterase I beta (ENPP3) T76285 INDICATI Phase 2 Renal cell carcinoma [ICD-11: 2C90] T76310 TARGETID T76310 T76310 TARGNAME Calcium release (Ca rele) T76310 INDICATI Phase 2 Postoperative inflammation [ICD-11: 1A00-CA43] T76369 TARGETID T76369 T76369 TARGNAME Liver carboxylesterase (CES1) T76369 INDICATI Phase 2/3 Arterial occlusive disease [ICD-11: BD40] T76369 INDICATI Discontinued in Phase 3 Chronic arterial occlusive disease [ICD-11: BD4Z] T76369 INDICATI Phase 2 Hyper-lipoproteinaemia [ICD-11: 5C80] T76369 INDICATI Clinical trial Mature B-cell lymphoma [ICD-11: 2A85] T76369 INDICATI Approved Peroxisomal disease [ICD-11: 5C57] T76369 INDICATI Approved Synthesis disorder [ICD-11: 5C52-5C59] T76396 TARGETID T76396 T76396 TARGNAME Geranylgeranyl transferase I (GGTase-I) T76396 INDICATI Phase 1 Lymphoma [ICD-11: 2A80-2A86] T76396 INDICATI Terminated Solid tumour/cancer [ICD-11: 2A00-2F9Z] T76414 TARGETID T76414 T76414 TARGNAME Glutamate receptor ionotropic NMDA 2B (NMDAR2B) T76414 INDICATI Approved Alpha-1-antitrypsin deficiency [ICD-11: 5C5A] T76414 INDICATI Terminated Alzheimer disease [ICD-11: 8A20] T76414 INDICATI Phase 1 Cardiac arrest [ICD-11: MC82] T76414 INDICATI Terminated Cerebral ischaemia [ICD-11: 8B1Z] T76414 INDICATI Investigative Cerebral ischaemic stroke [ICD-11: 8B11] T76414 INDICATI Withdrawn from market Chronic pain [ICD-11: MG30] T76414 INDICATI Phase 2 Depression [ICD-11: 6A70-6A7Z] T76414 INDICATI Phase 1 Dissociative neurological symptom disorder [ICD-11: 6B60] T76414 INDICATI Phase 1 Epilepsy/seizure [ICD-11: 8A61-8A6Z] T76414 INDICATI Discontinued in Phase 2 General pain disorder [ICD-11: 8E43] T76414 INDICATI Investigative Intracranial injury [ICD-11: NA07] T76414 INDICATI Phase 2 Multiple sclerosis [ICD-11: 8A40] T76414 INDICATI Terminated Neurodegenerative disorder [ICD-11: 8A20-8A23] T76414 INDICATI Phase 2 Neuropathy [ICD-11: 8C0Z] T76414 INDICATI Phase 2 Parkinsonism [ICD-11: 8A00] T76497 TARGETID T76497 T76497 TARGNAME Phosphogluconate dehydrogenase (PGD) T76497 INDICATI Approved Pituitary gland disorder [ICD-11: 5A60-5A61] T76630 TARGETID T76630 T76630 TARGNAME Cambridge pathology 1 antigen (CD52) T76630 INDICATI Approved Mature B-cell leukaemia [ICD-11: 2A82] T76630 INDICATI Approved Multiple sclerosis [ICD-11: 8A40] T76685 TARGETID T76685 T76685 TARGNAME Cannabinoid receptor 1 (CB1) T76685 INDICATI Phase 1 Acute diabete complication [ICD-11: 5A2Y] T76685 INDICATI Approved Anorexia nervosa [ICD-11: 6B80] T76685 INDICATI Phase 2 Cannabis use disorder [ICD-11: 6C41] T76685 INDICATI Investigative Central nervous system disease [ICD-11: 8A04-8D87] T76685 INDICATI Discontinued in Phase 1 Cerebral ischaemia [ICD-11: 8B1Z] T76685 INDICATI Phase 2 Chronic kidney disease [ICD-11: GB61] T76685 INDICATI Phase 2 Colorectal cancer [ICD-11: 2B91] T76685 INDICATI Patented General pain disorder [ICD-11: 8E43] T76685 INDICATI Discontinued in Phase 1 Hypertension [ICD-11: BA00-BA04] T76685 INDICATI Phase 2 Inborn lipid metabolism error [ICD-11: 5C52] T76685 INDICATI Approved Insomnia [ICD-11: 7A00-7A0Z] T76685 INDICATI Discontinued in Phase 2 Ischemia [ICD-11: 8B10-8B11] T76685 INDICATI Patented Low bone mass disorder [ICD-11: FB83] T76685 INDICATI Phase 1 Metabolic disorder [ICD-11: 5C50-5D2Z] T76685 INDICATI Phase 2/3 Nausea/vomiting [ICD-11: MD90] T76685 INDICATI Phase 2 Nicotine use disorder [ICD-11: 6C4A] T76685 INDICATI Approved Obesity [ICD-11: 5B80-5B81] T76685 INDICATI Investigative Ovarian cancer [ICD-11: 2C73] T76685 INDICATI Discontinued in Phase 2 Pain [ICD-11: MG30-MG3Z] T76685 INDICATI Patented Prostate cancer [ICD-11: 2C82] T76685 INDICATI Investigative Psychoactive substances use disorder [ICD-11: 6C4G] T76685 INDICATI Discontinued in Phase 2 Psychotic disorder [ICD-11: 6A20-6A25] T76685 INDICATI Discontinued in Phase 1 Schizophrenia [ICD-11: 6A20] T76685 INDICATI Phase 1 Type 2 diabetes mellitus [ICD-11: 5A11] T76685 INDICATI Phase 3 Urinary tract infection [ICD-11: GC08] T76685 INDICATI Discontinued in Phase 2 Zoster [ICD-11: 1E91] T76701 TARGETID T76701 T76701 TARGNAME Cyclin D1/E2F pathway (CCND1/E2F pathway) T76701 INDICATI Discontinued in Phase 2 Qualitative platelet defect [ICD-11: 3B62] T76846 TARGETID T76846 T76846 TARGNAME Melanocortin receptor 3 (MC3R) T76846 INDICATI Preclinical Obesity [ICD-11: 5B80-5B81] T76846 INDICATI Preclinical Sexual dysfunction [ICD-11: HA00-HA01] T76846 INDICATI Preclinical Type 2 diabetes mellitus [ICD-11: 5A11] T76855 TARGETID T76855 T76855 TARGNAME Staphylococcus Elongation factor Tu (Stap-coc tuf) T76855 INDICATI Phase 2 Acne vulgaris [ICD-11: ED80] T76855 INDICATI Phase 1 Bacterial infection [ICD-11: 1A00-1C4Z] T76904 TARGETID T76904 T76904 TARGNAME Catechol-O-methyl-transferase (COMT) T76904 INDICATI Phase 2 Depression [ICD-11: 6A70-6A7Z] T76904 INDICATI Discontinued in Phase 2 Pain [ICD-11: MG30-MG3Z] T76904 INDICATI Approved Parkinsonism [ICD-11: 8A00] T76904 INDICATI Phase 3 Restless legs syndrome [ICD-11: 7A80] T76904 INDICATI Preclinical Schizophrenia [ICD-11: 6A20] T76904 INDICATI Investigative Type 2 diabetes mellitus [ICD-11: 5A11] T76910 TARGETID T76910 T76910 TARGNAME Glycogen synthase kinase-3 alpha (GSK-3A) T76910 INDICATI Phase 2 Acute myeloid leukaemia [ICD-11: 2A60] T76910 INDICATI Patented Allergic/hypersensitivity disorder [ICD-11: 4A80-4A8Z] T76910 INDICATI Patented Brain cancer [ICD-11: 2A00] T76910 INDICATI Approved Epilepsy/seizure [ICD-11: 8A61-8A6Z] T76910 INDICATI Phase 2 Fragile X chromosome [ICD-11: LD55] T76910 INDICATI Patented Ovarian cancer [ICD-11: 2C73] T76910 INDICATI Phase 2 Substance abuse [ICD-11: 6C40] T76910 INDICATI Patented Transplant rejection [ICD-11: NE84] T76914 TARGETID T76914 T76914 TARGNAME Voltage-gated potassium channel Kv1.3 (KCNA3) T76914 INDICATI Phase 1b/2a Idiopathic inflammatory myopathy [ICD-11: 4A41] T76914 INDICATI Terminated Postoperative inflammation [ICD-11: 1A00-CA43] T76914 INDICATI Phase 1b/2a Psoriasis [ICD-11: EA90] T76914 INDICATI Phase 1 Psoriatic arthritis [ICD-11: FA21] T76937 TARGETID T76937 T76937 TARGNAME Voltage-gated sodium channel alpha Nav1.3 (SCN3A) T76937 INDICATI Approved Angina pectoris [ICD-11: BA40] T76937 INDICATI Discontinued in Phase 2 Dissociative neurological symptom disorder [ICD-11: 6B60] T76937 INDICATI Investigative Pain [ICD-11: MG30-MG3Z] T77009 TARGETID T77009 T77009 TARGNAME Thioredoxin reductase (PRDX5) T77009 INDICATI Approved Brain cancer [ICD-11: 2A00] T77009 INDICATI Phase 3 Human immunodeficiency virus disease [ICD-11: 1C60-1C62] T77009 INDICATI Phase 1/2 Malignant haematopoietic neoplasm [ICD-11: 2B33] T77009 INDICATI Phase 1/2 Mature B-cell leukaemia [ICD-11: 2A82] T77009 INDICATI Phase 1/2 Mature B-cell lymphoma [ICD-11: 2A85] T77158 TARGETID T77158 T77158 TARGNAME Protein synthesis (hPRO synth) T77158 INDICATI Phase 2 Bacterial infection [ICD-11: 1A00-1C4Z] T77158 INDICATI Phase 2 Infectious meningitis [ICD-11: 1D01] T77158 INDICATI Phase 2 Melioidosis [ICD-11: 1C42] T77158 INDICATI Phase 2 Skin and skin-structure infection [ICD-11: 1F28-1G0Z] T77158 INDICATI Discontinued in Phase 2 Solid tumour/cancer [ICD-11: 2A00-2F9Z] T77190 TARGETID T77190 T77190 TARGNAME SLIT and NTRK-like family member 6 (SLITRK6) T77190 INDICATI Phase 1 Bladder cancer [ICD-11: 2C94] T77190 INDICATI Phase 1 Ureteral cancer [ICD-11: 2C92] T77195 TARGETID T77195 T77195 TARGNAME NADH dehydrogenase (MT-ND3) T77195 INDICATI Approved Parkinsonism [ICD-11: 8A00] T77236 TARGETID T77236 T77236 TARGNAME Cathepsin F (CTSF) T77236 INDICATI Patented Bone cancer [ICD-11: 2B5Z] T77236 INDICATI Patented Chronic obstructive pulmonary disease [ICD-11: CA22] T77236 INDICATI Patented Chronic pain [ICD-11: MG30] T77236 INDICATI Patented Digestive system disease [ICD-11: DE2Z] T77236 INDICATI Patented Hepatic fibrosis/cirrhosis [ICD-11: DB93] T77236 INDICATI Patented Multiple sclerosis [ICD-11: 8A40] T77236 INDICATI Patented Psoriasis [ICD-11: EA90] T77350 TARGETID T77350 T77350 TARGNAME Proteasome beta-8 (PS beta-8) T77350 INDICATI Phase 1 Multiple myeloma [ICD-11: 2A83] T77365 TARGETID T77365 T77365 TARGNAME Adenosine A2a receptor (ADORA2A) T77365 INDICATI Discontinued in Phase 3 Alzheimer disease [ICD-11: 8A20] T77365 INDICATI Phase 1/2 Arterial occlusive disease [ICD-11: BD40] T77365 INDICATI Phase 1 Choreiform disorder [ICD-11: 8A01] T77365 INDICATI Phase 2 Chronic obstructive pulmonary disease [ICD-11: CA22] T77365 INDICATI Phase 1/2 Colorectal cancer [ICD-11: 2B91] T77365 INDICATI Phase 3 Coronary atherosclerosis [ICD-11: BA80] T77365 INDICATI Phase 2 Diabetic foot ulcer [ICD-11: BD54] T77365 INDICATI Discontinued in Phase 1 General pain disorder [ICD-11: 8E43] T77365 INDICATI Phase 1/2 Glaucoma [ICD-11: 9C61] T77365 INDICATI Phase 2 Heart failure [ICD-11: BD10-BD1Z] T77365 INDICATI Phase 2 Hyper-lipoproteinaemia [ICD-11: 5C80] T77365 INDICATI Phase 3 Hypertension [ICD-11: BA00-BA04] T77365 INDICATI Phase 1/2 Lung cancer [ICD-11: 2C25] T77365 INDICATI Terminated Multiple sclerosis [ICD-11: 8A40] T77365 INDICATI Approved Orthostatic hypotension [ICD-11: BA21] T77365 INDICATI Discontinued in Phase 2 Pain [ICD-11: MG30-MG3Z] T77365 INDICATI Approved Parkinsonism [ICD-11: 8A00] T77365 INDICATI Phase 2 Prostate cancer [ICD-11: 2C82] T77365 INDICATI Approved Radionuclide imaging [ICD-11: N.A.] T77365 INDICATI Discontinued in Phase 2 Schizophrenia [ICD-11: 6A20] T77365 INDICATI Phase 1 Solid tumour/cancer [ICD-11: 2A00-2F9Z] T77365 INDICATI Phase 1 Unspecific substance use disorder [ICD-11: 6C4Z] T77365 INDICATI Phase 1 Vasomotor/allergic rhinitis [ICD-11: CA08] T77400 TARGETID T77400 T77400 TARGNAME Phosphodiesterase 2A (PDE2A) T77400 INDICATI Phase 2 Inborn purine/pyrimidine/nucleotide metabolism error [ICD-11: 5C55] T77400 INDICATI Phase 2 Indeterminate colitis [ICD-11: DD72] T77400 INDICATI Phase 2 Irritable bowel syndrome [ICD-11: DD91] T77400 INDICATI Phase 1 Mood disorder [ICD-11: 6A60-6E23] T77473 TARGETID T77473 T77473 TARGNAME Translationally-controlled tumor protein (TPT1) T77473 INDICATI Discontinued in Phase 1/2 Acute myeloid leukaemia [ICD-11: 2A60] T77515 TARGETID T77515 T77515 TARGNAME MHC class I NK cell receptor 2DS2 (CD158j) T77515 INDICATI Phase 2 Multiple myeloma [ICD-11: 2A83] T77534 TARGETID T77534 T77534 TARGNAME Phospholipase C (PLC) T77534 INDICATI Terminated Leukaemia [ICD-11: 2A60-2B33] T77534 INDICATI Phase 1 Solid tumour/cancer [ICD-11: 2A00-2F9Z] T77594 TARGETID T77594 T77594 TARGNAME Endoplasmic reticulum chaperone BiP (HSPA5) T77594 INDICATI Phase 1 Melanoma [ICD-11: 2C30] T77594 INDICATI Phase 1 Solid tumour/cancer [ICD-11: 2A00-2F9Z] T77613 TARGETID T77613 T77613 TARGNAME Phosphodiesterase 1B (PDE1B) T77613 INDICATI Investigative Mild neurocognitive disorder [ICD-11: 6D71] T77645 TARGETID T77645 T77645 TARGNAME TRAIL receptor 1 (TRAIL-R1) T77645 INDICATI Phase 2 Lung cancer [ICD-11: 2C25] T77645 INDICATI Discontinued in Phase 1/2 Solid tumour/cancer [ICD-11: 2A00-2F9Z] T77664 TARGETID T77664 T77664 TARGNAME Interferon-gamma (IFNG) T77664 INDICATI Approved Adaptive immunity immunodeficiency [ICD-11: 4A01] T77664 INDICATI Phase 1 Basal cell carcinoma [ICD-11: 2C32] T77664 INDICATI Discontinued in Phase 2 B-cell lymphoma [ICD-11: 2A86] T77664 INDICATI Phase 1 Cutaneous lupus erythematosus [ICD-11: EB50-EB5Z] T77664 INDICATI Phase 1/2 Human immunodeficiency virus disease [ICD-11: 1C60-1C62] T77664 INDICATI Discontinued in Phase 2 Indeterminate colitis [ICD-11: DD72] T77664 INDICATI Phase 1 Lupus erythematosus [ICD-11: 4A40] T77664 INDICATI Phase 3 Multiple sclerosis [ICD-11: 8A40] T77664 INDICATI Preclinical Prostate cancer [ICD-11: 2C82] T77664 INDICATI Phase 3 Psoriasis [ICD-11: EA90] T77664 INDICATI Discontinued in Phase 2 Rheumatoid arthritis [ICD-11: FA20] T77764 TARGETID T77764 T77764 TARGNAME Aurora B messenger RNA (AURKB mRNA) T77764 INDICATI Phase 2 Prostate cancer [ICD-11: 2C82] T77796 TARGETID T77796 T77796 TARGNAME Thyrotropin-releasing hormone receptor (TRHR) T77796 INDICATI Approved Central nervous system disease [ICD-11: 8A04-8D87] T77796 INDICATI Investigative Endocrine disease [ICD-11: 5B3Z] T77796 INDICATI Discontinued in Phase 2 Mild neurocognitive disorder [ICD-11: 6D71] T77796 INDICATI Discontinued in Phase 3 Neurodegenerative disorder [ICD-11: 8A20-8A23] T77796 INDICATI Phase 3 Pain [ICD-11: MG30-MG3Z] T77913 TARGETID T77913 T77913 TARGNAME Histamine H1 receptor (H1R) T77913 INDICATI Approved Allergic/hypersensitivity disorder [ICD-11: 4A80-4A8Z] T77913 INDICATI Phase 1 Alzheimer disease [ICD-11: 8A20] T77913 INDICATI Approved Anxiety disorder [ICD-11: 6B00-6B0Z] T77913 INDICATI Phase 2 Asthma [ICD-11: CA23] T77913 INDICATI Phase 1 Attention deficit hyperactivity disorder [ICD-11: 6A05] T77913 INDICATI Phase 1 Bipolar disorder [ICD-11: 6A60] T77913 INDICATI Approved Breathing abnormality [ICD-11: MD11] T77913 INDICATI Approved Conjunctiva disorder [ICD-11: 9A60] T77913 INDICATI Withdrawn from market Corneal disease [ICD-11: 9A76-9A78] T77913 INDICATI Approved Cough [ICD-11: MD12] T77913 INDICATI Approved Depression [ICD-11: 6A70-6A7Z] T77913 INDICATI Approved Episodic vestibular syndrome [ICD-11: AB31] T77913 INDICATI Approved Headache [ICD-11: 8A80-8A84] T77913 INDICATI Approved Insomnia [ICD-11: 7A00-7A0Z] T77913 INDICATI Approved Morning sickness disorder [ICD-11: SC00] T77913 INDICATI Approved Nasopharyngitis [ICD-11: CA00] T77913 INDICATI Approved Nausea/vomiting [ICD-11: MD90] T77913 INDICATI Phase 2 Obesity [ICD-11: 5B80-5B81] T77913 INDICATI Discontinued in Phase 2 Pain [ICD-11: MG30-MG3Z] T77913 INDICATI Approved Parkinsonism [ICD-11: 8A00] T77913 INDICATI Approved Pruritus [ICD-11: EC90] T77913 INDICATI Phase 2 Respiratory system disease [ICD-11: CB40-CB7Z] T77913 INDICATI Approved Rheumatoid arthritis [ICD-11: FA20] T77913 INDICATI Phase 2 Schizophrenia [ICD-11: 6A20] T77913 INDICATI Approved Sleep-wake disorder [ICD-11: 7A00-7B2Z] T77913 INDICATI Approved Vasomotor/allergic rhinitis [ICD-11: CA08] T77990 TARGETID T77990 T77990 TARGNAME Staphylococcus Iron-regulated surface determinant B (Stap-coc isdB) T77990 INDICATI Phase 2/3 Staphylococcal/streptococcal disease [ICD-11: 1B5Y] T78111 TARGETID T78111 T78111 TARGNAME Nicotinic acetylcholine receptor (nAChR) T78111 INDICATI Discontinued in Preregistration Abnormal micturition [ICD-11: MF50] T78111 INDICATI Discontinued in Phase 2 Alzheimer disease [ICD-11: 8A20] T78111 INDICATI Phase 2 Asthma [ICD-11: CA23] T78111 INDICATI Phase 1/2 Attention deficit hyperactivity disorder [ICD-11: 6A05] T78111 INDICATI Approved Corneal disease [ICD-11: 9A76-9A78] T78111 INDICATI Phase 1/2 Diabetic foot ulcer [ICD-11: BD54] T78111 INDICATI Approved Essential hypertension [ICD-11: BA00] T78111 INDICATI Phase 1 Human immunodeficiency virus disease [ICD-11: 1C60-1C62] T78111 INDICATI Approved Insecticide [ICD-11: N.A.] T78111 INDICATI Discontinued in Phase 2 Mild neurocognitive disorder [ICD-11: 6D71] T78111 INDICATI Phase 2 Mood disorder [ICD-11: 6A60-6E23] T78111 INDICATI Phase 1 Motor neuron disease [ICD-11: 8B60] T78111 INDICATI Phase 1 Multiple sclerosis [ICD-11: 8A40] T78111 INDICATI Phase 2 Neuropathy [ICD-11: 8C0Z] T78111 INDICATI Approved Nicotine use disorder [ICD-11: 6C4A] T78111 INDICATI Discontinued in Phase 1 Pain [ICD-11: MG30-MG3Z] T78111 INDICATI Phase 2 Parkinsonism [ICD-11: 8A00] T78111 INDICATI Discontinued in Phase 1 Rheumatoid arthritis [ICD-11: FA20] T78111 INDICATI Discontinued in Phase 2 Schizophrenia [ICD-11: 6A20] T78114 TARGETID T78114 T78114 TARGNAME Complement decay-accelerating factor (CD55) T78114 INDICATI Phase 1/2 Bladder cancer [ICD-11: 2C94] T78114 INDICATI Phase 2 Brain cancer [ICD-11: 2A00] T78114 INDICATI Discontinued in Phase 1 Colorectal cancer [ICD-11: 2B91] T78114 INDICATI Phase 1/2 Lung cancer [ICD-11: 2C25] T78114 INDICATI Phase 1/2 Melanoma [ICD-11: 2C30] T78114 INDICATI Phase 1/2 Prostate cancer [ICD-11: 2C82] T78114 INDICATI Phase 1/2 Stomach cancer [ICD-11: 2B72] T78173 TARGETID T78173 T78173 TARGNAME Candida Squalene epoxidase (Candi ERG1) T78173 INDICATI Approved Dermatophytosis [ICD-11: 1F28] T78173 INDICATI Approved Fungal infection [ICD-11: 1F29-1F2F] T78173 INDICATI Phase 2 Nail/perionychium infection [ICD-11: EE12] T78198 TARGETID T78198 T78198 TARGNAME Purine nucleoside phosphorylase (PNP) T78198 INDICATI Phase 2 Diabetes mellitus [ICD-11: 5A10] T78198 INDICATI Phase 2 Gout [ICD-11: FA25] T78198 INDICATI Phase 1/2 Malignant haematopoietic neoplasm [ICD-11: 2B33] T78198 INDICATI Phase 1/2 Mycosis fungoides [ICD-11: 2B01] T78198 INDICATI Phase 2 Psoriasis [ICD-11: EA90] T78198 INDICATI Discontinued in Phase 1 Rheumatoid arthritis [ICD-11: FA20] T78244 TARGETID T78244 T78244 TARGNAME Vasoactive intestinal polypeptide receptor (VIPR) T78244 INDICATI Discontinued in Phase 2 Asthma [ICD-11: CA23] T78277 TARGETID T78277 T78277 TARGNAME Asparaginase (ASRGL1) T78277 INDICATI Approved Malignant haematopoietic neoplasm [ICD-11: 2B33] T78277 INDICATI Phase 3 Mature B-cell lymphoma [ICD-11: 2A85] T78277 INDICATI Phase 1 Pancreatic cancer [ICD-11: 2C10] T78318 TARGETID T78318 T78318 TARGNAME Calcium-activated potassium channel KCa4.2 (KCNT2) T78318 INDICATI Phase 2 Acute myeloid leukaemia [ICD-11: 2A60] T78318 INDICATI Phase 2 Hodgkin lymphoma [ICD-11: 2B30] T78319 TARGETID T78319 T78319 TARGNAME Extracellular matrix receptor III (CD44) T78319 INDICATI Phase 2 Ovarian cancer [ICD-11: 2C73] T78319 INDICATI Phase 2 Retinopathy [ICD-11: 9B71] T78319 INDICATI Phase 1 Solid tumour/cancer [ICD-11: 2A00-2F9Z] T78356 TARGETID T78356 T78356 TARGNAME Thromboxane-A synthase (TBXAS1) T78356 INDICATI Phase 3 Angina pectoris [ICD-11: BA40] T78356 INDICATI Phase 2 Asthma [ICD-11: CA23] T78356 INDICATI Discontinued in Phase 2 Cardiac arrhythmia [ICD-11: BC9Z] T78356 INDICATI Phase 1 Indeterminate colitis [ICD-11: DD72] T78356 INDICATI Discontinued in Phase 2 Nephritic syndrome [ICD-11: GB40] T78356 INDICATI Phase 1 Thrombosis [ICD-11: DB61-GB90] T78356 INDICATI Phase 2 Type 2 diabetes mellitus [ICD-11: 5A11] T78381 TARGETID T78381 T78381 TARGNAME Interleukin-29 (IL29) T78381 INDICATI Phase 3 Acute myeloid leukaemia [ICD-11: 2A60] T78381 INDICATI Phase 1 Virus infection [ICD-11: 1A24-1D9Z] T78383 TARGETID T78383 T78383 TARGNAME Chemosensory receptor (CheR) T78383 INDICATI Phase 2 Depression [ICD-11: 6A70-6A7Z] T78393 TARGETID T78393 T78393 TARGNAME MIF messenger RNA (MIF mRNA) T78393 INDICATI Investigative Solid tumour/cancer [ICD-11: 2A00-2F9Z] T78429 TARGETID T78429 T78429 TARGNAME Inhibitor of nuclear factor kappa-B kinase beta (IKKB) T78429 INDICATI Phase 1 Acne vulgaris [ICD-11: ED80] T78429 INDICATI Phase 2 Alzheimer disease [ICD-11: 8A20] T78429 INDICATI Approved Mature B-cell lymphoma [ICD-11: 2A85] T78429 INDICATI Phase 2 Osteoarthritis [ICD-11: FA00-FA05] T78429 INDICATI Discontinued in Phase 1 Rheumatoid arthritis [ICD-11: FA20] T78510 TARGETID T78510 T78510 TARGNAME Cyclic nucleotide-gated channel alpha-3 (CNGA3) T78510 INDICATI Phase 1/2 Inherited retinal dystrophy [ICD-11: 9B70] T78552 TARGETID T78552 T78552 TARGNAME Membrane inhibitor of reactive lysis (CD59) T78552 INDICATI Phase 2 Macular degeneration [ICD-11: 9B75] T78552 INDICATI Phase 2 Retinopathy [ICD-11: 9B71] T78567 TARGETID T78567 T78567 TARGNAME Oncostatin-M-specific receptor beta (OSMR) T78567 INDICATI Phase 1 Idiopathic interstitial pneumonitis [ICD-11: CB03] T78567 INDICATI Phase 1 Pruritus [ICD-11: EC90] T78581 TARGETID T78581 T78581 TARGNAME Galanin receptor type 1 (GAL1-R) T78581 INDICATI Investigative Epilepsy/seizure [ICD-11: 8A61-8A6Z] T78585 TARGETID T78585 T78585 TARGNAME Interleukin-5 (IL5) T78585 INDICATI Approved Asthma [ICD-11: CA23] T78585 INDICATI Phase 3 Chronic obstructive pulmonary disease [ICD-11: CA22] T78585 INDICATI Phase 3 Chronic rhinosinusitis ICD-11: CA0A T78585 INDICATI Phase 3 Myeloproliferative neoplasm [ICD-11: 2A20] T78585 INDICATI Phase 3 Pulmonary eosinophilia [ICD-11: CB02] T78585 INDICATI Phase 3 Vasculitis [ICD-11: 4A44] T78590 TARGETID T78590 T78590 TARGNAME Polymorphonuclear neutrophil adhesion (PMNA) T78590 INDICATI Discontinued in Phase 1 Postoperative inflammation [ICD-11: 1A00-CA43] T78656 TARGETID T78656 T78656 TARGNAME 5-HT 1F receptor (HTR1F) T78656 INDICATI Approved Migraine [ICD-11: 8A80] T78656 INDICATI Approved Pituitary gland disorder [ICD-11: 5A60-5A61] T78692 TARGETID T78692 T78692 TARGNAME Inward rectifier potassium channel Kir3.4 (KCNJ5) T78692 INDICATI Phase 2 Acute myeloid leukaemia [ICD-11: 2A60] T78692 INDICATI Phase 2 Hodgkin lymphoma [ICD-11: 2B30] T78709 TARGETID T78709 T78709 TARGNAME 5-HT 1A receptor (HTR1A) T78709 INDICATI Discontinued in Phase 2 Abnormal micturition [ICD-11: MF50] T78709 INDICATI Withdrawn from market Addictive disorder [ICD-11: 6C50-6C5Z] T78709 INDICATI Phase 2 Alzheimer disease [ICD-11: 8A20] T78709 INDICATI Approved Anxiety disorder [ICD-11: 6B00-6B0Z] T78709 INDICATI Phase 3 Attention deficit hyperactivity disorder [ICD-11: 6A05] T78709 INDICATI Terminated Binge eating disorder [ICD-11: 6B82] T78709 INDICATI Phase 1 Bipolar disorder [ICD-11: 6A60] T78709 INDICATI Phase 2 Bulimia nervosa [ICD-11: 6B81] T78709 INDICATI Phase 2 Coronary atherosclerosis [ICD-11: BA80] T78709 INDICATI Phase 2 Dementia [ICD-11: 6D80-6D8Z] T78709 INDICATI Approved Depression [ICD-11: 6A70-6A7Z] T78709 INDICATI Discontinued in Phase 1 Dystonic disorder [ICD-11: 8A02] T78709 INDICATI Phase 1 Ejaculatory dysfunction [ICD-11: HA03] T78709 INDICATI Discontinued in Phase 2 Episode [ICD-11: N.A.] T78709 INDICATI Approved Hypertension [ICD-11: BA00-BA04] T78709 INDICATI Phase 2 Hypoactive sexual desire dysfunction [ICD-11: HA00] T78709 INDICATI Phase 2 Insomnia [ICD-11: 7A00-7A0Z] T78709 INDICATI Phase 2/3 Intellectual development disorder [ICD-11: LD90] T78709 INDICATI Phase 3 Juvenile idiopathic arthritis [ICD-11: FA24] T78709 INDICATI Phase 2 Malignant haematopoietic neoplasm [ICD-11: 2B33] T78709 INDICATI Investigative Mental/behavioural/neurodevelopmental disorder [ICD-11: 6E20-6E8Z] T78709 INDICATI Approved Migraine [ICD-11: 8A80] T78709 INDICATI Phase 2/3 Mild neurocognitive disorder [ICD-11: 6D71] T78709 INDICATI Approved Mood disorder [ICD-11: 6A60-6E23] T78709 INDICATI Discontinued in Phase 3 Muscular atrophy [ICD-11: 8B61] T78709 INDICATI Terminated Pain [ICD-11: MG30-MG3Z] T78709 INDICATI Phase 2 Parkinsonism [ICD-11: 8A00] T78709 INDICATI Phase 1/2 Postoperative inflammation [ICD-11: 1A00-CA43] T78709 INDICATI Preclinical Post-traumatic stress disorder [ICD-11: 6B40] T78709 INDICATI Patented Prostate hyperplasia [ICD-11: GA90] T78709 INDICATI Phase 3 Psoriasis [ICD-11: EA90] T78709 INDICATI Phase 2 Psychotic disorder [ICD-11: 6A20-6A25] T78709 INDICATI Phase 3 Schizophrenia [ICD-11: 6A20] T78709 INDICATI Phase 3 Sexual dysfunction [ICD-11: HA00-HA01] T78709 INDICATI Discontinued in Phase 3 Skin/mucosal anomaly [ICD-11: LD27] T78709 INDICATI Phase 2 Social anxiety disorder [ICD-11: 6B04] T78709 INDICATI Phase 2 Tonus and reflex abnormality [ICD-11: MB47] T78874 TARGETID T78874 T78874 TARGNAME Protein kinase (PK) T78874 INDICATI Phase 2 Acute myeloid leukaemia [ICD-11: 2A60] T78874 INDICATI Phase 2 Asthma [ICD-11: CA23] T78874 INDICATI Phase 2 Biliary tract cancer [ICD-11: 2C17] T78874 INDICATI Phase 1/2 Brain cancer [ICD-11: 2A00] T78874 INDICATI Phase 2 Breast cancer [ICD-11: 2C60-2C6Y] T78874 INDICATI Phase 1/2 Glaucoma [ICD-11: 9C61] T78874 INDICATI Phase 2 Liver cancer [ICD-11: 2C12] T78874 INDICATI Phase 2 Lung cancer [ICD-11: 2C25] T78874 INDICATI Phase 2/3 Solid tumour/cancer [ICD-11: 2A00-2F9Z] T78874 INDICATI Discontinued in Phase 1 Virus infection [ICD-11: 1A24-1D9Z] T78890 TARGETID T78890 T78890 TARGNAME Tissue factor pathway inhibitor (TFPI) T78890 INDICATI Phase 3 Christmas disease [ICD-11: 3B11] T78890 INDICATI Phase 3 Coagulation defect [ICD-11: 3B10] T78890 INDICATI Phase 3 Sepsis [ICD-11: 1G40-1G41] T78892 TARGETID T78892 T78892 TARGNAME ITGA4 messenger RNA (ITGA4 mRNA) T78892 INDICATI Phase 2 Multiple sclerosis [ICD-11: 8A40] T78915 TARGETID T78915 T78915 TARGNAME Tryptophan 5-hydroxylase 1 (TPH1) T78915 INDICATI Phase 2 Psychotic disorder [ICD-11: 6A20-6A25] T78915 INDICATI Phase 1 Pulmonary hypertension [ICD-11: BB01] T78932 TARGETID T78932 T78932 TARGNAME TYK2 tyrosine kinase (TYK2) T78932 INDICATI Phase 2 Asthma [ICD-11: CA23] T78932 INDICATI Approved Psoriasis [ICD-11: EA90] T78932 INDICATI Phase 2 Psoriatic arthritis [ICD-11: FA21] T78937 TARGETID T78937 T78937 TARGNAME Ribosome A (hRA) T78937 INDICATI Approved Bacterial infection [ICD-11: 1A00-1C4Z] T78937 INDICATI Approved Myeloproliferative neoplasm [ICD-11: 2A20] T79001 TARGETID T79001 T79001 TARGNAME Bacterial Chorismate synthase (Bact aroC) T79001 INDICATI Terminated Bacterial infection [ICD-11: 1A00-1C4Z] T79027 TARGETID T79027 T79027 TARGNAME Cytidine deaminase (CDA) T79027 INDICATI Phase 2 Solid tumour/cancer [ICD-11: 2A00-2F9Z] T79031 TARGETID T79031 T79031 TARGNAME Beta-secretase 1 (BACE1) T79031 INDICATI Phase 3 Alzheimer disease [ICD-11: 8A20] T79051 TARGETID T79051 T79051 TARGNAME EWS-FLI1 fusion gene mRNA (EWS-FLI1 mRNA) T79051 INDICATI Phase 1 Ewing sarcoma [ICD-11: 2B52] T79062 TARGETID T79062 T79062 TARGNAME 5-HT 7 receptor (HTR7) T79062 INDICATI Phase 1 Alzheimer disease [ICD-11: 8A20] T79062 INDICATI Phase 1 Attention deficit hyperactivity disorder [ICD-11: 6A05] T79062 INDICATI Phase 1 Bipolar disorder [ICD-11: 6A60] T79062 INDICATI Phase 2 Depression [ICD-11: 6A70-6A7Z] T79062 INDICATI Investigative Mental/behavioural/neurodevelopmental disorder [ICD-11: 6E20-6E8Z] T79062 INDICATI Phase 2 Mild neurocognitive disorder [ICD-11: 6D71] T79062 INDICATI Phase 1 Parkinsonism [ICD-11: 8A00] T79062 INDICATI Phase 2 Schizophrenia [ICD-11: 6A20] T79062 INDICATI Terminated Sleep-wake disorder [ICD-11: 7A00-7B2Z] T79068 TARGETID T79068 T79068 TARGNAME Bacterial Fatty acid synthetase I (Bact inhA) T79068 INDICATI Phase 2 Bacterial infection [ICD-11: 1A00-1C4Z] T79068 INDICATI Approved HIV-infected patients with tuberculosis [ICD-11: 1B10-1B14] T79068 INDICATI Terminated Malaria [ICD-11: 1F40-1F45] T79068 INDICATI Approved Mycobacterium infection [ICD-11: 1B10-1B21] T79157 TARGETID T79157 T79157 TARGNAME Epiregulin (EREG) T79157 INDICATI Phase 1/2 Chronic kidney disease [ICD-11: GB61] T79160 TARGETID T79160 T79160 TARGNAME Glial cell line-derived neurotrophic factor (GDNF) T79160 INDICATI Phase 1/2 Muscular atrophy [ICD-11: 8B61] T79162 TARGETID T79162 T79162 TARGNAME R-spondin-3 (RSPO3) T79162 INDICATI Phase 1 Colorectal cancer [ICD-11: 2B91] T79162 INDICATI Phase 1 Solid tumour/cancer [ICD-11: 2A00-2F9Z] T79184 TARGETID T79184 T79184 TARGNAME Staphylococcus Accessory gene regulator protein A (Stap-coc agrA) T79184 INDICATI Preclinical Staphylococcal/streptococcal disease [ICD-11: 1B5Y] T79232 TARGETID T79232 T79232 TARGNAME Vasopressin V1a receptor (V1AR) T79232 INDICATI Approved Acute diabete complication [ICD-11: 5A2Y] T79232 INDICATI Phase 2 Anxiety disorder [ICD-11: 6B00-6B0Z] T79232 INDICATI Phase 2 Atopic eczema [ICD-11: EA80] T79232 INDICATI Approved Autism spectrum disorder [ICD-11: 6A02] T79232 INDICATI Discontinued in Phase 2 Cardiovascular disease [ICD-11: BA00-BE2Z] T79232 INDICATI Phase 3 Childbirth associated breast/lactation disorder [ICD-11: JB46] T79232 INDICATI Phase 2 Choreiform disorder [ICD-11: 8A01] T79232 INDICATI Phase 2 Depression [ICD-11: 6A70-6A7Z] T79232 INDICATI Phase 2 Female pelvic pain [ICD-11: GA34] T79232 INDICATI Preclinical Heart failure [ICD-11: BD10-BD1Z] T79232 INDICATI Approved Hypertension [ICD-11: BA00-BA04] T79232 INDICATI Approved Hypo-osmolality/hyponatraemia [ICD-11: 5C72] T79232 INDICATI Phase 1/2 Intermittent explosive disorder [ICD-11: 6C73] T79232 INDICATI Approved Localisation [ICD-11: N.A.] T79232 INDICATI Investigative Male infertility [ICD-11: GB04] T79232 INDICATI Phase 2 Post-traumatic stress disorder [ICD-11: 6B40] T79232 INDICATI Phase 2 Sepsis [ICD-11: 1G40-1G41] T79232 INDICATI Discontinued in Phase 1 Sexual dysfunction [ICD-11: HA00-HA01] T79249 TARGETID T79249 T79249 TARGNAME Thymidylate synthase messenger RNA (TYMS mRNA) T79249 INDICATI Investigative Colorectal cancer [ICD-11: 2B91] T79249 INDICATI Approved Solid tumour/cancer [ICD-11: 2A00-2F9Z] T79368 TARGETID T79368 T79368 TARGNAME CEBPA messenger RNA (CEBPA mRNA) T79368 INDICATI Phase 1/2 Liver cancer [ICD-11: 2C12] T79401 TARGETID T79401 T79401 TARGNAME Dengue virus Envelope (DENV E) T79401 INDICATI Preclinical Dengue fever [ICD-11: 1D2Z] T79422 TARGETID T79422 T79422 TARGNAME M1-prime segment of membrane-expressed IgE (M1 IgE) T79422 INDICATI Phase 2 Asthma [ICD-11: CA23] T79473 TARGETID T79473 T79473 TARGNAME Luteinizing hormone receptor (LHCGR) T79473 INDICATI Approved Female infertility [ICD-11: GA31] T79473 INDICATI Terminated Heart disease [ICD-11: BA41-BA42] T79473 INDICATI Discontinued in Phase 3 Leukaemia [ICD-11: 2A60-2B33] T79473 INDICATI Phase 1 Male infertility [ICD-11: GB04] T79473 INDICATI Phase 2 Myelodysplastic syndrome [ICD-11: 2A37] T79473 INDICATI Approved Pituitary gland disorder [ICD-11: 5A60-5A61] T79473 INDICATI Investigative Solid tumour/cancer [ICD-11: 2A00-2F9Z] T79534 TARGETID T79534 T79534 TARGNAME P450-dependent ergosterol synthesis (PDE synth) T79534 INDICATI Discontinued in Phase 2 Fungal infection [ICD-11: 1F29-1F2F] T79591 TARGETID T79591 T79591 TARGNAME Thyroid hormone receptor alpha (THRA) T79591 INDICATI Phase 3 Heart failure [ICD-11: BD10-BD1Z] T79591 INDICATI Approved Hyper-lipoproteinaemia [ICD-11: 5C80] T79591 INDICATI Approved Hypo-thyroidism [ICD-11: 5A00] T79591 INDICATI Clinical trial Skin postprocedural disorder [ICD-11: EL8Y] T79724 TARGETID T79724 T79724 TARGNAME Bacterial Hydroxymethyl-dihydropterin pyrophosphokinase (Bact folK) T79724 INDICATI Preclinical Schizophrenia [ICD-11: 6A20] T79747 TARGETID T79747 T79747 TARGNAME Protein-serine O-palmitoleoyltransferase porcupine (PORCN) T79747 INDICATI Phase 1 Idiopathic interstitial pneumonitis [ICD-11: CB03] T79747 INDICATI Phase 1 Solid tumour/cancer [ICD-11: 2A00-2F9Z] T79798 TARGETID T79798 T79798 TARGNAME MAP kinase p38 (MAPK12) T79798 INDICATI Phase 2 Alzheimer disease [ICD-11: 8A20] T79798 INDICATI Phase 2 Cardiomyopathy [ICD-11: BC43] T79798 INDICATI Discontinued in Phase 2 Cardiovascular disease [ICD-11: BA00-BE2Z] T79798 INDICATI Preclinical Chronic kidney disease [ICD-11: GB61] T79798 INDICATI Discontinued in Phase 2 Indeterminate colitis [ICD-11: DD72] T79798 INDICATI Phase 2 Lupus erythematosus [ICD-11: 4A40] T79798 INDICATI Phase 2 Osteoarthritis [ICD-11: FA00-FA05] T79798 INDICATI Phase 2 Pain [ICD-11: MG30-MG3Z] T79798 INDICATI Discontinued in Phase 2 Psoriasis [ICD-11: EA90] T79798 INDICATI Phase 2 Rheumatoid arthritis [ICD-11: FA20] T79798 INDICATI Approved (orphan drug) Thrombocytopenia [ICD-11: 3B64] T79961 TARGETID T79961 T79961 TARGNAME Muscarinic acetylcholine receptor M5 (CHRM5) T79961 INDICATI Approved Abnormal micturition [ICD-11: MF50] T79961 INDICATI Terminated Alzheimer disease [ICD-11: 8A20] T79961 INDICATI Approved Anterior uveitis [ICD-11: 9A96] T79961 INDICATI Approved Appearance/behaviour symptom [ICD-11: MB23] T79961 INDICATI Approved Asthma [ICD-11: CA23] T79961 INDICATI Investigative Attention deficit hyperactivity disorder [ICD-11: 6A05] T79961 INDICATI Approved (orphan drug) Brain disease [ICD-11: 8C70-8E61] T79961 INDICATI Approved Central and peripheral nervous disease [ICD-11: 8A04-8E7Z] T79961 INDICATI Approved Chronic obstructive pulmonary disease [ICD-11: CA22] T79961 INDICATI Approved Cognition symptoms/signs/clinical sympton [ICD-11: MB21] T79961 INDICATI Approved Cough [ICD-11: MD12] T79961 INDICATI Withdrawn from market Depression [ICD-11: 6A70-6A7Z] T79961 INDICATI Approved Digestive system disease [ICD-11: DE2Z] T79961 INDICATI Investigative Dissociative neurological symptom disorder [ICD-11: 6B60] T79961 INDICATI Approved Female pelvic pain [ICD-11: GA34] T79961 INDICATI Approved Functional bladder disorder [ICD-11: GC50] T79961 INDICATI Terminated Gastric ulcer [ICD-11: DA60] T79961 INDICATI Approved Gastritis [ICD-11: DA42] T79961 INDICATI Approved General examination [ICD-11: QA00] T79961 INDICATI Approved Glaucoma [ICD-11: 9C61] T79961 INDICATI Approved Hypertension [ICD-11: BA00-BA04] T79961 INDICATI Approved Infectious gastroenteritis/colitis [ICD-11: 1A40] T79961 INDICATI Approved Irritable bowel syndrome [ICD-11: DD91] T79961 INDICATI Discontinued in Phase 2 Mild neurocognitive disorder [ICD-11: 6D71] T79961 INDICATI Investigative Myasthenia gravis [ICD-11: 8C6Y] T79961 INDICATI Approved Nystagmus [ICD-11: 9C84] T79961 INDICATI Approved Oesophagus motility disorder [ICD-11: DA21] T79961 INDICATI Approved Pain [ICD-11: MG30-MG3Z] T79961 INDICATI Approved Pancreatitis [ICD-11: DC31-DC34] T79961 INDICATI Approved Parkinsonism [ICD-11: 8A00] T79961 INDICATI Approved Peptic ulcer [ICD-11: DA61] T79961 INDICATI Approved Polyuria [ICD-11: MF55] T79961 INDICATI Discontinued in Phase 1 Schizophrenia [ICD-11: 6A20] T79961 INDICATI Phase 3 Solid tumour/cancer [ICD-11: 2A00-2F9Z] T79961 INDICATI Approved Tonus and reflex abnormality [ICD-11: MB47] T79961 INDICATI Approved Unspecific substance harmful effect [ICD-11: NE6Z] T79961 INDICATI Approved Urgency [ICD-11: N.A.] T79961 INDICATI Investigative Vasomotor/allergic rhinitis [ICD-11: CA08] T80002 TARGETID T80002 T80002 TARGNAME Lymphocyte antigen 75 (LY75) T80002 INDICATI Phase 1 Breast cancer [ICD-11: 2C60-2C6Y] T80011 TARGETID T80011 T80011 TARGNAME eIF4E-BP2 messenger RNA (eIF4E-BP2 mRNA) T80011 INDICATI Phase 2 Lung cancer [ICD-11: 2C25] T80011 INDICATI Phase 2 Prostate cancer [ICD-11: 2C82] T80011 INDICATI Phase 2 Solid tumour/cancer [ICD-11: 2A00-2F9Z] T80020 TARGETID T80020 T80020 TARGNAME Neural cell adhesion molecule L1 (L1CAM) T80020 INDICATI Phase 1 Adrenal cancer [ICD-11: 2D11] T80020 INDICATI Phase 1 Brain cancer [ICD-11: 2A00] T80024 TARGETID T80024 T80024 TARGNAME Myostatin (MSTN) T80024 INDICATI Phase 1/2 Idiopathic inflammatory myopathy [ICD-11: 4A41] T80024 INDICATI Phase 2 Muscular atrophy [ICD-11: 8B61] T80024 INDICATI Phase 1/2 Muscular dystrophy [ICD-11: 8C70] T80024 INDICATI Phase 1/2 Retinopathy [ICD-11: 9B71] T80276 TARGETID T80276 T80276 TARGNAME PI3-kinase alpha (PIK3CA) T80276 INDICATI Approved Breast cancer [ICD-11: 2C60-2C6Y] T80276 INDICATI Phase 1/2 Colorectal cancer [ICD-11: 2B91] T80276 INDICATI Approved Follicular lymphoma [ICD-11: 2A80] T80276 INDICATI Approved Malignant haematopoietic neoplasm [ICD-11: 2B33] T80276 INDICATI Phase 2 Prostate cancer [ICD-11: 2C82] T80276 INDICATI Investigative Rheumatoid arthritis [ICD-11: FA20] T80276 INDICATI Phase 2/3 Solid tumour/cancer [ICD-11: 2A00-2F9Z] T80338 TARGETID T80338 T80338 TARGNAME Activin receptor type IIB (ACVR2B) T80338 INDICATI Investigative Nervous system paraneoplastic/autoimmune disorder [ICD-11: 8E4A] T80387 TARGETID T80387 T80387 TARGNAME GABA(A) receptor beta-2 (GABRB2) T80387 INDICATI Discontinued in Phase 1 Anxiety disorder [ICD-11: 6B00-6B0Z] T80387 INDICATI Approved Depression [ICD-11: 6A70-6A7Z] T80387 INDICATI Phase 3 Epilepsy/seizure [ICD-11: 8A61-8A6Z] T80387 INDICATI Discontinued in Phase 3 Female pelvic pain [ICD-11: GA34] T80387 INDICATI Phase 2 Indeterminate colitis [ICD-11: DD72] T80387 INDICATI Approved Insomnia [ICD-11: 7A00-7A0Z] T80387 INDICATI Approved Mental/behavioural/neurodevelopmental disorder [ICD-11: 6E20-6E8Z] T80387 INDICATI Investigative Postoperative inflammation [ICD-11: 1A00-CA43] T80387 INDICATI Phase 3 Status epilepticus [ICD-11: 8A66] T80387 INDICATI Approved Tonus and reflex abnormality [ICD-11: MB47] T80387 INDICATI Phase 2 Tremor-related disorder [ICD-11: 8A04] T80452 TARGETID T80452 T80452 TARGNAME Mucin (MUC) T80452 INDICATI Discontinued in Phase 3 Herpes simplex infection [ICD-11: 1F00] T80452 INDICATI Phase 2 Vitamin deficiency [ICD-11: 5B55-5B5F] T80518 TARGETID T80518 T80518 TARGNAME Synaptic transmission (ST) T80518 INDICATI Phase 1 Epilepsy/seizure [ICD-11: 8A61-8A6Z] T80701 TARGETID T80701 T80701 TARGNAME Bone resorption factor (BRF) T80701 INDICATI Discontinued in Phase 2 Low bone mass disorder [ICD-11: FB83] T80782 TARGETID T80782 T80782 TARGNAME VEGFR1 messenger RNA (VEGFR1 mRNA) T80782 INDICATI Phase 1/2 Alzheimer disease [ICD-11: 8A20] T80782 INDICATI Phase 2 Multiple myeloma [ICD-11: 2A83] T80782 INDICATI Phase 2 Myelodysplastic syndrome [ICD-11: 2A37] T80782 INDICATI Phase 1/2 Retinopathy [ICD-11: 9B71] T80782 INDICATI Phase 2 Solid tumour/cancer [ICD-11: 2A00-2F9Z] T80782 INDICATI Approved Thrombocytopenia [ICD-11: 3B64] T80886 TARGETID T80886 T80886 TARGNAME Transcription regulator protein BACH1 (Bach1) T80886 INDICATI Phase 1 Sickle-cell disorder [ICD-11: 3A51] T80896 TARGETID T80896 T80896 TARGNAME Estrogen receptor beta (ESR2) T80896 INDICATI Phase 1/2 Alzheimer disease [ICD-11: 8A20] T80896 INDICATI Approved Breast cancer [ICD-11: 2C60-2C6Y] T80896 INDICATI Approved Cushing syndrome [ICD-11: 5A70] T80896 INDICATI Phase 3 Hepatitis virus infection [ICD-11: 1E50-1E51] T80896 INDICATI Investigative Herpes simplex infection [ICD-11: 1F00] T80896 INDICATI Phase 3 Hyper-lipoproteinaemia [ICD-11: 5C80] T80896 INDICATI Phase 2 Indeterminate colitis [ICD-11: DD72] T80896 INDICATI Withdrawn from market Irregularities [ICD-11: N.A.] T80896 INDICATI Discontinued in Phase 3 Low bone mass disorder [ICD-11: FB83] T80896 INDICATI Approved Menopausal disorder [ICD-11: GA30] T80896 INDICATI Investigative Postoperative inflammation [ICD-11: 1A00-CA43] T80896 INDICATI Phase 2 Prostate cancer [ICD-11: 2C82] T80896 INDICATI Phase 2 Prostate hyperplasia [ICD-11: GA90] T80896 INDICATI Phase 1 Sepsis [ICD-11: 1G40-1G41] T80896 INDICATI Terminated Solid tumour/cancer [ICD-11: 2A00-2F9Z] T80896 INDICATI Discontinued in Phase 1 Thrombocytopenia [ICD-11: 3B64] T80896 INDICATI Withdrawn from market Trematode disease [ICD-11: 1F8Y] T80896 INDICATI Approved Vasomotor/allergic rhinitis [ICD-11: CA08] T80912 TARGETID T80912 T80912 TARGNAME T-cell immune regulator 1 (TCIRG1) T80912 INDICATI Phase 1 Skeletal anomaly ICD-11: LD24 T80942 TARGETID T80942 T80942 TARGNAME Matrix metalloproteinase (MMP) T80942 INDICATI Phase 1/2 Brain cancer [ICD-11: 2A00] T80942 INDICATI Discontinued in Phase 1 Indeterminate colitis [ICD-11: DD72] T80942 INDICATI Discontinued in Phase 1 Osteoarthritis [ICD-11: FA00-FA05] T80942 INDICATI Approved Pediculosis [ICD-11: 1G00] T80942 INDICATI Terminated Postoperative inflammation [ICD-11: 1A00-CA43] T80942 INDICATI Terminated Rheumatoid arthritis [ICD-11: FA20] T80942 INDICATI Phase 1/2 Solid tumour/cancer [ICD-11: 2A00-2F9Z] T80975 TARGETID T80975 T80975 TARGNAME Vascular endothelial growth factor receptor 2 (KDR) T80975 INDICATI Phase 3 Acute diabete complication [ICD-11: 5A2Y] T80975 INDICATI Phase 1/2 Alzheimer disease [ICD-11: 8A20] T80975 INDICATI Phase 2 Brain cancer [ICD-11: 2A00] T80975 INDICATI Approved Breast cancer [ICD-11: 2C60-2C6Y] T80975 INDICATI Phase 2 Cardiovascular disease [ICD-11: BA00-BE2Z] T80975 INDICATI Phase 2 Chronic pain [ICD-11: MG30] T80975 INDICATI Patented Circulatory system disease [ICD-11: BE2Z] T80975 INDICATI Approved Colorectal cancer [ICD-11: 2B91] T80975 INDICATI Phase 1/2 Digestive organ benign neoplasm [ICD-11: 2E92] T80975 INDICATI Approved Gastrointestinal stromal tumour [ICD-11: 2B5B] T80975 INDICATI Phase 1 Head and neck cancer [ICD-11: 2D42] T80975 INDICATI Phase 3 Liver cancer [ICD-11: 2C12] T80975 INDICATI Phase 2 Lung cancer [ICD-11: 2C25] T80975 INDICATI Approved Malignant digestive organ neoplasm [ICD-11: 2C11] T80975 INDICATI Phase 2 Melanoma [ICD-11: 2C30] T80975 INDICATI Phase 2 Metastatic lymph node neoplasm [ICD-11: 2D60] T80975 INDICATI Phase 2 Multiple myeloma [ICD-11: 2A83] T80975 INDICATI Phase 2 Myelodysplastic syndrome [ICD-11: 2A37] T80975 INDICATI Phase 1/2 Non-small-cell lung cancer [ICD-11: 2C25] T80975 INDICATI Phase 1 Oesophagogastric junction cancer ICD-11: 2B71 T80975 INDICATI Phase 2 Ovarian cancer [ICD-11: 2C73] T80975 INDICATI Phase 3 Peritoneal cancer [ICD-11: 2C51] T80975 INDICATI Approved Renal cell carcinoma [ICD-11: 2C90] T80975 INDICATI Phase 2 Sarcoma [ICD-11: 2A60-2C35] T80975 INDICATI Approved Solid tumour/cancer [ICD-11: 2A00-2F9Z] T80975 INDICATI Approved Stomach cancer [ICD-11: 2B72] T80975 INDICATI Approved Thrombocytopenia [ICD-11: 3B64] T80975 INDICATI Approved Thyroid cancer [ICD-11: 2D10] T81100 TARGETID T81100 T81100 TARGNAME SLC5A2 messenger RNA (SLC5A2 mRNA) T81100 INDICATI Approved Type 2 diabetes mellitus [ICD-11: 5A11] T81103 TARGETID T81103 T81103 TARGNAME Caspase 2 messenger RNA (CASP2 mRNA) T81103 INDICATI Phase 2/3 Glaucoma [ICD-11: 9C61] T81103 INDICATI Phase 3 Optic nerve disorder [ICD-11: 9C40] T81183 TARGETID T81183 T81183 TARGNAME Adrenergic receptor Alpha-1 (ADRA1) T81183 INDICATI Discontinued in Phase 3 Cardiovascular disease [ICD-11: BA00-BE2Z] T81183 INDICATI Approved Headache [ICD-11: 8A80-8A84] T81183 INDICATI Approved Heart failure [ICD-11: BD10-BD1Z] T81183 INDICATI Approved Hypertension [ICD-11: BA00-BA04] T81183 INDICATI Withdrawn from market Obesity [ICD-11: 5B80-5B81] T81183 INDICATI Approved Orthostatic hypotension [ICD-11: BA21] T81183 INDICATI Phase 1/2 Postoperative inflammation [ICD-11: 1A00-CA43] T81183 INDICATI Approved Prostate hyperplasia [ICD-11: GA90] T81281 TARGETID T81281 T81281 TARGNAME Desmoglein-3 (DSG3) T81281 INDICATI Phase 1 Pemphigus [ICD-11: EB40] T81311 TARGETID T81311 T81311 TARGNAME Endoplasmin (HSP90B1) T81311 INDICATI Phase 2 Lung cancer [ICD-11: 2C25] T81358 TARGETID T81358 T81358 TARGNAME CDC7-related kinase (CDC7) T81358 INDICATI Phase 1/2 Malignant haematopoietic neoplasm [ICD-11: 2B33] T81358 INDICATI Phase 1 Solid tumour/cancer [ICD-11: 2A00-2F9Z] T81386 TARGETID T81386 T81386 TARGNAME Positive transcription elongation factor b (P-TEFb) T81386 INDICATI Phase 1 Malignant haematopoietic neoplasm [ICD-11: 2B33] T81386 INDICATI Phase 1 Solid tumour/cancer [ICD-11: 2A00-2F9Z] T81443 TARGETID T81443 T81443 TARGNAME Toll-like receptor 4 (TLR4) T81443 INDICATI Preregistration Allergic/hypersensitivity disorder [ICD-11: 4A80-4A8Z] T81443 INDICATI Phase 1 Diabetes mellitus [ICD-11: 5A10] T81443 INDICATI Phase 1 Hepatitis virus infection [ICD-11: 1E50-1E51] T81443 INDICATI Phase 2 Malignant haematopoietic neoplasm [ICD-11: 2B33] T81443 INDICATI Investigative Melanoma [ICD-11: 2C30] T81443 INDICATI Phase 3 Prostate cancer [ICD-11: 2C82] T81443 INDICATI Phase 3 Sepsis [ICD-11: 1G40-1G41] T81443 INDICATI Phase 1 Solid tumour/cancer [ICD-11: 2A00-2F9Z] T81503 TARGETID T81503 T81503 TARGNAME Bacterial DNA gyrase B (Bact gyrB) T81503 INDICATI Phase 1/2 Mycobacterium infection [ICD-11: 1B10-1B21] T81548 TARGETID T81548 T81548 TARGNAME Mycobacterium Heat shock protein 65 (MycB groL2) T81548 INDICATI Discontinued in Phase 3 Cervical intraepithelial neoplasia [ICD-11: 2E66] T81569 TARGETID T81569 T81569 TARGNAME Zinc finger protein Helios (IKZF2) T81569 INDICATI Phase 1 Solid tumour/cancer [ICD-11: 2A00-2F9Z] T81694 TARGETID T81694 T81694 TARGNAME Rhinovirus Protein 1 (HRV P1D) T81694 INDICATI Discontinued in Phase 2 Virus infection [ICD-11: 1A24-1D9Z] T81695 TARGETID T81695 T81695 TARGNAME Membrane glycoprotein OX2 (CD200) T81695 INDICATI Phase 2 Acute myeloid leukaemia [ICD-11: 2A60] T81695 INDICATI Phase 1/2 Mature B-cell leukaemia [ICD-11: 2A82] T81695 INDICATI Phase 1 Solid tumour/cancer [ICD-11: 2A00-2F9Z] T81735 TARGETID T81735 T81735 TARGNAME DNA-dependent protein kinase catalytic (PRKDC) T81735 INDICATI Investigative Prostate cancer [ICD-11: 2C82] T81735 INDICATI Phase 1/2 Rectum cancer [ICD-11: 2B92] T81735 INDICATI Phase 1/2 Solid tumour/cancer [ICD-11: 2A00-2F9Z] T81774 TARGETID T81774 T81774 TARGNAME Tubulin polymerization (TubP) T81774 INDICATI Phase 2 Colorectal cancer [ICD-11: 2B91] T81774 INDICATI Approved Epidermal dysplasias [ICD-11: EK90] T81774 INDICATI Phase 2 Prostate cancer [ICD-11: 2C82] T81780 TARGETID T81780 T81780 TARGNAME Ubiquitin-activating enzyme E1 (UBAE1) T81780 INDICATI Investigative Leukaemia [ICD-11: 2A60-2B33] T81830 TARGETID T81830 T81830 TARGNAME SIK family kinase 3 (SIK3) T81830 INDICATI Phase 1 Ovarian cancer [ICD-11: 2C73] T81850 TARGETID T81850 T81850 TARGNAME Squalene synthetase (FDFT1) T81850 INDICATI Discontinued in Phase 2 Arterial occlusive disease [ICD-11: BD40] T81850 INDICATI Discontinued in Phase 3 Hyper-lipoproteinaemia [ICD-11: 5C80] T81892 TARGETID T81892 T81892 TARGNAME XIAP messenger RNA (XIAP mRNA) T81892 INDICATI Phase 2 Lymphoma [ICD-11: 2A80-2A86] T81892 INDICATI Phase 2 Solid tumour/cancer [ICD-11: 2A00-2F9Z] T81900 TARGETID T81900 T81900 TARGNAME Insulin-degrading enzyme (IDE) T81900 INDICATI Phase 2 Inherited retinal dystrophy [ICD-11: 9B70] T81900 INDICATI Approved Skin and skin-structure infection [ICD-11: 1F28-1G0Z] T81905 TARGETID T81905 T81905 TARGNAME Histamine receptor (HR) T81905 INDICATI Terminated Allergic/hypersensitivity disorder [ICD-11: 4A80-4A8Z] T81905 INDICATI Approved Asthma [ICD-11: CA23] T81905 INDICATI Discontinued in Phase 2 Breast cancer [ICD-11: 2C60-2C6Y] T81905 INDICATI Terminated Carcinoid syndrome [ICD-11: 5B10] T81905 INDICATI Phase 2 Chronic pain [ICD-11: MG30] T81905 INDICATI Approved Diagnostic imaging [ICD-11: N.A.] T81905 INDICATI Phase 3 Vasomotor/allergic rhinitis [ICD-11: CA08] T81916 TARGETID T81916 T81916 TARGNAME Kruppel like factor 4 (KLF4) T81916 INDICATI Phase 1 Solid tumour/cancer [ICD-11: 2A00-2F9Z] T82028 TARGETID T82028 T82028 TARGNAME Sodium/hydrogen exchanger 1 (SLC9A1) T82028 INDICATI Phase 3 Angina pectoris [ICD-11: BA40] T82028 INDICATI Discontinued in Phase 2 Cardiac arrhythmia [ICD-11: BC9Z] T82028 INDICATI Terminated Genetic cardiac arrhythmia [ICD-11: BC65] T82028 INDICATI Investigative Myocardial infarction [ICD-11: BA41-BA43] T82051 TARGETID T82051 T82051 TARGNAME P53 messenger RNA (TP53 mRNA) T82051 INDICATI Phase 2 Acute myeloid leukaemia [ICD-11: 2A60] T82051 INDICATI Investigative Hearing disorder [ICD-11: AB50-AB57] T82051 INDICATI Phase 2 Kidney failure [ICD-11: GB60-GB6Z] T82075 TARGETID T82075 T82075 TARGNAME Bacterial Celldivision protein FtsZ (Bact ftsZ) T82075 INDICATI Phase 1 Infectious meningitis [ICD-11: 1D01] T82078 TARGETID T82078 T82078 TARGNAME Toll-like receptor 2 (TLR2) T82078 INDICATI Phase 2 Diabetes mellitus [ICD-11: 5A10] T82078 INDICATI Discontinued in Phase 1 Melanoma [ICD-11: 2C30] T82078 INDICATI Phase 2 Myelodysplastic syndrome [ICD-11: 2A37] T82078 INDICATI Phase 1/2 Pancreatic cancer [ICD-11: 2C10] T82078 INDICATI Phase 3 Prostate cancer [ICD-11: 2C82] T82078 INDICATI Investigative Radiation effect [ICD-11: NF00] T82078 INDICATI Phase 1/2 Solid tumour/cancer [ICD-11: 2A00-2F9Z] T82083 TARGETID T82083 T82083 TARGNAME P2Y purinoceptor 4 (P2RY4) T82083 INDICATI Discontinued in Phase 3 Lung cancer [ICD-11: 2C25] T82105 TARGETID T82105 T82105 TARGNAME Biliary glycoprotein 1 (CEACAM1) T82105 INDICATI Phase 1/2 Solid tumour/cancer [ICD-11: 2A00-2F9Z] T82146 TARGETID T82146 T82146 TARGNAME Retinoic acid receptor gamma (RARG) T82146 INDICATI Approved Acne vulgaris [ICD-11: ED80] T82146 INDICATI Approved Acute myeloid leukaemia [ICD-11: 2A60] T82146 INDICATI Phase 2 Emphysema [ICD-11: CA21] T82146 INDICATI Approved Kaposi sarcoma [ICD-11: 2B57] T82146 INDICATI Approved Muscle calcification/ossification [ICD-11: FB31] T82146 INDICATI Approved Psoriasis [ICD-11: EA90] T82240 TARGETID T82240 T82240 TARGNAME Immunoglobulin gamma Fc receptor III (FCGR3) T82240 INDICATI Phase 1/2 BCR-ABL1-negative chronic myeloid leukaemia [ICD-11: 2A41] T82240 INDICATI Phase 1/2 Mastocytosis [ICD-11: 2A21] T82240 INDICATI Phase 1/2 Myelodysplastic syndrome [ICD-11: 2A37] T82240 INDICATI Approved (orphan drug) Thrombocytopenia [ICD-11: 3B64] T82266 TARGETID T82266 T82266 TARGNAME Voltage-gated L-type calcium channel (L-CaC) T82266 INDICATI Approved Angina pectoris [ICD-11: BA40] T82266 INDICATI Phase 2 Asthma [ICD-11: CA23] T82266 INDICATI Phase 2a Bipolar disorder [ICD-11: 6A60] T82266 INDICATI Phase 2 Cardiovascular disease [ICD-11: BA00-BE2Z] T82266 INDICATI Phase 2 Dementia [ICD-11: 6D80-6D8Z] T82266 INDICATI Phase 3 Essential hypertension [ICD-11: BA00] T82266 INDICATI Approved Hypertension [ICD-11: BA00-BA04] T82266 INDICATI Phase 3 Irritable bowel syndrome [ICD-11: DD91] T82266 INDICATI Approved Neuropathy [ICD-11: 8C0Z] T82266 INDICATI Approved Oesophagus motility disorder [ICD-11: DA21] T82266 INDICATI Investigative Pain [ICD-11: MG30-MG3Z] T82266 INDICATI Discontinued in Phase 3 Unspecific body region injury [ICD-11: ND56] T82277 TARGETID T82277 T82277 TARGNAME Cancer/testis antigen 1 (NY-ESO-1) T82277 INDICATI Phase 1/2 Esophageal cancer [ICD-11: 2B70] T82277 INDICATI Phase 1/2 Lung cancer [ICD-11: 2C25] T82277 INDICATI Phase 1 Melanoma [ICD-11: 2C30] T82277 INDICATI Phase 1/2 Multiple myeloma [ICD-11: 2A83] T82277 INDICATI Phase 2 Ovarian cancer [ICD-11: 2C73] T82277 INDICATI Phase 2 Solid tumour/cancer [ICD-11: 2A00-2F9Z] T82277 INDICATI Phase 1/2 Synovial sarcoma [ICD-11: 2B5A] T82309 TARGETID T82309 T82309 TARGNAME TWIK-related spinal cord potassium channel (TRESK) T82309 INDICATI Investigative Adaptive immunity immunodeficiency [ICD-11: 4A01] T82349 TARGETID T82349 T82349 TARGNAME Bacterial Cell membrane (Bact CM) T82349 INDICATI Approved Antimicrobial drug resistance [ICD-11: MG50-MG52] T82349 INDICATI Phase 2 Atopic eczema [ICD-11: EA80] T82349 INDICATI Approved Bacterial infection [ICD-11: 1A00-1C4Z] T82349 INDICATI Phase 3 Burn and burn infection [ICD-11: ND90-NE2Z] T82349 INDICATI Approved Clostridium difficile enterocolitis [ICD-11: 1A04] T82349 INDICATI Terminated Fungal infection [ICD-11: 1F29-1F2F] T82349 INDICATI Phase 3 Mycobacterium infection [ICD-11: 1B10-1B21] T82349 INDICATI Phase 2 Postoperative inflammation [ICD-11: 1A00-CA43] T82383 TARGETID T82383 T82383 TARGNAME Tyrosine-protein kinase UFO (AXL) T82383 INDICATI Approved Acute myeloid leukaemia [ICD-11: 2A60] T82383 INDICATI Phase 2 Breast cancer [ICD-11: 2C60-2C6Y] T82383 INDICATI Phase 2 Kaposi sarcoma [ICD-11: 2B57] T82383 INDICATI Phase 2 Lung cancer [ICD-11: 2C25] T82383 INDICATI Phase 1/2 Mature B-cell leukaemia [ICD-11: 2A82] T82383 INDICATI Investigative Metastatic malignant neoplasm [ICD-11: 2D50-2E09] T82383 INDICATI Phase 2 Multiple myeloma [ICD-11: 2A83] T82383 INDICATI Phase 2 Myelodysplastic syndrome [ICD-11: 2A37] T82383 INDICATI Phase 2 Ovarian cancer [ICD-11: 2C73] T82383 INDICATI Preclinical Peritoneal cancer [ICD-11: 2C51] T82383 INDICATI Phase 1/2 Solid tumour/cancer [ICD-11: 2A00-2F9Z] T82391 TARGETID T82391 T82391 TARGNAME Mitochondrial complex I (NDUFA13) T82391 INDICATI Phase 3 Cardiomyopathy [ICD-11: BC43] T82393 TARGETID T82393 T82393 TARGNAME TNF alpha converting enzyme (ADAM17) T82393 INDICATI Phase 1/2 Breast cancer [ICD-11: 2C60-2C6Y] T82393 INDICATI Preclinical Chronic obstructive pulmonary disease [ICD-11: CA22] T82393 INDICATI Terminated Indeterminate colitis [ICD-11: DD72] T82393 INDICATI Phase 2 Rheumatoid arthritis [ICD-11: FA20] T82463 TARGETID T82463 T82463 TARGNAME Cocaine (Coca) T82463 INDICATI Phase 2 Cocaine use disorder [ICD-11: 6C45] T82494 TARGETID T82494 T82494 TARGNAME T-cell receptor (TCR) T82494 INDICATI Phase 1 Acute myeloid leukaemia [ICD-11: 2A60] T82494 INDICATI Phase 1/2 Bladder cancer [ICD-11: 2C94] T82494 INDICATI Phase 2 Graft-versus-host disease [ICD-11: 4B24] T82494 INDICATI Phase 1/2 Head and neck cancer [ICD-11: 2D42] T82494 INDICATI Phase 1/2 Liposarcoma [ICD-11: 2B59] T82494 INDICATI Phase 1 Liver cancer [ICD-11: 2C12] T82494 INDICATI Phase 1/2 Melanoma [ICD-11: 2C30] T82494 INDICATI Phase 1/2 Multiple myeloma [ICD-11: 2A83] T82494 INDICATI Phase 1/2 Multiple sclerosis [ICD-11: 8A40] T82494 INDICATI Phase 1 Myelodysplastic syndrome [ICD-11: 2A37] T82494 INDICATI Phase 1/2 Neuroendocrine carcinoma [ICD-11: 2C34] T82494 INDICATI Phase 1/2 Ovarian cancer [ICD-11: 2C73] T82494 INDICATI Phase 2 Psoriasis [ICD-11: EA90] T82494 INDICATI Phase 2 Solid tumour/cancer [ICD-11: 2A00-2F9Z] T82494 INDICATI Phase 1/2 Synovial sarcoma [ICD-11: 2B5A] T82514 TARGETID T82514 T82514 TARGNAME Neurokinin receptor (NKR) T82514 INDICATI Terminated General pain disorder [ICD-11: 8E43] T82543 TARGETID T82543 T82543 TARGNAME Neuronal acetylcholine receptor beta-2 (CHRNB2) T82543 INDICATI Discontinued in Phase 2 Alzheimer disease [ICD-11: 8A20] T82543 INDICATI Phase 1 Depression [ICD-11: 6A70-6A7Z] T82543 INDICATI Phase 2 Hyperhidrosis [ICD-11: EE00] T82543 INDICATI Phase 3 Nicotine use disorder [ICD-11: 6C4A] T82543 INDICATI Discontinued in Phase 2 Thrombosis [ICD-11: DB61-GB90] T82577 TARGETID T82577 T82577 TARGNAME Angiotensin-converting enzyme (ACE) T82577 INDICATI Phase 2 Asthma [ICD-11: CA23] T82577 INDICATI Approved Cardiovascular disease [ICD-11: BA00-BE2Z] T82577 INDICATI Discontinued in Phase 2/3 Chronic kidney disease [ICD-11: GB61] T82577 INDICATI Discontinued in Phase 2 Depression [ICD-11: 6A70-6A7Z] T82577 INDICATI Approved Heart failure [ICD-11: BD10-BD1Z] T82577 INDICATI Approved Hypertension [ICD-11: BA00-BA04] T82577 INDICATI Phase 1 Hypotension [ICD-11: BA20-BA21] T82577 INDICATI Discontinued in Phase 2/3 Kidney failure [ICD-11: GB60-GB6Z] T82577 INDICATI Phase 2/3 Thrombosis [ICD-11: DB61-GB90] T82624 TARGETID T82624 T82624 TARGNAME Inositol 1,4,5-trisphosphate receptor (ITPR) T82624 INDICATI Approved Hypertension [ICD-11: BA00-BA04] T82665 TARGETID T82665 T82665 TARGNAME Protein arginine methyltransferase 5 (PRMT5) T82665 INDICATI Phase 1 Brain cancer [ICD-11: 2A00] T82665 INDICATI Phase 2 Breast cancer [ICD-11: 2C60-2C6Y] T82665 INDICATI Phase 1 Malignant haematopoietic neoplasm [ICD-11: 2B33] T82665 INDICATI Phase 1 Myelodysplastic syndrome [ICD-11: 2A37] T82665 INDICATI Phase 2 Solid tumour/cancer [ICD-11: 2A00-2F9Z] T82668 TARGETID T82668 T82668 TARGNAME Kynurenine oxoglutarate transaminase II (AADAT) T82668 INDICATI Preclinical Mild neurocognitive disorder [ICD-11: 6D71] T82668 INDICATI Preclinical Schizophrenia [ICD-11: 6A20] T82723 TARGETID T82723 T82723 TARGNAME Bacterial Oxoacyl-[acyl-carrier-protein] synthase II (Bact fabF) T82723 INDICATI Investigative Bacterial infection [ICD-11: 1A00-1C4Z] T82723 INDICATI Investigative Malaria [ICD-11: 1F40-1F45] T82723 INDICATI Investigative Urinary tract infection [ICD-11: GC08] T82739 TARGETID T82739 T82739 TARGNAME Plasma kallikrein (KLKB1) T82739 INDICATI Approved Innate/adaptive immunodeficiency [ICD-11: 4A00] T82739 INDICATI Approved Retinal vascular occlusion [ICD-11: 9B74] T82739 INDICATI Phase 2 Retinopathy [ICD-11: 9B71] T82795 TARGETID T82795 T82795 TARGNAME Beta-catenin (CTNNB1) T82795 INDICATI Phase 1/2 Colon cancer [ICD-11: 2B90] T82795 INDICATI Phase 1 Desmoid tumour [ICD-11: 2F7C] T82795 INDICATI Approved Solid tumour/cancer [ICD-11: 2A00-2F9Z] T82795 INDICATI Phase 1/2 Systemic sclerosis [ICD-11: 4A42] T82841 TARGETID T82841 T82841 TARGNAME Insulin (INS) T82841 INDICATI Approved Acute diabete complication [ICD-11: 5A2Y] T82841 INDICATI Phase 3 Diabetes mellitus [ICD-11: 5A10] T82841 INDICATI Approved Kidney malfunction [ICD-11: MG02] T82841 INDICATI Phase 3 Malaria [ICD-11: 1F40-1F45] T82841 INDICATI Phase 1 Metabolic disorder [ICD-11: 5C50-5D2Z] T82841 INDICATI Phase 3 Type 2 diabetes mellitus [ICD-11: 5A11] T82841 INDICATI Approved Type-1/2 diabete [ICD-11: 5A10-5A11] T82913 TARGETID T82913 T82913 TARGNAME Plasmodium Elongation factor 1-alpha 1 (Malaria MEF-1) T82913 INDICATI Phase 1 Bacterial infection [ICD-11: 1A00-1C4Z] T82943 TARGETID T82943 T82943 TARGNAME microRNA hsa-miR-17 (MIR17) T82943 INDICATI Phase 1 Autosomal dominant polycystic kidney disease [ICD-11: GB81] T82958 TARGETID T82958 T82958 TARGNAME Cytomegalovirus Glycoprotein B (CMV gB) T82958 INDICATI Phase 1 Cytomegaloviral disease [ICD-11: 1D82] T83011 TARGETID T83011 T83011 TARGNAME Monoamine oxidase type B (MAO-B) T83011 INDICATI Phase 1/2 Acquired hypomelanotic disorder [ICD-11: ED63] T83011 INDICATI Phase 2 Alzheimer disease [ICD-11: 8A20] T83011 INDICATI Preclinical Bacterial infection [ICD-11: 1A00-1C4Z] T83011 INDICATI Investigative Central nervous system disease [ICD-11: 8A04-8D87] T83011 INDICATI Approved Dementia [ICD-11: 6D80-6D8Z] T83011 INDICATI Approved Depression [ICD-11: 6A70-6A7Z] T83011 INDICATI Phase 2 General pain disorder [ICD-11: 8E43] T83011 INDICATI Approved Hypertension [ICD-11: BA00-BA04] T83011 INDICATI Approved Malaria [ICD-11: 1F40-1F45] T83011 INDICATI Approved Migraine [ICD-11: 8A80] T83011 INDICATI Discontinued in Phase 3 Mild neurocognitive disorder [ICD-11: 6D71] T83011 INDICATI Discontinued in Phase 1 Multiple myeloma [ICD-11: 2A83] T83011 INDICATI Patented Muscular dystrophy [ICD-11: 8C70] T83011 INDICATI Discontinued in Phase 3 Nausea/vomiting [ICD-11: MD90] T83011 INDICATI Investigative Neurodegenerative disorder [ICD-11: 8A20-8A23] T83011 INDICATI Investigative Obesity [ICD-11: 5B80-5B81] T83011 INDICATI Approved Parkinsonism [ICD-11: 8A00] T83011 INDICATI Investigative Primary psychotic disorder manifestation [ICD-11: 6A25] T83011 INDICATI Patented Prostate cancer [ICD-11: 2C82] T83011 INDICATI Patented Skin cancer [ICD-11: 2C30-2C37] T83011 INDICATI Patented Skin tag/polyp [ICD-11: EK71] T83051 TARGETID T83051 T83051 TARGNAME Bacterial Ribosome (Bact RIBS) T83051 INDICATI Preclinical HIV-infected patients with tuberculosis [ICD-11: 1B10-1B14] T83051 INDICATI Approved Infectious gastroenteritis/colitis [ICD-11: 1A40] T83051 INDICATI Phase 2 Influenza [ICD-11: 1E30-1E32] T83059 TARGETID T83059 T83059 TARGNAME Tankyrase (TNKS) T83059 INDICATI Phase 1 Brain cancer [ICD-11: 2A00] T83059 INDICATI Phase 2 Breast cancer [ICD-11: 2C60-2C6Y] T83059 INDICATI Phase 2 Ovarian cancer [ICD-11: 2C73] T83059 INDICATI Phase 1/2 Solid tumour/cancer [ICD-11: 2A00-2F9Z] T83103 TARGETID T83103 T83103 TARGNAME Interleukin (IL) T83103 INDICATI Phase 2 Crohn disease [ICD-11: DD70] T83103 INDICATI Phase 2 Lupus erythematosus [ICD-11: 4A40] T83145 TARGETID T83145 T83145 TARGNAME Nuclear factor NF-kappa-B (NFKB) T83145 INDICATI Phase 1 Acute myeloid leukaemia [ICD-11: 2A60] T83145 INDICATI Phase 2 Acute/subacute hepatic failure [ICD-11: DB91] T83145 INDICATI Terminated Asthma [ICD-11: CA23] T83145 INDICATI Phase 2 Atopic eczema [ICD-11: EA80] T83145 INDICATI Phase 2 Choreiform disorder [ICD-11: 8A01] T83145 INDICATI Patented Circulatory system disease [ICD-11: BE2Z] T83145 INDICATI Terminated Cystic fibrosis [ICD-11: CA25] T83145 INDICATI Phase 3 Diabetes mellitus [ICD-11: 5A10] T83145 INDICATI Discontinued in Phase 1 Female genital system disease [ICD-11: GA6Z] T83145 INDICATI Phase 2 Fungal infection [ICD-11: 1F29-1F2F] T83145 INDICATI Patented Immune system disease [ICD-11: 4A01-4B41] T83145 INDICATI Phase 2 Indeterminate colitis [ICD-11: DD72] T83145 INDICATI Approved Irritable bowel syndrome [ICD-11: DD91] T83145 INDICATI Phase 3 Lupus erythematosus [ICD-11: 4A40] T83145 INDICATI Patented Mineral absorption/transport disorder [ICD-11: 5C64] T83145 INDICATI Discontinued in Phase 1 Multiple myeloma [ICD-11: 2A83] T83145 INDICATI Phase 3 Multiple sclerosis [ICD-11: 8A40] T83145 INDICATI Patented Muscle disorder [ICD-11: FB32-FB3Z] T83145 INDICATI Phase 3 Muscular dystrophy [ICD-11: 8C70] T83145 INDICATI Patented Nervous system disease [ICD-11: 8A00-8E7Z] T83145 INDICATI Patented Neurodegenerative disorder [ICD-11: 8A20-8A23] T83145 INDICATI Phase 2 Psoriasis [ICD-11: EA90] T83145 INDICATI Approved Rheumatoid arthritis [ICD-11: FA20] T83145 INDICATI Phase 1/2 Skin and skin-structure infection [ICD-11: 1F28-1G0Z] T83145 INDICATI Patented Skin disease [ICD-11: EA00-EM0Z] T83145 INDICATI Phase 2 Solid tumour/cancer [ICD-11: 2A00-2F9Z] T83145 INDICATI Phase 1 Type 2 diabetes mellitus [ICD-11: 5A11] T83174 TARGETID T83174 T83174 TARGNAME Protein kinase C iota (PRKCI) T83174 INDICATI Terminated Solid tumour/cancer [ICD-11: 2A00-2F9Z] T83192 TARGETID T83192 T83192 TARGNAME Ciliary neurotrophic factor (CNTF) T83192 INDICATI Phase 1/2 Ovarian cancer [ICD-11: 2C73] T83193 TARGETID T83193 T83193 TARGNAME Transient receptor potential cation channel V1 (TRPV1) T83193 INDICATI Discontinued in Phase 2 Acute/chronic pain [ICD-11: MG30-MG31] T83193 INDICATI Phase 1 Asthma [ICD-11: CA23] T83193 INDICATI Phase 2 Atopic eczema [ICD-11: EA80] T83193 INDICATI Phase 1 Chronic pain [ICD-11: MG30] T83193 INDICATI Investigative Cough [ICD-11: MD12] T83193 INDICATI Discontinued in Phase 2 Esophagus sensitivity [ICD-11: DA2Y-DA2Z] T83193 INDICATI Phase 2 Functional bladder disorder [ICD-11: GC50] T83193 INDICATI Discontinued in Phase 2 Gastro-oesophageal reflux disease [ICD-11: DA22] T83193 INDICATI Approved General pain disorder [ICD-11: 8E43] T83193 INDICATI Phase 1 Intellectual development disorder [ICD-11: LD90] T83193 INDICATI Phase 3 Knee osteoarthritis [ICD-11: FA01] T83193 INDICATI Phase 2 Lower limb mononeuropathy [ICD-11: 8C11] T83193 INDICATI Discontinued in Phase 1 Migraine [ICD-11: 8A80] T83193 INDICATI Discontinued in Phase 2 Neuropathy [ICD-11: 8C0Z] T83193 INDICATI Phase 1 Osteoarthritis [ICD-11: FA00-FA05] T83193 INDICATI Phase 3 Pain [ICD-11: MG30-MG3Z] T83193 INDICATI Phase 2 Rheumatoid arthritis [ICD-11: FA20] T83193 INDICATI Discontinued in Phase 2 Zoster [ICD-11: 1E91] T83198 TARGETID T83198 T83198 TARGNAME Cysteines of Keap1 (KEAP1 Cysteines) T83198 INDICATI Preclinical Multiple sclerosis [ICD-11: 8A40] T83198 INDICATI Preclinical Psoriasis [ICD-11: EA90] T83198 INDICATI Phase 2 Pulmonary hypertension [ICD-11: BB01] T83198 INDICATI Phase 2 Urinary system clinical sympton [ICD-11: MF8Y] T83202 TARGETID T83202 T83202 TARGNAME Ribosomal protein S6 kinase alpha-1 (RSK1) T83202 INDICATI Preclinical Mature B-cell leukaemia [ICD-11: 2A82] T83335 TARGETID T83335 T83335 TARGNAME Human immunodeficiency virus Transmission (HIV Tran) T83335 INDICATI Phase 3 Bacterial infection [ICD-11: 1A00-1C4Z] T83369 TARGETID T83369 T83369 TARGNAME Coagulation factor IX (F9) T83369 INDICATI Approved Bleeding disorder [ICD-11: GA20-GA21] T83369 INDICATI Phase 3 Christmas disease [ICD-11: 3B11] T83369 INDICATI Discontinued in Phase 3 Circulatory system disease [ICD-11: BE2Z] T83369 INDICATI Approved Coagulation defect [ICD-11: 3B10] T83369 INDICATI Discontinued in Phase 3 Coronary atherosclerosis [ICD-11: BA80] T83369 INDICATI Phase 2 Pregnancy/childbirth/puerperium maternal infection [ICD-11: JB63] T83369 INDICATI Discontinued in Phase 1 Sepsis [ICD-11: 1G40-1G41] T83369 INDICATI Discontinued in Phase 3 Thrombosis [ICD-11: DB61-GB90] T83369 INDICATI Terminated Viral encephalitis [ICD-11: 1C80] T83376 TARGETID T83376 T83376 TARGNAME Tumor suppressor candidate 2 (TUSC2) T83376 INDICATI Phase 1/2 Lung cancer [ICD-11: 2C25] T83386 TARGETID T83386 T83386 TARGNAME Folate receptor alpha (FOLR1) T83386 INDICATI Phase 1 Endometrial cancer [ICD-11: 2C76] T83386 INDICATI Phase 3 Lung cancer [ICD-11: 2C25] T83386 INDICATI Approved Malaria [ICD-11: 1F40-1F45] T83386 INDICATI Approved Ovarian cancer [ICD-11: 2C73] T83386 INDICATI Phase 2 Renal cell carcinoma [ICD-11: 2C90] T83386 INDICATI Phase 2 Solid tumour/cancer [ICD-11: 2A00-2F9Z] T83391 TARGETID T83391 T83391 TARGNAME Fructose-1,6-bisphosphatase (FBP) T83391 INDICATI Phase 2 Type 2 diabetes mellitus [ICD-11: 5A11] T83561 TARGETID T83561 T83561 TARGNAME HIF-1 responsive protein RTP801 (DDIT4) T83561 INDICATI Phase 2 Retinopathy [ICD-11: 9B71] T83585 TARGETID T83585 T83585 TARGNAME Wiskott-Aldrich syndrome protein (WAS) T83585 INDICATI Phase 3 Qualitative platelet defect [ICD-11: 3B62] T83611 TARGETID T83611 T83611 TARGNAME MHC class II antigen DRB1*1 (HLA-DRB1) T83611 INDICATI Approved Multiple sclerosis [ICD-11: 8A40] T83687 TARGETID T83687 T83687 TARGNAME B-cell-activating factor receptor (TNFRSF13C) T83687 INDICATI Phase 2 Pemphigus [ICD-11: EB40] T83687 INDICATI Phase 2 Rheumatoid arthritis [ICD-11: FA20] T83687 INDICATI Phase 2 Sjogren syndrome [ICD-11: 4A43] T83717 TARGETID T83717 T83717 TARGNAME Neuronal acetylcholine receptor alpha (NACHRA) T83717 INDICATI Approved Tonus and reflex abnormality [ICD-11: MB47] T83793 TARGETID T83793 T83793 TARGNAME Human immunodeficiency virus Negative factor (HIV nef) T83793 INDICATI Phase 2 Human immunodeficiency virus disease [ICD-11: 1C60-1C62] T83797 TARGETID T83797 T83797 TARGNAME Hepatocyte growth factor (HGF) T83797 INDICATI Phase 1 Acute myeloid leukaemia [ICD-11: 2A60] T83797 INDICATI Phase 3 Angina pectoris [ICD-11: BA40] T83797 INDICATI Discontinued in Phase 2 Brain cancer [ICD-11: 2A00] T83797 INDICATI Phase 3 Chronic arterial occlusive disease [ICD-11: BD4Z] T83797 INDICATI Phase 3 Diabetic foot ulcer [ICD-11: BD54] T83797 INDICATI Phase 3 Graft-versus-host disease [ICD-11: 4B24] T83797 INDICATI Phase 2 Lung cancer [ICD-11: 2C25] T83797 INDICATI Phase 1 Lymphoma [ICD-11: 2A80-2A86] T83797 INDICATI Phase 2 Motor neuron disease [ICD-11: 8B60] T83797 INDICATI Phase 2 Multiple myeloma [ICD-11: 2A83] T83797 INDICATI Phase 3 Neuropathy [ICD-11: 8C0Z] T83797 INDICATI Phase 2 Pancreatic cancer [ICD-11: 2C10] T83797 INDICATI Phase 2 Peripheral Ischemic Ulcers ICD-11: BD41 T83797 INDICATI Phase 1 Solid tumour/cancer [ICD-11: 2A00-2F9Z] T83797 INDICATI Phase 2 Squamous cell carcinoma [ICD-11: 2B60-2D01] T83813 TARGETID T83813 T83813 TARGNAME 5-HT 2C receptor (HTR2C) T83813 INDICATI Phase 2 Acute diabete complication [ICD-11: 5A2Y] T83813 INDICATI Phase 2 Alzheimer disease [ICD-11: 8A20] T83813 INDICATI Phase 1 Anxiety disorder [ICD-11: 6B00-6B0Z] T83813 INDICATI Phase 3 Attention deficit hyperactivity disorder [ICD-11: 6A05] T83813 INDICATI Phase 3 Chronic insomnia [ICD-11: 7A00] T83813 INDICATI Approved Depression [ICD-11: 6A70-6A7Z] T83813 INDICATI Terminated Dissociative neurological symptom disorder [ICD-11: 6B60] T83813 INDICATI Phase 2 Malignant haematopoietic neoplasm [ICD-11: 2B33] T83813 INDICATI Approved Migraine [ICD-11: 8A80] T83813 INDICATI Discontinued in Phase 2 Mood disorder [ICD-11: 6A60-6E23] T83813 INDICATI Approved Obesity [ICD-11: 5B80-5B81] T83813 INDICATI Approved Pain [ICD-11: MG30-MG3Z] T83813 INDICATI Phase 2 Parkinsonism [ICD-11: 8A00] T83813 INDICATI Approved Pituitary gland disorder [ICD-11: 5A60-5A61] T83813 INDICATI Phase 1 Psychoactive substances use disorder [ICD-11: 6C4G] T83813 INDICATI Phase 2 Psychotic disorder [ICD-11: 6A20-6A25] T83813 INDICATI Phase 3 Schizophrenia [ICD-11: 6A20] T83813 INDICATI Phase 3 Sleep-wake disorder [ICD-11: 7A00-7B2Z] T83813 INDICATI Phase 2 Substance abuse [ICD-11: 6C40] T83813 INDICATI Phase 2 Tonus and reflex abnormality [ICD-11: MB47] T83875 TARGETID T83875 T83875 TARGNAME Monoamine oxidase type A (MAO-A) T83875 INDICATI Phase 1/2 Acquired hypomelanotic disorder [ICD-11: ED63] T83875 INDICATI Phase 2 Alzheimer disease [ICD-11: 8A20] T83875 INDICATI Discontinued in Phase 2 Anxiety disorder [ICD-11: 6B00-6B0Z] T83875 INDICATI Approved Depression [ICD-11: 6A70-6A7Z] T83875 INDICATI Discontinued in Phase 2 Epilepsy/seizure [ICD-11: 8A61-8A6Z] T83875 INDICATI Phase 2 General pain disorder [ICD-11: 8E43] T83875 INDICATI Phase 2 Mood disorder [ICD-11: 6A60-6E23] T83875 INDICATI Discontinued in Phase 1 Multiple myeloma [ICD-11: 2A83] T83875 INDICATI Approved Parkinsonism [ICD-11: 8A00] T83875 INDICATI Patented Prostate cancer [ICD-11: 2C82] T83875 INDICATI Patented Skin tag/polyp [ICD-11: EK71] T83875 INDICATI Phase 1 Substance abuse [ICD-11: 6C40] T83904 TARGETID T83904 T83904 TARGNAME NAD-dependent deacetylase sirtuin-2 (SIRT2) T83904 INDICATI Investigative Retinopathy [ICD-11: 9B71] T83905 TARGETID T83905 T83905 TARGNAME Placental cadherin (CDH3) T83905 INDICATI Phase 1 Solid tumour/cancer [ICD-11: 2A00-2F9Z] T83982 TARGETID T83982 T83982 TARGNAME Ubiquitin isopeptidase Y (USP8) T83982 INDICATI Preclinical Solid tumour/cancer [ICD-11: 2A00-2F9Z] T84040 TARGETID T84040 T84040 TARGNAME Transformation-sensitive protein p120 (TRPA1) T84040 INDICATI Phase 2 Chronic pain ICD-11: MG30 T84040 INDICATI Phase 1 Neuropathy [ICD-11: 8C0Z] T84040 INDICATI Investigative Pain [ICD-11: MG30-MG3Z] T84040 INDICATI Approved Upper respiratory tract disorder [ICD-11: CA0Z] T84117 TARGETID T84117 T84117 TARGNAME 5-HT 1E receptor (HTR1E) T84117 INDICATI Approved Pituitary gland disorder [ICD-11: 5A60-5A61] T84133 TARGETID T84133 T84133 TARGNAME Phosphodiesterase 10A (PDE10) T84133 INDICATI Phase 2 Choreiform disorder [ICD-11: 8A01] T84133 INDICATI Phase 2 Inborn purine/pyrimidine/nucleotide metabolism error [ICD-11: 5C55] T84133 INDICATI Phase 2 Irritable bowel syndrome [ICD-11: DD91] T84133 INDICATI Phase 2 Schizophrenia [ICD-11: 6A20] T84133 INDICATI Phase 1 Solid tumour/cancer [ICD-11: 2A00-2F9Z] T84160 TARGETID T84160 T84160 TARGNAME 5-HT 3 receptor (5HT3R) T84160 INDICATI Phase 3 Anxiety disorder [ICD-11: 6B00-6B0Z] T84160 INDICATI Investigative Dementia [ICD-11: 6D80-6D8Z] T84160 INDICATI Phase 1 Depression [ICD-11: 6A70-6A7Z] T84160 INDICATI Phase 1 Gastro-oesophageal reflux disease [ICD-11: DA22] T84160 INDICATI Phase 4 Irritable bowel syndrome [ICD-11: DD91] T84160 INDICATI Phase 1 Mild neurocognitive disorder [ICD-11: 6D71] T84160 INDICATI Phase 3 Mood disorder [ICD-11: 6A60-6E23] T84160 INDICATI Approved Nausea/vomiting [ICD-11: MD90] T84160 INDICATI Investigative Obesity [ICD-11: 5B80-5B81] T84160 INDICATI Discontinued in Phase 1 Obstructive sleep apnoea [ICD-11: 7A41] T84160 INDICATI Discontinued in Phase 2 Oesophageal/gastroduodenal disorder [ICD-11: DD90] T84160 INDICATI Discontinued in Phase 2 Oesophagus motility disorder [ICD-11: DA21] T84160 INDICATI Phase 1 Opioid use disorder [ICD-11: 6C43] T84160 INDICATI Phase 1 Schizophrenia [ICD-11: 6A20] T84160 INDICATI Phase 1 Sex development malformative disorder [ICD-11: LD2A] T84160 INDICATI Phase 2 Substance abuse [ICD-11: 6C40] T84160 INDICATI Phase 3 Testicular cancer [ICD-11: 2C80] T84160 INDICATI Terminated Unspecific substance use disorder [ICD-11: 6C4Z] T84173 TARGETID T84173 T84173 TARGNAME Glucosylceramidase (GBA) T84173 INDICATI Discontinued in Phase 2 Lysosomal disease [ICD-11: 5C56] T84173 INDICATI Approved Metabolic disorder [ICD-11: 5C50-5D2Z] T84316 TARGETID T84316 T84316 TARGNAME Voltage-gated calcium channel alpha-2/delta-1 (CACNA2D1) T84316 INDICATI Phase 3 Anxiety disorder [ICD-11: 6B00-6B0Z] T84316 INDICATI Phase 3 Cardiovascular disease [ICD-11: BA00-BE2Z] T84316 INDICATI Approved Chronic obstructive pulmonary disease [ICD-11: CA22] T84316 INDICATI Phase 3 Chronic pain [ICD-11: MG30] T84316 INDICATI Approved Hypertension [ICD-11: BA00-BA04] T84316 INDICATI Registered Neuropathy [ICD-11: 8C0Z] T84316 INDICATI Discontinued in Phase 2 Pain [ICD-11: MG30-MG3Z] T84397 TARGETID T84397 T84397 TARGNAME Tubulin beta-1 chain (TUBB1) T84397 INDICATI Investigative Lung cancer [ICD-11: 2C25] T84397 INDICATI Phase 2 Solid tumour/cancer [ICD-11: 2A00-2F9Z] T84439 TARGETID T84439 T84439 TARGNAME G-protein-coupled receptor PGR3 (GPR139) T84439 INDICATI Phase 1 Sex development malformative disorder [ICD-11: LD2A] T84457 TARGETID T84457 T84457 TARGNAME GABA(A) receptor (GABAR) T84457 INDICATI Approved Epilepsy/seizure [ICD-11: 8A61-8A6Z] T84457 INDICATI Phase 2 Fragile X chromosome [ICD-11: LD55] T84457 INDICATI Phase 3 Intellectual development disorder [ICD-11: LD90] T84457 INDICATI Phase 2 Mental/behavioural/neurodevelopmental disorder [ICD-11: 6E20-6E8Z] T84457 INDICATI Phase 2 Narcolepsy [ICD-11: 7A20] T84457 INDICATI Phase 1 Parkinsonism [ICD-11: 8A00] T84457 INDICATI Phase 2 Sleep-wake disorder [ICD-11: 7A00-7B2Z] T84457 INDICATI Phase 3 Social anxiety disorder [ICD-11: 6B04] T84457 INDICATI Phase 2 Tremor-related disorder [ICD-11: 8A04] T84472 TARGETID T84472 T84472 TARGNAME Geranylgeranyl transferase (GGTase) T84472 INDICATI Phase 1 Solid tumour/cancer [ICD-11: 2A00-2F9Z] T84486 TARGETID T84486 T84486 TARGNAME Oxytocin receptor (OTR) T84486 INDICATI Discontinued in Phase 1 Abortion [ICD-11: JA00] T84486 INDICATI Approved Acute diabete complication [ICD-11: 5A2Y] T84486 INDICATI Phase 2 Anxiety disorder [ICD-11: 6B00-6B0Z] T84486 INDICATI Approved Autism spectrum disorder [ICD-11: 6A02] T84486 INDICATI Phase 3 Childbirth associated breast/lactation disorder [ICD-11: JB46] T84486 INDICATI Phase 2 Depression [ICD-11: 6A70-6A7Z] T84486 INDICATI Phase 2 Ejaculatory dysfunction [ICD-11: HA03] T84486 INDICATI Approved Postpartum haemorrhage [ICD-11: JA43] T84486 INDICATI Phase 3 Preterm labour/delivery [ICD-11: JB00] T84486 INDICATI Phase 2 Sexual dysfunction [ICD-11: HA00-HA01] T84486 INDICATI Phase 2 Testicular dysfunction [ICD-11: 5A81] T84560 TARGETID T84560 T84560 TARGNAME Mitochondrial uncoupling protein 2 (UCP2) T84560 INDICATI Phase 2 Obesity [ICD-11: 5B80-5B81] T84575 TARGETID T84575 T84575 TARGNAME Samarium (SAM) T84575 INDICATI Approved Chronic pain [ICD-11: MG30] T84581 TARGETID T84581 T84581 TARGNAME Cytoplasmic thioredoxin reductase (TXNRD1) T84581 INDICATI Investigative Malaria [ICD-11: 1F40-1F45] T84581 INDICATI Phase 3 Psoriasis [ICD-11: EA90] T84581 INDICATI Phase 3 Rheumatoid arthritis [ICD-11: FA20] T84581 INDICATI Approved Solid tumour/cancer [ICD-11: 2A00-2F9Z] T84584 TARGETID T84584 T84584 TARGNAME Sarcoglycan alpha (SGCA) T84584 INDICATI Phase 1/2 Muscular dystrophy [ICD-11: 8C70] T84591 TARGETID T84591 T84591 TARGNAME Guanine nucleotide exchange factor (GNEF) T84591 INDICATI Phase 3 Lung cancer [ICD-11: 2C25] T84614 TARGETID T84614 T84614 TARGNAME Interleukin 31 receptor (IL31R) T84614 INDICATI Phase 3 Atopic eczema [ICD-11: EA80] T84621 TARGETID T84621 T84621 TARGNAME Steroid 11-beta-hydroxylase (CYP11B1) T84621 INDICATI Approved Breast cancer [ICD-11: 2C60-2C6Y] T84621 INDICATI Investigative Cardiomyopathy [ICD-11: BC43] T84621 INDICATI Approved Cushing syndrome [ICD-11: 5A70] T84621 INDICATI Investigative Heart failure [ICD-11: BD10-BD1Z] T84621 INDICATI Investigative Hyperaldosteronism [ICD-11: 5A72] T84631 TARGETID T84631 T84631 TARGNAME Coagulation factor Xa (F10) T84631 INDICATI Discontinued in Phase 3 Acute myeloid leukaemia [ICD-11: 2A60] T84631 INDICATI Discontinued in Phase 3 Angina pectoris [ICD-11: BA40] T84631 INDICATI Phase 2 Attention deficit hyperactivity disorder [ICD-11: 6A05] T84631 INDICATI Phase 3 Bleeding disorder [ICD-11: GA20-GA21] T84631 INDICATI Approved Blood-forming organ disease [ICD-11: 3C0Z] T84631 INDICATI Phase 3 Cerebral ischaemia [ICD-11: 8B1Z] T84631 INDICATI Approved Christmas disease [ICD-11: 3B11] T84631 INDICATI Approved Coagulation defect [ICD-11: 3B10] T84631 INDICATI Approved Coronary thrombosis [ICD-11: BA43] T84631 INDICATI Approved Deep vein thrombosis [ICD-11: BD71] T84631 INDICATI Discontinued in Phase 3 Myocardial infarction [ICD-11: BA41-BA43] T84631 INDICATI Discontinued in Phase 2 Psoriasis [ICD-11: EA90] T84631 INDICATI BLA submitted Renal cell carcinoma [ICD-11: 2C90] T84631 INDICATI Preclinical Solid tumour/cancer [ICD-11: 2A00-2F9Z] T84631 INDICATI Approved Supraventricular tachyarrhythmia [ICD-11: BC81] T84631 INDICATI Approved Thrombosis [ICD-11: DB61-GB90] T84631 INDICATI Approved Venous thromboembolism [ICD-11: BD72] T84634 TARGETID T84634 T84634 TARGNAME Cytochrome P450 26 (CYP26A1) T84634 INDICATI Investigative Asthma [ICD-11: CA23] T84634 INDICATI Phase 2/3 Oesophagitis [ICD-11: DA24] T84634 INDICATI Phase 2 Psoriasis [ICD-11: EA90] T84665 TARGETID T84665 T84665 TARGNAME Tromboxane A2 synthesis (TA2 synth) T84665 INDICATI Approved Postoperative inflammation [ICD-11: 1A00-CA43] T84703 TARGETID T84703 T84703 TARGNAME BDNF/NT-3 growth factors receptor (TrkB) T84703 INDICATI Phase 1 Adrenal cancer [ICD-11: 2D11] T84703 INDICATI Phase 1/2 Alzheimer disease [ICD-11: 8A20] T84703 INDICATI Patented Bone growth disorder [ICD-11: FB86] T84703 INDICATI Phase 1 Breast cancer [ICD-11: 2C60-2C6Y] T84703 INDICATI Patented Chronic pain [ICD-11: MG30] T84703 INDICATI Phase 2 Colorectal cancer [ICD-11: 2B91] T84703 INDICATI Patented General pain disorder [ICD-11: 8E43] T84703 INDICATI Investigative Neurodegenerative disorder [ICD-11: 8A20-8A23] T84703 INDICATI Approved Non-small-cell lung cancer [ICD-11: 2C25] T84703 INDICATI Patented Pruritus [ICD-11: EC90] T84703 INDICATI Approved Solid tumour/cancer [ICD-11: 2A00-2F9Z] T84703 INDICATI Patented Thymoma [ICD-11: 2C27] T84726 TARGETID T84726 T84726 TARGNAME Rho-associated protein kinase (ROCK) T84726 INDICATI Terminated Asthma [ICD-11: CA23] T84726 INDICATI Approved Glaucoma [ICD-11: 9C61] T84726 INDICATI Approved Myocardial infarction [ICD-11: BA41-BA43] T84726 INDICATI Phase 1 Ovarian cancer [ICD-11: 2C73] T84726 INDICATI Phase 1 Solid tumour/cancer [ICD-11: 2A00-2F9Z] T84726 INDICATI Phase 1/2 Spine/trunk injury [ICD-11: ND51] T84780 TARGETID T84780 T84780 TARGNAME Cellular inhibitor of apoptosis 1 (BIRC2) T84780 INDICATI Phase 1 Acute myeloid leukaemia [ICD-11: 2A60] T84780 INDICATI Phase 2 Lymphoma [ICD-11: 2A80-2A86] T84780 INDICATI Investigative Mature T-cell lymphoma [ICD-11: 2A90] T84780 INDICATI Phase 3 Metastatic lymph node neoplasm [ICD-11: 2D60] T84780 INDICATI Phase 2 Solid tumour/cancer [ICD-11: 2A00-2F9Z] T84885 TARGETID T84885 T84885 TARGNAME Picornavirus Capsid protein VP1 (PicVir VP1) T84885 INDICATI Phase 2 Virus infection [ICD-11: 1A24-1D9Z] T84886 TARGETID T84886 T84886 TARGNAME Solute carrier family 12 member 3 (SLC12A3) T84886 INDICATI Approved Essential hypertension [ICD-11: BA00] T84886 INDICATI Approved Hypertension [ICD-11: BA00-BA04] T84886 INDICATI Approved Oedema [ICD-11: MG29] T84894 TARGETID T84894 T84894 TARGNAME Casein kinase II (CSNK2) T84894 INDICATI Phase 3 Cervical cancer [ICD-11: 2C77] T84894 INDICATI Phase 2 Coronavirus infection [ICD-11: 1D92] T84894 INDICATI Phase 1/2 Liver cancer [ICD-11: 2C12] T84894 INDICATI Phase 1 Solid tumour/cancer [ICD-11: 2A00-2F9Z] T84972 TARGETID T84972 T84972 TARGNAME Streptococcus Elongation factor G (Stre-coc fusA) T84972 INDICATI Approved Bacterial infection [ICD-11: 1A00-1C4Z] T84972 INDICATI Phase 3 Infectious meningitis [ICD-11: 1D01] T84981 TARGETID T84981 T84981 TARGNAME C-C chemokine receptor type 7 (CCR7) T84981 INDICATI Phase 1 Malignant haematopoietic neoplasm [ICD-11: 2B33] T84981 INDICATI Phase 1 Mature B-cell leukaemia [ICD-11: 2A82] T85025 TARGETID T85025 T85025 TARGNAME Interleukin 7 receptor alpha (IL7R) T85025 INDICATI Phase 2 Atopic eczema [ICD-11: EA80] T85025 INDICATI Phase 1 Diabetes mellitus [ICD-11: 5A10] T85025 INDICATI Phase 2 Human immunodeficiency virus disease [ICD-11: 1C60-1C62] T85025 INDICATI Phase 1 Type 2 diabetes mellitus [ICD-11: 5A11] T85042 TARGETID T85042 T85042 TARGNAME Peroxisome proliferator-activated receptor (PPAR) T85042 INDICATI IND submitted Non-alcoholic fatty liver disease [ICD-11: DB92] T85042 INDICATI Phase 1/2 Pancreatic cancer [ICD-11: 2C10] T85072 TARGETID T85072 T85072 TARGNAME Human papillomavirus protein E7 (HPV E7) T85072 INDICATI Phase 2 Cervical cancer [ICD-11: 2C77] T85072 INDICATI Phase 3 Cervical intraepithelial neoplasia [ICD-11: 2E66] T85072 INDICATI Phase 3 Dysplasia [ICD-11: LB30-LD2F] T85072 INDICATI Phase 2 Genital organ in situ carcinoma [ICD-11: 2E67] T85072 INDICATI Phase 2 Sexually transmitted infection [ICD-11: 1A9Y-1A9Z] T85072 INDICATI Phase 1 Solid tumour/cancer [ICD-11: 2A00-2F9Z] T85076 TARGETID T85076 T85076 TARGNAME CBLB messenger RNA (CBLB mRNA) T85076 INDICATI Phase 2 Solid tumour/cancer [ICD-11: 2A00-2F9Z] T85158 TARGETID T85158 T85158 TARGNAME Lymphotoxin-alpha (LTA) T85158 INDICATI Phase 2 Rheumatoid arthritis [ICD-11: FA20] T85221 TARGETID T85221 T85221 TARGNAME Glucose-6-phosphatase (G6PC) T85221 INDICATI Phase 1 Inborn carbohydrate metabolism error [ICD-11: 5C51] T85228 TARGETID T85228 T85228 TARGNAME CCR3 messenger RNA (CCR3 mRNA) T85228 INDICATI Phase 2 Asthma [ICD-11: CA23] T85241 TARGETID T85241 T85241 TARGNAME Cell division cycle protein 20 homolog (CDC20) T85241 INDICATI Preclinical Solid tumour/cancer [ICD-11: 2A00-2F9Z] T85309 TARGETID T85309 T85309 TARGNAME Cystathionine beta-synthase (CBS) T85309 INDICATI Phase 1/2 Metabolism inborn error [ICD-11: 5C50] T85419 TARGETID T85419 T85419 TARGNAME Influenza NA messenger RNA (Influenza NA mRNA) T85419 INDICATI Preclinical Influenza [ICD-11: 1E30-1E32] T85421 TARGETID T85421 T85421 TARGNAME Jun N terminal kinase (JNK) T85421 INDICATI Phase 2 Cutaneous lupus erythematosus [ICD-11: EB50-EB5Z] T85421 INDICATI Phase 3 Dissociative neurological symptom disorder [ICD-11: 6B60] T85421 INDICATI Phase 2 Idiopathic interstitial pneumonitis [ICD-11: CB03] T85421 INDICATI Phase 2 Solid tumour/cancer [ICD-11: 2A00-2F9Z] T85421 INDICATI Phase 2 Type 2 diabetes mellitus [ICD-11: 5A11] T85426 TARGETID T85426 T85426 TARGNAME Hepatitis B virus Capsid protein (HBV C) T85426 INDICATI Phase 2 Hepatitis virus infection [ICD-11: 1E50-1E51] T85435 TARGETID T85435 T85435 TARGNAME Insulin receptor (INSR) T85435 INDICATI Approved Acute diabete complication [ICD-11: 5A2Y] T85435 INDICATI Phase 2 Alzheimer disease [ICD-11: 8A20] T85435 INDICATI Discontinued in Phase 1/2 Breast cancer [ICD-11: 2C60-2C6Y] T85435 INDICATI Phase 2 Crohn disease [ICD-11: DD70] T85435 INDICATI Phase 1 Diabetes mellitus [ICD-11: 5A10] T85435 INDICATI Terminated Hyper-lipoproteinaemia [ICD-11: 5C80] T85435 INDICATI Investigative Hypo-glycaemia [ICD-11: 5A41] T85435 INDICATI Investigative Lymphoma [ICD-11: 2A80-2A86] T85435 INDICATI Phase 1 Lysosomal disease [ICD-11: 5C56] T85435 INDICATI Phase 1 Multiple myeloma [ICD-11: 2A83] T85435 INDICATI Phase 2 Pain [ICD-11: MG30-MG3Z] T85435 INDICATI Phase 2 Pancreatic internal secretion disorder [ICD-11: 5A4Y] T85435 INDICATI Phase 4 Psychotic disorder [ICD-11: 6A20-6A25] T85435 INDICATI Approved Type 2 diabetes mellitus [ICD-11: 5A11] T85435 INDICATI Phase 1 Type-1/2 diabete [ICD-11: 5A10-5A11] T85467 TARGETID T85467 T85467 TARGNAME Prostaglandin E2 receptor EP3 (PTGER3) T85467 INDICATI Discontinued in Phase 1 Asthma [ICD-11: CA23] T85467 INDICATI Discontinued in Phase 2 Chronic arterial occlusive disease [ICD-11: BD4Z] T85467 INDICATI Phase 2 Glaucoma [ICD-11: 9C61] T85467 INDICATI Investigative Pain [ICD-11: MG30-MG3Z] T85467 INDICATI Clinical trial Solid tumour/cancer [ICD-11: 2A00-2F9Z] T85467 INDICATI Phase 2 Transplanted organ/tissue [ICD-11: QB63] T85507 TARGETID T85507 T85507 TARGNAME Sialic acid-binding immunoglobulin-like lectin 15 (SIGLEC15) T85507 INDICATI Phase 2 Non-small-cell lung cancer [ICD-11: 2C25] T85523 TARGETID T85523 T85523 TARGNAME Cardiac myosin (MYBPC3) T85523 INDICATI Phase 3 Cardiomyopathy ICD-11: BC43 T85523 INDICATI Phase 3 Heart failure [ICD-11: BD10-BD1Z] T85529 TARGETID T85529 T85529 TARGNAME T-cell-specific surface glycoprotein CD28 (CD28) T85529 INDICATI Phase 1/2 Brain cancer [ICD-11: 2A00] T85529 INDICATI Discontinued in Phase 1 Diabetes mellitus [ICD-11: 5A10] T85529 INDICATI Investigative Immune system disease [ICD-11: 4A01-4B41] T85529 INDICATI Phase 2 Lupus erythematosus [ICD-11: 4A40] T85529 INDICATI Phase 1 Malignant haematopoietic neoplasm [ICD-11: 2B33] T85529 INDICATI Phase 1 Mature B-cell lymphoma [ICD-11: 2A85] T85529 INDICATI Phase 3 Necrotising fasciitis [ICD-11: 1B71] T85529 INDICATI Phase 1/2 Osteosarcoma [ICD-11: 2B51] T85529 INDICATI Phase 1/2 Ovarian cancer [ICD-11: 2C73] T85529 INDICATI Phase 1/2 Prostate cancer [ICD-11: 2C82] T85529 INDICATI Phase 1/2 Respiratory infection [ICD-11: CA07-CA4Z] T85529 INDICATI Phase 1/2 Sarcoma [ICD-11: 2A60-2C35] T85529 INDICATI Phase 1 Solid tumour/cancer [ICD-11: 2A00-2F9Z] T85529 INDICATI Phase 1 Stomach cancer ICD-11: 2B72 T85529 INDICATI Approved Transplant rejection [ICD-11: NE84] T85544 TARGETID T85544 T85544 TARGNAME Target of rapamycin complex 2 MAPKAP1 (MTORC2) T85544 INDICATI Phase 1/2 Breast cancer [ICD-11: 2C60-2C6Y] T85544 INDICATI Phase 1 Pleural mesothelioma [ICD-11: 2C26] T85544 INDICATI Phase 1 Retinopathy [ICD-11: 9B71] T85544 INDICATI Phase 2 Solid tumour/cancer [ICD-11: 2A00-2F9Z] T85554 TARGETID T85554 T85554 TARGNAME T-cell activation antigen CD27 (CD27) T85554 INDICATI Phase 2 Brain cancer [ICD-11: 2A00] T85554 INDICATI Phase 2 Colorectal cancer [ICD-11: 2B91] T85554 INDICATI Phase 2 Head and neck cancer [ICD-11: 2D42] T85554 INDICATI Phase 1 Leukaemia [ICD-11: 2A60-2B33] T85554 INDICATI Phase 1 Lymphoma [ICD-11: 2A80-2A86] T85554 INDICATI Phase 2 Ovarian cancer [ICD-11: 2C73] T85554 INDICATI Phase 2 Renal cell carcinoma [ICD-11: 2C90] T85554 INDICATI Phase 1 Solid tumour/cancer [ICD-11: 2A00-2F9Z] T85574 TARGETID T85574 T85574 TARGNAME Angiotensin II receptor (AGTR) T85574 INDICATI Discontinued in Phase 2 Anemia [ICD-11: 3A00-3A9Z] T85574 INDICATI Phase 2 Hypertension [ICD-11: BA00-BA04] T85581 TARGETID T85581 T85581 TARGNAME Na-K-Cl cotransporter (NKCC) T85581 INDICATI Phase 2 Heart failure [ICD-11: BD10-BD1Z] T85605 TARGETID T85605 T85605 TARGNAME 5-HT receptor (5HTR) T85605 INDICATI Approved Anxiety disorder [ICD-11: 6B00-6B0Z] T85605 INDICATI Phase 2 Bipolar disorder [ICD-11: 6A60] T85605 INDICATI Terminated Carcinoid syndrome [ICD-11: 5B10] T85605 INDICATI Approved Cerebral ischaemia [ICD-11: 8B1Z] T85605 INDICATI Phase 3 Depression [ICD-11: 6A70-6A7Z] T85605 INDICATI Phase 3 Epilepsy/seizure [ICD-11: 8A61-8A6Z] T85605 INDICATI Phase 3 Epileptic encephalopathy [ICD-11: 8A62] T85605 INDICATI Investigative General pain disorder [ICD-11: 8E43] T85605 INDICATI Approved Headache [ICD-11: 8A80-8A84] T85605 INDICATI Phase 3 Insomnia [ICD-11: 7A00-7A0Z] T85605 INDICATI Phase 4 Irritable bowel syndrome [ICD-11: DD91] T85605 INDICATI Phase 1 Migraine [ICD-11: 8A80] T85605 INDICATI Approved Nausea/vomiting [ICD-11: MD90] T85605 INDICATI Withdrawn from market Obesity [ICD-11: 5B80-5B81] T85605 INDICATI Phase 1 Parkinsonism [ICD-11: 8A00] T85605 INDICATI Approved Pituitary gland disorder [ICD-11: 5A60-5A61] T85605 INDICATI Terminated Psychotic disorder [ICD-11: 6A20-6A25] T85605 INDICATI Approved Schizophrenia [ICD-11: 6A20] T85605 INDICATI Phase 1 Tension-type headache [ICD-11: 8A81] T85616 TARGETID T85616 T85616 TARGNAME Thioredoxin (TXN) T85616 INDICATI Phase 2 Solid tumour/cancer [ICD-11: 2A00-2F9Z] T85651 TARGETID T85651 T85651 TARGNAME Myc messenger RNA (MYC mRNA) T85651 INDICATI Phase 2 Coronary atherosclerosis [ICD-11: BA80] T85651 INDICATI Phase 2 Solid tumour/cancer [ICD-11: 2A00-2F9Z] T85670 TARGETID T85670 T85670 TARGNAME Nerve growth factor (NGF) T85670 INDICATI Phase 2 Alzheimer disease [ICD-11: 8A20] T85670 INDICATI Phase 3 Chronic pain [ICD-11: MG30] T85670 INDICATI Phase 3 General pain disorder [ICD-11: 8E43] T85670 INDICATI Phase 1/2 Neurodegenerative disorder [ICD-11: 8A20-8A23] T85670 INDICATI Phase 3 Osteoarthritis [ICD-11: FA00-FA05] T85670 INDICATI Phase 3 Pain [ICD-11: MG30-MG3Z] T85733 TARGETID T85733 T85733 TARGNAME DNA topoisomerase II beta (TOP2B) T85733 INDICATI Approved Breast cancer [ICD-11: 2C60-2C6Y] T85733 INDICATI Approved Chemoprotection [ICD-11: N.A.] T85733 INDICATI Investigative Respiratory system disease [ICD-11: CB40-CB7Z] T85733 INDICATI Phase 1 Solid tumour/cancer [ICD-11: 2A00-2F9Z] T85799 TARGETID T85799 T85799 TARGNAME Cyclin-dependent kinase 4 (CDK4) T85799 INDICATI Phase 1/2 Brain cancer [ICD-11: 2A00] T85799 INDICATI Approved Breast cancer [ICD-11: 2C60-2C6Y] T85799 INDICATI Phase 1 Liposarcoma [ICD-11: 2B59] T85799 INDICATI Approved Lung cancer [ICD-11: 2C25] T85799 INDICATI Phase 1 Malignant haematopoietic neoplasm [ICD-11: 2B33] T85799 INDICATI Phase 2 Mature B-cell lymphoma [ICD-11: 2A85] T85799 INDICATI Phase 1 Prostate cancer [ICD-11: 2C82] T85799 INDICATI Approved Psoriasis [ICD-11: EA90] T85799 INDICATI Terminated Retina cancer [ICD-11: 2D02] T85799 INDICATI Terminated Schizophrenia [ICD-11: 6A20] T85799 INDICATI Phase 3 Solid tumour/cancer [ICD-11: 2A00-2F9Z] T85857 TARGETID T85857 T85857 TARGNAME Thymic stromal lymphopoietin (TSLP) T85857 INDICATI Approved Asthma [ICD-11: CA23] T85857 INDICATI Phase 1 Atopic eczema [ICD-11: EA80] T85857 INDICATI Phase 2 Chronic obstructive pulmonary disease [ICD-11: CA22] T85889 TARGETID T85889 T85889 TARGNAME Phosphate (PHO) T85889 INDICATI Approved Mineral absorption/transport disorder [ICD-11: 5C64] T85943 TARGETID T85943 T85943 TARGNAME Proto-oncogene c-Src (SRC) T85943 INDICATI Phase 2 Acute myeloid leukaemia [ICD-11: 2A60] T85943 INDICATI Phase 2 BCR-ABL1-negative chronic myeloid leukaemia [ICD-11: 2A41] T85943 INDICATI Phase 1 Brain cancer [ICD-11: 2A00] T85943 INDICATI Approved Breast cancer [ICD-11: 2C60-2C6Y] T85943 INDICATI Phase 1 Cardiovascular disease [ICD-11: BA00-BE2Z] T85943 INDICATI Phase 1/2 Cervical cancer [ICD-11: 2C77] T85943 INDICATI Phase 1 Chronic obstructive pulmonary disease [ICD-11: CA22] T85943 INDICATI Phase 1/2 Endometrial cancer [ICD-11: 2C76] T85943 INDICATI Phase 3 Epidermal dysplasias [ICD-11: EK90] T85943 INDICATI Phase 1/2 Fallopian tube cancer [ICD-11: 2C74] T85943 INDICATI Phase 3 Gastrointestinal stromal tumour [ICD-11: 2B5B] T85943 INDICATI Investigative Gram-positive bacterial infection [ICD-11: 1B74-1F40] T85943 INDICATI Approved Ischemia [ICD-11: 8B10-8B11] T85943 INDICATI Phase 3 Leiomyosarcoma [ICD-11: 2B58] T85943 INDICATI Terminated Low bone mass disorder [ICD-11: FB83] T85943 INDICATI Phase 3 Malignant digestive organ neoplasm [ICD-11: 2C11] T85943 INDICATI Phase 2 Malignant haematopoietic neoplasm [ICD-11: 2B33] T85943 INDICATI Phase 1 Mature B-cell leukaemia [ICD-11: 2A82] T85943 INDICATI Phase 3 Metastatic digestive system neoplasm [ICD-11: 2D8Y] T85943 INDICATI Phase 3 Motor neuron disease [ICD-11: 8B60] T85943 INDICATI Phase 2 Multiple myeloma [ICD-11: 2A83] T85943 INDICATI Phase 3 Multiple sclerosis [ICD-11: 8A40] T85943 INDICATI Approved Myeloproliferative neoplasm [ICD-11: 2A20] T85943 INDICATI Investigative Nasopharyngeal cancer [ICD-11: 2B6B] T85943 INDICATI Phase 2 Osteosarcoma [ICD-11: 2B51] T85943 INDICATI Phase 3 Ovarian cancer [ICD-11: 2C73] T85943 INDICATI Phase 3 Pancreatic cancer [ICD-11: 2C10] T85943 INDICATI Phase 1 Parkinsonism [ICD-11: 8A00] T85943 INDICATI Phase 1/2 Peritoneal cancer [ICD-11: 2C51] T85943 INDICATI Phase 1 Postoperative inflammation [ICD-11: 1A00-CA43] T85943 INDICATI Phase 3 Sarcoma [ICD-11: 2A60-2C35] T85943 INDICATI Approved Solid tumour/cancer [ICD-11: 2A00-2F9Z] T85943 INDICATI Phase 3 Synovial sarcoma [ICD-11: 2B5A] T85944 TARGETID T85944 T85944 TARGNAME Pseudomonas UDP-3-O-acyl-GlcNAc deacetylase (Pseudo lpxC) T85944 INDICATI Terminated Gram-negative bacterial infection [ICD-11: 1F41-1G40] T85944 INDICATI Preclinical Pneumonia [ICD-11: CA40] T86014 TARGETID T86014 T86014 TARGNAME Sphingosine kinase 1 (SPHK1) T86014 INDICATI Terminated Arterial occlusive disease [ICD-11: BD40] T86014 INDICATI Investigative Circulatory system disease [ICD-11: BE2Z] T86014 INDICATI Investigative Nasopharyngeal cancer [ICD-11: 2B6B] T86014 INDICATI Phase 1/2 Ovarian cancer [ICD-11: 2C73] T86014 INDICATI Phase 1 Psychoactive substances use disorder [ICD-11: 6C4G] T86041 TARGETID T86041 T86041 TARGNAME ALAS1 messenger RNA (ALAS1 mRNA) T86041 INDICATI Approved Inborn porphyrin/heme metabolism error [ICD-11: 5C58] T86052 TARGETID T86052 T86052 TARGNAME Telomerase reverse transcriptase (TERT) T86052 INDICATI Phase 2 Acute myeloid leukaemia [ICD-11: 2A60] T86052 INDICATI Phase 1 Alzheimer disease [ICD-11: 8A20] T86052 INDICATI Phase 1 Brain cancer [ICD-11: 2A00] T86052 INDICATI Phase 2 Breast cancer [ICD-11: 2C60-2C6Y] T86052 INDICATI Phase 1 Chronic arterial occlusive disease [ICD-11: BD4Z] T86052 INDICATI Phase 1/2 Glaucoma [ICD-11: 9C61] T86052 INDICATI Phase 1/2 Head and neck cancer [ICD-11: 2D42] T86052 INDICATI Phase 2/3 Human immunodeficiency virus disease [ICD-11: 1C60-1C62] T86052 INDICATI Phase 1/2 Liver cancer [ICD-11: 2C12] T86052 INDICATI Phase 2 Lung cancer [ICD-11: 2C25] T86052 INDICATI Phase 2 Melanoma [ICD-11: 2C30] T86052 INDICATI Phase 2 Multiple myeloma [ICD-11: 2A83] T86052 INDICATI Phase 2/3 Myelodysplastic syndrome [ICD-11: 2A37] T86052 INDICATI Phase 2 Myeloproliferative neoplasm [ICD-11: 2A20] T86052 INDICATI Phase 1 Old age ICD-11: MG2A T86052 INDICATI Phase 2 Ovarian cancer [ICD-11: 2C73] T86052 INDICATI Phase 3 Pancreatic cancer [ICD-11: 2C10] T86052 INDICATI Phase 1 Prostate cancer [ICD-11: 2C82] T86052 INDICATI Phase 1 Solid tumour/cancer [ICD-11: 2A00-2F9Z] T86052 INDICATI Phase 2 Thrombocytosis [ICD-11: 3B63] T86057 TARGETID T86057 T86057 TARGNAME Urate anion exchanger 1 (URAT1) T86057 INDICATI Phase 3 Gout [ICD-11: FA25] T86057 INDICATI Approved Inborn purine/pyrimidine/nucleotide metabolism error [ICD-11: 5C55] T86072 TARGETID T86072 T86072 TARGNAME Low-density lipoprotein receptor-related protein 5 (LRP5) T86072 INDICATI Phase 1 Solid tumour/cancer [ICD-11: 2A00-2F9Z] T86115 TARGETID T86115 T86115 TARGNAME ApoC-III messenger RNA (APOC3 mRNA) T86115 INDICATI Phase 1 Arterial occlusive disease [ICD-11: BD40] T86115 INDICATI Approved Hyper-lipoproteinaemia [ICD-11: 5C80] T86115 INDICATI Phase 1 Metabolic disorder [ICD-11: 5C50-5D2Z] T86115 INDICATI Phase 1 Postoperative inflammation [ICD-11: 1A00-CA43] T86130 TARGETID T86130 T86130 TARGNAME Integrin alpha-4/beta-1 (ITGA4/B1) T86130 INDICATI Phase 2 Asthma [ICD-11: CA23] T86130 INDICATI Phase 3 Crohn disease [ICD-11: DD70] T86130 INDICATI Phase 2 Indeterminate colitis [ICD-11: DD72] T86130 INDICATI Phase 2 Multiple sclerosis [ICD-11: 8A40] T86130 INDICATI Terminated Postoperative inflammation [ICD-11: 1A00-CA43] T86130 INDICATI Phase 2 Rheumatoid arthritis [ICD-11: FA20] T86130 INDICATI Phase 3 Ulcerative colitis [ICD-11: DD71] T86161 TARGETID T86161 T86161 TARGNAME Prolyl endopeptidase (PREP) T86161 INDICATI Phase 2 Coeliac disease [ICD-11: DA95] T86161 INDICATI Terminated Human immunodeficiency virus disease [ICD-11: 1C60-1C62] T86161 INDICATI Phase 2 Influenza [ICD-11: 1E30-1E32] T86161 INDICATI Clinical trial Lung cancer [ICD-11: 2C25] T86161 INDICATI Phase 2 Mild neurocognitive disorder [ICD-11: 6D71] T86161 INDICATI Discontinued in Phase 1 Parkinsonism [ICD-11: 8A00] T86192 TARGETID T86192 T86192 TARGNAME Voltage-gated potassium channel Kv7 (KCNQ) T86192 INDICATI Approved Behcet disease [ICD-11: 4A62] T86192 INDICATI Phase 2 Chronic pain [ICD-11: MG30] T86192 INDICATI Withdrawn from market Epilepsy/seizure [ICD-11: 8A61-8A6Z] T86192 INDICATI Phase 2 General pain disorder [ICD-11: 8E43] T86192 INDICATI Discontinued in Phase 2 Parkinsonism [ICD-11: 8A00] T86254 TARGETID T86254 T86254 TARGNAME Tenascin (TNC) T86254 INDICATI Phase 1 Brain cancer [ICD-11: 2A00] T86254 INDICATI Phase 1/2 Malignant haematopoietic neoplasm [ICD-11: 2B33] T86254 INDICATI Phase 2 Solid tumour/cancer [ICD-11: 2A00-2F9Z] T86264 TARGETID T86264 T86264 TARGNAME Solute carrier family 40 member 1 (SLC40A1) T86264 INDICATI Phase 2 Acute disease anaemia [ICD-11: 3A90] T86264 INDICATI Phase 1 Anemia [ICD-11: 3A00-3A9Z] T86264 INDICATI Phase 1 Myelodysplastic syndrome [ICD-11: 2A37] T86264 INDICATI Phase 1 Myeloproliferative neoplasm [ICD-11: 2A20] T86264 INDICATI Phase 1 Thalassaemia [ICD-11: 3A50] T86271 TARGETID T86271 T86271 TARGNAME Calcium-activated potassium channel KCa2.2 (KCNN2) T86271 INDICATI Terminated Multiple myeloma [ICD-11: 2A83] T86271 INDICATI Clinical trial Myelopathy [ICD-11: 8B42] T86273 TARGETID T86273 T86273 TARGNAME G-protein coupled bile acid receptor 1 (GPBAR1) T86273 INDICATI Preclinical Hepatic fibrosis/cirrhosis [ICD-11: DB93] T86273 INDICATI Investigative Metabolic disorder [ICD-11: 5C50-5D2Z] T86273 INDICATI Phase 1/2 Type 2 diabetes mellitus [ICD-11: 5A11] T86321 TARGETID T86321 T86321 TARGNAME Extracellular sulfatase Sulf-2 (SULF2) T86321 INDICATI Phase 2 Brain cancer [ICD-11: 2A00] T86323 TARGETID T86323 T86323 TARGNAME Neural cell adhesion molecule 1 (NCAM1) T86323 INDICATI Phase 1/2 Acute myeloid leukaemia [ICD-11: 2A60] T86323 INDICATI Phase 1/2 Multiple myeloma [ICD-11: 2A83] T86323 INDICATI Phase 1 Myelodysplastic syndrome [ICD-11: 2A37] T86350 TARGETID T86350 T86350 TARGNAME Erbb3 tyrosine kinase receptor (Erbb-3) T86350 INDICATI Phase 2 Breast cancer [ICD-11: 2C60-2C6Y] T86350 INDICATI Phase 2 Colorectal cancer [ICD-11: 2B91] T86350 INDICATI Phase 2 Head and neck cancer [ICD-11: 2D42] T86350 INDICATI Phase 2 Lung cancer [ICD-11: 2C25] T86350 INDICATI Phase 1/2 Malignant mesenchymal neoplasm [ICD-11: 2B5D-2B5Y] T86350 INDICATI Phase 1 Metastatic lymph node neoplasm [ICD-11: 2D60] T86350 INDICATI Phase 2 Pancreatic cancer [ICD-11: 2C10] T86350 INDICATI Phase 2 Psoriasis [ICD-11: EA90] T86350 INDICATI Phase 2 Solid tumour/cancer [ICD-11: 2A00-2F9Z] T86350 INDICATI Phase 2 Squamous cell carcinoma [ICD-11: 2B60-2D01] T86364 TARGETID T86364 T86364 TARGNAME Vasoactive intestinal polypeptide receptor 1 (VIPR1) T86364 INDICATI Phase 2 Chronic obstructive pulmonary disease [ICD-11: CA22] T86364 INDICATI Phase 2 Pulmonary hypertension [ICD-11: BB01] T86385 TARGETID T86385 T86385 TARGNAME Cathepsin G (CTSG) T86385 INDICATI Discontinued in Phase 2 Atopic eczema [ICD-11: EA80] T86385 INDICATI Phase 2 Chronic obstructive pulmonary disease [ICD-11: CA22] T86385 INDICATI Preclinical Coronavirus infection [ICD-11: 1D92] T86385 INDICATI Discontinued in Phase 3 Dissociative neurological symptom disorder [ICD-11: 6B60] T86399 TARGETID T86399 T86399 TARGNAME Bromodomain-containing protein 2 (BRD2) T86399 INDICATI Phase 1/2 Acute myeloid leukaemia [ICD-11: 2A60] T86399 INDICATI Phase 1 Myelodysplastic syndrome [ICD-11: 2A37] T86399 INDICATI Phase 1 Prostate cancer [ICD-11: 2C82] T86399 INDICATI Phase 1 Solid tumour/cancer [ICD-11: 2A00-2F9Z] T86428 TARGETID T86428 T86428 TARGNAME CAAX farnesyltransferase beta (FNTB) T86428 INDICATI Terminated Colorectal cancer [ICD-11: 2B91] T86428 INDICATI Terminated Lung cancer [ICD-11: 2C25] T86428 INDICATI Terminated Solid tumour/cancer [ICD-11: 2A00-2F9Z] T86437 TARGETID T86437 T86437 TARGNAME HUMAN janus kinase 1 (JAK-1) T86437 INDICATI Phase 3 COVID-19 [ICD-11: 1D6Y] T86437 INDICATI Approved Myelofibrosis [ICD-11: 2A22] T86462 TARGETID T86462 T86462 TARGNAME Transthyretin (TTR) T86462 INDICATI Approved Amyloidosis [ICD-11: 5D00] T86462 INDICATI Phase 1 Amyloidosis ICD-11: 5D00 T86462 INDICATI Phase 3 Cardiomyopathy [ICD-11: BC43] T86513 TARGETID T86513 T86513 TARGNAME HUMAN interleukin-6 receptor (IL6R) T86513 INDICATI Phase 3 COVID-19 [ICD-11: 1D6Y] T86513 INDICATI Approved Rheumatoid arthritis [ICD-11: FA20] T86513 INDICATI Approved Vasculitis [ICD-11: 4A44] T86528 TARGETID T86528 T86528 TARGNAME Geranyltranstransferase (FDPS) T86528 INDICATI Phase 3 Acute myeloid leukaemia [ICD-11: 2A60] T86528 INDICATI Approved Bone paget disease [ICD-11: FB85] T86528 INDICATI Phase 1/2 Colorectal cancer [ICD-11: 2B91] T86528 INDICATI Phase 3 Focal/segmental autonomic disorder [ICD-11: 8D8A] T86528 INDICATI Approved Low bone mass disorder [ICD-11: FB83] T86528 INDICATI Phase 2 Mature T-cell lymphoma [ICD-11: 2A90] T86528 INDICATI Approved Mineral excesses [ICD-11: 5B91] T86528 INDICATI Approved Musculoskeletal system/connective tissue disease [ICD-11: FC0Z] T86528 INDICATI Phase 2 Myelodysplastic syndrome [ICD-11: 2A37] T86528 INDICATI Phase 2 Myeloproliferative neoplasm [ICD-11: 2A20] T86528 INDICATI Phase 1/2 Pancreatic cancer [ICD-11: 2C10] T86528 INDICATI Phase 2 Sexually transmitted infection [ICD-11: 1A9Y-1A9Z] T86528 INDICATI Investigative Solid tumour/cancer [ICD-11: 2A00-2F9Z] T86541 TARGETID T86541 T86541 TARGNAME Acid-sensing ion channel 2 (ASIC2) T86541 INDICATI Investigative General pain disorder [ICD-11: 8E43] T86552 TARGETID T86552 T86552 TARGNAME Tumor necrosis factor receptor type I (TNF-R1) T86552 INDICATI Phase 1 Acute respiratory distress syndrome [ICD-11: CB00] T86552 INDICATI Investigative Acute/subacute hepatic failure [ICD-11: DB91] T86552 INDICATI Terminated Alopecia [ICD-11: ED70] T86552 INDICATI Phase 3 Brain cancer [ICD-11: 2A00] T86552 INDICATI Investigative Chronic obstructive pulmonary disease [ICD-11: CA22] T86552 INDICATI Investigative Diabetes mellitus [ICD-11: 5A10] T86552 INDICATI Phase 1 Indeterminate colitis [ICD-11: DD72] T86552 INDICATI Phase 2 Intrathoracic organs injury [ICD-11: NB32] T86552 INDICATI Investigative Multiple sclerosis [ICD-11: 8A40] T86552 INDICATI Phase 3 Ovarian cancer [ICD-11: 2C73] T86552 INDICATI Investigative Rheumatoid arthritis [ICD-11: FA20] T86552 INDICATI Phase 1 Ulcerative colitis [ICD-11: DD71] T86573 TARGETID T86573 T86573 TARGNAME HUMAN inosine-5'-monophosphate dehydrogenase 2 (IMPDH2) T86573 INDICATI Investigative COVID-19 [ICD-11: 1D6Y] T86573 INDICATI Approved Hepatitis virus infection [ICD-11: 1E50-1E51] T86573 INDICATI Investigative Middle East Respiratory Syndrome [ICD-11: 1D64] T86573 INDICATI Investigative Severe acute respiratory syndrome [ICD-11: 1D65] T86577 TARGETID T86577 T86577 TARGNAME HUMAN mannose receptor (MRC1) T86577 INDICATI Investigative COVID-19 [ICD-11: 1D6Y] T86577 INDICATI Approved Type 2 diabetes mellitus [ICD-11: 5A11] T86591 TARGETID T86591 T86591 TARGNAME Peroxisome proliferator-activated receptor alpha (PPARA) T86591 INDICATI Phase 2 Acute diabete complication [ICD-11: 5A2Y] T86591 INDICATI Discontinued in Phase 1 Arterial occlusive disease [ICD-11: BD40] T86591 INDICATI Phase 3 Cardiovascular disease [ICD-11: BA00-BE2Z] T86591 INDICATI Phase 3 Diabetes mellitus [ICD-11: 5A10] T86591 INDICATI Phase 2 Dyslipidemia [ICD-11: 5C80-5C81] T86591 INDICATI Phase 1 Gout [ICD-11: FA25] T86591 INDICATI Discontinued in Phase 2 Heart failure [ICD-11: BD10-BD1Z] T86591 INDICATI Approved Hyperlipidemia [ICD-11: 5C80] T86591 INDICATI Approved Hyper-lipoproteinaemia [ICD-11: 5C80] T86591 INDICATI Preclinical Idiopathic interstitial pneumonitis [ICD-11: CB03] T86591 INDICATI Phase 3 Inborn lipid metabolism error [ICD-11: 5C52] T86591 INDICATI Preclinical Metabolic disorder [ICD-11: 5C50-5D2Z] T86591 INDICATI Phase 3 Non-alcoholic fatty liver disease [ICD-11: DB92] T86591 INDICATI Preclinical Rheumatoid arthritis [ICD-11: FA20] T86591 INDICATI Phase 1 Solid tumour/cancer [ICD-11: 2A00-2F9Z] T86591 INDICATI Approved Type 2 diabetes mellitus [ICD-11: 5A11] T86597 TARGETID T86597 T86597 TARGNAME HUMAN bromodomain-containing protein 2 (BRD2) T86597 INDICATI Investigative COVID-19 [ICD-11: 1D6Y] T86609 TARGETID T86609 T86609 TARGNAME Glycoside hydrolase (GlyH) T86609 INDICATI Preclinical Virus infection [ICD-11: 1A24-1D9Z] T86646 TARGETID T86646 T86646 TARGNAME HUMAN beta adrenergic receptor (BAR) T86646 INDICATI Investigative COVID-19 [ICD-11: 1D6Y] T86646 INDICATI Approved Heart failure [ICD-11: BD10-BD1Z] T86652 TARGETID T86652 T86652 TARGNAME PCSK9 messenger RNA (PCSK9 mRNA) T86652 INDICATI Phase 2 Cardiovascular disease [ICD-11: BA00-BE2Z] T86652 INDICATI Preclinical Coronary atherosclerosis [ICD-11: BA80] T86652 INDICATI Approved Hyper-lipoproteinaemia [ICD-11: 5C80] T86652 INDICATI Phase 1 Metabolic disorder [ICD-11: 5C50-5D2Z] T86671 TARGETID T86671 T86671 TARGNAME Orexin receptor (HCRTR) T86671 INDICATI Approved Insomnia [ICD-11: 7A00-7A0Z] T86674 TARGETID T86674 T86674 TARGNAME Influenza Hemagglutinin (Influ HA) T86674 INDICATI Phase 2 Influenza [ICD-11: 1E30-1E32] T86674 INDICATI Phase 2 Postoperative inflammation [ICD-11: 1A00-CA43] T86674 INDICATI Approved Virus infection [ICD-11: 1A24-1D9Z] T86679 TARGETID T86679 T86679 TARGNAME Adenosine A2b receptor (ADORA2B) T86679 INDICATI Discontinued in Phase 3 Alzheimer disease [ICD-11: 8A20] T86679 INDICATI Phase 1 Asthma [ICD-11: CA23] T86679 INDICATI Phase 1 Breathing abnormality [ICD-11: MD11] T86679 INDICATI Phase 1/2 Colorectal cancer [ICD-11: 2B91] T86679 INDICATI Phase 2 Heart failure [ICD-11: BD10-BD1Z] T86679 INDICATI Approved Herpes simplex infection [ICD-11: 1F00] T86679 INDICATI Phase 2 Hypertension [ICD-11: BA00-BA04] T86679 INDICATI Preclinical Ischaemic heart disease [ICD-11: BA6Z] T86679 INDICATI Phase 1 Lung cancer [ICD-11: 2C25] T86679 INDICATI Terminated Multiple sclerosis [ICD-11: 8A40] T86679 INDICATI Phase 1 Parkinsonism [ICD-11: 8A00] T86679 INDICATI IND submitted Solid tumour/cancer [ICD-11: 2A00-2F9Z] T86679 INDICATI Approved Supraventricular tachyarrhythmia [ICD-11: BC81] T86679 INDICATI Investigative Type 2 diabetes mellitus [ICD-11: 5A11] T86702 TARGETID T86702 T86702 TARGNAME Matrix metalloproteinase-3 (MMP-3) T86702 INDICATI Discontinued in Phase 2 Corneal disease [ICD-11: 9A76-9A78] T86702 INDICATI Discontinued in Phase 2 Hepatitis virus infection [ICD-11: 1E50-1E51] T86702 INDICATI Preclinical Idiopathic interstitial pneumonitis [ICD-11: CB03] T86702 INDICATI Terminated Multiple sclerosis [ICD-11: 8A40] T86702 INDICATI Discontinued in Phase 2 Myocardial infarction [ICD-11: BA41-BA43] T86702 INDICATI Discontinued in Phase 2 Osteoarthritis [ICD-11: FA00-FA05] T86702 INDICATI Terminated Rheumatoid arthritis [ICD-11: FA20] T86734 TARGETID T86734 T86734 TARGNAME Glutaminase (GLS) T86734 INDICATI Phase 2 Breast cancer [ICD-11: 2C60-2C6Y] T86734 INDICATI Phase 1 Leukaemia [ICD-11: 2A60-2B33] T86734 INDICATI Phase 2 Renal cell carcinoma [ICD-11: 2C90] T86734 INDICATI Phase 2 Solid tumour/cancer [ICD-11: 2A00-2F9Z] T86748 TARGETID T86748 T86748 TARGNAME Endosialin (CD248) T86748 INDICATI Phase 2 Colorectal cancer [ICD-11: 2B91] T86748 INDICATI Phase 2 Kaposi sarcoma [ICD-11: 2B57] T86748 INDICATI Phase 2 Melanoma [ICD-11: 2C30] T86748 INDICATI Phase 2 Neuroendocrine carcinoma [ICD-11: 2C34] T86748 INDICATI Phase 2 Sarcoma [ICD-11: 2A60-2C35] T86803 TARGETID T86803 T86803 TARGNAME STAT3 messenger RNA (STAT3 mRNA) T86803 INDICATI Phase 1/2 Solid tumour/cancer [ICD-11: 2A00-2F9Z] T86805 TARGETID T86805 T86805 TARGNAME HUMAN eukaryotic initiation factor-4A (eIF4A) T86805 INDICATI Investigative Mature T-cell lymphoma [ICD-11: 2A90] T86805 INDICATI Investigative Middle East Respiratory Syndrome [ICD-11: 1D64] T86805 INDICATI Phase 1/2 Solid tumour/cancer [ICD-11: 2A00-2F9Z] T86836 TARGETID T86836 T86836 TARGNAME Human Deoxyribonucleic acid (hDNA) T86836 INDICATI Approved Acute myeloid leukaemia [ICD-11: 2A60] T86836 INDICATI Phase 3 Bladder cancer [ICD-11: 2C94] T86836 INDICATI Approved Brain cancer [ICD-11: 2A00] T86836 INDICATI Approved Breast cancer [ICD-11: 2C60-2C6Y] T86836 INDICATI Approved Colorectal cancer [ICD-11: 2B91] T86836 INDICATI Approved Cystic fibrosis [ICD-11: CA25] T86836 INDICATI Phase 2 Endometrial cancer [ICD-11: 2C76] T86836 INDICATI Preclinical Fungal infection [ICD-11: 1F29-1F2F] T86836 INDICATI Discontinued in Phase 2 Head and neck cancer [ICD-11: 2D42] T86836 INDICATI Approved Hodgkin lymphoma [ICD-11: 2B30] T86836 INDICATI Phase 1 Human immunodeficiency virus disease [ICD-11: 1C60-1C62] T86836 INDICATI Phase 1 Influenza [ICD-11: 1E30-1E32] T86836 INDICATI Approved Kaposi sarcoma [ICD-11: 2B57] T86836 INDICATI Approved Leukaemia [ICD-11: 2A60-2B33] T86836 INDICATI Approved Liver cancer [ICD-11: 2C12] T86836 INDICATI Approved Lung cancer [ICD-11: 2C25] T86836 INDICATI Discontinued in Phase 3 Lupus erythematosus [ICD-11: 4A40] T86836 INDICATI Phase 3 Malaria [ICD-11: 1F40-1F45] T86836 INDICATI Approved Malignant digestive organ neoplasm [ICD-11: 2C11] T86836 INDICATI Phase 2 Mature B-cell lymphoma [ICD-11: 2A85] T86836 INDICATI Approved Mature T-cell lymphoma [ICD-11: 2A90] T86836 INDICATI Approved Melanoma [ICD-11: 2C30] T86836 INDICATI Phase 2 Metastatic tumour [ICD-11: 2D50-2E2Z] T86836 INDICATI Approved Multiple myeloma [ICD-11: 2A83] T86836 INDICATI Phase 1/2 Mycobacterium infection [ICD-11: 1B10-1B21] T86836 INDICATI Approved Myelodysplastic syndrome [ICD-11: 2A37] T86836 INDICATI Approved Myeloproliferative neoplasm [ICD-11: 2A20] T86836 INDICATI Approved Nutritional deficiency [ICD-11: 5B50-5B71] T86836 INDICATI Phase 2 Osteosarcoma [ICD-11: 2B51] T86836 INDICATI Approved Ovarian cancer [ICD-11: 2C73] T86836 INDICATI Approved Pancreatic cancer [ICD-11: 2C10] T86836 INDICATI Approved Prostate cancer [ICD-11: 2C82] T86836 INDICATI Phase 3 Respiratory infection [ICD-11: CA07-CA4Z] T86836 INDICATI Phase 1 Skin disease [ICD-11: EA00-EM0Z] T86836 INDICATI Approved Solid tumour/cancer [ICD-11: 2A00-2F9Z] T86836 INDICATI Phase 1 Squamous cell carcinoma [ICD-11: 2B60-2D01] T86836 INDICATI Discontinued in Phase 2 Stomach cancer [ICD-11: 2B72] T86837 TARGETID T86837 T86837 TARGNAME HUMAN calpain-2/calpain small subunit 1 heterodimer (CAPN2/CAPNS1) T86837 INDICATI Phase 2 COVID-19 [ICD-11: 1D6Y] T86885 TARGETID T86885 T86885 TARGNAME Beta-2-glycoprotein 1 (APOH) T86885 INDICATI Discontinued in Phase 1 Antiphospholipid syndrome [ICD-11: 4A45] T86918 TARGETID T86918 T86918 TARGNAME Pancreatic alpha-amylase (AMY2A) T86918 INDICATI Phase 3 Cystic fibrosis [ICD-11: CA25] T86918 INDICATI NDA filed Pancreatic malfunction [ICD-11: DC30-DC3Z] T86928 TARGETID T86928 T86928 TARGNAME HUMAN casein kinase II (CSK2) T86928 INDICATI Investigative COVID-19 [ICD-11: 1D6Y] T86928 INDICATI Phase 1/2 Liver cancer [ICD-11: 2C12] T86992 TARGETID T86992 T86992 TARGNAME Mycobacterium Fusion protein Rv2608-Rv3619-Rv3620-Rv1813 (MycB antigens) T86992 INDICATI Phase 2 HIV-infected patients with tuberculosis [ICD-11: 1B10-1B14] T87023 TARGETID T87023 T87023 TARGNAME Platelet-activating factor receptor (PTAFR) T87023 INDICATI Discontinued in Phase 1 Allergic/hypersensitivity disorder [ICD-11: 4A80-4A8Z] T87023 INDICATI Phase 3 Asthma [ICD-11: CA23] T87023 INDICATI Terminated Cardiac arrhythmia [ICD-11: BC9Z] T87023 INDICATI Investigative Cerebral ischaemia [ICD-11: 8B1Z] T87023 INDICATI Terminated Cerebral ischaemic stroke [ICD-11: 8B11] T87023 INDICATI Discontinued in Phase 2 Conjunctiva disorder [ICD-11: 9A60] T87023 INDICATI Phase 2 Dengue fever [ICD-11: 1D2Z] T87023 INDICATI Investigative Hepatitis virus infection [ICD-11: 1E50-1E51] T87023 INDICATI Phase 2 Indeterminate colitis [ICD-11: DD72] T87023 INDICATI Approved Ischaemic/haemorrhagic stroke [ICD-11: 8B20] T87023 INDICATI Phase 1 Obesity [ICD-11: 5B80-5B81] T87023 INDICATI Terminated Postoperative inflammation [ICD-11: 1A00-CA43] T87023 INDICATI Phase 2 Psoriasis [ICD-11: EA90] T87023 INDICATI Phase 2 Sepsis [ICD-11: 1G40-1G41] T87023 INDICATI Discontinued in Phase 1 Solid tumour/cancer [ICD-11: 2A00-2F9Z] T87023 INDICATI Terminated Thrombocytopenia [ICD-11: 3B64] T87023 INDICATI Terminated Thrombosis [ICD-11: DB61-GB90] T87023 INDICATI Phase 2 Unspecific body region injury [ICD-11: ND56] T87024 TARGETID T87024 T87024 TARGNAME Amyloid beta A4 protein (APP) T87024 INDICATI Approved Alzheimer disease [ICD-11: 8A20] T87024 INDICATI Phase 1 Amyloidosis [ICD-11: 5D00] T87024 INDICATI Investigative Brain cancer [ICD-11: 2A00] T87024 INDICATI Approved Diagnostic imaging [ICD-11: N.A.] T87024 INDICATI Investigative Dissociative neurological symptom disorder [ICD-11: 6B60] T87024 INDICATI Phase 1/2 Dystrophic epidermolysis bullosa [ICD-11: EC32] T87024 INDICATI Preclinical Intracranial injury [ICD-11: NA07] T87024 INDICATI Discontinued in Phase 2 Macular degeneration [ICD-11: 9B75] T87024 INDICATI Investigative Mild neurocognitive disorder [ICD-11: 6D71] T87024 INDICATI Phase 2 Retinopathy [ICD-11: 9B71] T87024 INDICATI Phase 3 Solid tumour/cancer [ICD-11: 2A00-2F9Z] T87075 TARGETID T87075 T87075 TARGNAME T-cell surface glycoprotein CD3 epsilon (CD3E) T87075 INDICATI Phase 2 Breast cancer [ICD-11: 2C60-2C6Y] T87075 INDICATI Phase 1/2 Melanoma [ICD-11: 2C30] T87075 INDICATI Phase 2 Mycosis fungoides [ICD-11: 2B01] T87075 INDICATI Phase 1 Prostate cancer [ICD-11: 2C82] T87075 INDICATI Phase 1 Solid tumour/cancer [ICD-11: 2A00-2F9Z] T87075 INDICATI Approved Transplant rejection [ICD-11: NE84] T87108 TARGETID T87108 T87108 TARGNAME Mesothelin (MSLN) T87108 INDICATI Phase 1/2 Breast cancer [ICD-11: 2C60-2C6Y] T87108 INDICATI Phase 1/2 Cervical cancer [ICD-11: 2C77] T87108 INDICATI Phase 1 Endometrial cancer [ICD-11: 2C76] T87108 INDICATI Phase 1 Fallopian tube cancer [ICD-11: 2C74] T87108 INDICATI Phase 1/2 Liver cancer [ICD-11: 2C12] T87108 INDICATI Phase 1/2 Lung cancer [ICD-11: 2C25] T87108 INDICATI Phase 1 Lymphatic vessel/lymph nodes disorder [ICD-11: BD9Z] T87108 INDICATI Phase 1 Mesothelial tumour [ICD-11: 2F10] T87108 INDICATI Phase 1 Mesothelin positive tumour [ICD-11: 2C51-2F10] T87108 INDICATI Phase 1 Metastatic malignant neoplasm [ICD-11: 2D50-2E09] T87108 INDICATI Phase 1 Metastatic pleura neoplasm [ICD-11: 2D72] T87108 INDICATI Phase 1/2 Non-small-cell lung cancer [ICD-11: 2C25] T87108 INDICATI Phase 1/2 Ovarian cancer [ICD-11: 2C73] T87108 INDICATI Phase 2 Pancreatic cancer [ICD-11: 2C10] T87108 INDICATI Phase 2 Peritoneal cancer [ICD-11: 2C51] T87108 INDICATI Phase 1 Pleural mesothelioma [ICD-11: 2C26] T87108 INDICATI Phase 1/2 Solid tumour/cancer [ICD-11: 2A00-2F9Z] T87108 INDICATI Phase 2 Stomach cancer [ICD-11: 2B72] T87109 TARGETID T87109 T87109 TARGNAME Casein kinase I delta (CSNK1D) T87109 INDICATI Preclinical Mature B-cell leukaemia [ICD-11: 2A82] T87109 INDICATI Preclinical Pancreatic cancer [ICD-11: 2C10] T87119 TARGETID T87119 T87119 TARGNAME Fungal Cell membrane (Fung CM) T87119 INDICATI Approved Candidosis [ICD-11: 1F23] T87119 INDICATI Approved Conjunctiva disorder [ICD-11: 9A60] T87119 INDICATI Approved Dermatophytosis [ICD-11: 1F28] T87166 TARGETID T87166 T87166 TARGNAME Glucokinase (GCK) T87166 INDICATI Phase 2 Acute diabete complication [ICD-11: 5A2Y] T87166 INDICATI Phase 1/2 Diabetes mellitus [ICD-11: 5A10] T87166 INDICATI Phase 1 Obesity [ICD-11: 5B80-5B81] T87166 INDICATI Phase 2 Type 2 diabetes mellitus [ICD-11: 5A11] T87206 TARGETID T87206 T87206 TARGNAME S100 calcium-binding protein B (S100B) T87206 INDICATI Phase 2/3 Ischaemic/haemorrhagic stroke [ICD-11: 8B20] T87206 INDICATI Terminated Type 2 diabetes mellitus [ICD-11: 5A11] T87237 TARGETID T87237 T87237 TARGNAME Cell differentiation (CD) T87237 INDICATI Phase 1/2 Acute myeloid leukaemia [ICD-11: 2A60] T87237 INDICATI Phase 1/2 Malignant haematopoietic neoplasm [ICD-11: 2B33] T87237 INDICATI Phase 1/2 Myelodysplastic syndrome [ICD-11: 2A37] T87237 INDICATI Phase 1/2 Myeloproliferative neoplasm [ICD-11: 2A20] T87259 TARGETID T87259 T87259 TARGNAME ITGAV messenger RNA (ITGAV mRNA) T87259 INDICATI Phase 2 Multiple sclerosis [ICD-11: 8A40] T87325 TARGETID T87325 T87325 TARGNAME COVID-19 papain-like proteinase (PL-PRO) T87325 INDICATI Phase 2 Alzheimer disease [ICD-11: 8A20] T87325 INDICATI Preclinical Coronavirus infection [ICD-11: 1D92] T87325 INDICATI Phase 3 COVID-19 [ICD-11: 1D6Y] T87325 INDICATI Phase 2b Episodic vestibular syndrome [ICD-11: AB31] T87325 INDICATI Preclinical Middle East Respiratory Syndrome [ICD-11: 1D64] T87325 INDICATI Phase 2 Pancreatic cancer [ICD-11: 2C10] T87325 INDICATI Preclinical Severe acute respiratory syndrome [ICD-11: 1D65] T87325 INDICATI Approved Substance abuse [ICD-11: 6C40] T87350 TARGETID T87350 T87350 TARGNAME Platelet-derived growth factor B (PDGFB) T87350 INDICATI Phase 1 Cystic fibrosis [ICD-11: CA25] T87350 INDICATI Phase 3 Diabetic foot ulcer [ICD-11: BD54] T87350 INDICATI Phase 2 Retinopathy [ICD-11: 9B71] T87374 TARGETID T87374 T87374 TARGNAME COVID-19 spike glycoprotein (S) T87374 INDICATI Phase 1 Coronavirus infection [ICD-11: 1D92] T87374 INDICATI Approved in EU COVID-19 [ICD-11: 1D6Y] T87374 INDICATI Preclinical Middle East Respiratory Syndrome [ICD-11: 1D64] T87467 TARGETID T87467 T87467 TARGNAME Folate receptor (FOLR) T87467 INDICATI Approved Folate deficiency anaemia [ICD-11: 3A02] T87467 INDICATI Approved Nutritional deficiency [ICD-11: 5B50-5B71] T87554 TARGETID T87554 T87554 TARGNAME HUMAN janus kinase 2 (JAK-2) T87554 INDICATI Phase 3 COVID-19 [ICD-11: 1D6Y] T87554 INDICATI Approved Myelofibrosis [ICD-11: 2A22] T87554 INDICATI Approved Myeloproliferative neoplasm [ICD-11: 2A20] T87608 TARGETID T87608 T87608 TARGNAME Mitochondrial gene transcription (MGT) T87608 INDICATI Discontinued in Phase 1 Solid tumour/cancer [ICD-11: 2A00-2F9Z] T87633 TARGETID T87633 T87633 TARGNAME HUMAN toll-like receptor 9 (TLR9) T87633 INDICATI Phase 2 COVID-19 [ICD-11: 1D6Y] T87670 TARGETID T87670 T87670 TARGNAME G-protein coupled receptor 55 (GPR55) T87670 INDICATI Approved Attention deficit hyperactivity disorder [ICD-11: 6A05] T87670 INDICATI Phase 1 Intellectual development disorder [ICD-11: LD90] T87675 TARGETID T87675 T87675 TARGNAME Aurora kinase A (AURKA) T87675 INDICATI Phase 3 Acute diabete complication [ICD-11: 5A2Y] T87675 INDICATI Phase 2 Acute myeloid leukaemia [ICD-11: 2A60] T87675 INDICATI Phase 2 Breast cancer [ICD-11: 2C60-2C6Y] T87675 INDICATI Phase 2 Liver cancer [ICD-11: 2C12] T87675 INDICATI Phase 2 Lung cancer [ICD-11: 2C25] T87675 INDICATI Phase 2 Malignant haematopoietic neoplasm [ICD-11: 2B33] T87675 INDICATI Phase 2 Prostate cancer [ICD-11: 2C82] T87675 INDICATI Phase 3 Solid tumour/cancer [ICD-11: 2A00-2F9Z] T87686 TARGETID T87686 T87686 TARGNAME Histone-lysine N-methyltransferase (HLNM) T87686 INDICATI Phase 1/2 Acute myeloid leukaemia [ICD-11: 2A60] T87686 INDICATI Investigative Leukaemia [ICD-11: 2A60-2B33] T87686 INDICATI Phase 1 Malignant haematopoietic neoplasm [ICD-11: 2B33] T87686 INDICATI Phase 1 Mature B-cell lymphoma [ICD-11: 2A85] T87742 TARGETID T87742 T87742 TARGNAME Gap junction protein (GJP) T87742 INDICATI Phase 2 Cardiac arrhythmia [ICD-11: BC9Z] T87742 INDICATI Phase 2 Supraventricular tachyarrhythmia [ICD-11: BC81] T87749 TARGETID T87749 T87749 TARGNAME Growth/differentiation factor 8 (GDF-8) T87749 INDICATI Phase 2 Muscle disorder [ICD-11: FB32-FB3Z] T87749 INDICATI Phase 2 Muscular atrophy [ICD-11: 8B61] T87749 INDICATI Phase 2 Muscular dystrophy [ICD-11: 8C70] T87831 TARGETID T87831 T87831 TARGNAME N-formyl peptide receptor (FPR1) T87831 INDICATI Phase 3 Peptic ulcer [ICD-11: DA61] T87831 INDICATI Investigative Postoperative inflammation [ICD-11: 1A00-CA43] T87871 TARGETID T87871 T87871 TARGNAME Neurotrophic tyrosine kinase ROR1 (ROR1) T87871 INDICATI Phase 2/3 Diffuse large B-cell lymphoma [ICD-11: 2A81] T87871 INDICATI Phase 1 Leukaemia [ICD-11: 2A60-2B33] T87871 INDICATI Phase 2 Mature B-cell leukaemia [ICD-11: 2A82] T87871 INDICATI Phase 2 Mature B-cell lymphoma [ICD-11: 2A85] T87871 INDICATI Phase 1 Prostate cancer [ICD-11: 2C82] T87871 INDICATI Phase 2 Solid tumour/cancer [ICD-11: 2A00-2F9Z] T87875 TARGETID T87875 T87875 TARGNAME Glucagon receptor messenger RNA (GCGR mRNA) T87875 INDICATI Phase 2 Acute diabete complication [ICD-11: 5A2Y] T87875 INDICATI Phase 2 Type 2 diabetes mellitus [ICD-11: 5A11] T87939 TARGETID T87939 T87939 TARGNAME Plasma kallikrein messenger RNA (KLKB1 mRNA) T87939 INDICATI Phase 3 Amyloidosis [ICD-11: 5D00] T87939 INDICATI Phase 3 Innate/adaptive immunodeficiency [ICD-11: 4A00] T87946 TARGETID T87946 T87946 TARGNAME Cytokine receptor unspecific (CRF) T87946 INDICATI Phase 2 Acute myeloid leukaemia [ICD-11: 2A60] T87946 INDICATI Discontinued in Phase 1 Alzheimer disease [ICD-11: 8A20] T87946 INDICATI Phase 1 Breast cancer [ICD-11: 2C60-2C6Y] T87946 INDICATI Phase 2 Head and neck cancer [ICD-11: 2D42] T87946 INDICATI Investigative Leukaemia [ICD-11: 2A60-2B33] T87946 INDICATI Phase 2 Rheumatoid arthritis [ICD-11: FA20] T87946 INDICATI Discontinued in Phase 2 Sepsis [ICD-11: 1G40-1G41] T87946 INDICATI Terminated Solid tumour/cancer [ICD-11: 2A00-2F9Z] T87946 INDICATI Phase 2 Squamous cell carcinoma [ICD-11: 2B60-2D01] T87975 TARGETID T87975 T87975 TARGNAME Fungal Proton pump (FPPCM) T87975 INDICATI Approved Seborrhoeic dermatitis [ICD-11: EA81] T88015 TARGETID T88015 T88015 TARGNAME COVID-19 3C-like protease (3CLpro) T88015 INDICATI Preclinical Coronavirus infection [ICD-11: 1D92] T88015 INDICATI Phase 3 COVID-19 [ICD-11: 1D6Y] T88015 INDICATI Approved Human immunodeficiency virus disease [ICD-11: 1C60-1C62] T88015 INDICATI Preclinical Middle East Respiratory Syndrome [ICD-11: 1D64] T88015 INDICATI Preclinical Severe acute respiratory syndrome [ICD-11: 1D65] T88023 TARGETID T88023 T88023 TARGNAME Lymphocyte activation antigen CD30 (TNFRSF8) T88023 INDICATI Phase 1/2 B-cell lymphoma [ICD-11: 2A86] T88023 INDICATI Investigative Diabetes mellitus [ICD-11: 5A10] T88023 INDICATI Phase 1 Follicular lymphoma [ICD-11: 2A80] T88023 INDICATI Approved Hodgkin lymphoma [ICD-11: 2B30] T88023 INDICATI Phase 1/2 Immune system disease [ICD-11: 4A01-4B41] T88023 INDICATI Phase 1/2 Immunoproliferative disorder [ICD-11: 2B32] T88023 INDICATI Phase 1/2 Leukaemia [ICD-11: 2A60-2B33] T88023 INDICATI Phase 1/2 Lymphatic vessel/lymph nodes disorder [ICD-11: BD9Z] T88023 INDICATI Phase 2 Lymphoma [ICD-11: 2A80-2A86] T88023 INDICATI Phase 2 Malignant haematopoietic neoplasm [ICD-11: 2B33] T88023 INDICATI Phase 2 Mature T-cell lymphoma [ICD-11: 2A90] T88023 INDICATI Phase 1/2 Multiple myeloma [ICD-11: 2A83] T88023 INDICATI Phase 2 Mycosis fungoides [ICD-11: 2B01] T88023 INDICATI Phase 2 Solid tumour/cancer [ICD-11: 2A00-2F9Z] T88182 TARGETID T88182 T88182 TARGNAME Vitamin K-dependent gamma-carboxylase (GGCX) T88182 INDICATI Approved Bleeding disorder [ICD-11: GA20-GA21] T88182 INDICATI Approved Vitamin deficiency [ICD-11: 5B55-5B5F] T88185 TARGETID T88185 T88185 TARGNAME Nicotinic acid receptor (HCAR2) T88185 INDICATI Phase 2 Arterial occlusive disease [ICD-11: BD40] T88185 INDICATI Phase 2 Cardiovascular disease [ICD-11: BA00-BE2Z] T88185 INDICATI Phase 2 Cerebral ischaemic stroke [ICD-11: 8B11] T88185 INDICATI Investigative Depression [ICD-11: 6A70-6A7Z] T88185 INDICATI Phase 2 Dyslipidemia [ICD-11: 5C80-5C81] T88185 INDICATI Phase 2 Hyper-lipoproteinaemia [ICD-11: 5C80] T88185 INDICATI Approved Inborn lipid metabolism error [ICD-11: 5C52] T88185 INDICATI Clinical trial Psoriasis [ICD-11: EA90] T88185 INDICATI Discontinued in Phase 2 Type 2 diabetes mellitus [ICD-11: 5A11] T88240 TARGETID T88240 T88240 TARGNAME Bacterial Dihydropteroate synthetase (Bact folP) T88240 INDICATI Approved Bacterial infection [ICD-11: 1A00-1C4Z] T88240 INDICATI Approved Cystitis [ICD-11: GC00] T88240 INDICATI Approved Dermatitis herpetiformis [ICD-11: EB44] T88240 INDICATI Approved Glanders [ICD-11: 1B92] T88240 INDICATI Approved Gram-positive bacterial infection [ICD-11: 1B74-1F40] T88240 INDICATI Investigative HIV-infected patients with tuberculosis [ICD-11: 1B10-1B14] T88240 INDICATI Approved Malaria [ICD-11: 1F40-1F45] T88240 INDICATI Approved Respiratory infection [ICD-11: CA07-CA4Z] T88240 INDICATI Approved Rheumatic fever [ICD-11: 1B40] T88240 INDICATI Approved Urinary tract infection [ICD-11: GC08] T88285 TARGETID T88285 T88285 TARGNAME Lactoylglutathione lyase (GLO1) T88285 INDICATI Phase 2 Influenza [ICD-11: 1E30-1E32] T88304 TARGETID T88304 T88304 TARGNAME DNA [cytosine-5]-methyltransferase 1 (DNMT1) T88304 INDICATI Phase 3 Acute myeloid leukaemia [ICD-11: 2A60] T88304 INDICATI Phase 2 Bladder cancer [ICD-11: 2C94] T88304 INDICATI Investigative Brain cancer [ICD-11: 2A00] T88304 INDICATI Phase 1 Diffuse large B-cell lymphoma [ICD-11: 2A81] T88304 INDICATI Phase 2 Kaposi sarcoma [ICD-11: 2B57] T88304 INDICATI Phase 2 Lung cancer [ICD-11: 2C25] T88304 INDICATI Phase 3 Myelodysplastic syndrome [ICD-11: 2A37] T88304 INDICATI Phase 3 Myeloproliferative neoplasm [ICD-11: 2A20] T88304 INDICATI Phase 2 Pancreatic cancer [ICD-11: 2C10] T88304 INDICATI Phase 1 Sickle-cell disorder [ICD-11: 3A51] T88304 INDICATI Phase 2 Solid tumour/cancer [ICD-11: 2A00-2F9Z] T88318 TARGETID T88318 T88318 TARGNAME Protein kinase C (PRKC) T88318 INDICATI Phase 2 Alzheimer disease [ICD-11: 8A20] T88318 INDICATI Discontinued in Phase 3 Cardiac arrhythmia [ICD-11: BC9Z] T88318 INDICATI Phase 2 Diabetic foot ulcer [ICD-11: BD54] T88318 INDICATI Phase 2 Human immunodeficiency virus disease [ICD-11: 1C60-1C62] T88318 INDICATI Phase 1 Melanoma [ICD-11: 2C30] T88318 INDICATI Phase 1 Parkinsonism [ICD-11: 8A00] T88318 INDICATI Terminated Postoperative inflammation [ICD-11: 1A00-CA43] T88318 INDICATI Phase 1 Psoriasis [ICD-11: EA90] T88318 INDICATI Phase 2 Solid tumour/cancer [ICD-11: 2A00-2F9Z] T88318 INDICATI Discontinued in Phase 3 Supraventricular tachyarrhythmia [ICD-11: BC81] T88318 INDICATI Phase 2 Transplant rejection [ICD-11: NE84] T88318 INDICATI Phase 3 Virus infection [ICD-11: 1A24-1D9Z] T88322 TARGETID T88322 T88322 TARGNAME Facilitates chromatin transcription complex (FACT) T88322 INDICATI Phase 1/2 Liver cancer [ICD-11: 2C12] T88322 INDICATI Phase 1 Solid tumour/cancer [ICD-11: 2A00-2F9Z] T88338 TARGETID T88338 T88338 TARGNAME Bacterial 23S ribosomal RNA (Bact 23S rRNA) T88338 INDICATI Approved Bacterial infection [ICD-11: 1A00-1C4Z] T88338 INDICATI Phase 2 Gram-positive bacterial infection [ICD-11: 1B74-1F40] T88338 INDICATI Approved Human immunodeficiency virus disease [ICD-11: 1C60-1C62] T88338 INDICATI Approved Pneumonia [ICD-11: CA40] T88360 TARGETID T88360 T88360 TARGNAME Respiratory syncytial virus protein N (RSV N) T88360 INDICATI Phase 2 Viral encephalitis [ICD-11: 1C80] T88360 INDICATI Phase 2 Virus infection [ICD-11: 1A24-1D9Z] T88430 TARGETID T88430 T88430 TARGNAME A-Raf messenger RNA (ARAF mRNA) T88430 INDICATI Phase 1 Solid tumour/cancer [ICD-11: 2A00-2F9Z] T88452 TARGETID T88452 T88452 TARGNAME Corticosteroid-binding globulin (SERPINA6) T88452 INDICATI Approved Asthma [ICD-11: CA23] T88452 INDICATI Approved Postoperative inflammation [ICD-11: 1A00-CA43] T88452 INDICATI Approved Respiratory system disease [ICD-11: CB40-CB7Z] T88452 INDICATI Phase 3 Retinopathy [ICD-11: 9B71] T88479 TARGETID T88479 T88479 TARGNAME Malondialdehyde (MDA) T88479 INDICATI Phase 3 Inborn lipid metabolism error [ICD-11: 5C52] T88483 TARGETID T88483 T88483 TARGNAME microRNA hsa-miR-155 (MIR155) T88483 INDICATI Phase 1 Diffuse large B-cell lymphoma [ICD-11: 2A81] T88483 INDICATI Phase 2 Keloid/hypertrophic scar [ICD-11: EE60] T88483 INDICATI Phase 1 Mature B-cell leukaemia [ICD-11: 2A82] T88483 INDICATI Phase 2 Mycosis fungoides [ICD-11: 2B01] T88483 INDICATI Phase 1 Systemic sclerosis [ICD-11: 4A42] T88505 TARGETID T88505 T88505 TARGNAME Nuclear factor erythroid 2-related factor 2 (Nrf2) T88505 INDICATI Preclinical Alpha-1-antitrypsin deficiency [ICD-11: 5C5A] T88505 INDICATI Approved Ataxic disorder [ICD-11: 8A03] T88505 INDICATI Phase 2 Breast cancer [ICD-11: 2C60-2C6Y] T88505 INDICATI Phase 2 Glaucoma [ICD-11: 9C61] T88505 INDICATI Phase 2 Lung cancer [ICD-11: 2C25] T88505 INDICATI Phase 2 Macular degeneration [ICD-11: 9B75] T88505 INDICATI Phase 1/2 Melanoma [ICD-11: 2C30] T88505 INDICATI Clinical trial Mental/behavioural/neurodevelopmental disorder [ICD-11: 6E20-6E8Z] T88505 INDICATI Preclinical Motor neuron disease [ICD-11: 8B60] T88505 INDICATI Preclinical Multiple sclerosis [ICD-11: 8A40] T88505 INDICATI Phase 1 Non-alcoholic fatty liver disease [ICD-11: DB92] T88505 INDICATI Phase 2 Pulmonary hypertension [ICD-11: BB01] T88505 INDICATI Phase 2 Subarachnoid haemorrhage [ICD-11: 8B01] T88505 INDICATI Phase 2 Urinary system clinical sympton [ICD-11: MF8Y] T88531 TARGETID T88531 T88531 TARGNAME G-protein coupled receptor 39 (GPR39) T88531 INDICATI Investigative Acute diabete complication [ICD-11: 5A2Y] T88537 TARGETID T88537 T88537 TARGNAME Mitochondrial protein unspecific (MP) T88537 INDICATI Phase 2 Alzheimer disease [ICD-11: 8A20] T88537 INDICATI Phase 1/2 Ataxic disorder [ICD-11: 8A03] T88537 INDICATI Phase 1/2 Muscular dystrophy [ICD-11: 8C70] T88537 INDICATI Phase 2 Type 2 diabetes mellitus [ICD-11: 5A11] T88547 TARGETID T88547 T88547 TARGNAME HUMAN opioid receptor sigma 1 (OPRS1) T88547 INDICATI Investigative COVID-19 [ICD-11: 1D6Y] T88547 INDICATI Approved Schizophrenia [ICD-11: 6A20] T88569 TARGETID T88569 T88569 TARGNAME Mutated oxalosuccinate decarboxylase (mIDH1) T88569 INDICATI Phase 1 Acute myeloid leukaemia [ICD-11: 2A60] T88569 INDICATI Phase 1 Solid tumour/cancer [ICD-11: 2A00-2F9Z] T88595 TARGETID T88595 T88595 TARGNAME MERS-CoV spike glycoprotein (S) T88595 INDICATI Phase 2/3 COVID-19 [ICD-11: 1D6Y] T88595 INDICATI Discontinued in Phase 1 Middle East Respiratory Syndrome [ICD-11: 1D64] T88595 INDICATI Preclinical Severe acute respiratory syndrome [ICD-11: 1D65] T88637 TARGETID T88637 T88637 TARGNAME Myosin (MYO) T88637 INDICATI Approved Cardiomyopathy [ICD-11: BC43] T88656 TARGETID T88656 T88656 TARGNAME Notch-2 receptor (NOTCH2) T88656 INDICATI Phase 2 Lung cancer [ICD-11: 2C25] T88656 INDICATI Phase 2 Pancreatic cancer [ICD-11: 2C10] T88697 TARGETID T88697 T88697 TARGNAME ANGPTL3 messenger RNA (ANGPTL3 mRNA) T88697 INDICATI Phase 2 Dyslipidemia [ICD-11: 5C80-5C81] T88697 INDICATI Phase 2 Hyper-lipoproteinaemia [ICD-11: 5C80] T88697 INDICATI Phase 2 Non-alcoholic fatty liver disease [ICD-11: DB92] T88697 INDICATI Phase 2 Type 2 diabetes mellitus [ICD-11: 5A11] T88714 TARGETID T88714 T88714 TARGNAME ADORA1 messenger RNA (ADORA1 mRNA) T88714 INDICATI Discontinued in Phase 2 Asthma [ICD-11: CA23] T88714 INDICATI Phase 2 Heart failure [ICD-11: BD10-BD1Z] T88729 TARGETID T88729 T88729 TARGNAME Mitochondrial uncoupling protein 1 (UCP1) T88729 INDICATI Phase 2 Obesity [ICD-11: 5B80-5B81] T88752 TARGETID T88752 T88752 TARGNAME Ras-related C3 botulinum toxin substrate 1 (RAC1) T88752 INDICATI Terminated Alzheimer disease [ICD-11: 8A20] T88806 TARGETID T88806 T88806 TARGNAME Integrin alpha-5/beta-1 (ITGA5/B1) T88806 INDICATI Terminated Herpes simplex infection [ICD-11: 1F00] T88806 INDICATI Phase 2 Lung cancer [ICD-11: 2C25] T88806 INDICATI Phase 1 Melanoma [ICD-11: 2C30] T88806 INDICATI Phase 2 Renal cell carcinoma [ICD-11: 2C90] T88847 TARGETID T88847 T88847 TARGNAME Dystrophin messenger RNA (DMD mRNA) T88847 INDICATI Approved Muscular dystrophy [ICD-11: 8C70] T88887 TARGETID T88887 T88887 TARGNAME Staphylococcus Plastid RNA polymerase beta (Stap-coc rpoB) T88887 INDICATI Approved Bowel habit change [ICD-11: ME05] T88887 INDICATI Phase 3 Postoperative inflammation [ICD-11: 1A00-CA43] T88975 TARGETID T88975 T88975 TARGNAME Phosphodiesterase 3A (PDE3A) T88975 INDICATI Approved Arterial occlusive disease [ICD-11: BD40] T88975 INDICATI Approved Asthma [ICD-11: CA23] T88975 INDICATI Discontinued in Phase 1 Cardiovascular disease [ICD-11: BA00-BE2Z] T88975 INDICATI Approved Heart failure [ICD-11: BD10-BD1Z] T88975 INDICATI Approved Thrombocytosis [ICD-11: 3B63] T89034 TARGETID T89034 T89034 TARGNAME Plasminogen (PLG) T89034 INDICATI Phase 2/3 Alzheimer disease [ICD-11: 8A20] T89034 INDICATI Approved Angina pectoris [ICD-11: BA40] T89034 INDICATI Approved Bleeding disorder [ICD-11: GA20-GA21] T89034 INDICATI Investigative Cerebral ischaemia [ICD-11: 8B1Z] T89034 INDICATI Phase 3 Cerebral ischaemic stroke [ICD-11: 8B11] T89034 INDICATI Phase 2 Cerebral ischaemic stroke ICD-11: 8B11 T89034 INDICATI Approved Menopausal disorder [ICD-11: GA30] T89034 INDICATI Investigative Menstrual cycle bleeding disorder [ICD-11: GA20] T89034 INDICATI Approved Myocardial infarction [ICD-11: BA41-BA43] T89034 INDICATI Clinical trial Otitis media [ICD-11: AA80-AB0Z] T89034 INDICATI Approved Procedure injury [ICD-11: NE81] T89034 INDICATI Approved Pulmonary thromboembolism [ICD-11: BB00] T89034 INDICATI Phase 2 Retinopathy [ICD-11: 9B71] T89034 INDICATI Investigative Solid tumour/cancer [ICD-11: 2A00-2F9Z] T89034 INDICATI Phase 2 Supraventricular tachyarrhythmia [ICD-11: BC81] T89039 TARGETID T89039 T89039 TARGNAME HUMAN sigma intracellular receptor 2 (TMEM97) T89039 INDICATI Investigative COVID-19 [ICD-11: 1D6Y] T89039 INDICATI Approved Schizophrenia [ICD-11: 6A20] T89041 TARGETID T89041 T89041 TARGNAME Steroid 17-alpha-monooxygenase (S17AH) T89041 INDICATI Phase 2 Breast cancer [ICD-11: 2C60-2C6Y] T89041 INDICATI Approved Prostate cancer [ICD-11: 2C82] T89055 TARGETID T89055 T89055 TARGNAME ERK activator kinase 2 (MEK2) T89055 INDICATI Investigative Cardiac arrest [ICD-11: MC82] T89055 INDICATI Phase 2 Lung cancer [ICD-11: 2C25] T89055 INDICATI Phase 3 Melanoma [ICD-11: 2C30] T89055 INDICATI Discontinued in Phase 1 Solid tumour/cancer [ICD-11: 2A00-2F9Z] T89055 INDICATI Phase 3 Thyroid cancer [ICD-11: 2D10] T89083 TARGETID T89083 T89083 TARGNAME HUMAN toll-like receptor 2 (TLR2) T89083 INDICATI Phase 2 COVID-19 [ICD-11: 1D6Y] T89086 TARGETID T89086 T89086 TARGNAME Toxic reactive metabolite (TRM) T89086 INDICATI Approved Nasopharyngitis [ICD-11: CA00] T89147 TARGETID T89147 T89147 TARGNAME Superoxide dismutase Mn (SOD Mn) T89147 INDICATI Phase 2 Pain [ICD-11: MG30-MG3Z] T89176 TARGETID T89176 T89176 TARGNAME Clostridium difficile DNA gyrase (CD gyr) T89176 INDICATI Phase 1 Clostridium difficile enterocolitis [ICD-11: 1A04] T89213 TARGETID T89213 T89213 TARGNAME Neuropeptide Y receptor type 1 (NPY1R) T89213 INDICATI Terminated Binge eating disorder [ICD-11: 6B82] T89213 INDICATI Discontinued in Phase 2 Cardiovascular disease [ICD-11: BA00-BE2Z] T89213 INDICATI Preclinical Heart disease [ICD-11: BA41-BA42] T89213 INDICATI Preclinical Hypertension [ICD-11: BA00-BA04] T89213 INDICATI Preclinical Obesity [ICD-11: 5B80-5B81] T89234 TARGETID T89234 T89234 TARGNAME C5 messenger RNA (C5 mRNA) T89234 INDICATI Phase 2 Haemolytic anemia [ICD-11: 3A20-3A2Z] T89251 TARGETID T89251 T89251 TARGNAME Apoptosis regulator BAX (BAX) T89251 INDICATI Phase 2/3 Ovarian dysfunction [ICD-11: 5A80] T89360 TARGETID T89360 T89360 TARGNAME Inosine-5'-monophosphate dehydrogenase 2 (IMPDH2) T89360 INDICATI Investigative Immune system disease [ICD-11: 4A01-4B41] T89360 INDICATI Phase 3 Pemphigus [ICD-11: EB40] T89360 INDICATI Approved Transplant rejection [ICD-11: NE84] T89361 TARGETID T89361 T89361 TARGNAME Cyclin-dependent kinase 6 (CDK6) T89361 INDICATI Phase 1/2 Brain cancer [ICD-11: 2A00] T89361 INDICATI Approved Breast cancer [ICD-11: 2C60-2C6Y] T89361 INDICATI Approved Lung cancer [ICD-11: 2C25] T89361 INDICATI Approved Psoriasis [ICD-11: EA90] T89361 INDICATI Terminated Retina cancer [ICD-11: 2D02] T89361 INDICATI Terminated Schizophrenia [ICD-11: 6A20] T89361 INDICATI Phase 3 Solid tumour/cancer [ICD-11: 2A00-2F9Z] T89415 TARGETID T89415 T89415 TARGNAME HUMAN toll-like receptor 6 (TLR6) T89415 INDICATI Phase 2 COVID-19 [ICD-11: 1D6Y] T89458 TARGETID T89458 T89458 TARGNAME HepG2 glucose transporter (SLC2A1) T89458 INDICATI Preclinical Skin disease [ICD-11: EA00-EM0Z] T89515 TARGETID T89515 T89515 TARGNAME Polypeptide deformylase (PDF) T89515 INDICATI Approved Anxiety disorder [ICD-11: 6B00-6B0Z] T89515 INDICATI Approved Breast cancer [ICD-11: 2C60-2C6Y] T89515 INDICATI Investigative Gram-positive bacterial infection [ICD-11: 1B74-1F40] T89515 INDICATI Phase 2/3 Indeterminate colitis [ICD-11: DD72] T89515 INDICATI Withdrawn from market Leukaemia [ICD-11: 2A60-2B33] T89515 INDICATI Discontinued in Phase 1 Liver vascular disorder [ICD-11: DB98] T89515 INDICATI Approved Malaria [ICD-11: 1F40-1F45] T89515 INDICATI Approved Mature T-cell lymphoma [ICD-11: 2A90] T89515 INDICATI Approved Psoriasis [ICD-11: EA90] T89515 INDICATI Phase 2 Solid tumour/cancer [ICD-11: 2A00-2F9Z] T89515 INDICATI Approved Toxoplasmosis [ICD-11: 1F57] T89529 TARGETID T89529 T89529 TARGNAME PTPN1 messenger RNA (PTPN1 mRNA) T89529 INDICATI Phase 2 Metabolic disorder [ICD-11: 5C50-5D2Z] T89529 INDICATI Approved Ophthalmic devices/implants/grafts injury [ICD-11: PK97] T89529 INDICATI Approved Postoperative inflammation [ICD-11: 1A00-CA43] T89529 INDICATI Phase 2 Type 2 diabetes mellitus [ICD-11: 5A11] T89534 TARGETID T89534 T89534 TARGNAME Estrogen receptor (ESR) T89534 INDICATI Approved Acne vulgaris [ICD-11: ED80] T89534 INDICATI Approved Acquired prion disease [ICD-11: 8E01] T89534 INDICATI Approved Adrenal cancer [ICD-11: 2D11] T89534 INDICATI Phase 3 Alzheimer disease [ICD-11: 8A20] T89534 INDICATI Preclinical Atrophy [ICD-11: 9A2Y-9C40] T89534 INDICATI Phase 1 Brain cancer [ICD-11: 2A00] T89534 INDICATI Approved Breast cancer [ICD-11: 2C60-2C6Y] T89534 INDICATI Phase 2 Breast in situ carcinoma [ICD-11: 2E65] T89534 INDICATI Approved Contraceptive management [ICD-11: QA21] T89534 INDICATI Phase 2 Diabetes mellitus [ICD-11: 5A10] T89534 INDICATI Discontinued in Phase 1 Dissociative neurological symptom disorder [ICD-11: 6B60] T89534 INDICATI Approved Dyspareunia [ICD-11: GA12] T89534 INDICATI Phase 3 Endometriosis [ICD-11: GA10] T89534 INDICATI Discontinued in Phase 2 Eye disorder [ICD-11: 9A01-9A0Z] T89534 INDICATI Phase 3 Female genital tract noninflammatory disorder [ICD-11: GA1Y] T89534 INDICATI Approved Female infertility [ICD-11: GA31] T89534 INDICATI Phase 3 Female pelvic pain [ICD-11: GA34] T89534 INDICATI Phase 3 Hyper-lipoproteinaemia [ICD-11: 5C80] T89534 INDICATI Withdrawn from market Irregularities [ICD-11: N.A.] T89534 INDICATI Preclinical Joint pain [ICD-11: ME82] T89534 INDICATI Investigative Leukaemia [ICD-11: 2A60-2B33] T89534 INDICATI Approved Low bone mass disorder [ICD-11: FB83] T89534 INDICATI Approved Male infertility [ICD-11: GB04] T89534 INDICATI Approved Menopausal disorder [ICD-11: GA30] T89534 INDICATI Approved Menstrual cycle bleeding disorder [ICD-11: GA20] T89534 INDICATI Phase 1 Metastatic tumour [ICD-11: 2D50-2E2Z] T89534 INDICATI Phase 2 Multiple sclerosis [ICD-11: 8A40] T89534 INDICATI Discontinued in Phase 3 Pain [ICD-11: MG30-MG3Z] T89534 INDICATI Phase 1/2 Parkinsonism [ICD-11: 8A00] T89534 INDICATI Approved Pituitary gland disorder [ICD-11: 5A60-5A61] T89534 INDICATI Phase 2 Prostate cancer [ICD-11: 2C82] T89534 INDICATI Preclinical Sexual dysfunction [ICD-11: HA00-HA01] T89534 INDICATI Approved Skeletal anomaly [ICD-11: LD24] T89534 INDICATI Approved Solid tumour/cancer [ICD-11: 2A00-2F9Z] T89534 INDICATI Discontinued in Phase 1 Thrombocytopenia [ICD-11: 3B64] T89534 INDICATI Withdrawn from market Trematode disease [ICD-11: 1F8Y] T89534 INDICATI Approved Vaginitis [ICD-11: GA02] T89534 INDICATI Discontinued in Phase 1 Virus infection [ICD-11: 1A24-1D9Z] T89573 TARGETID T89573 T89573 TARGNAME Staphylococcus Sortase A (Stap-coc srtA) T89573 INDICATI Preclinical Staphylococcal/streptococcal disease [ICD-11: 1B5Y] T89592 TARGETID T89592 T89592 TARGNAME MERS-CoV 3C-like proteinase (3CLpro) T89592 INDICATI Investigative COVID-19 [ICD-11: 1D6Y] T89592 INDICATI Approved Human immunodeficiency virus disease [ICD-11: 1C60-1C62] T89592 INDICATI Phase 2/3 Middle East Respiratory Syndrome [ICD-11: 1D64] T89592 INDICATI Preclinical Severe acute respiratory syndrome [ICD-11: 1D65] T89636 TARGETID T89636 T89636 TARGNAME MERS-CoV helicase (Hel) T89636 INDICATI Preclinical Middle East Respiratory Syndrome [ICD-11: 1D64] T89636 INDICATI Preclinical Severe acute respiratory syndrome [ICD-11: 1D65] T89658 TARGETID T89658 T89658 TARGNAME MERS-CoV RNA-directed RNA polymerase (RdRp) T89658 INDICATI Phase 3 COVID-19 [ICD-11: 1D6Y] T89658 INDICATI Approved Hepatitis virus infection [ICD-11: 1E50-1E51] T89658 INDICATI Preclinical Middle East Respiratory Syndrome [ICD-11: 1D64] T89658 INDICATI Preclinical Severe acute respiratory syndrome [ICD-11: 1D65] T89697 TARGETID T89697 T89697 TARGNAME Indoleamine 2,3-dioxygenase 1 (IDO1) T89697 INDICATI Phase 1 Acute myeloid leukaemia [ICD-11: 2A60] T89697 INDICATI Phase 1 B-cell lymphoma [ICD-11: 2A86] T89697 INDICATI Phase 1 Brain cancer [ICD-11: 2A00] T89697 INDICATI Phase 1 Colorectal cancer [ICD-11: 2B91] T89697 INDICATI Approved Depression [ICD-11: 6A70-6A7Z] T89697 INDICATI Phase 1 Head and neck cancer [ICD-11: 2D42] T89697 INDICATI Phase 3 Lung cancer [ICD-11: 2C25] T89697 INDICATI Phase 1 Lymphoma [ICD-11: 2A80-2A86] T89697 INDICATI Phase 3 Melanoma [ICD-11: 2C30] T89697 INDICATI Investigative Nasopharyngeal cancer [ICD-11: 2B6B] T89697 INDICATI Phase 1 Neuroendocrine carcinoma [ICD-11: 2C34] T89697 INDICATI Phase 1 Ovarian cancer [ICD-11: 2C73] T89697 INDICATI Phase 2 Pancreatic cancer [ICD-11: 2C10] T89697 INDICATI Phase 2 Prostate cancer [ICD-11: 2C82] T89697 INDICATI Phase 2 Renal cell carcinoma [ICD-11: 2C90] T89697 INDICATI Phase 2 Solid tumour/cancer [ICD-11: 2A00-2F9Z] T89697 INDICATI Phase 2 Stomach cancer [ICD-11: 2B72] T89697 INDICATI Phase 3 Ureteral cancer [ICD-11: 2C92] T89736 TARGETID T89736 T89736 TARGNAME SARS-CoV papain-like proteinase (PL-PRO) T89736 INDICATI Investigative COVID-19 [ICD-11: 1D6Y] T89736 INDICATI Approved Malignant haematopoietic neoplasm [ICD-11: 2B33] T89736 INDICATI Preclinical Middle East Respiratory Syndrome [ICD-11: 1D64] T89736 INDICATI Preclinical Severe acute respiratory syndrome [ICD-11: 1D65] T89736 INDICATI Approved Substance abuse [ICD-11: 6C40] T89747 TARGETID T89747 T89747 TARGNAME ABL messenger RNA (ABL mRNA) T89747 INDICATI Discontinued in Phase 2 Myeloproliferative neoplasm [ICD-11: 2A20] T89772 TARGETID T89772 T89772 TARGNAME Vesicular acetylcholine transporter (SLC18A3) T89772 INDICATI Discontinued in Phase 2 Motor neuron disease [ICD-11: 8B60] T89826 TARGETID T89826 T89826 TARGNAME SARS-CoV 3C-like protease (3CLpro) T89826 INDICATI Investigative COVID-19 [ICD-11: 1D6Y] T89826 INDICATI Approved Human immunodeficiency virus disease [ICD-11: 1C60-1C62] T89826 INDICATI Preclinical Middle East Respiratory Syndrome [ICD-11: 1D64] T89826 INDICATI Preclinical Severe acute respiratory syndrome [ICD-11: 1D65] T89846 TARGETID T89846 T89846 TARGNAME Herpesvirus DNA polymerase (KSHV DNAP) T89846 INDICATI Discontinued in Phase 2 Virus infection [ICD-11: 1A24-1D9Z] T89873 TARGETID T89873 T89873 TARGNAME Ferritin (FTH1) T89873 INDICATI Phase 1/2 Lymphoma [ICD-11: 2A80-2A86] T89879 TARGETID T89879 T89879 TARGNAME SARS-CoV RNA-directed RNA polymerase (RdRp) T89879 INDICATI Phase 3 COVID-19 [ICD-11: 1D6Y] T89879 INDICATI Approved Hepatitis virus infection [ICD-11: 1E50-1E51] T89879 INDICATI Preclinical Middle East Respiratory Syndrome [ICD-11: 1D64] T89879 INDICATI Preclinical Severe acute respiratory syndrome [ICD-11: 1D65] T89883 TARGETID T89883 T89883 TARGNAME Ryanodine receptor (RYR) T89883 INDICATI Approved Fever [ICD-11: MG26] T89883 INDICATI Phase 1 Muscular dystrophy [ICD-11: 8C70] T89917 TARGETID T89917 T89917 TARGNAME SARS-CoV helicase (Hel) T89917 INDICATI Preclinical Coronavirus infection [ICD-11: 1D92] T89917 INDICATI Preclinical Middle East Respiratory Syndrome [ICD-11: 1D64] T89917 INDICATI Preclinical Severe acute respiratory syndrome [ICD-11: 1D65] T89918 TARGETID T89918 T89918 TARGNAME Glycinamide ribonucleotide formyltransferase (GART) T89918 INDICATI Phase 2 Solid tumour/cancer [ICD-11: 2A00-2F9Z] T89950 TARGETID T89950 T89950 TARGNAME Calcitonin gene-related peptide (CALC) T89950 INDICATI Discontinued in Phase 2 Asthma [ICD-11: CA23] T89950 INDICATI Approved Migraine [ICD-11: 8A80] T89988 TARGETID T89988 T89988 TARGNAME C-C chemokine receptor type 2 (CCR2) T89988 INDICATI Investigative Alzheimer disease [ICD-11: 8A20] T89988 INDICATI Terminated Arterial occlusive disease [ICD-11: BD40] T89988 INDICATI Phase 2 Chronic kidney disease [ICD-11: GB61] T89988 INDICATI Phase 2 Chronic obstructive pulmonary disease [ICD-11: CA22] T89988 INDICATI Phase 1 Chronic pain [ICD-11: MG30] T89988 INDICATI Investigative General pain disorder [ICD-11: 8E43] T89988 INDICATI Phase 2 Human immunodeficiency virus disease [ICD-11: 1C60-1C62] T89988 INDICATI Discontinued in Phase 2 Insulin-resistance syndrome [ICD-11: 5A44] T89988 INDICATI Phase 1 Melanoma [ICD-11: 2C30] T89988 INDICATI Phase 2 Metastatic tumour [ICD-11: 2D50-2E2Z] T89988 INDICATI Phase 2 Multiple sclerosis [ICD-11: 8A40] T89988 INDICATI Phase 2 Pancreatic cancer [ICD-11: 2C10] T89988 INDICATI Terminated Postoperative inflammation [ICD-11: 1A00-CA43] T89988 INDICATI Phase 1 Retinopathy [ICD-11: 9B71] T89988 INDICATI Phase 1 Rheumatoid arthritis [ICD-11: FA20] T89988 INDICATI Phase 1 Solid tumour/cancer [ICD-11: 2A00-2F9Z] T89988 INDICATI Terminated Viral encephalitis [ICD-11: 1C80] T90035 TARGETID T90035 T90035 TARGNAME MERS-CoV spike glycoprotein S2 subunit (S S2) T90035 INDICATI Preclinical Middle East Respiratory Syndrome [ICD-11: 1D64] T90038 TARGETID T90038 T90038 TARGNAME HUMAN MYD88NF-kappa-B proinflammatory pathway (MYD88-NFKB pathway) T90038 INDICATI Phase 2 COVID-19 [ICD-11: 1D6Y] T90038 INDICATI Approved Hyperlipidemia [ICD-11: 5C80] T90048 TARGETID T90048 T90048 TARGNAME HUMAN interleukin-1 receptor 1 (IL1R1) T90048 INDICATI Phase 3 COVID-19 [ICD-11: 1D6Y] T90048 INDICATI Approved Rheumatoid arthritis [ICD-11: FA20] T90070 TARGETID T90070 T90070 TARGNAME HUMAN interleukin 8 (IL8) T90070 INDICATI Phase 2 COVID-19 [ICD-11: 1D6Y] T90286 TARGETID T90286 T90286 TARGNAME Fusion protein FGFR3-TACC3 (FGFR3-TACC3) T90286 INDICATI Investigative Nasopharyngeal cancer [ICD-11: 2B6B] T90391 TARGETID T90391 T90391 TARGNAME CYP3A4 messenger RNA (CYP3A4 mRNA) T90391 INDICATI Phase 2 Anxiety disorder [ICD-11: 6B00-6B0Z] T90457 TARGETID T90457 T90457 TARGNAME CD274 messenger RNA (CD274 mRNA) T90457 INDICATI Phase 1 Hepatitis virus infection [ICD-11: 1E50-1E51] T90553 TARGETID T90553 T90553 TARGNAME Microtubule affinity regulating kinase 3 (MARK3) T90553 INDICATI Phase 1/2 Peritoneal cancer [ICD-11: 2C51] T90553 INDICATI Phase 1 Solid tumour/cancer [ICD-11: 2A00-2F9Z] T90572 TARGETID T90572 T90572 TARGNAME Insulin-like growth factor-II (IGF2) T90572 INDICATI Phase 2 Breast cancer [ICD-11: 2C60-2C6Y] T90572 INDICATI Phase 1/2 Prostate cancer [ICD-11: 2C82] T90628 TARGETID T90628 T90628 TARGNAME Rab proteins geranylgeranyltransferase component A 1 (CHM) T90628 INDICATI Phase 3 Choroidal dystrophy ICD-11: 9B61 T90628 INDICATI Phase 1/2 Choroidal dystrophy [ICD-11: 9B61] T90648 TARGETID T90648 T90648 TARGNAME B-Raf messenger RNA (BRAF mRNA) T90648 INDICATI Phase 1 Melanoma [ICD-11: 2C30] T90648 INDICATI Phase 1 Parkinsonism [ICD-11: 8A00] T90648 INDICATI Phase 2 Solid tumour/cancer [ICD-11: 2A00-2F9Z] T90665 TARGETID T90665 T90665 TARGNAME PSD95-nNOS interaction (PSD95-nNOS PPI) T90665 INDICATI Investigative Anxiety disorder [ICD-11: 6B00-6B0Z] T90672 TARGETID T90672 T90672 TARGNAME G-protein coupled receptor 48 (LGR4) T90672 INDICATI Preclinical Solid tumour/cancer [ICD-11: 2A00-2F9Z] T90695 TARGETID T90695 T90695 TARGNAME PI3K/AKT/mTOR pathway (PAm pathway) T90695 INDICATI Discontinued in Phase 2 Dissociative neurological symptom disorder [ICD-11: 6B60] T90695 INDICATI Phase 1/2 Hydrocephalus [ICD-11: 8D64] T90695 INDICATI Approved Multiple myeloma [ICD-11: 2A83] T90695 INDICATI Phase 1 Radiation effect [ICD-11: NF00] T90695 INDICATI Approved Transplant rejection [ICD-11: NE84] T90768 TARGETID T90768 T90768 TARGNAME Human immunodeficiency virus Trans-activation response element (HIV TAR RNA element) T90768 INDICATI Phase 2 Human immunodeficiency virus disease [ICD-11: 1C60-1C62] T90782 TARGETID T90782 T90782 TARGNAME P2Y purinoceptor 6 (P2RY6) T90782 INDICATI Phase 1 Alzheimer disease [ICD-11: 8A20] T90782 INDICATI Discontinued in Phase 3 Lung cancer [ICD-11: 2C25] T90828 TARGETID T90828 T90828 TARGNAME Interleukin 5 receptor alpha (IL5RA) T90828 INDICATI Approved Asthma [ICD-11: CA23] T90828 INDICATI Phase 3 Chronic obstructive pulmonary disease [ICD-11: CA22] T90835 TARGETID T90835 T90835 TARGNAME Interleukin-1 receptor (IL1R) T90835 INDICATI Phase 1/2 Solid tumour/cancer [ICD-11: 2A00-2F9Z] T90848 TARGETID T90848 T90848 TARGNAME HGF/Met signaling pathway (HGF/Met pathway) T90848 INDICATI Phase 2/3 Alzheimer disease [ICD-11: 8A20] T90848 INDICATI Approved Lung cancer [ICD-11: 2C25] T90848 INDICATI Investigative Nasopharyngeal cancer [ICD-11: 2B6B] T90848 INDICATI Phase 2 Parkinsonism [ICD-11: 8A00] T90935 TARGETID T90935 T90935 TARGNAME Delta(24)-sterol reductase (DHCR24) T90935 INDICATI Preclinical Obesity [ICD-11: 5B80-5B81] T90985 TARGETID T90985 T90985 TARGNAME Bromodomain testis-specific protein (BRDT) T90985 INDICATI Phase 1 Testicular cancer [ICD-11: 2C80] T90989 TARGETID T90989 T90989 TARGNAME Fibroblast growth factor receptor 4 (FGFR4) T90989 INDICATI Phase 1/2 Liver cancer [ICD-11: 2C12] T90989 INDICATI Investigative Solid tumour/cancer [ICD-11: 2A00-2F9Z] T91023 TARGETID T91023 T91023 TARGNAME Roof plate-specific spondin-1 (RSPO1) T91023 INDICATI Phase 1 Digestive system disease [ICD-11: DE2Z] T91286 TARGETID T91286 T91286 TARGNAME Metalloreductase STEAP1 (STEAP1) T91286 INDICATI Phase 1 Prostate cancer [ICD-11: 2C82] T91331 TARGETID T91331 T91331 TARGNAME Fibroblast growth factor receptor 3 (FGFR3) T91331 INDICATI Phase 1/2 Alzheimer disease [ICD-11: 8A20] T91331 INDICATI Phase 2 Bladder cancer [ICD-11: 2C94] T91331 INDICATI Phase 2 Breast cancer [ICD-11: 2C60-2C6Y] T91331 INDICATI Phase 4 Coronary atherosclerosis [ICD-11: BA80] T91331 INDICATI Phase 2 Endometrial cancer [ICD-11: 2C76] T91331 INDICATI Approved Liver cancer [ICD-11: 2C12] T91331 INDICATI Phase 1 Multiple myeloma [ICD-11: 2A83] T91331 INDICATI Phase 2 Myeloproliferative neoplasm [ICD-11: 2A20] T91331 INDICATI Phase 4 Myocardial infarction [ICD-11: BA41-BA43] T91331 INDICATI Phase 3 Renal cell carcinoma [ICD-11: 2C90] T91331 INDICATI Terminated Retina cancer [ICD-11: 2D02] T91331 INDICATI Phase 2 Skeletal anomaly [ICD-11: LD24] T91331 INDICATI Phase 3 Solid tumour/cancer [ICD-11: 2A00-2F9Z] T91331 INDICATI Phase 1 Ureteral cancer [ICD-11: 2C92] T91390 TARGETID T91390 T91390 TARGNAME Staphylococcus Dehydrosqualene desaturase (Stap-coc crtN) T91390 INDICATI Investigative Staphylococcal/streptococcal disease [ICD-11: 1B5Y] T91435 TARGETID T91435 T91435 TARGNAME Neurotrophic tyrosine kinase ROR2 (ROR2) T91435 INDICATI Phase 2 Metastatic lymph node neoplasm [ICD-11: 2D60] T91435 INDICATI Phase 1/2 Renal cell carcinoma [ICD-11: 2C90] T91442 TARGETID T91442 T91442 TARGNAME Varicella-zoster virus DNA polymerase (VZV ORF28) T91442 INDICATI Phase 3 Herpes simplex infection [ICD-11: 1F00] T91442 INDICATI Approved Virus infection [ICD-11: 1A24-1D9Z] T91450 TARGETID T91450 T91450 TARGNAME Poly-N-acetyl glucosamine (PNAG) T91450 INDICATI Phase 2 Unspecific infection [ICD-11: 1H0Z] T91451 TARGETID T91451 T91451 TARGNAME E2 ubiquitin-conjugating enzyme T (UBE2T) T91451 INDICATI Investigative Nasopharyngeal cancer [ICD-11: 2B6B] T91451 INDICATI Phase 2 Rectum cancer [ICD-11: 2B92] T91480 TARGETID T91480 T91480 TARGNAME ATP-binding cassette transporter C8 (ABCC8) T91480 INDICATI Approved Acute diabete complication [ICD-11: 5A2Y] T91480 INDICATI Phase 1 Diabetes mellitus [ICD-11: 5A10] T91480 INDICATI Phase 3 Ischaemic/haemorrhagic stroke [ICD-11: 8B20] T91480 INDICATI Investigative Supraventricular tachyarrhythmia [ICD-11: BC81] T91480 INDICATI Approved Type 2 diabetes mellitus [ICD-11: 5A11] T91558 TARGETID T91558 T91558 TARGNAME Short transient receptor potential channel 4 (TRPC4) T91558 INDICATI Phase 2 Depression [ICD-11: 6A70-6A7Z] T91661 TARGETID T91661 T91661 TARGNAME Adenosine kinase (ADK) T91661 INDICATI Phase 1 Epilepsy/seizure [ICD-11: 8A61-8A6Z] T91661 INDICATI Terminated Pain [ICD-11: MG30-MG3Z] T91696 TARGETID T91696 T91696 TARGNAME Fibronectin (FN1) T91696 INDICATI Phase 2 Colorectal cancer [ICD-11: 2B91] T91696 INDICATI Approved Vitreous body disorder [ICD-11: 9B8Z] T91761 TARGETID T91761 T91761 TARGNAME T-cell-specific kinase (ITK) T91761 INDICATI Phase 1 Allergic/hypersensitivity disorder [ICD-11: 4A80-4A8Z] T91761 INDICATI Phase 1 Mature T-cell lymphoma [ICD-11: 2A90] T91761 INDICATI Investigative Postoperative inflammation [ICD-11: 1A00-CA43] T91761 INDICATI Phase 2 Psoriasis [ICD-11: EA90] T91894 TARGETID T91894 T91894 TARGNAME Proto-oncogene Mas (MAS) T91894 INDICATI Phase 3 Diabetic foot ulcer [ICD-11: BD54] T91894 INDICATI Phase 2 Lymphoma [ICD-11: 2A80-2A86] T91894 INDICATI Phase 2 Muscular dystrophy [ICD-11: 8C70] T91894 INDICATI Phase 2 Nausea/vomiting [ICD-11: MD90] T91894 INDICATI Phase 3 Sarcoma [ICD-11: 2A60-2C35] T92030 TARGETID T92030 T92030 TARGNAME Regenerating human pro-islet peptide (REG3A) T92030 INDICATI Phase 2 Liver disease [ICD-11: DB90-DB9Z] T92030 INDICATI Phase 1 Type 2 diabetes mellitus [ICD-11: 5A11] T92030 INDICATI Phase 1 Type-1/2 diabete [ICD-11: 5A10-5A11] T92035 TARGETID T92035 T92035 TARGNAME Hepatitis C virus Internal ribosome entry site messenger RNA (HCV IRES mRNA) T92035 INDICATI Discontinued in Phase 2 Hepatitis virus infection [ICD-11: 1E50-1E51] T92042 TARGETID T92042 T92042 TARGNAME GDNF receptor alpha-3 (GFRA3) T92042 INDICATI Phase 2 Pain [ICD-11: MG30-MG3Z] T92057 TARGETID T92057 T92057 TARGNAME Erbb4 tyrosine kinase receptor (Erbb-4) T92057 INDICATI Phase 3 Acute myeloid leukaemia [ICD-11: 2A60] T92057 INDICATI Approved Lung cancer [ICD-11: 2C25] T92057 INDICATI Phase 2 Lymphoma [ICD-11: 2A80-2A86] T92057 INDICATI Phase 1 Malignant haematopoietic neoplasm [ICD-11: 2B33] T92057 INDICATI Phase 2 Myeloproliferative neoplasm [ICD-11: 2A20] T92057 INDICATI Phase 3 Solid tumour/cancer [ICD-11: 2A00-2F9Z] T92072 TARGETID T92072 T92072 TARGNAME Adenosine A1 receptor (ADORA1) T92072 INDICATI Discontinued in Phase 1 Acute diabete complication [ICD-11: 5A2Y] T92072 INDICATI Discontinued in Phase 2 Allergic/hypersensitivity disorder [ICD-11: 4A80-4A8Z] T92072 INDICATI Phase 2 Cardiac arrhythmia [ICD-11: BC9Z] T92072 INDICATI Discontinued in Phase 3 Cardiovascular disease [ICD-11: BA00-BE2Z] T92072 INDICATI Discontinued in Phase 3 Diabetes mellitus [ICD-11: 5A10] T92072 INDICATI Discontinued in Phase 2 General pain disorder [ICD-11: 8E43] T92072 INDICATI Phase 1/2 Glaucoma [ICD-11: 9C61] T92072 INDICATI Phase 3 Heart failure [ICD-11: BD10-BD1Z] T92072 INDICATI Phase 2 Hyper-lipoproteinaemia [ICD-11: 5C80] T92072 INDICATI Discontinued in Phase 2 Hypertension [ICD-11: BA00-BA04] T92072 INDICATI Preclinical Ischaemic heart disease [ICD-11: BA6Z] T92072 INDICATI Phase 1 Ischaemic/haemorrhagic stroke [ICD-11: 8B20] T92072 INDICATI Discontinued in Phase 2 Kidney failure [ICD-11: GB60-GB6Z] T92072 INDICATI Phase 2 Mild neurocognitive disorder [ICD-11: 6D71] T92072 INDICATI Terminated Multiple sclerosis [ICD-11: 8A40] T92072 INDICATI Approved Orthostatic hypotension [ICD-11: BA21] T92072 INDICATI Phase 1 Parkinsonism [ICD-11: 8A00] T92072 INDICATI Investigative Sepsis [ICD-11: 1G40-1G41] T92072 INDICATI Phase 2 Supraventricular tachyarrhythmia [ICD-11: BC81] T92076 TARGETID T92076 T92076 TARGNAME Extracellular calcium-sensing receptor (CASR) T92076 INDICATI Preclinical Cerebral ischaemia [ICD-11: 8B1Z] T92076 INDICATI Approved Hyper-parathyroidism [ICD-11: 5A51] T92076 INDICATI Phase 3 Hypo-parathyroidism ICD-11: 5A50 T92076 INDICATI Phase 2 Low bone mass disorder [ICD-11: FB83] T92076 INDICATI Phase 3 Myelodysplastic syndrome [ICD-11: 2A37] T92076 INDICATI Phase 3 Urinary system disease [ICD-11: GC2Z] T92078 TARGETID T92078 T92078 TARGNAME Dihydropyrimidinase related protein 2 (DPYSL2) T92078 INDICATI Approved Epilepsy/seizure [ICD-11: 8A61-8A6Z] T92078 INDICATI Phase 3 Neuropathy [ICD-11: 8C0Z] T92124 TARGETID T92124 T92124 TARGNAME OX40L receptor (CD134) T92124 INDICATI Phase 3 Atopic eczema [ICD-11: EA80] T92124 INDICATI Phase 2 Metastatic malignant neoplasm [ICD-11: 2D50-2E09] T92124 INDICATI Phase 1 Prostate cancer [ICD-11: 2C82] T92124 INDICATI Phase 2 Solid tumour/cancer [ICD-11: 2A00-2F9Z] T92138 TARGETID T92138 T92138 TARGNAME Phosphodiesterase (PDE) T92138 INDICATI Terminated Acute diabete complication [ICD-11: 5A2Y] T92138 INDICATI Phase 3 Angina pectoris [ICD-11: BA40] T92138 INDICATI Discontinued in Phase 2 Asthma [ICD-11: CA23] T92138 INDICATI Investigative Cardiovascular disease [ICD-11: BA00-BE2Z] T92138 INDICATI Terminated Cerebral ischaemia [ICD-11: 8B1Z] T92138 INDICATI Discontinued in Phase 3 Heart failure [ICD-11: BD10-BD1Z] T92138 INDICATI Discontinued in Phase 2 Postoperative inflammation [ICD-11: 1A00-CA43] T92138 INDICATI Phase 3 Psoriasis [ICD-11: EA90] T92138 INDICATI Discontinued in Phase 1 Sepsis [ICD-11: 1G40-1G41] T92144 TARGETID T92144 T92144 TARGNAME Angiopoietin 1 receptor (TEK) T92144 INDICATI Phase 1 Breast cancer [ICD-11: 2C60-2C6Y] T92144 INDICATI Phase 2 Chronic arterial occlusive disease [ICD-11: BD4Z] T92144 INDICATI Investigative Ischemia [ICD-11: 8B10-8B11] T92144 INDICATI Phase 1 Mature B-cell lymphoma [ICD-11: 2A85] T92144 INDICATI Discontinued in Phase 1 Myelodysplastic syndrome [ICD-11: 2A37] T92144 INDICATI Phase 1/2 Myeloproliferative neoplasm [ICD-11: 2A20] T92144 INDICATI Phase 2 Retinopathy [ICD-11: 9B71] T92144 INDICATI Discontinued in Phase 1 Rheumatoid arthritis [ICD-11: FA20] T92144 INDICATI Investigative Sepsis [ICD-11: 1G40-1G41] T92144 INDICATI Phase 1 Solid tumour/cancer [ICD-11: 2A00-2F9Z] T92185 TARGETID T92185 T92185 TARGNAME PACAP type I receptor (PAC1R) T92185 INDICATI Phase 2 Migraine [ICD-11: 8A80] T92185 INDICATI Investigative Pituitary gland disorder [ICD-11: 5A60-5A61] T92281 TARGETID T92281 T92281 TARGNAME Neuronal pentraxin-2 (NPTX2) T92281 INDICATI Phase 2 Idiopathic interstitial pneumonitis [ICD-11: CB03] T92281 INDICATI Phase 2 Myeloproliferative neoplasm [ICD-11: 2A20] T92281 INDICATI Phase 2 Retinopathy [ICD-11: 9B71] T92281 INDICATI Phase 2 Thrombocytosis [ICD-11: 3B63] T92308 TARGETID T92308 T92308 TARGNAME DNA [cytosine-5]-methyltransferase (DNMT) T92308 INDICATI Phase 3 Acute myeloid leukaemia [ICD-11: 2A60] T92308 INDICATI Approved Myelodysplastic syndrome [ICD-11: 2A37] T92308 INDICATI Phase 3 Myeloproliferative neoplasm [ICD-11: 2A20] T92308 INDICATI Phase 3 Solid tumour/cancer [ICD-11: 2A00-2F9Z] T92328 TARGETID T92328 T92328 TARGNAME Ryanodine receptor 1 (RYR1) T92328 INDICATI Discontinued in Phase 2 Heart failure [ICD-11: BD10-BD1Z] T92403 TARGETID T92403 T92403 TARGNAME Sodium/hydrogen exchanger 3 (SLC9A3) T92403 INDICATI Discontinued in Phase 2 Angina pectoris [ICD-11: BA40] T92403 INDICATI Phase 2 Breathing abnormality [ICD-11: MD11] T92403 INDICATI Discontinued in Phase 2 Cardiac arrhythmia [ICD-11: BC9Z] T92403 INDICATI Phase 2 Chronic kidney disease [ICD-11: GB61] T92403 INDICATI Terminated Genetic cardiac arrhythmia [ICD-11: BC65] T92403 INDICATI Approved Irritable bowel syndrome [ICD-11: DD91] T92403 INDICATI Phase 2 Urinary system disease [ICD-11: GC2Z] T92424 TARGETID T92424 T92424 TARGNAME Integrin alpha-V/beta-5 (ITGAV/B5) T92424 INDICATI Terminated Herpes simplex infection [ICD-11: 1F00] T92424 INDICATI Discontinued in Phase 1 Low bone mass disorder [ICD-11: FB83] T92458 TARGETID T92458 T92458 TARGNAME Cytochrome P450 24 (CYP24A1) T92458 INDICATI Phase 2 Psoriasis [ICD-11: EA90] T92463 TARGETID T92463 T92463 TARGNAME RIP2 messenger RNA (RIP2 mRNA) T92463 INDICATI Phase 1 Cardiovascular disease [ICD-11: BA00-BE2Z] T92463 INDICATI Phase 1 Postoperative inflammation [ICD-11: 1A00-CA43] T92494 TARGETID T92494 T92494 TARGNAME Eukaryotic elongation factor 2 kinase (eEF-2K) T92494 INDICATI Approved Breast cancer [ICD-11: 2C60-2C6Y] T92609 TARGETID T92609 T92609 TARGNAME Adrenergic receptor alpha-1A (ADRA1A) T92609 INDICATI Discontinued in Phase 2 Abnormal micturition [ICD-11: MF50] T92609 INDICATI Discontinued in Phase 1 Depression [ICD-11: 6A70-6A7Z] T92609 INDICATI Terminated Genetic cardiac arrhythmia [ICD-11: BC65] T92609 INDICATI Terminated Glaucoma [ICD-11: 9C61] T92609 INDICATI Approved Hypertension [ICD-11: BA00-BA04] T92609 INDICATI Phase 3 Mild neurocognitive disorder [ICD-11: 6D71] T92609 INDICATI Phase 2 Pain [ICD-11: MG30-MG3Z] T92609 INDICATI Preclinical Post-traumatic stress disorder [ICD-11: 6B40] T92609 INDICATI Phase 3 Prostate cancer [ICD-11: 2C82] T92609 INDICATI Discontinued in Phase 2 Prostate disease [ICD-11: GA91] T92609 INDICATI Approved Prostate hyperplasia [ICD-11: GA90] T92609 INDICATI Investigative Sexual dysfunction [ICD-11: HA00-HA01] T92640 TARGETID T92640 T92640 TARGNAME Lysophosphatidic acid receptor 1 (LPAR1) T92640 INDICATI Phase 2 Fibrosis [ICD-11: GA14-GC01] T92640 INDICATI Phase 2 Idiopathic interstitial pneumonitis [ICD-11: CB03] T92640 INDICATI Phase 1 Psoriasis [ICD-11: EA90] T92640 INDICATI Phase 2 Systemic sclerosis [ICD-11: 4A42] T92653 TARGETID T92653 T92653 TARGNAME Neuropeptide Y receptor (NPYR) T92653 INDICATI Discontinued in Phase 1 Mood disorder [ICD-11: 6A60-6E23] T92678 TARGETID T92678 T92678 TARGNAME MALT lymphoma-associated translocation (MALT1) T92678 INDICATI Phase 1 Malignant haematopoietic neoplasm [ICD-11: 2B33] T92678 INDICATI Phase 1 Mature B-cell leukaemia [ICD-11: 2A82] T92687 TARGETID T92687 T92687 TARGNAME Gastric H(+)/K(+) ATPase (Proton pump) T92687 INDICATI Phase 2 Digestive system disease [ICD-11: DE2Z] T92687 INDICATI Phase 2 Duodenal ulcer [ICD-11: DA63] T92687 INDICATI Phase 3 Gastric ulcer [ICD-11: DA60] T92687 INDICATI Approved Gastro-oesophageal reflux disease [ICD-11: DA22] T92687 INDICATI Approved Helicobacter infection [ICD-11: DA42-DA63] T92687 INDICATI Approved Oesophageal ulcer [ICD-11: DA25] T92687 INDICATI Approved Peptic ulcer [ICD-11: DA61] T92687 INDICATI Discontinued in Preregistration Ulcerative colitis [ICD-11: DD71] T92689 TARGETID T92689 T92689 TARGNAME P2Y purinoceptor 11 (P2RY11) T92689 INDICATI Discontinued in Phase 3 Lung cancer [ICD-11: 2C25] T92750 TARGETID T92750 T92750 TARGNAME Complement factor I (CFI) T92750 INDICATI Terminated Cerebral ischaemia [ICD-11: 8B1Z] T92777 TARGETID T92777 T92777 TARGNAME Intestinal maltase-glucoamylase (MGAM) T92777 INDICATI Approved Acute diabete complication [ICD-11: 5A2Y] T92777 INDICATI Investigative Blood chemistry clinical sympton [ICD-11: MA18] T92777 INDICATI Phase 3 Cardiovascular disease [ICD-11: BA00-BE2Z] T92777 INDICATI Phase 1/2 Dengue fever [ICD-11: 1D2Z] T92777 INDICATI Phase 2 Human immunodeficiency virus disease [ICD-11: 1C60-1C62] T92777 INDICATI Approved Inborn carbohydrate metabolism error [ICD-11: 5C51] T92777 INDICATI Phase 3 Muscle disorder [ICD-11: FB32-FB3Z] T92777 INDICATI Phase 2 Type 2 diabetes mellitus [ICD-11: 5A11] T92803 TARGETID T92803 T92803 TARGNAME Dual-specificity tyrosine-phosphorylation regulated kinase 1A (DYRK1A) T92803 INDICATI Investigative Cytomegaloviral disease [ICD-11: 1D82] T92828 TARGETID T92828 T92828 TARGNAME Endothelin B receptor (EDNRB) T92828 INDICATI Discontinued in Phase 2 Cardiac arrhythmia [ICD-11: BC9Z] T92828 INDICATI Approved Cardiovascular disease [ICD-11: BA00-BE2Z] T92828 INDICATI Phase 3 Encephalopathy [ICD-11: 8E47] T92828 INDICATI Phase 2 Hypertension [ICD-11: BA00-BA04] T92828 INDICATI Phase 3 Kidney failure [ICD-11: GB60-GB6Z] T92828 INDICATI Phase 1/2 Melanoma [ICD-11: 2C30] T92828 INDICATI Phase 3 Myasthenia gravis [ICD-11: 8C6Y] T92828 INDICATI Phase 3 Neuromyelitis optica [ICD-11: 8A43] T92828 INDICATI Approved Pulmonary hypertension [ICD-11: BB01] T92828 INDICATI Phase 2 Solid tumour/cancer [ICD-11: 2A00-2F9Z] T92963 TARGETID T92963 T92963 TARGNAME Natriuretic peptide receptor (NPR3) T92963 INDICATI Phase 1 Heart failure [ICD-11: BD10-BD1Z] T93026 TARGETID T93026 T93026 TARGNAME Quinone reductase (NQO) T93026 INDICATI Phase 2 Motor neuron disease [ICD-11: 8B60] T93026 INDICATI Phase 2 Parkinsonism [ICD-11: 8A00] T93061 TARGETID T93061 T93061 TARGNAME Phosphorylated p68 RNA helicase (pDDX5) T93061 INDICATI Phase 2 Breast cancer [ICD-11: 2C60-2C6Y] T93061 INDICATI Phase 1 Solid tumour/cancer [ICD-11: 2A00-2F9Z] T93062 TARGETID T93062 T93062 TARGNAME Multidrug resistance protein 3 (ABCB4) T93062 INDICATI Discontinued in Phase 3 Acute myeloid leukaemia [ICD-11: 2A60] T93062 INDICATI Phase 2 Breast cancer [ICD-11: 2C60-2C6Y] T93062 INDICATI Discontinued in Phase 3 Solid tumour/cancer [ICD-11: 2A00-2F9Z] T93092 TARGETID T93092 T93092 TARGNAME Serine/threonine PP2A (PP2A) T93092 INDICATI Phase 2 Brain cancer [ICD-11: 2A00] T93092 INDICATI Phase 1 Solid tumour/cancer [ICD-11: 2A00-2F9Z] T93105 TARGETID T93105 T93105 TARGNAME Presenilin 1 (PSEN1) T93105 INDICATI Preregistration Osteoarthritis [ICD-11: FA00-FA05] T93105 INDICATI Preregistration Shoulder lesion [ICD-11: FB53] T93105 INDICATI Preregistration Soft tissue disorder [ICD-11: FB56] T93121 TARGETID T93121 T93121 TARGNAME Protein C-ets-2 (ETS2) T93121 INDICATI Phase 1 Ewing sarcoma [ICD-11: 2B52] T93122 TARGETID T93122 T93122 TARGNAME Brain-derived neurotrophic factor (BDNF) T93122 INDICATI Phase 2 Dissociative neurological symptom disorder [ICD-11: 6B60] T93145 TARGETID T93145 T93145 TARGNAME Pyruvate dehydrogenase kinase (PDHK) T93145 INDICATI Phase 1 Heart failure [ICD-11: BD10-BD1Z] T93145 INDICATI Phase 2 Pulmonary hypertension [ICD-11: BB01] T93145 INDICATI Phase 1 Type 2 diabetes mellitus [ICD-11: 5A11] T93262 TARGETID T93262 T93262 TARGNAME PKC-epsilon messenger RNA (PRKCE mRNA) T93262 INDICATI Investigative Human immunodeficiency virus disease [ICD-11: 1C60-1C62] T93283 TARGETID T93283 T93283 TARGNAME Prostatic acid phosphatase (ACPP) T93283 INDICATI Phase 2 Prostate cancer [ICD-11: 2C82] T93344 TARGETID T93344 T93344 TARGNAME Squalene monooxygenase (SQLE) T93344 INDICATI Terminated Coronary atherosclerosis [ICD-11: BA80] T93344 INDICATI Approved Dermatophytosis [ICD-11: 1F28] T93344 INDICATI Phase 3 Hepatic fibrosis/cirrhosis [ICD-11: DB93] T93344 INDICATI Terminated Hyper-lipoproteinaemia [ICD-11: 5C80] T93344 INDICATI Approved Skin fungal infection disorder [ICD-11: EA60] T93430 TARGETID T93430 T93430 TARGNAME ATP-binding cassette transporter (ABCA) T93430 INDICATI Phase 2 Insulin-resistance syndrome [ICD-11: 5A44] T93440 TARGETID T93440 T93440 TARGNAME Interleukin 6 receptor (IL6R) T93440 INDICATI Phase 3 Cutaneous lupus erythematosus [ICD-11: EB50-EB5Z] T93440 INDICATI Phase 2 Depression [ICD-11: 6A70-6A7Z] T93440 INDICATI Phase 2 Diabetes mellitus [ICD-11: 5A10] T93440 INDICATI Phase 3 Encephalopathy [ICD-11: 8E47] T93440 INDICATI Phase 3 Inflammatory spondyloarthritis [ICD-11: FA92] T93440 INDICATI Phase 3 Juvenile idiopathic arthritis [ICD-11: FA24] T93440 INDICATI Phase 2 Lupus erythematosus [ICD-11: 4A40] T93440 INDICATI Terminated Melanoma [ICD-11: 2C30] T93440 INDICATI Investigative Multiple myeloma [ICD-11: 2A83] T93440 INDICATI Phase 3 Neuromyelitis optica [ICD-11: 8A43] T93440 INDICATI Approved Rheumatoid arthritis [ICD-11: FA20] T93440 INDICATI Phase 3 Vasculitis [ICD-11: 4A44] T93450 TARGETID T93450 T93450 TARGNAME Interleukin-24 (IL24) T93450 INDICATI Phase 2 Solid tumour/cancer [ICD-11: 2A00-2F9Z] T93480 TARGETID T93480 T93480 TARGNAME UDP-glucuronosyltransferase 1A1 (UGT1A1) T93480 INDICATI Phase 1/2 Inborn porphyrin/heme metabolism error [ICD-11: 5C58] T93485 TARGETID T93485 T93485 TARGNAME Hepatitis B virus Reverse transcriptase priming/DNA synthesis (HBV RTP/DS) T93485 INDICATI Phase 1/2 Virus infection [ICD-11: 1A24-1D9Z] T93509 TARGETID T93509 T93509 TARGNAME Calcitonin gene-related peptide 1 (CALCA) T93509 INDICATI Phase 2 General pain disorder [ICD-11: 8E43] T93515 TARGETID T93515 T93515 TARGNAME P2Y purinoceptor 2 (P2RY2) T93515 INDICATI Phase 2 Cystic fibrosis [ICD-11: CA25] T93515 INDICATI Investigative Irritable bowel syndrome [ICD-11: DD91] T93515 INDICATI Discontinued in Phase 3 Lung cancer [ICD-11: 2C25] T93515 INDICATI Phase 3 Visual system disease [ICD-11: 9E1Z] T93548 TARGETID T93548 T93548 TARGNAME Integrin alpha-V/beta-8 (ITGAV/B8) T93548 INDICATI Phase 1 Solid tumour/cancer [ICD-11: 2A00-2F9Z] T93566 TARGETID T93566 T93566 TARGNAME LOX-5 messenger RNA (ALOX5 mRNA) T93566 INDICATI Discontinued in Phase 2 Asthma [ICD-11: CA23] T93566 INDICATI Discontinued in Phase 2 Pain [ICD-11: MG30-MG3Z] T93566 INDICATI Terminated Rheumatoid arthritis [ICD-11: FA20] T93627 TARGETID T93627 T93627 TARGNAME Human immunodeficiency virus GAG protein (HIV gag) T93627 INDICATI Phase 2 Human immunodeficiency virus disease [ICD-11: 1C60-1C62] T93653 TARGETID T93653 T93653 TARGNAME Cathepsin V (CTSV) T93653 INDICATI Patented Bone cancer [ICD-11: 2B5Z] T93653 INDICATI Patented Chronic pain [ICD-11: MG30] T93661 TARGETID T93661 T93661 TARGNAME Smad7 messenger RNA (Smad7 mRNA) T93661 INDICATI Phase 3 Crohn disease [ICD-11: DD70] T93661 INDICATI Phase 2 Ulcerative colitis [ICD-11: DD71] T93662 TARGETID T93662 T93662 TARGNAME Hyaluronidase (HYAL) T93662 INDICATI Phase 1 Cholelithiasis [ICD-11: DC11] T93662 INDICATI Approved Immunodeficiency [ICD-11: 4A00-4A85] T93662 INDICATI Phase 2 Lung cancer [ICD-11: 2C25] T93662 INDICATI Phase 2 Pancreatic cancer [ICD-11: 2C10] T93662 INDICATI Approved Schizophrenia [ICD-11: 6A20] T93662 INDICATI Phase 1 Stomach cancer [ICD-11: 2B72] T93703 TARGETID T93703 T93703 TARGNAME Cytokine unspecific (CYK) T93703 INDICATI Phase 1 Atopic eczema [ICD-11: EA80] T93703 INDICATI Phase 1 Vasomotor/allergic rhinitis [ICD-11: CA08] T93711 TARGETID T93711 T93711 TARGNAME Inactive rhomboid protein 2 (RHBDF2) T93711 INDICATI Investigative Skin disease [ICD-11: EA00-EM0Z] T93711 INDICATI Investigative Solid tumour/cancer [ICD-11: 2A00-2F9Z] T93783 TARGETID T93783 T93783 TARGNAME Human immunodeficiency virus Tat protein (HIV tat) T93783 INDICATI Phase 2 Human immunodeficiency virus disease [ICD-11: 1C60-1C62] T93783 INDICATI Approved Rheumatoid arthritis [ICD-11: FA20] T93788 TARGETID T93788 T93788 TARGNAME Glucose-dependent insulinotropic receptor (GPR119) T93788 INDICATI Phase 2 Acute diabete complication [ICD-11: 5A2Y] T93788 INDICATI Approved Attention deficit hyperactivity disorder [ICD-11: 6A05] T93788 INDICATI Phase 2 Stomach cancer [ICD-11: 2B72] T93788 INDICATI Phase 2 Type 2 diabetes mellitus [ICD-11: 5A11] T93798 TARGETID T93798 T93798 TARGNAME Cyclic nucleotide-gated channel alpha-1 (CNGA1) T93798 INDICATI Clinical trial Myelopathy [ICD-11: 8B42] T93878 TARGETID T93878 T93878 TARGNAME Solute carrier family 12 member 1 (SLC12A1) T93878 INDICATI Investigative Dissociative neurological symptom disorder [ICD-11: 6B60] T93878 INDICATI Approved Essential hypertension [ICD-11: BA00] T93878 INDICATI Approved Heart failure [ICD-11: BD10-BD1Z] T93878 INDICATI Approved Hypertension [ICD-11: BA00-BA04] T93878 INDICATI Approved Hypo-kalaemia [ICD-11: 5C77] T93878 INDICATI Approved Oedema [ICD-11: MG29] T93903 TARGETID T93903 T93903 TARGNAME Caspase-9 (CASP9) T93903 INDICATI Clinical trial Cystic fibrosis [ICD-11: CA25] T93903 INDICATI Investigative Solid tumour/cancer [ICD-11: 2A00-2F9Z] T93923 TARGETID T93923 T93923 TARGNAME Co-stimulatory molecule 4-1BB (CD137) T93923 INDICATI Phase 1/2 Acute myeloid leukaemia [ICD-11: 2A60] T93923 INDICATI Phase 1/2 B-cell lymphoma [ICD-11: 2A86] T93923 INDICATI Investigative Immune system disease [ICD-11: 4A01-4B41] T93923 INDICATI Phase 1 Lymphoma [ICD-11: 2A80-2A86] T93923 INDICATI Phase 2 Malignant haematopoietic neoplasm [ICD-11: 2B33] T93923 INDICATI Phase 1/2 Mature B-cell lymphoma [ICD-11: 2A85] T93923 INDICATI Phase 2 Melanoma [ICD-11: 2C30] T93923 INDICATI Phase 1/2 Non-small-cell lung cancer [ICD-11: 2C25] T93923 INDICATI Phase 2 Solid tumour/cancer [ICD-11: 2A00-2F9Z] T93955 TARGETID T93955 T93955 TARGNAME Aspergillus Mannitol-1-phosphate 5-dehydrogenase (Asperg mpdA) T93955 INDICATI Approved Bronchiectasis [ICD-11: CA24] T93955 INDICATI Approved Kidney failure [ICD-11: GB60-GB6Z] T93995 TARGETID T93995 T93995 TARGNAME Ubiquitin-like protein Nedd8 (NEDD8) T93995 INDICATI Phase 2 BCR-ABL1-negative chronic myeloid leukaemia [ICD-11: 2A41] T93995 INDICATI Phase 3 Myelodysplastic syndrome [ICD-11: 2A37] T93995 INDICATI Investigative Nasopharyngeal cancer [ICD-11: 2B6B] T93995 INDICATI Phase 1 Solid tumour/cancer [ICD-11: 2A00-2F9Z] T94033 TARGETID T94033 T94033 TARGNAME Coagulation factor IIa (F2) T94033 INDICATI Phase 2 Angina pectoris [ICD-11: BA40] T94033 INDICATI Terminated Asthma [ICD-11: CA23] T94033 INDICATI Discontinued in Phase 2 Atopic eczema [ICD-11: EA80] T94033 INDICATI Approved Bleeding disorder [ICD-11: GA20-GA21] T94033 INDICATI Phase 2 Cardiovascular disease [ICD-11: BA00-BE2Z] T94033 INDICATI Phase 2 Cerebral ischaemic stroke [ICD-11: 8B11] T94033 INDICATI Approved Coagulation defect [ICD-11: 3B10] T94033 INDICATI Phase 2/3 Coronary thrombosis [ICD-11: BA43] T94033 INDICATI Discontinued in Phase 1 Dissociative neurological symptom disorder [ICD-11: 6B60] T94033 INDICATI Discontinued in Phase 1 Genetic cardiac arrhythmia [ICD-11: BC65] T94033 INDICATI Approved Ischaemic/haemorrhagic stroke [ICD-11: 8B20] T94033 INDICATI Approved Multiple sclerosis [ICD-11: 8A40] T94033 INDICATI Approved Myocardial infarction [ICD-11: BA41-BA43] T94033 INDICATI Approved Nutritional deficiency [ICD-11: 5B50-5B71] T94033 INDICATI Discontinued in Phase 1 Pregnancy/childbirth/puerperium maternal infection [ICD-11: JB63] T94033 INDICATI Investigative Solid tumour/cancer [ICD-11: 2A00-2F9Z] T94033 INDICATI Discontinued in Phase 2 Supraventricular tachyarrhythmia [ICD-11: BC81] T94033 INDICATI Approved Thrombocytopenia [ICD-11: 3B64] T94033 INDICATI Approved Thrombosis [ICD-11: DB61-GB90] T94033 INDICATI Phase 2 Type 2 diabetes mellitus [ICD-11: 5A11] T94085 TARGETID T94085 T94085 TARGNAME Retinoic acid receptor alpha (RARA) T94085 INDICATI Phase 1 Acute myeloid leukaemia [ICD-11: 2A60] T94085 INDICATI Phase 2/3 Alzheimer disease [ICD-11: 8A20] T94085 INDICATI Investigative Colorectal cancer [ICD-11: 2B91] T94085 INDICATI Discontinued in Phase 1 Human immunodeficiency virus disease [ICD-11: 1C60-1C62] T94085 INDICATI Phase 3 Mature T-cell lymphoma [ICD-11: 2A90] T94085 INDICATI Phase 1 Myelodysplastic syndrome [ICD-11: 2A37] T94085 INDICATI Phase 1 Solid tumour/cancer [ICD-11: 2A00-2F9Z] T94119 TARGETID T94119 T94119 TARGNAME HUMAN PI3-kinase delta (PIK3CD) T94119 INDICATI Phase 2 COVID-19 [ICD-11: 1D6Y] T94119 INDICATI Approved Follicular lymphoma [ICD-11: 2A80] T94131 TARGETID T94131 T94131 TARGNAME HUMAN PI3-kinase gamma (PIK3CG) T94131 INDICATI Phase 2 COVID-19 [ICD-11: 1D6Y] T94131 INDICATI Approved Follicular lymphoma [ICD-11: 2A80] T94201 TARGETID T94201 T94201 TARGNAME SRSF protein kinase 1 (SRPK1) T94201 INDICATI Preclinical Retinopathy [ICD-11: 9B71] T94307 TARGETID T94307 T94307 TARGNAME HUMAN interferon gamma (IFNG) T94307 INDICATI Approved Adaptive immunity immunodeficiency [ICD-11: 4A01] T94307 INDICATI Phase 2/3 COVID-19 [ICD-11: 1D6Y] T94309 TARGETID T94309 T94309 TARGNAME Pancreatic triacylglycerol lipase (PNLIP) T94309 INDICATI Approved Bacterial infection [ICD-11: 1A00-1C4Z] T94309 INDICATI Phase 3 Cystic fibrosis [ICD-11: CA25] T94309 INDICATI Approved Obesity [ICD-11: 5B80-5B81] T94309 INDICATI Phase 1/2 Pancreas disease [ICD-11: DC35-DC3Z] T94309 INDICATI NDA filed Pancreatic malfunction [ICD-11: DC30-DC3Z] T94324 TARGETID T94324 T94324 TARGNAME Histone deacetylase 10 (HDAC10) T94324 INDICATI Investigative Solid tumour/cancer [ICD-11: 2A00-2F9Z] T94429 TARGETID T94429 T94429 TARGNAME Cytomegalovirus Terminase UL56 (CMV TRM1) T94429 INDICATI Approved Cytomegaloviral disease [ICD-11: 1D82] T94444 TARGETID T94444 T94444 TARGNAME Aldehyde oxidase (AOX1) T94444 INDICATI Phase 2 Prostate cancer [ICD-11: 2C82] T94444 INDICATI Approved Solid tumour/cancer [ICD-11: 2A00-2F9Z] T94444 INDICATI Approved Vitamin deficiency [ICD-11: 5B55-5B5F] T94471 TARGETID T94471 T94471 TARGNAME HUMAN complement C5 protein (C5) T94471 INDICATI Phase 3 COVID-19 [ICD-11: 1D6Y] T94471 INDICATI Approved Neuromyelitis optica [ICD-11: 8A43] T94471 INDICATI Approved Paroxysmal nocturnal haemoglobinuria [ICD-11: 3A21] T94479 TARGETID T94479 T94479 TARGNAME Ribosomal protein S6 kinase beta-1 (S6K1) T94479 INDICATI Phase 1 Alzheimer disease [ICD-11: 8A20] T94479 INDICATI Phase 1 Solid tumour/cancer [ICD-11: 2A00-2F9Z] T94479 INDICATI Clinical trial Ulcerative colitis [ICD-11: DD71] T94482 TARGETID T94482 T94482 TARGNAME Interleukin-20 (IL20) T94482 INDICATI Phase 2 Psoriasis [ICD-11: EA90] T94493 TARGETID T94493 T94493 TARGNAME Human immunodeficiency virus Adenovector Ad35 (HIV Ad35) T94493 INDICATI Phase 2 Human immunodeficiency virus disease [ICD-11: 1C60-1C62] T94501 TARGETID T94501 T94501 TARGNAME HUMAN complement C5 alpha (C5A) T94501 INDICATI Phase 2/3 COVID-19 [ICD-11: 1D6Y] T94514 TARGETID T94514 T94514 TARGNAME HUMAN colony-stimulating factor (GM-CSF) T94514 INDICATI Phase 3 COVID-19 [ICD-11: 1D6Y] T94514 INDICATI Phase 3 Rheumatoid arthritis [ICD-11: FA20] T94549 TARGETID T94549 T94549 TARGNAME HUMAN angiopoietin-2 (ANG-2) T94549 INDICATI Phase 2 COVID-19 [ICD-11: 1D6Y] T94692 TARGETID T94692 T94692 TARGNAME Low-density lipoprotein receptor (LDL-R) T94692 INDICATI Approved Lung cancer [ICD-11: 2C25] T94695 TARGETID T94695 T94695 TARGNAME Mothers against decapentaplegic homolog 7 (SMAD7) T94695 INDICATI Phase 3 Crohn disease [ICD-11: DD70] T94695 INDICATI Phase 2 Ulcerative colitis [ICD-11: DD71] T94718 TARGETID T94718 T94718 TARGNAME Lymphocyte activation gene 3 protein (LAG3) T94718 INDICATI Phase 1/2 Allergic/hypersensitivity disorder [ICD-11: 4A80-4A8Z] T94718 INDICATI Phase 1 Autoimmune disease [ICD-11: 4A40-4A45] T94718 INDICATI Phase 1 Brain cancer [ICD-11: 2A00] T94718 INDICATI Phase 1 Breast cancer [ICD-11: 2C60-2C6Y] T94718 INDICATI Investigative Diabetes mellitus [ICD-11: 5A10] T94718 INDICATI Phase 2 Lung cancer [ICD-11: 2C25] T94718 INDICATI Phase 1 Lymphoma [ICD-11: 2A80-2A86] T94718 INDICATI Phase 2/3 Malignant haematopoietic neoplasm [ICD-11: 2B33] T94718 INDICATI Approved Melanoma [ICD-11: 2C30] T94718 INDICATI Phase 1 Psoriasis [ICD-11: EA90] T94718 INDICATI Phase 2 Renal cell carcinoma [ICD-11: 2C90] T94718 INDICATI Phase 1/2 Solid tumour/cancer [ICD-11: 2A00-2F9Z] T94718 INDICATI Phase 2 Stomach cancer [ICD-11: 2B72] T94781 TARGETID T94781 T94781 TARGNAME HRSV Nucleoprotein messenger RNA (HRSV N mRNA) T94781 INDICATI Phase 2 Respiratory infection [ICD-11: CA07-CA4Z] T94781 INDICATI Phase 2 Viral encephalitis [ICD-11: 1C80] T94879 TARGETID T94879 T94879 TARGNAME HUMAN phosphodiesterase type 5 (PDE5) T94879 INDICATI Phase 3 COVID-19 [ICD-11: 1D6Y] T94879 INDICATI Approved Sexual dysfunction [ICD-11: HA00-HA01] T94880 TARGETID T94880 T94880 TARGNAME TYRO3 tyrosine kinase receptor (TYRO3) T94880 INDICATI Phase 1 Solid tumour/cancer [ICD-11: 2A00-2F9Z] T94912 TARGETID T94912 T94912 TARGNAME HUMAN C5a receptor (C5aR) T94912 INDICATI Phase 2 COVID-19 [ICD-11: 1D6Y] T94918 TARGETID T94918 T94918 TARGNAME COVID-19 RNA-directed RNA polymerase (RdRp) T94918 INDICATI Phase 1 African trypanosomiasis [ICD-11: 1F51] T94918 INDICATI Approved Candidosis [ICD-11: 1F23] T94918 INDICATI Approved COVID-19 [ICD-11: 1D6Y] T94918 INDICATI Phase 1 Filovirus disease [ICD-11: 1D60] T94918 INDICATI Approved Herpes simplex infection [ICD-11: 1F00] T94918 INDICATI Approved Influenza [ICD-11: 1E30-1E32] T94918 INDICATI Preclinical Middle East Respiratory Syndrome [ICD-11: 1D64] T94918 INDICATI Preclinical Severe acute respiratory syndrome [ICD-11: 1D65] T94933 TARGETID T94933 T94933 TARGNAME HUMAN basigin (BSG) T94933 INDICATI Phase 1/2 COVID-19 [ICD-11: 1D6Y] T94977 TARGETID T94977 T94977 TARGNAME Cardiotrophin-1 (CTF1) T94977 INDICATI Phase 1 Acute/subacute hepatic failure [ICD-11: DB91] T95108 TARGETID T95108 T95108 TARGNAME MHC class I antigen G (HLA-G) T95108 INDICATI Phase 1 Solid tumour/cancer [ICD-11: 2A00-2F9Z] T95139 TARGETID T95139 T95139 TARGNAME Cysteine protease (CYP) T95139 INDICATI Approved Trypanosomiasis [ICD-11: 1D51-1F53] T95183 TARGETID T95183 T95183 TARGNAME Ubiquitin carboxyl-terminal hydrolase 2 (USP2) T95183 INDICATI Preclinical Postoperative inflammation [ICD-11: 1A00-CA43] T95212 TARGETID T95212 T95212 TARGNAME Streptococcus Diphtheria protein (Stre DIPP) T95212 INDICATI Approved Otitis media [ICD-11: AA80-AB0Z] T95212 INDICATI Discontinued in Phase 2 Ulcer [ICD-11: CA02-CB40] T95241 TARGETID T95241 T95241 TARGNAME Calcium-activated potassium channel KCa2 (KCNN) T95241 INDICATI Phase 1/2 Ataxic disorder [ICD-11: 8A03] T95241 INDICATI Phase 1/2 Supraventricular tachyarrhythmia [ICD-11: BC81] T95241 INDICATI Phase 1 Tremor-related disorder [ICD-11: 8A04] T95286 TARGETID T95286 T95286 TARGNAME Myelin-associated glycoprotein (MAG) T95286 INDICATI Phase 2 Ischaemic/haemorrhagic stroke [ICD-11: 8B20] T95289 TARGETID T95289 T95289 TARGNAME Retinoic acid receptor RXR (RXR) T95289 INDICATI Phase 1 Breast cancer [ICD-11: 2C60-2C6Y] T95289 INDICATI Phase 1 Lung cancer [ICD-11: 2C25] T95289 INDICATI Phase 1 Pancreatic cancer [ICD-11: 2C10] T95289 INDICATI Phase 1 Prostate cancer [ICD-11: 2C82] T95289 INDICATI Phase 1 Solid tumour/cancer [ICD-11: 2A00-2F9Z] T95302 TARGETID T95302 T95302 TARGNAME Melanocortin receptor 5 (MC5R) T95302 INDICATI Phase 2 Acne vulgaris [ICD-11: ED80] T95302 INDICATI Phase 2 Sebaceous gland disorder [ICD-11: ED91] T95302 INDICATI Investigative Sexual dysfunction [ICD-11: HA00-HA01] T95339 TARGETID T95339 T95339 TARGNAME Beta-hematin formation (BHF) T95339 INDICATI Approved Malaria [ICD-11: 1F40-1F45] T95371 TARGETID T95371 T95371 TARGNAME Interferon alpha/beta receptor 1 (IFNAR1) T95371 INDICATI Phase 2 Hepatitis virus infection [ICD-11: 1E50-1E51] T95371 INDICATI Phase 2 Ovarian cancer [ICD-11: 2C73] T95379 TARGETID T95379 T95379 TARGNAME Selectin (SEL) T95379 INDICATI Phase 3 Asthma [ICD-11: CA23] T95379 INDICATI Phase 3 Circulatory system disease [ICD-11: BE2Z] T95385 TARGETID T95385 T95385 TARGNAME Interleukin-12 beta (IL12B) T95385 INDICATI Phase 1 Brain cancer [ICD-11: 2A00] T95385 INDICATI Phase 2 Breast cancer [ICD-11: 2C60-2C6Y] T95385 INDICATI Approved Conduction disorder [ICD-11: BC63] T95385 INDICATI Discontinued in Phase 2 Crohn disease [ICD-11: DD70] T95385 INDICATI Phase 2 Fallopian tube cancer [ICD-11: 2C74] T95385 INDICATI Phase 1 Indeterminate colitis [ICD-11: DD72] T95385 INDICATI Phase 1/2 Melanoma [ICD-11: 2C30] T95385 INDICATI Phase 2 Ovarian cancer [ICD-11: 2C73] T95385 INDICATI Phase 2 Peritoneal cancer [ICD-11: 2C51] T95385 INDICATI Phase 3 Psoriasis [ICD-11: EA90] T95385 INDICATI Phase 1 Rheumatoid arthritis [ICD-11: FA20] T95385 INDICATI Phase 1 Solid tumour/cancer [ICD-11: 2A00-2F9Z] T95399 TARGETID T95399 T95399 TARGNAME Myophosphorylase (PYGM) T95399 INDICATI Phase 2 Acute myeloid leukaemia [ICD-11: 2A60] T95399 INDICATI Discontinued in Phase 3 Mature B-cell leukaemia [ICD-11: 2A82] T95399 INDICATI Discontinued in Phase 2 Type 2 diabetes mellitus [ICD-11: 5A11] T95400 TARGETID T95400 T95400 TARGNAME Immunoglobulin epsilon Fc receptor gamma (FCERG) T95400 INDICATI Approved Asthma [ICD-11: CA23] T95400 INDICATI Approved Bacterial infection [ICD-11: 1A00-1C4Z] T95400 INDICATI Phase 2 Spontaneous urticaria [ICD-11: EB00] T95410 TARGETID T95410 T95410 TARGNAME Aspergillus Dihydroorotate dehydrogenase (Aspergillus DHODH) T95410 INDICATI Phase 2 Fungal infection [ICD-11: 1F29-1F2F] T95446 TARGETID T95446 T95446 TARGNAME Cytochrome P450 reductase (P450) T95446 INDICATI Terminated Eczema [ICD-11: EA80-EA89] T95446 INDICATI Terminated Pruritus [ICD-11: EC90] T95446 INDICATI Discontinued in Phase 2 Psoriasis [ICD-11: EA90] T95479 TARGETID T95479 T95479 TARGNAME Somatostatin (SST) T95479 INDICATI Approved Amino acid absorption/transport disorder [ICD-11: 5C60] T95488 TARGETID T95488 T95488 TARGNAME Interleukin-1 (IL1) T95488 INDICATI Phase 2 Rheumatoid arthritis [ICD-11: FA20] T95498 TARGETID T95498 T95498 TARGNAME NFE2-related factor 2 pathway (Nrf2 pathway) T95498 INDICATI Approved Multiple sclerosis [ICD-11: 8A40] T95515 TARGETID T95515 T95515 TARGNAME Keratin 6A messenger RNA (KRT6A mRNA) T95515 INDICATI Phase 1 Nail plate acquired deformity [ICD-11: EE10] T95515 INDICATI Phase 2 Viral encephalitis [ICD-11: 1C80] T95558 TARGETID T95558 T95558 TARGNAME Diacylglycerol O-acyltransferase 2 (DGAT2) T95558 INDICATI Phase 2 Cardiovascular disease [ICD-11: BA00-BE2Z] T95558 INDICATI Phase 2 Dyslipidemia [ICD-11: 5C80-5C81] T95558 INDICATI Phase 2 Hyper-lipoproteinaemia [ICD-11: 5C80] T95558 INDICATI Approved Inborn lipid metabolism error [ICD-11: 5C52] T95558 INDICATI Phase 2 Non-alcoholic fatty liver disease [ICD-11: DB92] T95616 TARGETID T95616 T95616 TARGNAME Integrin alpha-M (ITGAM) T95616 INDICATI Phase 1/2 Pancreatic cancer [ICD-11: 2C10] T95678 TARGETID T95678 T95678 TARGNAME Influenza M2 protein (Influ M) T95678 INDICATI Approved Influenza [ICD-11: 1E30-1E32] T95695 TARGETID T95695 T95695 TARGNAME SMN1 messenger RNA (SMN1 mRNA) T95695 INDICATI Approved Muscular atrophy [ICD-11: 8B61] T95860 TARGETID T95860 T95860 TARGNAME FOXO4-P53 interaction (FOXO4-P53 PPI) T95860 INDICATI Preclinical Pituitary gland disorder [ICD-11: 5A60-5A61] T95878 TARGETID T95878 T95878 TARGNAME Ribosomal protein S6 kinase alpha-6 (RSK6) T95878 INDICATI Preclinical Mature B-cell leukaemia [ICD-11: 2A82] T95899 TARGETID T95899 T95899 TARGNAME Clusterin messenger RNA (Clusterin mRNA) T95899 INDICATI Phase 3 Breast cancer [ICD-11: 2C60-2C6Y] T95899 INDICATI Phase 3 Lung cancer [ICD-11: 2C25] T95899 INDICATI Phase 3 Prostate cancer [ICD-11: 2C82] T95913 TARGETID T95913 T95913 TARGNAME PI3-kinase gamma (PIK3CG) T95913 INDICATI Phase 1 Adrenal cancer [ICD-11: 2D11] T95913 INDICATI Phase 2 Asthma [ICD-11: CA23] T95913 INDICATI Investigative Bacterial infection [ICD-11: 1A00-1C4Z] T95913 INDICATI Phase 1 B-cell lymphoma [ICD-11: 2A86] T95913 INDICATI Phase 1/2 BCR-ABL1-negative chronic myeloid leukaemia [ICD-11: 2A41] T95913 INDICATI Phase 2 Bladder cancer [ICD-11: 2C94] T95913 INDICATI Phase 2 Brain cancer [ICD-11: 2A00] T95913 INDICATI Phase 3 Breast cancer [ICD-11: 2C60-2C6Y] T95913 INDICATI Terminated Cardiovascular disease [ICD-11: BA00-BE2Z] T95913 INDICATI Phase 1 Central nervous system disease [ICD-11: 8A04-8D87] T95913 INDICATI Phase 1/2 Colorectal cancer [ICD-11: 2B91] T95913 INDICATI Phase 3 Diffuse large B-cell lymphoma [ICD-11: 2A81] T95913 INDICATI Phase 2 Endometrial cancer [ICD-11: 2C76] T95913 INDICATI Approved Follicular lymphoma [ICD-11: 2A80] T95913 INDICATI Phase 2 Head and neck cancer [ICD-11: 2D42] T95913 INDICATI Phase 1/2 Innate/adaptive immunodeficiency [ICD-11: 4A00] T95913 INDICATI Phase 1 Liver cancer [ICD-11: 2C12] T95913 INDICATI Phase 1 Lymphoma [ICD-11: 2A80-2A86] T95913 INDICATI Approved Malignant haematopoietic neoplasm [ICD-11: 2B33] T95913 INDICATI Approved Mature B-cell leukaemia [ICD-11: 2A82] T95913 INDICATI Phase 1 Melanoma [ICD-11: 2C30] T95913 INDICATI Phase 2 Metastatic lymph node neoplasm [ICD-11: 2D60] T95913 INDICATI Phase 3 Myelodysplastic syndrome [ICD-11: 2A37] T95913 INDICATI Phase 1/2 Myocardial infarction [ICD-11: BA41-BA43] T95913 INDICATI Phase 1 Pain [ICD-11: MG30-MG3Z] T95913 INDICATI Phase 1 Peritoneal cancer [ICD-11: 2C51] T95913 INDICATI Phase 1 Pleural mesothelioma [ICD-11: 2C26] T95913 INDICATI Investigative Postoperative inflammation [ICD-11: 1A00-CA43] T95913 INDICATI Investigative Prostate cancer [ICD-11: 2C82] T95913 INDICATI Phase 3 Rheumatoid arthritis [ICD-11: FA20] T95913 INDICATI Phase 3 Solid tumour/cancer [ICD-11: 2A00-2F9Z] T95913 INDICATI Discontinued in Phase 2 Type 2 diabetes mellitus [ICD-11: 5A11] T95923 TARGETID T95923 T95923 TARGNAME Lysophosphatidate-3 receptor (LPAR3) T95923 INDICATI Phase 2 Fibrosis [ICD-11: GA14-GC01] T95923 INDICATI Phase 2 Systemic sclerosis [ICD-11: 4A42] T95947 TARGETID T95947 T95947 TARGNAME Acid-sensing ion channel 3 (ASIC3) T95947 INDICATI Investigative Chronic pain [ICD-11: MG30] T95947 INDICATI Investigative Pain [ICD-11: MG30-MG3Z] T95998 TARGETID T95998 T95998 TARGNAME Cholinephosphate cytidylyltransferase (PCYT1B) T95998 INDICATI Phase 3 Solid tumour/cancer [ICD-11: 2A00-2F9Z] T96079 TARGETID T96079 T96079 TARGNAME C-X-C chemokine receptor type 4 (CXCR4) T96079 INDICATI Phase 2 Acute myeloid leukaemia [ICD-11: 2A60] T96079 INDICATI Phase 3 Breast cancer [ICD-11: 2C60-2C6Y] T96079 INDICATI Investigative Chronic arterial occlusive disease [ICD-11: BD4Z] T96079 INDICATI Investigative Diabetes mellitus [ICD-11: 5A10] T96079 INDICATI Phase 2 Human immunodeficiency virus disease [ICD-11: 1C60-1C62] T96079 INDICATI Phase 3 Innate/adaptive immunodeficiency [ICD-11: 4A00] T96079 INDICATI Preclinical Kaposi sarcoma [ICD-11: 2B57] T96079 INDICATI Approved Malignant haematopoietic neoplasm [ICD-11: 2B33] T96079 INDICATI Phase 1 Mature B-cell leukaemia [ICD-11: 2A82] T96079 INDICATI Investigative Mature B-cell lymphoma [ICD-11: 2A85] T96079 INDICATI Phase 1/2 Melanoma [ICD-11: 2C30] T96079 INDICATI Phase 1 Metastatic tumour [ICD-11: 2D50-2E2Z] T96079 INDICATI Approved Multiple myeloma [ICD-11: 2A83] T96079 INDICATI Phase 2 Myelodysplastic syndrome [ICD-11: 2A37] T96079 INDICATI Phase 1/2 Neuroendocrine carcinoma [ICD-11: 2C34] T96079 INDICATI Phase 1 Neutropenia [ICD-11: 4B00] T96079 INDICATI Phase 2 Pancreatic cancer [ICD-11: 2C10] T96079 INDICATI Investigative Psoriasis [ICD-11: EA90] T96079 INDICATI Phase 1/2 Renal cell carcinoma [ICD-11: 2C90] T96079 INDICATI Phase 1/2 Respiratory infection [ICD-11: CA07-CA4Z] T96079 INDICATI Phase 2 Retinopathy [ICD-11: 9B71] T96079 INDICATI Phase 1/2 Sarcoma [ICD-11: 2A60-2C35] T96079 INDICATI Phase 1/2 Solid tumour/cancer [ICD-11: 2A00-2F9Z] T96079 INDICATI Discontinued in Phase 1 Transplanted organ/tissue [ICD-11: QB63] T96144 TARGETID T96144 T96144 TARGNAME DNA topoisomerase II (TOP2) T96144 INDICATI Approved Acute myeloid leukaemia [ICD-11: 2A60] T96144 INDICATI Phase 3 Alzheimer disease [ICD-11: 8A20] T96144 INDICATI Approved Anogenital warts [ICD-11: 1A95] T96144 INDICATI Phase 1 Asthma [ICD-11: CA23] T96144 INDICATI Approved Bacterial infection [ICD-11: 1A00-1C4Z] T96144 INDICATI Approved Bladder cancer [ICD-11: 2C94] T96144 INDICATI Phase 2 Brain cancer [ICD-11: 2A00] T96144 INDICATI Approved Breast cancer [ICD-11: 2C60-2C6Y] T96144 INDICATI Approved Chemoprotection [ICD-11: N.A.] T96144 INDICATI Phase 2 Colorectal cancer [ICD-11: 2B91] T96144 INDICATI Approved Common warts [ICD-11: 1E80] T96144 INDICATI Phase 3 Diffuse large B-cell lymphoma [ICD-11: 2A81] T96144 INDICATI Terminated Endocarditis [ICD-11: BB40-BA42] T96144 INDICATI Phase 3 Follicular lymphoma [ICD-11: 2A80] T96144 INDICATI Approved Gonococcal infection [ICD-11: 1A70-1A7Z] T96144 INDICATI Approved HIV-infected patients with tuberculosis [ICD-11: 1B10-1B14] T96144 INDICATI Phase 3 Kaposi sarcoma [ICD-11: 2B57] T96144 INDICATI Terminated Leukaemia [ICD-11: 2A60-2B33] T96144 INDICATI Phase 3 Liver cancer [ICD-11: 2C12] T96144 INDICATI Phase 2 Lung cancer [ICD-11: 2C25] T96144 INDICATI Phase 1 Lymphoma [ICD-11: 2A80-2A86] T96144 INDICATI Phase 1/2 Malignant haematopoietic neoplasm [ICD-11: 2B33] T96144 INDICATI Approved Mature B-cell lymphoma [ICD-11: 2A85] T96144 INDICATI Discontinued in Phase 1 Metastatic lung neoplasm [ICD-11: 2D70] T96144 INDICATI Phase 3 Multiple sclerosis [ICD-11: 8A40] T96144 INDICATI Approved Otitis externa [ICD-11: AA00-AA13] T96144 INDICATI Approved Otitis media [ICD-11: AA80-AB0Z] T96144 INDICATI Phase 2 Ovarian cancer [ICD-11: 2C73] T96144 INDICATI Phase 2 Pancreatic cancer [ICD-11: 2C10] T96144 INDICATI Phase 2 Psoriasis [ICD-11: EA90] T96144 INDICATI Investigative Respiratory system disease [ICD-11: CB40-CB7Z] T96144 INDICATI Approved Solid tumour/cancer [ICD-11: 2A00-2F9Z] T96144 INDICATI Phase 1 Stomach cancer [ICD-11: 2B72] T96144 INDICATI Approved Syphilis [ICD-11: 1A61-1A6Z] T96144 INDICATI Phase 1 Thrombosis [ICD-11: DB61-GB90] T96144 INDICATI Approved Urinary tract infection [ICD-11: GC08] T96215 TARGETID T96215 T96215 TARGNAME Plasmodium Glutamate dehydrogenase (Malaria gdh) T96215 INDICATI Approved Bacterial infection [ICD-11: 1A00-1C4Z] T96235 TARGETID T96235 T96235 TARGNAME Glutamate receptor AMPA 4 (GRIA4) T96235 INDICATI Approved Neuropathy [ICD-11: 8C0Z] T96235 INDICATI Discontinued in Phase 3 Parkinsonism [ICD-11: 8A00] T96257 TARGETID T96257 T96257 TARGNAME Haemophilus influenzae CRM197 (Hae-influ CRM197) T96257 INDICATI Phase 2 Influenza [ICD-11: 1E30-1E32] T96257 INDICATI Phase 2 Pneumococcal infection [ICD-11: CA00-CA40] T96281 TARGETID T96281 T96281 TARGNAME Hepatitis C virus Envelope glycoprotein (HCV Env) T96281 INDICATI Terminated Hepatitis virus infection [ICD-11: 1E50-1E51] T96299 TARGETID T96299 T96299 TARGNAME Wnt protein (WNT) T96299 INDICATI Phase 1 Ovarian cancer [ICD-11: 2C73] T96299 INDICATI Terminated Sarcoidosis [ICD-11: 4B20] T96321 TARGETID T96321 T96321 TARGNAME Bacillus poly-gamma-d-glutamic acid (Bacillus PGA) T96321 INDICATI Preclinical Anthrax [ICD-11: 1B97] T96413 TARGETID T96413 T96413 TARGNAME Beta-glucuronidase (GUSB) T96413 INDICATI Approved Lysosomal disease [ICD-11: 5C56] T96413 INDICATI Phase 2 Periodontal disease [ICD-11: DA0C] T96476 TARGETID T96476 T96476 TARGNAME Plasmodium Merozoite surface protein 1 (Malaria MSP-1) T96476 INDICATI Phase 1/2 Malaria [ICD-11: 1F40-1F45] T96592 TARGETID T96592 T96592 TARGNAME Phosphoric monoester hydrolase (PMH) T96592 INDICATI Discontinued in Phase 1 Solid tumour/cancer [ICD-11: 2A00-2F9Z] T96623 TARGETID T96623 T96623 TARGNAME Heat shock protein 90 beta (HSP90B) T96623 INDICATI Phase 1 Breast cancer [ICD-11: 2C60-2C6Y] T96623 INDICATI Phase 1/2 Lung cancer [ICD-11: 2C25] T96623 INDICATI Phase 1/2 Malignant haematopoietic neoplasm [ICD-11: 2B33] T96623 INDICATI Phase 1 Mature B-cell leukaemia [ICD-11: 2A82] T96623 INDICATI Phase 1 Myeloproliferative neoplasm [ICD-11: 2A20] T96623 INDICATI Phase 1 Solid tumour/cancer [ICD-11: 2A00-2F9Z] T96623 INDICATI Phase 1 Stomach cancer [ICD-11: 2B72] T96627 TARGETID T96627 T96627 TARGNAME C-X-C motif chemokine 2 (CXCL2) T96627 INDICATI Phase 3 Multiple sclerosis [ICD-11: 8A40] T96685 TARGETID T96685 T96685 TARGNAME Hexokinase-2 (HK2) T96685 INDICATI Phase 2 Epidermal dysplasias [ICD-11: EK90] T96721 TARGETID T96721 T96721 TARGNAME Vascular endothelial growth factor (VEGF) T96721 INDICATI Phase 3 Colorectal cancer [ICD-11: 2B91] T96721 INDICATI Phase 3 Lung cancer [ICD-11: 2C25] T96721 INDICATI Phase 2 Macular degeneration [ICD-11: 9B75] T96721 INDICATI Investigative Multiple myeloma [ICD-11: 2A83] T96721 INDICATI Phase 3 Non-small-cell lung cancer [ICD-11: 2C25] T96721 INDICATI Approved Retinopathy [ICD-11: 9B71] T96721 INDICATI Phase 3 Solid tumour/cancer [ICD-11: 2A00-2F9Z] T96723 TARGETID T96723 T96723 TARGNAME SF3b complex (SF3b) T96723 INDICATI Phase 1 Acute myeloid leukaemia [ICD-11: 2A60] T96723 INDICATI Phase 1 Chronic myelomonocytic leukaemia [ICD-11: 2A40] T96723 INDICATI Phase 1 Myelodysplastic syndrome [ICD-11: 2A37] T96736 TARGETID T96736 T96736 TARGNAME Transforming protein RhoA (RHOA) T96736 INDICATI Discontinued in Phase 1 Solid tumour/cancer [ICD-11: 2A00-2F9Z] T96747 TARGETID T96747 T96747 TARGNAME Galactosyltransferase (GALT) T96747 INDICATI Phase 3 Pancreatic cancer [ICD-11: 2C10] T96760 TARGETID T96760 T96760 TARGNAME Growth/differentiation factor 5 (GDF-5) T96760 INDICATI Phase 2 Periodontal disease [ICD-11: DA0C] T96788 TARGETID T96788 T96788 TARGNAME ERBB2 messenger RNA (HER2 mRNA) T96788 INDICATI Phase 3 Breast cancer [ICD-11: 2C60-2C6Y] T96788 INDICATI Phase 2 Chronic pain [ICD-11: MG30] T96788 INDICATI Investigative Solid tumour/cancer [ICD-11: 2A00-2F9Z] T96816 TARGETID T96816 T96816 TARGNAME Plasmodium Enopyruvyl shikimate phosphate synthase (Malaria ESPS) T96816 INDICATI Investigative Malaria [ICD-11: 1F40-1F45] T96837 TARGETID T96837 T96837 TARGNAME Immunoglobulin gamma-1 heavy NIE (NIE) T96837 INDICATI Phase 1 Diabetes mellitus [ICD-11: 5A10] T96837 INDICATI Phase 1 Rheumatoid arthritis [ICD-11: FA20] T96845 TARGETID T96845 T96845 TARGNAME Interleukin-37 (IL37) T96845 INDICATI Approved Psoriasis [ICD-11: EA90] T96876 TARGETID T96876 T96876 TARGNAME Collagen VII (COL7A1) T96876 INDICATI Phase 3 Epidermolysis bullosa [ICD-11: EC3Z] T96892 TARGETID T96892 T96892 TARGNAME Maternal embryonic leucine zipper kinase (MELK) T96892 INDICATI Phase 1 Acute myeloid leukaemia [ICD-11: 2A60] T96892 INDICATI Phase 1 Breast cancer [ICD-11: 2C60-2C6Y] T96892 INDICATI Phase 1 Mature B-cell leukaemia [ICD-11: 2A82] T96892 INDICATI Phase 1 Mature B-cell lymphoma [ICD-11: 2A85] T96892 INDICATI Phase 1 Myelodysplastic syndrome [ICD-11: 2A37] T96892 INDICATI Phase 1 Myeloproliferative neoplasm [ICD-11: 2A20] T96894 TARGETID T96894 T96894 TARGNAME Leukemia inhibitory factor receptor (LIFR) T96894 INDICATI Phase 1/2 Male infertility [ICD-11: GB04] T96914 TARGETID T96914 T96914 TARGNAME Plasmodium DNA gyrase (Malaria gyrase) T96914 INDICATI Approved Bacterial infection [ICD-11: 1A00-1C4Z] T96914 INDICATI Approved Skin and skin-structure infection [ICD-11: 1F28-1G0Z] T96916 TARGETID T96916 T96916 TARGNAME Dickkopf-related protein 3 (DKK3) T96916 INDICATI Phase 1/2 Prostate cancer [ICD-11: 2C82] T97008 TARGETID T97008 T97008 TARGNAME S-adenosylmethionine synthase type-2 (MAT2A) T97008 INDICATI Phase 1 Lymphoma [ICD-11: 2A80-2A86] T97008 INDICATI Phase 1 Solid tumour/cancer [ICD-11: 2A00-2F9Z] T97035 TARGETID T97035 T97035 TARGNAME Tyrosinase (TYR) T97035 INDICATI Approved Acquired hypermelanosis [ICD-11: ED60] T97035 INDICATI Approved Acquired hypomelanotic disorder [ICD-11: ED63] T97035 INDICATI Patented Acquired melanotic macule/lentigine [ICD-11: ED61] T97035 INDICATI Phase 3 Melanoma [ICD-11: 2C30] T97035 INDICATI Patented Mineral absorption/transport disorder [ICD-11: 5C64] T97035 INDICATI Investigative Rheumatoid arthritis [ICD-11: FA20] T97035 INDICATI Patented Skin pigmentation genetic disorder [ICD-11: EC23] T97036 TARGETID T97036 T97036 TARGNAME Connecting peptide (C-peptide) T97036 INDICATI Phase 2 Acute diabete complication [ICD-11: 5A2Y] T97071 TARGETID T97071 T97071 TARGNAME Glutamate carboxypeptidase II (GCPII) T97071 INDICATI Phase 2 Adenocarcinoma [ICD-11: 2D40] T97071 INDICATI Phase 1/2 Bladder cancer [ICD-11: 2C94] T97071 INDICATI Phase 1/2 Cervical cancer [ICD-11: 2C77] T97071 INDICATI Approved Diagnostic imaging [ICD-11: N.A.] T97071 INDICATI Phase 1 General pain disorder [ICD-11: 8E43] T97071 INDICATI Phase 2 Influenza [ICD-11: 1E30-1E32] T97071 INDICATI Investigative Intracranial injury [ICD-11: NA07] T97071 INDICATI Phase 1 Non-small-cell lung cancer [ICD-11: 2C25] T97071 INDICATI Approved Prostate cancer [ICD-11: 2C82] T97071 INDICATI Phase 2 Solid tumour/cancer [ICD-11: 2A00-2F9Z] T97111 TARGETID T97111 T97111 TARGNAME Leukocyte antigen CD37 (CD37) T97111 INDICATI Phase 2 Diffuse large B-cell lymphoma [ICD-11: 2A81] T97111 INDICATI Preclinical Leukaemia [ICD-11: 2A60-2B33] T97111 INDICATI Phase 2 Malignant haematopoietic neoplasm [ICD-11: 2B33] T97111 INDICATI Phase 2 Mature B-cell leukaemia [ICD-11: 2A82] T97111 INDICATI Phase 2 Mature T-cell lymphoma [ICD-11: 2A90] T97111 INDICATI Phase 1 Solid tumour/cancer [ICD-11: 2A00-2F9Z] T97136 TARGETID T97136 T97136 TARGNAME MAPK signal-integrating kinase 1 (MKNK1) T97136 INDICATI Phase 2 Breast cancer [ICD-11: 2C60-2C6Y] T97136 INDICATI Phase 2 Colorectal cancer [ICD-11: 2B91] T97136 INDICATI Phase 2 Liver cancer [ICD-11: 2C12] T97136 INDICATI Phase 1/2 Lymphoma [ICD-11: 2A80-2A86] T97136 INDICATI Phase 1/2 Solid tumour/cancer [ICD-11: 2A00-2F9Z] T97141 TARGETID T97141 T97141 TARGNAME Myosin light kinase (MYLK) T97141 INDICATI Phase 2 Duodenal ulcer [ICD-11: DA63] T97155 TARGETID T97155 T97155 TARGNAME Serine/threonine-protein kinase ATR (FRP1) T97155 INDICATI Phase 2 Lung cancer [ICD-11: 2C25] T97155 INDICATI Phase 1 Lymphoma [ICD-11: 2A80-2A86] T97155 INDICATI Phase 1 Mature B-cell leukaemia [ICD-11: 2A82] T97155 INDICATI Phase 1/2 Solid tumour/cancer [ICD-11: 2A00-2F9Z] T97174 TARGETID T97174 T97174 TARGNAME Mannose-6-phosphate receptor (M6PR) T97174 INDICATI Approved Inborn carbohydrate metabolism error [ICD-11: 5C51] T97196 TARGETID T97196 T97196 TARGNAME ATM serine/threonine kinase (ATM) T97196 INDICATI Phase 1 Brain cancer [ICD-11: 2A00] T97196 INDICATI Clinical trial Lung cancer [ICD-11: 2C25] T97196 INDICATI Phase 1 Solid tumour/cancer [ICD-11: 2A00-2F9Z] T97257 TARGETID T97257 T97257 TARGNAME Transforming growth factor beta 1 (TGFB1) T97257 INDICATI Phase 2/3 Arterial occlusive disease [ICD-11: BD40] T97257 INDICATI Phase 1/2 Brain cancer [ICD-11: 2A00] T97257 INDICATI Approved Idiopathic interstitial pneumonitis [ICD-11: CB03] T97257 INDICATI Discontinued in Phase 2 Lesion [ICD-11: 8A00-8C12] T97257 INDICATI Phase 2 Liver cancer [ICD-11: 2C12] T97257 INDICATI Phase 2/3 Lung cancer [ICD-11: 2C25] T97257 INDICATI Investigative Osteoarthritis [ICD-11: FA00-FA05] T97257 INDICATI Phase 1 Pancreatic cancer [ICD-11: 2C10] T97257 INDICATI Phase 2 Retinopathy [ICD-11: 9B71] T97257 INDICATI Phase 3 Rheumatoid arthritis [ICD-11: FA20] T97257 INDICATI IND submitted Solid tumour/cancer [ICD-11: 2A00-2F9Z] T97257 INDICATI Phase 1 Systemic sclerosis [ICD-11: 4A42] T97353 TARGETID T97353 T97353 TARGNAME Integrin alpha-2/beta-1 (ITGA2/B1) T97353 INDICATI Phase 2 Indeterminate colitis [ICD-11: DD72] T97353 INDICATI Phase 2 Multiple sclerosis [ICD-11: 8A40] T97353 INDICATI Investigative Solid tumour/cancer [ICD-11: 2A00-2F9Z] T97388 TARGETID T97388 T97388 TARGNAME Uridine phosphorylase (UPP) T97388 INDICATI Investigative Nasopharyngitis [ICD-11: CA00] T97413 TARGETID T97413 T97413 TARGNAME Bombesin-like receptor 3 (BRS3) T97413 INDICATI Investigative Obesity [ICD-11: 5B80-5B81] T97553 TARGETID T97553 T97553 TARGNAME Serine/threonine-protein kinase (STK) T97553 INDICATI Phase 2 Liver cancer [ICD-11: 2C12] T97553 INDICATI Phase 2 Ovarian cancer [ICD-11: 2C73] T97553 INDICATI Phase 2 Solid tumour/cancer [ICD-11: 2A00-2F9Z] T97587 TARGETID T97587 T97587 TARGNAME Integrin alpha-4 (ITGA4) T97587 INDICATI Phase 2 Asthma [ICD-11: CA23] T97587 INDICATI Phase 2 Cerebral ischaemic stroke [ICD-11: 8B11] T97587 INDICATI Approved Crohn disease [ICD-11: DD70] T97587 INDICATI Phase 1 Diabetes mellitus [ICD-11: 5A10] T97587 INDICATI Phase 2 Epilepsy/seizure [ICD-11: 8A61-8A6Z] T97587 INDICATI Phase 2 Indeterminate colitis [ICD-11: DD72] T97587 INDICATI Approved Multiple sclerosis [ICD-11: 8A40] T97587 INDICATI Approved Ulcerative colitis [ICD-11: DD71] T97589 TARGETID T97589 T97589 TARGNAME Apoptosis signal-regulating kinase 1 (MAP3K5) T97589 INDICATI Phase 2 Chronic kidney disease [ICD-11: GB61] T97589 INDICATI Phase 2 Pulmonary hypertension [ICD-11: BB01] T97592 TARGETID T97592 T97592 TARGNAME Aurora kinase C (AURKC) T97592 INDICATI Phase 2 Malignant haematopoietic neoplasm [ICD-11: 2B33] T97592 INDICATI Phase 2 Prostate cancer [ICD-11: 2C82] T97592 INDICATI Phase 1 Solid tumour/cancer [ICD-11: 2A00-2F9Z] T97613 TARGETID T97613 T97613 TARGNAME Melatonin receptor type 1A (MTNR1A) T97613 INDICATI Phase 2 Alzheimer disease [ICD-11: 8A20] T97613 INDICATI Phase 2 Anxiety disorder [ICD-11: 6B00-6B0Z] T97613 INDICATI Terminated Circadian rhythm sleep disorder [ICD-11: 7A60-7A65] T97613 INDICATI Phase 2 Dementia [ICD-11: 6D80-6D8Z] T97613 INDICATI Withdrawn from market Depression [ICD-11: 6A70-6A7Z] T97613 INDICATI Approved Insomnia [ICD-11: 7A00-7A0Z] T97613 INDICATI Terminated Sleep-wake disorder [ICD-11: 7A00-7B2Z] T97617 TARGETID T97617 T97617 TARGNAME Sphingosine-1 phosphate receptor (S1PR) T97617 INDICATI Phase 2 Cutaneous lupus erythematosus [ICD-11: EB50-EB5Z] T97617 INDICATI Phase 3 Liver cancer [ICD-11: 2C12] T97617 INDICATI Approved Multiple sclerosis [ICD-11: 8A40] T97617 INDICATI Phase 2 Rheumatoid arthritis [ICD-11: FA20] T97621 TARGETID T97621 T97621 TARGNAME cAMP-dependent chloride channel F508 deletion (CFTR del F508) T97621 INDICATI Approved Cystic fibrosis [ICD-11: CA25] T97621 INDICATI Approved Intrathoracic organs injury [ICD-11: NB32] T97632 TARGETID T97632 T97632 TARGNAME Fungal Probable histone deacetylase HOS2 (Fung HOS2) T97632 INDICATI Phase 2 Candidosis [ICD-11: 1F23] T97655 TARGETID T97655 T97655 TARGNAME Adenylate cyclase type 2 (ADCY2) T97655 INDICATI Investigative Solid tumour/cancer [ICD-11: 2A00-2F9Z] T97701 TARGETID T97701 T97701 TARGNAME Voltage-gated T-type calcium channel (T-CaC) T97701 INDICATI Phase 2 Epilepsy/seizure [ICD-11: 8A61-8A6Z] T97701 INDICATI Phase 2 Parkinsonism [ICD-11: 8A00] T97701 INDICATI Phase 2 Tremor-related disorder [ICD-11: 8A04] T97713 TARGETID T97713 T97713 TARGNAME Amidophosphoribosyltransferase (PPAT) T97713 INDICATI Phase 4 Crohn disease [ICD-11: DD70] T97713 INDICATI Approved Mature B-cell lymphoma [ICD-11: 2A85] T97713 INDICATI Approved Transplant rejection [ICD-11: NE84] T97719 TARGETID T97719 T97719 TARGNAME HUMAN bruton tyrosine kinase (BTK) T97719 INDICATI Phase 2 COVID-19 [ICD-11: 1D6Y] T97719 INDICATI Approved Leukaemia [ICD-11: 2A60-2B33] T97725 TARGETID T97725 T97725 TARGNAME Virus Replication (Viru Repli) T97725 INDICATI Phase 3 Common warts [ICD-11: 1E80] T97725 INDICATI Phase 2 Herpes simplex infection [ICD-11: 1F00] T97725 INDICATI Phase 2 Influenza [ICD-11: 1E30-1E32] T97729 TARGETID T97729 T97729 TARGNAME HUMAN two pore channel subtype 2 (TPC2) T97729 INDICATI Phase 2/3 COVID-19 [ICD-11: 1D6Y] T97729 INDICATI Approved Hypertension [ICD-11: BA00-BA04] T97729 INDICATI Approved Ventricular tachyarrhythmia [ICD-11: BC71] T97740 TARGETID T97740 T97740 TARGNAME Palmitoyl-protein thioesterase 1 (PPT1) T97740 INDICATI Phase 1/2 Lysosomal disease ICD-11: 5C56 T97740 INDICATI Phase 2 Mature T-cell lymphoma [ICD-11: 2A90] T97740 INDICATI Phase 3 Multiple myeloma [ICD-11: 2A83] T97747 TARGETID T97747 T97747 TARGNAME HUMAN C-C chemokine receptor 5 (CCR5) T97747 INDICATI Phase 2 COVID-19 [ICD-11: 1D6Y] T97752 TARGETID T97752 T97752 TARGNAME Ebola virus VP24 messenger RNA (EV VP24 mRNA) T97752 INDICATI Phase 1 Filovirus disease [ICD-11: 1D60] T97759 TARGETID T97759 T97759 TARGNAME Hepatitis C virus Envelope glycoprotein E2 (HCV NS1) T97759 INDICATI Phase 2 Hepatitis virus infection [ICD-11: 1E50-1E51] T97765 TARGETID T97765 T97765 TARGNAME Macrophage inflammatory protein 1-alpha (CCL3) T97765 INDICATI Phase 1 Transplanted organ/tissue [ICD-11: QB63] T97766 TARGETID T97766 T97766 TARGNAME Leukocyte surface antigen CD47 (CD47) T97766 INDICATI Phase 1 Acute myeloid leukaemia [ICD-11: 2A60] T97766 INDICATI Phase 1 B-cell lymphoma [ICD-11: 2A86] T97766 INDICATI Phase 1/2 Colorectal cancer [ICD-11: 2B91] T97766 INDICATI Phase 2 Diffuse large B-cell lymphoma [ICD-11: 2A81] T97766 INDICATI Phase 1 Leukaemia [ICD-11: 2A60-2B33] T97766 INDICATI Phase 1 Lymphoma [ICD-11: 2A80-2A86] T97766 INDICATI Phase 1/2 Malignant haematopoietic neoplasm [ICD-11: 2B33] T97766 INDICATI Phase 1 Melanoma [ICD-11: 2C30] T97766 INDICATI Phase 1 Multiple myeloma [ICD-11: 2A83] T97766 INDICATI Phase 1 Mycosis fungoides [ICD-11: 2B01] T97766 INDICATI Phase 3 Myelodysplastic syndrome [ICD-11: 2A37] T97766 INDICATI Phase 1 Neuroendocrine carcinoma [ICD-11: 2C34] T97766 INDICATI Phase 1 Non-small-cell lung cancer [ICD-11: 2C25] T97766 INDICATI Phase 1/2 Ovarian cancer [ICD-11: 2C73] T97766 INDICATI Phase 1/2 Solid tumour/cancer [ICD-11: 2A00-2F9Z] T97766 INDICATI Phase 1 Squamous cell carcinoma [ICD-11: 2B60-2D01] T97766 INDICATI Phase 2/3 Stomach cancer ICD-11: 2B72 T97822 TARGETID T97822 T97822 TARGNAME Prostaglandin synthetase (PGS) T97822 INDICATI Investigative Postoperative inflammation [ICD-11: 1A00-CA43] T97873 TARGETID T97873 T97873 TARGNAME C-C chemokine receptor type 9 (CCR9) T97873 INDICATI Phase 3 Crohn disease [ICD-11: DD70] T97873 INDICATI Phase 1 Sjogren syndrome [ICD-11: 4A43] T97873 INDICATI Phase 1 Ulcerative colitis [ICD-11: DD71] T97917 TARGETID T97917 T97917 TARGNAME FMLP-related receptor I (FPR2) T97917 INDICATI Preclinical Alzheimer disease [ICD-11: 8A20] T97947 TARGETID T97947 T97947 TARGNAME Guanylyl cyclase C (GUCY2C) T97947 INDICATI Approved Chronic pancreatitis [ICD-11: DC32] T97947 INDICATI Phase 3 Crohn disease [ICD-11: DD70] T97947 INDICATI Approved Irritable bowel syndrome [ICD-11: DD91] T97947 INDICATI Phase 2 Malignant digestive organ neoplasm [ICD-11: 2C11] T97947 INDICATI Phase 1 Solid tumour/cancer [ICD-11: 2A00-2F9Z] T97947 INDICATI Phase 2 Ulcerative colitis [ICD-11: DD71] T97982 TARGETID T97982 T97982 TARGNAME HUMAN cyclophilin D (CYP3) T97982 INDICATI Approved Graft-versus-host disease [ICD-11: 4B24] T97982 INDICATI Investigative Middle East Respiratory Syndrome [ICD-11: 1D64] T97982 INDICATI Investigative Severe acute respiratory syndrome [ICD-11: 1D65] T98015 TARGETID T98015 T98015 TARGNAME Sodium/potassium transport (Na/K trans) T98015 INDICATI Phase 3 Essential hypertension [ICD-11: BA00] T98022 TARGETID T98022 T98022 TARGNAME Carboxypeptidase B2 (CPB2) T98022 INDICATI Phase 1 Cerebral ischaemia [ICD-11: 8B1Z] T98022 INDICATI Phase 1 Cerebral ischaemic stroke [ICD-11: 8B11] T98022 INDICATI Phase 1 Thrombosis [ICD-11: DB61-GB90] T98034 TARGETID T98034 T98034 TARGNAME Cyclin-dependent kinase 19 (CDK19) T98034 INDICATI Phase 1 Acute myeloid leukaemia [ICD-11: 2A60] T98034 INDICATI Phase 1 Myelodysplastic syndrome [ICD-11: 2A37] T98052 TARGETID T98052 T98052 TARGNAME SLAM family member 7 SLAMF7 (CS1) T98052 INDICATI Phase 2 Breast cancer [ICD-11: 2C60-2C6Y] T98052 INDICATI Approved Multiple myeloma [ICD-11: 2A83] T98052 INDICATI Phase 1 Solid tumour/cancer [ICD-11: 2A00-2F9Z] T98062 TARGETID T98062 T98062 TARGNAME Glycogen phosphorylase muscle form (GP) T98062 INDICATI Phase 2 Metabolic disorder [ICD-11: 5C50-5D2Z] T98062 INDICATI Discontinued in Phase 1 Type 2 diabetes mellitus [ICD-11: 5A11] T98091 TARGETID T98091 T98091 TARGNAME Inflammation-related GPCR EX33 (GPR84) T98091 INDICATI Phase 2 Idiopathic interstitial pneumonitis [ICD-11: CB03] T98091 INDICATI Phase 1 Type 2 diabetes mellitus [ICD-11: 5A11] T98092 TARGETID T98092 T98092 TARGNAME HUMAN cyclophilin A (CYPA) T98092 INDICATI Phase 3 Hepatitis virus infection [ICD-11: 1E50-1E51] T98092 INDICATI Investigative Middle East Respiratory Syndrome [ICD-11: 1D64] T98092 INDICATI Investigative Severe acute respiratory syndrome [ICD-11: 1D65] T98157 TARGETID T98157 T98157 TARGNAME Cerebroside-sulfatase (ARSA) T98157 INDICATI Approved Lysosomal disease [ICD-11: 5C56] T98179 TARGETID T98179 T98179 TARGNAME Phosphopantetheine adenylyltransferase (PPAT) T98179 INDICATI Terminated Bacterial infection [ICD-11: 1A00-1C4Z] T98196 TARGETID T98196 T98196 TARGNAME Cyclic pyranopterin monophosphate synthase (MOCS1) T98196 INDICATI Phase 2/3 Mineral deficiency [ICD-11: 5B5K] T98234 TARGETID T98234 T98234 TARGNAME Melanotransferrin (MELTF) T98234 INDICATI Phase 1 Solid tumour/cancer [ICD-11: 2A00-2F9Z] T98269 TARGETID T98269 T98269 TARGNAME Caspase-1 (CASP1) T98269 INDICATI Patented Contact dermatitis [ICD-11: EK00-EK0Z] T98269 INDICATI Phase 2 Epilepsy/seizure [ICD-11: 8A61-8A6Z] T98269 INDICATI Phase 2 Fibrosis [ICD-11: GA14-GC01] T98269 INDICATI Patented Fragrance/cosmetics phototoxic reaction [ICD-11: EK20] T98269 INDICATI Patented Irritant contact dermatitis [ICD-11: EK02] T98269 INDICATI Phase 2 Rheumatoid arthritis [ICD-11: FA20] T98269 INDICATI Phase 2 Type 2 diabetes mellitus [ICD-11: 5A11] T98271 TARGETID T98271 T98271 TARGNAME HUMAN adaptor-associated kinase 1 (AAK1) T98271 INDICATI Phase 3 COVID-19 [ICD-11: 1D6Y] T98271 INDICATI Approved Rheumatoid arthritis [ICD-11: FA20] T98278 TARGETID T98278 T98278 TARGNAME HUMAN type-1 angiotensin II receptor (AGTR1) T98278 INDICATI Phase 3 COVID-19 [ICD-11: 1D6Y] T98278 INDICATI Approved Hypertension [ICD-11: BA00-BA04] T98293 TARGETID T98293 T98293 TARGNAME PAK-4 protein kinase (PAK4) T98293 INDICATI Phase 1 Malignant haematopoietic neoplasm [ICD-11: 2B33] T98293 INDICATI Phase 1 Solid tumour/cancer [ICD-11: 2A00-2F9Z] T98311 TARGETID T98311 T98311 TARGNAME HUMAN angiotensin-converting enzyme (ACE) T98311 INDICATI Phase 3 COVID-19 [ICD-11: 1D6Y] T98311 INDICATI Approved Heart failure [ICD-11: BD10-BD1Z] T98311 INDICATI Approved Hypertension [ICD-11: BA00-BA04] T98390 TARGETID T98390 T98390 TARGNAME HUMAN angiotensin-converting enzyme 2 (ACE2) T98390 INDICATI Phase 2 COVID-19 [ICD-11: 1D6Y] T98390 INDICATI Investigative Severe acute respiratory syndrome [ICD-11: 1D65] T98397 TARGETID T98397 T98397 TARGNAME Thymidylate synthase (TYMS) T98397 INDICATI Phase 1 Solid tumour/cancer [ICD-11: 2A00-2F9Z] T98397 INDICATI Phase 2 Stomach cancer [ICD-11: 2B72] T98430 TARGETID T98430 T98430 TARGNAME Alpha-L-iduronidase (IDUA) T98430 INDICATI Phase 1/2 Lysosomal disease [ICD-11: 5C56] T98494 TARGETID T98494 T98494 TARGNAME Galanin receptor (GAL-R) T98494 INDICATI Phase 1/2 Mild neurocognitive disorder [ICD-11: 6D71] T98642 TARGETID T98642 T98642 TARGNAME PDZ binding kinase (PBK) T98642 INDICATI Investigative Nasopharyngeal cancer [ICD-11: 2B6B] T98691 TARGETID T98691 T98691 TARGNAME HUMAN cathepsin L (CTSL) T98691 INDICATI Preclinical Middle East Respiratory Syndrome [ICD-11: 1D64] T98691 INDICATI Preclinical Severe acute respiratory syndrome [ICD-11: 1D65] T98708 TARGETID T98708 T98708 TARGNAME Parathyroid hormone (PTH) T98708 INDICATI Phase 2 Low bone mass disorder [ICD-11: FB83] T98708 INDICATI Phase 2 Musculoskeletal system/connective tissue disease [ICD-11: FC0Z] T98708 INDICATI Terminated Parathyroid disease [ICD-11: 5A50-5A5Z] T98708 INDICATI Discontinued in Phase 2 Psoriasis [ICD-11: EA90] T98708 INDICATI Approved Skeletal anomaly [ICD-11: LD24] T98798 TARGETID T98798 T98798 TARGNAME Sodium/phosphate cotransporter 2B (SLC34A2) T98798 INDICATI Phase 1/2 Lung cancer [ICD-11: 2C25] T98798 INDICATI Phase 3 Ovarian cancer [ICD-11: 2C73] T98896 TARGETID T98896 T98896 TARGNAME Aggrecanase (ADAMTS5) T98896 INDICATI Phase 1 Osteoarthritis [ICD-11: FA00-FA05] T98906 TARGETID T98906 T98906 TARGNAME Polymerase unspecific (POL) T98906 INDICATI Discontinued in Phase 3 Solid tumour/cancer [ICD-11: 2A00-2F9Z] T98913 TARGETID T98913 T98913 TARGNAME Granulocyte colony-stimulating factor receptor (G-CSF-R) T98913 INDICATI Phase 2 Cardiovascular disease [ICD-11: BA00-BE2Z] T98913 INDICATI Phase 1 Diabetes mellitus [ICD-11: 5A10] T98913 INDICATI Investigative Leukaemia [ICD-11: 2A60-2B33] T98913 INDICATI Phase 2 Motor neuron disease [ICD-11: 8B60] T98913 INDICATI Approved Neutropenia [ICD-11: 4B00] T98913 INDICATI Phase 1 Pancreatic cancer [ICD-11: 2C10] T98913 INDICATI Investigative Postoperative inflammation [ICD-11: 1A00-CA43] T98913 INDICATI Approved Solid tumour/cancer [ICD-11: 2A00-2F9Z] T98917 TARGETID T98917 T98917 TARGNAME Mitochondrial rRNA methyltransferase 2 (MRM2) T98917 INDICATI Approved Bronchitis [ICD-11: CA20] T98917 INDICATI Phase 3 Pancreatic cancer [ICD-11: 2C10] T98917 INDICATI Approved Prostate disease [ICD-11: GA91] T98917 INDICATI Approved Urinary tract infection [ICD-11: GC08] T98933 TARGETID T98933 T98933 TARGNAME Thyroid hormone receptor beta (THRB) T98933 INDICATI Approved Hyper-lipoproteinaemia [ICD-11: 5C80] T98933 INDICATI Phase 2 Hypo-thyroidism [ICD-11: 5A00] T98933 INDICATI Phase 1 Inborn lipid metabolism error [ICD-11: 5C52] T98933 INDICATI Phase 1 Peroxisomal disease ICD-11: 5C57 T98933 INDICATI Clinical trial Skin postprocedural disorder [ICD-11: EL8Y] T98933 INDICATI Investigative Thyrotoxicosis [ICD-11: 5A02] T98945 TARGETID T98945 T98945 TARGNAME HUMAN dibasic-processing enzyme (Furin) T98945 INDICATI Preclinical Middle East Respiratory Syndrome [ICD-11: 1D64] T99009 TARGETID T99009 T99009 TARGNAME HUMAN dihydroorotate dehydrogenase (DHODH) T99009 INDICATI Phase 2/3 COVID-19 [ICD-11: 1D6Y] T99009 INDICATI Preclinical Middle East Respiratory Syndrome [ICD-11: 1D64] T99009 INDICATI Approved Multiple sclerosis [ICD-11: 8A40] T99009 INDICATI Preclinical Severe acute respiratory syndrome [ICD-11: 1D65] T99031 TARGETID T99031 T99031 TARGNAME ERK activator kinase (MEK) T99031 INDICATI Approved Melanoma [ICD-11: 2C30] T99031 INDICATI Phase 2 Phakomatoses/hamartoneoplastic syndrome ICD-11: LD2D T99031 INDICATI Phase 1 Solid tumour/cancer [ICD-11: 2A00-2F9Z] T99041 TARGETID T99041 T99041 TARGNAME HUMAN dipeptidyl peptidase 4 (DPP-4) T99041 INDICATI Phase 3 COVID-19 [ICD-11: 1D6Y] T99041 INDICATI Investigative Middle East Respiratory Syndrome [ICD-11: 1D64] T99041 INDICATI Approved Type 2 diabetes mellitus [ICD-11: 5A11] T99057 TARGETID T99057 T99057 TARGNAME HUMAN ERK activator kinase 1 (MEK1) T99057 INDICATI Approved Metastatic tumour [ICD-11: 2D50-2E2Z] T99057 INDICATI Investigative Middle East Respiratory Syndrome [ICD-11: 1D64] T99057 INDICATI Approved Phakomatoses/hamartoneoplastic syndrome [ICD-11: LD2D] T99057 INDICATI Investigative Severe acute respiratory syndrome [ICD-11: 1D65] T99089 TARGETID T99089 T99089 TARGNAME Serine/threonine-protein kinase B-raf (BRAF) T99089 INDICATI Approved Melanoma [ICD-11: 2C30] T99089 INDICATI Phase 2 Solid tumour/cancer [ICD-11: 2A00-2F9Z] T99149 TARGETID T99149 T99149 TARGNAME HUMAN ERK activator kinase 2 (MEK2) T99149 INDICATI Approved Metastatic tumour [ICD-11: 2D50-2E2Z] T99149 INDICATI Investigative Middle East Respiratory Syndrome [ICD-11: 1D64] T99149 INDICATI Approved Phakomatoses/hamartoneoplastic syndrome [ICD-11: LD2D] T99149 INDICATI Investigative Severe acute respiratory syndrome [ICD-11: 1D65] T99160 TARGETID T99160 T99160 TARGNAME MAP kinase signal-integrating kinase 2 (MKNK2) T99160 INDICATI Phase 2 Breast cancer [ICD-11: 2C60-2C6Y] T99160 INDICATI Phase 2 Colorectal cancer [ICD-11: 2B91] T99160 INDICATI Phase 2 Liver cancer [ICD-11: 2C12] T99160 INDICATI Phase 1/2 Lymphoma [ICD-11: 2A80-2A86] T99160 INDICATI Phase 1/2 Solid tumour/cancer [ICD-11: 2A00-2F9Z] T99189 TARGETID T99189 T99189 TARGNAME Sodium/bile acid cotransporter (SLC10A1) T99189 INDICATI Phase 2 Autoimmune liver disease [ICD-11: DB96] T99189 INDICATI Phase 2 Gallbladder/bile ducts/liver structural developmental anomaly [ICD-11: LB20] T99189 INDICATI Approved Hepatitis virus infection [ICD-11: 1E50-1E51] T99189 INDICATI Phase 2 Inborn porphyrin/heme metabolism error [ICD-11: 5C58] T99204 TARGETID T99204 T99204 TARGNAME Presenilin 2 (PSEN2) T99204 INDICATI Preregistration Osteoarthritis [ICD-11: FA00-FA05] T99204 INDICATI Preregistration Shoulder lesion [ICD-11: FB53] T99204 INDICATI Preregistration Soft tissue disorder [ICD-11: FB56] T99313 TARGETID T99313 T99313 TARGNAME Repulsive guidance molecule A (RGMA) T99313 INDICATI Phase 2 Multiple sclerosis [ICD-11: 8A40] T99313 INDICATI Phase 2 Spine/trunk injury [ICD-11: ND51] T99338 TARGETID T99338 T99338 TARGNAME Stimulator of interferon genes protein (TMEM173) T99338 INDICATI Phase 2 Head and neck cancer [ICD-11: 2D42] T99338 INDICATI Investigative Inborn purine/pyrimidine/nucleotide metabolism error [ICD-11: 5C55] T99338 INDICATI Phase 1 Lymphoma [ICD-11: 2A80-2A86] T99338 INDICATI Phase 1 Melanoma [ICD-11: 2C30] T99338 INDICATI Phase 2 Metastatic lymph node neoplasm [ICD-11: 2D60] T99338 INDICATI Phase 1/2 Solid tumour/cancer [ICD-11: 2A00-2F9Z] T99340 TARGETID T99340 T99340 TARGNAME Receptor-interacting protein 1 (RIPK1) T99340 INDICATI Phase 1 Alzheimer disease [ICD-11: 8A20] T99340 INDICATI Phase 2 Cutaneous lupus erythematosus [ICD-11: EB50-EB5Z] T99340 INDICATI Investigative Malignant haematopoietic neoplasm [ICD-11: 2B33] T99340 INDICATI Phase 2 Motor neuron disease [ICD-11: 8B60] T99340 INDICATI Phase 1 Nervous system paraneoplastic/autoimmune disorder [ICD-11: 8E4A] T99340 INDICATI Investigative Non-alcoholic fatty liver disease [ICD-11: DB92] T99340 INDICATI Phase 1/2 Pancreatic cancer [ICD-11: 2C10] T99340 INDICATI Preclinical Postoperative inflammation [ICD-11: 1A00-CA43] T99340 INDICATI Phase 2 Psoriasis [ICD-11: EA90] T99340 INDICATI Phase 1 Rheumatoid arthritis [ICD-11: FA20] T99340 INDICATI Phase 2 Ulcerative colitis [ICD-11: DD71] T99347 TARGETID T99347 T99347 TARGNAME Metabotropic glutamate receptor 5 (mGluR5) T99347 INDICATI Phase 1 Alzheimer disease [ICD-11: 8A20] T99347 INDICATI Phase 2 Anxiety disorder [ICD-11: 6B00-6B0Z] T99347 INDICATI Phase 2 Autism spectrum disorder [ICD-11: 6A02] T99347 INDICATI Investigative Central nervous system disease [ICD-11: 8A04-8D87] T99347 INDICATI Discontinued in Phase 2 Chronic pain [ICD-11: MG30] T99347 INDICATI Discontinued in Phase 2 Depression [ICD-11: 6A70-6A7Z] T99347 INDICATI Investigative Dissociative neurological symptom disorder [ICD-11: 6B60] T99347 INDICATI Phase 2/3 Fragile X chromosome [ICD-11: LD55] T99347 INDICATI Patented Gastro-oesophageal reflux disease [ICD-11: DA22] T99347 INDICATI Terminated General pain disorder [ICD-11: 8E43] T99347 INDICATI Terminated Migraine [ICD-11: 8A80] T99347 INDICATI Phase 2 Mood disorder [ICD-11: 6A60-6E23] T99347 INDICATI Phase 2/3 Parkinsonism [ICD-11: 8A00] T99347 INDICATI Phase 1 Schizophrenia [ICD-11: 6A20] T99347 INDICATI Phase 1 Sensation disturbance [ICD-11: MB40] T99347 INDICATI Phase 2 Tonus and reflex abnormality [ICD-11: MB47] T99379 TARGETID T99379 T99379 TARGNAME Thrombopoietin (THPO) T99379 INDICATI Phase 1 Ischaemic/haemorrhagic stroke [ICD-11: 8B20] T99379 INDICATI Phase 1 Myocardial infarction [ICD-11: BA41-BA43] T99379 INDICATI IND submitted Thrombocytopenia [ICD-11: 3B64] T99394 TARGETID T99394 T99394 TARGNAME Transmembrane activator and CAML interactor (TNFRSF13B) T99394 INDICATI Phase 1/2 Multiple myeloma [ICD-11: 2A83] T99397 TARGETID T99397 T99397 TARGNAME Voltage-dependent anion-selective channel 1 (VDAC1) T99397 INDICATI Phase 2 Epidermal dysplasias [ICD-11: EK90] T99402 TARGETID T99402 T99402 TARGNAME Metabotropic glutamate receptor 4 (mGluR4) T99402 INDICATI Investigative Anxiety disorder [ICD-11: 6B00-6B0Z] T99402 INDICATI Investigative Dissociative neurological symptom disorder [ICD-11: 6B60] T99402 INDICATI Phase 2 Parkinsonism [ICD-11: 8A00] T99455 TARGETID T99455 T99455 TARGNAME HUMAN fusion protein Bcr-Abl (Bcr-Abl) T99455 INDICATI Phase 3 COVID-19 [ICD-11: 1D6Y] T99455 INDICATI Investigative Middle East Respiratory Syndrome [ICD-11: 1D64] T99455 INDICATI Approved Myeloproliferative neoplasm [ICD-11: 2A20] T99455 INDICATI Investigative Severe acute respiratory syndrome [ICD-11: 1D65] T99524 TARGETID T99524 T99524 TARGNAME Trace amine-associated receptor-1 (TAAR1) T99524 INDICATI Approved Attention deficit hyperactivity disorder [ICD-11: 6A05] T99524 INDICATI Phase 1 Depression [ICD-11: 6A70-6A7Z] T99524 INDICATI Approved Focal/segmental autonomic disorder [ICD-11: 8D8A] T99524 INDICATI Approved Narcolepsy [ICD-11: 7A20] T99524 INDICATI Phase 2 Parkinsonism [ICD-11: 8A00] T99524 INDICATI Phase 3 Schizophrenia [ICD-11: 6A20] T99557 TARGETID T99557 T99557 TARGNAME T-cell receptor beta constant 1 (TRBC1) T99557 INDICATI Phase 1/2 Malignant haematopoietic neoplasm [ICD-11: 2B33] T99557 INDICATI Phase 1/2 Mature T-cell lymphoma [ICD-11: 2A90] T99566 TARGETID T99566 T99566 TARGNAME Free radical (FRD) T99566 INDICATI Phase 1 Brain cancer [ICD-11: 2A00] T99566 INDICATI Phase 3 Ischemia [ICD-11: 8B10-8B11] T99566 INDICATI Phase 3 Lung cancer [ICD-11: 2C25] T99566 INDICATI Phase 2 Lymphoma [ICD-11: 2A80-2A86] T99566 INDICATI Phase 2 Ovarian cancer [ICD-11: 2C73] T99566 INDICATI Phase 2/3 Pancreatic cancer [ICD-11: 2C10] T99566 INDICATI Phase 2 Prostate cancer [ICD-11: 2C82] T99566 INDICATI Phase 1 Solid tumour/cancer [ICD-11: 2A00-2F9Z] T99566 INDICATI Phase 2 Stomach cancer [ICD-11: 2B72] T99582 TARGETID T99582 T99582 TARGNAME HUMAN interleukin 6 (IL6) T99582 INDICATI Phase 3 COVID-19 [ICD-11: 1D6Y] T99582 INDICATI Approved Idiopathic multicentric Castlemans disease [ICD-11: 2A81] T99582 INDICATI Phase 3 Rheumatoid arthritis [ICD-11: FA20] T99616 TARGETID T99616 T99616 TARGNAME Trypanosoma Trypanothione reductase (Trypano TPR) T99616 INDICATI Investigative Kinetoplastids [ICD-11: 1F61-1G2Z] T99616 INDICATI Approved Light sensitivity impairment [ICD-11: 9D45] T99616 INDICATI Approved Thrombocytopenia [ICD-11: 3B64] T99641 TARGETID T99641 T99641 TARGNAME Acetaldehyde dehydrogenase (ALDH) T99641 INDICATI Approved Substance abuse [ICD-11: 6C40] T99685 TARGETID T99685 T99685 TARGNAME HUMAN mammalian target of rapamycin (mTOR) T99685 INDICATI Approved Advanced/metastatic breast cancer [ICD-11: 2C60] T99685 INDICATI Phase 2 Breast cancer [ICD-11: 2C60-2C6Y] T99685 INDICATI Phase 2 COVID-19 [ICD-11: 1D6Y] T99685 INDICATI Approved Lymphangioleiomyomatosis [ICD-11: CB07] T99685 INDICATI Investigative Middle East Respiratory Syndrome [ICD-11: 1D64] T99685 INDICATI Investigative Severe acute respiratory syndrome [ICD-11: 1D65] T99704 TARGETID T99704 T99704 TARGNAME V-set immunoregulatory receptor (VSIR) T99704 INDICATI Phase 1 Lymphoma [ICD-11: 2A80-2A86] T99704 INDICATI Phase 1 Solid tumour/cancer [ICD-11: 2A00-2F9Z] T99727 TARGETID T99727 T99727 TARGNAME Hyperpolarization cyclic nucleotide-gated channel (HCN) T99727 INDICATI Approved Angina pectoris [ICD-11: BA40] T99727 INDICATI Phase 1 Cardiac arrhythmia [ICD-11: BC9Z] T99727 INDICATI Phase 2 Pain [ICD-11: MG30-MG3Z] T99732 TARGETID T99732 T99732 TARGNAME Fibroblast growth factor-18 (FGF18) T99732 INDICATI Phase 2 Arthropathy [ICD-11: FA11-FA5Z] T99740 TARGETID T99740 T99740 TARGNAME Myb messenger RNA (MYB mRNA) T99740 INDICATI Phase 2 Malignant haematopoietic neoplasm [ICD-11: 2B33] T99765 TARGETID T99765 T99765 TARGNAME Small ubiquitin-related modifier (SUMO) T99765 INDICATI Preclinical Acute myeloid leukaemia [ICD-11: 2A60] T99799 TARGETID T99799 T99799 TARGNAME Cholinesterase (BCHE) T99799 INDICATI Phase 3 Alzheimer disease [ICD-11: 8A20] T99799 INDICATI Phase 1 Eexposure to noxious substances harmful effect [ICD-11: NE61] T99799 INDICATI Phase 3 Mild neurocognitive disorder [ICD-11: 6D71] T99799 INDICATI Approved Pain [ICD-11: MG30-MG3Z] T99799 INDICATI Approved Tonus and reflex abnormality [ICD-11: MB47] T99799 INDICATI Investigative Toxicity [ICD-11: N.A.] T99799 INDICATI Investigative Unspecific substance harmful effect [ICD-11: NE6Z] T99816 TARGETID T99816 T99816 TARGNAME Gastrin-releasing peptide receptor (GRPR) T99816 INDICATI Phase 1 Breast cancer [ICD-11: 2C60-2C6Y] T99816 INDICATI Phase 2 Irritable bowel syndrome [ICD-11: DD91] T99816 INDICATI Phase 2 Solid tumour/cancer [ICD-11: 2A00-2F9Z] T99818 TARGETID T99818 T99818 TARGNAME HUMAN sodium pump subunit alpha-1 (ATP1A1) T99818 INDICATI Investigative Middle East Respiratory Syndrome [ICD-11: 1D64] T99834 TARGETID T99834 T99834 TARGNAME HUMAN toll-like receptor 3 (TLR3) T99834 INDICATI Phase 1/2 COVID-19 [ICD-11: 1D6Y] T99834 INDICATI Investigative Middle East Respiratory Syndrome [ICD-11: 1D64] T99834 INDICATI phase 3 Postviral fatigue syndrome [ICD-11: 8E49] T99840 TARGETID T99840 T99840 TARGNAME Gamma-secretase (GS) T99840 INDICATI Phase 2 Alzheimer disease [ICD-11: 8A20] T99840 INDICATI Discontinued in Phase 2 Asthma [ICD-11: CA23] T99840 INDICATI Phase 3 Breast cancer [ICD-11: 2C60-2C6Y] T99840 INDICATI Approved Desmoid tumour [ICD-11: 2F7C] T99840 INDICATI Phase 3 General pain disorder [ICD-11: 8E43] T99840 INDICATI Phase 2 Mild neurocognitive disorder [ICD-11: 6D71] T99840 INDICATI Phase 1 Mineral absorption/transport disorder [ICD-11: 5C64] T99840 INDICATI Preregistration Osteoarthritis [ICD-11: FA00-FA05] T99840 INDICATI Phase 3 Parkinsonism [ICD-11: 8A00] T99840 INDICATI Preclinical Sexual dysfunction [ICD-11: HA00-HA01] T99840 INDICATI Preregistration Shoulder lesion [ICD-11: FB53] T99840 INDICATI Preregistration Soft tissue disorder [ICD-11: FB56] T99840 INDICATI Phase 2 Solid tumour/cancer [ICD-11: 2A00-2F9Z] T99884 TARGETID T99884 T99884 TARGNAME HUMAN toll-like receptor 7/9 signalling pathway (TLR7/9 pathway) T99884 INDICATI Phase 3 COVID-19 [ICD-11: 1D6Y] T99884 INDICATI Approved Malaria [ICD-11: 1F40-1F45] T99907 TARGETID T99907 T99907 TARGNAME Human immunodeficiency virus Maturation (HIV Mat) T99907 INDICATI Phase 2 Human immunodeficiency virus disease [ICD-11: 1C60-1C62] T99908 TARGETID T99908 T99908 TARGNAME HUMAN transmembrane protease serine 2 (TMPRSS2) T99908 INDICATI Phase 2 COVID-19 [ICD-11: 1D6Y] T99908 INDICATI Investigative Middle East Respiratory Syndrome [ICD-11: 1D64] T99908 INDICATI Investigative Severe acute respiratory syndrome [ICD-11: 1D65] T99909 TARGETID T99909 T99909 TARGNAME Mortalin (HSPA9) T99909 INDICATI Phase 2 Solid tumour/cancer [ICD-11: 2A00-2F9Z] T99912 TARGETID T99912 T99912 TARGNAME Kynureninase (KYNU) T99912 INDICATI Preclinical Bacterial infection [ICD-11: 1A00-1C4Z] T99912 INDICATI Preclinical Breast cancer [ICD-11: 2C60-2C6Y] T99935 TARGETID T99935 T99935 TARGNAME GPCR unspecific (GPCR) T99935 INDICATI Terminated Alzheimer disease [ICD-11: 8A20] T99935 INDICATI Discontinued in Phase 1 Depression [ICD-11: 6A70-6A7Z] T99935 INDICATI Discontinued in Phase 1 Functional bladder disorder [ICD-11: GC50] T99935 INDICATI Discontinued in Phase 1 Nausea/vomiting [ICD-11: MD90] T99935 INDICATI Terminated Prostate hyperplasia [ICD-11: GA90] T99935 INDICATI Discontinued in Phase 2 Sexual dysfunction [ICD-11: HA00-HA01] T99948 TARGETID T99948 T99948 TARGNAME Programmed cell death 1 ligand 1 (PD-L1) T99948 INDICATI Phase 1 Acute myeloid leukaemia [ICD-11: 2A60] T99948 INDICATI Phase 2 Biliary tract cancer [ICD-11: 2C17] T99948 INDICATI Phase 3 Bladder cancer [ICD-11: 2C94] T99948 INDICATI Phase 2 Brain cancer [ICD-11: 2A00] T99948 INDICATI Phase 3 Breast cancer [ICD-11: 2C60-2C6Y] T99948 INDICATI Phase 3 Colon cancer [ICD-11: 2B90] T99948 INDICATI Phase 1 Colorectal cancer [ICD-11: 2B91] T99948 INDICATI Phase 2 Diffuse large B-cell lymphoma [ICD-11: 2A81] T99948 INDICATI Phase 1 Follicular lymphoma [ICD-11: 2A80] T99948 INDICATI Phase 3 Head and neck cancer [ICD-11: 2D42] T99948 INDICATI Phase 1 Human immunodeficiency virus disease [ICD-11: 1C60-1C62] T99948 INDICATI Patented Inflammatory liver disease [ICD-11: DB97] T99948 INDICATI Phase 3 Liver cancer [ICD-11: 2C12] T99948 INDICATI Phase 3 Lung cancer [ICD-11: 2C25] T99948 INDICATI Phase 1/2 Lymphoma [ICD-11: 2A80-2A86] T99948 INDICATI Phase 1 Malignant haematopoietic neoplasm [ICD-11: 2B33] T99948 INDICATI Phase 3 Mature T-cell lymphoma ICD-11: 2A90 T99948 INDICATI Phase 3 Melanoma [ICD-11: 2C30] T99948 INDICATI Phase 1 Multiple myeloma [ICD-11: 2A83] T99948 INDICATI Phase 1 Myelodysplastic syndrome [ICD-11: 2A37] T99948 INDICATI Phase 3 Nasopharyngeal cancer [ICD-11: 2B6B] T99948 INDICATI Approved Neuroendocrine carcinoma [ICD-11: 2C34] T99948 INDICATI Approved Non-small-cell lung cancer [ICD-11: 2C25] T99948 INDICATI Phase 3 Ovarian cancer [ICD-11: 2C73] T99948 INDICATI Phase 2 Pancreatic cancer [ICD-11: 2C10] T99948 INDICATI Phase 2 Pleomorphic sarcoma [ICD-11: 2B54] T99948 INDICATI Patented Postoperative inflammation [ICD-11: 1A00-CA43] T99948 INDICATI Phase 3 Prostate cancer [ICD-11: 2C82] T99948 INDICATI Phase 3 Renal cell carcinoma [ICD-11: 2C90] T99948 INDICATI Approved Solid tumour/cancer [ICD-11: 2A00-2F9Z] T99948 INDICATI Phase 3 Squamous cell carcinoma [ICD-11: 2B60-2D01] T99948 INDICATI Phase 3 Stomach cancer [ICD-11: 2B72] T99948 INDICATI Phase 2 Testicular cancer [ICD-11: 2C80] T99948 INDICATI Phase 0 Ulcer [ICD-11: CA02-CB40] T99948 INDICATI Approved Ureteral cancer [ICD-11: 2C92] T99954 TARGETID T99954 T99954 TARGNAME Prostacyclin receptor (PTGIR) T99954 INDICATI Approved Abortion [ICD-11: JA00] T99954 INDICATI Discontinued in Phase 3 Arterial occlusive disease [ICD-11: BD40] T99954 INDICATI Discontinued in Preregistration Asthma [ICD-11: CA23] T99954 INDICATI Discontinued in Phase 3 Chronic kidney disease [ICD-11: GB61] T99954 INDICATI Phase 4 Coronary atherosclerosis [ICD-11: BA80] T99954 INDICATI Phase 3 Gout [ICD-11: FA25] T99954 INDICATI Discontinued in Phase 2 Hypertension [ICD-11: BA00-BA04] T99954 INDICATI Approved Pulmonary hypertension [ICD-11: BB01] T99954 INDICATI Terminated Solid tumour/cancer [ICD-11: 2A00-2F9Z] T99989 TARGETID T99989 T99989 TARGNAME Casein kinase I epsilon (CSNK1E) T99989 INDICATI Phase 2/3 Diffuse large B-cell lymphoma [ICD-11: 2A81] T99989 INDICATI Approved Follicular lymphoma [ICD-11: 2A80] T99989 INDICATI Phase 2 Malignant haematopoietic neoplasm [ICD-11: 2B33] T99989 INDICATI Phase 2 Mature B-cell leukaemia [ICD-11: 2A82] T99989 INDICATI Approved Mature B-cell lymphoma [ICD-11: 2A85] T99989 INDICATI Preclinical Pancreatic cancer [ICD-11: 2C10] T99993 TARGETID T99993 T99993 TARGNAME HUMAN vascular endothelial growth factor (VEGF) T99993 INDICATI Approved Colorectal cancer [ICD-11: 2B91] T99993 INDICATI Phase 2/3 COVID-19 [ICD-11: 1D6Y]